<SEC-DOCUMENT>0001493152-26-013924.txt : 20260331
<SEC-HEADER>0001493152-26-013924.hdr.sgml : 20260331
<ACCEPTANCE-DATETIME>20260331112601
ACCESSION NUMBER:		0001493152-26-013924
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260331
DATE AS OF CHANGE:		20260331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MDB Capital Holdings, LLC
		CENTRAL INDEX KEY:			0001934642
		STANDARD INDUSTRIAL CLASSIFICATION:	FINANCE SERVICES [6199]
		ORGANIZATION NAME:           	02 Finance
		EIN:				874366624
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41751
		FILM NUMBER:		26818834

	BUSINESS ADDRESS:	
		STREET 1:		4209 MEADOWDALE LN
		CITY:			DALLAS
		STATE:			TX
		ZIP:			95229
		BUSINESS PHONE:		310-526-5000

	MAIL ADDRESS:	
		STREET 1:		4209 MEADOWDALE LN
		CITY:			DALLAS
		STATE:			TX
		ZIP:			95229
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:MDBH="http://mdb.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_MDBH_mdb.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001934642 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_SquareFoot_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001934642</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="AsOf2024-12-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-12-31" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember" id="xdx2ixbrl0189" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="xdx2ixbrl0190" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:EffectOfDeconsolidationOfSubsidiary" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:EffectOfDeconsolidationOfSubsidiary" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:EffectOfDeconsolidationOfSubsidiary" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:DilutionOfDeferredGrantReimbursement" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentsSecurities" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncreaseDecreaseInPayablesToNoncustomers" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:PaymentsToAcquireInvestmentsSecurities" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ProceedsFromInvestmentsSecurities" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:PaymentForDeferredGrantReimbursement" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0602" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:WarrantsReceivedAsPartOfInvestmentBankingDeal" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0644" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember" id="xdx2ixbrl0800" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_custom_NonBrokerDealerMember" id="xdx2ixbrl0811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" contextRef="AsOf2025-12-31_custom_SimpleAgreementOnFutureEquitiesMember" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" contextRef="AsOf2025-12-31_custom_ImpairmentMember" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" contextRef="AsOf2025-12-31" id="xdx2ixbrl0819" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" contextRef="AsOf2024-12-31" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember" id="xdx2ixbrl0847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember" id="xdx2ixbrl0849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember" id="xdx2ixbrl0901" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember" id="xdx2ixbrl0903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0974" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMember</ix:nonNumeric>
  <ix:nonFraction name="MDBH:ContractWithCustomerLiabilityAmountsBilledNotRecognized" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0996" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2024-12-31" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ContractWithCustomerLiabilityAmountsBilledNotRecognized" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1002" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1004" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2025-12-31" id="xdx2ixbrl1006" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2024-12-31" id="xdx2ixbrl1012" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GrantCostsExpensed" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1015" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GrantsForEquipmentPurchased" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1018" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GrantFees" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1021" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GrantFundsReceived" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1024" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:RemovalOfBalanceDueToDeconsolidation" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1027" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2025-12-31" id="xdx2ixbrl1030" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2024-12-31" id="xdx2ixbrl1031" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31_custom_EliminationsMember" id="xdx2ixbrl1068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_EliminationsMember" id="xdx2ixbrl1074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:RealizedInvestmentGainsLossesOne" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:RealizedInvestmentGainsLossesOne" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:RealizedInvestmentGainsLossesOne" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1103" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1119" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1121" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1143" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1149" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1161" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1167" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1169" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="xdx2ixbrl1277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31_custom_EliminationsMember" id="xdx2ixbrl1287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_EliminationsMember" id="xdx2ixbrl1293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="xdx2ixbrl1459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="xdx2ixbrl1470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="xdx2ixbrl1472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="xdx2ixbrl1479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:DueToDeconsolidation" contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember" id="xdx2ixbrl1562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationToNonControllingInterest" contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember" id="xdx2ixbrl1566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationToNonControllingInterest" contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember" id="xdx2ixbrl1568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:OwnershipChangeOfNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember" id="xdx2ixbrl1570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:OwnershipChangeOfNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember" id="xdx2ixbrl1572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="xdx2ixbrl1612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="xdx2ixbrl1725" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="xdx2ixbrl1727" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1729" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1731" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1737" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1751" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1753" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1759" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1761" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="xdx2ixbrl1767" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="xdx2ixbrl1769" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1775" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1777" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="xdx2ixbrl1805" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="xdx2ixbrl1807" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="xdx2ixbrl1815" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="xdx2ixbrl1817" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="xdx2ixbrl1819" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="xdx2ixbrl1820" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="xdx2ixbrl1828" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="xdx2ixbrl1830" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="xdx2ixbrl1855" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="xdx2ixbrl1857" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1865" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1867" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1869" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1871" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="xdx2ixbrl1879" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="xdx2ixbrl1881" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1883" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="xdx2ixbrl1885" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2038" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2040" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2082" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-12-31" id="xdx2ixbrl2182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MDBH:DeferredTaxAssetsBonusExpense" contextRef="AsOf2024-12-31" id="xdx2ixbrl2195" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl2227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl2228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl2236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl2237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mdbh-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-20</xbrli:startDate>
        <xbrli:endDate>2023-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-20</xbrli:startDate>
        <xbrli:endDate>2023-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-202023-09-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-20</xbrli:startDate>
        <xbrli:endDate>2023-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01_custom_MDBMinnesotaOneIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MDBMinnesotaOneIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01_custom_MayoFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MayoFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SAFEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MDBH:SAFEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-26_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-26</xbrli:startDate>
        <xbrli:endDate>2024-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfNonPubliclyTradedCompaniesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfNonPubliclyTradedCompaniesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_NonBrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NonBrokerDealerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SimpleAgreementOnFutureEquitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:SimpleAgreementOnFutureEquitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SimpleAgreementOnFutureEquitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:SimpleAgreementOnFutureEquitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:ImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ImpairmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:ImpairmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MDBH:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DevelopedSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MDBH:DevelopedSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BrokerDealerAndIntellectualPropertyServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerAndIntellectualPropertyServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TechnologyDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_OtherSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EliminationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerIntellectualPropertyServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TechnologyDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OtherSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EliminationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerIntellectualPropertyServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OtherSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EliminationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerIntellectualPropertyServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OtherSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EliminationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonClassAMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember5368140">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember5368156">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExozymeTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ExozymeTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-152024-12-31_custom_ExozymesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-15</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExozymesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ExozymesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-15_custom_ExozymesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-14_custom_ExozymesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-142024-11-14_custom_ExozymesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-14</xbrli:startDate>
        <xbrli:endDate>2024-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_custom_ExozymesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-14_custom_ExozymesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-14_custom_ExozymesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ExozymesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ExozymesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_InvizyneTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:InvizyneTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-192022-09-21_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-19</xbrli:startDate>
        <xbrli:endDate>2022-09-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-19</xbrli:startDate>
        <xbrli:endDate>2022-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-28_custom_MarketBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-282025-04-28_custom_MarketBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-28</xbrli:startDate>
        <xbrli:endDate>2025-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-282025-04-28_custom_TimeBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-28</xbrli:startDate>
        <xbrli:endDate>2025-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-28_custom_TimeBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TimeBasedMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TimeBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MarketBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TimeBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MarketBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TimeBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MarketBasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ENDRAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MDBH:ENDRAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ExozymesMember5372140">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExozymesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicVenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MDBH:PublicVenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicVenturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MDBH:PublicVenturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DTCMembershipRequirementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:DTCMembershipRequirementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MinimumMember_custom_DTCMembershipRequirementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:DTCMembershipRequirementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MDBH:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PhaseIIclinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:PhaseIIclinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PhaseIIIclinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:PhaseIIIclinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NewDrugApplicationFirstMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NewDrugApplicationFirstMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NewDrugApplicationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NewDrugApplicationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_USFederalTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">MDBH:USFederalTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_FloridaIncomeTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">MDBH:FloridaIncomeTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-032026-02-03_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001934642</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-03</xbrli:startDate>
        <xbrli:endDate>2026-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SquareFoot">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>MDBH:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl1012" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001013" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001016" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001019" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001022" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001025" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001028" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="xdx2ixbrl1031" toRefs="Footnote001032"/>
  <ix:relationship fromRefs="Fact001088" toRefs="Footnote001279"/>
  <ix:relationship fromRefs="xdx2ixbrl1089" toRefs="Footnote001279"/>
  <ix:relationship fromRefs="xdx2ixbrl1090" toRefs="Footnote001279"/>
  <ix:relationship fromRefs="xdx2ixbrl1091" toRefs="Footnote001279"/>
  <ix:relationship fromRefs="Fact001092" toRefs="Footnote001279"/>
  <ix:relationship fromRefs="Fact001100" toRefs="Footnote001280"/>
  <ix:relationship fromRefs="xdx2ixbrl1101" toRefs="Footnote001280"/>
  <ix:relationship fromRefs="xdx2ixbrl1102" toRefs="Footnote001280"/>
  <ix:relationship fromRefs="xdx2ixbrl1103" toRefs="Footnote001280"/>
  <ix:relationship fromRefs="Fact001104" toRefs="Footnote001280"/>
  <ix:relationship fromRefs="Fact001106" toRefs="Footnote001281"/>
  <ix:relationship fromRefs="xdx2ixbrl1107" toRefs="Footnote001281"/>
  <ix:relationship fromRefs="xdx2ixbrl1108" toRefs="Footnote001281"/>
  <ix:relationship fromRefs="xdx2ixbrl1109" toRefs="Footnote001281"/>
  <ix:relationship fromRefs="Fact001110" toRefs="Footnote001281"/>
  <ix:relationship fromRefs="Fact001118" toRefs="Footnote001282"/>
  <ix:relationship fromRefs="xdx2ixbrl1119" toRefs="Footnote001282"/>
  <ix:relationship fromRefs="xdx2ixbrl1120" toRefs="Footnote001282"/>
  <ix:relationship fromRefs="xdx2ixbrl1121" toRefs="Footnote001282"/>
  <ix:relationship fromRefs="Fact001122" toRefs="Footnote001282"/>
  <ix:relationship fromRefs="Fact001302" toRefs="Footnote001481"/>
  <ix:relationship fromRefs="xdx2ixbrl1303" toRefs="Footnote001481"/>
  <ix:relationship fromRefs="xdx2ixbrl1304" toRefs="Footnote001481"/>
  <ix:relationship fromRefs="xdx2ixbrl1305" toRefs="Footnote001481"/>
  <ix:relationship fromRefs="Fact001306" toRefs="Footnote001481"/>
  <ix:relationship fromRefs="Fact001308" toRefs="Footnote001482"/>
  <ix:relationship fromRefs="xdx2ixbrl1309" toRefs="Footnote001482"/>
  <ix:relationship fromRefs="xdx2ixbrl1310" toRefs="Footnote001482"/>
  <ix:relationship fromRefs="xdx2ixbrl1311" toRefs="Footnote001482"/>
  <ix:relationship fromRefs="Fact001312" toRefs="Footnote001482"/>
  <ix:relationship fromRefs="Fact001314" toRefs="Footnote001483"/>
  <ix:relationship fromRefs="Fact001318" toRefs="Footnote001483"/>
  <ix:relationship fromRefs="Fact001320" toRefs="Footnote001484"/>
  <ix:relationship fromRefs="xdx2ixbrl1321" toRefs="Footnote001484"/>
  <ix:relationship fromRefs="xdx2ixbrl1322" toRefs="Footnote001484"/>
  <ix:relationship fromRefs="xdx2ixbrl1323" toRefs="Footnote001484"/>
  <ix:relationship fromRefs="Fact001324" toRefs="Footnote001484"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20250101__20251231_zbN0GLhDweqg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000014" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentAnnualReport_c20250101__20251231_zA9IXvqNJX9a"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE ANNUAL PERIOD ENDED <span id="xdx_90A_edei--DocumentPeriodEndDate_c20250101__20251231_z0ml49lHG7Ki"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20250101__20251231_zpNh5p9lirc1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000017" name="dei:CurrentFiscalYearEndDate">DECEMBER 31</ix:nonNumeric></span>, <span id="xdx_90D_edei--DocumentFiscalYearFocus_c20250101__20251231_zgO655qLTrU6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000018" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>OR</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentTransitionReport_c20250101__20251231_zQLDJHsZsF66"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <b><span id="xdx_900_edei--EntityFileNumber_c20250101__20251231_zXgegaeSGGa6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:EntityFileNumber">001-41751</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_900_edei--EntityRegistrantName_c20250101__20251231_z9yiEazT48p"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000021" name="dei:EntityRegistrantName">MDB
CAPITAL HOLDINGS, LLC</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zLwulPc5Zibk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20250101__20251231_zbgGpwmBcsfi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">87-4366624</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20250101__20251231_zLlB2RmxPhDk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityAddressAddressLine1">14135
                                            Midway Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250101__20251231_zXqEcCtUKzii"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite G-150</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20250101__20251231_z8cSFTo9V1L8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Addison</ix:nonNumeric></span>,
    <span id="xdx_906_edei--EntityAddressStateOrProvince_c20250101__20251231_z9lHMaJioOF1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">TX</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20250101__20251231_zMtAS7Fom23e"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">75001</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20250101__20251231_zfKGpKPxWgo6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:EntityAddressPostalZipCode">75001</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--CityAreaCode_c20250101__20251231_z6CmqU7Ex3Ka"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:CityAreaCode">(945)</ix:nonNumeric></span>
<span id="xdx_90E_edei--LocalPhoneNumber_c20250101__20251231_zavROCT6mkQ"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000031" name="dei:LocalPhoneNumber">262-9012</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20250101__20251231_zKWHh85Xf74j"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000032" name="dei:Security12bTitle">Class
    A Common Shares, representing Limited Liability Interests</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20250101__20251231_zzjuiqBbJTYg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000033" name="dei:TradingSymbol">MDBH</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20250101__20251231_zEIhaQyoAe44"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <b>Yes &#9744; <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zrmpPfnstCrh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. <b><span id="xdx_90F_edei--EntityVoluntaryFilers_c20250101__20251231_zg3gHspIQt41"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000036" name="dei:EntityVoluntaryFilers">Yes</ix:nonNumeric></span> &#9746; No
&#9744;</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the last 90 days. <b><span id="xdx_904_edei--EntityCurrentReportingStatus_c20250101__20251231_zd07rM7j2Epl"><span style="-sec-ix-hidden: xdx2ixbrl0037">YES</span></span></b></span><b>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; NO &#9744;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <b><span id="xdx_905_edei--EntityInteractiveDataCurrent_c20250101__20251231_zklLVVDdnht2"><span style="-sec-ix-hidden: xdx2ixbrl0038">YES</span></span></b></span><b>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; NO &#9744;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;non-accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2
of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Large
    Accelerated Filer</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9744;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accelerated
    Filer</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9744;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityFilerCategory_c20250101__20251231_zsihH6v2QEOb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000039" name="dei:EntityFilerCategory">Non-accelerated
    Filer</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9744;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Smaller
    Reporting Company</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntitySmallBusiness_c20250101__20251231_zQ0Qe4bX3YQe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000040" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
    Growth Company</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20250101__20251231_zQ4i9qZMfQO2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000041" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_902_edei--EntityExTransitionPeriod_c20250101__20251231_zLLS4tP1iQ2f"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_900_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zkhSLh6jdsgk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_902_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zk5bXGetol9k"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <b>YES &#9744; NO <span id="xdx_906_edei--EntityShellCompany_dbF_c20250101__20251231_zil8WQlxZQCb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2026 the number of outstanding shares of Class A Common Shares, representing limited liability interests, of the registrant
was <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zTwnLBvq9q0g"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonClassAMember" id="Fact000046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,300,132</ix:nonFraction></span>. There are also <span id="xdx_908_edei--EntityCommonStockSharesOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zXXEXoVNGA96"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember" id="Fact000047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> outstanding shares of Class B Common Shares, representing limited liability interests of the
registrant, each of which votes with the Class A Common Shares on all matters presented to the holders of the Class A Common Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The value of the Class A Common Shares on June 30, 2025, was $<span id="xdx_90D_edei--EntityPublicFloat_iI_c20250630_zpMP7LUlDWhf"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,178,831</ix:nonFraction></span>, the last business day of the registrant&#8217;s most recently
completed second fiscal quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentsIncorporatedByReferenceTextBlock_c20250101__20251231_zuG2lY42Mfb2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000049" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">Part I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_009">Part
    II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Item
    9C</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#a_018">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_019">Part
    III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_025">Part
    IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_027">Form 10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_028">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
this Annual Report, unless otherwise indicated, the &#8220;Company&#8221;, &#8220;MDB,&#8221; &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;
refer to MDB Capital Holdings, LLC and, where appropriate, together with its wholly-owned and controlled subsidiaries.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
in Item 7, contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)
that involve substantial risks and uncertainties. These forward-looking statements are not historical facts but are based on current
management expectations that involve substantial risks, uncertainties, and other factors, some of which are beyond our control and difficult
to predict and could cause actual results to differ materially from those expressed in, or implied by, these forward-looking statements.
Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements
by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221;
&#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or
other similar words. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements
including, but not limited to, any projections of revenue, gross profit, earnings or loss, tax provisions, cash flows or other financial
items; any statements of the plans, strategies or objectives of management for future operations; any statements regarding current or
future macroeconomic or industry-specific trends or events and the impact of those trends and events on us or our financial performance;
any statements regarding pending investigations, legal claims or tax disputes; any statements of expectation or belief; and any statements
of assumptions underlying any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause our
actual results of operations, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results,
as well as those of the markets we serve or intend to serve, to differ materially from those expressed in, or suggested by, these forward-looking
statements. These forward-looking statements are based on assumptions regarding our present and future business strategies and the environment
in which we operate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove
to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these
and other uncertainties, the inclusion of a projection or forward-looking statement in this annual report on Form 10-K should not be
regarded as a representation by us that our plans and objectives will be achieved. These risks and uncertainties include those described
or identified in &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should not place undue reliance on these forward-looking
statements, which apply only as of the date of this Annual Report on Form 10-K. Except as required by the federal securities laws, we
undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or
otherwise, to reflect events or circumstances occurring after the date of this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
factors that could cause those differences include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    future financial performance, including our expectations regarding our net revenue, operating expenses, and our ability to achieve
    and maintain future profitability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business plan and our ability to effectively manage our overall operations and growth, particularly in respect of our partner companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to anticipate trends, growth rates, and challenges in our securities brokerage and related businesses as broker dealer regulation
    evolves;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to evaluate potential partner companies and assess their potential growth and the challenges of their business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to evaluate the product and service development of the partner companies, product and service acceptance of the partner companies,
    and the inherent uncertainty of their product and service development and commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">how
    our partner companies are able to be financed and our ability to provide shareholder value to our holders of Class A Shares and Class
    B Shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to realize upon the value created by our partner companies by the distribution or sale of the securities we own of them;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory,
    legislative and judicial developments that impact our businesses and those of the partner companies and our ability to stay in compliance
    with laws and regulations that currently apply or become applicable to our business and those of the partner companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our partner companies to protect their respective intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our clients and service providers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify, complete and integrate potential strategic acquisitions of complementary companies, products, services, or technologies
    and our ability to successfully integrate such companies or assets into our overall structure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic conditions and trends and their impact on businesses of the group companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    expenses associated with being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise equity and debt capital to fund our operations and growth strategy, including possible developmental businesses
    and acquisitions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    revenue being lower than expected.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
above factors should not be construed as exhaustive and should be read with the other cautionary statements in this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introduction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB
Capital Holdings, LLC (&#8220;MDB&#8221;) serves as a foundational platform specializing in financing startups, partnering with co-founders,
and fostering value creation. This platform sets the stage for nascent ideas and entrepreneurial talent to take root. MDB is comprised
of a group of companies that together serve as this unified foundational platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the companies in our group, Public Ventures, LLC (&#8220;Public Ventures&#8221;), which operates under the D/B/A of &#8220;MDB
Capital,&#8221; operates as a growth catalyst, focusing on community-driven micro and small-cap financings and is a self-clearing broker dealer. It enables companies to
scale through the initial financing stages ranging from $5 million to sixty million dollars and facilitates their transition into
public markets with select IPOs valued in the range of twenty to fifty million dollars. Public Ventures also may provide financing
to post-IPO companies that continue to meet its overall business criteria for investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another
company in our group, PatentVest, Inc. (&#8220;PatentVest&#8221;) complements the platform as an integrated intellectual property (&#8220;IP&#8221;)
solution and IP service provider, acting as a strategic law firm to guide technology companies through the intricacies of IP law and
provides companies with IP strategy development. It plays a pivotal role in positioning companies to become leaders in their respective
spaces and curates premier opportunities for MDB and Public Ventures, which leads to our Big Idea Companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB
Minnesota One, Inc (&#8220;M1&#8221;), a partner company, was created in mid-2024 with the vision of developing a small molecule anti-senescence
platform comprised of pharmaceutical drugs or other products to aid in longevity and to inhibit certain forms of age-related diseases
(the &#8220;M1 Platform&#8221;). The focus of the M1 Platform is to treat <span style="background-color: white">senescent cells, which
are dysfunctional cells that have permanently stopped dividing, that have been implicated in the aging process, and that permit the development
of chronic low-grade inflammation. This chronic inflammation has been linked to a variety of age-related diseases, including multiple
fibrotic conditions that have limited treatment options and poor prognoses.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB
supports a continuous process, dubbed our Big Idea Pipeline, designed to surface new Big Idea Companies and other opportunities for
our platform. We believe that the Big Idea Pipeline showcases the progression of tech initiatives from discovery to
commercialization stages. Initially, in any given calendar cycle, a substantial number of potential tech ideas are scouted from
various sources, including referrals, universities, and conferences. From this broad pool, approximately 250 technologies are
identified annually as relevant and with potential alignment with our business model. A more focused group of these ideas, about 50,
evolves into, what we call, active Big Idea Companies. Progressing further, approximately ten of these companies reach advanced
stages within the selection process, indicating a deeper engagement and evaluation by MDB. At the pinnacle of the pipeline, as of
the date of filing this Annual Report on Form 10-K, two Big Idea Companies are currently in active negotiations, marking the final step before potential
partnership or investment. This is a continuous process with the Big Idea Pipeline in constant flux as new ideas emerge or evolve.
MDB&#8217;s disciplined and structured approach to vetting the Big Idea Pipeline allows us to cultivate and invest in innovative
technologies with the potential to scale and succeed in the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB&#8217;s
investment criteria focuses on six key areas to identify early-stage companies poised for success in public markets. These potential
partner companies should exhibit &#8220;Tech Leadership Potential,&#8221; with distinct differentiation that pioneers a new technological
category. &#8220;Platform Technology&#8221; is essential, with core technology that can span various vertical markets or indications.
They should be at an &#8220;Early Inflection Point,&#8221; where the timeline and costs to validate technology feasibility in the commercial
marketplace are reasonable. &#8220;Clear Market Insertion&#8221; is also critical, with technology disruption significant enough to incentivize
stakeholders for market entry. The target companies should have &#8220;Large Market Potential,&#8221; addressing substantial unmet needs
with vast market opportunities. Lastly, a &#8220;Strong IP Position&#8221; is necessary, meaning a robust and defensible intellectual
property stance with broad claims to secure a sustainable competitive edge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
essence, the investment philosophy is to scout for companies that not only stand at the vanguard of technology but also demonstrate the
capacity to disrupt markets, backed by solid intellectual property and clear pathways to market adoption and growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Together,
our platform represents a holistic approach to leadership development in the general technology industry. Our objective is to provide
a continuum of support to our partner companies, from inception through growth phases, culminating in market leadership. Each part of
the overall platform is integral to the journey of a start-up, providing tailored resources, expertise, management guidance and resources,
and financial backing as necessary to evolve our partner company into a significant player in the technology sector. This unity of purpose
exemplifies the strategic foresight of MDB&#8217;s commitment to launching Big Ideas and developing industry leaders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB
was founded in 1997, originally operating as MDB Capital Group, LLC, for the purpose of engaging with companies holding visionary technology,
inventors, and technology entrepreneurs. To maximize the impact of our actions and culture, under our business plan, we embark on each
journey with a company at an early point, typically acting as founders and providing the initial rounds of capital, in the manner of
a partner and usually before a specified management structure has been put in place. Part of our role as founders often includes locating
the technology that will form the basis of the new enterprise. The technologies may be found in universities, in larger companies where
it is not being used or understood, in start-up companies, and with inventors. Not only do we act as founders and providing the first
capital rounds, we assist with structuring the plans for the company development, such as the steps from research and development to
initial commercialization, the intellectual property strategy, business objectives, and financing. We refer to these subsidiary companies
as &#8220;partner companies.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
model typically includes a two-step financing approach with our partner companies: we put in seed capital, as founders, and the
first round of capital between $5 to $10 million to set the business on an operational foundation. Our plan is to then raise
additional amounts of substantive capital to bring the technology closer to validation or to be able to commence commercialization,
typically in the range of $20 to $60 million overall. We plan on additional financing by means of public offerings or alternative
value realization. Our community of sophisticated, individual investors with like-minded goals and values, supports our model, where
we will draw on their capital, knowledge, connections and expertise. We anticipate that value creation will be generated after any
number of years of patient ownership and corporate effort, and value realization might include any number of methods, such as
continued holding and operating, initial public offerings (&#8220;IPO&#8221;), joint ventures, licensing, asset sales and merger
transactions, depending on the particular business model and industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we successfully have used the private and public capital markets to finance growth companies. Being able to find
disruptive technologies to develop, acting as corporate founders, owners, directors and management, and conducting financing
activities for those companies in which we are strategically involved for the long term, we believe we have a different model of
helping companies grow than that of the typical private venture capital model. We refer to our approach as public venture capital.
We find the technology and then we work to analyze the technology leadership position by our surveying the marketplace so as to
establish a research and development and intellectual property development strategy to create a dominant position in the distinct
technology vertical. Then we create the basic company, we set up its management, we define its business plan, we nurture its
enterprise, and we provide its financings in its early-stage rounds, and then we likely will act as the underwriter or selling agent
for their IPO, other financing or disposition. It is our plan to remain involved with our partner companies for the long term. Where
there is an IPO, we plan to stay on for several years thereafter, by being members of the board, having consulting agreements,
providing strategic business advice, and participating in, advising on or facilitating further financing rounds. We believe, most
importantly, that one gauge of the partner company success is that the partner company will successfully foster community, where
community members who seek to create value at the companies, in connection with our self-clearing broker-dealer, Public Ventures. Our typical complete public and private follow-on offerings continue supporting their research, development,
growth and marketing of their technologies&#8217; potential. MDB, we believe, builds value by building partner companies with the
right foundations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Past
Examples</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
having been able to find disruptive technologies to develop, acting as corporate founders, owners, directors and management, and conducting
investing activities for those companies in which we have been strategically involved for the long term, we believe we now have a different
model for helping companies grow than that of the typical private venture capital model. We refer to our approach as public venture capital.
We find the technology, and then we work to analyze the technology leadership position and survey the marketplace so as to establish
a research and development and intellectual property development strategy to create a dominant position in the distinct technology vertical.
Then we create the basic company, we set up its management, we define its business plan, we nurture its enterprise, and we facilitate
its financings in its early-stage rounds of private funding. Then we likely will act as the underwriter or selling agent for their IPO,
other financing or disposition. It is our plan to remain involved with our partner companies for the long term. Where there is an IPO,
we plan to stay involved on for several years thereafter, by being members of the board, having consulting agreements, providing strategic
business advice, and participating in, advising on or facilitating further financing rounds. We believe that one gauge
of the partner company success is that the partner company will successfully complete a private and public follow-on offering to continue
supporting their research, development, growth and marketing of their technologies&#8217; potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
companies for which we started as founders and for which we conducted their IPOs, have traded for a period of time at near or over $1
billion in market value, which we believe is crucial for maximizing the probability the companies can raise sufficient capital to get
to commercialization. These companies are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Provention Bio, Inc. (&#8220;Provention&#8221;). Provention was established in 2016. Public Ventures created Provention to license molecules
from several larger pharmaceutical companies, conceived the business strategy, assisted in licensing negotiations, provided seed capital,
engaged the initial board of directors&#8217; members, and recruited C-level executives as well as executed the successful IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Cue BioPharma, Inc. (&#8220;Cue&#8221;). Cue was established in 2014. Public Ventures created Cue to license a platform technology from
Einstein University, engaged the members of the board of directors, recruited C- level executives, formed the corporate and IP strategy
and provided the seed capital and well as executing the successful IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Pulse Biosciences, Inc. (&#8220;Pulse&#8221;). Pulse was established in 2014, Public Ventures created a new entity that rolled up the
intellectual property from two academic institutions and one private entity. Public Ventures then completed a seed financing, created the
business and IP strategy and assembled the management team and Board. Subsequently Public Ventures successfully executed the IPO for
Pulse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, eXoZymes Inc, (formerly Invizyne Technologies Inc.) completed its IPO on November 14, 2024, having been set up in 2019 to
develop cell-free technology to optimize nature&#8217;s own biological processes to make chemicals used in many common applications.
MDB was one of the founders of the company, provided an initial funding of $5 million and a subsequent funding of $0.75 million and
provided executive management and several board members. Persons affiliated with MDB continue to be on the board of
directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Pillars</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have defined and refined the key pillars that support what we believe is our successful company creation approach.
These pillars are defined in Our Partner Company Criteria section. We believe that our model is only suitable for companies that can
be sustained in the public markets at an early stage. Typically, these companies own what appear to be category-defining technology
platforms capable of solving big problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a process to position partner companies for success, with the intention of maximizing the value early in a company&#8217;s
history. We seek to create a strong foundation during the development phase of the partner company. We believe that this helps the partner
company attract the best people who are capable of building a successful enterprise over the long term. We call this our &#8220;Rational
Design Process For New Companies.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
traditional perceived shortcoming of the public markets is that they attract investors focused on the short-term markets. We understand that to make early-stage
public venture feasible; we need to create a community of investors that have the intention of helping our companies get off the ground.
We believe our investors are committed community members who seek to create value at the companies in which they invest and are critical
to sustaining value. Our investors, unlike traditional institutional investors, generally have long holding periods and value long-term
impact over quarterly performance numbers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Community</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of our public venture model is our community of more than 500 sophisticated investors, entrepreneurs and microcap and small
cap market participants who have experience with our approach and who we believe will advocate for our public venture mission. In addition,
investors can have a significant impact by supporting the companies they invest in. We believe that this community is vital to the success
of our public venture model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have strived to create community of like-minded persons who share our vision and are supportive of the partner companies we have co-founded.
This group consists of patient company owners with a long-term focus on the value that can be unlocked upon the de-risking of our partner
companies&#8217; technologies. This long-term focus is key to building value and stability for early-stage companies in the public markets.
In addition, we believe that our community members are often authorities in multiple industries and are capable of providing support
to our partner companies with their invaluable access and reach. We believe that MDB shareholders will comprise this community and will
continue to participate in the partner companies through their MDB share ownership as well as participation in partner company direct
investment opportunities. MDB plans to sustain a cohesive community by keeping persons engaged and curious so that they continuously
help us improve our decision process as and when selecting partner companies with which to work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that MDB is strengthening our community of MDB shareholders and can simplify our process of developing partner companies. We
used a portion of our capital to identify and find partner companies. We believe that being a public company gives us greater
flexibility and nimbleness to source new technologies and make it quicker and easier to deploy capital towards opportunities that arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also will seek to foster community in connection with our broker-dealer, Public Ventures. Our typical Public Ventures Member will be a long-term
investor and/or entrepreneur who is motivated to help develop the next generation of growth companies. Public Ventures Members may or
may not be MDB shareholders. Members may or may not provide direct financing to partner companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holistic
and Sustainable Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
public venture model is fundamentally different than the typical venture capital fund model. We believe that bringing well developed
early-stage companies to either the public markets or fostering a merger and acquisition exit or other realization event, while still
taking care to address the unique nature and needs of these early-stage companies, provides more liquidity, efficiency, transparency,
better protections for investors and alignment of the interests of everyone involved as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventors/Universities/Co-founders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taking
companies public allows shareholders to own the same class of common stock as the company&#8217;s early founders. In addition, the
ownership interests of inventors, universities, and other co-founders become valuable, tradable shares when a company is public and listed
on an exchange. As a result, we believe that, in most cases, these ownership stakes will have much greater value than they would otherwise
have in the traditional venture capital model. We also believe that our model gives companies greater leeway to execute pivots or to
pursue other strategic initiatives, such as licensing, asset sales or corporate merger and acquisition transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Partner
Company Management &amp; Board Members</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the management and board members of our partner companies will benefit from the Company being public. The ability to grant
valuable, liquid equity as part of an employment compensation package is a strong incentive to attract and retain employees and align
their interests with those of the company at which they work. Being public can help a partner company raise substantial amounts of capital
more easily than as a private company or through traditional venture capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>MDB
Shareholders</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the MDB model, MDB shareholders can buy or sell their shares in the holding company in the open market at any time. These
shareholders will participate in our partner companies through the holding company structure, for example through the tax benefits
of holding an interest in a tax pass through entity or the overall value of the holding company as it reflects the values of our
subsidiaries. Where we think it beneficial for a partner company to raise capital directly, rather than taking additional funds from
the holding company, we may seek a method that can allow the MDB shareholders the ability to participate in additional capital
formation for a partner company. There are a few means by which the MDB shareholder may participate: for example, a further private
placement by the partner company, or by a registered public offering, such as an IPO or rights offering where the MDB shareholder
can invest new funds based on the distributed right. If the best course of action is an asset sale, a licensing arrangement or a
corporate merger or acquisition transaction of a partner company, then it is expected that MDB shareholders will receive a
distribution of the proceeds as a result of the transaction. Moreover, we believe that many of the MDB shareholders own their Class
A Common Shares because they are motivated by the opportunity to contribute their knowledge and experience to and engage with our
partner companies in an effort to improve them and enhance their value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Holding Company Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
each partner company will present its own investment dynamic, at the onset, we take a majority ownership stake in the partner companies
we co-found and to hold a significant controlling position through the early stages of development and early capital creation. We plan
on seeking one or two partner company opportunities a year, but there is no assurance that we will be able to find suitable opportunities
at that rate for inclusion in the holding company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to not be deemed an investment company under the regulation of the Investment Company Act of 1940, MDB will not operate in a manner
such that it is or holds itself out as being engaged in the business of investing, reinvesting, or trading in
securities. Additionally, it will maintain what are characterized as &#8220;investment securities&#8221; under the Investment Company
Act below forty percent (40%) of the value of the total assets of MDB on an unconsolidated basis, unless an exemption or safe harbor
applies under that legislation. Securities issued by companies other than consolidated companies are generally considered &#8220;investment
securities&#8221; for purposes of the Investment Company Act, unless other circumstances exist that have the holding company being actively
involved in the management of the underlying company. We consolidate these companies for financial statement purposes as long as
they are majority-owned subsidiaries in which we hold voting power of fifty percent (50%) or greater. We expect to continue to have an
active role in the management of our partner companies for a period of time before and after funding, such as an IPO. The Company&#8217;s Broker-Dealer subsidiary is excluded from the Investment Company Act of 1940, and therefore all
securities held by the Broker-Dealer are excluded from the asset calculation.&#8239;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
only for purposes of the Investment Company Act, but also to maintain our focus on exploring new investment opportunities through partner
companies, rather than holding partner companies for long term investment and increasing our asset base, our intention is to distribute
our partner companies and excess assets beyond what is needed to support the investments we plan to make under our public venture model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Getting
access to and deploying early-stage capital is very competitive. We believe our main competitors are traditional venture capital firms,
other funds specializing in microcap and small cap investing and investment banks focusing on microcap and small cap companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our approach provides multiple benefits compared to existing models and traditional methods. However, many of our competitors
are larger, have greater brand recognition, longer operating histories, established business relationships, access to greater amounts
of capital, and significantly greater resources. We believe that we will be able to compete on many fronts based on our history and reputation,
our plan to partner, encourage and support the development of our partner companies and their founders, our wide-ranging contacts in
the financial and industry sectors, our ability to provide capital as needed, our ability to source and diligence new technologies and
the experience of our professional human capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Group of Companies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Public
Ventures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholly-owned subsidiary, Public Ventures, licensed under the name Public Ventures LLC, a registered broker- dealer (CRD-: 42677/SEC-:
8-49951) is the backbone of our financing business. Public Ventures operates under the d/b/a of &#8220;MDB Capital.&#8221; In 2024 we
expanded its capabilities to act as a licensed clearing firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Vision</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that </span>venture-stage businesses are more likely to succeed when supported and financed by a community of long-term oriented,
like-minded investors and entrepreneurs who have experience building successful companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We envision building a close-knit
community of such clients for Public Ventures, whom we refer to as our Public Ventures &#8220;Members.&#8221; Our Members will have the
opportunity to submit start-up and developing companies as potential candidates for financing through Public Ventures and/or as partner
companies for MDB. Members may also, at their discretion and based on their expertise, actively assist in the development and growth of
the companies we finance, helping them become tomorrow&#8217;s industry leaders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that such a community of investors can foster the growth of promising public companies under $500 million in market value, also
known as microcap and/or small cap companies, by leveraging the knowledge of the community and sharing risk amongst its Members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are building a robust infrastructure to support our vision for Public Ventures. Our objective is to create a
high-end service platform that will make investing in the microcap and/or small cap segment more accessible to and efficient for the
Public Ventures Member community. Public Ventures recently began self-clearing operations of U.S equity securities and its FINRA
licensed self-clearing broker-dealer is capable of structuring and underwriting financing transactions as well as providing clearing
services that enable clients to trade, clear, and settle securities in these companies. We also are able to provide expanded account
maintenance activities, such as wire transfers, securities deposits and interest on cash deposits through typical cash management
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have successfully operated our broker-dealer for more than 28 years during which we have specialized in transactions for public venture
companies. During that time, we built internal processes to perform diligence and prioritize the financing of deals based on the investment
criteria that we have developed. We intend to leverage the lessons we have learned during these experiences to create processes, rating
systems and reports that will be made available to our Member community and can be used to supplement their own processes for evaluating
each opportunity and associated risks and making informed investment decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Public Venture Opportunity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the public markets have served as a significant funding source for companies with new ideas and enabled the growth and development
of visionary technologies that lead to advancements in our society. We believe that venture investing in the public markets is a
transparent and liquid method for investors to participate in venture capital. Public venture is available to all classes of
investors who all receive typically equal amounts of information about their investments. Companies like Amazon, Tesla, Walmart,
Home Depot, among others, were brought public at very early stages, and capital provided through the public markets enabled their
spectacular development into industry leaders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
dynamics have resulted in companies backed by traditional venture capital staying private for longer periods of time. In addition, regulatory
changes affecting broker-dealers have resulted in a shift to high volume trading that relies on payment for order flow to make up for
commission-less trading. This has resulted in broker-dealers devoting more resources to trading high volume, popular equities and away
from providing service to microcap and small-cap public venture companies and their securities. As a result, the needs of long-term investors
looking to support venture stage public companies and those of venture stage companies are not addressed by today&#8217;s brokerage firms
who cater to traders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the expected Public Ventures Member community, consisting of sophisticated individual investors, who are aware of the nature
of venture investments and seek to build tomorrow&#8217;s leading companies, can drive the future of public venture capital formation.
We believe that only this type of community can provide suitable financing options that will meet the needs of small public venture companies.
We have the unique opportunity to provide the right framework and platform infrastructure to this community that will enable its Members
to collectively underwrite public venture financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our Members to be entrepreneurial and involved in different ventures. Under our framework, they will be encouraged and rewarded
for successfully identifying business and ownership opportunities for the community that meet our criteria. We envision that our platform
will encourage and allow Members to share information and formulate the nature of and pricing for any financing opportunities through
the exchange of information about a particular opportunity. In addition, our framework is expected to consist of conducting diligence,
creating comparative analysis, providing company information, and implementing rating systems. We believe that this information and transparency
will enable high quality, informed decisions and facilitate market integrity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Members
and Member Sponsors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our intention to build our community of participants who share the collective goal of elevating and supporting development-stage companies
and have an investor rather than a trader mindset. Persons who share the values and vision of the organization can be invited into the
community as Members. We expect to encourage active participation of our Members such that they may be mentors of growth through starting,
running, or connecting companies within the community or by being active early investors in the various business and ownership opportunities
that arise. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Efficient
Back Office Support</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an out-source
service contract with MDB Capital, S.A, an affiliated Nicaraguan company with which the Company has worked for many years. MDB
Capital, S.A. is owned by two of the principal shareholders and officers of the Company. The services that are typically out-sourced
include administrative services to support Public Ventures and PatentVest, such as back office and accounting services related to
brokerage and clearing firms, background investigations, preparing investment research reports, patent searches and analysis, and
customer support services. Services that will be requested will be only those that can be provided by an out-source company within
the context of U.S. privacy laws, FINRA regulation, and other applicable U.S. financial service and other regulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on prior Executive Orders imposing new and expanding prior sanctions on Nicaraguan businesses and on U.S. persons doing business in
Nicaragua, however, there may be disruption to our being able to contract for out-sourced services with Nicaraguan entities. Therefore,
we may have to adjust our business plan accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Self-Clearing</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024 Public Ventures
began self-clearing U.S. equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PatentVest</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PatentVest business plan
is to be a venture invention and commercialization intelligence platform specifically created to assist technologists, advisors, venture
capital investors, and established companies optimize technology commercialization. The PatentVest process takes in information from our
proprietary patent database and transforms the information about inventions and intellectual property from a complex legal process into
a manageable, measurable business process. The PatentVest process clearly defines the boundaries of an invention by providing context
for previously developed ideas and analyzes how the invention, and therefore patent claims, differ from the discovered prior art in order
to rationalize the essential distinctions that are the key value drivers. Understanding these boundaries, as well as how protectable and
valuable these boundaries are, is essential to better guide strategic business and patentability decisions. In our experience, this PatentVest
process answers the most important questions for a technology platform: how to innovate, how to improve its ideas, and how to deploy these
ideas where they matter most.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our process seeks to include
the following elements and outcomes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Improve idea prioritization &#8211; Allows inventors and financial backers to weigh the value of a given idea by ascertaining the uniqueness
of such invention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Enhance the value of an invention &#8211; Understanding invention boundaries allows patent attorneys to draft patent claims in a way
that confers the most available protection without being encumbered by prior art.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Optimize strategic decisions &#8211; Deeply understand the competitive landscape, identify issues that possible partners are trying to
solve, prioritize markets where an invention might be the most valuable, and identify possible acquirers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PatentVest
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over twenty
years ago, PatentVest&#8217;s founders recognized that intellectual property was the most valuable asset for technology companies and
began building a proprietary patent database and software platform to help companies manage these assets. During these years, PatentVest
has been continuously iterating uses for available information to potentially enable better investment decisions as well as to guide
the development of such technology once investment decisions were made. We believe that PatentVest has helped start-up companies move
from having novel ideas to becoming technology leaders. As a result, in our opinion, PatentVest is capable of providing the backbone
of an investment idea selection process, as well as forming intellectual property and business development strategies. We believe utilizing
the PatentVest Innovation in a Box process will enhance our ability to optimize our selection process with respect to partner companies
as well as when selecting underwriting candidates for Public Ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also believe that the PatentVest services will aid companies to define their intellectual property assets in their capital raising activities
and will be available to other companies that see to build their intellectual property outside of the context of working with MDB and
Public Ventures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PatentVest
Objective</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_002.jpg" alt="" style="width: 670px"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PatentVest
starts with a technology assessment, where it evaluates the technology to establish whether or not the technology is unique and a
company can create a leadership position with the identified intellectual property. Assessment is extensive covering an
investigation into the players in the particular industry space, whether the technology truly is innovating, can value be created
with the technology, what is the market and can there ultimately be value creation. The assessment phase includes an examination of
existing patents and applications, scientific publications and other public data. After the assessment, a strategy is developed,
which include where to focus R&amp;D, what to patent or keep as a trade secret, and the jurisdictions in which to protect the
intellectual property, and based on the assessment and strategy, help develop a business plan to progress the intellectual property.
PatentVest also may provide development budgets and help identify critical persons with which to work with. PatentVest is able to
implement prosecution of patents and other intellectual property, maintain surveillance of the intellectual property space, and
provide reporting on developments in the particular intellectual property space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the PatentVest process provides a fundamental advantage to helping create a leadership position for a company with unique
intellectual property. By knowing and understanding the particular intellectual property space, having a focused R&amp;D and intellectual
property development plan, a coherent business plan, and providing the related aspects of setting up a development company with the right
persons and financial backing, the success of the company in being a value creator in its industry vertical is improved. As part of this
overall process, the involvement of Public Ventures can add to the value creation with its financing resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
has been our experience when evaluating, investing in or advising technology companies that intellectual property strategy development
and related processes are most often led by attorneys and is separate from the other invention and business processes at these companies.
We have seen that this work is typically outsourced and, as a result, key company personnel are often neither engaged in the claim drafting
process nor are aware of how their patents have potentially changed during prosecution. Many of the inventors and business executives
with whom we have engaged have a modest knowledge regarding what their claims cover or what the boundaries of their claims are in relation
to other companies. We believe that it is very difficult, if not impossible, to truly understand either what a company &#8220;owns&#8221;
or to effectively evaluate a given invention&#8217;s potential uniqueness and ultimately its potential value without this perspective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the companies that will derive the greatest benefit from PatentVest&#8217;s services are technology companies with a few current
active patent applications that are expected to primarily drive the value of their companies with their inventions. The analysis and
information provided by the PatentVest process, as documented in reports to its clients, is expected to guide technology companies as
they seek to prioritize ideas and develop their intellectual property and business strategies. We believe that PatentVest not only
provides MDB with additional clarity in selecting its partner companies and Public Ventures in selecting underwriting candidates, but
also to any technology company in their decision-making processes seeking to maximize the value of their inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
PatentVest Model</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use PatentVest to help technology companies innovate and deploy their innovations in the most valuable manner as well as to support
our processes. We believe that PatentVest has one of the most comprehensive global patent databases available, containing more than 148
million patents and covering 116 countries. PatentVest has built software processes and tools that make it possible to efficiently mine
vast amounts of data and structure this data in a way that can be analyzed by its team of analysts. In addition, PatentVest has assembled
the human capital required to cost-effectively analyze such data and build the reports for companies that are expected to be the backbone
of our services. Our objective is to serve approximately 30 client companies at any one time once we have scaled our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PatentVest
has developed different report formats that provide information within context in a way that we think can be quickly processed by decision-makers
and help provide answers to the most valuable questions for the companies we target as our business development opportunities. The
insights presented in our reports are the culmination of a long, iterative process that we have refined by the constant questioning of
which data is valuable to building technology companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">PatentVest
as a Law Firm</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2022, the Supreme Court of the State of Arizona licensed
PatentVest to practice law as an Alternative Business Structure, or ABS. An ABS is a business entity that includes non-lawyers that have
an economic interest or decision-making authority in a law firm. We develop and maintain a team of highly trained legal professionals
and staff that principally provide legal services related to intellectual property matters under federal law. Matters that we are undertaking
are generally be patent prosecution and intellectual property protection. Through offering legal services we enhance the value of inventions
by addressing questions of strategy and perspective along with the technical merits of an invention. The provision of legal services by
PatentVest are limited to those technology companies specifically engaged by PatentVest for such services and is intended to provide all
the rights and privileges of the attorney-client relationship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the only other state that permits an ABS like ownership is Colorado, which is a more limited authorization than afforded by Arizona,
PatentVest will not be able to expand its Arizona ABS into other states. The focus of the PatentVest ABS is on patent issues and patent
prosecution which is largely a federal practice, therefore the restriction of its practice to the State of Arizona is not seen as a limitation.
Where it has clients that seek legal representation outside of the State of Arizona, the PatentVest ABS will make referrals to firms
licensed in appropriate jurisdictions. In late 2025, the Company commenced a process to spin off PatentVest as a separate standalone entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MDB
Minnesota One</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M1,
is a partner company, with the vision of developing a small molecule anti-senescence platform comprised of pharmaceutical drugs or
other products to aid in longevity and to inhibit certain forms of age-related diseases. The focus
of the M1 Platform is to treat <span style="background-color: white">senescent cells, which are dysfunctional cells that have
permanently stopped dividing, that have been implicated in the aging process, and that permit the development of chronic low-grade
inflammation. This chronic inflammation has been linked to a variety of age-related diseases, including multiple fibrotic conditions
that have limited treatment options and poor prognoses.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Studies
conducted at Mayo Clinic have shown the potential of certain molecules to target and eliminate senescent cells with a significant therapeutic
window, reversing fibrosis across multiple conditions. The global longevity and anti-senescence therapy market is projected to reach
nearly $45 billion by 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, M1 entered into a Patent and Know-How License Agreement (the &#8220;License Agreement&#8221;) with the Mayo Foundation
for Medical Education and Research (&#8220;Mayo&#8221;) for certain patent rights and associated technology pursuant to which M1 intends
to develop the M1 Platform. The License Agreement grants M1 rights to develop and commercialize Mayo&#8217;s patented technology and
know-how for all fields of use on a worldwide basis. Under the terms of the License Agreement, M1 holds an exclusive license of patent
rights and a non-exclusive license for the associated technology to make, have made, use, offer for sale, sell, and import licensed products
and derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of initial consideration for the License Agreement, M1 issued 1,980,000 shares of common stock equity to Mayo; which at that time
represented thirty-three percent of its shares. M1 also paid an initial license fee of $150,000 as part of the initial consideration.
M1 will pay earned royalties on future net sales (including modest minimum annual royalties, which commence in the second year of the
term of the License Agreement and gradually increase and plateau over time, and which will be credited against earned royalties due on
net sales), and a percentage of any sublicensing income. The earned royalty commences after the first commercial sale of a licensed product.
At December 31, 2025 there were no accrued royalties recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the License Agreement, M1 is required to achieve certain development milestones within designated time periods. For select development
milestones, as listed below, M1 will be required to make a payment to Mayo, also as noted below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    payment of $0.25 million for Phase II clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    payment of $1.5 million for Phase III clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    payment of $2 million for FDA New Drug Application (NDA) acceptance, for the first instance of a licensed product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    payment of $5 million for NDA approval, for each instance of a licensed product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the development milestones noted above are not required to have been met and have not been met. There are other
developmental milestones in the License Agreement relating to funding of the business and to initiating various clinical trial phases
over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M1
is currently in the pre-clinical development stage of the M1 Platform and is undertaking important feasibility studies, iterative testing,
and collection of drug safety and toxicity data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Broker-Dealer
Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
broker-dealer subsidiary, Public Ventures is subject to regulations governing every aspect of its securities business, including the
execution of securities transactions; capital requirements; record-keeping and reporting procedures; relationships with clients, including
the handling of cash and margin accounts; the experience of and training requirements for certain employees; and business interactions
with firms that are not members of regulatory bodies. As a participant in the financial services industry, it is subject to the complex
and extensive regulation of the U.S. federal and state regulatory agencies, self-regulatory organizations and securities exchanges and
certain other authorities with oversight on banking and money laundering. The laws, rules and regulations comprising the regulatory framework
applicable to broker-dealers are constantly changing, as are the interpretation and enforcement of existing laws, rules and regulations.
The effect of any such changes cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Ventures is registered as a securities broker-dealer with the SEC and is required to be a member of FINRA. FINRA is a self-regulatory
body composed of members, such as our broker-dealer subsidiary, that have agreed to abide by its rules and regulations. FINRA may expel,
fine and otherwise discipline member firms and their employees. Public Ventures is also licensed as a broker-dealer in 33 states in the
U.S., requiring it to comply with the laws, rules and regulations of each state. Additionally, Public Ventures might register in additional
states from time to time as needed. Each state may revoke the license to conduct securities business, fine, and otherwise discipline
broker-dealers and their employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Ventures is subject to the SEC&#8217;s Uniform Net Capital Rule, Rule 15c3-1, which may limit our ability to make withdrawals of capital
from the broker-dealer subsidiary. The Uniform Net Capital Rule sets the minimum level of net capital a broker-dealer must maintain and
also requires that a portion of a broker-dealer&#8217;s assets be relatively liquid. In addition, Public Ventures is subject to certain
notification requirements related to withdrawals of excess net capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to the PATRIOT Act of 2001 (the &#8220;Patriot Act&#8221;), which imposes obligations regarding the prevention and
detection of money-laundering activities, including the establishment of client due diligence, client verification and other compliance
policies and procedures. Failure to comply with these requirements may result in monetary, regulatory and, in the case of the USA Patriot
Act, criminal penalties. We are subject to the Securities Investor Protection Act of 1970, which created the Securities Investors Protection
Corporation (SIPC), which provides certain client protection to clients related to their brokerage accounts. We are subject to certain
treasury regulations, such as Regulation T, relating to how money may be lent to clients and used, and the rules related to margin accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
are also subject to ongoing duties of financial responsibility, client protection and good conduct. These include, among other things,
(i) client funds and securities must be segregated from the broker-dealer&#8217;s proprietary business operations, (ii) maintaining basic
bookkeeping requirements including records of trades, receipts, positions held in different securities, trial balances, complaints, and
compliance, together with reports to be filed periodically, (iii) executing orders on behalf of clients to ensure the best execution
possible, disclosing information relevant to investors, charging prices in line with market conditions, and disclosing conflicts of interest,
(iv) only recommending investments or strategies that are suitable for the clients concerned, (v) communicating in a fair, balanced,
and not misleading way with clients, (vi) observing rules concerning maximum value of gifts made to clients and political contributions,
and (vii) filing reports of any suspicious activities noted by the broker-dealer, including investments over predefined monetary limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
Regulation Best Interest requires that a broker-dealer and its associated persons act in a retail client&#8217;s best interest and not
place their own financial or other interests ahead of a retail client&#8217;s interests when recommending securities transactions or
investment strategies, including recommendations of types of accounts. To meet this best interest standard, a broker-dealer must satisfy
four component obligations, including a disclosure obligation, a care obligation, a conflict-of-interest obligation, and a compliance
obligation, and both broker-dealers and investment advisers are required to provide disclosures about their standard of conduct and conflicts
of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the SEC, various states have proposed or adopted laws and regulations seeking to impose new standards of conduct on broker-dealers
that, as written, differ from the SEC&#8217;s new regulations and may lead to additional implementation costs if adopted. The SEC did
not indicate an intent to preempt state regulation in this area, and some of the state proposals would allow for a private right of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
regulators, including the SEC, FINRA and state securities regulators and attorneys general, conduct both targeted and industry-wide investigations
of certain practices relating to the financial services industry, including sales and marketing practices, valuation practices, and compensation
arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
variety of data privacy laws to protect personal information obligate broker-dealers to provide notice about its data handling practices,
to offer certain opt-outs, and to implement reasonable security measures to deter unauthorized access. Broker-dealer internal and external
electronic communications may only be made on approved devices and platforms that are encrypted and secure and will capture all communications
in the broker-dealer&#8217;s records. The cost and burden of taking cybersecurity measures, having personnel oversee compliance and staying
current with respect to new technology developments continues to grow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
broker-dealer accounting, administrative and operations personnel are responsible for financial controls, internal and external financial
reporting, compliance with regulatory and legal requirements, office and personnel services, management information and telecommunications
systems, and the processing of our securities transactions. We are subject to the privacy laws applicable to financial institutions in
respect of our securities business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the securities industry, our broker-dealer subsidiary is subject to regular reviews of and investigations into our operations,
some of which progress to regulatory actions that may result in fines, censures, and limitations on activity. At this time, we are cooperating with the reviews, and we do not know whether or not it will
escalate to regulatory action and, if it does, what violations of rules and regulations may be asserted against the broker-dealer and
what the potential final resolutions might be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Self-Clearing
Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2024, Public Ventures began self-clearing U.S. equity securities. As part of this process, in addition to the broker-dealer regulation
described above, Public Ventures is subject to regulation directed to self-clearing operations and must demonstrate that its financial,
operational and systems capacities are able to perform this business while complying with regulations, including those of the SEC, FINRA,
Depository Trust Clearing Corporation (&#8220;DTCC&#8221;), and National Securities Clearing Corporation (&#8220;NSCC&#8221;). To operate
the self-clearing activity, we must meet different capitalization requirements than those of an introducing broker-dealer, maintaining
a capital structure with various cash and cash equivalent assets and retaining access to necessary lines of credit that can assure our
ability to comply with changing deposit requirements. We expect that these regulations will continue to undergo substantial changes and
may require additional capital as settlement operations moves to T+0 in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Data
Protection and Cyberattack Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of our operations and in the processing of transactions, we collect, process, store, disclose, use, share and/or transmit
personal information and other sensitive data from current, past and prospective clients as well as our employees in and across multiple
jurisdictions. The regulatory framework for privacy issues worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable
future. There are federal, state and foreign laws and regulations regarding privacy, data security and the collection, processing, use,
storage, protection, sharing and/or transmission of personal information and sensitive data. For example, the Gramm-Leach-Bliley Act
(&#8220;GLBA&#8221;) (along with its implementing regulations) restricts certain collection, processing, storage, use and disclosure
of personal information, requires notice to individuals of privacy practices and provides individuals with certain rights to prevent
the use and disclosure of certain nonpublic or otherwise legally protected information. Additionally, many states continue to enact legislation
on matters of privacy, information security, cybersecurity, data breach and data breach notification requirements. For example, as of
January 1, 2020, the California Consumer Privacy Act (&#8220;CCPA&#8221;) grants additional consumer rights with respect to data privacy
in California. The CCPA, among other things, entitles California residents to know how their personal information is being collected
and shared, to access or request the deletion of their personal information and to opt out of certain sharing of their personal information.
The CCPA is subject to further amendments pending certain proposed regulations that are being reviewed and revised by the California
Attorney General. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches
that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with,
data breach litigation. We cannot predict the impact of the CCPA on our business, operations or financial condition, but it could result
in liabilities and/or require us to modify certain processes or procedures, which could result in additional costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the California Privacy Rights Act (&#8220;CPRA&#8221;) was passed in November 2020 and went into effect in most material respects starting
on January 1, 2023. The CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the
CCPA, including by expanding clients&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new
state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the CPRA
are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial
costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect more states to enact legislation similar to the CCPA and the CPRA, which provide clients with new privacy rights and increase
the privacy and security obligations of entities handling certain personal information of such clients. The CCPA has prompted a number
of proposals for new federal and state-level privacy legislation, such as in Virginia and Colorado, both with laws that took effect in
2023. It is anticipated that all such laws will add additional complexity, have variation in requirements, restrictions and potential
legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful
data and could result in increased compliance costs and/or changes in business practices and policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our broker-dealer, Public Ventures, is subject to SEC Regulation S-P, which requires that businesses maintain policies and
procedures addressing the protection of client information and records. This includes protecting against any anticipated threats or
hazards to the security or integrity of client records and information and against unauthorized access to or use of client records
or information. SEC Regulation S-P also requires businesses to provide initial and annual privacy notices to clients describing
information sharing policies and informing clients of their rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the interpretation and application of many privacy and data protection laws are uncertain, it is possible that these laws may be interpreted
and applied in a manner that is inconsistent with our existing data management practices or the features of our services and platform
capabilities. If so, in addition to the possibility of fines, lawsuits and other claims, we could be required to fundamentally change
our business activities and practices or modify our platform, which could have an adverse effect on our business. Any violations or perceived
violations of these laws, rules and regulations by us, or any third parties with which we do business, may require us to change our business
practices or operational structure, including limiting our activities in certain states and/or jurisdictions, addressing legal claims
by governmental entities or private actors, sustaining monetary penalties, sustaining reputational damage, expending substantial costs,
time and other resources and/or sustaining other harms to our business. Furthermore, our online, external-facing privacy policy and website
make certain statements regarding our privacy, information security and data security practices with regard to information collected
from our clients or visitors to our website. Failure or perceived failure to adhere to such practices may result in regulatory scrutiny
and investigation, complaints by affected clients or visitors to our website, reputational damage and/or other harm to our business.
If either we, or the third-party service providers with which we share client data, are unable to address privacy concerns, even if unfounded,
or to comply with applicable privacy or data protection laws, regulations and policies, it could result in additional costs and liability
to us, damage our reputation, inhibit sales and harm our business, financial condition results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, we collect, process, use and retain sensitive and confidential information regarding our clients and prospective
clients, including data provided by and related to clients and their transactions, as well as other data of the counterparties to their
payments. We also have arrangements in place with certain third-party service providers that require us to share client information.
Although we devote resources and management focus to ensuring the integrity of our systems through information security and business
continuity programs, our facilities and systems, and those of third-party service providers, are vulnerable to actual or threatened external
or internal security breaches, acts of vandalism, theft, fraud or misconduct on the part of employees, other internal sources or third
parties, computer viruses, phishing attacks, internet interruptions, disruptions or losses, misplaced or lost data, ransomware, unauthorized
encryption, denial-of-service attacks, social engineering, unauthorized access, spam or other attacks, natural disasters, fires, terrorism,
war, telecommunications or electrical interruptions or failures, programming or human errors or malfeasance and other similar malicious
or inadvertent disruptions or events. We and our third-party service providers from time to time have experienced and may in the future
continue to experience such instances. In some cases, the bad actors facilitated unauthorized financial transactions. We also face security
threats from malicious third parties that could obtain unauthorized access to our systems and networks, which threats we anticipate will
continue to grow in scope and complexity over time. These events could interrupt our business or operations, result in legal claims or
proceedings, result in significant legal and financial exposure, supervisory liability under U.S. federal or state, or non-U.S. laws
regarding the privacy and protection of information, including personal information, damage to our reputation and a loss of confidence
in the security of our systems, products and services. Although the impact to date from these events has not had a material adverse effect
on us, no assurance is given that this will be the case in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
security risks in the financial services industry have increased recently, in part because of new technologies, the use of the internet
and telecommunications technologies (including mobile devices) to conduct financial and other business transactions and the increased
sophistication and activities of organized criminals, perpetrators of fraud, hackers, terrorists and other malicious third parties. In
addition to cyberattacks and other security breaches involving the theft of sensitive and confidential information, hackers, terrorists,
sophisticated nation-state and nation-state supported actors and other malicious third parties recently have engaged in attacks that
are designed to disrupt key business services, such as consumer-facing websites. We and our third-party service providers may not be
able to anticipate or implement effective preventive measures against all security breaches of these types, especially because the techniques
used to sabotage or to obtain unauthorized access to our or our third-party service providers&#8217; technology, systems, networks and/or
physical facilities in which data is stored or through which data is transmitted change frequently and because attacks can originate
from a wide variety of sources. We employ detection and response mechanisms designed to contain and mitigate security incidents. Nonetheless,
early detection efforts may be thwarted by sophisticated attacks and malware designed to avoid detection. We also may fail to detect
the existence of a security breach related to the information of our clients and to prevent or detect service interruption, system failure
or data loss. Further, as a significant number of people work from home, these cybersecurity risks may be heightened by an increased
attack surface across our business and those of our clients and third-party service providers. We cannot guarantee that our efforts,
or the efforts of those upon whom we rely and partner with, will be successful in preventing any such information security incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
access by unauthorized persons to, or the improper disclosure by us of, confidential information regarding our clients or our proprietary
information, software, methodologies and business secrets could interrupt our business or operations, result in significant legal and
financial exposure, supervisory liability, damage to our reputation or a loss of confidence in the security of our systems, products
and services, all of which could have a material adverse impact on our business. In addition, there recently have been a number of well-publicized
attacks or breaches affecting companies in the financial services industry that have heightened concern by clients, which could also
intensify regulatory focus, cause clients to lose trust in the security of the industry in general and result in reduced use of our services
and increased costs, all of which could also have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The different states and federal
government have enacted laws requiring companies to notify individuals, regulatory authorities and/or others of security breaches involving
certain types of data. In addition, our agreements with certain partners and service providers may require us to notify them in the event
of a security breach. Such mandatory disclosures are costly, could lead to negative publicity, may cause our clients, partners and service
providers to lose confidence in the effectiveness of our security measures and require us to expend significant capital and other resources
to respond to and/or alleviate problems caused by the actual or perceived security breach. A security breach of any of our vendors that
processes personal information of our clients may pose similar risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
security breach may also cause us to breach client contracts. Our agreements with certain partners and service providers may require
us to use industry-standard or reasonable measures to safeguard personal information. We also may be subject to laws that require us
to use industry-standard or reasonable security measures to safeguard personal information. A security breach could lead to claims by
our clients or other relevant stakeholders that we have failed to comply with such legal or contractual obligations. As a result, we
could be subject to legal action or our clients could end their relationships with us. There can be no assurance that the limitations
of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages, and in some
cases our client agreements may not limit our remediation costs or liability with respect to data breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
resulting from security breaches may adversely affect our business. Unauthorized access to our technology, systems, networks or physical
facilities, or those of our third-party service providers, could result in litigation with our clients or other relevant stakeholders.
These proceedings could force us to spend money in defense or settlement, divert management&#8217;s time and attention, increase our
costs of doing business or adversely affect our reputation. We could be required to fundamentally change our business activities and
practices or modify our products and/or technology capabilities in response to such litigation, which could have an adverse effect on
our business. If a security breach were to occur, and the confidentiality, integrity or availability of personal information was disrupted,
we could incur significant liability, or our technology, systems or networks may be perceived as less desirable, which could negatively
affect our business and damage our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have adequate insurance coverage with respect to liabilities that result from any cyberattacks or other security breaches or
disruptions suffered by us or third parties upon which we rely. The successful assertion of one or more large claims against us that
exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition
of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that
our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers
will not deny coverage as to any future claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we take precautions to prevent consumer identity fraud, it is possible that identity fraud may still occur or has occurred, which may
adversely affect the performance of our products and services or subject us to scrutiny or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arizona
Law Firm Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
law firm owned and operated by PatentVest is subject to the Arizona Supreme Court under Rule 31.1(c) and the Arizona Code of Judicial
Administration, or ACJA, Section 7.209, relating to Alternative Business Structures, or ABS. An ABS is an entity that includes non-lawyers
who have an economic interest or decision-making authority as defined in ACJA 7-209 which may employ, associate with, or engage a lawyer
or lawyers to provide legal services to third parties. An ABS (1) must employ at least one person who is an active member in good standing
of the State Bar of Arizona who will supervise the practice of law under the rules of the Arizona Supreme Court for the entity, (2) has
been licensed by the Arizona Supreme Court after application to the Committee on ABSs, and (3) provide legal services by persons
authorized to do so and in compliance with the Rules of Supreme Court as generally applied to the practice of law and the particular
regulations applicable to an ABS. An approval is made in favor of an ABS application if the Committee on ABSs finds that the applicant
meets, among others, the following objectives: (a) protecting and promoting the public interest; (b) promoting access to legal services;
and (c) encouraging an independent, strong, diverse, and effective legal profession. The Committee on ABSs should also find that the
applicant (a) has lawyers providing legal services to consumers that will act with the independence that is consistent with the lawyers&#8217;
professional responsibilities and standards, (b) the lawyers will make decisions in their practice that are in the best interest of clients,
(c) the ABS maintains confidentiality consistent with Arizona Rule of Supreme Court 42, and (d) the other business policies or procedures
of the ABS do not interfere with a lawyers&#8217; duties and responsibilities to clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ABS is also subject to all the rules and regulations associated with the ethical rules of a law firm operating in the State of Arizona.
These rules are found in Section 7-209 of the Code of Judicial Administration and the Arizona Supreme Court Rules. Together the rules
address issues relating to (i) conflict of interest situations for client representation, (ii) issues relating to the sale of a law practice,
(iii) law firm owner responsibilities such as for having sufficient managerial authority, effective internal policies and procedures,
and procedures for the conformity of law employees to the rules of professional conduct and procedures for non-law employees, and (iv)
adequate trust account requirements, including the annual certification requirement. The rules also address code of conduct issues such
as lawyer independence in the provision of services, the diligent and promptness of rendering legal services, and record maintenance,
among others. An ABS and its law employees are subject to the disciplinary rules 46 et. seq. of the Arizona Supreme Court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the only other state that permits an ABS like ownership is Colorado, which is a more limited authorization than afforded by Arizona,
PatentVest will not be able to expand its Arizona ABS into other states. The focus of the PatentVest ABS, however, is on patent issues
and patent prosecution, which is largely a federal practice, therefore the restriction of its practice to the State of Arizona is not
seen as a limitation on its operations. Where it has clients that seek legal representation outside of the State of Arizona, the PatentVest
ABS will make referrals to firms licensed in appropriate jurisdictions. In recent months, certain states have sought to restrict or limit business dealings with firms based in Arizona and to require fee-sharing
arrangements with local entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>U.S.
Foreign Corrupt Practices Act</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and individuals from engaging in certain activities to obtain
or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the
payment of anything of value to any foreign government official, government staff member, political party or political candidate in an
attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes
interactions with certain healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that
impose similar obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of filing this Annual Report on Form 10-K, overall there are 14 full time employees of MDB, employed directly or indirectly through MDB
CG Management, Inc. (&#8220;MDB Management&#8221;). We also engage from time-to-time consultants for various activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB
Management also has an agreement with MDB Capital S.A., an affiliated Nicaraguan company, for MDB Capital S.A. to provide services to
the Company on an out-source, as required service basis, overall there are 40 full time contractors assigned to MDB. The services are provided on a specific request, within an identified scope
of activity, from time to time. Primarily the services are administrative support services, research activities, and analytical services
as necessitated by the holding company, Public Ventures, PatentVest and partner companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our business develops, we establish partner companies and we enhance our operations, we anticipate the number of employees and consultants
will grow. In addition, we also anticipate adding human capital contractors, consultants, clinical research organizations and collaborative
businesses to perform clinical studies, toxicology assessment, manufacturing, regulatory, and other operational functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings
arising in the ordinary course of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Holding Company Taxation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
may be subject to U.S. federal income tax on your share of our taxable income, regardless of whether you receive any cash distributions
from us.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class A Common Shares are securities issued by a limited liability company and represent limited liability interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
current law, so long as certain conditions are satisfied, we should be treated, for U.S. federal income tax purposes, as a partnership and not as a corporation. As such,
MDB will generally not be subject to U.S. federal income tax. Instead, each shareholder of MDB will be required to take into account
its allocable share of each item of MDB&#8217;s income, gain, loss, deduction or credit, whether or not MDB distributes any cash to it,
including distributions or dividends MDB receives from its corporate entities (i.e., in partner companies). Consequently, it is possible
that in any year, a shareholder&#8217;s tax liability arising from MDB could exceed the distributions made to him, her or it by MDB.
Thus, there may be years in which a shareholder&#8217;s tax liability exceeds its share of distributed cash from MDB. If this were to
occur, a shareholder would have to use funds from other sources to satisfy his, her or its tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
may be subject to state, local and other taxes, depending on your own particular circumstances.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to U.S. federal income taxes, each shareholder may incur income tax liabilities under the state or local income tax laws of
certain jurisdictions in which MDB will operate, as well as in the jurisdiction of that shareholder&#8217;s residence or domicile. State
and local income tax laws vary from one location to another, and federal, state and local income tax laws are both complex and subject
to change. The income tax aspects of an investment in MDB are complicated, and each shareholder should review them with his, her or its
own professional advisors familiar with the shareholder&#8217;s own income tax situation and with the income tax laws and regulations
applicable to the shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocations
of income and loss may be re-determined by the IRS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder&#8217;s distributive share of MDB income, gains, losses, deductions and credits for U.S. federal income tax purposes is generally
determined as set forth in the limited liability company agreement governing our company, which we refer to as the operating agreement,
unless such items are allocated in a manner that has no &#8220;substantial economic effect.&#8221; If it is determined that the allocations
in the operating agreement do not possess substantial economic effect, then the IRS might seek to allocate MDB related items in a different
manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MDB
may provide delayed final Schedules K-1.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDB
may not be able to provide final Schedules K-1 to shareholders for any given fiscal year until after April 15 of the following year.
The board of directors will endeavor to provide shareholders with final Schedules K-1 or with estimates of the taxable income or loss
allocated to their shares on or before April 15, but final Schedules K-1 may not be available until MDB has received tax&#8211;reporting
information necessary to prepare final Schedules K-1. Shareholders may be required to obtain extensions of time to file their U.S. federal,
state, and local income tax returns (which do not provide taxpayers with an extension of time to pay any tax that may be due on such
tax returns). Each prospective shareholder should consult with its own advisor as to the advisability and tax consequences of an investment
in MDB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are treated as a corporation for U.S. federal income tax purposes, the value of the shares could be materially adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the Class A Common Shares of MDB that you hold will depend in part on MDB being treated as a partnership for U.S. federal income
tax purposes. We intend to manage our affairs so that, upon becoming a &#8220;publicly traded partnership&#8221; within the meaning of
Section 7704 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), we will not be taxable as a corporation because
90% or more of our gross income in each taxable year will be &#8220;qualifying income&#8221;. However, there is no assurance or guarantee that we will meet on an ongoing basis the applicable requirements to be taxable
as a partnership and, as discussed below, current law may change so as to cause, in either event, MDB to be treated as a corporation
for U.S. federal income tax purposes. If we were treated as a corporation for U.S. federal income tax purposes, then, among other things,
(i) we would become subject to corporate income tax and (ii) distributions to our shareholders would be taxable as dividends for U.S.
federal income tax purposes to the extent of our earnings and profits. In addition, because a tax would be imposed upon MDB as a corporation,
its cash available for distribution would be substantially reduced. We have not requested, and do not plan to request, a ruling from
the IRS on this or any other tax matter affecting us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
structure involves complex provisions of U.S. federal and state income tax law for which no clear precedent or authority may be available.
Our structure is also subject to potential legislative, judicial or administrative change and differing interpretations, possibly on
a retroactive basis.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal income tax treatment of holders of our common shares, including the Class A Common Shares representing limited liability
interests, depends in some instances on determinations of fact and interpretations of complex provisions of U.S. federal income tax law
for which no clear precedent or authority may be available. You should be aware that the U.S. federal and state income tax rules are
constantly under review by persons involved in the legislative process, the IRS and the U.S. Treasury Department, and state governments
frequently resulting in revised interpretations of established concepts, statutory changes, revisions to regulations and other modifications
and interpretations. The IRS pays close attention to the proper application of tax laws to partnerships and entities taxed as partnerships.
The present U.S. federal income tax treatment of an investment in our shares may be modified by administrative, legislative or judicial
interpretation at any time, and any such action may affect investments and commitments previously made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Complying
with certain tax-related requirements may cause us to forego otherwise attractive business or investment opportunities or enter into
acquisitions, borrowings, financings or arrangements we may not have otherwise entered into.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for us to be treated as a partnership for U.S. federal income tax purposes, and not as a publicly traded partnership taxable as
a corporation, we expect that at least 90% of our gross income in each taxable year will need to be &#8220;qualifying income&#8221; on
a continuing basis and we must not be, if we were a corporation, required to register as an investment company under the Investment Company
Act. In order to obtain such treatment, we (or our subsidiaries) may decide to forego attractive business or investment opportunities.
This may cause us to incur additional tax liabilities and/or adversely affect our ability to operate solely to maximize our cash flow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders
may be subject to restrictions on deductibility of expenses and other losses.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the shareholders to utilize any tax losses generated by an investment in MDB may be subject to a number of limitations under
the Code, including the basis limitations, the passive activity loss limitations, the &#8220;at-risk&#8221; limitations, and the excess
business loss limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
legislative or regulatory action could significantly change the tax aspects of an investment in our shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion of tax aspects contained in this filing is based on law currently in effect and certain proposed Treasury Regulations. Nonetheless,
shareholders should be aware that new administrative, legislative or judicial action could significantly change the tax aspects of an
investment in our shares. Any such change may be retroactive with respect to transactions entered into or contemplated before the effective
date of such change and could have a material adverse effect on the tax consequences of your investment in MDB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our General Business Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Although
our partner company model has been successful in the past, there is no assurance that we will continue to be successful in selecting
our partner companies or that these partner companies will generate income returns at the same or similar levels as those of our prior
partner companies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that MDB will continue to be as successful as when our broker-dealer business was operating as a single, stand-alone
business. As a reorganized holding company, we have a limited operating history. We believe that because of the reorganization of our
Company, we are subject to some or all of the risks inherent in the establishment of a new enterprise. Some of the risks may arise from
the absence of a significant consolidated operating history, the addition of management responsibilities as a public company, including
the production of K-1 tax documents for owners of the Company&#8217;s shares, and lack of experience in complying with reporting and
other obligations associated with being a publicly traded company listed on Nasdaq. If our business plan, operating as a holding company,
turns out to be unsuccessful, investors may lose some or all of their investment in MDB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
in MDB are cautioned that the past successes of the management as executed via their privately held broker-dealer business are no assurance
that the newly re-reorganized company will continue to have the same successes or result in same value creation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
might require additional capital to support operations and business growth and to fund our partner companies; this capital might not
be available on terms favorable to us, or all, when needed.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have funded MDB operations since inception in 2022 primarily through equity financings and revenue generated by the services provided
through Public Ventures. We cannot be certain when or if our operations will generate sufficient cash to fully fund our ongoing operations
or the growth of our business. We intend to continue to make investments in our business, particularly in our partner companies, to respond
to business opportunities and challenges, including developing new products and services, enhancing our operating infrastructure, expanding
our operations, and acquiring complementary businesses and technologies. All of the foregoing may require us to secure additional funds.
Additional financing may not be available on terms favorable to us, if at all. If we incur additional debt, or issue preferred equity
securities, the holders of these debt or preferred security holders would have rights senior to holders of our equity to make claims
on our assets, and the terms of any debt could restrict our operations, including our ability to make distributions on our equity. Because
our decision to raise capital in the future will depend on numerous considerations, including factors beyond our control, we cannot predict
or estimate the amount, timing, dilutive effect or nature of any future issuances of securities. As a result, our equity holders bear
the risk that future issuances of debt or equity securities could reduce the value of our Class A Common Shares and dilute their interests.
Our inability to obtain adequate financing or financing on terms satisfactory to us, when we require it, could significantly limit our
ability to continue supporting our business growth and responding to business opportunities and challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business depends upon our ability to make good decisions regarding the deployment of capital into new or existing partner companies and,
ultimately, the performance of our partner companies, both of which are uncertain.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we make poor decisions regarding the deployment of capital into new or existing partner companies, our business model will not succeed.
Our success as a holding company ultimately depends on our ability to choose the right partner companies, develop these companies, such
that these partner companies are operationally successful. If one or more of our partner companies does not succeed, the value of our
assets could be significantly reduced resulting in substantial impairments or write-offs, which could cause the results of our operations
and the price of our Class A Common Shares to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks relating to our partner companies include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
most of our partner companies have a history of operating losses and a limited operating history;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the new technologies that our partner companies attempt to develop and launch commercially may never be developed or may never adequately
developed to be commercial or even if commercially developed, may not be accepted in the marketplace;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the new technologies that our partner companies develop may not be accepted quickly enough or broadly enough resulting in additional
need funding to sustain the partner company or the decision to abandon the business at a loss;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
intensifying competition affecting the products and services that our partner companies offer could adversely affect their businesses,
financial condition, results of operations, cash flows and prospects for growth;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
technologies of our partner companies that are subject to regulatory examination, testing and approval, may not be approved by any required
regulatory authorities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inability to adapt to the rapidly changing marketplaces;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inability to manage growth;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the need for additional capital to fund partner company operations, which we may not be able to fund or which may not be available from
third parties on acceptable terms, if at all;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inability to protect partner company intellectual property rights and/or the costs and limitations that partner companies infringe on
the intellectual property rights of others;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inability to put into place, monitor and maintain appropriate compliance programs related to employees, safety or other regulatory requirements
which could result in legal liability, bad press and significant additional costs to investigate, address and remediate such issues;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
certain of our partner companies could face legal liabilities from claims made against them based upon their operations, products or
work;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the impact of economic downturns on their operations, results and growth prospects;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inability to attract and retain qualified personnel; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business model does not rely upon the receipt of operating cash flows from our partner companies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
public venture business model does not rely upon the receipt of operating cash flows from our partner companies. We anticipate that our
partner companies, while we own them and they are developing their businesses, will not generate revenues or positive cash flow. To the
extent that our partner companies generate any cash from operations, they will retain the funds to develop their own businesses. Our
overall day to day operations will rely on cash on hand, dividends from the operation of Public Ventures and PatentVest, and our ability
to generate capital from capital raising activities to finance our overall operations and fund the partner companies. If we need capital
to fund current and new partner companies, we will seek to raise additional capital. If we are unable to find ways of monetizing our
holdings or to raise additional capital on attractive terms, we may face liquidity issues that will require us to curtail our new business
efforts, constrain our ability to execute our business strategy, and limit our ability to provide financial support to our existing partner
companies. We may also finance our partner companies through their securities offerings or selling, licensing, or joint venturing their
businesses. There is no assurance that we will be able to raise any such funding or funding in sufficient amounts to support the early
stages of development of our partner companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 60pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
success depends, in part, on the successful development of our partner companies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this time, we cannot identify the various specific risks that our partner companies will face other than the challenges typically faced
by early-stage companies, as well as risks related to general regulatory issues, general technology and product development issues, meeting
capital requirements, and market approach and penetration issues that all such early stage and development companies will face in their
evolution. To the extent that any of our partner companies fail during the development phase or experience delay until they reach a point
where they are able to successfully market their technologies or products in a financially sustainable way, our investment in those partner
companies and your investment in MDB will be impaired, and you may sustain a loss in your investment and return on investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be successful, we will need to grow the current businesses and grow the overall size of MDB and, more particularly, the number and businesses
of partner companies. Our success will depend on finding and nurturing early-stage companies and transforming them into successful companies
through our managerial and funding resources, including sources of external funding. Expanding the number of partner companies will impose
significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate
additional employees at the MDB (parent) level and at the partner company level. In addition, our management may have to divert a disproportionate
amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities
at our partner companies. Our future financial and business performance and our ability to compete effectively will depend, in part,
on our ability to effectively manage our future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
partner companies are expected to be early-stage development companies, which will make it difficult to judge and evaluate their
businesses and their future success.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
partner companies are and will continue to be early-stage companies, none of which, it is anticipated, initially will have any finalized
products or well-defined development, intellectual property, marketing or distribution plans. Because of these factors and the absence
of an operating history, it will be difficult for potential investors to fully evaluate the planned technologies and prospective operations
and future potential of our partner companies. As early-stage companies, they will be subject to all the risks inherent in the initial
organization, financing, expenditures, complications and delays associated with new businesses. Investors should evaluate an investment
in us in light of all of the risks inherent and uncertainties encountered by early-stage companies operating in competitive environments.
There can be no assurance that our efforts to finance and nurture our partner companies will be successful or that any of our partner
companies will ultimately develop their products to a point where the companies reach profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>One
of our subsidiaries, Public Ventures, is subject to Securities and Exchange Commission and FINRA regulation, DTC participant requirements,
and settlement bank agreements, and, if not compliant with those regulations, may be subject to fines, limitations on activity and financial
impairment.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of our subsidiaries is a securities broker-dealer, subject to a wide range of regulations under the oversight of the Securities and Exchange
Commission, FINRA and state securities regulators, and other financially-oriented governmental authorities. To conduct its clearing operations,
it is subject to DTCC participant requirements and the terms of its settlement bank agreements. Public Ventures is currently subject
to regulations related to its status as a broker-dealer and is subject to all the regulatory requirements of the Securities and Exchange
Commission applicable to our securities clearing operations. As is common in the securities industry, we are subject to regular reviews
of and investigations into our operations, some of which progress to regulatory actions that may result in fines, censures, and limitations
on activity. Currently, we are the subject of a review of past broker-dealer activities, which may be either resolved or escalated. We
do not know at this time whether this review will be escalated to regulatory action, and if it is, what the regulatory assertions would
be and what the resolution of such assertions might be. Any adverse result may impair the value of the overall company and a loss of
investment value in MDB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
partner companies are likely to be operating in businesses that are subject to extensive regulation, which if not compliant with those
regulations may be subject to fines, limitations on activity and financial impairment.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
partner companies will likely be subject to a large range of regulations, especially if they are engaged in development of medical or
pharmaceutical therapies, medical devices and technologies subject to export and import controls. The failure to adhere to any applicable
laws or regulations relating to their business conduct may result in investigations, fines, limitations on activities and recalls. The
partner company subject to these kinds of sanctions, and possibly MDB, also could suffer from development, marketing, financial and reputational
damage. There may be consequential impairment of the value of the overall company and a loss of investment value in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
plan to operate as a company not regulated under the Investment Company Act of 1940. We may have to buy, sell or retain assets when we
would otherwise not wish to do so in order to avoid registration under the Investment Company Act.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our operations are not subject to the Investment Company Act of 1940 (the &#8220;Investment Company Act&#8221;). We do not hold
ourselves out as conducting the business of investing, reinvesting or trading in securities. Rather, we found, own and operate our partner
companies to help them develop their businesses. We will have control of our partner companies through a majority ownership position,
by being actively engaged on the board of directors and by being involved in the certain management decision processes of the partner
companies. We are actively engaged in the development of these companies including creation of the business strategy and path to value
creation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Investment Company Act regulates companies that are engaged in the business of investing, reinvesting, owning, holding or trading in
securities. Under the Investment Company Act, a company may be deemed to be an investment company if it owns investment securities with
a value exceeding 40% of the value of its total assets (excluding government securities and cash items) on an unconsolidated basis, unless
an exemption or safe harbor applies. We refer to this test as the &#8220;40% Test.&#8221; Securities issued by companies other than majority-owned
partner companies are generally considered &#8220;investment securities&#8221; for the purpose of the Investment Company Act, unless
other circumstances exist, such as the holding company management being actively involved in the management of the underlying company.
Additionally, there may be other exemptions that we might be eligible to use to avoid regulation under the Investment Company Act. As
a company that builds value by cofounding early-stage technology and life sciences companies, we believe we are not engaged in the business
of investing, reinvesting or trading in securities. Consequently, we do not believe that we are not now and will not be an investment
company under the Investment Company Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are monitoring our compliance with the 40% Test and conduct our business activities to comply with this test and other exemptions such
that we are exempt from the Investment Company Act. It is not feasible for us to be regulated as an investment company because the Investment
Company Act rules are inconsistent with our strategy of actively helping our partner companies in their efforts to build value. We may
need to take various actions, however, that we would otherwise not pursue in order to remain in compliance with the 40% Test. For example,
we may need to retain a majority interest in a partner company that we no longer consider strategic, we may not be able to acquire an
interest in a company unless we are able to obtain a majority ownership interest in the company, or we may be limited in the manner or
timing in which we sell or distribute our interests in a partner company. Our ownership levels also may be affected if our partner companies
are acquired by third parties or if our partner companies issue stock which dilutes our majority ownership. The actions may require us
to take actions to avoid application of the Investment Company Act of 1940 so as to maintain compliance with the 40% Test that could
adversely affect our ability to create and realize value at our partner companies. The Company&#8217;s Broker-Dealer subsidiary is excluded from the Investment Company Act of 1940, and therefore all securities held by
the Broker-Dealer are excluded from the asset calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
ability to retain our senior professionals and recruit additional professionals is critical to the success of our business, and our failure
to do so may adversely affect our reputation, business, results of operations, cash flows and financial condition.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
people are one of our most valuable resources. Our ability to source attractive technologies and companies to deploy our capital
depends upon the reputation, judgment, and execution skills of our senior professionals, particularly our directors and senior
management. Despite our efforts to retain valuable employees, members of our management team may terminate their employment with us
on short notice. The loss of the services of any of our executive officers or other key employees could potentially harm our
business, operating results, cash flows or financial condition. Currently, we do not maintain key man insurance policies with
respect to any of our executive officers or employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Adverse Impact of U.S. and Nicaraguan Political and Regulatory Environments on Our Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations are subject to risks associated with the political, economic, and regulatory environments in both the United States
and Nicaragua, where we conduct business. Any changes in government policies, regulations, or political instability in either country
could have a material adverse effect on our ability to operate effectively and profitably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, shifts in trade policies, foreign relations, and regulatory frameworks may impact our ability to do business in Nicaragua.
Additionally, any restrictions on international trade, sanctions, or policy changes affecting business dealings with Nicaragua could
increase costs or limit our ability to operate within the country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Nicaragua, political instability, civil unrest, or changes in government leadership could lead to policy shifts, economic uncertainty,
or regulatory changes that impact our business. Potential risks include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in the list of sanctioned countries where U.S. businesses and individuals are restricted or prohibited from engaging in trade, investment,
    or other business activities. These restrictions are primarily enforced by the U.S. Department of the Treasury&#8217;s Office of
    Foreign Assets Control (OFAC) and are based on economic sanctions, national security concerns, and foreign policy objectives.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expropriation
    or nationalization risks, which could result in asset seizures or limitations on foreign-owned businesses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Civil
    unrest or political turmoil that may disrupt workforce availability or local market stability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the political or economic environment in either country deteriorates or if new regulations are imposed that negatively impact our ability
to conduct business in Nicaragua, our financial condition, results of operations, and growth prospects could be materially and adversely
affected. We continue to monitor political developments and assess potential risks to mitigate any significant impacts on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We out-source aspects of our business operations
in Nicaragua.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged an affiliated
company, MDB Capital S.A., located in Nicaragua to provide specific services from time to time, on an as out-source, as requested basis.
Currently, we believe that the Company, PatentVest and our partner companies will use the service company for various activities. We believe
that having services performed on a contract basis in Nicaragua will provide cost benefits for our operations in the United States that
will enhance our business operational competitiveness. In order to function effectively and efficiently when engaging companies in Nicaragua,
we believe that we will have to help train the persons responsible for our service requests so as to have available when needed knowledgeable
staffing for our projects. There can be no assurance that our out-sourcing these contract services in Nicaragua will be at competitive
and at cost saving rates or that we will be able to find the services there that are able to carry out the required functions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not we will be
able to continue to use out-sourcing companies located in Nicaragua will depend on the extent that the United States imposes restrictions
on US persons and entities engaging in commerce with companies that employ Nicaraguan persons or are located in Nicaragua. Currently there
are Executive Orders in place that restrict immigration of designated groups of individuals into the United States and restrictive sanctions
on certain trade-related activities between United States and Nicaragua. In conjunction with the Executive Orders, other departments of
the United States government have imposed complimentary sanctions on activities under their jurisdictions to expand the effect of the
Executive Orders. The effect and extent of the sanctions, including Executive Order 13851, dated October 24, 2022, is not yet known, but
could potentially prohibit both imports from and exports to Nicaragua. Whether these sanctions will be interpreted to include a prohibition
on our current and proposed service arrangements to be provided by companies and persons in Nicaragua is yet unknown. But if the sanctions
extend to our out-source service arrangements with Nicaraguan persons and entities, we will face disruption obtaining certain services,
and we will have to find replacement service providers or personnel. We may have difficulty in finding qualified, competent replacements
for those functions fulfilled by our Nicaraguan contract party. If we have to find those kinds of replacements, we also would expect our
costs to increase, thereby losing the advantage of our Nicaraguan resources.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our significant and concentrated equity investment in eXoZymes.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s equity investment in eXoZymes represents a significant portion of our total assets and is reported as an equity method
investment on our balance sheet. As such, fluctuations in the value of this investment may have a material impact on our financial position
and the results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
November 2024, eXoZymes has been a publicly traded company and its operational and strategic decisions have been directed by its board
and management. As a public company its stock price is determined by the market and investor reaction to its product developmental
decisions and performance. The actual performance of eXoZymes will depend on many factors, such as its product discovery and development,
its ability to enter into strategic alliances or licensing arrangements, its ability to generate revenues, the maintenance of its financial
resources, regulatory compliance and developments that impact its products, and broader economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
as eXoZymes is in an early stage of its commercial development, its financial performance may be unpredictable, and periods of volatility
or underperformance may result in non-cash losses and/or impairment charges on our investment. A sustained decline in the value of our
investment could also negatively affect key financial ratios and limit our ability to raise additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the size and concentration of our investment in eXoZymes, any material change in its value&#8212;positive or negative&#8212;will directly
affect our financial statements, potentially causing significant variability in our reported earnings and equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, investors should consider the inherent risks associated with holding a large, concentrated, and volatile equity investment
when evaluating our financial condition and future prospects and a decision to invest or hold an investment in our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>There
may be securities market risks resulting from owning the equity securities of our partner companies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we are not engaged
in the business of investing, reinvesting, or trading in securities, we will own a controlling or other positions in our partner companies
pursuant to our business model. We generally will be active in the management and development of our partner companies, as well as actively
monitoring their operations to keep abreast of their business development. In time, we anticipate that we will monetize the value we hold
in our partner companies. Our monetization process will contemplate the typical forms of merger and acquisition transactions, such as
licensing, private and public offerings, asset or company sales and registered common stock distributions. To the extent that any of our
partner companies become publicly traded, their value will become subject to market fluctuations. Any fluctuation in the value of our
partner companies&#8217; securities, for whatever reason, may affect the value of MDB as a holding company resulting in a partial or total
loss of your investment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
could experience competition from other potential acquirers when we seek to establish partner companies, which may result in not being
able to acquire them or having to invest at a higher valuation, thus increasing our risk of loss and reducing potential future gains.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we will face competition from other capital providers and acquisition-oriented entities as we seek to acquire and develop
our partner companies. Some of our competitors have more experience identifying and acquiring companies in various industries and have
greater financial and management resources, brand name recognition or industry contacts than we possess. We compete with those firms
on a number of factors, including our history and reputation, our ability to partner, encourage and support development of each company,
the abilities and experience of our professionals in working with development-stage companies, and our ability to source and perform
due diligence on new technologies and companies. In addition, even though we seek to acquire technologies at their very early stages
of development, we may still pay higher prices in our acquisitions and partner company creation because of competition from other potential
acquirers and higher valuations. This could increase the risk of loss and result in lower gains to the holding company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be limited in our ability to attract and continue to employ personnel engaged by our partner companies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to recruit and retain existing and future personnel for our partner companies, we may need to increase the level of compensation
that we pay and have to use equity grants as incentives. As our partner companies are subsidiaries, we may not be able to use the value
of the partner company for equity grants and similar compensation arrangements. We may have to deploy other incentives, such as higher
salaries, better benefits or equity in MDB. Any of these may adversely affect the value of MDB or increase our consolidated expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to maintain a work environment that reinforces our culture of collaboration, motivation and alignment of interests with investors.
The effects of becoming public, including potential changes in our compensation structure, could adversely affect this culture. If we
do not continue to develop and implement the right processes and tools to manage our changing enterprise and maintain our culture, our
ability to compete successfully and achieve our business objectives could be impaired, which could negatively impact our business, financial
condition, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>There
is significant competition for the time and capital of our community members and they have no obligation to continue to own MDB member
interests, or participate in the development of the partner companies as envisioned by our business model.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will rely on our community of sophisticated investors that have experience with our public venture approach for partner company formation,
development and funding. There is competition for their time and capital. There is no obligation for an investor that is part of our
community to continue to participate in our public venture approach or even to hold securities of MDB. As is common, investors will circulate
in and out of our community as their interests change over time. The loss of a prominent or an active community participant may diminish
the effectiveness of our community and may lead others to change their participation level within the community.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of Ukrainian and Israeli Conflict</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we believe that the conflicts involving the Ukraine and Israel do not have any direct impact on our operations, financial condition or
financial reporting. We believe the conflicts will have only a general impact on our operations in the same manner as it is having a
general impact on all businesses that have their operations in North America as a result of international sanctions and embargo regulations,
possible shortages of goods and goods incorporating parts that may be supplied from the Ukraine, Russia or Israel, supply chain challenges,
and the international and US domestic inflationary results of the conflict and government spending for and funding of our country&#8217;s
response. We do not believe we will be targeted for cyber-attacks in connection with the conflicts, but as a financial institution, we
are aware that we may be a general target for cyber-attacks. We have no operations in the countries directly involved in the conflicts
or are specifically impacted by any of the sanctions and embargoes, as we principally operate in the United States. Other than general
securities market trends, we do not have reason to believe that investors will evaluate the company as having special risks or exposures
related to the conflicts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impact of the Iran Conflict</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we believe that the ongoing military conflict involving Iran (the &#8220;Iran Conflict&#8221;), including
actions by the United States and Israel, does not have any direct impact on our operations, financial condition or financial reporting.
We believe the conflict will have only a general impact on our operations in the same manner as it is having a general impact on all businesses
that have their operations in North America as a result of international sanctions and embargo regulations, possible disruptions to global
energy supplies and oil prices due to tensions in the Strait of Hormuz and the Middle East region, shortages of goods and supply chain
challenges, and the international and US domestic inflationary results of the conflict and government spending for and funding of our
country&#8217;s response. We do not believe we will be specifically targeted for cyber-attacks in connection with the conflict, but as
a financial institution, we are aware that we may be a general target for cyber-attacks, including potentially from state-sponsored actors
associated with the conflict. We have no operations in Iran or the countries directly involved in the conflict and are not specifically
impacted by any of the sanctions and embargoes, as we principally operate in the United States. Other than general securities market trends,
we do not have reason to believe that investors will evaluate the company as having special risks or exposures related to the conflict.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
collection, processing, use, storage, sharing and transmission of personal information and other sensitive data are subject to stringent
and changing state, federal and international laws, regulations and standards and policies and could give rise to liabilities as a result
of our failure or perceived failure to protect such data, comply with privacy and data protection laws and regulations or adhere to the
privacy and data protection practices that we articulate to our clients.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of our operations and the processing of transactions, we collect, process, store, disclose, use, share and/or transmit personal
information and other sensitive data from current, past and prospective clients as well as our employees in and across multiple jurisdictions.
The regulatory framework for privacy issues worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future.
There are federal, state and foreign laws and regulations regarding privacy, data security and the collection, processing, use, storage,
protection, sharing and/or transmission of personal information and sensitive data. For example, the Gramm-Leach-Bliley Act (&#8220;GLBA&#8221;)
(along with its implementing regulations) restricts certain collection, processing, storage, use and disclosure of personal information,
requires notice to individuals of privacy practices and provides individuals with certain rights to prevent the use and disclosure of
certain non-public or otherwise legally protected information. Additionally, many states continue to enact legislation on matters of privacy,
information security, cybersecurity, data breach and data breach notification requirements. For example, as of January 1, 2020, the California
Consumer Privacy Act (&#8220;CCPA&#8221;) grants additional consumer rights with respect to data privacy in California. The CCPA, among
other things, entitles California residents to know how their personal information is being collected and shared, to access or request
the deletion of their personal information and to opt out of certain sharing of their personal information. The CCPA is subject to further
amendments pending certain proposed regulations that are being reviewed and revised by the California Attorney General. The CCPA provides
for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal
information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. We cannot
predict the impact of the CCPA on our business, operations or financial condition, but it could result in liabilities and/or require
us to modify certain processes or procedures, which could result in additional costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the California Privacy Rights Act (&#8220;CPRA&#8221;) was passed in November 2020 and it will be effective in most material respects
starting on January 1, 2023. The CPRA imposes additional obligations on companies covered by the legislation and will significantly modify
the CCPA, including by expanding clients&#8217; rights with respect to certain sensitive personal information. The CPRA also creates
a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the
CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial
costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect more states to enact legislation similar to the CCPA and the CPRA, which provide clients with new privacy rights and increase
the privacy and security obligations of entities handling certain personal information of such clients. The CCPA has prompted a number
of proposals for new federal and state-level privacy legislation, such as in Virginia and Colorado, both with laws to take effect in
2023. It is anticipated that all such laws will add additional complexity, have variation in requirements, restrictions and potential
legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful
data and could result in increased compliance costs and/or changes in business practices and policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our broker-dealer, Public Ventures is subject to SEC Regulation S-P, which requires that businesses maintain policies and procedures
addressing the protection of client information and records. This includes protecting against any anticipated threats or hazards to the
security or integrity of client records and information and against unauthorized access to or use of client records or information. Regulation
S-P also requires businesses to provide initial and annual privacy notices to clients describing information sharing policies and informing
clients of their rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the interpretation and application of many privacy and data protection laws are uncertain, it is possible that these laws may be interpreted
and applied in a manner that is inconsistent with our existing data management practices or the features of our services and platform
capabilities. If so, in addition to the possibility of being subjected to fines, lawsuits and other claims, we could be required to fundamentally
change our business activities and practices or modify our platform, which could have an adverse effect on our business. Any violations
or perceived violations of these laws, rules and regulations by us, or any third parties with which we do business, may require us to
change our business practices or operational structure, including limiting our activities in certain states and/or jurisdictions, addressing
investigations or being subjected to legal claims by governmental entities or private actors, sustaining monetary penalties, sustaining
reputational damage, expending substantial costs, time and other resources and/or sustaining other harms to our business. Furthermore,
our online, external-facing privacy policy and website make certain statements regarding our privacy, information security and data security
practices with regard to information collected from our clients or visitors to our website. Failure or perceived failure to adhere to
such practices may result in regulatory scrutiny and investigation, complaints by affected clients or visitors to our website, reputational
damage and/or other harm to our business. If either we, or the third-party service providers with which we share client data, are unable
to address privacy concerns, even if unfounded, or to comply with applicable privacy or data protection laws, regulations and policies,
it could result in additional costs and liability to us, damage our reputation, inhibit sales and harm our business, financial condition,
results of operations, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cyberattacks
and other security breaches or disruptions suffered by us or third parties upon which we rely could have a materially adverse effect
on our business, harm our reputation and expose us to public scrutiny or liability.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, we collect, process, use and retain sensitive and confidential information regarding our clients and prospective
clients, including data provided by and related to clients and their transactions, as well as other data of the counterparties to their
payments. We also have arrangements in place with certain third-party service providers that require us to share client information.
Although we devote resources and management focus to ensuring the integrity of our systems through information security and business
continuity programs, our facilities and systems, and those of third-party service providers, are vulnerable to actual or threatened external
or internal security breaches, acts of vandalism, theft, fraud or misconduct on the part of employees, other internal sources or third
parties, computer viruses, phishing attacks, internet interruptions, disruptions or losses, misplaced or lost data, ransomware, unauthorized
encryption, denial-of-service attacks, social engineering, unauthorized access, spam or other attacks, natural disasters, fires, terrorism,
war, telecommunications or electrical interruptions or failures, programming or human errors or malfeasance and other similar malicious
or inadvertent disruptions or events. We and our third-party service providers from time to time have experienced and may in the future
continue to experience such instances. In some cases, the bad actors facilitated unauthorized financial transactions. We also face security
threats from malicious third parties that could obtain unauthorized access to our systems and networks, which threats we anticipate will
continue to grow in scope and complexity over time. These events could interrupt our business or operations, result in legal claims or
proceedings, result in significant legal and financial exposure, supervisory liability under U.S. federal or state, or non-U.S. laws
regarding the privacy and protection of information, including personal information, damage to our reputation and a loss of confidence
in the security of our systems, products and services. Although the impact to date from these events has not had a material adverse effect
on us, no assurance is given that this will be the case in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
security risks in the financial services industry have increased recently, in part because of new technologies, the use of the internet
and telecommunications technologies (including mobile devices) to conduct financial and other business transactions and the increased
sophistication and activities of organized criminals, perpetrators of fraud, hackers, terrorists and other malicious third parties. In
addition to cyberattacks and other security breaches involving the theft of sensitive and confidential information, hackers, terrorists,
sophisticated nation-state and nation-state supported actors and other malicious third parties recently have engaged in attacks that
are designed to disrupt key business services, such as consumer-facing websites. We and our third-party service providers may not be
able to anticipate or implement effective preventive measures against all security breaches of these types, especially because the techniques
used to sabotage or to obtain unauthorized access to our or our third-party service providers&#8217; technology, systems, networks and/or
physical facilities in which data is stored or through which data is transmitted change frequently and because attacks can originate
from a wide variety of sources. We employ detection and response mechanisms designed to contain and mitigate security incidents. Nonetheless,
early detection efforts may be thwarted by sophisticated attacks and malware designed to avoid detection. We also may fail to detect
the existence of a security breach related to the information of our clients and to prevent or detect service interruption, system failure
or data loss. Further, as a significant number of people work from home, these cybersecurity risks may be heightened by an increased
attack surface across our business and those of our clients and third-party service providers. We cannot guarantee that our efforts,
or the efforts of those upon whom we rely and partner with, will be successful in preventing any such information security incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
access by unauthorized persons to, or the improper disclosure by us of, confidential information regarding our clients or our proprietary
information, software, methodologies and business secrets could interrupt our business or operations, result in significant legal and
financial exposure, supervisory liability, damage to our reputation or a loss of confidence in the security of our systems, products
and services, all of which could have a material adverse impact on our business. In addition, there recently have been a number of well-publicized
attacks or breaches affecting companies in the financial services industry that have heightened concern by clients, which could also
intensify regulatory focus, cause clients to lose trust in the security of the industry in general and result in reduced use of our services
and increased costs, all of which could also have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most jurisdictions in the
United States have enacted laws requiring companies to notify individuals, regulatory authorities and/or others of security breaches involving
certain types of data. In addition, our agreements with certain partners and service providers may require us to notify them in the event
of a security breach. Such mandatory disclosures are costly, could lead to negative publicity, may cause our clients, partners and service
providers to lose confidence in the effectiveness of our security measures and require us to expend significant capital and other resources
to respond to and/or alleviate problems caused by the actual or perceived security breach. A security breach of any of our vendors that
processes personal information of our clients may pose similar risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
security breach may also cause us to breach client contracts. Our agreements with certain partners and service providers may require
us to use industry-standard or reasonable measures to safeguard personal information. We also may be subject to laws that require us
to use industry-standard or reasonable security measures to safeguard personal information. A security breach could lead to claims by
our clients or other relevant stakeholders that we have failed to comply with such legal or contractual obligations. As a result, we
could be subject to legal action or our clients could end their relationships with us. There can be no assurance that the limitations
of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages, and in some
cases our client agreements may not limit our remediation costs or liability with respect to data breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
resulting from security breaches may adversely affect our business. Unauthorized access to our technology, systems, networks or physical
facilities, or those of our third-party service providers, could result in litigation with our clients or other relevant stakeholders.
These proceedings could force us to spend money in defense or settlement, divert management&#8217;s time and attention, increase our
costs of doing business or adversely affect our reputation. We could be required to fundamentally change our business activities and
practices or modify our products and/or technology capabilities in response to such litigation, which could have an adverse effect on
our business. If a security breach were to occur, and the confidentiality, integrity or availability of personal information was disrupted,
we could incur significant liability, or our technology, systems or networks may be perceived as less desirable, which could negatively
affect our business and damage our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have adequate insurance coverage with respect to liabilities that result from any cyberattacks or other security breaches or
disruptions suffered by us or third parties upon which we rely. The successful assertion of one or more large claims against us that
exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition
of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that
our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers
will not deny coverage as to any future claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we take precautions to prevent consumer identity fraud, it is possible that identity fraud may still occur or has occurred, which may
adversely affect the performance of our products and services or subject us to scrutiny or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Pertaining to Partner Companies in General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Based
on our business model, some or all of our partner companies likely will need to raise capital from time to time to fund their operations.
We may not be able to fund some or all of these amounts, and the amounts may not be available from third parties on acceptable terms,
or at all.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that our partner companies will be able to obtain initial and additional financing on acceptable terms, or at all,
when needed. Because our resources and our ability to raise capital are limited and if we do not have funds in reserve for additional
capital infusions, we may not be able to provide our partner companies with sufficient capital resources at times when needed to enable
them to reach a cash flow positive position. We also may fail to accurately project the capital needs of our partner companies for purposes
of our cash flow planning. If our partner companies need to, but are not able to, raise capital from us or other outside sources, then
they may need to cease or scale back operations. If our partner companies raise capital from outside sources, the terms of such financings
may significantly reduce or eliminate the value of such partner companies. In all such events, our ownership interest in any such partner
company could lose some or all of its value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business
strategy. In addition, the loss of the services of the founders of our partner companies could adversely impact their business prospects
and the value of our ownership of the partner company.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to properly develop our partner companies and be successful in our business model depends in large part upon our ability to attract
and retain at the partner company level and at the MDB level highly qualified managerial, scientific, and technical personnel. We will
need to hire additional personnel as we further develop and grow our partner companies. Competition for skilled personnel usually is
intense. We may not be able to hire and retain highly qualified personnel on acceptable terms. If we are unable to attract and retain
high-quality personnel, especially for our partner companies, the rate and success at which they can develop and commercialize products
or succeed at all could be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Some
intellectual property of our partner companies will be funded through government programs, thus being subject to federal regulation such
as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S. industry. Compliance with these regulations
may limit exclusive rights, subject the companies to expenditure of resources with respect to reporting requirements, and limit the ability
to contract with foreign manufacturers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
research is funded in part by the U.S. government, the resulting intellectual property is subject to certain federal regulations pursuant
to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. In particular, the federal government retains a &#8220;nonexclusive, nontransferable,
irrevocable, paid-up license&#8221; for its own benefit to inventions produced with its financial assistance. The Bayh-Dole Act also
provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require
the contractor or successors in title to the patent or other intellectual property to grant a &#8220;nonexclusive, partially exclusive,
or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the intellectual property owner refuses to do
so, the government may grant the license itself. Intellectual property discovered under government-funded programs is also subject to
certain reporting requirements, compliance with which may require our partner companies or licensors to expend substantial resources.
Such intellectual property is also subject to a preference for U.S. industry, which may limit the ability to contract with foreign product
manufacturers for products covered by the intellectual property. Moreover, collaboration with academic institutions to accelerate research
or development may be limited or create the march in right. Further, the partner companies may choose to license intellectual property
in the future that may be subject to government rights pursuant to the Bayh-Dole Act. If, in the future, a partner company co-owns or
licenses in technology that is critical to its business that is developed in whole or in part with federal funds subject to the Bayh-Dole
Act, its ability to enforce or otherwise exploit patents covering the technology may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Some
of our partner companies may be unable to protect their proprietary rights and may infringe on the proprietary rights of others.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
partner companies, during their development, will typically assert various forms of intellectual property protection. Intellectual
property is likely to constitute an important part of our partner companies&#8217; assets and competitive strengths. Federal law,
most typically, copyright, patent, trademark and trade secret laws, generally protects intellectual property rights. State law also
addresses property rights. Although we expect that our partner companies will take reasonable efforts to protect the rights to their
intellectual property, the complexity of United States, individual state and international trade secret, copyright, trademark and
patent law, coupled with the limited resources of these partner companies and the demands of quick delivery of products and services
to market, create a risk that their efforts will prove inadequate to prevent misappropriation of our partner companies&#8217;
technology, third parties may develop similar technology independently, or they will otherwise be unable to adequately protected
their trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our partner companies also license intellectual property from third parties, and it is possible that they could become subject to
infringement actions based upon their use of the intellectual property licensed from those third parties. Our partner companies generally
obtain representations as to the origin and ownership of such licensed intellectual property; however, this may not adequately protect
them. Any claims against our partner companies&#8217; proprietary rights, with or without merit, could subject our partner companies
to costly litigation and the diversion of their technical and management personnel from other business concerns. If our partner companies
incur costly litigation and their personnel are not effectively deployed, the expenses and losses incurred by our partner companies will
increase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
our partner companies enter into intellectual property license agreements, if they fail to adhere to their obligations thereunder, they
may lose the ability to continue the license. Such a loss may be materially adverse to the business and future of a partner company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties have and may assert infringement or other intellectual property claims against our partner companies based on their patents or
other intellectual property claims. Even though we believe our partner companies&#8217; products do not infringe any third-party&#8217;s
patents, they may have to pay substantial legal fees to defend against such claims as well as damages, possibly including treble damages,
if it is ultimately determined that such claims have merit. They may have to obtain a license to sell their products if it is determined
that their products infringe another person&#8217;s intellectual property. Our partner companies might be prohibited from selling their
products before they obtain a license, which, if available at all, may require them to pay substantial royalties. Even if infringement
claims against our partner companies are without merit, defending these types of lawsuits takes significant time, may be expensive and
may divert management attention from other business concerns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
partner companies have limited foreign intellectual property rights and may not be able to protect their intellectual property rights
throughout the world.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
our partner companies have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents
in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the
United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual
property rights to the same extent as do federal and state laws in the United States. Consequently, our partner companies may not be
able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. Many countries have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If our partner companies or any of their licensors are forced to grant a license
to third parties with respect to any patents relevant to their business, their competitive position may be impaired, and their business,
financial condition, results of operations and prospects may be adversely affected. Also, competitors may use the technologies in jurisdictions
where our partner companies have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where there is patent protection but where enforcement is not as strong as that in the United States. These products
may compete with the products of our partner companies in jurisdictions where they do not have any issued patents and patent claims or
other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult
for our partner companies to stop the infringement of patents or marketing of competing products by third parties in violation of proprietary
rights generally. Proceedings to enforce patent and other intellectual property rights in foreign jurisdictions could result in substantial
costs and divert management efforts and attention from other aspects of business operations, could put the patents at risk of being invalidated
or interpreted narrowly and patent applications at risk of not issuing and could provoke third parties to assert claims against our partner
companies. The intellectual property holder may not prevail in any lawsuits that are initiated and the damages or other remedies awarded,
if any, may not be commercially meaningful. Accordingly, efforts by our partner companies to enforce their intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that they develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
partner companies may incur substantial costs as a result of litigation or other proceedings relating to intellectual property, including
patents, and they may be unable to protect their rights to their products and technology.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our partner companies or their licensors choose to go to court to stop a third party from using the inventions claimed in their owned
or in-licensed patents, that third party may ask the court to rule that the patents are invalid and/or should not be enforced against
that third party. These lawsuits are expensive and would consume time and other resources even if our partner companies were successful
in stopping the infringement of these patents. In addition, there is a risk that the court will decide that these patents are not valid
and that our partner companies do not have the right to stop others from using the inventions. There is also the risk that, even if the
validity of these patents is upheld, the court will refuse to stop the third party on the ground that such third party&#8217;s activities
do not infringe our owned or in-licensed patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
terms may be inadequate to protect a competitive position for an adequate amount of time.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. non-provisional filing date. Various extensions, such as patent term adjustments and/or extensions, may
be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering a product are obtained, once
the patent life has expired, our partner companies may be open to competition from competitive products. Given the amount of time required
for the development, testing and regulatory review of new products, patents protecting new products might expire before or shortly after
such products are commercialized. As a result, a patent portfolio may not provide sufficient rights to exclude others from commercializing
products similar or identical to those of the partner companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
efforts to maintain and protect our intellectual property rights through means in addition to registration may not be sufficient to protect
our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patents that our partner companies and we have are important assets. Our partner companies and we also rely on our unpatented proprietary
technology, trade secrets, processes and know-how. Generally, protection of intellectual property rights will be through filed patents,
registered trademarks and registered copyrights. Other proprietary information will be protected through a combination of trade secret
laws and confidentiality, non-disclosure and assignment of invention agreements with employees, contractors, collaborators, vendors,
consultants, advisors and third parties. Despite these measures, intellectual property rights could be challenged, invalidated, circumvented
or misappropriated. To pursue enforcement of these kinds of agreements could involve significant expense, potentially hinder or limit
use of intellectual property rights, or potentially result in the inability to use the intellectual property rights in question. If an
alternative cost-effective solution were not available, there may be an adverse effect on our financial position and performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcing
intellectual property rights against one or more third parties can be expensive and time-consuming, and an adverse result in any proceeding
could put the intellectual property rights at risk of being invalidated or narrowed in scope of coverage. Patent and trademark challenges
would increase the cost of development, engineering and marketing our products. There may not be adequate resources available to enforce
any of the intellectual property rights. In addition, the ability to enforce intellectual property rights depends on the ability to detect
infringement, and the ability to obtain evidence of infringement. Where enforcement is sought, a claim may not prevail or the damages,
if any, may not be commercially meaningful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
trademarks and trade names are not adequately protected, then our partner companies may not be able to build name recognition in the
markets of interest and their business may be adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
trademark or trade name may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
Our partner companies may not be able to protect their rights to their trademarks and trade names or may be forced to stop using their
names. At times, competitors may adopt trade names or trademarks similar to those of our partner companies, thereby impeding their ability
to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement
claims brought by owners of other registered trade names or trademarks that incorporate variations of our unregistered trade names or
trademarks. If the partner companies are unable to establish name recognition based on our trademarks and trade names, they may not be
able to compete effectively and our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborations
of various sorts, by our partner companies, such as with respect to research, testing, clinical trials, manufacturing and distribution,
will be important to their respective businesses. Their inability to enter into collaboration arrangements as needed, or if such collaborations
are not successful, may adversely impact their respective businesses.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
partner companies will likely seek to collaborate with third parties to engage in product research, clinical trials, marketing, manufacturing,
and distribution as part of its strategy. If our partner companies fail to enter into or maintain collaboration arrangements, as needed
and on reasonable terms, their ability to develop their business could be delayed, or the costs of development and commercialization
increased beyond what would be reasonable and ultimately hindered to the point of business cessation. Furthermore, our partner companies
may need to obtain the use of intellectual property rights held by third parties in order to develop their products. As a result, the
growth of a particular business or product may depend in part on the ability to acquire or in-license these intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
collaboration arrangements between partner companies and third parties may pose a number of risks, including, but not limited to, the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
collaborators have significant discretion in determining the efforts and resources that they will apply;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
collaborators may not perform their obligations as expected;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
collaborators may elect not to continue or renew development or commercialization programs or license arrangements;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with products
of our partner companies or products the collaborators have may be viewed as competitive with product of our partner companies causing
them to cease to devote resources to the commercialization of our partner company products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing
of a product candidate or product;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
collaborators may not commit sufficient resources to the marketing and distribution of our partner company product or products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of
development, might cause delays or terminations of the research, development or commercialization of products, might lead to additional
responsibilities for our partner companies, or might result in litigation or arbitration, any of which would be time- consuming and expensive;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
collaborations may be terminated by the collaborator, and, if terminated, our partner companies may require more capital to pursue further
development or commercialization of the applicable product; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
collaborations may not be negotiated on a timely basis or acceptable terms, if at all, or they may require substantial additional capital
so as to be able to pursue and fund a collaboration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
collaborations do not result in the successful discovery, development and commercialization of product candidates or if one of the collaborators
terminates its agreement, our partner companies may not receive any future research funding or milestone or royalty payments under such
collaboration. If a collaborator terminates its agreement, the partner company may find it more difficult to attract new collaborators,
and the perception of the product or the business and financial condition of our partner company could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to M1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M1
has a limited operating history on which to evaluate its ability to achieve its operating objectives.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M1
was founded in 2024, has a limited operating history, and only has incurred losses to date. Therefore, there can be no assurance that
the efforts of M1 to develop the M1 Platform will produce a commercial product, market acceptance or revenues that will sustain its business.
With a limited operating history and no commercialized products at this time, it will be difficult for investors to make predictions
about its future success or viability and any predictions may not be as accurate as they could be if it had a longer operating history
or a company history of successfully developing, commercializing and generating revenue from pharmaceutical products for a mass market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M1
may not be successful in its efforts to advance from the pre-clinical development stage and to fully develop a small molecule senescence
platform.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key element of M1&#8217;s strategy is to develop the M1 Platform, which is intended to be comprised of pharmaceutical drugs or other
products designed to aid in longevity and to inhibit certain forms of age-related diseases. The focus of the M1 Platform is to treat
<span style="background-color: white">senescent cells, which are dysfunctional cells that have permanently stopped dividing, have been
implicated in the aging process and the development of chronic low-grade inflammation. This chronic inflammation has been linked to a
variety of age-related diseases, including multiple fibrotic conditions that have limited treatment options and poor prognoses.</span>
Although its R&amp;D (research and development) efforts to date, which have been focused on pre-clinical development, have resulted in
what is believed to be potential pipeline of products, M1 may not be successful in finalizing the development of products to the stage
of commercial viability or be able to continue to identify and develop other pipeline products. Even if M1 is successful in continuing
to build its product pipeline, not all potential pipeline products it identifies will be suitable for development as pharmaceutical drugs
or as other commercial products. Although management believes its efforts to develop the M1 Platform will demonstrate commercial success
and deliver on the promise of aiding in longevity and inhibiting certain age-related diseases, if M1 is unsuccessful in these efforts,
the value of M1 will be significantly impaired or fully lost, and our holding company investors may suffer loss in relation to the investment
in M1. Further, in such an event, M1 may have to curtail or cease its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to PatentVest</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
PatentVest does not identify the full range of patent opportunities relevant to clients&#8217; intellectual property portfolio, its reputation
will be harmed and it may be liable for service failure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the primary services that PatentVest provides its clients is an analysis of their intellectual property portfolio and how the portfolio
may be protected and expanded through additional patent and other IP protection opportunities. We believe that its ability to attract
and retain clients depends on its ability to identify actual and potential patent assets for clients. Although there is no guarantee
that we will be able to identify all potential patent opportunities, if we miss a patent opportunity or fail to provide the services
contracted by clients in a workmanlike manner, then the reputation of PatentVest will be harmed, and it may be liable for damages due
to providing its services negligently.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
clients do not agree that the patents opportunities identified in the PatentVest reports are relevant to their businesses, PatentVest
will have difficulty retaining and attracting new clients, which could harm its operating results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clients of PatentVest use the services to help them analyze their existing and potential intellectual property. If the clients perceive
that the analysis and the opportunities are not relevant to their business requirements, then they will not find value in its reports
and services. This may harm its reputation and make it difficult to retain a client and attract new clients, with an adverse consequence
to operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PatentVest
is dependent on relationships with third parties, including public sources, to provide it with data, information and other services;
if any of these relationships change, its business could be adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PatentVest reports and services are developed using data, information or services obtained from third-party providers and public sources.
The commercial relationships with third-party providers whose capabilities complement those of PatentVest, may also be competitors which
might make PatentVest vulnerable to unpredictable price increases and unfavorable licensing terms. If public sources of data that are
relied upon were to begin competing with PatentVest directly, or if they were to increase the cost that PatentVest pays to access their
data, otherwise prohibit if from collecting and synthesizing the data they provide, or cease existing altogether, PatentVest may not
be able to perform its services and operating results could be adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PatentVest
might not be able to scale its business as fast as it believes can be done or be able to maintain the quality of its services and reports.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PatentVest
has operated, to date, on a small scale, and it has not yet proven its ability to commercialize services on a large scale. In order to do this successfully, it may have to make additional technology
and relationship investments that could delay or limit its ability to develop its client base and commercialize its reports and consultative
services. The reports may be found to be ineffective, unreliable or otherwise unsatisfactory to potential clients as there may be unforeseen
complications in the processes of scaling. These complications could delay or limit the ability of PatentVest to provide client services
or reports, could increase the cost of its consultative and report products, prevent it from implementing processes of the appropriate
quality and completeness, and thereby cause the business to suffer. Moreover, PatentVest needs to grow sales, marketing and support staff
or make appropriate arrangements with strategic partners to market, sell and support its clients and service and report products. If
PatentVest is not able to compete effectively with others while scaling commercially on a timely basis, in sufficient quantities or on
commercially reasonable terms, it will suffer a loss of business reputation and clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
believe patent analysis is a highly competitive business, and if PatentVest fails to develop widespread brand awareness in a cost-effective
manner, the business may suffer.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
services and reports offered by PatentVest compete with many other providers of similar services, such as other companies performing
intellectual property analytics, law firms, and patent filing firms. The services provided are subject to technological changes and evolving
client demands. We believe that in order for PatentVest to achieve market acceptance and to maintain and grow a client base, it is critical
to develop and maintain the quality of its services and reports and to increase the awareness of the brand. If we fail to provide what
the client requires, and it fails to promote and maintain its brand successfully, it may fail to attract or retain clients to the extent
necessary to realize a sufficient return on its brand-building efforts and to sustain the business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PatentVest
is licensed to offer legal services under Arizona law, and it plans to offer legal services as part of its package of intellectual property
service offerings. As a result, PatentVest must comply with the ethical and legal provisions, licensing responsibilities and obligations
of a law firm under the laws of the State of Arizona.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PatentVest
has obtained a license from the State of Arizona to provide legal services, and it will provide legal and related services in order to
enhance the overall package of the PatentVest intellectual property related service and report products. Being licensed to provide legal
services will likely impact the non-legal aspects of PatentVest&#8217;s business as it must comply with the regulatory responsibilities
and ethical obligations of operating a law firm as dictated by Arizona law and ethical standards. In respect of those services provided
to clients that constitute providing legal advice, PatentVest will have to abide by the many obligations that must be observed by attorneys,
including (i) complying with confidentiality obligations towards its legal clients, (ii) discharging attorney-client privilege obligations,
(iii) adhering to legal compliance, ethical and regulatory standards of Arizona, (iv) avoiding conflicts of interest, (v) handling of
client funds, if any, and (vi) acting in the best interests of the client. There may be instances when the legal rights of a client of
the PatentVest law group must take precedence over a business interest of PatentVest and may limit its ability to provide advice or business
services to others with respect to intellectual property matters, scope of claims and pursuit of patent claims or require PatentVest
to cease providing intellectual property advice and strategy to a particular client altogether. The failure to operate the legal business
in compliance with the responsibilities and ethical requirements placed by Arizona on law firms will subject the PatentVest law practice
to sanctions by regulators and the bar association and may result in malpractice liability for PatentVest. Additionally, the legal regulatory
authorities of Arizona may require PatentVest to cease operation of this aspect of our overall business altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to Public Ventures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Public
Ventures conducts offerings where we will act as a placement agent or an underwriter, and thus we are subject to underwriter and similar
liability.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our business, as it has been conducted over the last 28 or so years through Public Ventures, we expect to act as an underwriter
and placement agent in a number of capacities. We may be a single underwriter or placement agent of a securities offering or a co-underwriter
or placement agent participating in a securities offering. There are other types of offering where Public Ventures may be characterized
as an underwriter. In each of these instances, it will bear a liability dictated by Section 11(a) of the Securities Act of 1933, as amended
(&#8220;Securities Act&#8221;). Under the Securities Act, an underwriter is liable at law or in equity if any part of the registration
statement or offering documentation used in the offering of securities, in which we participate as an &#8220;underwriter&#8221; as generally
interpreted by the securities laws, &#8220;contained an untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary to make the statements therein not misleading&#8230;.&#8221; What constitutes an offering document
with respect to underwriter liability applies to any manner of offering materials. This liability also extends to private offerings of
securities and their documentation, where Public Ventures may act as a placement agent. In determining materiality, a court will not
inquire into limitations on the underwriter&#8217;s or placement agent&#8217;s ability to conduct its due diligence investigation and
assessment of the offeror, but will instead assess whether the statements, taken together and in context, would have misled a reasonable
investor about the nature of the investment. Section 11(b) of the Securities Act provides two affirmative defenses to Section 11(a) liability:
the expert defense and the non-expert defense, which are collectively known as the due diligence defense. Although we conduct due diligence
for all of our transactions, there is no assurance that the level of due diligence will uncover any failings in the materials used by
investors, or that it will uncover deliberate misstatements. Therefore, for any offering of securities, Public Ventures may become liable
as an underwriter or placement agent. Such a liability will have a significant impact on our overall business in terms of monetary cost
and also on our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Public Ventures self-clearing capabilities
facilitate its operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the start of 2024, Public Ventures began self-clearing U.S equity securities. As part of this process, in addition to the broker-dealer
regulation described above, Public Ventures will be subject to regulation directed to self-clearing operations and must demonstrate that
its financial, operational and systems capacities are able to perform this business while complying with regulations, including those
of the SEC, FINRA, Depository Trust Clearing Corporation (&#8220;DTCC&#8221;), and National Securities Clearing Corporation (&#8220;NSCC&#8221;).
To operate the self-clearing activity, we must meet different capitalization requirements than those of an introducing broker-dealer,
maintaining a capital structure with various cash and cash equivalent assets and retaining access to necessary lines of credit that can
assure our ability to comply with changing deposit requirements. We expect that these regulations will continue to undergo substantial
changes and may require additional capital as settlement operations move T+0 settlement in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Self-clearing requires us to finance transactions and maintain margin
deposits at clearing organizations. Self-clearing exposes our business to operational risks, including business and technology disruption;
operational inefficiencies; liquidity, financing and regulatory risks; and potentially increased expenses. We have in the past and may
in the future also encounter difficulties with self-clearing that lead to operating inefficiencies, technology issues, dissatisfaction
amongst our client base, disruption in the infrastructure that supports the business, inadequate liquidity, increased margin requirements
with clearing organizations and third-party settlement agents who provide financing with respect to transactions, reductions in available
borrowing capacity and financial loss. Any such delay, disruption, expense or failure could adversely affect our ability to effect transactions
and manage our exposure to risk. Moreover, any of these events could have a material adverse effect on our business, financial condition,
operating results and cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
a broker-dealer, Public Ventures will have to expend considerable resources on maintaining adequate compliance practices. The failure
to be in regulatory compliance may result in fines, sanctions and the possible curtailment of operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the broker-dealer operations and the self-clearing operations are subject to extensive regulation. In addition, regulators perceive that
engaging in business with &#8220;small and micro-cap&#8221; companies (those with market capitalizations of $300 million and under) and
&#8220;penny&#8221; stocks (stocks with market prices of less than $1.00) is an especially high-risk activity, and therefore extensively
review and supervise such business activities. Public Ventures focuses on this niche as we believe it offers a significant opportunity
for clients of Public Ventures and other persons to gain value on their securities holdings, and we believe that such companies need
access to capital. By focusing on this business, however, Public Ventures will likely increase the potential for regulatory oversight
and the potential for regulatory action against the firm. Certain aspects of the regulatory regime, including the Know Your Client (KYC)
and Anti Money Laundering (AML) requirements. The ability to oversee KYC and AML requirements is critical to its ability to expand our
client networks and increase the volume of transactions the firm performs as required by its business model. If Public Ventures is not
able to fulfill its regulatory obligations, it may be fined, have to change its business at greater cost, or be required to cease its
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the direct employees of Public Ventures, other persons in our overall corporate structure may be considered subject to FINRA
review and subject to the supervision by the broker-dealer. Therefore, the Company must maintain a structure that ensures all of the
parts of the Company will strictly adhere to FINRA rules so as to avoid any fines, limitations on the ability to conduct business or
actual business closure. The loss or curtailment of the business of Public Ventures would result in a significant loss of business opportunity
and revenues to the Company, and would result in a significant impairment to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be exposed to more cybersecurity threats as we expand our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the expansion in the business to include clearing services, the Company handles increased amounts of sensitive financial and other information
about investors and company clients&#8217; holdings and transactions that can be targeted by cybercriminals. We will need to have in
place an adequate internal security infrastructure to protect clients&#8217; information and assets and minimize potential liabilities
for the business. In addition, as cybersecurity threats become more and more sophisticated, we will have to continually expend funds
to upgrade and expand our security measures, maintain insurance and overall be vigilant to protect our operations and clients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
clearing operations of Public Ventures will require contractual arrangements with several key industry entities, which, if not followed,
will require it to terminate that portion of its business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
establish and to operate a clearing business, Public Ventures has entered into contractual arrangements with the Depository Trust Company,
National Securities Clearing Corporation and a settlement bank. These are complex sets of arrangements that must be strictly adhered
to, otherwise Public Ventures will not be able to use their services. Without these services, Public Ventures will not be able to clear
trades for clients. Not only does Public Ventures require these agreements, but as a result of them it will need to maintain systems
and interaction platforms with them and other parties in the settlement process. Information technology implemented include a core clearing
system, an order management system, and a corporate communications system, amongst others. These many activities happen in parallel and
require significant effort to successfully implement and maintain. Failure to maintain any of the individual systems would prevent Public
Ventures from conducting its self-clearing business. Part of the risk the firm faces includes its vendors&#8217; continuous capacity
to fulfill the service levels promised to Public Ventures. Public Ventures has chosen novel providers with excellent technology but lesser
track records. Assuring these suppliers will continue to deliver their promised services is necessary for the successful maintenance
of the technological platform the business requires to operate. The failure in any of the many aspects described above may prevent our
operations from being performed or possibly require us to terminate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Public
Ventures will have to maintain adequate capitalization levels to conduct its broker-dealer and clearing businesses.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
operate the broker-dealer and self-clearing operations, Public Ventures must meet different capitalization requirements in the Company.
To do this, it will have to maintain within the capital structure of the various cash and cash equivalent assets and retain access to
necessary lines of credit that can assure its ability to comply with changing deposit requirements of the SEC and of the Depositary Trust
Clearing Company (&#8220;DTCC&#8221;), and the National Securities Clearing Corporation (&#8220;NSCC&#8221;). It is expected that these regulations
will undergo substantial changes, from time to time, which could require additional capital as settlement operations move to T+1 (one
day after the settlement date) and T+0 settlement in the future. Without the required capital at any time, Public Ventures will not be
able to operate its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Settlement
bank services are difficult to arrange, without which Public Ventures will not be able to operate a clearing business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are only a limited number of banks currently offering settlement services to clearing firms. Public Ventures could be unable to continue
providing clearing services if it is unable to maintain a settlement bank arrangement, or if its current settlement bank decides to exit
this business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hiring
and organizing personnel for the clearing operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be able to operate its self-clearing activities, Public Ventures must hire and retain the human talent capable of handling the operational
activities and fulfilling the compliance requirements of the business. Trading and settlement and compliance personnel are necessary
to manage the operations. Further expertise in financial matters and obligations for self-clearing are also required. Although it has
a conservative approach to launching the business and onboarding clients to cause less stress on the organization, the firm&#8217;s
ability to perform going forward nonetheless depends on successfully recruiting, training and retaining new personnel. As part of these
recruitment and retention efforts, the firm must ensure that it can maintain an adequate supervising and leadership structure capable
of supporting the successful development of its business model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Where
permitted by regulation, Public Ventures will use an overseas out-source provider for some of the self-clearing operation activities
although political and social instability and the threat of sanctions by countries, including the United States, may disrupt or hinder
the delivery of such services and result in increased costs.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a contract with a Nicaraguan company to provide, on an out-sourced, as requested basis, certain back-office services that support
our broker dealer activities and patent related services and other requirements. We plan to expand and use this service facility, where
permitted, for certain aspects of the self-clearing operations that Public Ventures engages in. We believe that these operations provide
a competitive advantage to the Company and facilitate developing this new business in an efficient and profitable manner, as human resources
and technological infrastructure in Nicaragua allows local companies to provide quality service at the level expected by US clients at
a fraction of the cost. Any disruption to social and political stability in Nicaragua could affect the contractor&#8217;s capacity to
achieve its goals. The current political environment in Nicaragua is unsettled due to a political crisis that erupted in 2018, which
has yet to be resolved. Continued or escalated political instability and the possibility of sanctions from other countries, including
the United States, could disrupt local business and may hinder or disrupt the delivery of services to our United States operations. The
United States has several Executive Orders in force which impose sanctions regarding immigration of certain groups of persons and imposing
wider sanctions in respect of certain trading activities. We constantly monitor the situation and have a business continuity strategy
in place to assure consistent operations and activities in the United States. To the extent we are prohibited from contracting with entities
in Nicaragua, our expenses may increase, and there may be disruption in our workforce that will have to be replaced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Being a Public Company and Owning Our Class A Common Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Control
by management may limit your ability to influence the outcome of director elections and other transactions requiring shareholder approval.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
persons, Anthony DiGiandomenico and Christopher Marlett, own all the Class B Common Shares. The Class A Common Shares have one vote
per share, and the Class B Common Shares have five votes per share. The Class A Common Shares and Class B Common Shares vote
together as a single class on all matters, including the election of directors. There are 5,000,000 Class B Common Shares issued and
outstanding, currently representing <b>90.8%</b> of the aggregate voting authority of our common shares immediately prior to the
date of this filing. Therefore, even if the maximum Class A offered shares, as currently approved by the Board of the Directors, are sold, the Class B Common Shares will continue to be
able to dictate the outcome of all matters put before the shareholders. There is no automatic or voluntary conversion of the Class B
Common Shares into Class A Common Shares, thus the Class B Common Shares will have control of MDB for an indefinite period of
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, the Class B Common Shares have significant influence over corporate actions requiring shareholder approval, including
the following actions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    determine the composition and to elect the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    amend or prevent a change in our operating agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    effect or prevent a merger, sale of assets or other corporate transaction; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    control the outcome of any other matter submitted to our shareholders for vote.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of the Class B Common Shares may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain
control of MDB, which in turn could reduce our shares price or prevent our Class A Common Shareholders from realizing a premium over
our share price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
transfers by holders of Class B Common Shares generally will result in those shares converting to Class A Common Shares, subject to limited
exceptions, such as certain transfers effected for estate planning purposes. The conversion of Class B Common Shares to Class A Common
Shares will have the effect, over time, of increasing the relative voting power of those holders of Class B Common Shares who retain
their shares in the long term. As a result, it is possible that the persons or entities continuing to hold our Class B Common Shares
could gain significant voting control as other holders of Class B Common Shares sell or otherwise convert their shares into Class A Common
Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are deemed a &#8220;controlled company&#8221; under the listing rules of Nasdaq because our Class B Common Shares are held by two persons
who have more than 50% control of the Company. As a controlled company, MDB will be exempt from certain of the corporate governance obligations
that other companies must follow when listing on Nasdaq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class B Common Shares are held by two persons who have control over the operations of the Company. Therefore, MDB is a controlled company
under the Nasdaq listing rules and is exempt from certain listing requirements, including having (i) a board comprised of a majority
of independent directors, (ii) a compensation committee, and (iii) a director nominations committee. Additionally, we are not be required
to hold annual meetings. Management intends to take advantage of these exemptions. Accordingly, shareholders will not have the same protections
afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. Notwithstanding the
exemption, currently we have a board that has several independent directors, we are required to have and will have an audit committee,
and related party transactions will have to be reviewed by the audit committee. Shareholder approval will be required for stock options
or purchase plans, and the financial statements must be audited by an independent public accountant that is registered with the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
dual class structure of our currently issued equity securities may adversely affect the trading market for our Class A Common Shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
stock index providers, such as S&amp;P Dow Jones, exclude companies with multiple classes of shares of equity from being added to certain
stock indices, including the S&amp;P 500. In addition, several stockholder advisory firms and large institutional investors oppose the
use of multiple class structures. As a result, the dual class structure of our currently issued equity may prevent the inclusion of our
Class A Common Shares in such indices, may cause stockholder advisory firms to publish negative commentary about our corporate governance
practices or otherwise seek to cause us to change our capital structure, and may result in large institutional investors not purchasing
shares of our Class A Common Shares. Any exclusion from stock indices could result in a less active trading market for our Class A Common
Shares. Any actions or publications by stockholder advisory firms or institutional investors critical of our corporate governance practices
or capital structure could also adversely affect the value of our Class A Common Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
existence of our registered broker-dealer subsidiary may delay or prevent takeover attempts of our Company.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third party attempting to acquire us or a substantial position in our equity securities may be delayed or ultimately prevented from doing
so by change in ownership or control regulations to which our regulated broker-dealer subsidiary is subject. FINRA Rule 1017 generally
provides that FINRA approval must be obtained in connection with any transaction resulting in a single person or entity owning, directly
or indirectly, 25% or more of a member firm&#8217;s equity and would include a change of control of a parent company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
capital structure may have anti-takeover effect.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of our preferred shares that may be issued at the discretion of the board of directors with the terms it determines may have
an anti-takeover effect. The board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the
relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to
the preferred shares of each series. The board of directors, without shareholder approval, will be able to issue preferred shares with
voting and other rights that could adversely affect the voting power and other rights of the holders of the common shares and could also
have anti-takeover effects. The ability of our board of directors to issue preferred shares without shareholder approval could have the
effect of delaying, deferring or preventing a change of control of the Company or the removal of existing management. We currently have
no preferred shares issued and outstanding as the date hereof. Although we do not currently intend to issue any preferred shares, we
cannot assure you that we will not do so in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fact that the Class B Common Shares have a right to five votes per Class B Common Share on all matters presented for a vote to the shareholders,
including in the vote for directors, and the fact that the Class B Common Shares currently have a majority ownership position of all
the common shares, means that they have an anti-takeover effect, because it would be difficult for an insurgent to overcome the authority
that the Class B Common Shares has in the governance of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions for shareholder business proposals and director nominations in the operating agreement also could have an anti-takeover effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of securities with voting authority greater than the Class A Common Shares will have a voting and control dilutive effect on
outstanding Class A Common Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the board of directors issues any of the preferred shares or obtains shareholder approval for a new class of common shares with voting
rights in excess of the one vote per one Class A Common Share, the holders of Class A Common Shares will suffer a voting dilutive effect,
in addition to any other economic dilution resulting from the issuance of those securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may make distributions of the securities of our partner companies, including cash and rights to purchase equity of a partner companies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
aspect of our business plan is to distribute to our shareholders assets of the parent company, which may include the securities of
our partner companies after they go public, rights to purchase the equity of these companies, and/or cash and other property, from time
to time. The distribution of a right to purchase the equity of a partner company may come at a time when a recipient does not have the
ability to exercise the right, and thereby lose the opportunity that the right affords. Any distribution of securities of a partner company,
cash and other property may have an adverse impact on the value of your Class A Common Shares. On the other hand, we do not plan to regularly
make any periodic distributions, therefore investors should not look to any distribution that we might make to be a regular income item
in an investor&#8217;s portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
incur costs as a result of operating as a public company, and our board of directors is required to devote substantial time to oversight
of compliance requirements and corporate governance practices.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company listed in the U.S., we incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act,
the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules
and regulations impose various requirements on listed public companies, including the establishment and maintenance of effective disclosure
and financial controls and corporate governance practices. Our board of directors, management and other personnel will need to devote
a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial
compliance costs and make some activities more time-consuming and costly. However, these rules and regulations are often subject to varying
interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time
as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters
and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control
over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report
on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with
Section 404 within the prescribed periods, we will be engaged in a process to document and evaluate our internal controls over financial
reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially
engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting,
continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and
implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is
a risk that we will not be able to conclude, within the prescribed timeframe, that our internal controls over financial reporting are
effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial
markets due to a loss of confidence in the reliability of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even after we no longer qualify
as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage
of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this filing and our periodic
reports and proxy statements. We cannot predict if investors will find our Class A Common Shares less attractive because we may rely on
these exemptions. If some investors find our Class A Common Shares less attractive as a result, there may be a less active trading market
for our Class A Common Shares, and our share price may be lower or more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are a smaller reporting company within the
meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to smaller reporting
companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with
other public companies.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule 12b-2 of the Exchange
Act defines a &#8220;smaller reporting company&#8221; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned
subsidiary of a parent that is not a smaller reporting company and that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 24px; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">had a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter, computed by multiplying the aggregate worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity; or</span></td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">in the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public offering price of the shares; or</span></td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: center">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">in the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a smaller reporting
company, we are not required to include a Compensation Discussion and Analysis section in our proxy statements; we provided the
required two years of financial statements; and provided the table of selected financial data as required for a smaller reporting company. We also have other
&#8220;scaled&#8221; disclosure requirements that are less comprehensive than issuers that are not smaller reporting companies which
could make our securities less attractive to potential investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We do not have key-man insurance.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not maintain,
nor do we have plans to obtain, key-man insurance for our principal officers. Our business is highly dependent on the continued services
of these individuals. The loss of any of their contributions could have a material adverse effect on our operations. Without the financial
support typically provided by such insurance to recruit and transition new leadership, we may face challenges in maintaining business
continuity and strategic direction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The price of our Class A Common Shares may
be volatile, and could, upon listing on the Nasdaq Capital Market, decline significantly and rapidly. Market volatility may affect the
value of an investment in our Class A Common Shares and could subject us to litigation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our Class
A Common Shares may fluctuate substantially. The price of our Class A Common Shares in the market on any particular day will depend on
many factors including, but not limited to, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">price and volume fluctuations in the overall stock market from time to time;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">investor demand for our Class A Common Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">significant volatility in the market price and trading volume of companies operating in the diverse businesses of our core companies and our partner companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">variations in our operating results and market conditions specific to our businesses sectors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the emergence of new competitors or new technologies of our partner companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">operating and market price performance of other companies that investors deem comparable;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes or departures of any of our board of directors, senior management or key employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">commencement of, or involvement in, litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in governmental regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes in our earnings, and fluctuations in our quarterly operating results; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">general economic conditions and trends.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, following periods
of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that
company. Due to the potential volatility of our share price, we may therefore be the target of securities litigation in the future. Securities
litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if the market
for equity stocks of companies in our industry or industry segments, or the stock market in general, experiences a loss of investor confidence,
the market price of our Class A Common Shares could decline for reasons unrelated to our business, financial condition, or results of
operations. If any of the foregoing occurs, it could cause the price of our Class A Common Shares to fall and may expose us to lawsuits
that, even if unsuccessful, could be costly to defend and a distraction to our Board of Directors and management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain recent initial public offerings of
companies with relatively small public floats have experienced extreme volatility that was seemingly unrelated to the underlying performance
of the company. Our Class A Common Shares may potentially experience rapid and substantial price volatility, which may make it difficult
for prospective investors to assess the value of our Class A Common Shares.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the general
volatility risks discussed in this filing, our Class A Common Shares may be subject to rapid and substantial price volatility. We may
experience extreme stock price volatility unrelated to our actual or expected operating performance, financial condition or prospects,
making it difficult for prospective investors to assess the rapidly changing value of our Class A Common Shares. Recently, there have
been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent
initial public offerings, especially among companies with relatively smaller public floats. As a company with a relatively small public
float and recent IPO, the Class A Common Shares may experience greater stock price volatility, extreme price run-ups, lower trading volume,
large spreads in bid and asked prices, and less liquidity than large-capitalization companies. The aspects of the trading in the Class
A Common Shares may be unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult
for prospective investors to assess the value of our common stock. Because of the low public float and the absence of any significant
trading volume, the reported prices may not reflect the price at which you would be able to sell shares if you want to sell any shares
you own or buy shares if you wish to buy share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the trading volumes of
the Class A Common Shares are low, persons buying or selling in relatively small quantities may easily influence the prices of the Class
A Common Shares. A low volume of trades could also cause the price of the Class A Common Shares to fluctuate greatly, with large percentage
changes in price occurring in any trading day session. Broad market fluctuations and general economic and political conditions may also
adversely affect the market price of the Class A Common Shares. The volatility also could adversely affect the ability of the company
to issue additional shares of common stock or other securities and the ability to obtain stock market based financing in the future. No
assurance can be given that an active market in our Class A Common Shares will develop or be sustained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The United States stock markets recently have
experienced price and volume fluctuations due to many factors, including federal government policies, inflationary pressures, changing
interest rates, and the conflicts in Ukraine and Iran.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market has recently
experienced significant price and volume fluctuations that have affected and continue to affect the market prices of equity securities
of many companies, with the financial service and technology sectors more volatile than others. These fluctuations often have been unrelated
or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general
economic, political and market conditions such as federal government policies, inflation, the prospect of a recession, and interest rate
changes may negatively impact the market price of our Class A Common Shares. These fluctuations may be even more pronounced in the trading
market for our Class A Common Shares shortly following the listing of our Class A Common Shares on the Nasdaq Capital Market as a result
of the supply and demand forces described above. If the market price of our Class A Common Shares after our listing does not exceed the
opening public price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past,
companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation.
We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and
divert our management&#8217;s attention from other business concerns, which could harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b><span id="a_004"></span>Item 1B. Unresolved
Staff Comments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act, and therefore we are not required to provide information under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b><span id="a_005"></span>Item 1C. Cybersecurity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&#160;</p>

<p id="xdx_98C_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-OJROE_zPzk1YjXUmG3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000053-01" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">We incorporate by reference
the disclosure about cybersecurity regulation that is generally applicable to MDB from section Part I, Item 1, Business &#8211; Regulation
&#8211; Data Protection ad Cybersecurity Regulation.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C02_gBFCRMPFAIAMT-OJROE_zyddu5i2hLT5"><ix:continuation continuedAt="ConU000053-02" id="ConU000053-01">&#160;</ix:continuation></span></p>

<div id="xdx_C06_gBFCRMPFAIAMT-OJROE_zO5baPQRMmq5"><ix:continuation continuedAt="ConU000053-03" id="ConU000053-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not had any reportable
cybersecurity breaches, including what we may perceive or recognize as cybersecurity incidents or credible threats during the fiscal year
ended December 31, 2025. To date, as a result, there has not been any material adverse effect on our business operations or financial
condition. If there is a cybersecurity attack and an infiltration of our files, data, customer data and the like, there would be a material
adverse effect on our business, our reputation, our operations and financial condition. For example, our reputation would be damaged in
the event of a cybersecurity infiltration. If there were a cybersecurity infiltration, we could lose access to our data which would disrupt
our operations, and we even may not be able to operate. Such a loss of access might be temporary or permanent, and it might be localized
or general. The level of disruption will depend on our backup systems. Our clients financial and other data could be taken and used against
us to damage our reputation or cause harm to our clients in different ways. In the latter instance, we may be liable for monetary damages
to our clients. We may be held for cyber ransom, which would be loss to our financial resources. Our inability to operate, payment of
damages, payment of ransom, and the costs of reparation of our systems, consultants and tangential expenses will all result in damage
to our business and our financial resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MDB Holdings and its subsidiaries
including Public Ventures, our regulated broker-dealer, <span id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_dbF_c20250101__20251231_zyoxShBxRKKj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">we have <span id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zTViQMCcuC3a" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">implemented</ix:nonNumeric></span> a comprehensive cybersecurity program aimed at identifying,
monitoring, and mitigating cybersecurity risks to the best of our ability. Our security program encompasses information security responsibilities,
incident response, and is diligently managed by our information technology department. Cybersecurity is integrated into our overall risk
management framework, with consultation from subject matter experts to assess and address potential cyber risks and their impacts.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_909_ecyd--CybersecurityRiskRoleOfManagementTextBlock_dbF_c20250101__20251231_zXSW81eyiwn4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000056" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Management is committed to
providing the Audit Committee with regular cybersecurity updates, at least annually or more often as needed, based on emerging threats
or specific incidents. These updates cover risk assessments, the current threat landscape, and any recent cybersecurity incidents.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information technology
department has put in place robust governance measures for information security. This includes control requirements for change management,
patching processes, the implementation of multifactor authentication, comprehensive data backup strategies, and continuous security monitoring.
Additionally, management continues to enhance our security controls, with any significant issues promptly reported to the Audit Committee.</p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0C_gBFCRMPFAIAMT-OJROE_znVgR35ztG71"><ix:continuation id="ConU000053-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b><span id="a_006"></span>Item 2. Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We own no real property. Our
principal office is located in Addison, Texas. In July 2022, we secured a lease for approximately 5,500 square feet of office space, with
the lease set to expire in July 2030. This space serves as our principal executive offices and for general office use. The base monthly
rental rate is $12.5 thousand until July 2024, after which it will increase to $12.8 thousand. Subsequent increases are scheduled as follows:
to $13.0 thousand in July 2025, $13.2 thousand in July 2026, $13.5 thousand in July 2027, $13.7 thousand in July 2028, and finally, to
$14.0 thousand in July 2029, continuing through the end of the lease term in July 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our leased
spaces is at local market rates, and there is sufficient space available to permit the specific operations to obtain additional or other
space if and when required. We do not believe that if there is additional space or other space required, that the cost will be prohibitive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b><span id="a_007"></span>Item 3. Legal
Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights
under contracts with our customers and regulatory review which may result in various kinds of penalties, such as censures and monetary
fines. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have
a material effect upon our financial condition, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><b><span id="a_008"></span>Item 4. Mine
Safety Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_009"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_010"></span>Item 5. Market for Registrant&#8217;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trading Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Class A Common Shares
currently are quoted on Nasdaq under the symbol &#8220;MDBH&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2026, we had
approximately 3,210 shareholders of record of the Class A Common Shares and we believe over 79 shareholders who hold their Class A Common
Shares in street name. In addition, we have a second class of equity, the Class B Common Shares, that are held by Christopher Marlett and <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony DiGiandomenico</span>, and do
not trade on any public market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Distributions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any dividends
or made any distributions related to our equity securities, to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may make registered and
other distributions of the securities of our partner and or subsidiary companies and of cash to our holders of the Class A Common Shares
and Class B Common Shares. It is our plan, from time to time, depending on the circumstances, to distribute the securities of our partner
companies as they go public and after they go public, including rights to purchase the equity of these companies, and cash and other property,
from time to time. Some of these distributions of securities may be dictated by our operational plan not to be subject to the Investment
Company Act of 1940.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether any distributions,
the kinds of distributions, and the value of distributions are made will depend on many factors and will be determined by the management
of MDB, from time to time. Investors should not look to any distribution that we might make to be a regular income item in an investor&#8217;s
portfolio. Distributions of a right to purchase the equity of a partner company may come at a time when a recipient does not have the
ability to exercise the right, and thereby the recipient may lose the opportunity that the right affords. Any distribution of securities
of a partner company, cash and other property may have an adverse impact on the value of Class A Common Shares in the market. Distributions
of the equity of our partner companies may not result in an overall investor gain on the Class A Common Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tax Issues Related to Distributions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB believes that it will
be treated as a partnership for U.S. federal income tax purposes and that it will not be taxed as a corporation. The tax position of MDB
as a publicly traded partnership is complex, and persons should consult with their own tax advisors about holding an interest in MDB.
The following brief discussion does not address U.S. state taxes or any taxes of any jurisdiction outside of the U.S. For tax exempt organizations
and non-U.S. holders of Class A Common Shares, there are additional rules that should be considered that are not discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company generally expects
to receive income in the form of dividends from its equity investments in some partner companies and capital proceeds from the sale of
partner companies or their securities from others, with all such partner companies expected to be treated as corporations for U.S. federal
tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For U.S. federal income tax
purposes, a partnership is generally not a taxable entity but rather is a &#8220;flow-through&#8221; entity whose items of taxable income,
gain, loss, deduction and credit are passed through to, and reported by, its partners, in this case the holders of our classes of Common
Shares. Thus, each Common Share holder will be required to report on its U.S. federal income tax return its allocable share of items of
taxable income, gain, loss, deduction, or credit realized by MDB. This will include the portion of dividends received from the corporate
partner companies and capital proceeds from the sale of corporate partner companies or their securities. Each item generally will have
the same character and source as would be the case if the Common Share holder realized the item directly. This rule applies without regard
to whether the Common Share holder receives or will receive any cash distributions from MDB. Accordingly, for any taxable year of MDB,
a Common Share holder may be required to report and pay tax on his share of items of MDB&#8217;s income without receiving sufficient (or
any) cash distributions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, the character of
partnership items of taxable income, gain, loss, deduction and credits also passes through to its partners. For example, to the extent
MDB has gains subject to ordinary income tax rates, each holder of Common Shares will be required to report, and pay taxes on, its allocable
share of such gains. Those holders of Common Shares who are individuals will generally be subject to reduced tax rates on their allocable
share of dividends received by MDB from corporate partner companies, to the extent such dividends constitute &#8220;qualified dividend
income&#8221; under section 1(h)(11) of the Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operating agreement of
MDB that governs the rights of the holder of Common Shares contains certain allocations of income, gain, losses, and deductions that could
be reallocated by the IRS if it were determined that the allocations did not have &#8220;substantial economic effect&#8221; under Section
704(b) of the Code, and the allocations were not made in accordance with the holders of Common Shares respective interests in MDB, taking
into account all relevant facts and circumstances. If the IRS does not respect an allocation and the distributive portions of income and
loss are adjusted, the holders of Common Shares may be required to file amended income tax returns which could subject the investors to
additional taxes, interest, and penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB may apply certain conventions
in determining and allocating items for tax purposes in order to reduce the complexity and costs of administration. MDB intends for the
application of any such conventions to be consistent with the intent of the partnership provisions of the Code and the applicable Treasury
Regulations, and that the resulting allocations will have substantial economic effect or otherwise should be respected as being in accordance
with members&#8217; interests in MDB for federal income tax purposes. The Code and existing Treasury Regulations do not expressly permit
adoption of these conventions, and it is possible that the IRS could successfully challenge MDB&#8217;s use of any such allocations methods
on the ground that they do not satisfy the technical requirements off the Code or Treasury Regulations, requiring a member to report a
greater or lesser share of items of income, gain, loss, deduction, or credit than if such method were respected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The assumptions and conventions
used in making tax allocations may cause a holder of Common Shares to be allocated more or less income or loss for federal income tax
purposes than its proportionate share of the economic income or loss realized by MDB during the period it held its shares. This &#8220;mismatch&#8221;
between taxable and economic income or loss in some cases may be temporary, reversing itself in a later period when the shares are sold,
but could be permanent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Distributions by MDB to a
holder of Common Shares generally will not be taxable to the holder for U.S. federal income tax purposes to the extent of the tax basis
in the Common Shares immediately before the distribution. Cash distributions in excess of such basis generally will be considered to be
gain from the sale or exchange of the Common Shares, taxable as further described herein. Any reduction in the portion of MDB&#8217;s
liabilities included in the basis of the holders&#8217; Common Shares may be treated as a distribution of cash to such holder. A decrease in
a holder&#8217;s ownership interest in MDB because of an issuance of additional shares may decrease such holder&#8217;s portion of nonrecourse
liabilities, potentially resulting in a corresponding deemed distribution of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of Common Shares
will recognize gain on the complete liquidation of its Common Shares only to the extent the amount of money received by the holder exceeds
its adjusted tax basis in its Common Shares. Any such gain recognized by a holder generally will be capital gain, but may be taxable as
ordinary income, either in whole or in part, under certain circumstances. No loss may be recognized on a distribution in liquidation of
Common Shares, unless the holder receives no property other than money and/or substantially appreciated &#8220;inventory items&#8221;
and &#8220;unrealized receivables&#8221; (both as defined by Section 751 of the Code).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The adjusted tax basis of
a holder of Common Shares in its Common Shares is important for several reasons including, but not limited to, determining:
(1) the current deductibility of the distributive share of Company losses; (2) income tax consequences of distributions; and (3) gain
or loss on the sale of Common Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Securities Authorized for
Issuance Under Equity Compensation Plans (in thousands, except exercise price)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Plan category</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">securities to be</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">issued upon</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">exercise of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">outstanding awards</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="margin: 0">(in thousands)</p>
<p style="margin-top: 0; margin-bottom: 0"> </p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted-average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">exercise price of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">outstanding awards</p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">securities remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">available for</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">future issuance</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">under equity</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">compensation plans</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="margin: 0">(in thousands)</p>

</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-size: 10pt; text-align: left">2022 Equity Incentive Award Plan approved by security holders(1)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 14%; font-size: 10pt; text-align: right">4,682</td><td style="width: 1%; font-size: 10pt; text-align: left"><p style="margin: 0">(2)</p></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">4.25</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,760</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity award plans not approved by security holders</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,682</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">(2)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4.25</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,760</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The 2022 Equity Incentive Award Plan provides for awards for up to 6.0
million shares of Class A shares, plus 25% of outstanding Class A shares at any time. As of December 31, 2025, there are a total of 7.3
million Class A shares available for issuance, which includes the shares issued of 0.84 million since October 20, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Represents Restricted Stock Unit awards
of 1.08 million shares which do not require payment of an exercise price, the weighted average exercise price of outstanding awards
is for the 3.6 million of stock option awards with an exercise price of $4.25.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_011"></span>Item 6. [RESERVED]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7</b>. <b><span id="a_012"></span>Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB Capital Holdings,
LLC (the &#8220;Company&#8221; or &#8220;MDB&#8221;), a Delaware limited liability company, is a holding company that has three
wholly-owned subsidiaries: MDB CG Management Company (&#8220;MDB Management&#8221;); Public Ventures, LLC, d/b/a MDB Capital
(&#8220;Public Ventures&#8221;); and PatentVest, Inc. (&#8220;PatentVest&#8221;), and has one majority-owned partner company MDB
Minnesota One, Inc. (&#8220;MDB Minnesota One&#8221;) and one minority owned company eXoZymes Technologies, Inc., formerly known as
Invizyne Technologies, Inc., (&#8220;eXoZymes&#8221;), that was majority owned and is consolidated until November 14, 2024, when
eXoZymes issued securities in its IPO. Because MDB no longer holds a majority ownership interest in eXoZymes, the company is no
longer consolidated in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB Management is principally
an &#8220;administrative&#8221; entity whose purpose is to conduct and, wherever possible, to consolidate shared services/resources for
our US-based operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Public Ventures is a U.S.
registered broker-dealer under the Exchange Act and is a member of FINRA and the Texas State Securities Board. Public Ventures is managed
by Christopher A. Marlett, who is also a founder of MDB. Public Ventures operates on a fully disclosed basis with a nonrelated FINRA member
firm, Interactive Brokers, LLC (&#8220;Interactive Brokers&#8221;), and is not required to maintain a clearing deposit. Interactive Brokers
is the clearing firm and custodian of investments maintained by Public Ventures. Public Ventures also operates as a self-clearing broker
dealer, and began carrying accounts for customers in January 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PatentVest is a wholly-owned
subsidiary that performs intellectual property validation services for Public Ventures&#8217; due diligence functions on the intellectual
property of partner and prospective partner companies and creates an intellectual property roadmap for such partner companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Minnesota One is a majority
owned subsidiary and was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">eXoZymes was formed with the objective of taking nature&#8217;s building blocks to make molecules of interest, effectively simplifying
nature. eXoZymes is a biology technology development company that is a minority-owned subsidiary as of the date of the financial statements
included in this annual report. eXoZymes&#8217;s technology is a differentiated and unique synthetic biology platform which is designed
to enable the scalable exploration of a large number of molecules and properties found in nature. eXoZymes was majority owned by MDB Capital
Holdings, up until November 14, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 14, 2024, eXoZymes
completed its initial public offering, in which it sold common stock, reducing MDB Capital Holdings&#8217; ownership interest from
approximately 60% to 47%. As a result, effective November 14, 2024, eXoZymes became a minority owned company and is now accounted for
under the equity method of accounting. As noted below, we recognized a gain of $39.3 million on the date of deconsolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results of Operations</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has determined
its reporting units in accordance with ASC (Accounting Standards Codification) 280, Segment Reporting. The Company currently operates
in two reportable segments: a broker dealer &amp; intellectual property service and technology development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s consolidated
statements of operations as discussed herein are presented below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Consolidated Results of Operations for the
Years Ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker dealer (Notes 1 and 2)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(331</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(275</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(56</td><td style="width: 1%; font-size: 10pt; text-align: left"><p style="margin: 0">)</p></td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gain on investment securities, net from non-licensed broker dealer (Notes 1 and 2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Realized gain on investment securities, net from the licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income (from our licensed broker dealer)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,282</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,221</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,061</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment of investment securities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(200</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">200</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">861</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">411</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">450</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,911</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,157</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,754</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,969</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,057</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(5,088</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,833</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,486</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">347</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,937</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,112</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(1,175</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,103</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">922</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">181</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">556</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,137</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(581</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,239</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,608</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(369</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total general and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,637</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29,322</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,685</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,637</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,790</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,153</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net operating loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(17,726</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(28,633</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">10,907</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income and (expense):</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(37</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(72</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">72</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest income (from U.S. Treasury Bills)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">617</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,179</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(562</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gain related to dilution events</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">61</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(69</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain on deconsolidation of subsidiary</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,307</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(39,307</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(16,973</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,023</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(28,996</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(16,984</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,021</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(29,005</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(420</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,862</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(21,266</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11,601</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(32,867</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net income (loss) attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(21,245</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,691</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(32,936</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Operating Income.</span></i>
For the years ended December 31, 2025 and 2024, operating income was derived primarily from the Company&#8217;s broker
dealer and intellectual property service segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended
December 31, 2025, operating income was generated from the Company&#8217;s fees from investment banking transactions in the
broker-dealer and intellectual property services. The increase compared to the year ended December 31. 2024 is
attributable to investment banking activity, as the Company executed significantly larger transactions during the year ended December 31. 2025. For the
year ended December 31, 2024, operating income was generated from the Company&#8217;s fees from investment banking transactions
in the broker-dealer and patent related intellectual property services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">General and Administrative
Costs.</span></i> During the year ended December 31, 2025, and 2024, several factors contributed to changes in various expense
categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Compensation Expense: The majority of the decrease in compensation expense was attributable to the deconsolidation of eXoZymes, as well as the exchange of restricted stock units to options during the period.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Related Party Operating Expenses: The increase is primarily due to the outsourcing of support services related to the Company&#8217;s self-clearing operations and community group within the broker-dealer, as well as services provided by the intellectual property segment.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Professional Fees: The decrease compared to the year ended December
    31, 2024 was largely due to a reduction in audit and consulting fees that were primarily associated with reporting activities
    completed in 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Information Technology Costs: Costs increased from the year ended December 31, 2024, driven by higher expenses incurred for self-clearing operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clearing and Other Charges: The decrease is in line with investment
    banking activity, as these costs generally correlate with investment banking transactions, which compared to the year ended December
    31, 2024 had larger fee generating transactions.</span></td></tr>
  <tr style="height: 33.75pt; vertical-align: top">
    <td style="height: 33.75pt">&#160;</td>
    <td style="height: 33.75pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="height: 33.75pt; text-align: justify"><span style="font-size: 10pt">Other General and Administrative Costs: The primary driver for the decrease in general and administrative expenses was the deconsolidation of eXoZymes, which resulted in the removal of related operating costs from the condensed consolidated financials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Research and Development
Costs</span>.</i> For the years ended December 31, 2025 and 2024, research and development costs derived from the Company&#8217;s
technology segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025 research and development expenses decreased compared to the same period in the year ended December 31. 2024, due to the deconsolidation of
eXoZymes. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Other Income</span>. </i>For
the year ended December 31, 2025, the decrease in other income compared to the year ended December 31, 2024 was
the result of less interest generated on U.S. Treasury Bill interest from cash used in operating activities during the year. The
decrease in gain on deconsolidation of subsidiary was an event that happened in November 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equity
Method Investee</span></i>. For the year ended December 31, 2025, the increase in equity in loss of equity method investee was due to recording
the net loss for eXoZymes as equity investee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Income Taxes</span>. </i>For the year ended December 31, 2025, the increase in income taxes was
a result increased revenues at the broker-dealer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline">Broker Dealer and Intellectual
Property Service Segment (Public Ventures and PatentVest) Results of Operations for the Years Ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker dealer (Notes 1 and 2)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(331</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(275</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">(56</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gain on investment securities, net from non-licensed broker dealer (Notes 1 and 2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Realized gain on investment securities, net from the licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income (from our licensed broker dealer)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,282</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,221</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,061</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment of investment securities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(200</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">200</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">861</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">411</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">450</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,911</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,157</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,754</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,875</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,226</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(351</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,471</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,301</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">170</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,005</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">820</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">185</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">968</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">805</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">163</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">556</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,137</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(581</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">742</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">806</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(64</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,617</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8,095</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(478</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,617</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,095</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(478</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net operating (loss) income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(2,706</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(5,938</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,232</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(37</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">471</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">465</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(990</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(779</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(211</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">(Loss) income before income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,150</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,140</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,990</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net (loss) income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,161</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,979</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net (loss) income attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net (loss) income attributable to controlling interests</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,161</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,140</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,979</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Operating
Income.</span></i> For the year ended December 31, 2025, operating income was generated from the Company&#8217;s fees from investment banking transactions in the broker-dealer and patent related intellectual property services. The increase compared to the
year ended December 31, 2024 is attributable to investment banking activity, as the Company executed significantly larger
transactions in the year ended December 31, 2025. For the year ended December 31, 2024, operating income was generated from the Company&#8217;s fees
from investment banking transactions in the broker-dealer and patent related intellectual property services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">General and Administrative
Costs</span>.</i></b> During the years ended December 31, 2025, and 2024, respectively, several factors contributed to changes in various
expense categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Compensation Expense: The decrease in compensation expense was driven by departure of personnel during 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Related Party Operating Expenses: The increase is primarily due to the outsourcing of support services related to the Company&#8217;s self-clearing operations and community group within the broker-dealer, as well as services provided by the intellectual property segment.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Professional Fees: There was an increase in professional fees compared to the previous periods, primarily due to increased consulting, legal, and tax. Furthermore, there was an increase in consulting fees associated with the self-clearing operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Information Technology Costs: Information technology costs for the year ended December 31, 2025 saw an increase from the year ended December 31, 2024, driven by higher costs with the initiation of self-clearing operations and increased cloud computing costs.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clearing and Other Charges: The decrease is in line with investment
    banking activity, as these costs generally correlate with investment banking transactions, which compared to the year ended December
    31, 2024 had larger fee generating transactions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Other General and Administrative Costs: The decrease in other general and administrative costs was due to lower expenses in advertising and promotions and decreased spending on travel and conferences.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Other Income</span>. </i>For
the year ended December 31, 2025, the increase in interest expense compared to the year ended December 31, 2024 is primarily due to
inter-company subordinated loans for the broker-dealer, which are eliminated for consolidation purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Income Taxes</span>.</i>
For the year ended December 31, 2025, the increase in income taxes was a result of increased revenues at the broker-dealer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline">Technology Segment
(MDB Minnesota One and eXoZymes</span>) Results of Operations for the Years Ended December 31, 2025 and
2024. The results for eXoZymes are presented through November 14, 2024, which represents the date of deconsolidation from the
Company&#8217;s financial statements (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-size: 10pt; text-align: left">Total operating income, net</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,062</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(2,062</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,206</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(1,142</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">34</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(34</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">133</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(133</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total general and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,435</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,371</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">64</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,903</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,839</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net operating loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,903</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,839</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(92</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">92</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Interest income</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Loss before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,992</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,928</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,994</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,930</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss attributable to controlling interests</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(43</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,904</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,813</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Operating Income.</span></i></b>
There was no activity during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">General and Administrative
Costs</span>.</i></b> During the years ended December 31, 2025, and 2024, several factors contributed to changes in various
expense categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Compensation Expense: The decrease in compensation expense was attributable to the deconsolidation of eXoZymes.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Professional Fees: The decrease in professional fees was attributable to the deconsolidation of eXoZymes, that was offset by legal fees for M1.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Information Technology Costs: The decrease in information technology costs was attributable to the deconsolidation of eXoZymes.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Other General and Administrative Costs: The decrease in general and administrative costs was attributable to the deconsolidation of eXoZymes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Research and Development
Costs.</span></i> The research and development costs were incurred by the Company&#8217;s technology development segment. For the year ended
December 31, 2025, R&amp;D expenses decreased compared to the same period in the year ended December 31, 2024, due to the deconsolidation of eXoZymes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline">Consolidated Balance Sheets
at December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">ASSETS</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">13,217</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">20,437</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(7,220</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash segregated in compliance with regulations</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,331</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">844</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,487</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Receivables to related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">13</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(51</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Clearing deposits</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,738</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">262</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">433</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">488</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(55</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">124</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">25</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">99</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the licensed broker dealer (Notes 1 and 2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,166</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,858</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,308</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer (Notes 1 and 2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">235</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">235</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Equity method investment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">37,543</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">41,764</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,221</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred costs related to deferred revenue</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">27</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(13</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">117</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">90</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">27</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">547</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">641</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(94</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">63,740</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">71,976</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,236</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">LIABILITIES AND EQUITY</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">267</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">324</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(57</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">95</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">72</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Payables to customers</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,189</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">773</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,416</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Payables to related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(22</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liability</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">609</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">711</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(102</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,161</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,903</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,258</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Equity:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Paid-in-capital</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">80,493</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">68,721</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11,772</td><td style="font-size: 10pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated income (deficit)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(19,803</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,442</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21,245</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total MDB Capital Holdings, LLC Members&#8217; equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">60,690</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">70,163</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(9,473</td><td style="font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(111</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">60,579</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">70,073</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,494</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">63,740</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">71,976</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,236</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Financial Condition:</span></i></b>
Overall, the reduction in assets was primarily attributed to their utilization for operational activities during the period. The increase
in cash segregated in compliance with regulations stemmed from customer deposits. The increase
in investment securities at fair value was due to an increase in the value of common stock and warrants over the period and the receipt
of warrants for investment banking activities. The decrease in prepaid expenses stemmed from the amortization of prepaid insurance over
the period. The increase in accounts receivable is due to an increase in activity from legal and strategy fees earned. The decrease in
related party receivable is due to the payoff of a loan to an equity method investment. The decrease in equity method investment is directly
tied to the Company&#8217;s portion of the net loss. Finally, the reduction in property and equipment and right-of-use asset was due
to its regular utilization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The decrease in accounts payable
and accrued expenses stemmed from normal course of business activity. The increase in payables to customers stemmed from customer deposits. The decrease in related party payables was due to taxes paid on behalf of employees being settled
during the year ended December 31, 2025. Finally, the reduction in lease liability was due to its routine utilization.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decrease in equity was
primarily due from the current period net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in non-controlling
interest resulted from the net loss experienced by M1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity and Capital Resources &#8211; December
31, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s consolidated
statements of cash flows as discussed herein are presented below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Net cash used in operating activities</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(5,684</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(9,038</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net cash provided by (used in) investing activities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(49</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,892</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">69</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and cash equivalents</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(5,733</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,923</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2025, the
Company had working capital of $13.2 million, as compared to working capital of $19.8 million at December 31, 2024, reflecting a decrease
in working capital of $6.6 million for the year ended December 31, 2025. The decrease in working capital during the year ended December
31, 2025, was primarily the result of the expenditures to fund the Company&#8217;s operating expenses. At December 31, 2025, the Company
had cash of $15.5 million, of which $2.3 million was cash segregated in compliance with regulations that is not to fund its operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Operating Activities</span></i></b><i>.
</i>For the year ended December 31, 2025, operating activities used cash of $5.7 million. Operating activities use of cash represented
a combination of increased activity in the broker dealer, increased professional and consulting fees related to year end audits and issuance
of the tax preparation fees related to the publicly traded partnership</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December 31, 2024, operating activities used cash of
$9.0 million. The main driver for the increase in net income compared to the year ended December 31. 2024 was the
gain of the deconsolidation of eXoZymes, which was offset by stock-based compensation expense. Additional cash outflows
resulted from the accretion of U.S. Treasury Bills held at amortized cost and the acquisition of investment securities. The deconsolidation
also led to a decrease in accounts payable and grants receivable related to eXoZymes. These impacts were offset by increases in clearing
deposits and customer payables, attributable to the launch of self-clearing operations. There was also a decrease in accrued expenses
due to bonus payments made during the three months ended March 31, 2024, along with a reduction in payables to non-customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Investing Activities</span></i></b><i>.</i>
There was an investment in the development of self-clearing software for the year ended December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the year ended December 31,
2024, the increase in cash flows from investing activities was primarily attributable to the proceeds from the sale and maturity of U.S.
Treasury Bills and purchases of investment securities. These inflows were partially offset by the reinvestment of proceeds into new U.S.
Treasury Bills, transfers of cash to support operating activities, and investments in money market funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i><span style="text-decoration: underline">Financing Activities</span></i></b><i>.</i>
For the year ended December 31, 2024, financing activities consisted primarily of the non-cash recognition of previously deferred initial
public offering costs, which were reclassified to additional paid-in capital upon completion of the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Note 2 to the consolidated financial statements for the discussion
of recent accounting pronouncements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
financial statements in conformity with accounting principles general accepted in the United States requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. We have identified certain accounting policies as being critical because they require us to make difficult,
subjective, or complex judgments about matters that are uncertain. We believe that the judgment, estimates, and assumptions used in
the preparation of our audited consolidated financial statements are appropriate
given the factual circumstances at the time. However, actual results could differ, and the use of other assumptions or estimates
could result in material differences in our results of operations or financial condition. Our critical accounting estimates are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenue recognition
&#8211; Investment Banking and Warrants Valuation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company receives income
from underwriting fees. As an underwriter, the Company assists clients to raise capital via the placement of various types of investment
securities of private and publicly traded company issuers. Underwriting fees are primarily based on the issuance price and quantity of
the underlying instruments and are recognized as revenue typically upon execution of the client&#8217;s transaction. The Company generally
does not incur costs to obtain contracts with customers that are eligible for deferral or receive fees prior to recognizing revenue related
to investment banking transactions. If the Company did have any contract assets or liabilities related to these revenues it would be recorded
on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue recognition may involve
the bundling of investment banking services with other financial instruments. In such cases, we estimate the fair value of the services
provided and allocate the revenue accordingly. This estimation process involves significant judgment and sensitivity to market conditions.
Additionally, our investment banking activities may include the compensation for our services in warrants granted to us. The valuation
of these warrants requires significant estimates, including the use of option pricing models like the Black-Scholes model. The key assumptions
in this valuation process include the stock price on the date of valuation, the exercise price of the warrant, the term to expiry, risk-free
interest rate, and the expected volatility of the underlying stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Valuation Allowance
for Net Deferred Tax Asset</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A valuation allowance is provided
for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits,
or that future deductibility is uncertain. At December 31, 2025 and 2024, Public Ventures, PatentVest,
MDB Minnesota One, and MDB CG Management have established a full valuation allowance against all net deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Fair Value of Financial
Instruments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the
price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation
methodologies used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1 &#8212; Valuations
based on quoted prices for identical assets and liabilities in active markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2 &#8212; Valuations
based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable
or can be corroborated by observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 &#8212; Valuations
based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.
These valuations require significant judgment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the
price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the
market and the degree that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy
is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of U.S. Treasury
Bills and public equity securities are based on quoted market prices and are classified as level 1 of the fair value hierarchy. The fair
value of public equity securities that are not actively traded is based on quoted market prices of similar instruments and other significant
inputs derived from or corroborated by observable market data and are classified as level 2 of the fair value hierarchy. The fair value
of warrants is based on a Black-Scholes model, which considers the stock price at the date of the valuation, the warrant strike price,
the term to expiry, the risk-free rate of return, and the expected volatility of the underlying stock. The level in the fair value hierarchy
for warrants depends primarily on whether the stock price is determinable from active trades, and whether the expected volatility of the
underlying stock is observable and are either classified as level 2 or level 3. The fair value of non-public equity securities and simple
agreements for future equity is based on the initial investment, less impairment, and they are classified as level 3 in the fair value
hierarchy. For the significant unobservable inputs and assumptions used in level 3 fair value measurements, see Fair Value of Financial
Instruments section of Note 2: <i>Summary of Significant Accounting Policies</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Accounting for Research
Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has and will
develop partner companies that receives, grant reimbursements, which are netted against research and development expenses in the consolidated
statement of operations. Grant reimbursements for capitalized assets are recognized over the useful life of the assets, with the unrecognized
portion considered a deferred liability and are included in accounts payable and accrued expenses in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grants that operate on a reimbursement
basis are recognized on the accrual basis are revenues to extent of disbursements and commitments that are allowable for reimbursement
of allowable expenses incurred as of December 31, 2025 and 2024 and expected to be received from funding sources in the subsequent year.
Management considers such receivables at December 31, 2024 to be fully collectable, there were no grant receivables at December 31, 2025, due to the historical experience with the
Federal Government of the United States of America. Accordingly, no allowance for grants receivable was recorded in the accompanying consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research grants received from organizations are subject to the contract
agreement as to how our partner companies conducts their research activities, and our partner companies are required to comply with the
agreement terms relating to those grants. Amounts received under research grants are nonrefundable, regardless of the success of the underlying
research project, to the extent that such amounts are expended in accordance with the approved grant project. Our partner companies are
permitted to draw down (a process of submitting expenses for reimbursement) the research grants after incurring the related expenses.
Amounts received under research grants are offset against the related research and development costs in the Company&#8217;s consolidated
statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Stock Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and its subsidiaries
may periodically issue common shares, stock options and restricted stock units to officers, directors, employees, and consultants for
services rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are
generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock-based
payments to officers, directors, employees, and consultants by measuring the cost of services received in exchange for equity awards utilizing
the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company&#8217;s
financial statements over the vesting period of the awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of share options
granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables,
the most significant of which are the expected life of the stock option, the exercise price of the share option as compared to the fair
market value of the common shares on the grant date, and the estimated volatility of the common shares. Unless sufficient historical exercise
data is available, the expected life of the stock option is calculated as the mid-point between the vesting period and the contractual
term (the &#8220;simplified method&#8221;). The estimated volatility is based on the implied volatility by using comparable companies
of the Company&#8217;s common shares, calculated utilizing a look-back period approximately equal to the contractual life of the stock
option being granted. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market
value of the common shares is determined by reference to the quoted market price of the Company&#8217;s common shares on the grant date.
The expected dividend yield is based on the Company&#8217;s expectation of dividend payouts and is assumed to be zero. The fair value
of performance based restricted stock units was determined by using an independent valuation expert.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Business Activities and Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 20, 2023, the Company completed an IPO, which consisted of the sale of 1.67 million shares of Class A Common Shares at $12.00 per share, for gross proceeds of $20.0 million
that have been used for operations and funding its partner companies, as well as identifying and developing new partner companies.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 14, 2024, eXoZymes,
formerly known as Invizyne, previously a corporate subsidiary of the Company, completed its initial public offering,
reducing MDB&#8217;s ownership interest to 47%. As a result, the Company no longer consolidates eXoZymes Inc for financial reporting purposes
and now accounts for its investment using the equity method under ASC 323-Investments&#8212;Equity Method and Joint Ventures. For federal income tax purposes, MDB is treated as a partnership
and is not subject to entity-level taxation. As a result, no deferred tax assets (&#8220;DTAs&#8221;) or deferred tax liabilities (&#8220;DTLs&#8221;)
are recognized at the partnership level for differences between the book and tax basis of the equity method investment. Any tax consequences
related to book-tax basis differences will be recognized at the partner level upon disposition of the investment or other taxable events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>External Risks Associated with the Company&#8217;s
Business Activities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Inflation Risk</span>.</i>
The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general
economy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Supply Chain Issues</span>.</i>
The Company does not currently expect that supply chain issues will have a significant impact on its business activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">Potential Recession</span>.</i>
There are various indications that the United States economy may be entering a recessionary period. Although unclear at this time an economic
recession would likely impact the general business environment and the capital markets, which could, in turn, affect the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is continuing
to monitor these matters and will adjust its current business and financing plans as more information and guidance become available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principal Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Net Capital Requirement
(Public Ventures</i></b><i>)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Public Ventures is subject to
the uniform net capital rule (SEC Rule 15c3-1) of the SEC, which requires both
the maintenance of minimum net capital and the maintenance of maximum ratio of aggregate indebtedness to net capital. At December 31,
2025 and 2024, Public Ventures had net capital of $8.7 million and $10.7 million, respectively, which was $8.45 million and $10.45 million
in excess of the minimum $0.25 million, as required by the SEC Commission Rule 15c3-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has subordinated loans
with its Parent company totaling $13.2 million and $1.8 million of accrued interest payable, which is subordinated to other liabilities
of the Company, and is considered members&#8217; equity for calculating net capital, and is not included in aggregate indebtedness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Minimum net capital is based upon
the greater of the statutory minimum net capital of $0.25 million or 2% of aggregate customer debits, which was $0 at December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To comply with to DTCC membership
requirements, the Company has committed to maintain at least $5.0 million of net capital in excess of the $0.25 million minimum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirement to comply
with the Uniform Net Capital Rule 15c3-1 may limit Public Ventures&#8217; ability to issue dividends to its parent company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Indemnification Provisions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Public Ventures has agreed
to indemnify its clearing broker for losses that the clearing broker may sustain from the accounts of customers. Should a customer not
fulfill its obligation on a transaction, Public Ventures may be required to buy or sell securities at prevailing market prices in the
future on behalf of its customer. The indemnification obligations of Public Ventures to its clearing brokers have no maximum amount. All
unsettled trades at December 31, 2025 and 2024, have subsequently settled with no resulting material liability to Public Ventures. For
the years ended December 31, 2025 and 2024, Public Ventures had no material loss due to counterparty failure, and had no obligations outstanding
under the indemnification arrangement as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>MDB Minnesota One</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 1, 2024, MDB Minnesota
One (&#8220;M1&#8221;) entered into a Patent and Know-How License Agreement (the &#8220;License Agreement&#8221;) with the Mayo Foundation
for Medical Education and Research (&#8220;Mayo&#8221;) for certain patent rights and associated technology pursuant to which M1 intends
to develop a small molecule senescence platform. The License Agreement grants M1 rights to develop and commercialize Mayo&#8217;s patented
technology and know-how for all fields of use on a worldwide basis. Under the terms of the License Agreement, M1 holds an exclusive license
of patent rights and a non-exclusive license for the associated technology to make, have made, use, offer for sale, sell, and import licensed
products and derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of initial consideration
for the License Agreement, M1 issued 1.98 million shares of common stock equity to Mayo; which at that time represented thirty-three percent
of its shares. M1 also paid an initial license fee of $0.15 million as part of the initial consideration. M1 will pay earned royalties
on future net sales (including modest minimum annual royalties, which commence in the second year of the term of the License Agreement
and gradually increase and plateau over time, and which will be credited against earned royalties due on net sales), and a percentage
of any sublicensing income. The earned royalty commences after the first commercial sale of a licensed product. At December 31, 2025 there
were no accrued royalties recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the License Agreement,
M1 is required to achieve certain development milestones within designated time periods. For select development milestones, as listed
below, M1 will be required to make a payment to Mayo, also as noted below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">A payment of $0.25 million for Phase II clinical trial initiation, for the first instance of a
licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">A payment of $1.5 million for Phase III clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">A payment of $2 million for FDA New Drug Application (NDA) acceptance, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">A payment of $5 million for NDA approval, for each instance of a licensed product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 the development milestones noted above are not required to have been met and have not been met. There are other
developmental milestones in the License Agreement relating to funding of the business and to initiating various clinical trial phases
over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M1
is currently in the pre-clinical development stage of the M1 Platform and is undertaking important feasibility studies, iterative testing,
and collection of drug safety and toxicity data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trends, Events and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as discussed above,
we are not currently aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition
in the near term, although it is possible that new trends or events may develop in the future that could have a material effect on our
financial condition</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_013"></span>Item 7A. Quantitative and Qualitative Disclosures
About Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company, as defined by Rule 12b-2 of the Exchange Act, therefore are not required to provide the information under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_014"></span>Item 8. Financial Statements and Supplementary
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are included herein, beginning on page F-1. The information required by this item is incorporated herein by reference to the
consolidated financial statements set forth in Item 15. &#8220;Exhibits and Financial Statement Schedules&#8221; of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><b><span id="a_015"></span>Item 9. Changes in and
Disagreements with Accountants on Accounting and Financial Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt"><b><span id="a_016"></span>Item 9A.
Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <i>Evaluation of Disclosure
Controls and Procedures. </i>Based on management&#8217;s evaluation (with the participation of our Chief Executive Officer (CEO) and Chief
Financial Officer (CFO)), as of the end of the period covered by this report, our CEO and CFO have concluded that our disclosure controls
and procedures (as defined in Rules 13a-15I and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), are
effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the
Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated
and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely
decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <i>Inherent Limitation
on Controls. </i>Management, including the CEO and CFO, does not expect that our disclosure controls and procedures will prevent or detect
all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide
only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance
that misstatements due to errors or fraud will not occur or that all control issues and instances of fraud, if any, within the Company
have been detected. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls
must be considered relative to their costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <i>Management</i>&#8217;<i>s
Report on Internal Control over Financial Reporting. </i>Our management is responsible for establishing and maintaining adequate internal
control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control
over financial reporting includes policies and procedures that: (a) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect our transactions and dispositions of assets; (b) provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that
our receipts and expenditures are being made only in accordance with authorizations of our management and Board of Directors; and (c)
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
could have a material effect on our financial statements. Our internal control over financial reporting is a process designed with the
participation of our principal executive officer and principal financial officer or persons performing similar functions to provide reasonable
assurance to our management and board of directors regarding the reliability of financial reporting and preparation of financial statements
for external purposes in accordance with generally accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management holds the
responsibility for preparing accurate financial statements and ensuring they faithfully represent our financial status and
operations in line with accounting principles generally accepted in the Untied States (GAAP).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also tasked with establishing
and upholding sufficient internal controls over financial reporting, as stipulated in the Exchange Act. These controls aim to offer reasonable
assurance about the fairness of our financial reporting and the accuracy of financial information. Despite the robust nature of our internal
control systems, they are subject to inherent limitations, including human error and the potential bypassing of controls, thus providing
only reasonable&#8212;not absolute&#8212;assurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our internal controls over
financial reporting encompass procedures for maintaining detailed records that reflect our transactions accurately, ensuring transactions
are recorded as needed for financial statement preparation in compliance with GAAP, and safeguarding company assets through authorized
management and director actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a thorough evaluation led by our Chief Financial Officer, based on
the Committee of Sponsoring Organizations of the Treadway Commission (COSO)2013 framework, based on its evaluation, our management concluded
that our internal control over financial reporting was effective as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K does not include an attestation from our public accounting firm regarding internal control over financial reporting, following SEC rules
that allow us to present only management&#8217;s report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A material weakness in our internal control framework, identified during
the fiscal year ended December 31, 2024, was fully remediated and corrected in during 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company remains steadfast
in our commitment to maintaining robust internal controls and financial reporting processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Inherent Limitations on Effectiveness of Controls
and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s management,
including the Chief Executive Officer and Chief Financial Officer, believes that disclosure controls and procedures and internal control
over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable
assurance level. However, management does not expect that the disclosure controls and procedures or the internal control over financial
reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company
have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures
may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur
and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt"><b><span id="a_017"></span>Item 9B.
Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_904_ecustom--NoInsiderTradingFlag_dbT_c20250101__20251231_z0jGQeMgltlg" title="No insider trading flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000058" name="MDBH:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_018"></span>Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_019"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt"><b><span id="a_020"></span>Item 10.
Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Information about our Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s current
directors as of the filing date of this report are set forth below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 8%"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 56%"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Christopher Marlett</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer, Chairman of Board and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Anthony DiGiandomenico</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">59</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Head of New Venture Discovery, and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">George Brandon</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">66</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">President, and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Mo Hayat</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Head of Corporate Development &amp; Chief Legal Officer, and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Jeremy James</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">48</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">Daniel Torpey</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Sean Magennis</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>

<tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Jeb Terry</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">71</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Christopher Marlett</i></b>.
Christopher Marlett has been the chief executive officer and chairman of the board of directors and a director of the Company since inception
on August 10, 2021. Mr. Marlett has been since 1997, the Chief Executive Officer and a co-founder of Public Ventures (formerly known as
MDB Capital Group, LLC). Over his 36 years of working in the securities industry, he has led multiple financings for venture stage public
companies and has dedicated his efforts to optimizing this method to launch promising technology/business platforms. He has been integral
in co-founding and developing the commercialization and financing strategy for all the companies MDB has taken public. In addition, he
has served as a board member of several of the public companies in the early stages. He has invested significant efforts in developing
a human capital development platform in Nicaragua that has led to the creation of the largest call center park in the country employing
approximately 3,000 people and several knowledge process outsourcing operations to support MDB&#8217;s businesses. He developed the first
patent services company in Nicaragua that was sold to Murgitroyd an LSE-listed patent attorney and services platform. He is the co-founder
of PatentVest and developed the platform from inception in 2003. He holds a Bachelor of Science degree in Business Administration from
the University of Southern California. Mr. Marlett&#8217;s leadership and financial experience position him well to serve as a member
of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Anthony DiGiandomenico</i></b>.
Anthony DiGiandomenico has been the Head of New Venture Discovery and director since the inception of the Company on August 10. 2021.
He has also served on the board of directors of ENDRA Life Sciences Inc. (Nasdaq: NDRA), a developer of enhanced ultrasound technology,
from July 2013 until present, the board of directors of Provention Bio, Inc., a developer of multiple drug therapies, from January 2017
until May 2020 and the board of directors of Cue Biopharma, Inc., that develops novel biologic drugs for the selective modulation of the
human immune system to treat a broad range of cancers and autoimmune disorders from January 2016 to October 2019. Since he co-founded
Public Ventures (formerly known as MDB Capital Group, LLC) in 1997, Mr. DiGiandomenico has been enabling investment into early-stage disruptive
technologies. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy
spaces. Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a BS in Finance
from the University of Colorado. Mr. DiGiandomenico&#8217;s financial expertise, general business acumen and significant executive leadership
experience position him well to make valuable contributions to our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>George Brandon</i></b>.
George Brandon has served as President of the Company since its inception on August 10, 2021, and as a director of the Company since January
14, 2022. Mr. Brandon&#8217;s 36 years of varied investment experience has included the last 12 years with Public Ventures (formerly known
as MDB Capital Group, LLC). Mr. Brandon&#8217;s business focus has primarily been marketing &amp; strategy development and community building
in and around entrepreneurial start-ups, micro-cap, and small-cap companies. Prior to joining MDB, he served as a partner of Trinity River
Advisors, LLC, a turnaround consulting firm targeting small companies dealing with financial distress. He received his education at Concordia
University in Irvine, CA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Mohammad &#8220;Mo&#8221;
Hayat</i></b>. Mo Hayat has served as the Head of Corporate Development and Chief Legal Officer of the Company since May 2024, Chief of
Entrepreneurship &amp; Operations of the Company since its inception on August 10, 2021 to May 2024, and as a director of the Company
since January 14, 2022. Mr. Hayat has also served as the Chief Executive Officer of Invizyne Technologies Inc (currently eXoZymes Inc)
since its inception in April 2019 to August 2022, the role of President from August 2022 to February 2025, and in the role of Executive
Chairman of Invizyne Technologies Inc (currently eXoZymes Inc) from inception in April 2019 to February 2025. Mr. Hayat founded and has
operated Mora Partners Inc., a consulting and investment firm since September 2006. Notable prior experiences for Mr. Hayat include serving
as an Associate at Latham and Watkins from 2001 to 2006, as Partner at Raines Law Group from 2006 to 2009, as EVP of Business Development
at Fulham Company Ltd from 2009 to 2015, and as Associate General Counsel Corporate, M&amp;A, and Venture Capital at Hewlett Packard Enterprise
from 2015 to 2017. Mr. Hayat also served on the board of directors of Fulham Company Ltd. from January 2019 to August 2022. Mr. Hayat
received his Juris Doctorate in 2001 from UC Berkeley School of Law and a Bachelor of Science in Biological Chemistry in 1997 from Pepperdine
University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Jeremy James</i></b>.
Jeremy James has been the Chief Financial Officer of the Company since May 2024, before that he served as the Chief Accounting Officer
of the Company from June 2022 to May 2024. From December 2020 to June 2022, Mr. James served as Vice President/Controller of Cottonwood
Financial. From November 2016 to September 2020, Mr. James served as the Director of Revenue of Orthofix. From January 2012 to November
2016, Mr. James served as a Senior Manager in the consulting practice of Ernst and Young. From May 1999 to January 2012, Mr. James served
as a Manager with CBIZ/Mayer Hoffman McCann, an audit and tax firm. Mr. James received a Bachelor of Science degree in Accounting from
Azusa Pacific University. Mr. James is a Certified Public Accountant licensed in the states of Texas and California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sean Magennis</i></b>.
Sean Magennis has served as a director of the Company since May 2, 2022. Mr. Magennis has served as Chairman of Mutual Capital Alliance
since January of 2023. Mr. Magennis has served as President of CEO Coaching International, a global CEO coaching business, from November
2021 to November 2022. Previously, Mr. Magennis served as CEO and Chairman of Capital 54, a family office, from July 2020 to November
2021, as Global President and COO of YPO, a global community of chief executives, from May 2013 to July 2020, as Member of Gateway Green
Energy Holdings, LLC, an operator power plants and energy assets, from 2009 to present, as President of Meximae Financiera Corporation,
a real estate developer in Mexico, from January 2003 to August 2008, as President of Thomas International Management Systems from 1991
to 2003, as President of Thomas International, A Caldwell Interest, from 1992 to 1996, and Global President, Board Member and Chapter
Chairman of Entrepreneurs Organization from 1991 to 2007. Mr. Magennis is a decisive and proactive business builder with extensive growth,
acquisition, turnaround, and international experience. He is adept at developing high performing teams who deliver results through collaboration.
He combines vision with positive pragmatism to transform strategies into actionable, measurable opportunities utilizing strong analytical
and problem-solving skills.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Daniel &#8220;Dan&#8221;
Torpey</i></b>. Daniel &#8220;Dan&#8221; Torpey has served as an independent director of the Company since June 17, 2024. Mr. Torpey retired
as an Assurance partner from Ernst &amp; Young LLP after a 25-year career where he was a member of the Audit and Forensic and Integrity
practices where he held various leadership positions. He is a qualified financial expert pursuant to the rules of the Securities and Exchange
Commission, NYSE and NASDAQ and serves as the Chairperson of the Audit Committee for the Company. Mr. Torpey is a Certified Public Accountant
licensed in the state of New York and Texas and is a Certified Director of the National Association of Corporate Directors (NACD). Prior
to Ernst &amp; Young LLP, he was a partner at Arthur Anderson LLP from July 2001 &#8211; May 2002, and a partner and held various other
titles at PricewaterhouseCoopers (and its predecessor firm Coopers &amp; Lybrand) from 1992 &#8211; 2001. Mr. Torpey served as an auditor
in EY&#8217;s audit practice from 1989 &#8211; 1992. Mr. Torpey served as a staff and senior accountant at Matson Driscoll &amp; Damico,
LLP. from 1986-1989. Mr. Torpey&#8217;s experience allows him to add auditing, accounting, technology and analytics, governance and leadership
expertise to the Company. Mr. Torpey received his Bachelor of Science in Accountancy from St. John&#8217;s University, Jamaica, New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Jeb Terry, Sr.</i></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Jeb Terry, Sr. is a seasoned investor with more than 20 years of expertise in microcap medical and biotechnology companies, where he
has consistently identified and capitalized on high-potential opportunities in this dynamic and innovation-driven sector. Drawing on
a career spanning venture capital, leveraged buyouts, emerging international markets, and public equities, Mr. Terry brings a multifaceted
perspective to investment decision-making.&#160;Since January 1, 2026 Mr. Terry has managed his personal family office and is also currently
managing the Wilson Foundation since December 2015.&#160;&#160;Previously, Mr. Terry founded and served as President of Aberdeen Investment
Management LLC from September 2010 through December 31, 2025, where he led investment strategy and portfolio management with a sharp
focus on undervalued microcap opportunities in life sciences. Prior to founding Aberdeen Investment Management, Mr. Terry held senior
roles at a top-20 commercial bank, advised ultra-high-net-worth family offices, and worked within a bulge-bracket investment bank. Mr.
Terry was a principal in venture capital and private equity and founded and managed a hedge fund specializing in dynamic hedging strategies
for concentrated public holdings on behalf of large family office<b>&#160;</b>clients. Mr. Terry holds an MBA from Columbia Business
School and a BBA from Southern Methodist University</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Composition/Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
currently consists of seven persons. Under our operating agreement the board of directors may establish the number of persons
serving on the board of directors from time to time by resolution, up to a maximum of 12 persons. Three of our directors, Daniel
Torpey, Sean Magennis and Jeb Terry are independent within the meaning of Nasdaq&#8217;s rules. Jeb Terry and Daniel Torpey are
&#8220;financial experts&#8221; as that term is defined in SEC regulations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because our Class B Common
Shares are held by two persons and represents more than 50% voting control of MDB, we are a &#8220;controlled company&#8221; under the
listing rules of Nasdaq. As a controlled company, we are exempt from many of the corporate governance obligations that other companies
must follow when listed on Nasdaq. Management intends to take advantage of these exemptions as long as it is a controlled company. As
such, we will be exempt from the certain of the corporate governance rules under the Rule 5600 Series, as follows: (i) having a board
comprised of a majority of independent directors (Rule 5605(b)), iii) having a compensation committee (Rule 5605(d)), and (iii) having
a director nominations committee (Rule 5605(e)). Additionally, we are not required to hold annual meetings. Notwithstanding these exemptions,
we have an audit committee comprised solely of independent directors, which among other things reviews related party transactions. Also,
notwithstanding the exemptions, Class A Common shareholder approval will be required for stock option or purchase plans, and our financial
statements must be audited by an independent public accountant that is registered with the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established an audit
committee. The audit committee is responsible for, among other things: (i) retaining and overseeing our independent accountants; (ii)
assisting the board of directors in its oversight of the integrity of our financial statements, the qualifications, independence and performance
of our independent auditors; (iii) reviewing and approving the plan and scope of the internal and external audit; (iv) pre-approving any
audit and non-audit services provided by our independent auditors; (v) approving the fees to be paid to our independent auditors; (vi)
reviewing with our chief executive officer and chief financial officer and independent auditors the adequacy and effectiveness of our
internal controls; (vii) reviewing hedging transactions; and (viii) reviewing and assessing annually the audit committee&#8217;s performance
and the adequacy of its charter. The audit committee also reviews and approves all transactions with affiliated parties. Our board of
directors has adopted a written charter for the audit committee, which is available on our website.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the Audit Committee
are Dan Torpey, Sean Magennis and Jeb Terry, each of whom satisfies the &#8220;independence&#8221; requirements of Rule 10A-3 under the
Exchange Act and Rule5605(c)(2) of the Nasdaq Marketplace Rules. Mr. Torpey serves as the chairman of the audit committee. Each of Messrs.
Jeb Terry and Dan Torpey is a &#8220;financial expert&#8221; as that term is defined in SEC regulations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board&#8217;s Role in Risk Oversight</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors is
primarily responsible for overseeing our risk management processes. Our board of directors, as a whole, determines our appropriate level
of risk, assesses the specific risks that we face, and reviews management&#8217;s strategies for adequately mitigating and managing the
identified risks. Although our board of directors administers this risk management oversight function, one or more committees of our board
of directors may support our board of directors in discharging its obligations. For example, the audit committee reviews our major financial
risk exposures and the steps management has taken to monitor and control such exposures and it will reviews matters relating to legal
compliance that have a material effect on the Company financial statements and certain other limited areas of governance and will report
to our board of directors regarding such matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted a code of business conduct and ethics that applies to all of our employees, officers, and directors. The full text of our code
of business conduct and ethics will be posted on the Investor Relations section of our website. The reference to our website address in
this filing does not include or incorporate by reference the information on our website into this filing. We intend to disclose future
amendments to certain provisions of our code of business conduct and ethics, or waivers of these provisions, on our website or in public
filings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Insider Trading Arrangements and Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted an insider
trading compliance policy governing the purchase, sale, and/or other dispositions of our securities by our directors, officers, and employees
that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the exchange listing
standards applicable to us. The insider trading policy prohibits the use of material non-public information about the Company when making
decisions to purchase, sell, give away or otherwise trade in the Company&#8217;s securities or to provide such information to others outside
the Company. We have established black-out periods to which covered persons are subject related to the filing of our regular reports with
the Securities and Exchange Commission. The Company may impose additional black-out periods from time to time as other types of material
non-public information occur when material non-public events or disclosures are pending. Covered persons are permitted to trade in the
Company&#8217;s securities only when there is no black-out period in effect and such trade has been pre-cleared by the appointed Company
officer, or when a qualified 10b5-1 plan has been established in accordance with federal securities laws. No covered person has adopted
or terminated a Rule 10b5-1 trading plan during the last fiscal quarter of the fiscal year to which this report relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clawback Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted a written policy to recover &#8220;excess&#8221; compensation that is granted, earned, or vested based wholly or in part upon
the attainment of a financial reporting measure. The compensation includes both cash-based and equity-based incentives. The compensation
covered includes incentive awards awarded to any individuals (including former employees) who served as an executive officer during the
three most recently completed fiscal years preceding the date on which the preparation of an accounting restatement is required, provided
that the executive officers were awarded more incentive awards than they would have received if the financial statements had been prepared
correctly. The recovery will include an executive incentive award even if the executive was not involved in preparing the financial statements
or did not commit misconduct that led to the restatement. Restatements attributable to an inadvertent error also will subject executive
officers to the recovery of previously received incentive awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Section 16(a) Beneficial Ownership Reporting
Compliance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) requires our executive officers, directors and persons who beneficially
own more than 10% of our common stock to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons
are required by SEC regulations to furnish us with copies of all Section 16(a) reports filed by such persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based solely on our review
of the copies of reports furnished to us, we believe that during the fiscal year ended December 31, 2025, all executive officers, directors
and greater than 10% beneficial owners of our Class A and Class B Common Shares complied with the reporting requirements of Section 16(a)
of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Principles for Members of Board
of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not provide director fees to board members who also receive salaries
from MDB, its subsidiaries, or partner companies. Should we appoint independent directors, the board of directors will decide their compensation
upon their appointment and on an ongoing basis thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any defined
a compensation plan for our directors. We may adopt one or more forms of compensation arrangements, including cash and stock-based compensation
arrangements in the future. Any stock-based compensation plans will be subject to the approval of the holders of the Class A Common Shares
as required by the listing rules of Nasdaq and any other applicable laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also will reimburse any
persons that are independent members of our board of directors for their reasonable expenses incurred in connection with attending meetings
of our board of directors, committee meetings and other activities they undertake on our behalf and on behalf of our subsidiaries and
partner companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the compensation
earned by or awarded or paid in 2025 and 2024 to the individuals who served as our independent directors during such period (in thousands).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fee</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Bonus</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options<br/>
Awards</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Nonequity<br/>
Incentive<br/>
Plan<br/>
Compensation</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Nonqualified<br/>
Deferred<br/>
Compensation<br/>
Earnings</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>All Other<br/>
Compensation</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 29%"><span style="font-size: 10pt">Susanne Meline</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 4%; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">50</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">34</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">84</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">136</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">186</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Matthew Hayden</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">26</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">76</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">272</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">322</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Sean Magennis</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">34</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">84</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">136</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">186</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Dan Torpey</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">118</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">75</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Limitation of Liability of Directors and Indemnification
of Directors and Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB provides indemnification
to each person who was or is a party or is threatened to be made a party to or is involved in any threatened, pending, or completed action,
suit, or proceeding, whether civil, criminal, administrative, or investigative by reason of the fact that he, or a person of whom he is
the legal representative, is or was a director or officer or is or was serving at the request of MDB as a director or officer of another
corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to employee benefit plans against
all expenses, liability, and loss. The board may authorize the advance of expenses in connection with any proceeding where the person
is entitled to indemnification. MDB may purchase and maintain insurance to protect itself and any director, officer, employee or other
agent against any expense, whether or not MDB would have the power to indemnify the person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing
provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed
in the Securities Act and is, therefore, unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into indemnification
agreements with each of the persons serving on the board of directors and executive officers of MDB. The indemnification agreements provide
for indemnification against expenses, judgments, fines and penalties actually and reasonably incurred by an indemnitee in connection with
threatened, pending or completed actions, suits or other proceedings, subject to certain limitations. The indemnification agreements also
provide for the advancement of expenses in connection with a proceeding prior to a final, non-appealable judgment or other adjudication,
provided that the indemnitee provides an undertaking to repay to us any amounts advanced if the indemnitee is ultimately found not to
be entitled to indemnification by us. The indemnification agreement sets forth procedures for making and responding to a request for indemnification
or advancement of expenses, as well as dispute resolution procedures that apply to any dispute between us and an indemnitee arising under
the indemnification agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also arrange that there
are indemnification agreements between our partner companies and their officers and directors. These indemnification agreements provide
for indemnification against expenses, judgments, fines and penalties actually and reasonably incurred by an indemnitee in connection with
threatened, pending or completed actions, suits or other proceedings, subject to certain limitations. The indemnification agreements also
provide for the advancement of expenses in connection with a proceeding prior to a final, non-appealable judgment or other adjudication,
provided that the indemnitee provides an undertaking to repay to us any amounts advanced if the indemnitee is ultimately found not to
be entitled to indemnification by us. The indemnification agreement form sets forth procedures for making and responding to a request
for indemnification or advancement of expenses, as well as dispute resolution procedures that apply to any dispute between us and an indemnitee
arising under the indemnification agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_021"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section provides an overview
of the compensation awarded to, earned by, or paid to each individual who served as our principal executive officer and our next two most
highly compensated executive officers in respect of their service to our company during the years ended December 31, 2025, and 2024. The
amounts indicated for the year ending December 31, 2025, do not include any amounts that may be awarded in 2026 as bonus compensation
for 2025. We refer to these individuals as our named executive officers. The compensation information disclosed herein for our three named
executive officers is disclosed in accordance with SEC requirements; such disclosure does not include the compensation for our other executive
officers. Our named executive officers for the years ended December 31, 2025 and 2024 respectively, are (in thousands):</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Name and<br/>
Principal Position</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Salary</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Bonus</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Options<br/>
Awards</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Non-equity<br/>
Incentive<br/>
Plan<br/>
Compensation</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Nonqualified<br/>
Deferred<br/>
Compensation<br/>
Earnings</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>All Other<br/>
Compensation</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 29%"><span style="font-size: 10pt">Christopher Marlett, CEO </span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 4%; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">350</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; text-align: right"><span style="font-size: 10pt">1,350</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">350</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">340</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">13</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">703</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Mo Hayat, Head of Corporate Development &amp; Chief Legal Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">681</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">152</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,133</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Anthony DiGiandomenico, Head of New Venture Discovery</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1,300</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">300</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">340</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">13</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">653</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options Exercisable as of December 31, 2025
and 2024 (in thousands, except exercise price):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of<br/> securities<br/> underlying<br/> unexercised<br/> options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercisable</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of<br/> securities<br/> underlying<br/> unexercised<br/> options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>unexercisable</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Equity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>incentive</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>plan awards:<br/> Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>securities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>underlying</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>unexercised</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>unearned</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>options</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Option</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercise price</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Option</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>expiration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>date</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; width: 20%">Christopher Marlett, CEO</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; width: 10%">2025</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">267</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; text-align: right">633</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">4.25</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt; text-align: right">04/28/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.44</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">01/31/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Mo Hayat, Head of Corporate Development &amp; Chief Legal Officer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">267</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">633</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4.25</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">04/28/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">244</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">68</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.44</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">01/31/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Anthony DiGiandomenico, Head of New Venture Discovery</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">267</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">633</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4.25</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">04/28/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2.44</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: right">01/31/2028</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, in addition
to the cash compensation, we grant equity based awards to our named executive officers, which are generally subject to vesting based on
each of our named executive officer&#8217;s continued service with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Employment Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Christopher Marlett </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, through MDB Management,
entered into an employment agreement with Christopher Marlett on April 15, 2022. Mr. Marlett acts as the Chief Executive Officer of the
Company. Mr. Marlett is paid an initial base annual salary of $350 thousand, which may be increased at the discretion of the board of
the Company. He is also entitled to an annual bonus each fiscal year, one-third of which is purely discretionary, and two-thirds of which
to be determined by the board of the Company based on agreed key performance indicators. Mr. Marlett is entitled to participate in benefit
plans of the Company generally available to employees and executives. Mr. Marlett will generally work in the Dallas, Texas metropolitan
area, and he is to be reimbursed for expenses associated with his employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Marlett was granted one
million RSUs for Class A Common Shares which vest over five years of the employment agreement, a portion of the RSUs have a performance
condition tied to the vesting, contingent on his continued employment with the Company. On April 15, 2024 Mr. Marlett forfeited 50 thousand
RSUs, leaving 950 thousand RSUs available for vesting. In April 2025 the remaining 900 thousand RSUs were exchanged for 900 thousand stock
options, after 50 thousand RSUs had vested in 2024. Of the 900 thousands stock options, 400 thousand stock options are time vesting, while 500 thousand stock options
only vest only when a United States national securities exchange and before the ten year anniversary of the date of grant, if and when
(y) a Class A Common Share has traded in the market on which the Class A Common Shares are listed for any 90 consecutive calendar days
at an average price of $20.00 or more during the period commencing the date of grant and prior to the ten year anniversary of the date
of grant, with an average monthly trading volume of 2.0 million Class A Common Shares or more during the 90 consecutive calendar day period,
or (z) a Class A Common Shares has traded in the market on which the Class A Common Shares are listed for any 90 consecutive calendar
days at an average price of $25.00 or more during the period commencing the date of grant and prior to the ten year anniversary of the
date of grant; provided further, that if there is a distribution of cash, stock or other property by the Company on the Class A Common
Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced by the value of any one or more per share distributions
after the date of grant until vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreement for
Mr. Marlett provides for termination under a number of circumstances, including for and without cause, all of which are set forth with
particularity in the agreement. Depending on the circumstance, Mr. Marlett will be paid certain severance amounts of up to a year&#8217;s
salary and pro rata amounts of the annual bonus, and various insurance premiums for health, dental and vision continued under the COBRA
benefits. The agreement provides, in addition to any director indemnification agreement, indemnification in relation to acts undertaken
as an executive of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mo Hayat </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, through MDB Management,
entered into an employment agreement with Mo Hayat on April 15, 2022. Mr. Hayat currently acts as the Head of Corporate Development and
Chief Legal Officer of the Company. Mr. Hayat is paid an initial base annual salary of $300 thousand, which may be increased at the discretion
of the board of the Company. He is also entitled to an annual bonus each fiscal year, one-third of which is purely discretionary, and
two-thirds of which to be determined by the board of the Company based on agreed key performance indicators. Mr. Hayat is entitled to
participate in benefit plans of the Company generally available to employees and executives. Mr. Hayat will generally work in the Los
Angeles, California metropolitan area, and he is to be reimbursed for expenses associated with his employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Hayat was granted one million
RSUs for Class A Common Shares which vest over five years of the employment agreement, a portion of the RSUs have a performance condition
tied to the vesting, contingent on his continued employment with the Company. In April 2025 the remaining 900 thousand RSUs were exchanged
for 900 thousand stock options, after 100 thousand RSUs had vested in 2024.  Of the 900 thousands stock options, 400 thousand stock options are time vesting, while 500 thousand stock options
only vest only when a United States national securities exchange and before the ten year anniversary of the date of grant, if and when
(y) a Class A Common Share has traded in the market on which the Class A Common Shares are listed for any 90 consecutive calendar days
at an average price of $20.00 or more during the period commencing the date of grant and prior to the ten year anniversary of the date
of grant, with an average monthly trading volume of 2.0 million Class A Common Shares or more during the 90 consecutive calendar day period,
or (z) a Class A Common Shares has traded in the market on which the Class A Common Shares are listed for any 90 consecutive calendar
days at an average price of $25.00 or more during the period commencing the date of grant and prior to the ten year anniversary of the
date of grant; provided further, that if there is a distribution of cash, stock or other property by the Company on the Class A Common
Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced by the value of any one or more per share distributions
after the date of grant until vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreement for
Mr. Hayat provides for termination under a number of circumstances, including for and without cause, all of which are set forth with particularity
in the agreement. Depending on the circumstance, Mr. Hayat will be paid certain severance amounts of up to a year&#8217;s salary and pro
rata amounts of the annual bonus, and various insurance premiums for health, dental and vision continued under the COBRA benefits. The
agreement provides, in addition to any director indemnification agreement, indemnification in relation to acts undertaken as an executive
of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Jeremy James </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, through MDB Management,
has employed Mr. Jeremy James on an at-will basis since June 8, 2022. Mr. James currently acts as the Chief Financial Officer of the Company.
Mr. James is paid an initial base annual salary of $250 thousand, which may be increased at the discretion of the board of the Company.
He is also entitled to an annual bonus each fiscal year, one-third of which is purely discretionary, and two-thirds of which to be determined
by the board of the Company based on agreed key performance indicators. Mr. James is entitled to participate in benefit plans of the Company
generally available to employees and executives. Mr. James will generally work in the Dallas, Texas metropolitan area, and he is to be
reimbursed for expenses associated with his employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. James was granted 100
thousand RSUs for Class A Common Shares that vest over five years on each anniversary of the employment, contingent on his continued employment
of Mr. James.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB adopted an equity incentive
award plan, the 2022 Equity Incentive Award Plan, that permits it to grant directors, officers, employees and others that contribute to
the success of the Company stock options, restricted stock, restricted share units, deferred stock and other equity-based awards. The
ultimate value of these various awards is dependent on increases in our Class A Common Share price. Awards are granted to provide the
holder of an award with a personal financial interest in our long-term success, encourage retention through vesting provisions and enable
us to compete for the services of employees in an extremely competitive market and industry. Objectives of the long-term incentive portion
of our compensation package includes aligning the personal and financial interests of management and other employees with shareholder
interests; balancing short-term decision-making with a focus on improving shareholder value over the long-term; and providing a means
to attract, reward and retain a skilled management team.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2022 Equity Incentive
Award Plan provides for award grants of up to a base amount of 6.0 million Class A Common Shares, plus an additional 25% of the issued
and outstanding Class A Common Shares outstanding from time to time. As of December 31, 2025, there were 7.3 million Class A Common Shares
committed to the plan. Of this amount, 5.5 million Class A Common Shares were under outstanding awards, and there were 1.8 million Class
A Common Shares available for future grant. The plan is characterized as an &#8220;evergreen&#8221; plan, which means as the number of
Class A Common Shares outstanding increases, the number of Class A Common Shares available for grant under the 2022 Equity Incentive Award
Plan increases. Shareholder approval is required for the plan to comply with certain IRS and Nasdaq requirements. Both the board of directors
and shareholders have approved the plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors may
grant awards under the plan for up to ten years from the date of plan adoption. The board of directors or a committee thereof will determine
the form of award and its terms, such as the vesting period, the exercise period, any vesting criteria that might include performance
goals and termination provisions. Typically, termination will be as a result of retirement, disability and the end of employment. Awards
may not be issued at less than the fair market value of a Class A Common Share at the time of award. Although awards are typically exercised
for a cash payment, the board of directors or applicable committee may issue the awards on a net exercise, or cashless, basis. Management
makes recommendations to the board of directors or committee about the form of the award, the amount of the award levels and its terms.
Management monitors overhang (a measure of potential earnings dilution from stock awards) as well as run rate (the rate at which stock
awards are being awarded from our equity plans) when making recommendations to the board of directors or applicable committee regarding
plan awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards Under Plan as of
December 31, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB has granted
restricted stock unit, or RSU, awards and options awards to Messrs. Marlett and Hayat for an aggregate of 1.8 million Class A stock
options, which awards vest as to 20% each year from the date of the person&#8217;s employment agreement, so long as the person
remains employed by MDB. James for an aggregate of 70 thousand Class A Common Shares, which awards vest as to 20% each year from the
date of the person&#8217;s employment agreement, so long as the person remains employed by MDB. As of December 31, 2025, of these
granted RSUs and options, 1.87 million in the aggregate are still subject to issuance in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB has issued stock option awards to certain key persons for an aggregate
of 3.6 million Class A Common Shares, of which 1.8 million continue to be subject to outstanding awards. These awards generally vest as
to 20% of one-half of the total number of granted stock options on the thirteenth (13) month anniversary of the listing of the Class A
Common Shares on a United States national exchange and then at the rate of 10% of one-half of the total number of stock options each six
months after the date of the initial vesting until the last vesting on the fifth year anniversary of the date of grant, at which any previously
unvested stock options will fully vest. The other half of the stock options will vest at any time after the 13th month anniversary of
the listing of the Class A Common Shares on a United States national securities exchange and before the ten year anniversary of the date
of grant, if and when (y) a Class A Common Share has traded in the market on which the Class A Common Shares are listed for any 90 consecutive
calendar days at an average price of $20.00 or more during the period commencing the date of grant and prior to the ten year anniversary
of the date of grant, with an average monthly trading volume of 2.0 million Class A Common Shares or more during the 90 consecutive calendar
day period, or (z) a Class A Common Shares has traded in the market on which the Class A Common Shares are listed for any 90 consecutive
calendar days at an average price of $25.00 or more during the period commencing the date of grant and prior to the ten year anniversary
of the date of grant; provided further, that if there is a distribution of cash, stock or other property by the Company on the Class A
Common Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced by the value of any one or more per share distributions
after the date of grant until vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDB has issued RSU awards
to various employees and other persons for an aggregate of 1,079,500 Class A Common Shares that generally vest over a period of five years,
with 20% of granted RSUs vesting on the thirteenth (13) month anniversary of the listing of the Class A Common Shares on a United States
national exchange and then at the rate of 10% of the original amount of RSUs each six months after the date of the initial vesting until
the last vesting on the fifth year anniversary of the date of grant, at which any previously unvested RSUs will fully vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the above RSU awards
have provisions for an acceleration of vesting for a change of control of MDB and in the discretion of the board of directors or a committee
thereof and may be adjusted by the board of directors or a committee thereof as provided in the plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt"><b><span id="a_022"></span>Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of our Class A Common Shares and Class B Common Shares by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each shareholder of our Class A Common Shares who is known by us to beneficially own 5% or more of our Class A Common Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each shareholder of our Class B Common Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of our executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of the members of the board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">all of the members of the board of directors and current executive officers as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
based on the rules and regulations of the SEC as defined in Rule 13d-3 of the Exchange Act. A person has beneficial ownership of Class
A Common Shares and Class B Common Shares if such individual has the power to vote and/or dispose of the shares. This power may be sole
or shared and direct or indirect. In computing the number of shares beneficially owned by a person and the percentage ownership of that
person, shares that are subject to options or warrants held by that person and exercisable as of, or within 60 days of, the initial closing
are counted as outstanding. These shares, however, are not counted as outstanding for the purposes of computing the percentage ownership
of any other person(s). Except as may be indicated in the footnotes to this table and pursuant to applicable community property laws,
each person named in the table has sole voting and dispositive power with respect to the Class A Common Shares and Class B Common Shares
set forth opposite that person&#8217;s name. Unless indicated below, the address of each individual listed below is c/o MDB Capital Holdings,
LLC, 14135 Midway Road, Suite G-150, Addison, TX 75001.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Applicable percentage ownership
in the following table is based on 5,300,132 Class A Common Shares and 5,000,000 Class B Common Shares outstanding as of March 31, 2026.
Because the Class A Common Shares and the Class B Common Shares vote together on all matters, we also give the percentage ownership of
the combined classes, allocating one vote for each Class A Common Share and five votes for each Class B Common Share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Class A</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Class B</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Percent of<br/>
Combined<br/>
Total</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(1)</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Percent of<br/>
Class (2)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Number<br/>
(1)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Percent of<br/>
Class (3)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>Voting<br/>
Power % (4)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Named Executive Officers and Directors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-size: 10pt">Christopher Marlett (5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-size: 10pt">166,720</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-size: 10pt">3,755,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-size: 10pt">75.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-size: 10pt">62.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Anthony DiGiandomenico (5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">96,149</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1,245,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">24.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">20.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">George Brandon (5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">105,248</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Mo Hayat (5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">1.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Jeremy W. James (6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">23,339</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Sean Magennis (6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">30,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Dan Torpey (7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">27,100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Jeb Terry (8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4,166</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">0.0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">All executive officers and directors as a group (8 persons) (9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">552,722</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">5,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">100.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">84.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Based on a total of 5,300,132 Class A Common Shares issued and outstanding as of March 31, 2026.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Based on a total of 5,000,000 shares of the Class B Common Shares issued and outstanding as of March 31, 2026.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Based on a total of 10,300,132 Class A and Class B Common Shares issued and outstanding as of March 31, 2026, with each Class A Common Share entitled to one vote and each Class B Common Share entitled to five votes, representing a total of 30,300,132 votes in respect of shareholder matters presented to the holders of Common Shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include 900,000 unexcised stock options for the Class A Common Shares vesting through April 2027.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include 70,000 restricted share units (RSUs) for the Class A Common Shares vesting through June of 2027.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include 80,000 restricted share units (RSUs) for the Class A Common Shares vesting through June of 2029.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>(8)</td>
    <td style="text-align: justify"><p style="margin: 0">Does not include 100,000 unexcised stock options for the Class A Common Shares vesting through February of 2031.</p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include 290,000 restricted share units (RSUs) for the Class A Common Shares vesting through April of 2027 through June of 2029 and 3,700,000 unexcised stock options for the Class A Common Shares vesting through February of 2031.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt"><b><span id="a_023"></span>Item 13.
Certain Relationships and Related Transactions, and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Transactions with Related
Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marlett and DiGiandomenico
own all the Class B Common Shares, each of which has five votes per share and vote together with the Class A Common Shares as a single
class on all matters on which a vote of the common shares is required, including the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marlett and DiGiandomenico
own MDB Capital S.A., a Nicaraguan entity, that provides services to the Company and its subsidiaries on an out-source, as requested basis.
During the years ended December 31, 2025, and 2024, respectively, the Company paid MDB Capital S.A. $1.8 million and $1,6 million, respectively.
MDB Capital Holdings, LLC continues to have a service agreement with MDB Capital S.A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2025, PatentVest, a 100% entity owned by MDB Capital Holdings, LLC, engaged in transactions with ENDRA Life Sciences
Inc &#8211; NDRA on Nasdaq, a company for which one of our executive officers, Anthony DiGiandomenico, Chief of Transactions, serves
as a board member.. For the year ended December 31, 2025 and 2024, respectively, there were no revenue recognized between MDB
Capital entities and ENDRA. However, costs incurred amounting to $81 thousand related to transactions with ENDRA were recognized
during the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2025 and 2024, PatentVest, a 100% entity owned by MDB Capital Holdings, LLC, engaged in transactions with eXoZymes, a company of which
the Company owns 47% of recognized revenue of $91 thousand and $41 thousand, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December 31, 2025, the Company recorded related party
accrued receivables totaling $13 thousand for services performed by PatentVest on behalf of eXoZymes. Additionally, the Company recorded
accrued expenses of $1 thousand payable to PatentVest, representing reimbursable expenses incurred in the ordinary course of business.
During the year ended December 31, 2024, the Company recorded related party accrued receivables totaling $64 thousand. This amount includes
$42 thousand for services performed by PatentVest on behalf of eXoZymes and $22 thousand related to taxes paid by the Company on behalf
of certain officers, which was reimbursed in full by January 31, 2025. Additionally, the Company recorded accrued expenses of $23 thousand
payable to officers and directors, representing reimbursable expenses incurred in the ordinary course of business. All transactions were
conducted on an arm&#8217;s-length basis and are expected to be settled in the normal course of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Policy for Evaluating Related Party
Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Related party transactions
will be reviewed by the audit committee, generally under its authority to review situations that give rise to conflicts of interest, as
set forth in the Audit Committee Charter. The policy of the Company is to evaluate those situations where an individual&#8217;s private
interests interfere or conflict in any way (or even appear to interfere or conflict) with the interests of the Company. A common situation
is one that involves a transaction between the Company and a party that is a director, officer or employee, or their respective related
parties or affiliates or an entity under the control of those persons. The audit committee shall review the material facts of all related
party transactions with the objective of determining to either approve or disapprove the Company entering into the transaction. The audit
committee will review the relevant facts and circumstances of a related party transactions taking into account, among other factors, (i)
whether the transaction was undertaken in the ordinary course of business of the Company, (ii) whether the related party transaction was
initiated by the Company or the related party, (iii) whether the transaction is proposed to be, or was, entered into on terms no less
favorable to the Company than terms that could have been reached with an unrelated third party, (iv) the purpose of, and the potential
benefits to the Company of, the related party transaction, (v) the approximate dollar value and the terms of the obligations involved
in the related party transaction, (vi) the extent of the related party&#8217;s interest in the transaction, and (vii) any other information
that would be material to investors in light of the circumstances of the particular transaction. Approval may be a standing approval for
the same types of transactions, where it is warranted. The audit committee may also ratify related party transactions that have occurred,
but related parties are encouraged to seek prior approval of a transaction so as not to face the situation of having to unwind or modify
it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_024"></span>Item 14. Principal Accountant Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
December 31, 2025 and 2024, RBSM, LLP was the Company&#8217;s independent registered public accounting firm.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
fees billed to us by our independent registered public accounting firm (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Audit fees (1)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">302</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">250</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Audit-related fees (2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">153</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">100</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Tax fees</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total principal accountant fees and services</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">455</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">350</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td><span style="font-size: 10pt">Audit fees consisted primarily of fees for the audit of our annual financial statements and reviews of the financial statements included in our quarterly reports and current reports.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td><span style="font-size: 10pt">Audit-related fees consist of fees billed for services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under Audit fees. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_025"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-align: justify; text-indent: -55.1pt"><b><span id="a_026"></span>Item 15.
Exhibits and Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>a. Documents Filed as Part
of this Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.8pt; text-align: justify; text-indent: 27.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.8pt; text-align: justify; text-indent: 27.2pt">The following consolidated
financial statements of MDB Capital Holdings, LLC are filed as part of this Annual Report on Form 10-K:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.8pt; text-indent: 27.2pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 0.1in; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 0.75in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number</p></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">CONSOLIDATED FINANCIAL STATEMENTS INDEX</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (RBSM LLP; New York, NY, PCAOB ID No. 587)</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_002"><span style="font-size: 10pt">Consolidated Balance Sheets &#8211;December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_003"><span style="font-size: 10pt">Consolidated Statements of Operations &#8211; Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_004"><span style="font-size: 10pt">Consolidated Statements of Changes in Equity &#8211; Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_005"><span style="font-size: 10pt">Consolidated Statements of Cash Flows &#8211; Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_006"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>b. Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Exhibit Index&#8221;
on the page following the consolidated financial statements and related footnotes and the signature page to this Annual Report on Form
10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>c. Financial Statement
Schedules </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No financial statement schedules
are filed herewith because (i) such schedules are not required, or (ii) the information has been presented in the aforementioned financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="a_027"></span>Item 16. Form 10-K Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has elected not
to provide the summary of information under this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.8pt; text-align: justify; text-indent: 27.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 0.1in; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 0.75in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Page</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Number</p></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">CONSOLIDATED FINANCIAL STATEMENTS INDEX</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (<span id="xdx_90F_edei--AuditorName_c20250101__20251231_zVV3QTHfdw37"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000059" name="dei:AuditorName">RBSM LLP</ix:nonNumeric></span>; <span id="xdx_90E_edei--AuditorLocation_c20250101__20251231_z53WXpixhjY6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000060" name="dei:AuditorLocation">New York</ix:nonNumeric></span>, NY, PCAOB ID No. <span id="xdx_90E_edei--AuditorFirmId_c20250101__20251231_zqRIAIjlxIK4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000061" name="dei:AuditorFirmId">587</ix:nonNumeric></span>)</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_002"><span style="font-size: 10pt">Consolidated Balance Sheets &#8211;December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_003"><span style="font-size: 10pt">Consolidated Statements of Operations &#8211; Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_004"><span style="font-size: 10pt">Consolidated Statements of Changes in Equity &#8211; Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_005"><span style="font-size: 10pt">Consolidated Statements of Cash Flows &#8211; Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><a href="#f_006"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 80%"><img src="form10-k_003.jpg" alt=""/></td>
    <td style="width: 20%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New York Office:</i></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">805 Third Avenue</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10022</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">212.838-5100</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>www.rbsmllp.com</i></b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_001"></span>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Members and Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">MDB Capital Holdings, LLC and Subsidiaries</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Addison, Texas</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_989_edei--AuditorOpinionTextBlock_c20250101__20251231_zIq03IJOVcE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000062" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of MDB Capital Holdings, LLC and Subsidiaries (collectively, the &#8220;Company&#8221;)
as of December 31, 2025 and 2024, and the related consolidated statements of operations, equity and cash flows for each of the two years
in the period ended December 31, 2025, and the related notes (collectively referred to as the consolidated financial statements). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December
31, 2025, in conformity with accounting principles generally accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b><i>/s/ RBSM LLP</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">We have served as the Company&#8217;s auditor
since 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">New York, NY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">March 31, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MDB CAPITAL HOLDINGS, LLC AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_002"></span>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands, except share count):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_pn3n3_zZtWz2XCHOJk" summary="xdx: Statement -  Consolidated Balance Sheets" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">As of December 31,</p>
</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20251231_zRik7umDcOd2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_z1hmGZ6tAhJl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_z6EhakKT4jN" style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maAzGOw_zLCqtCLVaUE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,217</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,437</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_i01I_maAzGOw_zqTsH5Sh7Ped" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cash segregated in compliance with regulations</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" contextRef="AsOf2025-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,331</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsReceivableNet_i01I_maAzGOw_zUbtE2LakLuj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2025-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherReceivables_i01I_maAzGOw_zhun8WqPmTrd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Related party receivables</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DepositsAssets_i01I_maAzGOw_z05SYHJjKlw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Clearing deposits</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2025-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,738</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maAzGOw_z1WxDpH7K2vk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">513</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_i01I_maAzGOw_zB9oMCl8Dda3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the licensed broker dealer (Notes 1 and
    2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" contextRef="AsOf2025-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,166</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,858</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_i01I_maAzGOw_zajlOrz7aXfd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer (Notes 1 and 2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="AsOf2025-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--EquityMethodInvestments_i01I_maAzGOw_zJTE5OT5cyXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Equity method investment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2025-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,543</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2024-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,764</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredCosts_i01I_maAzGOw_z9aBu34ztXSh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred costs related to deferred revenue</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2025-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzGOw_zjaf7GboyH04" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzGOw_ztIpnFYwSLT5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">547</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_mtAzGOw_zY0qYuiynf8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">71,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zAWsJjplw5Vj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">LIABILITIES AND EQUITY</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_i01_zI7aMWjEaF5f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><p style="margin: 0">Liabilities:</p></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableCurrentAndNoncurrent_i02I_maLzctH_zx1LB2Yeum0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">324</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_i02I_maLzctH_zqMo6H2Zgbmc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherLiabilities_i02I_maLzctH_zS1XfUsBi6kg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Related party payables</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2025-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PayablesToCustomersCurrentAndNonCurrent_i02I_maLzctH_zE0cDn2Vy7ii" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Payables to customers</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:PayablesToCustomersCurrentAndNonCurrent" contextRef="AsOf2025-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,189</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:PayablesToCustomersCurrentAndNonCurrent" contextRef="AsOf2024-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">773</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_i02I_maLzctH_zeASOsv9qtBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">609</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">711</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Liabilities_i01TI_mtLzctH_maLASEznUM_zuQXNi3GF38d" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,161</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,903</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommitmentsAndContingencies_i01I_maLASEznUM_zbzP4Xt3yRte" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Commitments and Contingencies (Note 10)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0130">-</span></span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0131">-</span></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zpiYiNeOoz58" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Equity:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_maSEzhWb_zwt6ohRm9mF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Preferred shares, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_zR5oJsfiVnIb" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_z9DPKFQPi3wl" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares at <span id="xdx_90D_eus-gaap--PreferredStockNoParValue_iI_do_c20251231_zOL2BWrVaHA1" title="Preferred stock, no par value"><span id="xdx_90F_eus-gaap--PreferredStockNoParValue_iI_do_c20241231_zix4BTeEpQSa" title="Preferred stock, no par value"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2025-12-31" id="Fact000143" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_dn_c20251231_z7xmImtHK5t2" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_dn_c20241231_zJ3iXJ90zHkl" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20251231_zVq2I0PVOzUh" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20241231_zkziAVBsHBXe" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0137">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zP117k0bLIYa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Class A Common Shares, <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z8ofqZA0Qazf" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zdyUFYw9n2U6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares at <span id="xdx_904_eus-gaap--CommonStockNoParValue_iI_pid_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEr9sTQNstsi" title="Common stock, no par value"><span id="xdx_906_eus-gaap--CommonStockNoParValue_iI_pid_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z1XswuZAgxK3" title="Common stock, no par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember" id="Fact000162" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact000164" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zltZzaNPHWke" title="Common stock, shares, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCug1H8KhO38" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,138,632</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zI5waMeD6kZd" title="Common stock, shares, issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCDXVTsuG6B2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,950,632</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0156">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zSs64CpcLBIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Class B Common Shares, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znpgIptDMYB2"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z6wA6j2aoyc1"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span>
authorized shares at <span id="xdx_905_eus-gaap--CommonStockNoParValue_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z89U0hWc2UE4"><span id="xdx_905_eus-gaap--CommonStockNoParValue_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zraj8fCHi3T2"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact000178" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember" id="Fact000179" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span>
par value; <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z4OdEy4pN0C" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdoOuJc56gp1" title="Common stock, shares outstanding"><span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpYztEzZmBt8" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zCUrujXpZKJ3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>
shares issued and outstanding</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0174">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0175">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_maSEzhWb_zlbLxhtarFJ7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, value</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0189">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0190">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_maSEzhWb_zU1k9EbUsJzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Additional paid-in-capital</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80,493</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68,721</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzhWb_z5Ez4STyo5q" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated income (deficit)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,803</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,442</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_mtSEzhWb_maSEIPAzrbS_zpwbIJbowjwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total MDB Capital Holdings, LLC equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,690</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,163</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MinorityInterest_i02I_maSEIPAzrbS_zbvgTS0gtDl4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_maLASEznUM_mtSEIPAzrbS_zP9ridFFmtcb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,579</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,073</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEznUM_zsLdalMclOjf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">71,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to consolidated
financial statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MDB CAPITAL HOLDINGS, LLC AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_003"></span>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands, except per share data and share count)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_pn3n3_z1bEqq6vxXqh" summary="xdx: Statement - Consolidated Statements of Operations" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20251231_z4vvpLjlv6xd" style="font-size: 10pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z1xCZXwS8Icc" style="font-size: 10pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLossAbstract_iB_zkBtnQD1YJdb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_i01N_di_msOILzqRv_z9CYsoRV4fwi" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer (Notes 1 and 2)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2025-01-01to2025-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2024-01-012024-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_i01_maOILzqRv_zyfO9Z7J9RGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gain on investment securities, net from non-licensed broker dealer (Notes 1 and 2)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" contextRef="From2025-01-01to2025-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--RealizedInvestmentGainsLosses_i01_maOILzqRv_zixFGBsbAjwa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Realized gain on investment securities, net from the licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2025-01-01to2025-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FeeIncome_i01_maOILzqRv_zG7K579whSZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income (from our licensed broker dealer)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,282</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2024-01-012024-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,221</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_msOILzqRv_zmsKOjIjS1Y2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment of investment securities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2024-01-012024-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OtherOperatingIncome_i01_maOILzqRv_zuRgsqMEzyz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">861</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2024-01-012024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtOILzqRv_maNOILzr2p_z0GdeRVYvJi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total operating income, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,911</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,157</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zR1Q5VvnRekb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvMTXcXGLkph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CompensationCosts_i02_maGAAEzeyK_zkzTIFJJuRZe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:CompensationCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,969</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:CompensationCosts" contextRef="From2024-01-012024-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,057</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--OperatingExpenseRelatedParty_i02_maGAAEzeyK_zbRfjjOAvZF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:OperatingExpenseRelatedParty" contextRef="From2025-01-01to2025-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,833</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:OperatingExpenseRelatedParty" contextRef="From2024-01-012024-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,486</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfessionalFees_i02_maGAAEzeyK_zQnQuX3ttSf2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-01to2025-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,937</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,112</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommunicationsAndInformationTechnology_i02_maGAAEzeyK_zgHcBIwbpDD4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2025-01-01to2025-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,103</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2024-01-012024-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">922</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ClearingAndOtherCharges_i02_maGAAEzeyK_zUy4Cs6Z3U46" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2025-01-01to2025-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">556</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2024-01-012024-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,137</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_maGAAEzeyK_zDiig0CGyD68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,239</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,608</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i02T_mtGAAEzeyK_maOEzYPk_z34V86WrsV26" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total general and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,637</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,322</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzYPk_zFVDzRH2htQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs, net of grants $<span id="xdx_900_ecustom--ResearchAndDevelopmentGrants_pn3n3_c20250101__20251231_zxMkgQbRyXG4" title="Research and development, Grants"><ix:nonFraction name="MDBH:ResearchAndDevelopmentGrants" contextRef="From2025-01-01to2025-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--ResearchAndDevelopmentGrants_pn3n3_c20240101__20241231_zWmjmHbL284g" title="Research and development, Grants"><ix:nonFraction name="MDBH:ResearchAndDevelopmentGrants" contextRef="From2024-01-012024-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,003</ix:nonFraction></span> in 2024 and 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,468</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingCostsAndExpenses_iT_mtOEzYPk_msNOILzr2p_zPRHl7rKctZa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,637</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2024-01-012024-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,790</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NetOperatingIncomeLoss_iT_mtNOILzr2p_maILFCOz6dP_zplCtQGixdC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net operating loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,726</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,633</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestAndOtherIncomeAbstract_iB_zyqiZDo8r3k1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income and expenses:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--MiscellaneousIncome_i01_maILFCOz6dP_zbbqVkGUZ65b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2024-01-012024-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncome_i01_maILFCOz6dP_zU77AagXAVx3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">617</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,179</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpenseNonoperating_i01N_di_msILFCOz6dP_zL0dkaClZksc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--GainRelatedToDilutionEvents_i01_maILFCOz6dP_zqfij5tbX2L" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gain related to dilution events</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-01to2025-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_i01_maILFCOz6dP_zNFBt2YzsO0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain on deconsolidation of subsidiary</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="From2024-01-012024-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,307</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz6dP_maILFCOzGCm_zhXk7aonsVz6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,973</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,023</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_msILFCOzGCm_zdgwY1cVdewe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_iT_mtILFCOzGCm_maPLz18V_ze3KJQiDnROb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,984</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,021</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IncomeLossFromEquityMethodInvestment_i01_maPLz18V_zZYkFwIOMITb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,282</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">420</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ProfitLoss_iT_maNILz147_mtPLz18V_z9UGeQFUHWal" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,266</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,601</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILz147_zNe6tYo0iMVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtNILz147_zIG9JJTnXzW" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net income (loss) attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareAbstract_iB_zVWMp9OwC905" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Income (loss) per share attributable to MDB Capital Holdings, LLC:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z7qaZPp1Mo8j" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) per Class A Common Share &#8211; basic</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact000316" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact000317" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zRp4MEVmW2H6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Weighted average number of Class A Common Shares outstanding &#8211; basic</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact000319" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,022,742</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact000320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,424,484</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareBasic_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zEn6zYNrtS8a" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) per Class B Common Share &#8211; basic</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.10</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.18</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqjgebCpdQZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Weighted average of number Class B Common Shares outstanding &#8211; basic</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zevQJexpncy6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) per Common Share &#8211; basic</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000328" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.10</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.18</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZFQcFdYWNye" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Weighted average of number Common Shares outstanding &#8211; basic</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--EarningsPerShareDiluted_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJvXXOJaUMUb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) per Class A Common Share &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact000334" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.91</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact000335" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zgysMDlO6Phg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted number of Class A Common Shares outstanding</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact000337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,145,212</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,462,904</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zjxo6xI4CZtl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) per Class B Common Share &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.91</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zPrW1Qz8dmQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted number of Class B Common Shares outstanding</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_z5J4YI2DZkE9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) per Common Share &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.91</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000347" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zWZwKT7rgLFi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted number of Common Shares outstanding</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MDB CAPITAL HOLDINGS, LLC AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_004"></span>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years Ended December 31, 2025 and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zCpUInYcXFf7" summary="xdx: Statement - Consolidated Statements of Changes in Equity" style="border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassAMember_zrhzW9LyapGa" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--CommonClassBMember_zWr0H6p0KNr4" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zJbSe3Qy2Tgk" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zUxUFlz2btek" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zIZaKpqw0q42" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_zKy0Lqb1NaO5" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A <br/> Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B <br/> Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">Income</p></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Noncontrolling</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>(Deficit)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Interest</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_43A_c20250101__20251231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z7mP9TbYKvAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt">Balance, December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zMWapcDazs67" title="Balance, shares" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,951</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zvfQD6O1Ip81" title="Balance, shares" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68,721</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,442</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000356" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,073</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zZIby8jLb4r2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Issuance of Class A Common Shares</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjLwYdfiuq3f" title="Issuance of Class A Common Shares, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">188</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zeVAYf4n9fbj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000374" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,772</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,772</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--Netincomeloss1_z9UwqIAT03T4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,245</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2025-01-01to2025-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,266</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20250101__20251231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zLE88vTwwj5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance, December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zD6BihfAO4m8" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zYSXFuy7EHWk" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000388" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000389" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,803</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000390" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,579</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A <br/> Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B <br/> Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Paid-In</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Accumulated</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">Income</p></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Noncontrolling</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Interest</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zI3zTMDWq0T1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt">Balance, December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z49bVA3Gelc7" title="Balance, shares" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,296</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_znaspjHUpt0h" title="Balance, shares" style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,406</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,092</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,321</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zjnfdOe5hMWb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Balance</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z8bJHKrKs38d" title="Balance, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,296</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zakNBE2auEjb" title="Balance, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49,406</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,092</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,321</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_zKZoRobykpoh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Ownership change of non-controlling interest</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zMUE0wV04ZCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Issuance of Class A Common Shares</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsyR2hxnS5yf" title="Issuance of Class A Common Shares, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">655</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zdmmuWHhvEtf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,435</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,435</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EffectOfDeconsolidationOfSubsidiary_zXx2Brrjwaz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Effect of deconsolidation of subsidiary</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:EffectOfDeconsolidationOfSubsidiary" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,880</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:EffectOfDeconsolidationOfSubsidiary" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,836</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:EffectOfDeconsolidationOfSubsidiary" contextRef="From2024-01-012024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,716</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--Netincomeloss1_zNhh6I4dZT2f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,534</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,933</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,601</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--Netincomeloss1_zDsRH6cDYcqa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,534</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,933</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:Netincomeloss1" contextRef="From2024-01-012024-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,601</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zGQU0xM4yagd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance, December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zE1AYDdOqbu4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,951</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zdEACymInMw6" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68,721</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_znoBgYRzlm99" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKKIYjKESfF8" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,951</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zrePJ08CKUe" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68,721</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MDB CAPITAL HOLDINGS, LLC AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_005"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years Ended December 31, 2025 and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_306_112_pn3n3_zX2Ic60schU2" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_znvQpr1xMlW5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zqBbdQ69R7f3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zubHlEQuZDu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProfitLoss_i01_maNCPBUzKj8_z6bvrqlh27u2" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Net income (loss)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,266</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,601</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zwyJpuPnpgE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Adjustments to reconcile net income (loss) to net cash used in operating activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--UnrealizedGainLossOnInvestments_i02N_di_msNCPBUzKj8_zuwrCYvlaaa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Unrealized loss on investment securities, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">246</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">275</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_i02N_di_msNCPBUzKj8_zK47dUB9Qz9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Accretion of investments at amortized cost (U.S Treasury Bills)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" contextRef="From2024-01-012024-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">534</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--RealizedInvestmentGainsLosses_i02N_di_msNCPBUzKj8_zPuTjIXptzsa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Realized loss (gain) on investment securities, net from the licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2025-01-01to2025-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maNCPBUzKj8_z9oZ1wAf83w1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,772</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,435</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EquityMethodInvestmentDividendsOrDistributions_i02_maNCPBUzKj8_zq897nPOJJy8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Effect of deconsolidation of subsidiary</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" contextRef="From2024-01-012024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,716</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzKj8_zWt08ZARVRI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation of property and equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-01-01to2025-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">230</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInDeferredIncomeTaxes_i02N_di_msNCPBUzKj8_z5GH1II0O5Re" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred costs related to revenue</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DilutionOfDeferredGrantReimbursement_i02_maNCPBUzKj8_z33rQ7NL8KEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Dilution of deferred grant reimbursement</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:DilutionOfDeferredGrantReimbursement" contextRef="From2024-01-012024-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">41</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeconsolidationGainOrLossAmount_i02N_di_msNCPBUzKj8_zGT3bGfKXOc6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on deconsolidation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,307</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--PortionOfLossFromEquityInvestment_i02_maNCPBUzKj8_z1E0tQKKYtu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Portion of loss from equity investment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:PortionOfLossFromEquityInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,282</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:PortionOfLossFromEquityInvestment" contextRef="From2024-01-012024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GainRelatedToDilutionEvents_i02N_di_msNCPBUzKj8_z5I0HDniexK8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Gain related to dilution events</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-01to2025-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal_i02_maNCPBUzKj8_ztoqTCgvj8k9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Warrants issued as part of an investment banking deal</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" contextRef="From2024-01-012024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">297</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_i02N_di_msNCPBUzKj8_zN2q0wwb6qE8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Share of loss from equity method investment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IncomeRecognizedFromWarrantsReceived_i02N_di_msNCPBUzKj8_z7Cae3JUEIYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Income recognized from warrants received</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeRecognizedFromWarrantsReceived" contextRef="From2025-01-01to2025-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,889</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeRecognizedFromWarrantsReceived" contextRef="From2024-01-012024-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">659</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ImpairmentOfInvestmentsSecurities_i02_maNCPBUzKj8_zGxOOWdUrXBh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment of investment securities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ImpairmentOfInvestmentsSecurities" contextRef="From2024-01-012024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_maNCPBUzKj8_zct1bFHwhSJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred revenue</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2024-01-012024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzKj8_zyFFP0lEE8vb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in ROU Asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-012024-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,679</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maNCPBUzKj8_zGP8M6w0ax3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Change in lease liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">103</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,705</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zB1aqC5UgMo5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i03B_zws51ch39Pxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">(Increase) decrease in -</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherReceivables_i04N_di_msNCPBUzKj8_zpXaZUw0eqal" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Grants receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2024-01-012024-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">882</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i04N_di_msNCPBUzKj8_zXszKUFu6YWi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts receivable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-01to2025-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInDueFromRelatedPartiesCurrent_i04N_di_msNCPBUzKj8_z6Qy9AAuJEU9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Related party receivables</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" contextRef="From2025-01-01to2025-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">51</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" contextRef="From2024-01-012024-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i04N_di_msNCPBUzKj8_zYl3N2Wvzgcd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000563" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInDepositOtherAssets_i04N_di_msNCPBUzKj8_zzVdhi0u21Pf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Clearing deposits</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">262</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2024-01-012024-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,478</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i03B_zeYYIABiVYna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Increase (decrease) in -</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i04_maNCPBUzKj8_zX0hheQMo0dl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts payable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">252</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i04_maNCPBUzKj8_zRquCXEEpCGe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,033</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInDueToRelatedPartiesCurrent_i04_maNCPBUzKj8_zbE3YwXZjMdi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Related party payables</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2025-01-01to2025-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2024-01-012024-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPayablesToCustomers_i04_maNCPBUzKj8_zI038kL5T4x1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 20pt">Payables to customers</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPayablesToCustomers" contextRef="From2025-01-01to2025-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,417</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPayablesToCustomers" contextRef="From2024-01-012024-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">772</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInPayablesToNoncustomers_i04_maNCPBUzKj8_z6qEDVoGk7T2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Payables to non-customers</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0584">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncreaseDecreaseInPayablesToNoncustomers" contextRef="From2024-01-012024-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,405</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzblv_mtNCPBUzKj8_zkPheJRXGPf2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,684</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,038</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z3HyGYeGUgs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PaymentsToAcquireInvestmentsSecurities_i01N_di_msNCPBUzwU8_zAdWEGIqlOeh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Purchases of investment securities, at amortized cost (U.S. Treasury Bills)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:PaymentsToAcquireInvestmentsSecurities" contextRef="From2024-01-012024-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,766</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ProceedsFromInvestmentsSecurities_i01_maNCPBUzwU8_zhuXthm3HOKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Proceeds from payments and maturities of investment securities, at amortized cost (U.S. Treasury Bills)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ProceedsFromInvestmentsSecurities" contextRef="From2024-01-012024-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,959</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquireEquityMethodInvestments_i01N_di_msNCPBUzwU8_zQ3tEySYLTVi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accretion of equity investments</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="From2024-01-012024-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,747</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--PaymentForDeferredGrantReimbursement_i01N_di_msNCPBUzwU8_zqfAAwowKJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred grant reimbursement</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0602">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:PaymentForDeferredGrantReimbursement" contextRef="From2024-01-012024-12-31" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsForProceedsFromProductiveAssets_i01N_di_msNCPBUzwU8_zPtLmWV7IEWg" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Purchases of property and equipment</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromProductiveAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromProductiveAssets" contextRef="From2024-01-012024-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">546</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzwU8_maCCERCzblv_zKoFhTXxJEJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by (used in) investing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,892</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zUMWy3Ubt9Ml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromPaymentsToMinorityShareholders_i01_maNCPBUzAy6_zHLo6wCic4Sh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Acquisition of non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0614">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" contextRef="From2024-01-012024-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzAy6_maCCERCzblv_zMTvbtoXLmO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzblv_zEVYZtezGItj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000620" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,733</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,923</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zZA6CNvWmCjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,281</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,358</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zOny3N5jbMih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS - END OF YEAR</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,548</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-transform: uppercase; text-align: left">Supplemental disclosures of cash flow information:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Cash paid for -</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxesPaidNet_i01_zKZQWTb9Geii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z1rGZlhZiKM6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-transform: uppercase; text-align: left">Non-cash investing and financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WarrantsReceivedAsPartOfInvestmentBankingDeal_i01_z77YqkOQyr45" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Warrants received as part of an investment banking deal</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:WarrantsReceivedAsPartOfInvestmentBankingDeal" contextRef="From2024-01-012024-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">657</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear_i01_z9jLx0k4zmxg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Relinquishment of deferred costs of initial public offering from prior year</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" contextRef="From2024-01-012024-12-31" id="Fact000642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">323</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment_i01_z1Gbvlf5MCu5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Investment securities, at cost less impairment, received in lieu of cash payment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" contextRef="From2024-01-012024-12-31" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering_i01_zjMAK31o8EBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Issuance of warrants to purchase Class A stock related to the initial public offering closed on September 20, 2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" contextRef="From2024-01-012024-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a reconciliation
of the amount of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the total of the same
such amounts shown in the consolidated statements of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_112_pn3n3_z62O0pWeKBIl" summary="xdx: Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin: 0">Years Ended December 31,</p>

</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zDBmSQ8aNfb5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zPRc346X2X8h" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzpre_zJxHU1nPN3Ta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,217</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,437</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations_iI_maCCERCzpre_zDewLuMzKow4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash segregated in compliance with regulations</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" contextRef="AsOf2025-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,331</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" contextRef="AsOf2024-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzpre_zy3xjKjJalPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,548</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MDB CAPITAL HOLDINGS, LLC AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="f_006"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Years Ended December 31, 2025 and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000659" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zkzaZ4LO8kPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. <span id="xdx_820_znzVrhQ6zlii">Organization and Description of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Capital Holdings, LLC (&#8220;the
Company&#8221; or &#8220;MDB&#8221;), a Delaware limited liability company, is a holding company that has three wholly-owned subsidiaries:
MDB CG Management Company (&#8220;MDB Management&#8221;); Public Ventures, LLC, d/b/a MDB Capital (&#8220;Public Ventures&#8221;); and
PatentVest, Inc. (&#8220;PatentVest&#8221;), and MDB Minnesota One (&#8220;M1&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Management is principally an &#8220;administrative&#8221;
entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for our US-based operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures is a U.S. registered
broker-dealer under the Securities Exchange Act of 1934, and is a member of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;)
and the Texas State Securities Board. Public Ventures operates on a fully disclosed basis with a nonrelated FINRA member firm, Interactive
Brokers, LLC (&#8220;Interactive Brokers&#8221;), and is not required to maintain a clearing deposit. Interactive Brokers is the clearing
firm and custodian of investments maintained by Public Ventures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">PatentVest is a wholly-owned subsidiary
that performs intellectual property validation services for Public Ventures&#8217;, due diligence functions on the intellectual property
of partner and prospective partner companies, and creates an intellectual property roadmap for such partner companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">M1 is a majority owned subsidiary
and was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;). The objective of
the License Agreement is for Minnesota One to develop a small molecule senescence platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On September 20, 2023, MDB completed
an initial public offering, consisting of the sale of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn4n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z0bspOUwJAEc" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000661" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="Shares">1.67</ix:nonFraction></span> million shares of Class A Common Shares at $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbd1Aqld8785" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span> per share, for gross
proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zRtvOJlTSsK7" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000665" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million. Accordingly, the Company received total gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjsfc4fiXtte" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000667" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million from the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn4n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zABDTLkJSHD" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000669" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="Shares">1.67</ix:nonFraction></span> million shares
of Class A Common Shares, or $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zW3POXn2rZgd" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000671" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.4</ix:nonFraction></span> million net of $<span id="xdx_90A_eus-gaap--OtherExpenses_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zM0S2lXoM4Za" title="Offering expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember" id="Fact000673" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million of offering expenses. In conjunction with the IPO, the Company issued warrants
to the placement agent to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn2n3_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z27rOZeewFVg" title="Warrants to puchase common shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000675" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="Shares">16.7</ix:nonFraction></span> thousand shares of Class A Common Shares, exercisable upon issuance for a period of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKTktnDm914" title="Warrants term"><ix:nonNumeric contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000677" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span> years at
$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBN0muUEESWh" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span> per share, for a cash consideration of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFo4Y6aYbFTe" title="Cash consideration per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>/share. The placement agent&#8217;s warrants had a fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn2n3_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5bVsPCpf8zh" title="Warrants fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember" id="Fact000683" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">65.4</ix:nonFraction></span> thousand, as
calculated pursuant to the Black-Scholes option-pricing model and accounted for as issuance costs that were accounted for as equity instruments
and recorded against paid in capital. The inputs used to determine the fair value was Common Stock price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z285dQ5xu3Xe" title="Common stock price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-20_us-gaap_WarrantMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span>, option exercise price
of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYQjRKCtfARa" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-09-20_us-gaap_WarrantMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></span>, expected life in years of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9gLUmTvWgGl" title="Estimated life"><ix:nonNumeric contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000689" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.45</ix:nonNumeric></span> years, with a contract life of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGG31Y8m87fi" title="Contract life"><ix:nonNumeric contextRef="AsOf2023-09-20_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000691" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span> years, risk-free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPozmDGfIN39" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.79</ix:nonFraction></span>%, expected annual volatility
of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSttQ5itcJcj" title="Expected annual volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">59.99</ix:nonFraction></span>%, and annual rate of dividends of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuRUDrw3cnL5" title="Annual rate of dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember" id="Fact000697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2024, the founding ownership
of M1 had MDB owning <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MDBMinnesotaOneIncMember_zAuSzCMlDHv3" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-07-01_custom_MDBMinnesotaOneIncMember" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67</ix:nonFraction></span>% and Mayo owning <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MayoFoundationMember_zZ3hjBOHmsP5" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-07-01_custom_MayoFoundationMember" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span>% of the issued and outstanding
common stock. M1 was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo. After
the initial formation of M1 and finalization and entry into a license agreement between Mayo and M1, MDB entered into a Term Equity Purchase
Agreement (&#8220;Purchase Agreement&#8221;) to provide capital for operations of M1 in exchange for the issuance of shares of common
stock of M1 to MDB. The objective of the License Agreement is for M1 to develop a small molecule senescence platform. Under the terms
of the License Agreement M1 has paid an up-front license fee to Mayo of One Hundred Fifty Thousand Dollars ($<span id="xdx_909_eus-gaap--AdvancesToAffiliate_iI_pn3n3_c20240701_zwPm1CLki7b3" title="Up-front fees"><ix:nonFraction name="us-gaap:AdvancesToAffiliate" contextRef="AsOf2024-07-01" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span> thousand). To maintain
its rights under the License Agreement, M1 is subject to achieving certain developmental and funding milestones within designated time
periods and to paying Mayo royalties on net sales of licensed products. Under the terms of the Purchase Agreement, MDB may invest up to
$<span id="xdx_906_eus-gaap--Investments_iI_pn5n6_c20240701_zVtWwfD9CV2d" title="Investments"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2024-07-01" id="Fact000705" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million over a five-year period into M1 in amounts and increments tied to its business operating requirements. In an ancillary agreement
to the license agreement, Mayo has the right of participation in future financings of M1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000707" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8aA90zjScb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. <span id="xdx_827_zWU5FLj60lpk">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000709" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbvuMgc7HMkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Basis of Presentation and Principles
of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accompanying consolidated financial
statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and include the financial statements of wholly-owned and majority owned subsidiaries. All material intercompany accounts
and transactions have been eliminated in consolidation. Non-controlling interests at December 31, 2025 and 2024 relate to the interests
of third parties in the partially owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The managing members of the Company
have a controlling interest in PatentVest, S.A., a company organized and based in Nicaragua (which was renamed MDB Capital, S.A in 2022).
As the Company itself does not have a controlling financial interest in this entity, management has determined PatentVest, S.A. is not
a variable interest entity and should not be consolidated as it has no ownership interests, so has excluded this entity from the Company&#8217;s
consolidated financial statements. It is the Company&#8217;s policy to reevaluate this conclusion on an annual basis or if there are significant
changes in ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000711" name="MDBH:DeconsolidationPolicyTextBlock"><p id="xdx_84E_ecustom--DeconsolidationPolicyTextBlock_z9F9sgQUCM07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Deconsolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon the occurrence of certain events
and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated
variable interest entities. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company
records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair
value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the
carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary&#8217;s
assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company evaluated whether the
deconsolidation should be presented as a discontinued operation in its consolidated financial statements as of the deconsolidation date.
This assessment considers whether the deconsolidation constitutes a strategic shift that has, or will have, a major impact on the Company&#8217;s
operations or financial results. Based on this evaluation, the Company concluded that the deconsolidation does not meet the criteria
for presentation as a discontinued operation. Accordingly, the Consolidated Statement of Operations includes the results of operations
for the deconsolidated entity through November 14, 2024, the effective date of deconsolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000713" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zeX1leJLKmW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Equity method investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company applies the equity method
to account for investments in entities where it has the ability to exercise significant influence over the operating and financial policies
of the investee. Under the equity method, the investment in eXoZymes Inc, (&#8220;eXoZymes &#8220;), formerly Invizyne Technologies
Inc. (&#8220;Invizyne&#8221;)&#8221;, is initially recorded at cost and subsequently
adjusted to reflect the Company&#8217;s proportional share of the investee&#8217;s results of operations in its consolidated financial
statements. Equity method investments are periodically reviewed for any other-than-temporary declines in value. The Company&#8217;s investment
in eXoZymes is presented as &#8220;Equity method investment&#8221; on the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Any excess of the acquisition cost
over the Company&#8217;s share of the net fair value of eXoZymes&#8217; identifiable assets and liabilities at the acquisition date is
recognized as goodwill, which is included in the carrying amount of the investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company increases its interest
in an affiliate accounted for under the equity method while retaining significant influence, it applies the acquisition method only to
the additional interest acquired, leaving the previous interest unchanged. Conversely, when there is a decrease in the interest in an
affiliate accounted for under the equity method while retaining significant influence, the Company derecognizes a proportionate part of
its investment and recognizes any resulting gain or loss in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000715" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWOfx76LB65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We account for income taxes using the
asset and liability method, under which we would recognize the amount of taxes payable or refundable for the current year and deferred
tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns.
We measure current and deferred tax assets and liabilities based on provisions of enacted tax law. We evaluate the realization of our
deferred tax assets based on all available evidence and establish a valuation allowance to reduce deferred tax assets when it is more
likely than not that they will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000717" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zqrc9oBsVfg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period, as well as the
disclosure of contingent assets and liabilities. Some of those judgments can be subjective and complex, and therefore, actual results
could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience
and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available
information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate,
those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related
to assumptions used in the valuation of investment securities, accruals for potential liabilities, valuing equity instruments issued for
services, assumptions used in the valuation of the equity method investment and gains on the deconsolidation of the subsidiary, the estimate
of the fair value of the lease liability and related right of use assets, net realizable value of receivables, useful life of property
and equipment, determining impairment of long-lived assets, and the realization of any deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000719" name="MDBH:EmergingGrowthCompanyPolicyTextBlock"><p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWbadvRIbCGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is an &#8220;emerging growth
company,&#8221; or &#8220;EGC&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified
by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to opt out of the
extended transition periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000721" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znoJLvxnNDo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company considers highly liquid
investments with original maturities or remaining maturities upon purchase of three months or less to be cash equivalents. There were
$<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zrDGrtDWZr0f" title="Cash Equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million and $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zGBlfJQ1PcEf" title="Cash Equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.8</ix:nonFraction></span> million cash equivalents held by the Company at December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s policy is to
maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit
Insurance Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;).
The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_pn4n6_c20251231_z9yskUhQkfTb" title="Cash, FDIC insured limits"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.25</ix:nonFraction></span>
million and $<span id="xdx_906_ecustom--CashSIPCInsuredAmount_iI_pn5n6_c20251231_zFYU47D2MVbb" title="Cash, SIPC insured limits"><ix:nonFraction name="MDBH:CashSIPCInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million. At December 31, 2025, the Company held $<span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20251231_zix1xGBhe045" title="Unsegregated cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.7</ix:nonFraction></span>
million of unsegregated cash and $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zMs7qsmkP4nf" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span>
million of cash equivalents. For the years ended December 31, 2025 and 2024, respectively, the Company had approximately $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zviXm48akQ9h" title="Cash uninsured limits"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2025-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.2</ix:nonFraction></span>
million and $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zPtWfFI5fLa2" title="Cash uninsured limits"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000737" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span>
million of cash and segregated cash in financial institutions in excess of FDIC insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company periodically reviews the
financial condition of the financial institutions and assesses the credit risk of such investments. The Company did not experience any
credit risk losses during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s membership agreement
with the Depository Trust Clearing Corporation (&#8220;DTCC&#8221;) requires that we maintain a line of credit with our settlement bank in the amount $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20251231_zoKJtkzFEFIf" title="Line of credit"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2025-12-31" id="Fact000739" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million, to be drawn down upon as
needed for self-clearing operations. The Company has established a line of credit with its settlement bank, Lakeside Bank, which is collateralized
by a $<span id="xdx_901_eus-gaap--Deposits_iI_pn5n6_c20251231_zRlQibc6QRh7" title="Deposit"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2025-12-31" id="Fact000741" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million deposit of cash at Lakeside. The collateral amount may be withdrawn, but the availability of the line of credit is dependent
upon the maintenance of such compensating balance and is included in cash and cash equivalents on the Statement of Financial Condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000743" name="MDBH:SegregatedCashAndDepositsPolicyTextBlock"><p id="xdx_842_ecustom--SegregatedCashAndDepositsPolicyTextBlock_zEdxvQaMMd95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Segregated Cash and Deposits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">From time to time the Company provides
deposits or enters into agreements that would require funds to be held in a segregated cash account. At December 31, 2025 and 2024, respectively,
the Company had $<span id="xdx_90F_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20251231_zW4DOkMjezg" title="Cash segregated in compliance with regulations"><ix:nonFraction name="us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" contextRef="AsOf2025-12-31" id="Fact000745" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20241231_zH4eJBfqO7pj" title="Cash segregated in compliance with regulations"><ix:nonFraction name="us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" contextRef="AsOf2024-12-31" id="Fact000747" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million of segregated cash consisting of funds held in reserve for customers and non-customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000749" name="us-gaap:DepositContractsPolicy"><p id="xdx_843_eus-gaap--DepositContractsPolicy_zXe17lXZT4Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Clearing Deposits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is obligated to maintain
security deposits with the DTCC and National Securities Clearing Corporation (&#8220;NSCC&#8221;). At December 31, 2025 and 2024, these deposits totaled $<span id="xdx_900_eus-gaap--DepositsAssets_iI_pn5n6_c20251231_zDAy8NALC5y6" title="Clearing deposits"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2025-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million and $<span id="xdx_90D_eus-gaap--DepositsAssets_iI_pn5n6_c20241231_zclBROS6osn9" title="Clearing deposits"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2024-12-31" id="Fact000753" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000755" name="MDBH:PrepaidAndOtherCurrentAssetsPolicyTextBlock"><p id="xdx_84E_ecustom--PrepaidAndOtherCurrentAssetsPolicyTextBlock_zNKUuAkbGSea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Prepaid and other current assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has prepaid and other current
assets totaling $<span id="xdx_906_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20251231_zj7INjmPlGV9" title="Prepaid and other current assets"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000757" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></span> thousand at December 31, 2025 consisting of acquired intangible assets totaling $<span id="xdx_90A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20250101__20251231_z0yEmAC6bRb4" title="Intangible assets acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2025-01-01to2025-12-31" id="Fact000759" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span> thousand, prepaid professional
fees totaling $<span id="xdx_905_ecustom--PrepaidProfessionalFees_pn3n3_c20250101__20251231_zllM01zlh6Ul" title="Prepaid professional fees"><ix:nonFraction name="MDBH:PrepaidProfessionalFees" contextRef="From2025-01-01to2025-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> thousand, security deposits totaling $<span id="xdx_90B_eus-gaap--SecurityDeposit_iI_pn3n3_c20251231_zrMtKd7vB4x5" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2025-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span> thousand, prepaid insurance $<span id="xdx_902_eus-gaap--PrepaidInsurance_iI_pn3n3_c20251231_zK9n860ZZMZ6" title="Prepaid insurance"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2025-12-31" id="Fact000765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></span> thousand, various prepaid expense of $<span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20251231_zRKRbjQictU3" title="Various prepaid expense"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></span>
thousand, and other assets of $<span id="xdx_901_eus-gaap--OtherAssets_iI_pn3n3_c20251231_zxLCMJrZIVxk" title="Other assets"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></span> thousand. Prepaid and other expenses totaling $<span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20241231_z1eqPWY77Zpd" title="Prepaid and other expenses"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">513</ix:nonFraction></span> thousand at December 31, 2024 consisting of acquired
intangible assets totaling $<span id="xdx_90B_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_z69yTaaoZwKd" title="Intangible assets acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2024-01-012024-12-31" id="Fact000773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span> thousand, prepaid professional fees totaling $<span id="xdx_900_ecustom--PrepaidProfessionalFees_pn3n3_c20240101__20241231_zO8uio7h2SUg" title="Prepaid professional fees"><ix:nonFraction name="MDBH:PrepaidProfessionalFees" contextRef="From2024-01-012024-12-31" id="Fact000775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> thousand, security deposits totaling $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn3n3_c20241231_zk8QBjBoucW4" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2024-12-31" id="Fact000777" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span> thousand, prepaid
insurance $<span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20241231_zEeAzlURSyjc" title="Prepaid insurance"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact000779" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></span> thousand, various prepaid expense of $<span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20241231_z42b4Zoa3uJ4" title="Various prepaid expense"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span> thousand, and other assets of $<span id="xdx_90A_eus-gaap--OtherAssets_iI_pn3n3_c20241231_zRlD3U4ITts" title="Other assets"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2024-12-31" id="Fact000783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></span> thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000785" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zepmYoy0mMLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leases of the Company consist primarily
of contracts for the right to use and direct use of an individual property. Leases were analyzed for evidence of significant additional
components and to determine if these components were separately identifiable within the context of the contract. As an accounting policy,
to account for these components, the Company has elected the practical expedient for property leases that have both lease and non-lease
components for them to be combined into a single component and account for as a lease. This policy is effective for all current and future
property operating leases and applied uniformly and will be disclosed as such within the financial statements. Operating lease assets
are included within right-of-use assets and the corresponding operating lease liabilities are included within liabilities on the Company&#8217;s
consolidated balance sheet as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has elected not to present
short-term leases on the consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not
contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other right-of-use assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. Because the
Company&#8217;s leases do not provide an implicit rate of return, the Company used the Company&#8217;s incremental borrowing rate based
on the information available at lease commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000787" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zaeBpyEiNdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Stock Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Stock-based compensation primarily
consists of restricted stock units with service or market/performance conditions. Equity awards are measured at the fair market value
of the underlying stock at the grant date. The Company recognized stock based compensation expense using the straight-line attribution
method over the requisite service period. The Company&#8217;s subsidiary issued stock-options and the fair value is determined utilizing
Black-Scholes options-pricing model. The Company accounts for forfeitures as they occur, rather than applying an estimated forfeiture
rate. For performance-based restricted stock units, the compensation cost is recognized based on the number of units expected to vest
upon the achievement of the performance conditions. Shares are issued on the vesting dates net of the applicable statutory tax withholding
to be paid by us on behalf of our employees. As a result, fewer shares are issued to the employee than the number of awards outstanding.
The Company records a liability for the tax withholding to be paid by it as a reduction to Additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000789" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_842_eus-gaap--InvestmentPolicyTextBlock_zjbe21QMRo1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Investment Securities </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company strategically invests funds
in U.S. Treasury Bills, early-stage technology companies, and equity securities and options of publicly traded and privately held companies.
The Company classifies investment securities as investment securities, at amortized cost, investment securities, at fair value, or investment
securities, at cost less impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at amortized
cost</i> &#8211; From time to time the Company will hold funds in investment securities, at amortized cost. This is comprised of debt
securities held by MDB and are classified as investment securities held-to-maturity and carried at amortized cost if management has the
positive intent and ability to hold the securities to maturity. Initially, the cost of these securities was recorded, and later on, they
were assessed at amortized cost, which was modified for unamortized purchase premiums and discounts, and also for credit losses provision.
Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective-interest
method. Such amortization and accretion are included in the other operating income in the statements of operations. Interest income is
recognized when earned. The Company recognizes estimated expected credit losses over the life of the investment security through the allowance
for credit losses account. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost
basis of the investment security to present the net amount expected to be collected. In determining expected credit losses, the Company
considers relevant qualitative factors including, but not limited to, term and structure of the instrument, credit rating by rating agencies
and historic credit losses adjusted for current conditions and reasonable and supportable forecasts. The Company holds investments in
U.S. Treasury Bills or money market funds backed by U.S. Treasury Bills, so there are no expected credit losses. Declines in fair value
of these securities is due to changes in market interest rates, and because it expects to hold these securities until maturity, it does
not expect to realize any losses. There were no investment securities, at amortized cost as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at fair value
</i>- This is comprised of equity investments held by the broker dealer subsidiary and are reported at fair value with changes in fair
value recognized in the statement of operations. Purchases and sales of equity securities, consisting of common stock and warrants to
purchase common stock, are recorded based on the respective market price quotations on the trade date. Realized gains and losses on investments
represent the net gains and losses on investments sold during the period based on the average cost method. Differences between the fair
value of investments at the beginning of the year and the end of the year are recorded on the income statement as unrealized gains and
losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at cost less
impairment</i> - This is comprised of equity securities without a readily determinable fair value held by the broker dealer subsidiary,
the Company has elected to apply the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable
price changes. The Company will reassess whether such an investment qualifies for the measurement alternative at each reporting period.
In evaluating an investment for impairment or observable price changes, we will use inputs including recent financing events, as well
as other available information regarding the investee&#8217;s historical and forecasted performance. The Company has assessed this investment
and determined that the current impairment of such securities held at the year ended December 31, 2025 is accurate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities are as follows
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Broker/Dealer Securities</b></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000791" name="MDBH:ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock"><p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zQRLhofnSVV3" style="display: none">Schedule of Investment Securities Broker Dealer</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at fair value:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Common stock of publicly traded companies</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,571</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember" id="Fact000794" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,528</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Warrants of publicly traded companies</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember" id="Fact000796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,937</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember" id="Fact000797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,330</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrants of non-publicly traded companies</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember" id="Fact000799" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">658</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_custom_BrokerDealerMember" id="Fact000802" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_custom_BrokerDealerMember" id="Fact000803" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z9OkuMpESene" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Non-Broker/Dealer Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000805" name="MDBH:ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock"><p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><b><span id="xdx_8BF_zJ7jauHHoWlg">Schedule of Investment Securities Non-Broker Dealer</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Investment securities, at fair value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Common stock of publicly traded companies</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember" id="Fact000807" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_custom_NonBrokerDealerMember" id="Fact000810" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at cost less impairment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Simple agreement on future equities (not market listed)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" contextRef="AsOf2024-12-31_custom_SimpleAgreementOnFutureEquitiesMember" id="Fact000814" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Impairment</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" contextRef="AsOf2024-12-31_custom_ImpairmentMember" id="Fact000817" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at cost less impairment</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zuwmTRHBqnx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For investment securities at fair value
held at the end of each year, net unrealized loss of $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20250101__20251231_zsuIBnQqld4g" title="Net unrealized gain (loss) on investment securities"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">246</ix:nonFraction></span> thousand and $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20240101__20241231_z6mVQU83Glli" title="Net unrealized gain (loss) on investment securities"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">275</ix:nonFraction></span> thousand were recognized in the statement of operations for
years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000826" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1icpMWXqG9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree
that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the
lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company determines the fair value
of its financial instruments based on a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value
into three levels:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - Observable inputs such as
quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - Inputs, other than quoted
prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - Unobservable inputs in which
there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s financial instruments primarily consist of cash and investment
securities. These investment securities and securities sold and not yet purchased are recorded at fair value as of the balance sheet date,
with unrealized gains and losses resulting from changes in fair value recognized in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A description of the valuation techniques
applied to the Company&#8217;s major categories of assets and liabilities measured at fair value on a recurring basis is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at fair value
and securities sold, not yet purchased: These securities are valued based on quoted prices from the exchange or other trading platform.
To the extent these securities are actively traded, valuation adjustments are not applied, and they are categorized in level 1 of the
fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A description of the valuation techniques
applied to the Company&#8217;s other financial assets and liabilities is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at amortized
cost: The fair value of U.S. Treasury Bills classified as held-to-maturity investment securities is based on the market price and is classified
as level 1 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at cost
less impairment: Non-public equity securities and simple agreements for future equity are valued based on the initial investment,
less impairment. The Company determined that an impairment is warranted. Since these securities are not actively traded, we will
apply valuation adjustments when they become available, and they are categorized in level 3 of the fair value hierarchy. The Company
fully impaired a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) that was previously valued at $<span id="xdx_907_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SAFEMember_zfEVnkDkesF5" title="Impairment of securities"><ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2023-01-012023-12-31_custom_SAFEMember" id="Fact000828" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span>
thousand and stock that was previously valued at $<span id="xdx_909_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231_zjICz0hNW6R2" title="Impairment of securities"><ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2023-01-012023-12-31" id="Fact000830" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span>
thousand both were held at the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000835-01" escape="true" id="Fact000835" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z82LCnEDOUFb" style="display: none">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment securities, at fair value, held by the licensed broker dealer</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember" id="Fact000837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,571</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,571</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" title="Investment securities, at fair value, held by the non-licensed broker dealer" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" title="Investment securities, at fair value, held by the non-licensed broker dealer" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" title="Investment securities, at fair value, held by the non-licensed broker dealer" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" title="Investment securities, at fair value, held by the non-licensed broker dealer" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="Fact000855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,463</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="Fact000859" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,595</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value </td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact000861" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,806</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member" id="Fact000863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000865" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,463</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2025-12-31" id="Fact000867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,401</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zIWcQtXRunp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000872-01" escape="true" id="Fact000872" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zLQDKsgMVcPa" style="display: none">Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31" id="Fact000874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31" id="Fact000876" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receipt from investment banking fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2025-01-01to2025-12-31" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,690</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Unrealized gain</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2025-12-31" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,463</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2025-12-31" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,463</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zwiD6wiM66M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000889-01" escape="true" id="Fact000889" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zYKZqfnooG2" style="display: none">Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants</span></span></p>

<table cellspacing="0" cellpadding="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" title="Warrants, Fair value" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,463</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MinimumMember" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">95.92</ix:nonFraction></span> -&#160;&#160;<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MaximumMember" id="Fact000895" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">120.3</ix:nonFraction></span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" title="Weighted measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember" id="Fact000897" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">115.45</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_z2C5euSaftok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zlqM1QVW6kJb"><ix:continuation continuedAt="ConU000835-02" id="ConU000835-01"><b>The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):</b></ix:continuation></span></p>

<div id="xdx_C04_gL3SOFVAALMOR-YZJZHH_zKHclHGg20w9"><ix:continuation continuedAt="ConU000835-03" id="ConU000835-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment Securities (held by our licensed broker dealer)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember" id="Fact000899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,528</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" title="Investment securities, at fair value" style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,528</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">668</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000911" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" title="Investment securities, at fair value" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact000913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,330</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact000915" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,528</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="Fact000917" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" title="Investment securities, at fair value" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentSecuritiesAtFairValue" contextRef="AsOf2024-12-31" id="Fact000921" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zWa3Fx0mjlFf"><ix:continuation id="ConU000835-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2024, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C04_gL3FVAMORBUIR-BRK_zQrFBAw5dIYe"><ix:continuation continuedAt="ConU000872-02" id="ConU000872-01">&#160;</ix:continuation></span></p>

<div id="xdx_C08_gL3FVAMORBUIR-BRK_z3xAKOAdAp5d"><ix:continuation continuedAt="ConU000872-03" id="ConU000872-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31" id="Fact000923" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,134</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,134</ix:nonFraction></td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gains</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000927" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">472</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; text-align: left">Unrealized (loss) gains</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">472</ix:nonFraction></td><td style="display: none; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31" id="Fact000931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31" id="Fact000933" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C05_gL3FVAMORBUIR-BRK_z2jUR5Nf99T4"><ix:continuation id="ConU000872-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C09_gL3FVAALMORAN-L_zDICDGAXkhH3"><ix:continuation continuedAt="ConU000889-02" id="ConU000889-01"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)</b>:</ix:continuation></span></p>

<div id="xdx_C02_gL3FVAALMORAN-L_z8NPe4RhThA9"><ix:continuation continuedAt="ConU000889-03" id="ConU000889-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" title="Warrants, Fair value" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000935" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" title="Range of inputs" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">111.03</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" title="Weighted measurement input" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">111.03</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C08_gL3FVAALMORAN-L_zFRFYdbkeMvc"><ix:continuation id="ConU000889-03">&#160;</ix:continuation></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000941" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_846_eus-gaap--DebtPolicyTextBlock_zgWoIHtxQztb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Secured Debt&#8211;- Revolving
Credit Facility</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company entered into a revolving
credit facility with a bank, (the &#8220;Lender&#8221;) on July 26, 2024 for a commitment of up to $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0EOvrB8hnAd" title="Revolving credit, maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2024-07-26_us-gaap_RevolvingCreditFacilityMember" id="Fact000943" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million and which matures <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zhhYByZAPftd" title="Maturity date"><ix:nonNumeric contextRef="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember" format="ixt:datemonthdayyearen" id="Fact000945" name="us-gaap:LineOfCreditFacilityExpirationDate1">July
26, 2025</ix:nonNumeric></span>. The loan has a variable interest rate equal to a defined index, currently the Lender&#8217;s rate on the sale of Federal Funds,
plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zBayzkWHgzIa" title="Variable rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.25</ix:nonFraction></span>%. The loan commenced with a calculated interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zpgvzJk0sZ65" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-07-26_us-gaap_RevolvingCreditFacilityMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>%. If the Lender determines, in its sole discretion, that the index
becomes unavailable or unreliable, either temporary, indefinitely, or permanently, during the term of this loan, the Lender may amend
this loan by designating a substantially similar substitute index. The agreement provides for a quarterly payment of the greater of accrued
interest or a non-usage fee of $<span id="xdx_907_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn3n3_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zmaGjZ86t8Ae" title="Credit non-usage fee"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span> thousand. The Company has not made any draw downs on the credit facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company granted the Lender a
security interest in a cash checking account held at the bank as collateral. The Lender has a right of setoff available from this
cash account when the line of credit is accessed. As of December 31, 2025 and 2024, there was $<span id="xdx_904_eus-gaap--Deposits_iI_pn5n6_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyQmiqWvezV7" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember" id="Fact000953" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--Deposits_iI_pn5n6_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXBTreFjla7j" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember" id="Fact000955" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million deposited in this account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is responsible for the
payment of all of the Lender&#8217;s legal and other fees incurred in connection with administering the loan. The Company has incurred
no such costs or debt issue costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025 and 2024, there are <span id="xdx_909_eus-gaap--LineOfCredit_iI_do_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZIwhsjYOybh" title="Outstanding indebtedness"><span id="xdx_90A_eus-gaap--LineOfCredit_iI_do_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkDXvC2Zhwpe" title="Outstanding indebtedness"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember" id="Fact000957" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember" id="Fact000959" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> outstanding indebtedness under the credit facility and interest expense totaled $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zeQjdwsqGVrk" title="Interest payable"><span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zjlzMwhVXdI7" title="Interest payable"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>. The Company is in compliance with all
covenants under the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000965" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyma5WBbqKKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment are recorded
at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from disposition
of property and equipment are included in the statement of operations when realized. Depreciation is provided using the straight-line
method over the following estimated useful lives:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000967" name="MDBH:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"><p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none">Schedule
of Estimated Useful Lives of Property
and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_LaboratoryEquipmentMember" format="ixt-sec:duryear" id="Fact000969" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Developed software</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_DevelopedSoftwareMember" format="ixt-sec:duryear" id="Fact000971" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000973" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0974">Lesser of the lease duration or the life of the improvements</span></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zPIXDQXW8b0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000976" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z8fPKC7TjJZh" style="display: none">Schedule of Property And Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024<span></span></b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Developed software</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2025-12-31" id="Fact000978" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2024-12-31" id="Fact000979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total property and equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31" id="Fact000981" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000982" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact000984" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000985" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000987" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000988" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zSieLJh9Yjw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000990" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_ziTtwP2xkno9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company generates revenue primarily
from providing brokerage services and underwriting through Public Ventures. PatentVest and eXoZymes, have
had limited activity during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Brokerage revenues consist of (i) trade-based
commission income from executed trade orders, (ii) net realized gains and losses from proprietary trades, and (iii) other income consisting
primarily of stock loan income earned on customer accounts. Public Ventures recognizes revenue from trade-based commissions and other
income when performance obligations are satisfied through the transfer of control, as specified in the contract, of promised services
to the customers of Public Ventures. Commissions are recognized on a trade date basis. Public Ventures believes that each executed trade
order represents a single performance obligation that is fulfilled on the trade date because that is when the underlying financial instrument
is identified, the pricing is agreed upon, and the risks and rewards of ownership have been transferred to/from the customer. When another
party is involved in transferring a good or service to a customer, Public Ventures assesses whether revenue is presented based on the
gross consideration received from customers (principal) or net of amounts paid to a third party (agent). Public Ventures has determined
that it is acting as the principal as the provider of the brokerage services and therefore records this revenue on a gross basis. Clearing,
custody and trade administration fees incurred from Interactive Brokers, the Company&#8217;s clearing firm, are recorded effective as
of the trade date. The costs are treated as fulfillment costs and are recorded in operating expenses in the consolidated statements of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Brokerage revenue is measured by the
transaction price, which is defined as the amount of consideration that Public Ventures expects to receive in exchange for services to
customers. The transaction price is adjusted for estimates of known or expected variable consideration based upon the individual contract
terms. Variable consideration is recorded as a reduction to revenue based on amounts that Public Ventures expects to refund back to the
customer. There were no variable considerations for the years ended December 31, 2025, and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment banking revenues
consist of private placement and underwriting fees. The Company generally does not incur costs to obtain contracts with customers
that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions, and
therefore, as of December 31, 2025 and 2024, the Company did not have any contract assets or liabilities related to these revenues
on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into underwriting agreements, to act as an underwriter and security offerings which include distribution and sale of securities
to investors. These agreements allow non-defaulting underwriters and the issuer&#8217;s representative to seek substitute purchasers within
36 hours if the Company defaults on its commitment. If replacements are not found and the default exceeds 10% of the offering, the agreement
may be terminated without liability. Under ASC 606, revenue is recognized only upon transfer of cash from the escrow account from investors
which is the final receipt of payment, as well receipt of warrants and common stock on the date of closing, with no recognition for defaulted
or terminated portions until resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Private placement fees are related
to non-underwritten transactions such as private placements of equity securities, private investments in public equity, and Rule 144A
private offerings and are recorded on the closing date of the transaction. Client reimbursements for costs associated for private placement
fees are recorded gross within investment banking and various expense captions, excluding compensation. The Company typically receives
payments on private placements transactions at the completion of the contract. The Company views the majority of placement fees as a single
performance obligation that is satisfied when the transaction is complete, and the revenue is recognized at that point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Taxes and regulatory fees assessed
by a government authority or agency that are both imposed on and concurrent with a specified revenue-producing transaction, which are
collected by Public Ventures from a customer, are excluded from revenue and recorded against general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures does not incur any
costs to obtain contracts with customers for revenues that are eligible for deferral or receive fees prior to recognizing revenue, and
therefore, as of December 31, 2025 and 2024, Public Ventures did not have any contract assets or liabilities related to these revenues
in its consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December 31,
2025 and 2024, the Company&#8217;s technology development segment did not have any revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">PatentVest recognizes revenue when performance
obligations are satisfied by transferring promised goods and services to customers in an amount the Company expects to receive in exchange
for those goods or services. PatentVest enters into contracts that can include various combinations of its offerings which are generally
capable of being distinct and accounted for as a separate performance obligation for the entire contract or a portion of the contract.
When performance obligations are combined into a single contract, PatentVest utilizes stand-alone selling price to allocate the transaction
price among the performance obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Certain contracts or portions of contracts
are duration-based, which in the event of customer cancellation, provide PatentVest with an enforceable right to a proportional payment
for the portion of the services provided. Accordingly, revenue from duration-based contracts is recognized using a time-based measure
of progress, which PatentVest believes best depicts how it satisfies its performance obligations in these arrangements as control is continuously
transferred throughout the contract period. Revenue from certain contracts is recognized over the expected period of performance using
a single measure of progress, typically based on hours incurred. Payments received in advance of services being rendered are recorded
as a component of contract liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000992" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock"><p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The PatentVest&#8217;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zzOhoIIdeFQf" style="display: none">Schedule of Changes in Deferred Revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Balance as of December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" title="Deferred revenue, Balance" style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-12-31" id="Fact000994" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" title="Amounts billed but not recognized" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" title="Revenue recognized" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2024-01-012024-12-31" id="Fact000998" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance as of December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" title="Deferred revenue, Balance" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" title="Amounts billed but not recognized" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" title="Revenue recognized" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" title="Deferred revenue, Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zwq8sGRWvSh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001008" name="MDBH:AccountingForResearchGrantsPolicyTextBlock"><p id="xdx_845_ecustom--AccountingForResearchGrantsPolicyTextBlock_zKADqWpB076k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Research Grants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes, receives grant reimbursements, which are netted against research and development expenses in the consolidated statement of operations.
Grant reimbursements for capitalized assets are recognized over the useful life of the assets, with the unrecognized portion recorded
as deferred grant reimbursements and included in liabilities in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Grants function on a reimbursement
model are accounted for using the accrual method. They are treated as reductions to expenses, corresponding to the amount of disbursements
and obligations eligible for reimbursement. These are for permissible expenses incurred as of December 31, 2024. The reimbursements are
anticipated to be received from the respective funding entities in the following year. Management considers such receivables at December
31, 2024, to be fully collectable due to the historical experience with the Federal Government of the United States of America. Accordingly,
no allowance for credit losses on the grants receivable was recorded in the accompanying consolidated financial statements. The Company was not engaged in any research grants for the year ended December 31. 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001010" name="MDBH:GrantsReceivableActivityTableTextBlock"><p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zvvVxNvqM2t4" style="display: none">Summary of Grants Receivable Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024<span id="xdx_F5E_zzT4nWlrl6oh">(1)</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Balance at beginning of year<span id="xdx_F49_zeT54RJrBuT1">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2023-12-31" id="Fact001013" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">882</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant costs expensed</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GrantCostsExpensed" contextRef="From2024-01-012024-12-31" id="Fact001016" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,897</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grants for equipment purchased</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GrantsForEquipmentPurchased" contextRef="From2024-01-012024-12-31" id="Fact001019" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GrantFees" contextRef="From2024-01-012024-12-31" id="Fact001022" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grant funds received</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:GrantFundsReceived" contextRef="From2024-01-012024-12-31" id="Fact001025" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,173</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Removal of balance due to deconsolidation of eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:RemovalOfBalanceDueToDeconsolidation" contextRef="From2024-01-012024-12-31" id="Fact001028" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">702</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt"><ix:footnote id="Footnote001032" xml:lang="en-US">In 2024, eXoZymes was deconsolidated
from the Company&#8217;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</ix:footnote></span></td>
</tr></table>
</ix:nonNumeric><p id="xdx_8A0_z4a8wDrTKNud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes has received three grants
provided by the National Institute of Health, the Department of Energy and Department of Defense through December 31, 2024. The first
grant was awarded on October 1, 2023 and the latest of these grants was set to expire on May 14, 2026, however grants can be extended,
or new phases can be granted, extending the expiration of the grant. None of the grants have commitments made by the parties, provisions
for recapture, or any other contingencies, beyond complying with the normal terms of each research and development grant. Research grants
received from organizations are subject to the contract agreement as to how eXoZymes, formerly known as eXoZymes, conducts its research
activities, and eXoZymes is required to comply with the agreement terms relating to those grants. Amounts received under research grants
are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance
with the approved grant project. eXoZymes is permitted to draw down the research grants after incurring the related expenses. Amounts
received under research grants are offset against the related research and development costs in the Company&#8217;s consolidated statement
of operations. For the years ended December 31, 2025 and 2024, grants amounting $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20251231_zx1DsG46DI38" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_zvUD2nyd6316" title="Research and development costs"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million, were offset against
the research and development costs. Grant drawdowns, which includes grants costs expensed, grants for equipment purchased, and grant fees,
for the years ended December 31, 2025 and 2024, totaled $<span id="xdx_90B_ecustom--GrantDrawdowns_c20250101__20251231_zX0Wcdhg4k9d" title="Grant drawdowns"><ix:nonFraction name="MDBH:GrantDrawdowns" contextRef="From2025-01-01to2025-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--GrantDrawdowns_pn5n6_c20240101__20241231_zTw0cXZNZD38" title="Grant drawdowns"><ix:nonFraction name="MDBH:GrantDrawdowns" contextRef="From2024-01-012024-12-31" id="Fact001040" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million, respectively, which included grant costs expensed, grants
for equipment purchased, and grants fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001042" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zFio8zeF0yx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Research and Development Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses
relating to the development of eXoZymes&#8217; technology. For the years ended December 31, 2025 and 2024, research and development costs
prior to offset of the grants amounted to $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseGross_c20250101__20251231_zHnagssCOgN4" title="Net of grant received"><ix:nonFraction name="MDBH:ResearchAndDevelopmentExpenseGross" contextRef="From2025-01-01to2025-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseGross_pn5n6_c20240101__20241231_zw8WD44tPH7l" title="Net of grant received"><ix:nonFraction name="MDBH:ResearchAndDevelopmentExpenseGross" contextRef="From2024-01-012024-12-31" id="Fact001046" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million, respectively, which included grant costs expensed, grants fees, and research
and development costs, net of the grant received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001048" name="MDBH:PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock"><p id="xdx_84B_ecustom--PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_zNGl6M1zDfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Patent and Licensing Legal and Filing
Fees and Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Due to the significant uncertainty
associated with the successful development of one or more commercially viable products based on the Company&#8217;s research efforts and
related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its
intellectual property are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Patent and licensing legal and filing
fees and costs were $<span id="xdx_90A_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20250101__20251231_zAAazgXGyKU5" title="Patent and licensing legal and filing fees and costs"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2025-01-01to2025-12-31" id="Fact001050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></span> thousand and $<span id="xdx_902_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20240101__20241231_zE6M4QA6cWb5" title="Patent and licensing legal and filing fees and costs"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-01-012024-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">296</ix:nonFraction></span> thousand for the years ended December 31, 2025 and 2024, respectively. Patent and licensing
legal and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001054" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zssHT9mtPbQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>ASU 2021-10, Government Assistance
(Topic 832): Disclosures by Business Entities about Government Assistance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On January 1, 2020, The Company adopted
ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;)
and retrospectively applied the guidance to prior transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The amendments in ASU 2021-10 require
the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting
model by analogy: (1) information about the nature of the transactions and the related accounting policy used to account for the transactions;
(2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each
financial statement line item; and (3) significant terms and conditions of the transactions, including commitments and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Management does not believe that any
other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#8217;s
consolidated financial statement presentation or disclosures.</p>

</ix:nonNumeric><p id="xdx_85E_zcQgKELri1l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001056" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zqY4SbD7RhTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. <span id="xdx_822_zedJztFAtkf1">Segment Reporting</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In its operation of the business, management,
including the Company&#8217;s chief operating decision maker, who is also the Company&#8217;s Chief Executive Officer, reviews certain
financial information, including segmented profit and loss and balance sheet statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company currently operates in <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zba93brjOd7k" title="Number of reportable segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-12-31" id="Fact001058" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">two</ix:nonFraction></span>
reportable segments: a broker dealer &amp; intellectual property service and technology development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The broker dealer &amp; intellectual
property service segment currently has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer
firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking
due diligence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The technology development segment
currently has two subsidiaries, eXoZymes, and M1. eXoZymes is a research and development stage
company synthetic biology company, that is consolidated in the Statement of Operations up to November 14, 2024. M1 research
and development stage company that is developing a small molecule senescence platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Non-income generating subsidiaries
for management of the business, including MDB Management are reported in the Other column in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The segments are based on the discrete
financial information reviewed by the Chief Executive Officer to make resource allocation decisions and to evaluate performance. The reportable
segments are each managed separately because they will provide a distinct product or provide services with different processes. All reported
segment revenues are derived from external customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accounting policies of the Company&#8217;s
reportable segments are in consideration of ASC 280 and the same as those described in the summary of significant accounting policies
(see Note 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU001063-01" escape="true" id="Fact001063" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock"><p id="xdx_89D_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_gL3LLABGATTB-CUTW_zvEk2dnfJff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following sets forth the long-lived
assets and total assets by segment at December 31, 2025 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zkO4me2B3pk8" style="display: none">Schedule of Long-lived Assets and Total Assets by Segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerAndIntellectualPropertyServiceMember_zeGm3LNUjGIj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer and<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zcbZMLyosrsl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology<br/> Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zGlPhHZ2RzWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zC2bHg5bN0Ua" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_z0NyLqDFEtca" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_pn3n3_zzu8fMKvlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-size: 10pt; text-align: justify">Long-lived assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31_custom_BrokerDealerAndIntellectualPropertyServiceMember" id="Fact001065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31_custom_OtherSegmentsMember" id="Fact001067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">547</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact001069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">664</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_zrwrkCQlJ5h" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_BrokerDealerAndIntellectualPropertyServiceMember" id="Fact001071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,128</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_TechnologyDevelopmentMember" id="Fact001072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_OtherSegmentsMember" id="Fact001073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,609</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact001075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,740</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zsjWS16NaZB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU001080-01" escape="true" id="Fact001080" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MWGIM_zm6DXnzPilq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zPloS8TgOQDa" style="display: none">Schedule of Statement of Operation by Segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zmsUppUTSRGa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zrWrHbGhlL63" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zW5BrpeC8f9h" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z1OiMiy5lO65" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zR2CtlQalrc" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_z0HvKk5gBVg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_i01N_pn3n3_di_zLQAyD0Qvvgl" style="vertical-align: bottom; background-color: White">
    <td style="width: 30%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer <span id="xdx_F4B_zewLDUAXxTw8">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" contextRef="From2025-01-01to2025-12-31" id="Fact001092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_i01I_pn3n3_z3XCdhHMah51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer (1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" contextRef="From2025-01-01to2025-12-31" id="Fact001098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--RealizedInvestmentGainsLossesOne_i01_pn3n3_zMkq46JflBx4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Realized gain on investment securities, net from the licensed broker dealer <span id="xdx_F47_zDOEqJXPcqz7">(2)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:RealizedInvestmentGainsLossesOne" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:RealizedInvestmentGainsLossesOne" contextRef="From2025-01-01to2025-12-31" id="Fact001104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FeeIncome_i01_pn3n3_z75w6lRdU654" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income from the licensed broker dealer <span id="xdx_F40_zo1u9pGYbML9">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,282</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2025-01-01to2025-12-31" id="Fact001110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,282</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_zxitFAN2Fjp3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherOperatingIncome_i01_pn3n3_zz7DiKDnrtk5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income <span id="xdx_F4D_zdiglk5bUe8j">(4)</span></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">861</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2025-01-01to2025-12-31" id="Fact001122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">861</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_pn3n3_zesmzpastxF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,911</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,911</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zJGRCuuKpyec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zsXiVkEKYe91" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LaborAndRelatedExpense_i02_pn3n3_zdiHBXM7mDxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,875</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,094</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,969</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingExpense_i02_pn3n3_zYfTjFL1toq7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,471</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">362</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,833</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_pn3n3_z3ySzdMJZG93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,005</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">868</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-01to2025-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,937</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommunicationsAndInformationTechnology_i02_pn3n3_zJfQcRLb3Llj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">968</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2025-01-01to2025-12-31" id="Fact001164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,103</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ClearingAndOtherCharges_i02_pn3n3_zpPAGMTrpmre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">556</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2025-01-01to2025-12-31" id="Fact001170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">556</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_pn3n3_znbwBwmr5zb7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">742</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,497</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,239</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02T_pn3n3_zAOk4nWkddFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,617</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,956</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,637</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i02_pn3n3_zskYsgAMkCJl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_pn3n3_zLgZCyfaTS5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,617</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,956</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact001194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,637</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NetOperatingIncomeLoss_iT_pn3n3_zrIierldZ4T1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net operating (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001196" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,706</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001197" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001198" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,956</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,726</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_pn3n3_zojnS0jg4fef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--MiscellaneousIncome_pn3n3_zLrqgUQKpwvl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2025-01-01to2025-12-31" id="Fact001212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_pn3n3_di_z7eafuHWNQ52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">990</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="Fact001217" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">990</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherNonoperatingIncome_i01_pn3n3_zKw4Aws7eeVf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">471</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,136</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-012025-12-31_custom_EliminationsMember" id="Fact001223" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">990</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2025-01-01to2025-12-31" id="Fact001224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">617</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--GainRelatedToDilutionEvents_i01_pn3n3_zcBNWLxpXySk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain related to dilution events</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2025-01-01to2025-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zTkZ8Yb74lx6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain on deconsolidation of subsidiary</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_zuFjLfJo3MTe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001238" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,150</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001239" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001240" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,759</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact001242" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,973</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zMBLAtT4rIz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_pn3n3_zzgkoWOiXIw" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001250" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,161</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,759</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact001254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,984</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeLossFromEquityMethodInvestment_i01_pn3n3_ziwMXHlip1ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001258" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,282</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact001260" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,282</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_iT_pn3n3_zobhMCmM7mL3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001262" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,161</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001264" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,041</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001266" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,266</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zVxxXDefdtL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001269" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact001272" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_pn3n3_zdPCaBKfaeGe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001274" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember" id="Fact001275" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember" id="Fact001276" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001278" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span id="xdx_F0D_zEor9fRn3qpi" style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span id="xdx_F15_zgbWJ4PSadxe" style="font-size: 10pt"><ix:footnote id="Footnote001279" xml:lang="en-US">Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F09_zGLgxMMdFQN9" style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F17_zOe2PuXCzajk" style="font-size: 10pt"><ix:footnote id="Footnote001280" xml:lang="en-US">Includes realized gains on securities held by the broker-dealer.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F05_z4JoAFWJTPN1" style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span id="xdx_F11_zFxNmoNpBLpi" style="font-size: 10pt"><ix:footnote id="Footnote001281" xml:lang="en-US">Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.</ix:footnote></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F03_zUWsCc363nV3" style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span id="xdx_F12_zUyKanJjUJle" style="font-size: 10pt"><ix:footnote id="Footnote001282" xml:lang="en-US">Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zoLhQ72RvHFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C03_gL3LLABGATTB-CUTW_zZCbmgn9oyGj"><ix:continuation continuedAt="ConU001063-02" id="ConU001063-01">The following sets forth the long-lived
assets and total assets by segment at December 31, 2024 (in thousands):</ix:continuation></span></p>

<div id="xdx_C0E_gL3LLABGATTB-CUTW_zk7ARLLz2F94"><ix:continuation continuedAt="ConU001063-03" id="ConU001063-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_z8BIYhWOFah8" summary="xdx: Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zxfqZ3K4Y2tb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zwebjIF7XvUb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology<br/> Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zwt74Hy0bln7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z4xjSKBLaOA3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zykqqBau8oYe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrent_iI_zcB5szCPRVQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-size: 10pt; text-align: justify">Long-lived assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001284" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31_custom_OtherSegmentsMember" id="Fact001286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact001288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">732</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iI_zEbvqLQ6XxQ8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,754</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_TechnologyDevelopmentMember" id="Fact001291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_OtherSegmentsMember" id="Fact001292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,221</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">71,976</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C07_gL3LLABGATTB-CUTW_z7w7ePXwXSrk"><ix:continuation id="ConU001063-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zuVkSPH6Si92"><ix:continuation continuedAt="ConU001080-02" id="ConU001080-01">&#160;</ix:continuation></span></p>

<div id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zKvMYYxqAfxd"><ix:continuation continuedAt="ConU001080-03" id="ConU001080-02"><table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zxDkWDamkN9a" summary="xdx: Disclosure - Schedule of Statement of Operation by Segment (Details)" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zNgyo9QxRcDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zVBQNxHgGlHe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zfLHp1q4wxLk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z6aN42ks42Yi" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_z30lEVjjKxWj" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_zKRi1AQrpD9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrealizedGainLossOnInvestments_i01_zyb7rlhTFXw9" style="vertical-align: bottom; background-color: White">
    <td style="width: 30%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer  <span id="xdx_F43_zWUs8Dto14ke">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">275</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2024-01-012024-12-31" id="Fact001306" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">275</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FeeIncome_i01_z6d9ZzKadMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income from the licensed broker dealer <span id="xdx_F42_z5fs0BmS5l03">(2)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,221</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:FeeIncome" contextRef="From2024-01-012024-12-31" id="Fact001312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,221</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_ztiPAN9vDBPc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment loss <span id="xdx_F4A_z2dxI5NLo03f">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:ImpairmentOfInvestmentSecurities" contextRef="From2024-01-012024-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherOperatingIncome_i01_zyNFBZXjfPZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income <span id="xdx_F4D_zt1W4aTYGOT9">(4)</span></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncome" contextRef="From2024-01-012024-12-31" id="Fact001324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">411</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_zHvhMmllsUH3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,157</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,157</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zMmiKetVtgrb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvbbvLQPhjTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_i02_zqK1qW87qCrj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,226</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,062</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001346" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,769</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2024-01-012024-12-31" id="Fact001348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,057</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_i02_zrPywaAV9Cwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,301</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">185</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-012024-12-31" id="Fact001354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,486</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_zGxKygTch0B" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001356" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">820</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,206</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001358" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,086</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31" id="Fact001360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,112</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommunicationsAndInformationTechnology_i02_zLQaYBeMtBTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">805</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CommunicationsAndInformationTechnology" contextRef="From2024-01-012024-12-31" id="Fact001366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">922</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ClearingAndOtherCharges_i02_zh7JLkyObDE3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,137</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ClearingAndOtherCharges" contextRef="From2024-01-012024-12-31" id="Fact001372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,137</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_zZ34HDAX8LPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001374" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">806</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001375" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,669</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact001378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,608</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i02T_zZhBF38SfJsa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,095</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,435</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001382" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,792</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact001384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,322</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zIHEVSPhbYY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,468</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact001390" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,468</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_zvCDo2CdarEk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,095</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001393" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,903</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,792</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact001396" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,790</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NetOperatingIncomeLoss_iT_z02ABQ5Zs9Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net operating (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001398" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,938</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001399" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,903</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,792</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:NetOperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001402" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,633</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_ztBJeXpqWF0i" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--MiscellaneousIncome_zuWi4EoOwQah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1411">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:MiscellaneousIncome" contextRef="From2024-01-012024-12-31" id="Fact001414" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_zY0krAMLtmAj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001416" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">779</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="Fact001419" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">799</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact001420" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncome_i01_zfjLtL3YPDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001422" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">465</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001424" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,510</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31_custom_EliminationsMember" id="Fact001425" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">799</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31" id="Fact001426" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,179</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainRelatedToDilutionEvents_i01_zZnbGs53y3dl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gain related to dilution events</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:GainRelatedToDilutionEvents" contextRef="From2024-01-012024-12-31" id="Fact001432" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zPqWOkFi4UC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">Gain on deconsolidation of subsidiary</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,307</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1437">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-01-012024-12-31" id="Fact001438" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,307</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zkk18ubnFh3d" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001440" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,140</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001441" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,992</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,155</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1443">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact001444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,023</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_zN3z37vUv7y2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1449">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001450" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_zel5TqRLBvLa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001452" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,140</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001453" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,994</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,155</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31" id="Fact001456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,021</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeLossFromEquityMethodInvestment_i01_zjOzGfZpvHW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1459">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001460" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">420</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:IncomeLossFromEquityMethodInvestment" contextRef="From2024-01-012024-12-31" id="Fact001462" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">420</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ProfitLoss_iT_zxSS0fvY1v51" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001464" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,140</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001465" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,994</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,735</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact001468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,601</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zPA4DtmKvFQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001471" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact001474" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_z4NUZU0Rd7Ig" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net income and (loss) attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember" id="Fact001476" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember" id="Fact001477" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,904</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember" id="Fact001478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,735</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001480" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,691</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F0C_zItwKHS2g4Kh" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F19_zX8aEhgzrEuk" style="font-size: 10pt"><ix:footnote id="Footnote001481" xml:lang="en-US">Includes unrealized gains and
losses on securities held by the broker-dealer.</ix:footnote></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F09_zBzu6syX8buj" style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span id="xdx_F16_zorbWRAAllIf" style="font-size: 10pt"><ix:footnote id="Footnote001482" xml:lang="en-US">Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.</ix:footnote></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F02_zyhMfb3EvK0b" style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span id="xdx_F14_ztBZbU7oANQ5" style="font-size: 10pt"><ix:footnote id="Footnote001483" xml:lang="en-US">Includes impairment loss of assets
from the reduced fair value of the asset.</ix:footnote></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F0E_zCCvHQu57k5a" style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span id="xdx_F1A_zdtty7wgl7m" style="font-size: 10pt"><ix:footnote id="Footnote001484" xml:lang="en-US">Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.</ix:footnote></span></td>
</tr></table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zYgOk9fNWKxg"><ix:continuation id="ConU001080-03">&#160;</ix:continuation></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001486" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbT32cUspVz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4. <span id="xdx_821_znnEikvNcEoh">Equity and Non-Controlling Interests</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Equity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Preferred shares &#8211; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_z4BPQ5xp2mX7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact001488" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span>
shares authorized, <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_z6MdOwb2BUW1" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zmUVNqMFALi6" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact001490" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact001492" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding. The board of directors may designate preferred shares to be issued, and may rank
preferred shares as junior to, on parity with or senior to other preferred shares (in each case, with respect to distributions or other
payments in respect of shares). Since the board of directors may set all the terms of any class of preferred shares, these are considered
&#8220;blank check&#8221; preferred shares. Currently the board has not defined dividend and liquidation preference, participation rights,
call prices and dates, sinking-fund requirements, or terms that may change the conversation or exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Class A Common Shares &#8211; <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zNftXpF7D32a" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact001494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,000,000</ix:nonFraction></span>
shares authorized, <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHQy6flaBmHl" title="Common stock, shares, issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zrX3IxQo2ydl" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,950,632</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2024. These shares are common shares and have one vote per
share. Currently there is not a defined dividend or liquidation preference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Class B Common Shares &#8211; <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zQr9uU8Y3Hql" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact001500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>
shares authorized, <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZ95B7Sjniee" title="Common stock, shares, issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAKt2iGo4EGc" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December 31, 2024. These shares are common shares and have five votes per share.
Currently there is not a defined dividend or liquidation preference. These shares may be converted one to one for Class A Common Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Placement Agent and Selling Agent
Warrants &#8211; <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zL57LYQMhBFe" title="Placement agent and selling agent warrants"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember_us-gaap_IPOMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,420</ix:nonFraction></span> warrants of Class A common shares have been issued as part of the private placement and the initial public offering.
The Placement Agent and Selling Agent Warrants are subject to standard anti-dilution provisions and may include cashless exercise provisions
under certain circumstances. The issuance of the Placement and Selling Agent Warrants is a customary part of compensation for the placement
or selling agent&#8217;s services in connection with prior offerings.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-Controlling Interests</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2024 M1 was incorporated.
During the year ended December 31, 2024, the ownership interest in M1, ranged from <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zPlOXYx5EBNk" title="Ownership interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MinimumMember" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.0</ix:nonFraction></span>% to <span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zgIRLn3G5yNi" title="Ownership interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MaximumMember" id="Fact001510" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.9</ix:nonFraction></span>% (weighted average of <span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_znwaragf88ci" title="Ownership interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember" id="Fact001512" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.47</ix:nonFraction></span> %), with
the non-controlling interest ranging from <span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zG6RFwYL43r3" title="Non-controlling interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MinimumMember" id="Fact001514" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33.0</ix:nonFraction></span>% to <span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zYoO7sZOuep8" title="Non-controlling interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MaximumMember" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.1</ix:nonFraction></span>% (weighted average of <span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_zqybr6fXCRA4" title="Ownership interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.53</ix:nonFraction></span>%).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company held a weighted average of <span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20251231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_z67fcHuaYfzl" title="Ownership interest by parent"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.84</ix:nonFraction></span>% ownership interest in M1, with the remaining <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20251231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_zUgUEhVNjwBc" title="Ownership interest by NCI"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.16</ix:nonFraction></span>% representing NCI. During the year
ended December 31, 2024, the ownership interest in eXoZymes, ranged from <span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zij2aaGvQ0Vh" title="Ownership interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.94</ix:nonFraction></span>% to <span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zFxgOv51fUh1" title="Ownership interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47.0</ix:nonFraction></span>%, with the non-controlling
interest ranging from <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zgBPdVgO7LR9" title="Non-controlling interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39.06</ix:nonFraction></span> % to <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zLjv4TDRDaCa" title="Non-controlling interest rate"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember" id="Fact001530" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53.0</ix:nonFraction></span>%. On November 14, 2024 the ownership of eXoZymes by MDB moved below 50%, therefore
on that day the eXoZymes was deconsolidated from the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During each period, controlling and
non-controlling interests changes as a result of capital infusions from MDB. For the years ended December 31, 2025,
and 2024, there were capital infusions of $<span id="xdx_907_eus-gaap--ProceedsFromContributionsFromParent_pn3n3_c20250101__20251231_z3OhzTWMfmO" title="Capital infusions"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="From2025-01-01to2025-12-31" id="Fact001532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></span> thousand (M1) and $<span id="xdx_907_eus-gaap--ProceedsFromContributionsFromParent_pn3n3_c20240101__20241231_zO1fSF66FOza" title="Capital infusions"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromParent" contextRef="From2024-01-012024-12-31" id="Fact001534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">177</ix:nonFraction></span> thousand (M1), respectively. The NCI ownership will be equal to the
NCI percentage as of the reporting period. Therefore, there will be a redistribution of equity between MDB and the non-controlling interest
owner. As of December 31, 2025, the Company&#8217;s equity interest in M1 was <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zkv73oRc6s9" title="Equity interest rate"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MinimumMember" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.9</ix:nonFraction></span>% to <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zjtMVKmqrHJa" title="Equity interest rate"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MaximumMember" id="Fact001538" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.8</ix:nonFraction></span>%, and the remaining equity interest was owned
by the non-controlling interests as presented below. As of December 31, 2024, the Company&#8217;s equity interest in M1 was <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zTKvLFrPhfYe" title="Equity interest rate"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember5368140" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.9</ix:nonFraction></span>% to <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zUOUseYen9Y4" title="Equity interest rate"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember5368156" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67.0</ix:nonFraction></span>%,
and the remaining equity interest was owned by the non-controlling interests as presented below (in thousands):</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001544" name="MDBH:ScheduleOfEquityAndNonControllingInterestsTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfEquityAndNonControllingInterestsTableTextBlock_z9Is05pwWqf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zicnOOB87EGb" style="display: none">Schedule of Equity and Non-Controlling Interests</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Non-controlling interest net loss</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--NetIncomeLoss_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zWr6RDg9fa57" title="Non-controlling net loss" style="width: 16%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001546" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_ztA2iFFOG2Z1" title="Non-controlling net loss" style="width: 16%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001548" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">276</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Weighted average non-controlling percentage</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z1bJQyiL07ij" title="Weighted average non-controlling percentage" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:WeightedAverageNonControllingPercentage" contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001550" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.16</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zEj8rkCBjvm4" title="Weighted average non-controlling percentage" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:WeightedAverageNonControllingPercentage" contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001552" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32.53</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net loss non-controlling interest</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zdZMLh4owWm6" title="Net loss non-controlling interest" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001554" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zgRUoT5KtNzi" title="Net loss non-controlling interest" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001556" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Prior period balance</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--MinorityInterest_iS_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zMurvPsBzLN5" title="Prior period balance">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001558" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--MinorityInterest_iS_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zKE3C98v5r68" title="Prior period balance"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001560" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Removal of prior period balance of eXoZymes due to deconsolidation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zxxbfXPqBvLk" title="Removal of prior period balance of Exozyme due to deconsolidation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1562">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zcqxZHWj9WQ7" title="Removal of prior period balance of Exozyme due to deconsolidation" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:DueToDeconsolidation" contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001564" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zCr9gC2yi8nd" title="Stock-based compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1566">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z7EZ9iT65vmj" title="Stock-based compensation" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Ownership change of non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z6hMl72ml2h4" title="Ownership change of non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zRcWaomFVX13" title="Ownership change of non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Ending period balance</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--MinorityInterest_iE_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zPCK1BhahCs8" title="Ending period balance">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001574" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--MinorityInterest_iE_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zIZVBDMi0Gtf" title="Ending period balance">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember" id="Fact001576" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z1Lzyg2PEibk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">If there is a change in the parent
ownership in a subsidiary from an additional investment or from the issuance of stock based compensation, a change of the non-controlling
ownership is recognized based on the amount invested as required, and per ASC 810-45-21A, the carrying amount of the non-controlling interest
is adjusted to reflect the change in the non-controlling ownership in the subsidiary&#8217;s net assets. Since there was a change in the
equity, a reclassification of the non-controlling interest in the subsidiary&#8217;s net assets is required and demonstrated in the ending
period balance above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001578" name="MDBH:DeconsolidationDisclosureTextBlock"><p id="xdx_808_ecustom--DeconsolidationDisclosureTextBlock_zgA2s0FZ7ZJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 &#8211; <span id="xdx_827_zZ5CivyykUNc">Deconsolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On November 14, 2024 (the &#8220;Deconsolidation
Date&#8221;), the Company deconsolidated eXoZymes from its financial statements due to its ownership interest falling below 50%, resulting
in the loss of a controlling financial interest. This change occurred in connection with eXoZymes&#8217; completion of its initial public
offering, which reduced the Company&#8217;s ownership stake.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The consolidated financial statements
as of December 31, 2024 reflect the inclusion of eXoZymes&#8217; financial results through the Deconsolidation Date. For the period from
November 15, 2024 through December 31, 2024, the Company accounted for its investment in eXoZymes under the equity method, recognizing
its proportionate share of eXoZymes&#8217; net loss in the amount of $<span id="xdx_903_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_pn3n3_c20241115__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zYwaPYnN6aU6" title="Equity method, net loss"><ix:nonFraction name="us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" contextRef="From2024-11-152024-12-31_custom_ExozymesIncMember" id="Fact001580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">420</ix:nonFraction></span> thousand, based on eXoZymes&#8217; total net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_pn3n3_c20241115__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zqRhCrcg4bp4" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-152024-12-31_custom_ExozymesIncMember" id="Fact001582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">893</ix:nonFraction></span> thousand
for that period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, the Company
continues to hold a 47% interest in eXoZymes Class A common stock. While the Company and eXoZymes share certain officers, board members,
and accounting personnel, the two entities operate independently. eXoZymes also utilizes professional services provided by PatentVest,
a wholly owned subsidiary of the Company&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The assessment of the potential
impairment of the Company&#8217;s equity method investments when indicators such as a history of operating losses, a negative
earnings and cash flow outlook, and the financial condition and prospects for the investee&#8217;s business segment might indicate a
loss in value. The Company has not recognized any impairment loss on investment in unconsolidated affiliate to
date.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001584" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znmQzXpgD9Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 40pt; text-align: justify">The following table represents the
consolidated balance sheet of xXoZymes immediately prior to the Deconsolidation Date (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zaLyXtrRNZ45" style="display: none">Schedule
of Consolidated Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td colspan="2" id="xdx_49E_20241231__srt--ConsolidatedEntitiesAxis__custom--ExozymesMember_zTaT0KOHYLYe" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><b>December
                                            31, 2024</b></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_zZ7Bta7BJts1" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; font-size: 10pt; text-align: left">Cash and cash equivalents</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001586" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">68</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GrantsReceivable_i01I_pn3n3_zBeZI8Qfk3d9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-left: 0.25in">Grants receivable</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001588" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">701</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pn3n3_zSb3j8rkuW35" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">441</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredOfferingCosts_i01I_pn3n3_zM7K82YpJtRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred IPO Costs</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">550</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_zPkogiIDJgB7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001594" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">710</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_zyo8gcPejVH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset, net</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,366</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_pn3n3_zMMW3LhApfK7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001598" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,836</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Deficit</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_i01I_pn3n3_zZlZGfilAbul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001600" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">851</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_i01I_pn3n3_zu2hkw194UL8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001602" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherReceivables_i01I_pn3n3_zqAZYoN9Lrph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Due to affiliates</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001604" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,479</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredGrantReimbursement_i01I_pn3n3_zvCJLMY52BEf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred grant reimbursement</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredGrantReimbursement" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001606" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zOPU1t4Ro0xc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001608" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,417</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_i01TI_pn3n3_zvJfKbAAatkd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total liabilities</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,118</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Deficit:</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_zXc173vBPXRk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Common shares</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_z2W5ji9NjBbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Paid-in-capital</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,120</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_zlTZ9Z1if509" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001616" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,402</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_zJobKiQ0UCja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001618" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,282</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_zXIMBmWesci4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31_custom_ExozymesMember" id="Fact001620" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,836</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_ziXdUjgiIncb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At December 31, 2024
eXoZymes had current assets of approximately $<span id="xdx_904_eus-gaap--AssetsCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zBGLgRPknX2a" title="Current assets"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31_custom_ExozymesIncMember" id="Fact001622" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.8</ix:nonFraction></span> million, total assets of approximately $<span id="xdx_90D_eus-gaap--Assets_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_z83nOlXaNTI3" title="Total assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_ExozymesIncMember" id="Fact001624" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.0</ix:nonFraction></span> million, current liabilities of approximately
$<span id="xdx_903_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zizTKcSwYHd" title="Current liabilities"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31_custom_ExozymesIncMember" id="Fact001626" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million and total liabilities of approximately $<span id="xdx_90E_eus-gaap--Liabilities_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zaYX6y0DKaj6" title="Total liabilities"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31_custom_ExozymesIncMember" id="Fact001628" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million. For the year ended December 31, 2024, eXoZymes had revenues of $<span id="xdx_907_eus-gaap--Revenues_c20240101__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zkRAaCwJTjQk" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_ExozymesIncMember" id="Fact001630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and
a net loss of approximately $<span id="xdx_902_eus-gaap--NetIncomeLoss_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zEU4OVlT1Rb8" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_ExozymesIncMember" id="Fact001632" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.9</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001634" name="MDBH:ScheduleOfGainOnDeconsolidationTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfGainOnDeconsolidationTableTextBlock_zjocbmbLWKXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following represents the calculation
of the gain on deconsolidation of eXoZymes from the consolidated financial statements of the Company (in thousands, except for share
price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zhsrE4JjEvP" style="display: none">Schedule
of Gain on Deconsolidation</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt; text-align: left">eXoZymes Class A common shares retained on November 14, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_z8OxGjezDJwl" title="Class A common shares retained"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2024-11-15_custom_ExozymesIncMember" id="Fact001636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,931</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Quoted closing price of eXoZymes Class A common shares at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaqtv82MfCF9" title="Quoted closing price of Class A common shares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-14_custom_ExozymesIncMember" id="Fact001638" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.36</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Subtotal of quoted closing price of eXoZymes Class A common shares at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zKN8E9VImEtd" title="Subtotal of quoted closing price of Class A common shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2024-11-14_custom_ExozymesIncMember" id="Fact001640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">40,727</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fair value of warrants held for eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zFYz9Y9eXRe2" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-11-142024-11-14_custom_ExozymesIncMember" id="Fact001642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,327</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair value of equity method investment retained by eXoZymes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zebt75n0aUSh" title="Fair value of equity method investment"><ix:nonFraction name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="AsOf2024-11-14_custom_ExozymesIncMember" id="Fact001644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,054</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Carrying Value of the NCI</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iNI_pn3n3_di_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zzAECntclUEh" title="Carrying Value of the NCI">(<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-11-14_custom_ExozymesIncMember" id="Fact001646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">921</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Carrying value of eXoZymes assets at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--CarryingValueOfAssets_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zjHrObnUdcc8" title="Carrying value of assets"><ix:nonFraction name="MDBH:CarryingValueOfAssets" contextRef="AsOf2024-11-14_custom_ExozymesIncMember" id="Fact001648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,282</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Less carrying value of former investment into eXoZymes&#160;&#160;at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--LessCarryingValueOfFormerInvestment_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_zLptOMZvyKp6" title="Less carrying value of former investment">(<ix:nonFraction name="MDBH:LessCarryingValueOfFormerInvestment" contextRef="AsOf2024-11-15_custom_ExozymesIncMember" id="Fact001650" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,787</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Carrying value of warrants held for eXoZymes at November 14,2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--CarryingValueOfWarrants_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaMrQyJUqbZa" title="Carrying value of warrants">(<ix:nonFraction name="MDBH:CarryingValueOfWarrants" contextRef="AsOf2024-11-14_custom_ExozymesIncMember" id="Fact001652" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">321</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Gain on deconsolidation</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_z40mjl1Vfus7" title="Gain on deconsolidation"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2024-11-142024-11-14_custom_ExozymesIncMember" id="Fact001654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,307</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zk0nTGECPGL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001656" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock"><p id="xdx_802_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zbezwg98FQp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 &#8211; <span id="xdx_829_zp5M2beOTH1f">Equity Method Investment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On November 14, 2024, eXoZymes underwent
an initial public offering in which MDB&#8217;s ownership interest in eXoZymes decreased from <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241113__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zl6ffa1Zv9Tf" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-11-13_custom_ExozymesMember" id="Fact001658" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction>%</span> to <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241114__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zUCiomo9wflj" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-11-14_custom_ExozymesMember" id="Fact001660" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47</ix:nonFraction>%</span>. MDB and eXoZymes deconsolidated
the financial statements as the investment in eXoZymes fell below <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241114__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember__srt--RangeAxis__srt--MaximumMember_zdcSFPm1e83k" title="Ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-11-14_custom_ExozymesMember_srt_MaximumMember" id="Fact001662" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction>%</span> majority ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The fair value of the equity method investment
was determined based on the number of eXoZymes shares held by MDB and the market price of eXoZymes stock on the deconsolidation date.
This valuation also included the estimated fair value of warrants held in eXoZymes, along with an assessment of the investment for any
potential impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s portion of the net loss
for the year ended December 31, 2025, was $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn4n6_c20250101__20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zNIIsWO4GPRj" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_ExozymesMember" id="Fact001664" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">4.28</ix:nonFraction></span> million. As of December 31, 2025, MDB owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zWmZIg4BFAd5" title="Owned shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-12-31_custom_ExozymesMember" id="Fact001666" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3.93</ix:nonFraction></span> million shares of eXoZymes shares, representing
a <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvizyneTechnologiesIncMember_z81oc0FCbj0f" title="Equity method investment, percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-12-31_custom_InvizyneTechnologiesIncMember" id="Fact001668" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46.76</ix:nonFraction>%</span> ownership of eXoZymes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001670" name="us-gaap:EquityMethodInvestmentsTextBlock"><p id="xdx_893_eus-gaap--EquityMethodInvestmentsTextBlock_zhVkgjWMqWm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following summarizes the Company&#8217;
consolidated balance sheet equity method investment as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zFC2ZkijDefc" style="display: none">Schedule
of Equity Method Investment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrying
    Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024,
    carrying amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--EquityMethodInvestments_iS_c20250101__20251231_zzwPfe5YKIl8" title="Equity method investments, balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2024-12-31" id="Fact001672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41,764</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portion of loss
    from eXoZymes</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_c20250101__20251231_zgqyyMSX7w7k" title="Portion of loss from Invizyne" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" contextRef="From2025-01-01to2025-12-31" id="Fact001674" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain related to dilution events</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--EquityMethodInvestmentsGainRelatedToDilutionEvents_c20250101__20251231_ziSrlYOB3bLl" title="Gain related to dilution events" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MDBH:EquityMethodInvestmentsGainRelatedToDilutionEvents" contextRef="From2025-01-01to2025-12-31" id="Fact001676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2025, carrying amount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--EquityMethodInvestments_iE_c20250101__20251231_zqB3C2Vu0QZ4" title="Equity method investments, balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="AsOf2025-12-31" id="Fact001678" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,543</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001680" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPDd0uIJVI04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. <span id="xdx_824_z3jktA0KWVCa">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 28, 2025, Mo Hayat, Chris
Marlett, George Brandon, and Anthony DiGiandomenico voluntarily relinquished their outstanding restricted stock units (RSUs) in exchange
for stock options for an equivalent number of Class A shares and similar vesting schedules. This exchange was executed as part of a broader
equity compensation strategy aimed at aligning long-term incentives with shareholder value creation. The terms of the stock options, including
exercise price and vesting schedules, were approved by the Company&#8217;s Board of Directors in accordance with the existing equity incentive
plan and Section 16 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Between April 19, 2022 and September
21, 2022, the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20220419__20220921__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLIEmyYPcSVf" title="Restricted stock units, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-04-192022-09-21_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001682" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">3.7</ix:nonFraction></span> million restricted stock units (&#8220;RSUs&#8221;). <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_c20220419__20220921__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zThsIeTXp9z6" title="Restricted stock units, description"><ix:nonNumeric contextRef="From2022-04-192022-09-21_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001684" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription">These units vested 20% of one-half of the total
number of RSUs, by each individual person, on the thirteenth (13) month anniversary, October 20, 2024, of the listing of the Class A Shares
on a United States national exchange, then vesting would be at a rate of 10% of one-half the number of RSUs each six months after the
date of the initial vesting, until the last vesting on the fifth year anniversary of the date of grant, at which any previously unvested
would fully vest. These RSUs were granted to officers, directors, employees, and contractors. These RSU began to vest upon the completion
of the initial public offering by the Company on September 20, 2023, compensation expense related to these RSUs has been recorded. The
Company expensed the RSUs based on the average expense over the vesting period.</ix:nonNumeric></span> In 2024 an additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zan42jS1kTcf" title="Stock options to purchase"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember" id="Fact001686" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">295</ix:nonFraction></span> thousands RSUs were
granted, <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z846gwOaERc" title="Number of restricted stock units, canceled or forfeited"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember" id="Fact001688" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">320</ix:nonFraction></span> thousand RSUs were either canceled or forfeited, and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvmROqV0feg8" title="RSU vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember" id="Fact001690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">655</ix:nonFraction></span> thousand RSUs vested. The total unrecognized compensation expense
based on the share price sold in the 2022 private placement as of December 31, 2025 was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNjcxOdYQF1l" title="Unrecognized stock-based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember" id="Fact001692" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million. The weighted average of the remaining
restricted stock units at December 31, 2025 was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeQeQ5rW0vSj" title="Remaining weighted average years"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember" format="ixt-sec:duryear" id="Fact001694" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.6</ix:nonNumeric></span> years and at December 31, 2024 was <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQwnF7tFo9T2" title="Remaining weighted average years"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember" format="ixt-sec:duryear" id="Fact001696" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.4</ix:nonNumeric></span> years. During the year ended December 31, 2025,
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaSQjJmGISik" title="Cancelled shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001698" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">128</ix:nonFraction></span> thousand RSUs were canceled due to holder leaving the Company and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQDfxkxLnOn7" title="Number of restricted stock units, cancelled and converted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001700" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span> million RSUs were exchanged and converted to stock options.
As a result of the modification, the fair value of the awards immediately after the modification was determined to be $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzjNvplrJRVi" title="Fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001702" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million compared
to the fair value of the original restricted stock unit awards of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvs415EmwFD1" title="Restricted stock unit, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001704" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.8</ix:nonFraction></span> million immediately prior to the modification. The modification
resulted to a decrease in the aggregate fair value of the awards and in accordance with ASC 718-Compensation&#8212;Stock Compensation, no incremental compensation costs need
to be recognized over the remaining requisite service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 19, 2022 the Company granted
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20220419__20220419__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzQYquawYwc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001705" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">2</ix:nonFraction></span>
million restricted stock units (&#8220;RSUs&#8221;). <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_c20220419__20220419__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxNuFCThasGb"><ix:nonNumeric contextRef="From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription">These
units will vest 20% of one-half of the total number of RSUs, by each individual person, starting on the thirteenth (13) month anniversary
of the listing of the Class A Shares on a United States national exchange, October 20, 2024, when a Class A Share has traded in the market
on which the Class A Shares are listed for any 90 consecutive calendar days at an average price of $20.00 or more during the period commencing
the date of grant and prior to the five year anniversary of the date of grant, with an average monthly trading volume of 2 million Class
A Shares or more during the 90 consecutive calendar day period, or a Class A Shares has traded in the market on which the Class A Shares
are listed for any 90 consecutive calendar days at an average price of $25.00 or more during the period commencing the date of grant
and prior to the five year anniversary of the date of grant; provided further, that if there is a distribution of cash, stock or other
property by the Company on the Class A Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced, from time to time,
by the value of any one or more per share distributions after the date of grant until vested.</ix:nonNumeric></span> As these RSUs did not begin to vest
until the completion of an initial public offering, which was completed on September 20, 2023, by the Company, which was outside of the
control of the Company, compensation expense related to these RSUs has been recorded. On April 28, 2025 all of the market based RSUs
were modified and exchanged for stock options in their place. The unvested portion of the market based RSUs was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCFNbbv9hmT1" title="Unvested portion market value"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2025-04-28_custom_MarketBasedMember" id="Fact001708" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.7</ix:nonFraction></span>
million and the incremental value of $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z9SwRIdmiA7"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-04-28_custom_MarketBasedMember" id="Fact001709" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span>
million in the exchange for a total amortized amount of $<span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zJO0Bb5DxCU8" title="Sharebased payment award amortized amount"><ix:nonFraction name="MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" id="Fact001711" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.2</ix:nonFraction></span>
million that will be amortized over the <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zUxZzeUTTuD2" title="Stock-based compensation term life"><ix:nonNumeric contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" format="ixt-sec:duryear" id="Fact001713" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">10</ix:nonNumeric></span></span>ten-year life
of the award. There is not an estimated unrecognized compensation expense, as all the RSUs were modified and exchanged for stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001715" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0NIG6VYd1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of restricted stock unit
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zNRnXuYqfBMe" style="display: none">Schedule
of Restricted Stock Unit Activity</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Time-Based</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Performance-Based</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of<br/> Restricted<br/> Stock Units</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of<br/> Restricted<br/> Stock Units</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Restricted stock units outstanding at December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcYZnmL3I8b5" title="Number of Restricted Stock Units, outstanding" style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="Fact001717" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,995</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zqNSYST50oIh" title="Weighted Average Grant Date Fair Value, outstanding" style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.90</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zkaJgIL5huh2" title="Number of Restricted Stock Units, outstanding" style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="Fact001721" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4QJWNJ6qGGb" title="Weighted Average Grant Date Fair Value, outstanding" style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_MarketBasedMember" id="Fact001723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.91</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Granted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1Xwaw4SCDn7" title="Number of Restricted Stock Units, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1725">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z2u4HiT6DUGg" title="Weighted Average Grant Date Fair Value, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1727">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zyqFuyZr33f7" title="Number of Restricted Stock Units, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1729">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zeizSkZc1sfe" title="Weighted Average Grant Date Fair Value, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1731">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Vested</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrMbe9Lnsmbj" title="Number of Restricted Stock Units, outstanding" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">188</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zBVBRPeCZXVd" title="Weighted Average Grant Date Fair Value, outstanding" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001735" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.69</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWs0a40oFnT1" title="Number of Restricted Stock Units, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1737">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Exchanged/Modified</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHoRwosIwOJd" title="Number of Restricted Stock Units, Exchanged/Modified" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001739" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">1,600</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1xvaAPwrEO1" title="Weighted Average Grant Date Fair Value, Exchanged/Modified" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001741" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zp1OHG0r3gmk" title="Number of Restricted Stock Units, Exchanged/Modified" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="Fact001743" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">2,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z6RbXw0kdMhg" title="Weighted Average Grant Date Fair Value, Exchanged/Modified" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="Fact001745" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.91</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z4k47XUbV0Nf" title="Number of Restricted Stock Units, outstanding" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001747" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">128</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcihfXXzFDc4" title="Weighted Average Grant Date Fair Value, outstanding" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001749" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.97</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z3zQdk8OwVLk" title="Number of Restricted Stock Units, outstanding" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4GuxS4E82l" title="Weighted Average Grant Date Fair Value, outstanding" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1753">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restricted stock units outstanding at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zpcXx5SInOsh" title="Number of Restricted Stock Units, outstanding" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001755" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,079</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zr3VC3Pa3Tzk" title="Weighted Average Grant Date Fair Value, outstanding" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001757" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.78</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zFXarj62x0Gd" title="Number of Restricted Stock Units, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z1aVgoJo0Od5" title="Weighted Average Grant Date Fair Value, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1761">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restricted stock units at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEhKd4WFY34k" title="Exercisable and vested restricted stock, outstanding" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="Fact001763" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">655</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zptrfDqfPAS" title="Weighted Average Grant Date Fair Value, Exercisable and vested" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TimeBasedMember" id="Fact001765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zvHvN4N3O1ck" title="Exercisable and vested restricted stock, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztr1g4c4adQj" title="Weighted Average Grant Date Fair Value, Exercisable and vested" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted stock units at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zN5XjccM0T43" title="Exercisable and vested restricted stock, outstanding" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">843</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z6Vfvyb6UDXj" title="Weighted Average Grant Date Fair Value, Exercisable and vested" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001773" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.93</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zw6vq84NHZei" title="Exercisable and vested restricted stock, outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1775">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zAsqLiuFA3Jb" title="Weighted Average Grant Date Fair Value, Exercisable and vested" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1777">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zetV5s6CvD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 28, 2025, in exchange for
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_ziGALF7LAPcc" title="Unvested, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" id="Fact001779" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span> million unvested time-based RSUs, stock options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zmFzdoNXFtx4" title="Stock options to purchase"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" id="Fact001781" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.6</ix:nonFraction></span> million shares of Common Shares were granted at an exercise price of
$<span id="xdx_90B_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zq0hN5z9Hj3h" title="Exercise price per share, granted"><ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" id="Fact001783" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.25</ix:nonFraction></span> per share, which was equal to the closing price of the Common Shares immediately prior to the date of grant, and are exercisable
for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHbNHE9xww12" title="Exercisable period"><ix:nonNumeric contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" format="ixt-sec:duryear" id="Fact001785" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric></span> years. One-half of the stock options vested immediately on grant, with the remaining stock options vesting ratably
over a period of <span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zt8zo2l3M0D8" title="Remaining stock options vesting period"><ix:nonNumeric contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" format="ixt-sec:duryear" id="Fact001787" name="MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting">2</ix:nonNumeric></span> years, subject to continued service. The inputs used to determine the fair value of this stock option grant were as
follows: (1) Common Stock price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zlgWwmoHFNgd" title="Common stock price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-04-28_custom_TimeBasedMember" id="Fact001789" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.25</ix:nonFraction></span> per share; (2) exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEqC5QGGkwi1" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-04-28_custom_TimeBasedMember" id="Fact001791" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.25</ix:nonFraction></span> per share; (3) expected life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zK02b7ouC7a8" title="Estimated life"><ix:nonNumeric contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" format="ixt-sec:duryear" id="Fact001793" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span> years; (4) risk-free
interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNVFUN1ChH3" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" id="Fact001795" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.23</ix:nonFraction></span>%; (5) expected annual volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zflp6LWiWpUi" title="Expected annual volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" id="Fact001797" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.65</ix:nonFraction></span>%; and (6) an annual dividend rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsL5AcSWJpJf" title="Expected annual volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-04-282025-04-28_custom_TimeBasedMember" id="Fact001799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%. The total unrecognized compensation
expense based on the pre-modification valuation of the shares price sold in the 2022 private placement as of December 31, 2025 was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTbTjzXUOath" title="Unrecognized stock-based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-12-31_custom_TimeBasedMember_us-gaap_PrivatePlacementMember" id="Fact001801" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" escape="true" id="Fact001803" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--TimeBasedMember_zLD0G36Gj603" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of time-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except
for share price and contractual life):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zaIxCcuCKHl7">Schedule
of Time-Based Stock Option Activity</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Time-based stock options outstanding at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zUFfjZngfKX1" title="Number of Options, time-based stock options outstanding, beginning" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1805">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zF8A3iUEoFi5" title="Weighted average exercise price, time-based stock options outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-size: 10pt">Exchanged/Modified</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z8EfKrinwPr" title="Number of Options, exchanged/modified" style="width: 13%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,600</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zXQLEHweryof" title="Weighted average exercise price, exchanged/modified" style="width: 13%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" id="Fact001811" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.75</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zvCgtdBmjcJf" title="Weighted average remaining contractual life (in years), time-based stock options exchanged/modified"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" format="ixt-sec:duryear" id="Fact001813" name="MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2">10.00</ix:nonNumeric></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhdt6Ax7uwm4" title="Number of Options, exercised" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNifTcXSWT6" title="Weighted average exercise price, exercised" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zL5UIVZTf7v5" title="Number of Options, expired/cancelled" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zFTQtDvgYof3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Time-based stock options outstanding at December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zxeyitO6Lmaj" title="Number of Options, time-based stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001822" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcbs40YBwQRd" title="Weighted average exercise price, time-based stock options outstanding" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001824" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zPnmRpdpdFrk" title="Weighted average remaining contractual life (in years), time-based stock options outstanding"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" format="ixt-sec:duryear" id="Fact001826" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.32</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zYKJL7GYeGgl" title="Number of Options, stock options exercisable" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrbZX0M8Po8i" title="Weighted average exercise price, stock options exercisable" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1830">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhELFJfAVxA5" title="Number of Options, stock options exercisable" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001832" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,067</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zu8BnDbm2s9j" title="Weighted average exercise price, stock options exercisable" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_TimeBasedMember" id="Fact001834" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.75</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zasVp7qzfOOg" title="Weighted average remaining contractual life (in years), stock options exercisable"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TimeBasedMember" format="ixt-sec:duryear" id="Fact001836" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.32</ix:nonNumeric></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z1IfYhxmTf4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, on April 28, 2025, in
exchange for <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn6n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z753q2DcMUq1" title="Unvested, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" id="Fact001838" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">2</ix:nonFraction></span> million unvested market-based RSUs, stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn6n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5Ps6Pw8u4Wg" title="Stock options to purchase"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" id="Fact001840" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">2</ix:nonFraction></span> million shares of Common Shares were granted at an exercise
price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zaApLbRlFDHe" title="Exercise price per share, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" id="Fact001842" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.25</ix:nonFraction></span> per share, which was equal to the closing price of the Common Shares immediately prior to the date of grant, and are exercisable
for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zlwp7UUsi3bl" title="Exercisable period"><ix:nonNumeric contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" format="ixt-sec:duryear" id="Fact001844" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric></span> years. The stock options vest if either (a) the Common Shares has traded in the market on which the shares are listed
for at least 30 trading days at an average price per share of $<span id="xdx_905_ecustom--AveragePricePerShare_iI_pip0_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5rm3LLTF075" title="Average price per share"><ix:nonFraction name="MDBH:AveragePricePerShare" contextRef="AsOf2025-04-28_custom_MarketBasedMember" id="Fact001846" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">20.00</ix:nonFraction></span> or more, whether consecutive or non-consecutive, or (b) there are
distributions of cash, stock or other property by the Company to the holders of the Common Shares, at a value per share of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pp0p0_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5IRk0iVwDtg"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-04-28_custom_MarketBasedMember" id="Fact001847" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USDPShares">20.00</ix:nonFraction></span> or more
in the aggregate, subject to continued service. Once vested, the stock options will be exercisable for the remainder of the <span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4ThRkF7dNca" title="Exercisable period"><ix:nonNumeric contextRef="From2025-04-282025-04-28_custom_MarketBasedMember" format="ixt-sec:duryear" id="Fact001849" name="MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting">10</ix:nonNumeric></span>-year grant
date period. The total unrecognized compensation expense based on the post-modification valuation of the unamortized amount and the incremental
value as of December 31, 2025 was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMdhZ7ejTCyj" title="Unrecognized stock-based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-12-31_us-gaap_PrivatePlacementMember" id="Fact001851" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.2</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" escape="true" id="Fact001853" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_896_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--MarketBasedMember_zSj7a8TViAnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of market-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price and contractual life):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z7SJ0ngWr4Ha">Schedule
of Market-Based Stock Option Activity</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Market-based stock options outstanding at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_znVElCvTtbO" title="Number of Options, market-based stock options outstanding, beginning" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1855">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z8bzdP5EKSwa" title="Weighted average exercise price, market-based stock options outstanding" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1857">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-size: 10pt">Exchanged/Modified</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zwhp0TTKRO27" title="Number of Options, exchanged/modified" style="width: 13%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="Fact001859" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zPVa6oNLHFD1" title="Weighted average exercise price, exchanged/modified" style="width: 13%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" id="Fact001861" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.02</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztiHtKLirGWa" title="Weighted average remaining contractual life (in years), exchanged/modified"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" format="ixt-sec:duryear" id="Fact001863" name="MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1">10.00</ix:nonNumeric></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zOqaMejvrJG5" title="Number of Options, exercised" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zqOF4ETqdDP4" title="Weighted average exercise price, exercised" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1867">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zZNzSIxvM2N6" title="Number of Options, expired/cancelled" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1869">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zpF6y5AKNak" title="Weighted average exercise price, expired/cancelled" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Market-based stock options outstanding at December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zb28UOMM6DM7" title="Number of Options, market-based stock options outstanding, at the end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="Fact001873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCjLE2mChIg5" title="Weighted average exercise price, market-based stock options outstanding" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_MarketBasedMember" id="Fact001875" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.02</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zDhONlxIRaGa" title="Weighted average remaining contractual life (in years), market-based stock options outstanding"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MarketBasedMember" format="ixt-sec:duryear" id="Fact001877" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.32</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zHZbRNuMefMk" title="Number of Options, stock options exercisable" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1879">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zM9LuLdr3QY4" title="Weighted average exercise price, stock options exercisable" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWSW0D39vlN6" title="Number of Options, stock options exercisable" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1883">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zcmQYB5a4R01" title="Weighted average exercise price, stock options exercisable" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1885">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zQNfMg9lWQ98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001887" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z4AFW1sconlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. <span id="xdx_825_zs0b4gwQ1qIj">Earnings Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s computation of
earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable
to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but
presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if
they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive
effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Loss per common share is computed by
dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted
loss per common share was the same for all periods presented because stock warrants outstanding were anti-dilutive, for a total of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z87kbfmkXFh2" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact001889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">43</ix:nonFraction></span>
thousand warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Earning Earnings per share is presented
below for the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001891" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zVPR881P9PVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic earnings per share is calculated
at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zkaqjXOfKsOg" style="display: none">Schedule
of Basic and Fully Diluted</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsKeAY7lHbP4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqhdj2uVj8o" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z36dGnq7Fvc8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zx6NEZoPZlae" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Years Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Basic</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
    31, 2025</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    A Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Class
    B Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    A Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    B Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zXbCmKGZ1m5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Net income (loss) attributable to MDB Capital
    Holdings, LLC</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact001893" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,768</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact001894" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,477</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact001895" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,817</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact001896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,875</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_zdsrVE2OJzT5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Weighted average shares outstanding &#8211; basic</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact001898" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,023</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact001899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact001900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,424</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact001901" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_z2P4Xqk9dke1" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Net income (loss) per share &#8211; basic</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact001903" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.14</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact001904" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.10</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact001905" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact001906" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.18</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fully diluted earnings per share is
calculated at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49C_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkBtQU8M7Ca2" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_492_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpgRvnXgjrMj" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49B_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJViQEtjkvYh" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49C_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zADIBaE7C4Dk" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zvw8leYB2UVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left">Net income (loss) attributable to MDB Capital Holdings, LLC</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact001908" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,714</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact001909" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,531</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact001910" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,650</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact001911" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,042</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_zMBcPh8ZtcTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted shares outstanding &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact001913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,145</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact001914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact001915" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9,463</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact001916" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zbLkXkAoW93g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net income (loss) per share &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember" id="Fact001918" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.91</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember" id="Fact001919" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.91</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember" id="Fact001920" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember" id="Fact001921" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.81</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zPauISGOoIgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Class A Common Shares and Class B common
stock are equal for ownership purposes, but Class B shares have five times the voting rights of Class A shares and Class B shares can
be exchanged on a one-to-one basis for purposes of sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001923" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zy5DaESs1tE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. <span id="xdx_82A_zRReezvqviBl">Related Party Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The principal members of the Company
have a controlling interest in PatentVest, S.A. (renamed MDB Capital, S.A. in 2022), a company organized and based in Nicaragua that provides
outsourced services to the Company and other non-related entities. During the years ended December 31, 2025 and 2024, the Company paid
$<span id="xdx_909_eus-gaap--CostsAndExpensesRelatedParty_pn5n6_c20250101__20251231_zFmmqfEy9S5d" title="Related party expenses"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2025-01-01to2025-12-31" id="Fact001925" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction> </span>million and $<span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_pn5n6_c20240101__20241231_zIAJB4tlmxZc" title="Related party expenses"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2024-01-012024-12-31" id="Fact001927" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million, respectively, which is inclusive of expenses and fees, for contracted labor, recorded against general and
administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December 31,
2025 and 2024, PatentVest, engaged in transactions with ENDRA Life Sciences Inc &#8211; NDRA on Nasdaq, a company for which one of our
executive officer serve as a board member. Anthony DiGiandomenico, our Chief of Transactions. For the year ended December 31, 2024, there
were no revenues recognized between MDB entities and ENDRA. However, costs incurred amounting to $<span id="xdx_906_eus-gaap--OperatingExpenses_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ENDRAMember_zry4x5xp5rGl"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_ENDRAMember" id="Fact001928" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></span> thousand
related to transactions with ENDRA were recognized during the year. For the year ended December 31, 2025 there was no revenue or costs
recognized during the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December
31, 2025 and 2024, PatentVest engaged in transactions with eXoZymes, a company of which the Company owns 47% of recognized revenues
of $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExozymesMember_zIwL0dXdKU0d"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_ExozymesMember5372140" id="Fact001929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></span>
thousand and $<span id="xdx_90C_eus-gaap--Revenues_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExozymesMember_zkt2EhGbubua"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_ExozymesMember" id="Fact001930" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></span>
thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company recorded related party accrued receivables totaling $<span id="xdx_907_eus-gaap--InterestReceivable_iI_pn3n3_c20251231_zrxbUWq1s0k2" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2025-12-31" id="Fact001932" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></span> thousand for services performed by PatentVest on behalf of eXoZymes.
Additionally, the Company recorded accrued expenses of $<span id="xdx_905_ecustom--AccruedExpenses_iI_pn3n3_c20251231_zZOjUc2ayASh" title="Accrued expenses"><ix:nonFraction name="MDBH:AccruedExpenses" contextRef="AsOf2025-12-31" id="Fact001934" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span> thousand payable to PatentVest, representing reimbursable expenses incurred
in the ordinary course of business. During the year ended December 31, 2024, the Company recorded related party accrued receivables totaling
$<span id="xdx_90F_eus-gaap--InterestReceivable_iI_pn3n3_c20241231_zgM48hmwSoa1" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2024-12-31" id="Fact001936" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></span> thousand. This amount includes $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20240101__20241231_z9ulUjPQSuM1" title="Value issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31" id="Fact001938" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span> thousand for services performed by PatentVest on behalf of eXoZymes and $<span id="xdx_903_eus-gaap--IncomeTaxesPaid_pn3n3_c20240101__20241231_zrGqj35yvBkj" title="Tax paid"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2024-01-012024-12-31" id="Fact001940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></span> thousand related to
taxes paid by the Company on behalf of certain officers, which was reimbursed in full by January 31, 2025. Additionally, the Company recorded
accrued expenses of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_c20241231_zR1FMnEN4Kz8" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001942" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></span> thousand payable to officers and directors, representing reimbursable expenses incurred in the ordinary course
of business. All transactions were conducted on an arm&#8217;s-length basis and are expected to be settled in the normal course of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001944" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zE7XaO71sRXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. <span id="xdx_82D_zBhnqu6KJad7">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Legal Claims</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company may be subject to legal
claims and actions from time to time as part of its business activities. As of December 31, 2025 and 2024, the Company was not subject
to any pending or threatened legal claims or actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Net Capital Requirement (Public
Ventures)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures is subject to the uniform
net capital rule (SEC Rule 15c3-1) of the Securities and Exchange Commission (the &#8220;SEC&#8221;), which requires both the maintenance
of minimum net capital and the maintenance of maximum ratio of aggregate indebtedness to net capital. At December 31, 2025 and 2024, Public
Ventures had net capital of $<span id="xdx_90D_esrt--NetCapital_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_z11nfEJ8vmEg" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2025-12-31_custom_PublicVenturesMember" id="Fact001946" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.7</ix:nonFraction></span> million and $<span id="xdx_907_esrt--NetCapital_iI_pn5n6_c20241231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_z4BaHx3yrAG8" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2024-12-31_custom_PublicVenturesMember" id="Fact001948" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.7</ix:nonFraction></span> million, respectively, which was $<span id="xdx_90F_esrt--NetCapital_iI_pn4n6_c20251231_zmHNoXFBvw3c" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2025-12-31" id="Fact001950" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">8.45</ix:nonFraction></span> million and $<span id="xdx_900_esrt--NetCapital_iI_pn4n6_c20241231_zrjiJslOYAQi" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2024-12-31" id="Fact001952" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">10.45</ix:nonFraction></span> million in excess of the
minimum $<span id="xdx_90C_esrt--NetCapital_iI_pn3n3_c20241231__srt--RangeAxis__srt--MinimumMember_z7dvS3CN8DP" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact001954" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> thousand, as required by the Securities and Exchange Commission Rule 15c3-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the broker dealer had existing subordinated loans with MDB, the Parent company, totaling $<span id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_zTE1SPbeHWl5" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2025-12-31_custom_PublicVenturesMember" id="Fact001956" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.2</ix:nonFraction></span> million and $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_zF6aug1UB27e" title="Interest expense"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2025-12-31_custom_PublicVenturesMember" id="Fact001958" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million of accrued interest
payable, is subordinated to other liabilities of the Company, and is considered members&#8217; equity for calculating net capital, and
is not included in aggregate indebtedness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Minimum net capital is based upon
the greater of the statutory minimum net capital of $<span id="xdx_90D_esrt--NetCapital_iI_pn3n3_c20251231__srt--RangeAxis__srt--MinimumMember_zVgCntn59agb" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2025-12-31_srt_MinimumMember" id="Fact001960" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span>
thousand or <span id="xdx_906_eus-gaap--RatioOfIndebtednessToNetCapital1_iI_pid_dp_uPure_c20251231_zIFVH3ucJoTl" title="Percentage of aggregate indebtedness"><ix:nonFraction name="us-gaap:RatioOfIndebtednessToNetCapital1" contextRef="AsOf2025-12-31" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>%
of aggregate customer debits, which were $<span id="xdx_90B_esrt--MinimumNetCapitalRequiredForEntity1_iI_c20251231_z59sN8Ojxkok" title="Aggregate indebtedness calculated amount"><span id="xdx_90D_esrt--MinimumNetCapitalRequiredForEntity1_iI_c20241231_zekO2MN0yzr7" title="Aggregate indebtedness calculated amount"><ix:nonFraction name="srt:MinimumNetCapitalRequiredForEntity1" contextRef="AsOf2025-12-31" id="Fact001964" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="srt:MinimumNetCapitalRequiredForEntity1" contextRef="AsOf2024-12-31" id="Fact001966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>
at December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">To comply with DTCC membership requirements,
the Company has committed to maintain at least $<span id="xdx_907_esrt--NetCapital_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__custom--DTCMembershipRequirementsMember_zA4hJ1U0Of79" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2025-12-31_custom_DTCMembershipRequirementsMember" id="Fact001968" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million of net capital in excess of the $<span id="xdx_905_esrt--NetCapital_iI_pn3n3_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--DTCMembershipRequirementsMember_zgh8tzyFYTZ" title="Net capital"><ix:nonFraction name="srt:NetCapital" contextRef="AsOf2025-12-31_srt_MinimumMember_custom_DTCMembershipRequirementsMember" id="Fact001970" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> thousand minimum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The requirement
to comply with the Uniform Net Capital Rule 15c3-1 may limit Public Ventures&#8217; ability to issue dividends to its parent company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Indemnification Provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures has agreed to indemnify
its clearing broker for losses that the clearing brokers may sustain from the accounts of customers. Should a customer not fulfill its
obligation on a transaction, Public Ventures may be required to buy or sell securities at prevailing market prices in the future on behalf
of its customer. The indemnification obligations of Public Ventures to its clearing brokers have no maximum amount. All unsettled trades
at December 31, 2025 and 2024, have subsequently settled with no resulting material liability to Public Ventures. For the years ended
December 31, 2025 and 2024, Public Ventures, had no material loss due to counterparty failure and had no obligations outstanding under
the indemnification arrangement as of December 31, 2025 and 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001972" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_807_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z3dzmvQHZyh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. <span id="xdx_829_zUIoaJuN5tyh">Employee Benefit Plans</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Management and eXoZymes, both sponsored individual 401(k) defined contribution plans for the benefit of each company&#8217;s eligible employees.
Public Ventures offered its employees a sponsored 401(k) defined contribution plan for the benefit of the employees; this plan was terminated
on July 30, 2021. The plans allow eligible employees to contribute a portion of their annual compensation, not to exceed annual limits
established by the Department of Treasury. eXoZymes makes matching contributions for participating employees up to a certain percentage
of the employee contributions; matching contributions were funded for the year ended December 31, 2025 and 2024. Benefits under the eXoZymes
plan were available to all employees, and employees become fully vested in the employer contribution upon receipt. For the year ended
December 31, 2025 and 2024, a total of $<span id="xdx_908_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20250101__20251231_zXwZ4CApO8Y3" title="Employer contribution"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2025-01-01to2025-12-31" id="Fact001974" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">392</ix:nonFraction></span> thousand and $<span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20240101__20241231_zJ8wKeNAW0Zd" title="Employer contribution"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2024-01-012024-12-31" id="Fact001976" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">659</ix:nonFraction></span> thousand, respectively, was contributed to the plans. The costs for eXoZymes
are recorded up to November 14, 2024, the date of the consolidation of eXoZymes. The majority of the expense was included in general and
administrative cost, however, for any research and development employees. their portion of the expense is recorded in research and
development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Management and eXoZymes also provide
health and related benefit plans for eligible employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001978" name="MDBH:ExclusiveLicenseAgreementTextBlock"><p id="xdx_803_ecustom--ExclusiveLicenseAgreementTextBlock_zV9KIqd4mTGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. <span id="xdx_82D_zo4jPDpO1Wc5">Exclusive License Agreement (MDB Minnesota
One)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2024, M1 entered into a Patent and Know-How License Agreement (the &#8220;License Agreement&#8221;) with the Mayo for certain patent rights and associated technology pursuant to which M1 intends
to develop a small molecule senescence platform. The License Agreement grants M1 rights to develop and commercialize Mayo&#8217;s patented
technology and know-how for all fields of use on a worldwide basis. Under the terms of the License Agreement, M1 holds an exclusive license
of patent rights and a non-exclusive license for the associated technology to make, have made, use, offer for sale, sell, and import licensed
products and derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As part of initial consideration for
the License Agreement, M1 issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn4n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zXwIuoAClVte" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_custom_LicenseAgreementMember" id="Fact001980" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="Shares">1.98</ix:nonFraction></span> million shares of common stock equity to Mayo; which at that time represented thirty-three percent
of its shares. M1 also paid an initial license fee of $<span id="xdx_903_eus-gaap--ProceedsFromLicenseFeesReceived_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zyQ6VkdsixKj" title="License fee"><ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="From2025-01-012025-12-31_custom_LicenseAgreementMember" id="Fact001982" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span> thousand as part of the initial consideration. M1 will pay earned royalties
on future net sales (including modest minimum annual royalties, which commence in the second year of the term of the License Agreement
and gradually increase and plateau over time, and which will be credited against earned royalties due on net sales), and a percentage
of any sublicensing income. The earned royalty commences after the first commercial sale of a licensed product. At December 31, 2025 there
were no accrued royalties recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Under the License Agreement, M1 is
required to achieve certain development milestones within designated time periods. For select development milestones, as listed below,
M1 will be required to make a payment to Mayo, also as noted below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-left: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_90C_ecustom--PaymentForLicensedProducts_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseIIclinicalMember_zmfcbZj7oNz3" title="Payments for licensed products"><ix:nonFraction name="MDBH:PaymentForLicensedProducts" contextRef="From2025-01-012025-12-31_custom_PhaseIIclinicalMember" id="Fact001984" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span> thousand for Phase II clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_900_ecustom--PaymentForLicensedProducts_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseIIIclinicalMember_zH9qxrElD2j6" title="Payments for licensed products"><ix:nonFraction name="MDBH:PaymentForLicensedProducts" contextRef="From2025-01-012025-12-31_custom_PhaseIIIclinicalMember" id="Fact001986" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million for Phase III clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_908_ecustom--PaymentForLicensedProducts_pn6n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NewDrugApplicationFirstMember_zS3M5Iu2Ert6" title="Payments for licensed products"><ix:nonFraction name="MDBH:PaymentForLicensedProducts" contextRef="From2025-01-012025-12-31_custom_NewDrugApplicationFirstMember" id="Fact001988" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million for FDA New Drug Application (NDA) acceptance, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_909_ecustom--PaymentForLicensedProducts_pn6n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NewDrugApplicationMember_zUwBkglZ7Qla" title="Payments for licensed products"><ix:nonFraction name="MDBH:PaymentForLicensedProducts" contextRef="From2025-01-012025-12-31_custom_NewDrugApplicationMember" id="Fact001990" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million for NDA approval, for each instance of a licensed product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025 the development
milestones noted above are not required to have been met and have not been met. There are other developmental milestones in the License
Agreement relating to funding of the business and to initiating various clinical trial phases over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">If M1 materially breaches the terms
of the License Agreement, and such material breach remains uncured after an opportunity to cure, Mayo may terminate the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001992" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zUK2O2odT5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. <span id="xdx_82C_zUOBdiWmOTd7">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For operating leases, the Company records
right-of-use assets and corresponding lease liabilities in the consolidated balance sheets for all leases with terms longer than twelve
months. The Company has one operating leases, with no variable lease costs, and no finance leases as of December 31, 2025. The Company
has three operating leases, with no variable lease costs, and no finance leases as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes was consolidated up to November 14, 2024. In October 2023, eXoZymes, made changes to an existing lease agreement that was originally entered
into in August 2021, which resulted in an extension of the lease term by an additional 14 months. The revised lease maintained the same
escalation rate for lease payments as the previous arrangement. To account for this modification, the Company reevaluated the remaining
lease term at the time of execution. As the Company was actively utilizing the premises, adjustments were made to reflect the revaluation
of both the right-to-use asset and the corresponding lease liability in line with the updated lease term. This was originally entered
into in August 2021, with a term of 60 months beginning on August 24, 2021 and ending on September 30, 2026, with an option to extend
for 60 additional months and was further modified on April 3, 2023 for an additional 21 months with the lease ending date of April 30,
2028. At the time the lease commenced, it was not probable the Company would exercise the one five-year option to extend the facility
lease; therefore, this extension option is not included in the lease analysis. The initial base rent is $<span id="xdx_906_eus-gaap--AdvanceRent_iI_pn2n3_c20230403_zOrb49EBqXHh" title="Initial rent, per month"><ix:nonFraction name="us-gaap:AdvanceRent" contextRef="AsOf2023-04-03" id="Fact001994" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">14.3</ix:nonFraction></span> thousand per month. The
lease provides for annual increases. The base rent for the lease in the final year is $<span id="xdx_906_ecustom--BaseRent_iI_pn2n3_c20230403_zHHhl4ENM1w3" title="Base rent, per month"><ix:nonFraction name="MDBH:BaseRent" contextRef="AsOf2023-04-03" id="Fact001996" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">16.7</ix:nonFraction></span> thousand per month. Additionally, eXoZymes
was responsible for annual operating cost increases of <span id="xdx_906_ecustom--AnnualOperatingCostIncreasePercentage_pid_dp_uPure_c20230403__20230403_zfYeAiywufni" title="Annual operating cost increase percentage"><ix:nonFraction name="MDBH:AnnualOperatingCostIncreasePercentage" contextRef="From2023-04-032023-04-03" id="Fact001998" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>%, which are included in the rent. Since eXoZymes is not consolidated for 2025,
the information above was only calculated for 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Furthermore, in October 2023, eXoZymes
made changes to a second existing lease agreement that was originally entered into in April 2023, which resulted in an extension of the
lease term by an additional <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20231031_zbZkClSu4JY4" title="Extension term of lease"><ix:nonNumeric contextRef="AsOf2023-10-31" format="ixt-sec:durmonth" id="Fact002000" name="us-gaap:LesseeOperatingLeaseRenewalTerm">12</ix:nonNumeric></span> months. The revised lease maintained the same escalation rate for lease payments as the previous arrangement.
To account for this modification, the Company reevaluated the remaining lease term at the time of execution. As the Company was actively
utilizing the premises, adjustments were made to reflect the revaluation of both the right-to-use asset and the corresponding lease liability
in line with the updated lease term. This was originally entered into in April 2023, with a term of <span id="xdx_901_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230430_zlnbAds7lC0c" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-04-30" format="ixt-sec:durmonth" id="Fact002002" name="us-gaap:LesseeOperatingLeaseTermOfContract">60</ix:nonNumeric></span> months beginning on July 1, 2023
and ending on June 30, 2028, with an <span id="xdx_900_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20231001__20231031_zwS4zRfsuX66" title="Option to extend"><ix:nonNumeric contextRef="From2023-10-012023-10-31" id="Fact002004" name="us-gaap:LesseeOperatingLeaseOptionToExtend">option to extend for 60 additional months</ix:nonNumeric></span>. At the time the lease commenced, it was not probable the
Company would exercise the one five-year option to extend the facility lease; therefore, this extension option is not included in the
lease analysis. The initial base rent is $<span id="xdx_90B_eus-gaap--AdvanceRent_iI_pn2n3_c20231031_zimDouZf19Fl" title="Initial rent, per month"><ix:nonFraction name="us-gaap:AdvanceRent" contextRef="AsOf2023-10-31" id="Fact002006" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">13.3</ix:nonFraction></span> thousand per month. The lease provides for annual increases. The base rent for the lease
in the final year is $<span id="xdx_909_ecustom--BaseRent_iI_pn2n3_c20231031_zOOUjB2LxYZ2" title="Base rent, per month"><ix:nonFraction name="MDBH:BaseRent" contextRef="AsOf2023-10-31" id="Fact002008" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">15.4</ix:nonFraction></span> thousand per month. Additionally, eXoZymes is responsible for annual operating cost increases of <span id="xdx_900_ecustom--AnnualOperatingCostIncreasePercentage_pid_dp_uPure_c20231001__20231031_zMpkMVYzYn64" title="Annual operating cost increase percentage"><ix:nonFraction name="MDBH:AnnualOperatingCostIncreasePercentage" contextRef="From2023-10-012023-10-31" id="Fact002010" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%, which
are included in the rent. Since eXoZymes is not consolidated for 2024, the information above is only calculated for 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2022 the Company executed
a lease for new office space in the Dallas, Texas metropolitan area, the space was occupied on December 20, 2022. The lease with a term
of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220701_z8jj1P3YxUP4" title="Lease term"><ix:nonNumeric contextRef="AsOf2022-07-01" format="ixt-sec:durmonth" id="Fact002012" name="us-gaap:LesseeOperatingLeaseTermOfContract">91</ix:nonNumeric></span> months and began once we took control of the space on December 20, 2022 and ending on July 20, 2030, without an option to extend.
The initial base rent was $<span id="xdx_90A_eus-gaap--AdvanceRent_iI_pn2n3_c20220701_zgbc6wWnRQSa" title="Initial rent, per month"><ix:nonFraction name="us-gaap:AdvanceRent" contextRef="AsOf2022-07-01" id="Fact002014" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">12.6</ix:nonFraction></span> thousand per month, after 7 months of free rent. The lease provides for annual increases. The base rent
for the lease in the final year is $<span id="xdx_90E_ecustom--BaseRent_iI_pn2n3_c20220701_zs9C7KhoVuNi" title="Base rent, per month"><ix:nonFraction name="MDBH:BaseRent" contextRef="AsOf2022-07-01" id="Fact002016" format="ixt:numdotdecimal" decimals="-2" scale="3" unitRef="USD">13.9</ix:nonFraction></span> thousand per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term, and lease liabilities represent the Company&#8217;s obligation to make lease payments.
Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments
over the lease term. The Company&#8217;s uses the implicit rate in its lease calculations when it is readily determinable. Since the Company&#8217;s
leases do not provide implicit rates, to determine the present value of lease payments, management uses the Company&#8217;s estimated
incremental borrowing rate for a fully collateralized loan with a similar term of the lease that is based on the information available
at the inception of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002018" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_894_eus-gaap--LeaseCostTableTextBlock_zcyi91Cll9N7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zYDZFo55hxxa" style="display: none">Schedule
of Operating Lease Cost</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zCKawW5PDac1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zjzFaqA7Ev74" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the years ended<br/> December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands)</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating leases:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGoaBcBEOIbe" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Right-of-use assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact002020" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">547</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact002021" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zRFElbfZ4ZSj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002023" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">609</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact002024" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">711</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Weighted average remaining lease term in years</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0EjF7nH5IDj" title="Weighted average remaining lease term in years"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:duryear" id="Fact002026" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.50</ix:nonNumeric></span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z0RqdCP4mfr3" title="Weighted average remaining lease term in years"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact002028" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">5.50</ix:nonNumeric></span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average discount rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zmt9KFdlbMb5" title="Weighted average discount rate" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-12-31" id="Fact002030" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.80</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zGXmDHvaklDb" title="Weighted average discount rate" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact002032" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.80</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20250101__20251231_zxj2KKkAE6W5" title="Cash paid for amounts included in the measurement of lease liabilities" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" contextRef="From2025-01-01to2025-12-31" id="Fact002034" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20240101__20241231_zgaMVKNdJDza" title="Cash paid for amounts included in the measurement of lease liabilities" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" contextRef="From2024-01-012024-12-31" id="Fact002036" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Right-of-use assets obtained in exchange for lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20250101__20251231_zURnBbXxJzlk" title="Right-of-use assets obtained in exchange for lease liabilities" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2038">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zhuGuRj2fZg6" title="Right-of-use assets obtained in exchange for lease liabilities" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2040">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating lease cost</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseCost_pn3n3_c20250101__20251231_zuuKVtWVIzRd" title="Operating lease cost" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact002042" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseCost_pn3n3_c20240101__20241231_zeyRz5xTtDD3" title="Operating lease cost" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact002044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Short-term lease costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShortTermLeaseCost_pn3n3_c20250101__20251231_zi4tqVKiEof4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact002045" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShortTermLeaseCost_pn3n3_c20240101__20241231_zbMTuMMFIOFa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact002046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total operating lease costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20250101__20251231_zv6gYrYFLE72" title="Total operating lease costs" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2025-01-01to2025-12-31" id="Fact002048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_z09HYx2IOQjb" title="Total operating lease costs" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-12-31" id="Fact002050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zW7QOwEQ0Fr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002052" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv6zURXrkuzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Future payments due under operating
leases for the as of December 31, 2025 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zw3gXW3FsdC3" style="display: none">Schedule
of Future payments Due Under Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold">Year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zzbHKODGLgHg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDS7_zES5JhybPDJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt; text-align: left">2026</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact002054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDS7_zDnAigxsp8bc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact002056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDS7_zxb1Lo3G6KT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">2028</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-12-31" id="Fact002058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">163</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_maLOLLPzDS7_z9YwNxh7JEbi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2029 and thereafter</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" contextRef="AsOf2025-12-31" id="Fact002060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDS7_z97i8F0RU613" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-size: 10pt">Total</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact002062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">740</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zqZ6CZSIgoaa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less effects of discounting</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact002064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">131</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgjG2x8hK6x" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">609</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zkJVMofiFoji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002068" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zJSER0ACJL27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. <span id="xdx_820_zqzQhPaHqntg">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is a limited liability
company treated as a partnership for federal and state income tax purposes, with the exception of the state of Texas, in which income
tax liabilities and/or benefits of the Company are passed through to its unitholders. Limited liability companies are subject to Texas
margin tax. Additionally, the Company&#8217;s subsidiaries, Public Ventures, MDB Management, PatentVest, and M1 are Subchapter&#160;C-corporations
subject to federal and state income taxes. As such, with the exception of the state of Texas and certain subsidiaries, the Company is
not a taxable entity; it does not directly pay federal and state income taxes and recognition has not been given to federal and state
income taxes for the operations of the Company, except as set forth in the tables below. Amounts recognized for income taxes are reported
in &#8220;income tax expense (benefit)&#8221; on the consolidated statements of operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s taxable income
or loss, which may vary substantially from the net income or net loss reported on the consolidated statements of operations, is includable
in the federal and state income tax returns of each unitholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002070" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zmkUgBiHEERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income tax expense (benefit) (including
Subchapter C-corporations) consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zfHTorENI9Hc" style="display: none">Schedule
of Income Taxes Expenses (benefit)</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_zmL8e6kRXQBh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zXFx652RV0j5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maITEBztXD_zZ7yL2tEhxv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; padding-left: 10pt">Federal</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2072">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maITEBztXD_zzv7Q7MT9qAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">State</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_znPsIyABZBZa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Federal</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_zNbpwR3ZhDbj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">State</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2082">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBztXD_zco7tXUdo9fc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zTgQHL8fh1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Total cash taxes paid net of refunds
received in 2025 was $<span id="xdx_902_eus-gaap--IncomeTaxesPaid_c20250101__20251231_zP747hdDcI9g" title="Cash taxes paid"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2025-01-01to2025-12-31" id="Fact002087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025, the Company had approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USFederalTaxMember_zmDmrqeTlnNk" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31_custom_USFederalTaxMember" id="Fact002089" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">23.3</ix:nonFraction></span> million and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--FloridaIncomeTaxMember_zYrsJrIj4bEa" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31_custom_FloridaIncomeTaxMember" id="Fact002091" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million of net operating loss carryforwards
for U.S. federal and Florida income tax purposes, respectively. These net operating losses may be carried forward indefinitely</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Effective for the year ended December
31, 2025, the Company adopted ASU 2023-09-Improvements to Income Tax Disclosures, prospectively. The reconciliation of income tax expense (including Subchapter C-corporations)
computed at the U.S. federal statutory income tax rate of 21% to the recognized income tax expense for the year ended December 31, 2025,
presented in accordance with the disclosure requirements of ASU 2023-09-Improvements to Income Tax Disclosures, is as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002093" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zThUWxlxqKsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfl3scupFN3l" style="display: none">Schedule
of Federal Statutory Tax Rate to The Effective Tax Rate</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year Ended December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">U.S Federal statutory income rate</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20250101__20251231_zAzgeeZpppFj" title="U.S Federal statutory income rate, Amount" style="width: 16%; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002095" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,463</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20250101__20251231_zFxJyMOFBuA4" title="U.S Federal statutory income rate, Rate"><ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002097" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State, net of federal tax benefit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20250101__20251231_zbXy9kIlY7wl" title="State, net of federal tax benefit, Amount" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact002099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20250101__20251231_zMr0pwJiICR1" title="State, net of federal tax benefit, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact002101" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.04</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Nontaxable or nondeductible items</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Income/loss excluded from nontaxable entities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20250101__20251231_zfzJQFRskkMi" title="Income/loss excluded from nontaxable entities, Amount" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" contextRef="From2025-01-01to2025-12-31" id="Fact002103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">944</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20250101__20251231_zhyVeG40ffe1" title="Income/loss excluded from nontaxable entities, Rate">(<ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" contextRef="From2025-01-01to2025-12-31" id="Fact002105" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.44</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_zBXuJlTncBea" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-left: 10pt">Permanent differences</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td title="Income/loss excluded from nontaxable entities, Amount" style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_zJdrdulDazCc" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-left: 10pt">Permanent differences</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td title="Income/loss excluded from nontaxable entities, Amount" style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Meals and entertainment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maMahiYA_c20250101__20251231_z0QGSTT1dyMj" title="Meals and entertainment, Amount" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2025-01-01to2025-12-31" id="Fact002109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_maKamaLI_c20250101__20251231_zprancH9EwFl" title="Meals and entertainment, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" contextRef="From2025-01-01to2025-12-31" id="Fact002111" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.04</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Stock options</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maMahiYA_c20250101__20251231_zQWDLG7PYlDh" title="Stock options, Amount" style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2025-01-01to2025-12-31" id="Fact002113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">614</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maKamaLI_c20250101__20251231_zltTUL71zoP2" title="Stock options, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2025-01-01to2025-12-31" id="Fact002115" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.06</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Equity award vesting</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--IncomeTaxReconciliationEquityInEquityAwardVestingAmount_pn3n3_maMahiYA_c20250101__20251231_zcq5YDq12oxd" title="Equity award vesting, Amount" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeTaxReconciliationEquityInEquityAwardVestingAmount" contextRef="From2025-01-01to2025-12-31" id="Fact002117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_pid_dp_uPure_maKamaLI_c20250101__20251231_zqlTNBcH1AP" title="Equity award vesting, Rate">(<ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" contextRef="From2025-01-01to2025-12-31" id="Fact002119" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.24</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Modification of equity awards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--IncomeTaxReconciliationModificationOfEquityAwardsAmount_pn3n3_maMahiYA_c20250101__20251231_z3WSaoPZkhS2" title="Modification of equity awards, Amount" style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeTaxReconciliationModificationOfEquityAwardsAmount" contextRef="From2025-01-01to2025-12-31" id="Fact002121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,194</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maKamaLI_c20250101__20251231_zZ9V0lzmB0q9" title="Equity award vesting, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2025-01-01to2025-12-31" id="Fact002123" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">10.95</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Return-to-provision adjustments</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20250101__20251231_zRrcBz3dkZSl" title="Return-to-provision adjustments, Amount" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2025-01-01to2025-12-31" id="Fact002125" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20250101__20251231_zW6LSLqiL1nc" title="Return-to-provision adjustments, Rate"><ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact002127" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.22</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_zWIBshQTkSc6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; text-align: left">Other</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td title="Return-to-provision adjustments, Amount" style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_zOBsHs9AIRxh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; text-align: left">Other</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td title="Return-to-provision adjustments, Amount" style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20250101__20251231_zvBKtMBpy216" title="Valuation allowance, Amount" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact002131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">502</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20250101__20251231_zH8KcsFkBxYa" title="Valuation allowance, Rate">(<ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact002133" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.52</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Effective rate</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20250101__20251231_zL9SnUxJsz4f" title="Effective rate, Amount" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20250101__20251231_zXDBeGuz56c7" title="Effective rate, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="Fact002137" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.05</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A reconciliation of the federal
statutory tax rate to the effective tax rate (including Subchapter&#160;C-corporations) for the year ended December 31, 2024 and
2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S Federal statutory
    income rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20240101__20241231_z5gZGmcJCLba" title="U.S Federal statutory income rate, Amount" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MDBH:IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact002139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,453</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20240101__20241231_zUkTSgGBrsNk" title="U.S Federal statutory income rate, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact002141" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State, net of federal tax
    benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20240101__20241231_z055pwdywtk2" title="State, net of federal tax benefit, Amount" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact002143" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">246</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20240101__20241231_zvUxl03iC6W3" title="State, net of federal tax benefit, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact002145" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.11</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income/loss excluded from
    nontaxable entities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20240101__20241231_zCS3MINvK0Ag" title="Income/loss excluded from nontaxable entities, Amount" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="MDBH:IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" contextRef="From2024-01-012024-12-31" id="Fact002147" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20240101__20241231_zbH5oGARhAbf" title="Income/loss excluded from nontaxable entities, Rate">(<ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" contextRef="From2024-01-012024-12-31" id="Fact002149" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">68.57</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maMahiYA_c20240101__20241231_zLDKKFiB4Zxd" title="Permanent differences, Amount" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MDBH:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" contextRef="From2024-01-012024-12-31" id="Fact002151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zcJdGiB4y7ck" title="Permanent differences, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="Fact002153" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.49</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return-to-provision adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20240101__20241231_zyah9TbCQK0h" title="Return-to-provision adjustments, Amount" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-012024-12-31" id="Fact002155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zTmjsZdVVGtg" title="Return-to-provision adjustments, Rate"><ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="From2024-01-012024-12-31" id="Fact002157" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.04</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maMahiYA_c20240101__20241231_zIHFoGxynuai" title="Other, Amount" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" contextRef="From2024-01-012024-12-31" id="Fact002159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKamaLI_c20240101__20241231_zbTPDKiJGemb" title="Other, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2024-01-012024-12-31" id="Fact002161" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.65</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20240101__20241231_zc4fcKcW0Pbh" title="Valuation allowance, Amount" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MDBH:IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact002163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,966</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20240101__20241231_zUobJyjPhofk" title="Valuation allowance, Rate"><ix:nonFraction name="MDBH:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact002165" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">42.52</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20240101__20241231_zlpCL3taBE1k" title="Effective rate, Amount" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20240101__20241231_zLq7wG2Fh661" title="Effective rate, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="Fact002169" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.02</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002171" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zW4pGONifQD1" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt">Start-up expenditures</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsInStartupExpenditures" contextRef="AsOf2025-12-31" id="Fact002176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsInStartupExpenditures" contextRef="AsOf2024-12-31" id="Fact002177" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Organizational expenditures</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsInOrganizationalExpenditures" contextRef="AsOf2025-12-31" id="Fact002179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sec 174 &#8211; Research and development costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact002183" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsStockCompensation" contextRef="AsOf2025-12-31" id="Fact002185" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,795</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsStockCompensation" contextRef="AsOf2024-12-31" id="Fact002186" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,524</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Lease liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002188" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">128</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2024-12-31" id="Fact002189" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment principally due to differences in depreciation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact002191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact002192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Bonus expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsBonusExpense" contextRef="AsOf2025-12-31" id="Fact002194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2195">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Charitable contribution carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" contextRef="AsOf2025-12-31" id="Fact002197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" contextRef="AsOf2024-12-31" id="Fact002198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsImpairmentExpense" contextRef="AsOf2025-12-31" id="Fact002200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="MDBH:DeferredTaxAssetsImpairmentExpense" contextRef="AsOf2024-12-31" id="Fact002201" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Intangible Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2025-12-31" id="Fact002203" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact002204" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2025-12-31" id="Fact002206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,890</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2024-12-31" id="Fact002207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,781</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact002209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,625</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact002210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,124</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="Fact002212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">327</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact002213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">399</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Right-of-use asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2025-12-31" id="Fact002218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2024-12-31" id="Fact002219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Investment securities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:DeferredTaxLiabilitiesInvestmentSecurities" contextRef="AsOf2025-12-31" id="Fact002221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="MDBH:DeferredTaxLiabilitiesInvestmentSecurities" contextRef="AsOf2024-12-31" id="Fact002222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2025-12-31" id="Fact002224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">327</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact002225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">399</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2228">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Deferred tax assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="Fact002230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">327</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact002231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">399</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2025-12-31" id="Fact002233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">327</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact002234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">399</ix:nonFraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Other noncurrent assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2236">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><p id="xdx_8AA_zTugmM3Fiugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In assessing the realizability of deferred
tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. At December&#160;31, 2025, based on projections of future taxable
income for the periods in which the deferred tax assets are deductible, a valuation allowance of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20251231_zrhos06hqse4" title="Decrease in deferred tax assets valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact002239" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.6</ix:nonFraction></span> million was recorded
for tax carry forwards and attributes to reduce the net deferred tax assets to an amount that is more likely than not to be recognized.
The amount of deferred tax assets considered realizable could be reduced in the future if estimates of future taxable income during the
carry forward period are reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with the applicable accounting
standards, the Company recognizes only the impact of income tax positions that, based on their merits, are more likely than not to be
sustained upon audit by a taxing authority. To evaluate its current tax positions in order to identify any material uncertain tax positions,
the Company developed a policy of identifying and evaluating uncertain tax positions that considers support for each tax position, industry
standards, tax return disclosures and schedules and the significance of each position. It is the Company&#8217;s policy to recognize interest
and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company had no material uncertain tax positions
at December&#160;31, 2025 and December&#160;31, 2024. The tax years 2022 &#8211; 2025 remain open to examination for federal income tax
purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002241" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zm0IcdkhnTN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. <span id="xdx_82D_zixxhF4wmjnl">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On February 3, 2026, the Company granted<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260203__20260203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVN81gISSZgj" title="Restricted stock units, granted">
<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2026-02-032026-02-03_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember" id="Fact002243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,500</ix:nonFraction></span> restricted stock units (RSUs) to employees pursuant to its equity incentive plan.</p>

</ix:nonNumeric><p id="xdx_81E_zG4zvRpxRNfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="a_028"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">MDB CAPITAL HOLDINGS, LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt">(the &#8220;Registrant&#8221;)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Christopher A. Marlett</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Christopher A. Marlett</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/Jeremy W. James</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Jeremy W. James</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 50%; padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="width: 3%; padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 47%"><span style="font-size: 10pt"><i>/s/ Christopher A. Marlett</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Christopher A. Marlett, Chief Executive Officer and Chairman of the Board (Principal Executive Officer) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Jeremy W. James</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Anthony DiGiandomenico</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Anthony DiGiandomenico, Head of New Venture Discovery and Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ George Brandon</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">George Brandon, President and Director </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Mo Hayat</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Mo Hayat, Head of Corporate Development &amp; Chief Legal Officer and Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Matthew Hayden</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Matthew Hayden, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Jeb Terry</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Jeb Terry, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Sean Magennis</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Sean Magennis, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Dated: March 31, 2026</span></td>
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><i>/s/ Daniel Torpey</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Daniel Torpey, Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 105; Options: NewSection; Value: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Exhibit</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315223023793/ex1-1.htm" style="-sec-extract: exhibit">Selling Agency Agreement (Incorporated herein by reference to Exhibit 1.1 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex3-1.htm" style="-sec-extract: exhibit">Limited Liability Company Certificate of Formation dated August 10, 2022 (incorporated herein by reference to Exhibit 3.1 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222036687/ex3-2.htm" style="-sec-extract: exhibit">Limited Liability Company Agreement of MDB Capital Holdings, LLC dated November 9, 2022 (incorporated herein by reference to Exhibit 3.2 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex4-1.htm" style="-sec-extract: exhibit">Form of Registrant&#8217;s Class A Common Share certificate (incorporated herein by reference to Exhibit 4.1 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315223008757/ex4-2.htm" style="-sec-extract: exhibit">Form of Selling Agent&#8217;s Warrant (incorporated herein by reference to Exhibit 4.2 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-3.htm">Description of Capital Stock.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex10-1.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement by and between the registrant and each of its directors and executive officers (incorporated herein by reference to Exhibit 10.1 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex10-2.htm" style="-sec-extract: exhibit">2022 Equity Incentive Award Plan (incorporated herein by reference to Exhibit 10.2 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex10-3.htm" style="-sec-extract: exhibit">Form of RSU Award Agreement under 2022 Equity Incentive Award Plan for grants after July 1, 2022 (incorporated herein by reference to Exhibit 10.3 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex10-4.htm" style="-sec-extract: exhibit">Employment Agreement by and between the registrant and Christopher Marlett, dated April 15, 2022 (incorporated herein by reference to Exhibit 10.4 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex10-5.htm" style="-sec-extract: exhibit">Employment Agreement by and between the registrant and Mo Hayat, dated April 15, 2022 (incorporated herein by reference to Exhibit 10.5 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315223023793/ex10-6.htm" style="-sec-extract: exhibit">MDB Capital, S.A. Service Agreement, dated January 1, 2022, as amended and restated June 1, 2023 (incorporated herein by reference to Exhibit 10.6 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex10-7.htm" style="-sec-extract: exhibit">Form of Warrant issued June 22, 2022 to placement agents in the June Private Offering (incorporated herein by reference to Exhibit 10.7 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315222031441/ex14-1.htm" style="-sec-extract: exhibit">Code of Business Code and Ethics (October 2022 (incorporated herein by reference to Exhibit 14.1 to the Registration Statement on Form S-1 as filed on July 20, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315224012008/ex19-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy, 2023 (incorporated herein by reference to Exhibit 19.1 to the Annual Report on Form 10-K for Fiscal Year 2023, filed March 29, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">Subsidiaries</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">23.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm">Consent of Independent Registered Public Accounting Firm</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1
    *</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2
    *</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Financial and Accounting, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1934642/000149315224012008/ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback Policy 2023 (incorporated herein by reference to Exhibit 99.1 to the Annual Report on Form 10-K for the Fiscal Year 2023, filed March 29, 2024).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">+</span></td>
    <td><span style="font-size: 10pt">Indicates a management contract or compensatory plan.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">*</span></td>
    <td><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">**</span></td>
    <td><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 106; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>ex4-3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Authorized Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Authorized Amount</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently have two classes
of equity representing our limited liability membership interests, which we have denominated in our operating agreement as common shares
and preferred shares. The common shares are divided into two classes, the Class A Common Shares and Class B Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total number of shares of all classes currently authorized is 110.0
million shares, consisting of (i) 10.0 million preferred shares, and (ii) 100.0 million common shares, of which 95.0 million shares are
denominated as Class A Common Shares and 5.0 million shares are denominated as Class B Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Preferred Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our preferred shares are similar
to &ldquo;blank check preferred stock&rdquo; that is typical with stock corporations that are federally taxed as &ldquo;C&rdquo; corporations.
The board of directors or a committee thereof is authorized, at any time and from time to time, to issue preferred shares, in any number
of series and amount, pursuant to a share designation. The preferred shares may rank junior to, on parity with or senior to (in each case,
with respect to distributions or other payments in respect of shares) any classes or series of shares existing immediately prior to the
board of director authorization and issuance), for consideration that may be cash, any tangible or intangible property or any benefit
to MDB, or any combination thereof, and such other rights and powers, such as voting, dividend, and liquidation, as may be fixed by the
board of directors or a committee thereof, unless all of the shares which MDB is authorized to issue, have been issued, subscribed for,
or otherwise committed to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Overview</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Delaware law is very flexible
in how the rights of limited liability interests of a limited liability company may be established. We have designated our securities
as common shares and preferred shares representing our limited liability interests, and subdivided the common shares into two classes.
The corporate governance rights of the two classes of common shares are defined in our operating agreement, and generally, they are similar
to the rights of a holder of stock in a corporation organized under Delaware law, which is why we have designated them as shares rather
than LLC units or membership interests or other designations typical of limited liability companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our operating agreement we
have adopted governance and operational provisions that are similar to the rights of a common shareholder in a typical Delaware corporation.
For example, the following are typical terms of a stock corporation which we have adopted for our common shares representing limited liability
interests: (i) the fiduciary duties of our directors and officers are the same as a Delaware stock corporation, (ii) our shares are fully
paid and non-assessable like those of a Delaware stock corporation, (iii) there are no pre-emptive rights, (iv) no consent of the Company
is required to become a shareholder of MDB, (v) holders of our common shares have the full range of inspection rights of our corporate
records like shareholders of a Delaware stock corporation, (vi) meetings of the shareholders of MDB are similar to those of a Delaware
stock corporation, including the fixing of a meeting date, notice requirements for a meeting, quorum requirements, voting procedures and
inspector of elections provisions, (vii) the operation of our board of directors follows the law provisions of a Delaware stock corporation,
and (viii) the indemnification of directors and officers follows the law provisions applicable to a Delaware stock corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because we are a limited liability
company, which will be treated as a partnership under the Internal Revenue Code and related regulations, the holders of our common shares
will be taxed on the basis of the laws and regulations applicable to pass-through entities for federal tax purposes. Pass-through taxation
means that any profits or losses earned by MDB pass through the business and on to the holders of the shares representing the limited
liability interests. This characteristic of our common shares is the most significant difference between our common shares and the stock
of a Delaware corporation that is taxed as a &ldquo;C&rdquo; corporation which is not a pass through type entity under the Internal Revenue
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Common Shares &ndash; Both
Class A Common Shares and Class B Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Class A Common Shares and
the Class B Common Shares are the same except as specifically described in the section &ldquo;Class B Shares Only&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; <U>Distributions</U>.
Subject to the rights of any preferred shares, the holders of the Class A Common Shares and Class B Common Shares will be entitled to
participate ratably on a share for share basis as if all the common shares were a single series in distributions, whether in cash, shares,
securities of entities within the company group or otherwise, as may be declared by the board of directors from time to time; provided
that any distributions payable in common shares (or payable in rights to subscribe for or purchase common shares or securities or indebtedness
convertible into or exchangeable for common shares) shall be declared and paid at the same rate on all the common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&#9679; </B><U>Voting</U>.
The Class A Common Shares and Class B Common Shares are the two currently authorized classes of common shares and are currently all the
outstanding voting shares of the Company. Their voting rights may be subject to any rights of any future class of preferred shares that
are authorized in the discretion of the board of directors and issued. The two classes of common shareholders vote as a single class on
all matters submitted to a vote of the shareholders holding voting shares, including directors, with each Class A Common Share entitled
to one vote and each Class B Common Share entitled to five votes. The common shareholders are not entitled to cumulate votes in the election
of directors. The holders of the common shares may take action by written consent of the holders of not less than a majority of the common
shares entitled to vote at a meeting of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#9679; <U>Quorum</U>. Quorum
for the purposes of holding a meeting of the common shareholders is one-third of the shares of both classes entitled to vote at a meeting
of the shareholders. When a quorum is present the vote of the holders of at least a majority of the voting power of all the common shares
entitled to vote that are present, in person or by proxy, shall be valid and binding on the Company, unless the matter to be acted upon
is one which the operating agreement expressly provides for a different vote. Where the operating agreement does not address the vote
required, then the vote will be as provided in the DGCL as if the Company were a Delaware corporation. Directors will be elected by a
plurality of the votes that are present, in person or by proxy, at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&#9679; </B><U>Liquidation</U>.
In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of our company, after all creditors shall have been
satisfied, and subject to the payment of all sums payable in respect of preferred shares, if any, the common shareholders will share in
all distributions of the remaining assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&#9679; </B><U>No Preferential
Rights</U>. Except as otherwise provided in a share designation or as determined by the board of directors, no shareholder has any preemptive,
preferential or other similar right with respect to the issuance of any shares, whether such shares are unissued, held in treasury or
hereafter created.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&#9679; </B><U>Share Transfer
Restrictions</U>. Share transactions entered into through the facilities of a national securities exchange on which the shares will be
listed for trading will be unrestricted. No other transaction of shares may be transferred if it would (i) violate the then applicable
U.S. federal or state securities laws or rules and regulations of the SEC, any state securities commission or any other governmental authority
with jurisdiction over the transfer, (ii) terminate our existence under the laws of Delaware, the jurisdiction of our formation, or (iii)
cause us to be treated as an association taxable as a corporation or otherwise to be taxed as an entity for U.S. federal income tax purposes
(to the extent not already so treated or taxed). Our board of directors may impose restrictions on the transfer of shares if it receives
an opinion of counsel that restrictions are necessary or advisable to avoid a significant risk of our becoming taxable as a corporation
or otherwise becoming taxable as an entity for U.S. federal income tax purposes. Our board of directors may impose restrictions by amending
the operating agreement without the consent of any shareholder or other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><I>Class B Shares Only Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although the Class A Common Shares
and Class B Common Shares vote together on all matters, including directors, the Class B Common Shares have five votes per share compared
to the Class A Common Shares which have only one vote per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At any time and from time to time,
in any amount, the holders of the Class B Common Shares, acting together or separately with the other holders of the Class B Common Shares,
may convert each share of Class B Common Share into one Class A Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Placement Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the private
placement of Class A Common Shares completed June 2022, the Company issued to two registered sales agents engaged by the by the Company
warrants to purchase 18 thousand Class A Common Shares which are exercisable for 10 years at $13.00 per share. The warrants to purchase
8 thousand Class A Common Shares that were issued to Cambria Capital LLC, a soliciting dealer in the initial public offering, as non-cash
compensation in the June 2022 private placement have been amended such that they are not exercisable more than five years from the date
of commencement of sales in the initial public offering. These securities are deemed underwriter compensation under FINRA Rule 5110 for
purposes of the initial public offering and are subject to a lock up of 180 days from the commencement date of the initial public offering
pursuant to FINRA Rule 5110(e)(1) and in compliance with the FINRA lock-up restrictions and exceptions pursuant to FINRA Rule 5110(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Selling Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the initial
public offering of MDB, there were issued warrants to purchase 16,666 Class A Common Shares to the selling agent. The selling agent&rsquo;s
warrants are exercisable commencing six months after the date of commencement of sales in the IPO (in compliance with FINRA Rule 5110(e)(1))
and will be exercisable until the fifth anniversary of the date of commencement of sales in the initial public offering. The exercise
price for the selling agent&rsquo;s warrants is 125% of the public offering price, or $15.00 per share. The selling agent&rsquo;s warrants
are not be redeemable. The selling agent&rsquo;s warrants provide for cashless exercise, and immediate &ldquo;piggyback&rdquo; registration
rights, with a duration of seven years from the date of commencement of sales in the initial public offering (in compliance with FINRA
Rule 5110(g)(8)(D)), with respect to the registration of the Class A Common Shares underlying the warrants. We have registered the selling
agent&rsquo;s warrants and the shares underlying the selling agent&rsquo;s warrants in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The selling agent&rsquo;s warrants
and the Class A Common Shares underlying the selling agent&rsquo;s warrants have been deemed compensation by FINRA and are therefore subject
to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA. The selling agent, or permitted assignees under such rule, may not exercise,
sell, transfer, assign, pledge, or hypothecate the selling agent&rsquo;s warrants or the Class A Common Shares underlying the selling
agent&rsquo;s warrants, nor will the selling agent or permitted assignees engage in any hedging, short sale, derivative, put, or call
transaction that would result in the effective economic disposition of the selling agent&rsquo;s warrants or the underlying shares for
a period of 180 days from the date of commencement of sales in the initial public offering, except that they may be transferred, in whole
or in part, by operation of law or by reason of our reorganization, or to any selling agent or selected dealer participating in the initial
public offering and their officers, partners or registered representatives if the selling agent&rsquo;s warrants or the underlying shares
so transferred remain subject to the foregoing lock-up restrictions for the remainder of the time period. The selling agent&rsquo;s warrants
will provide for adjustment in the number and price of such warrants (and the Class A Common Shares underlying such warrants) to prevent
dilution in the event of a stock dividend, stock split or other reclassification of the Class A Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Meetings of Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Meetings of shareholders may be
held at such place, either within or without the State of Delaware, as may be designated by the board of directors. The board of directors
may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote
communication. The annual meetings of the shareholders, for the purpose of election of directors and for such other business as may lawfully
come before it, shall be held on such date and at such time as may be fixed by resolution of the board of directors as determined by the
board of directors. Special meetings of the shareholders may be called for any purpose or purposes, at any time, by the chairman of the
board or the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors. Written notice
of each meeting of shareholders, specifying the place, if any, date and hour and purpose or purposes of the meeting, and the means of
remote communication, if any, by which shareholders and proxyholders may be deemed to be present in person and vote at such meeting, shall
be given not less than 10 nor more than 60 days before the date of the meeting to each shareholder entitled to vote thereat. The majority
of the outstanding shares entitled to vote at a meeting will constitute a quorum for the transaction of business, except that when specified
business is to be voted on by a class or series of shares voting as a separate class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At an annual meeting of the shareholders,
if and when one is held, only such business shall be conducted as shall have been properly brought before the meeting. To be properly
brought before an annual meeting, business (other than nominations of directors) must be brought before the meeting (i) by or at the direction
of the board of directors, or (ii) by a shareholder of record of our company at the time of the giving of the notice required in the paragraph
(b) hereof, who is entitled to vote and the meeting. The foregoing clause (ii) shall be the exclusive means for a shareholder to propose
business (other than business included in the company proxy materials pursuant to Rule 14a-8 under the Exchange Act at an annual meeting
of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to any other applicable
requirements for business to be properly brought before an annual meeting by a record shareholder, (i) the record shareholder must have
given timely notice thereof in writing to the secretary of the company, (ii) any such business must be a proper matter for shareholder
action under Delaware law and (c) the record shareholder and the beneficial owner, if any, on whose behalf any such proposal is made,
must have acted in accordance with the representations set forth in the Business Solicitation Statement (as defined below). To be timely,
a record shareholder&rsquo;s notice must be delivered to the secretary at the company&rsquo;s principal executive offices not less than
90 days or more than 120 days prior to the first anniversary of the date on which the company first mailed its proxy materials for the
previous year&rsquo;s annual meeting of shareholders. however, if the company did not hold an annual meeting the previous year, or if
the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding
year&rsquo;s annual meeting, then to be timely, notice by the shareholder must be delivered to the secretary at the company&rsquo;s principal
executive offices not later than the close of business on the later of (i) the 90th day prior to such annual meeting or (ii) the 10th
day following the day on which public announcement of the date of such meeting is first made. in no event shall any adjournment or postponement
of an annual meeting or the announcement thereof commence a new time period for the giving of a shareholder&rsquo;s notice as described
above. Other than with respect to shareholder proposals relating to director nomination(s), a shareholder&rsquo;s notice to the secretary
shall set forth as to each matter the shareholder proposes to bring before the annual meeting (i) a brief description of the business
desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (ii) the name and
record address of the record shareholder proposing such business and the beneficial owner, if any, on whose behalf the proposal is made,
(iii) the class, series, and number of shares of the company which are owned, directly or indirectly, beneficially and of record by the
record shareholder, (iv) any material interest of the record shareholder in such business and the beneficial owner, if any, on whose behalf
the proposal is made, (v) as to the shareholder giving the notice and any Shareholder Associated Person (as defined below) or any member
of such shareholder&rsquo;s immediate family sharing the same household, whether and the extent to which any hedging or other transaction
or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including, but
not limited to, any short position or any borrowing or lending of shares) has been made, the effect or intent of which is to mitigate
loss or generate profit to or manage the risk or benefit of share price changes for, or to increase or decrease the voting power of, such
shareholder, such Shareholder Associated Person or family member with respect to any share of the company (each, a &ldquo;Relevant Hedge
Transaction&rdquo;), (vi) as to the shareholder giving the notice and any Shareholder Associated Person or any member of such shareholder&rsquo;s
immediate family sharing the same household, to the extent not set forth pursuant to the immediately preceding clause, (a) whether and
the extent to which such shareholder, Shareholder Associated Person or family member has direct or indirect beneficial ownership of any
option, warrant, convertible security, share appreciation right, or similar right with an exercise or conversion privilege or a settlement
payment or mechanism at a price related to any class or series of shares of the company, whether or not such instrument or right shall
be subject to settlement in the underlying class or series of shares of the company or otherwise, or any other direct or indirect opportunity
to profit or share in any profit derived from any increase or decrease in the value of shares of the company (a &ldquo;Derivative Instrument&rdquo;),
(b) any proxy, contract, arrangement, understanding, or relationship pursuant to which either party has a right to vote, directly or indirectly,
any shares of any security of the company, (c) any rights to distributions on the shares of the company owned beneficially by such shareholder,
Shareholder Associated Person or family member that are separated or separable from the underlying shares of the company, (d) any proportionate
interest in shares of the company or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which
such shareholder, Shareholder Associated Person or family member is a general partner or, directly or indirectly, beneficially owns an
interest in a general partner and (e) any performance-related fees (other than an asset-based fee) that such shareholder, Shareholder
Associated Person or family member is entitled to be based on any increase or decrease in the value of shares of the company or Derivative
Instruments, if any, as of the date of such notice (which information shall be supplemented by such shareholder and beneficial owner,
if any, not later than 10 days after the record date for the meeting to disclose such ownership as of the record date), and (vii) a statement
whether or not such person intends or is part of a group that intends to deliver a proxy statement or form of proxy to holders of at least
the percentage of voting power of all Shares reasonably believed to be sufficient to carry the proposal and/or otherwise to solicit votes
or proxies in support of such proposal (such statement, a &ldquo;Business Solicitation Statement&rdquo;). &ldquo;Shareholder Associated
Person&rdquo; of any shareholder shall mean (i) any person controlling or controlled by, directly or indirectly, or acting in concert
with, such Shareholder, (ii) any beneficial owner of shares of the company owned of record or beneficially by such shareholder or (iii)
any person controlling, controlled by or under common control with such Shareholder Associated Person. The chairman of an annual meeting
shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting, and if he
should so determine he shall so declare to the meeting, and any such business not properly brought before the meeting shall not be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nothing in the operating agreement
shall affect the right of a shareholder to request inclusion of a proposal in the company&rsquo;s proxy statement or information statement
pursuant to Rule 14a-8 under the Exchange Act, and any proposal submitted in compliance with Rule 14a-8 under the Exchange Act and included
in the company&rsquo;s proxy statement or information statement pursuant thereto shall be deemed to be properly before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nominations for directors by the
shareholders will be similarly restricted as shareholder proposals described above in terms of the notice requirements. The shareholder&rsquo;s
notice relating to director nomination(s) shall set forth (a) as to each person whom the shareholder proposes to nominate for election
or re-election as a director, (i) the name, age, business address and residence address of the person, (ii) the principal occupation or
employment of the person, (iii) the class, series and number of shares of the company which are beneficially owned by the person, (iv)
any other information relating to the person that is required to be disclosed in solicitations for proxies for election of directors pursuant
to Regulation 14A under the Exchange Act and such person&rsquo;s written consent to serve as a director if elected; (b) as to the record
shareholder giving the notice, and the beneficial owner, if any, on whose behalf the proposal was made, (i) the name and record address
of the shareholder, and (ii) the class, series and number of shares of the company which are beneficially owned; (c) as to the record
shareholder giving the notice and any Shareholder Associated Person or any member of such shareholder&rsquo;s immediate family sharing
the same household, to the extent not set forth pursuant to the immediately preceding clause, whether and the extent to which any Relevant
Hedge Transaction has been entered into; and (d) as to the shareholder giving the notice and any Shareholder Associated Person or any
member of such shareholder&rsquo;s immediate family sharing the same household, (1) whether and the extent to which any Derivative Instrument
is directly or indirectly beneficially owned, (2) any proxy, contract, arrangement, understanding, or relationship pursuant to which either
party has a right to vote, directly or indirectly, any shares of any security of the company, (3) any rights to distributions on the shares
of the company owned beneficially by such shareholder that are separated or separable from the underlying shares of the company, (4) any
proportionate interest in shares of the company or Derivative Instruments held, directly or indirectly, by a general or limited partnership
in which such shareholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner and (5)
any performance-related fees (other than an asset-based fee) that such shareholder is entitled to be based on any increase or decrease
in the value of shares of the company or Derivative Instruments, if any, as of the date of such notice, including without limitation any
such interests held by members of such shareholder&rsquo;s immediate family sharing the same household (which information shall be supplemented
by such shareholder and beneficial owner, if any, not later than 10 days after the record date for the meeting to disclose such ownership
as of the record date); and (e) a statement whether or not such person or its nominee intends or is part of a group that intends to deliver
a proxy statement or form of proxy to holders of at least the percentage of voting power of all shares reasonably believed to be sufficient
to elect the nominee or nominees proposed to be nominated and/or otherwise to solicit votes or proxies in support of such nomination (the
&ldquo;Nomination Solicitation Notice&rdquo;). The company may require any proposed nominee to furnish such other information as may reasonably
be required by the company to determine the eligibility of such proposed nominee to serve as a director of the company. No person shall
be eligible for election as a director of the Company unless nominated in accordance with the procedures set forth herein. These provisions
shall not apply to nomination of any persons entitled to be separately elected by holders of Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the shareholder making a nomination
or a qualified representative of such shareholder does not appear at the annual meeting to present a nomination submitted, such nomination(s)
shall not be presented or voted upon at the annual meeting. For purposes of the foregoing sentence, to be considered a qualified representative
of a shareholder, a person must be a duly authorized manager, officer or partner of such shareholder or must be authorized by such shareholders
in writing to act as such in the event a qualified representative of a shareholder will appear at a meeting and make a nomination in
lieu of a shareholder, the shareholder must provide the notice of such designation at least twenty-four hours prior to the meeting. If
no such advance notice is provided only the shareholder may make the nomination and the nomination may be disregarded in the event the
shareholder fails to appear and make the nomination. The chairman of the meeting shall, if the facts warrant, determine and declare to
the meeting that a nomination was not made in accordance with the foregoing procedure, and if he should so determine, he shall so declare
to the meeting and the defective nomination shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The number of directors which
shall constitute the whole of the board of directors shall be not less than three (3) or more than twelve (12), until changed by amendment
to the operating agreement. Only the board of directors shall have the power to change the number of directors within that limit. Currently,
the number of directors of our company has been fixed at eight (8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The directors shall be elected
to one-year terms by a plurality vote of the common shares represented in person or by proxy at the shareholders&rsquo; meeting and entitled
to vote on the election of directors. Elected directors shall hold office until the annual meeting when their terms expire and until their
successors shall be duly elected and qualified. Directors need not be shareholders. If, for any reason, the board of directors shall not
have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the shareholders
called for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Anti-Takeover Effects</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The existence of our preferred
shares that permits the board of directors to issue shares with the terms it determines in its discretion may have an anti-takeover effect.
The board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating,
optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series.
The board of directors, without shareholder approval, will be able to issue preferred shares with voting and other rights that could adversely
affect the voting power and other rights of the holders of the common shares and could also have anti-takeover effects. The ability of
our board of directors to issue preferred shares without shareholder approval could have the effect of delaying, deferring or preventing
a change of control of the Company or the removal of existing management. We currently have no preferred shares issued and outstanding
as the date hereof. Although we do not currently intend to issue any preferred shares, we cannot assure you that we will not do so in
the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fact that the Class B Common
Shares have a right to five votes per Class B Common Share on all matters presented for a vote to the shareholders, including in the vote
for directors, and the fact that the Class B Common Shares currently have a majority ownership position of all the common shares, means
that they have an anti-takeover effect, because it would be difficult for an insurgent to overcome the authority that the Class B Common
Shares has in the governance of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The provisions for shareholder
business proposals and director nominations in the operating agreement, both described above, also could have an anti-takeover effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>K-1 Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have engaged PricewaterhouseCoopers
LLP (&ldquo;PwC&rdquo;) to provide to the holders of the Class A Common Shares and Class B Common Shares, periodic reports of the income
or loss related to their holding Class A Common Shares in MDB for the tax years 2021 &ndash; 2024. As part of their services, PwC will
solicit from brokers, nominees and transfer agents partner information as required by I.R.C. &sect; 6031(c) necessary to report Schedule
K-1s. This will include trade activity during the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Schedule K-1s for investors
will show taxable income on an annual basis, prorated on a monthly basis for Class A Common Shares transferred during the calendar year.
Special allocations of discrete transaction items will be reported on a Schedule K-1 for the month they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company plans for Schedule
K-1s to be sent out as soon as reasonably practicable after the end of the fiscal year. Our agreement with our Schedule K-1 service provider
calls for them to send final or best estimates of the Schedule K-1 information to shareholders within 90 days after the year end, with
every effort to meet the April 15th individual tax filing date, without extension. Following this initial delivery of information, shareholders
should work with the Company&rsquo;s Schedule K-1 service provider to correct their Schedule K-1 of any incorrect information reported,
such as personal information (name, address, federal ID number) and number of Class A Common Shares held and date acquired, transferred,
or sold. Where there is correcting information provided to the Schedule K -1 service provider, an updated Schedule K-1 will be provided
to a shareholder prior to September 15th.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for the Class A Common Shares issued by the Company is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598, with a general telephone
number of 212-828-8436 and a general email of info@vstocktransfer.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following are the significant subsidiaries of
MDB Capital Holdings, LLC as of December 31, 2025 and the states or jurisdictions in which they are organized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Name</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Location of Formation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">Ownership</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">MDB CG Management Company</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 30%">Delaware</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 24%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Public Ventures, LLC</TD><TD>&nbsp;</TD>
    <TD>Texas</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">PatentVest, Inc.</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">MDB Minnesota One, Inc.</TD><TD>&nbsp;</TD>
    <TD>Delaware</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">eXoZymes Technologies, Inc.</TD><TD>&nbsp;</TD>
    <TD>Nevada</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MDB Capital Holdings, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Addison, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We consent to the incorporation by reference in the registration statement
on Form S-8, Registration Statement No. 333-280090, pertaining to the 2022 Equity Inceptive Plan of MDB Capital Holdings, LLC, of our report dated March 31, 2026 relating to
the consolidated financial statements of MDB Capital Holdings, LLC included in its Annual Report (Form 10-K) for the year ended December
31, 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>/s/
    RBSM LLP</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">New York, New York</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a) and 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Christopher A. Marlett, the Chief Executive Officer
of MDB Capital Holdings, LLC certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">1. I have reviewed this annual
report on Form 10-K of MDB Capital Holdings, LLC for the fiscal year ended December 31, 2025;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">2. Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">3. Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4. The registrant&rsquo;s other
certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5. The registrant&rsquo;s other
certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated this 31<SUP>st</SUP> day of March
2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher A. Marlett</I></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>Christopher A. Marlett</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief Executive Officer</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a) and 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Jeremy W. James, the Chief Financial Officer of
MDB Capital Holdings, LLC certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">1. I have reviewed this annual
report on Form 10-K of MDB Capital Holdings, LLC for the fiscal year ended December 31, 2025;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">2. Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">3. Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4. The registrant&rsquo;s other
certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal
quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5. The registrant&rsquo;s other
certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated this 31<SUP>st</SUP> day of March
2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Jeremy W. James</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Jeremy W. James</B>&nbsp;</P></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief Financial Officer</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 1350, CHAPTER
63 OF TITLE 18, UNITED STATES CODE, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Annual
Report on Form 10-K for the year ended December 31, 2025 (the &ldquo;Report&rdquo;) of MDB Capital Holdings, LLC (the &ldquo;Registrant&rdquo;),
as filed with the Securities and Exchange Commission on the date hereof, I, Christopher A. Marlett, the Chief Executive Officer of the
Registrant, hereby certify, to the best of my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">1. The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">2. The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Christopher A. Marlett</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Christopher A. Marlett,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This certification accompanies this Annual Report
on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Such certification will not be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company
specifically incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 1350, CHAPTER
63 OF TITLE 18, UNITED STATES CODE, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Annual
Report on Form 10-K for the year ended December 31, 2025 (the &ldquo;Report&rdquo;) of MDB Capital Holdings, LLC (the &ldquo;Registrant&rdquo;),
as filed with the Securities and Exchange Commission on the date hereof, I, Jeremy W. James, Chief Financial Officer of the Registrant,
hereby certify, to the best of my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">1. The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">2. The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Jeremy W. James</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jeremy W. James,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This certification accompanies this Annual Report
on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Such certification will not be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company
specifically incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'D!!,# 2(  A$! Q$!_\0
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M^2,\ 4[R6_Y[O^0_PI\'^H3_ '14E $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
M$'DM_P ]W_(?X4>2W_/=_P A_A4]% $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
M$'DM_P ]W_(?X4>2W_/=_P A_A4]% $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
M$'DM_P ]W_(?X4>2W_/=_P A_A4]% $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
M$'DM_P ]W_(?X4>2W_/=_P A_A4]% $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
M$'DM_P ]W_(?X4>2W_/=_P A_A4]% $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
M$'DM_P ]W_(?X4>2W_/=_P A_A4]% $'DM_SW?\ (?X4>2W_ #W?\A_A4]%
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M?TH @^SM_P ]Y/TH^SM_SWD_2K%% %?R&_Y[R?I1Y#?\]Y/TJQ29H @\AO\
MGO)^E'D-_P ]Y/TJQ10!7\AO^>\GZ4>0W_/>3]*L44 5_(;_ )[R?I1Y#?\
M/>3]*L44 5_(;_GO)^E'D-_SWD_2K%% %?R&_P">\GZ4>0W_ #WD_2K%% %?
MR&_Y[R?I1Y#?\]Y/TJQ10!7\AO\ GO)^E'D-_P ]Y/TJQ10!7\AO^>\GZ4>0
MW_/>3]*L44 5_(;_ )[R?I1Y#?\ />3]*L44 5_(;_GO)^E'D-_SWD_2K%%
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MS9>()4C>S2)5,._&"A'4#-85[XO\?-I?B;7+7Q!&EGHNIF$6[0*6D7=C&<=
M,4 ?1%%9^E:C'?Z?:3,\:SS6Z3-$&&5W*#TZXYK0H **** "BBB@ HHHH **
M** "BBB@ HHHH I1?</^\W\S11%]P_[S?S-% %F#_4)_NU)FHX/^/=/]VG'-
M &#/))'XCNMBJ\[6:F!6.,X)R,_7%-\C6;'$\,PO9)?];$YVJC=BOL/2I9-
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M[%VMI(BDJX.0JOC(7VHD^%/VKQ-;:I?^([^\M[6[^UQ6TR(65\Y \S&=H]*
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MW-Q=M<.(_*0LN"%SGGU/O6O28]ZI2:5D9RIQDU)K8!TI:**DT"BBB@ HHHH
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MZ48I:* "BBB@ HHHH **** "BBB@ HHHH CG_P!1)_NFH-/_ ./<?[QJ>?\
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M ,\;?_OX?\*M9HS0!5WW_P#SQM_^_A_PHWW_ /SQM_\ OX?\*LE@!DD 49H
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M4;[_ /YXV_\ W\/^%6J* *N^_P#^>-O_ -_#_A1OOO\ GC;_ /?P_P"%6J*
M(XC(4_>A5;T4Y%2444 0?\OH_P"N?]:E8D*=N,]LU%_R^C_KG_6IZ *F;_\
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MW_Y"%'DW7_/W_P"0A3_M=O\ \]XO^^Q1]KM_^>\7_?8HL^P<R[C/)NO^?O\
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MG>%K'[<TESFZNS81F25(ESMP!ZOC\JSK3QQXCU?1_!]AI=]%8ZG=RSV-^;B
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M[;3M3L81*L6HW)N92&Y#$@X'H,CI[TBB#_A,UC::UGTJ[BU%9(XX[0E2TOF
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M[><Q7&GR7X4 9"(H8@^_S59;Q$(?#$NN7&GW,$<<9D$#8,A7L<#IG.?:LU/
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M/.:4:!I8AM8?L:&.UC>*%3DA$8;6'T(XJ?3=-M=)LDL[*,QP1_=4N6Q^))-
M%NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_U$G^Z:@T__CW'
M^\:GG_U$G^Z:@T__ (]Q_O&@"W1110 4444 %%%% !0>E%(>E %#2?\ D')_
MO-_Z$:NA5 QA?RJA'ITT*[(KZ5$R2%VJ<9.?2G_8[G_H(S?]\+_A5RLVW<RB
MY)6L7=HSG S]*3:N#\J\]>*I_8[K_H(R_P#?"_X4?8[K_H(R_P#?"_X4K+N5
MS/L7"BGL/RH**1@J"/0BJ?V.Z_Z",O\ WPO^%'V.Z_Z"4O\ WPO^%%EW#FEV
M+A0'.0/RH*@XR ?J*I_8[K_H(R_]\+_A6/-<W\?BBWTP7[^3);M*3L7.0?I5
M1I\VS(G5Y+77Y'28!QZCOB@*N,;1CTQ5/['='_F(R_\ ?"_X4?8[K_H)2_\
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M6XL7_MJ=S-//<S2QA]YQ,@3!; Y  / Q0!:U3QS!#HE]=06UQ!<P6WVF)+R
MH)8]P!9?4<].O(K1A\66<HN4-K?1SP1";R)("KO&3@,H)Y&?R[UFW?@NXU.S
MFAU/69KB3[*UI!*L*H8E)!+''WF.T<]/:B^\$2ZKYLNI:L]S<;$BB;R%5%16
M#D,G1MQ S]* +%MXNBU/5=*M[%"([B:>&Y29,21,D>\#KCTYYXJUJ/B[3].U
M&YL7@O9IK6)9I_(@+B.-LX8D?0^]4='\$Q:3J,5Z+D%TN9+CRXH%BCR\0C("
MCH.,TV\\-:K=>)-8O+?4S96M];PP';&LA8 ,&(S]UOFX//TH T+CQ=IMM=VL
M+K.8;KR_*NE3,1W_ '><YYR!G'>J.G>.(+G3VN;K3[R"8W4EM#"(\M,RLP^7
MGT7)]*I2?#>S^TH8+D1P(\#IOMU>5/*V@*LAY"G;T'J?6K%UX$CNX&AEO!(D
M5X]W:++;JPC+DEU89^<'<?0CB@"TWCS2<1B*&]N)'BDE,44!9D"-M?<.Q!J3
M3O%::GXCDTZWLIWMOLL5S'>!?D8."1GTZ?GFDTGPE#I<ZSI*FX6DELRQ0+&I
MWOO+ #\J?I'AAM&OK::WOV:)+-+26)HP?,V9VMGL?F- '1T444 %%%% !111
M0 4444 4HON'_>;^9HHB^X?]YOYFB@"S!_J$_P!T5)4<'^H3_=%24 -9U4C)
M SZFC.:IZGID.J0+#.SA%</\C8.1[U;1 B!1G &!S3TL3=W\CF=1\90:;8:W
M/+9RM/I<RQ&W4Y:;> 4*_7/Z&F:GXUMK&V$\$/GP_85OGDWX5$9E5<GWR3_P
M$U+J7A;[9XQL=:695MXX\7-OC_7.N?*;_@.YOS%9EIX$FM-#U?3_ +6DK7DR
MBW9E.(8%;<D?X9;\Z11OP^+-$FLI[J*]#Q6[B.7;&Q96/0;<9Y[<<U5;QOHO
M]H:9:Q3O,-15S%+'&S*"I (/'!R<<],<U4USPMJ%]JMQ>V-W%$DRP*\!9XQ*
M(]^0S)R =PZ>E5=(\(:IH\VGW$-S9O)!=7,DJ-YFTQS;20I.3N&T<GK0!T^J
M^(-,T01G4;CR0^2"49@ .I) .![FH9?%>A07;VLFI0":-/-==V=J8!W$] ,$
M<]ZRO%?AK4==N,V]U$+9K9X##-)(JH[?\M $(W''&#Q5-/ 3?V%J=A)=(LUV
MELJSQJ<@PHH&>^,KGCUH ZG3M;T_5H));&X\T1-MD&TJR'&>5(!''-<['\1-
M*FM;&\42+!<7;VSET8%"JL1@8^;.WH/6M#PSH,^E2WEU>>2;JY*!FCEDDRJC
M RS\]S5*P\,:A;R::ES/;/!IU_+<Q%%;<Z.'X.> P+]NPH U9?%VA0V-O>-J
M"&"X!,112Q('WC@#( [D].]6!X@TIK6>Y6]B,,#JDC@Y 9L;1^.X8]<UR$O@
M*^2Y:[M+N+S6DN0T3221)Y<LF\<ISD=QT/M26_A>5?%5A;6UO-!I=I!&;W<F
M(IY8O]5LR23C)SGLHH ['5-;T[2%A-_<K"9FVQKM+,V.N  3@=SVK(M/'&D2
MZ3#?W5Q'"DTDJQ!,R%U1RN\!1G'&<]!FK6KZ5J$FLV>K:9+:_:(8G@:.Z5BK
M(Q!R"O(((_&L+3O".M:+]GN;&ZT^6]\F6"83Q,L6UY6D!4#D$%L$=#Q0!OS>
M*=+M7>2XO+9+01Q.DPDW;O,)"\#L<<>M._X2[0_[.6_^W+Y#2F$?(VXR#JNS
M&[(],5SUMX#FM$M(UNXY$@:T8[D(W&*1G; Z '=@#MBEU;0[W3M6FUJS$LD[
MWIFB$%N)@BM$J,'3<"<[>JG- &M=^*UDL6O=&M4U*TC#F><3K&D93JN6ZM[5
MN:=>QZEIMM>PAA'<1+(H88(!&>:X[1O#=W=^'FBU2VB9[C53?R0W*;?DW9&5
M7@'C.#D>M=PBA4"J  !@ #&* '4444 %%%% !1110 4444 %%%% !1110!!_
MR^C_ *Y_UJ>H/^7T?]<_ZU/0 AZ4P.I8@$9'7VI[=*SX-+@M]2N+Y#(9I\;@
M6.T8]!35NI,F[JR&Z]JO]B:-/J30--'!M:14."$R S?@,G\*H?\ "660\4R:
M(58;+3[3]I_@/<I]0I#?0UN75O'=V<UO,NZ*5#&Z^H(P:X0_#ZZ;PM%IS:F/
M[0%V97N]IRT1'EE/^_6%^HI%%ZS^(.G-+%_:*_8$EM8[J,R$L=CLP!; ^48
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MYX#?*9K==TL:(S,G3&0!GG(P*KZEH-PWA[3]/TZ9!-I\D#Q-< E7\K'#8YY
M[50N/"NH-::M]GO(8KF_OTNG*[U#H%53$S#Y@#M/(H USXNT,:='?_;E-O)(
M8D(5BQ<=5V8W9'<8XJE9>.-(FL9+VXN$BA^U2P0E,R&54/+@ $X]?2LG3O!>
MJZ5<IJ-K<V1O8[J:58I/,:+9(BJ1N)+;@4!S^%0)X"U2,I=I?6[WOFW+.JM)
M#&RS.&XV<@@CIT- ';7.M:?::8-1FN4%HP4I*OS!]WW=N.N>V*IS>+M#M[:"
M>6^58YP63Y&)V@X)(QE0#P2<55N?#A_X1&#1;>&T;R50!)=X3(.>"#N4YZ')
M(K!D\#:PZPS2ZDEU=M;O:W EFE13&7+* RG<V <?-UH ZR;Q1HUO?QV,E_']
MHDVD*H+ ;ONY(X&>V3S5<>-/#S122IJ4<BQN(SY:LQ+G/R@ 9+<'@<\50TSP
M[JFA7LD>F2V']GW#Q22K-&YDC*JJ$)@X((48R>/>J+^!)XM&TB&UN8DO-.GF
MFR&>-)?-+;LE?F!PPY]J -G_ (3/1VUFRT^.8R?;+<SQ3(A*8!Q@G''?KTQS
M6EI>NZ=K2NVGW'G*F,G8RC!Z$9 R#ZBN=L?"M[ILVG26C6($<$\-U$XD93YK
MARRY))Y'.>N>U7?">@ZAHC727-Q"+5@H@M(&=HXL9R5W\J#D?*.!B@#IJ***
M "BBB@ HHHH **** (Y_]1)_NFH-/_X]Q_O&IY_]1)_NFH-/_P"/<?[QH MT
M444 %%%% !1110 4444 )BC%+10!5U"=[6RDF0*64<!NG6H0NJ?WK3\FI=8_
MY!<WT'\Q5T52T5S-J\K%+;JG]ZT_)J3;JG]^T_)JB\2ZLV@^&]1U98A*;2!I
M1&3C=@=,UPNG_%^UC2?^WK1(&C$!5]/E^U(WFYVJ< $-QR*.;R0^3S9WY75/
M[UI^35GR:/J,FNQ:KYUL'CA,03:V""<YK"MOB98K]M^V13-(E\]K;VUK;N\[
MA45R63U //:M+3_B#H6JZQ9Z982W%Q-=P"XC:. E ASRQ_AY&.>]5&HX[6)E
M24MVS;VZI_>M/R:C;JG]^T_)JYKQ!\0+?0?&6F:$\'F1W&W[5<;L"V+G;'D?
M[1%5-?\ BOI>CR7MO;V-]>W-E=);7"I 0BEF ^]T)YX'?%3S>2'R>;.QQJG]
MZT_)J9*=42-GS:':"<8:KL$HG@CE",H=0VUUPPSV([&DN?\ CWE_W#_*A2UV
M0..F[$M)3/:Q3$8+H&('N*FJKIO_ "#;7_KDO\JMTFK-H<7=(3%&*6BD6%%%
M% !1110 4444 %0)_P ?DG^XO]:GJ!/^/R3_ '%_K0!/1110 5R.O>-X="UA
M+-X(YHMT:RLDV9(]Y !*X[9'4@XZ5UU<]J'A#3=1NKB>9KI1<NDD\4<Y5)'3
M&UB/48'Y4 48?&-R^+F31WCTW[:;(W'G MOW[ VW^Z6P/7FHK7QK<W-G9WL^
MD/;6-[,UM#/YRLRR995)7'W25P#^E6=-\$6=HYDN+BXG/VR2\\KS6$/F%BP;
M9TR,_F,TS1/ MEI=M:)<7%S=/;.\JHTK>4)&+?.$Z X8T 9NE>+;B.VMA.+B
M]O9K.T\N(E55Y92_.<<?=))/8<5HZOXNN]%LHGO=-@CNV+G[/]JR651G<N%)
M(/N!BKI\&Z1]G\E8Y5Q#%$K+*0R"(DH5/8@L>:1_!U@Y1VNM1^T!'C:?[4WF
M2*V"58^G Z8H PW\7ZA=/JUQ#;[-+BTF.]BE1P)4W*QS@@@GC'/3%:#^+IXH
MI[F/37FTZR9([JZ,JAPQ +%5Q\P&X9Z>U7/^$-TH1B-!<)%]B^PNBS$"2+!P
M&]2,G!]Z=/X/TN:Y:5OM(CD*--;K,1%,R@!2Z]SP/KCF@"C:^,IY[R/?I+I8
M27SV"7/G DR*2 =O]TXQGUJ[X6\2MXC6X9K5+9H2 8C-ND0\\.F 5/'T-6E\
M.Z>MLD 20(EV;U?G.1*6+$_3)/%+I7AZSTF]GNXI+F:YF18VEN)3(P122%!/
M89- &O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2
MB^X?]YOYFBB+[A_WF_F:* +,'^H3_=%25'!_J$_W14E "$T9JAJD%[<0HMC<
MBWD$@)<KGY>XQ5R,,$4.=Q Y..M.RM<E-WM8SI_$FE6MAJ%[/=+';Z>YCNF8
M']VPP<'_ +Z'YT7_ (CTS32@N)R&>'SU"J6)CRJ[N/=E'XUS>M^&;J^\8HBV
MXDT34@DNHY/ >$$*,=]P*C_@%94'A?69?#6M6]_;M)<*D>G68#?-);1OD/GL
M6S^E(H],WC&<\4;QU[>M>;ZWX6O[:[O(='MI(])>2UGE@C&\2$;Q)M4L,G[A
M(R,XINE^$;J?4=+^TQWAT^(7<HCG7REC9C'Y:E%8_+D$@$\8H ]*#@G%&\"O
M./"&@:I9:Y:S7RW<=U#'*+N3R%$=PQ/!,F\E^>1QQ[4WQ%I.L7GBDW<%A,)H
M+N!K::"%<-$"NYFD+9!^\-H'3UH ](\Q?7I2[Q7ES^$=0@T:WG\BX>5]1FEO
MHROG/)%O?RP$+ ,HR#MSWS72Z1H$TG@6?29Y+E6G$OE>>@1X@22@ !. .,#-
M '6;Q2!P21CI7F-GH?B>_O;6?48I(H]6E5]1C\SBV6 @HH_W]HS]:L>%=!U6
MT\06T]\+Q+N$S?:IA HCN-Q.,R;\OV(XXQ0!Z!'?VTMY-:)*&G@"M(G=0W3\
M\5/O%>?>(/#\LFL>));;2I6NM0T]5MKR$#A@"&4MG@],4^^TF[T&>9-,TJZN
M;:YT=K5! VXK<98Y?)XW;OO>U ':P:E;W-[=6D3$S6I42@C&-PR/KQ4EQ=);
M6TL[J[+$I8B-2S''H!R3[5YG<V5[H.DR:M<@P7UD+.:V1Y,&X9(0LD7N6&X?
M7!KHSI%\OPXU"V"R/JE[:S2N ?F\Z0$X!]L@?A0!UJRJZ@\C(R >M+YBYQWK
MSR7PM=,NHZB+.7^TUO[>2UEWG<J*(PVWG@8#Y'?FBV\*WMK:V%W:020:LUY<
M^=.6)*QOYFW//W?N$#M0!Z'Y@YHW@=:\PM/#%U?"TM(-,O-+E6TDCU*YE?(G
MEP-A!R=Y\P;]W&!QWQ3KC2]=U&P%]J^FL9;VX"7$2Q"=K>*-2J;4) .YMS$\
MX#"@#T634;6*^6R>4"Y>)IEC[E%(!(_$BGV]TES;QS*KHL@!"R+M;\0>AKS3
M1?#EY;7NB76I:1<SO%;75LKLH+0'S 8BW/ VYZ9QTIT/A"\NM+O7OK*8WD>C
MP1VK&0@I.H<G;@\,#MYH ].WC..]9%MXJTF[U/\ L^&=S.6=$)B=4=E^\%8C
M!([X->:Z^C ZC;7-LEWK-Q/#Y-TMUB2,'9^[V [LC!X (/4FO1/[*^U^*?ME
MR;EH[-%-K&P A5V!#,,<EL''/3MUH WP<T4#BB@ HHHH **** (/^7T?]<_Z
MU/4'_+Z/^N?]:GH *2ANG%9MO+J1U.X6:.(60QY+ G>?J/2FE>_D3*5FE;<O
MS7$-N@>:1(T)"AG.!DG 'XFD^TP_:/L_F)YVW?Y>X;MN<9QZ9JCXATI=;\/W
MNGMPTT1"-_=<<JWX, :\U:;6FMU\:I97(U.X8Z8;?:<K'MV*V/03 MGT-(H]
M3M]1L[N5H[>YBE=1N8(X.!DC/Y@C\*LYKS:3PY-IUU?065W>VOV#18EA:V.!
M)*I<Y/'S<]O>JD^NZU/K]E-&]Q;-]IMX9;<R2$R(P7>XC"[0O)YSQB@#U&.:
M.5=T;!ER1E3GIUI^:XSP#;I8Z+?6OGW37$-W.)HYV8^6=[$8SZC!R.N:YS0]
M;O6LM+O+:_U;4=282M>VD@.TQ!7/ (PIR%"D=: /5'E2-"[L%0=68X IV[CI
M7B[SZMJNDZQ:2W%U-:RZ:MULCEED:.02#*[F4'.W.5'I6CJ>HZX-8:&POY([
M41P'2Y9II?WP/WBRA#YA)R""00/SH ]7W"FI*DJ!XV5U/1E.0:\_C35TDCU%
MK_46E;6FM7@+'RQ;LQ7A<=!U#5B6S2:7X,L8[75+V*6WGE%U:S22H7(+817"
MG:>A Z$F@#UMY4C +L%!( +'&2>@IVX5Q/BQ/[1\&Z7=2_;[=$N;6>7!(EC7
M<-Q;'< \^XK(OM2U!+B^,6H:C_:\=RBZ9:(&,4\'R[2>,,""Q9B<@T >F[N>
ME&:Y/Q9<S0ZAID=S=75GH[B7[3/:Y#"0 >6I8 E5/S?4@"N?O]0F4W/F:MK$
M3):QMI&Q&!N6P<EQM^9BW!!QQ0!Z9NJN]_:QF/=<1CS)/*3+#YG_ +H]^#Q[
M5P0_MTI>ZK->WZ74&I01I:J?W00B/S!MQ\PRS<]L54TB*?3BMK;3WQN!XAE^
MT1REF"QL92IY' (*G(H ]0W9HW5Y>H\0VN@Z?<P7^IW%Y?:=<-.DASMD5=R%
M1CY6ZCWJ76O$NIWXNI= DN7A2SM_,;RV0)F7]X1\I.X+UP"10!Z7FEKD_ \^
MHSV5Z;NY6XMQ<8MB)'D*KM&5+NJEN<X/X5UE !1110 4444 %%%% !1110!'
M/_J)/]TU!I__ ![C_>-3S_ZB3_=-0:?_ ,>X_P!XT 6Z*** "BBB@ HHI,\T
M +129I<TK@%%)FBF!1UC_D%S?0?S%715?4+=[JSDA1@K,."1QUJ #5?[UG^3
M56Z,V[2O876]*AUW1;S2[AW2&[B:)V3[P!]*QYO FC/ING6,$"6L=C=0W2F!
M%4R/&.-V!SG)S6Q_Q-O^G+\FHSJWK9?DU*WF'/Y,YF[^&VGSW5S>V^HW]G?3
M7LEXMS;N \9D4*ZC(QM( ZUH>'? ^E^%[TW.G>:,VB6NUVSPK%MV>N26.:UL
MZMZV?Y-6.^O:DOBJ/0O*M3(]L;@2Y;& <8Q51@Y;,3JI;IE+4OAAX?UBXU2Z
MU".2XO;]]XNG;]Y;X "B/T QQ4DWP]T^?1M1T^2]O,WUVEX]RK 2+*H7# X]
M5!KH/^)MZV?Y-1_Q-O6S_)JFWF/G\F7((S#!'&9&D**%+N<LV!U/O27)_P!'
ME_W#_*JO_$V];/\ )J9(FJR1LA:T&X$<!J:6NXG/39EC3?\ D&VO_7)?Y5;J
M"UB-O:PPD@E$"DCO@5-FDW=MEQ5DA:*3-%(H6BF[J7- "T444 %%%% !4"?\
M?DG^XO\ 6IZ@3_C\D_W%_K0!/29I:HZK:SWEDT-M<M;2E@1*HR1@YIK5BDVE
M=%W-85_XLLM/U"XLFM-0GDMD5YFM[9I%C# D9(]@:V($>.%%=R[ 8+D8)/K7
M&:QX9UF_U;7KJQU&YL6G@@6W\MP$E90=P;C(],CUI CKK?4[.Z@MIH;B-H[E
M \)W &13W /-2_:X-[IYT>Y!EUWC*CW':O,+SPCJ4^H%QI]Q';SPVRVRPM$6
ML?+ W+O;E>06RN<YIFM:'J%K!XED@TMUM[BUN&DEG\MG9V(VB-U^<ANX;[O:
M@9ZFES!*&,<L;A#AMK [3Z'TIJ7EN\(F2>)HB<;PX*Y^M><3>&M1O4G?3]#7
M2X5M(XI;;SE47S"16*Y4GC:"-QY.ZI7\+W.HW#R1Z&-/TV6\M&:P9E&X1EB\
MA53@<$#'?% 'H1O;<6XN#-%Y)Z2;QM/X]*J6^N65Q9WEV'*06DDD<KMP!LZG
MZ5Q4GAB[LM3EE&CK>Z/%J,DL6G(5"[7B0!U4_+PX?@^I(K4\/:!<P>#]4TVZ
MT^*V:ZFN6CMBX=55\[030!TT&K6-Q917D=U%]GE *2%P <]!]?:K32*HRQ '
MJ3Q7F]OH,\$&FR7'A(7-M%8_96L,Q#RYAC,N,[2&Z;NHQTK6O/#FH7'PZM=#
MG!EN0T(E59#PHE#,H;OA>,]\4 =<+RV+1J)XBTGW!O'S?3UJ./4;=H3+(WD*
M)#&#,0N2#CCGOVKSS5_!EW_;MP+>UE^P2- ;22U$2_9%3&1N;YDY!;Y<YR>]
M4Y-"O]5C@U"&":\L/,O4\E8XV.7ERL@63C! QGJ* /5'NH8W1))41GX168 M
M]/6J4&O6%VI-K)]HVW!MW$9!*,#@YYZ9'6N-MO#EUI]TBWNA/K0>WMXX)YIT
M+6Q1<,K$XQS\VY1S3[?PY=6\DUO!I*VSKK NOM<>P"2(EB",<_+GH10!W@NH
M&D>,31ET&74,,K]1VI%O+=PY2:-A']\AP=OU]*\VL_"^J""SMDT<6M[:1SB[
MU$2J?MNZ-E !SN;<Q#'=C;BK5QX+-O96L5KI;"-]*^SWB6LBQN\@9&7D\,1A
MNO7IWH ]!CN(I8A+'(CQGD.K @_C34O;:2,R)/$R*=I97! /I7+Z+9:Q;>#[
MZW%E;PWA\W[+&\2)O!'RF14RH)[XXKE;3P9J4MQ,CZ9+'8S_ &,RQS&)-[1R
MDN=L? &/Q- 'J7VRW,'G^='Y/_/3>-OY]*@T_5K;4_M7V?<?LT[6[DCJP )Q
MZCD5Q%]X5NK;57F@TE+K1XM0^T?V:A55D5H0NY5/RY5\G:<=<UH^&="U"S\-
M:Y9_9AI<]Y<W$EJBN&$(=0$.1Z'M0!T]SJUC:6=U=S7,0AM5+3,&!V >N*@C
M\0Z=+?+:+.NYH%N%<L K*S%0 <]<CI7!+X3O;VT^S0^'X],,>ES6MR6D5EO)
M64!>GW@&!;<W//UJ_#X3347,UUH$=O$-'-M%;R!/W<VYB<!20">#D4 =XUS"
MDR1-(BR/]U"P!;Z#O2I<12-M216;J5# GKBO+SX1UN2^C-[%<SR2K:LMQ#Y6
MZ QJH8%V^9<$$_+G.:ZWP=X>&BVMY-<6RI?75Y/))(3EBAD8H,]A@CB@#J**
M** "BBB@ HHHH I1?</^\W\S11%]P_[S?S-% %F#_4)_NBI*C@_U"?[HJ2@!
M#UHSBJ&J7%[;P*UC:BXE+@%"V/E[G-7$+,@+KM; R/0T[:7(4DY.(>='M9MZ
M[5X)W# I);B&$9DD1!C.68#BO.O$.GSR>([SPNGG)9>(F2Y,D>?W6P8F&>Q.
MV,CZFLR0WVM>'=6O+M9([G3+:/2E9ES^^$BF5P.X.$I%GKF:,@UYMK6K:]H5
MS=Z<E]/=0A[9VNG"(\*2;PPW8V@90<D<;J;IFJ>(M2U'3+(:IMMW^U2-+$4E
M:6.,Q[%+@;=V202.WOS0!Z7FC-><^$=?UO4M:M5NK@'S4E-Y:R2H3$P/&U -
MRX/!R>16C=:M(WBB\M[W77TS[/+$MI:JBXN$(!+'();))''3% ':YHS[5Y,?
M&&K->SRVMW,(;BUO'6&:1)'@:-24)15!0Y'0DYKJM N=3M_$,=A>ZA+>Q7.F
M)>;I4"F.3=M8# '!R..V* .OS1FO-M4\3:]I.LW=N2\MMI4YO+MO*R9;-\!5
M7'=26/'9*S[[Q%XG@E$4]V;:;[''<VY>2.-)7=B2K!@2P7Y5VK@]Z /6<BC(
MKEO$VI75K'I$<EX=-M;F4K>7B 'RL)D*"1A0S<;CZ>]8TFHZQ+J+#2]9EOK2
MUTEKM"(5S=RB1PJDXZ< ''7 H [^2-)=N]%;:<C<,X-.W 8'K7E-EXLU9=-N
M9YKV6>)[:+<5GB,D,[N%SPN(TP3G=G&*B@U2^U"2R.HZS-##8:R8!=1RHP9&
MAR S[0&^8D X[T >N9HR*\UTCQ#KMWXIAAEG5"U[-#/9RRIQ"N=I5 -P. K9
M)P<FM;Q'JNKZ;K L+21C_:\:PV+;,BWF!PY/ML.[GNM '9EU4$L0 !DD]J1)
M4D171@RL,@@Y!%>677B74'UU;>.[F:UGN)[*6WGD1FPL;_-Y84%.5R"6YS3O
M^$IGT7PO?P/>?9YX]*M)-.0IR24PVT8^;YASZ4 >IEA4<=Q%,&\J1)-IP=K
MX/H<5YLVM:S>^)9;&64(#??9FLY)D57MR.H3&\DCG<#[5O>$])2'4]0U.!+.
MVMF+6<5M9CY<1N?G<]W/Z>] '5FWB,PE\M#(!@.5&[\ZE%%% !1110 4444
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M(Y$\K>3NW=\XK6BE&5W;9F%=N<;*^Z+/]G>(CTUZ+_P$7_&D_LWQ%_T'H_\
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M<1*I9G<CK^%0IR;MI]R*<4E?7\3'_L?Q?_T-,'_@ O\ C2?V/XQ_Z&JW_P#
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M[W"7/FPRE661%V@@]N"01WK:CD26-9$961AE64Y!'J*=0 BC:H&<X[FEHHH
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MH3T9HJAJMQ=VMBTEE;_:)PRA8\XSSS^E4E=V)E+E5V7LTR2>.$ RR(@)P"S
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MX@(&7QC<S,"2&7@8Z59L]8UK3_#EKXGU34WN+3SR;J!85"QP9901@9)!VDT
M>@^:F_9N&_&=N><>N*=NKS&]US7K*WDOF0-?2:9]I"B)=T"/. !G'\*'D'N*
M;'XKUC3;2?4I+DWVF6TZQ</'+(QD0A0QC&.)-N,=FYZ4 >H9H!S7F,.O>)Y;
M2^M+B^@M;W2;?R[N>10D<DSN"F"00,)GGIDC-==X/U3^U=#$QGN)F29X6>?8
M22I[,GRL/1AUH Z&BBB@ HHHH **** "BBB@"E%]P_[S?S-%$7W#_O-_,T4
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M.D>"+B/5+>\OHK9=L=VZ1QG<+629U8!./X0#SZFN^XIBR(Y.UE.TX.#G!]*
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MA;7GVN21V-].8RYR1'O.T#VQ6W0 4444 %%%% !1110 4444 %%%% !1110
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M[M;FUN(M**E[22X*F:0EN3.02=^, >P[&NXBFCGC#QNKH<X9&!![=13^,<4
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MIVNCZ9-J%XY2WA7<[*I8]<=!R>35/3O$FG:G=M:1-/%<JGF>5<P/$Q7.-P#
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M./I56SUFRO;C[/%.!<>4DIA?Y756SC(_ UYOX:TBZN=(T5[319;6XC\V2XU
MR*1.A#C;G.X[B1P1QBK$'A;4H89(UTO;?7&BP6ZW@*YBE12'5FSD$@@9&: /
M0+O5[.T>V$DP(N)A A0Y ?!//IP#5Y'610R,&4\@@Y!KS\^'XM1_LZ*+PLVG
M6\=[#)<I(R 2*J.,D*3D D<GDYKI/#&F2:3'J-MY/DVQO9'MHP>!&<'@=AG/
M% &]1110 4444 %%%% $<_\ J)/]TU7T_P#X]_\ @1JQ/_J)/]TU7T__ (]_
M^!&@"WBC:!VH)JE9ZM:W\]Q# Y,D#%)%(Q@T[-HEM)I%QE# @@$'@@UE'PUH
MQTN'3AI\*VD#;XHDROEMDG((Y!Y/YU!XJU.ZT[3K=;)D2ZO+J*TCED&5B+G[
MQ'? !Q[XK,U2+6M$M(Y6UZ:[26\MHQYL"*R[I0&Y4#((.,8I%&U%X:T:"$PQ
M:; L1C>(H%X*.=S#\2 34">#] B@DA32X@LA5F()W$KG:=V<Y&3WK$M/B/97
M6I+ L<0MY7E2.3SQN4Q@DF1<?(IVG!S]:@3XF(T-T?[-,TT30"-+:7<)1*^P
M8+*.0?P]Z .B?P?X?DB2,Z5!B,LR8R"I8@L00<@G S5I?#^DK;+;C3K<0K ;
M<1[!M\LG)7'IGGZU@6_B2^L]8O%U*#;#]HM8&19 RVID0\YQR"V ?K6I#XF@
M?P_?ZW)"Z65LTNQAR94C)&X?4@XH T--TBPTB)XK"W6%7;<Y#$ECC')/)X%)
M;:/IUIC[/:1QXC,7RC^ DL1^9)KB]5\3ZS;ZG$+NTDL(3IDUSLAF5]Q#Q@<X
MX9=QSVYJCJVL>*#<:T]O(T:?VC;Z? %G4"-6V9(!0_,=W4YQGIQ0!Z#'HNFQ
M7%I<1V4*S6<1AMW"\Q(<94>W J!?#&C)//,NG0AYU99,9P0WWL#H,]\=:YRU
M^($$>HQZ<T2N$N/L3L;@--Y@&"Q4#E<\9X]<5&OQ(9M/L+F738[1M05GMA=7
M00%%^\S$ XYP .^>U '776BZ;>HZW5G%*KP?9V##K'G.WZ9&:B?PYI$EH]J]
MA&T,BHK*V23L^[SG.1V/6N;'Q FN8)+BQT:2:""P6^G+S!"J;F4J!CD_(2.Q
MIDWBC4F_X2"5H@FGV@@:WEAD E =48#!&.=QZ].E '56>@Z98+ MK911"!F>
M,@<AF&&;/4DCN:AF\+:)<2*\NG0L58OW )+;CD9YY.>:Q)O'2IXA.D1P02EW
MDABDCF+?O%4MAAMP.A'!)%9]E\0;JVT'1WU."T&HWUNUQE[@1QE%QDYQP23@
M ?G0!WEK9V]DKK!$(P\C2,!W8]34X.:X[Q!XCNY_AW_;6C*89[E8O+\SAHP[
MA3U!Y&>/SJ&+Q==Z>MW:3:9/,NFF.WEN'N%9I9G"[%' R26Y. !0!W%%<?=>
M,;VPF^PW6CXU(RPI'#'<!D=9"0&#8[$'/%-@\9WQN +K1##!'?"PGD%P&VRG
M&"HQRO(YX//2@#L2<4M<SJFJZK;^+;#3[2"&2SFM9996:3:RE2!D<'IGIWS6
M+I7C>[L-"L[K7;)A#-:2S1W(E#-(8QDAEQ\I(Z<]J /0**YCPWXNC\07L]IY
M422Q1+,&@F\U-K'&"<###N*KP^,KE\W,FD-'IJWQL6N#."V[?L#!<?=S@=<^
MU '79]Z6N%B\937D6GWTUE/8V4M\\(;S%8RA$E+$C'W?DXQS4\OC:XLK!;Z^
MTAH;6XMI+BT(F#,^Q"^UACY25&1UH [.BL2UUJ:3PZVKWUHEBOEF58Y9APF,
M@LW1?Z5SEO\ $C[1%*D>E-->+<PP)%#+E7\T':0S 8QM.<B@#OJ*Y?0=7UJ^
MU_5K6_LX(K>V=%4I+N*DH&V].>2>:Z@=* "H$_X_)/\ <7^M3U G_'Y)_N+_
M %H GJN]E;R2%WB!8]3DU8K$\6>)[3PCX?GU>\CDECB*H$CZLS' '/ Y[T :
M/]GVO_/$?F?\:/[/M?\ GB/S/^-8&D>-([NR6?5M.GT9I+A+:%;EU<3NPRNQ
MDR#]:GN_'7AFP+_:M9MH=D[V[%R1B1!EEZ=0"* -C^S[7_GB/S/^-']GVO\
MSQ'YG_&LR+QCX?GLHKR+5(&@EN?LB/R,S?W,8SFJ,_Q T"2PU:73-2M+ZYTV
M!YI($EV\+UY(QCW&: .A_L^U_P">(_,_XT?V?:_\\1^9_P :X*Y^*L=O+=1G
M2V8V_P!BR5F!#?:.F#CM^M=0GC;PW+K,VD)K%LVH0[O,M\G<-HR1[D8Z"@#5
M_L^U_P">(_,_XT?V?:_\\1^9_P :QM+\=^%]:NGMM.UNSN)DB,S*KXP@ZGGT
MIMO\0/"EU9WEW!KMD]O9X^T2!\!,G ^N>V* -O\ L^U_YXC\S_C1_9]K_P \
M1^9_QJ'2-;TW7;!;[2[R*[MF) DC.1D=0?0^QK0H J_V?:_\\1^9_P :/[/M
M?^>(_,_XU:HH J_V?:_\\1^9_P :/[/M?^>(_,_XU:HH J_V?:_\\1^9_P :
M/[/M?^>(_,_XU:HH J_V?:_\\1^9_P :/[/M?^>(_,_XU:HH J_V?:_\\1^9
M_P :/[/M?^>(_,_XU:HH J_V?:_\\1^9_P :/[/M?^>(_,_XU:HH J_V?:_\
M\1^9_P :/[/M?^>(_,_XU:HH J_V?:_\\1^9_P :/[/M?^>(_,_XU:HH BAM
MXH,^6FW/7DU+110 4444 4HON'_>;^9HHB^X?]YOYFB@"S!_J$_W14E1P?ZA
M/]T5)0!GZK-?06ZMI]NL\I< HS8&WN<U<CW%%+C#8Y'7!J2BG?2Q*CK>YYAK
M3V&F>*;R[3[#J$TMW"9+&ZMV%RK?*H,$G<=\8QUYJVNK33-J37FMSQ:DC72+
MI?EC9L56V<;2<$ -NSSFO03&C.&*@L.AQR*3RD#;]J[L8SCFD4>5-K_B+[?%
M#',MLT:6GV2*258HYE95+$IM);)+#@C&!6I#<ZT6MKQ]4NI%NM7GL7MR@V+#
MEPI'&<C:#FO03&I(8J"R]#CI2[!Z#\J /*-,:3_A%M*M(-0N)G-C>).S %X)
M%B^X#C*X-26\E[H&EVT-E*ZH-'M7><P*SPJ\N'88'.U<G!SZUZD(E&<*!DY/
M%&P'J!Z=* ,+19[>;2[W[-K$VJQ*6'FRX)7Y?NA@!NKA]'T+5QX:T[5+73;#
M39+*PDDCEM26N+EC&0JL-H&,D$YSR!7JRQJB[5 "CH ,8I0H P, 4 >4^*?$
MG]KZ//%9WKRPIIUO/*4A+;)?/3G&/O 9^7VJU<7\UW?-9V^I3:MIL=S92BXD
M09CF,OS(" ,C: V/X:]*$**"%50#Z"E$2KPH &<X [T >8Z=K%PUO:Q:EJ\V
MD6ACN)(Y88E3S9!.XQ]W'"A3MQSFG77B74O^$IMEM+R<0B_AM'BEE ,B, "X
MB"<*<Y#;O\*]+:%& #*I .0"!P:/)7?OVJ6]2.: /*=%GN].TS2H;2>:\NTU
M.\62"=0QC8),57IE<\'/?-33^(-2BTIYM,URYO[M]-FEND>(?Z)*JY4@8^4[
MOEVGK^%>H^4H)( !)R3B@1(-V%4%NIQUH \[U&ZUO31>V:ZXYW6EM<K<7>$V
MLSE70.%(4,!P2#C-=7X4U$ZGX>MKDM<DL64FX*LQ(8CJH 8<<$=16R8U;@@$
M'@@BE5 H 4  = !0 ZBBB@ HHHH **** "BBB@ HHHH **** (/^7T?]<_ZU
M/4'_ "^C_KG_ %J>@ -)D4'I6=;ZDT^IW-F;29!#C$Q'R-[ ^M"BW=KH3*2B
MTGU-'@T$"JU_I]OJ5F]K=*[0OC<%=D)Y]5(-><:%]LTZPT4:05:\U2ZN()IK
MV624)'&7((!;J-H'O04>H<4GR^M>;GQGJ%Q>%/+2XTJ\ANQ!(T'E9,2,>#O+
M$':0>![5+#XEUM;*ZO8/L*V&G&U1H2C%Y%=(RWS9XQOXZY[T >B8%'%<GXMU
M672;NTG@CC:1;6[F0N3P4C!'0XP?>LZ;Q+K^FD_;!97"BSBU!O)C92L6\+*O
M).2 =P/M0!WGRT?+7GMSXTU6YOHH=,A0VUV\S6DZ0^:7CBPN0-PSN8DYSPHI
MK^*_$LEO>W*P65K]@TR*^FMY5+,['?N0,#@ A.#SC- 'H@Q2_+7G::_J]E-K
M]Z;N"2'[5!'!#*I"P>:L>&8Y^Z-QR,<FIKWQ+K]E?G1XWT^[OC<V\2W 0K&%
ME#Y#*"<,NS.,\@T =]@4<5Q]KKFK0>*H].U22".WD;RH'C@)6X8)D_.&.QLY
M^4CH.M&L:]JD>I:M%8S6-K%I5LEPXNE),^X%N#D;5XQGGF@#L.*/EK@?^$JU
MN6"\U2)+2+3[6>W0VTD;>:RR*A;YLX!&_CCM6SK^JZC;:_I.E6$]I;_;DF9I
M;A2V"@! 49&3STH Z7"^E&%KS>[\<:L=/(LEADU"V2>2X6.#?&Z1.5#ABZ[5
M)!]33&\4:K9G7=;$T<ULEG:30V)4Y0RJ.<YZ DD\<XH ]*^7VI>#7G\?B7Q,
MTR6+V\$4LMY%#'=3P[0R.C,W[L.2""O'/(-,CU77;SQ)I-M)?V\#P75W;7&R
M,^7/L56!QG@[3TYP: /0@%48   ]*7Y17)^'=>U*\UBYL=5\J&?:TL,"1<&,
M-C<L@8AQTST()Z5R&I:]);>-AK,[7,>EB]-K!(LI+/(B[3!Y><*K,2VXC^'M
MQ0!ZWQFC(KEO$\NI+J_AY+&^2T66Z=90Z;@_[LG!Y'_Z\5D_\)/KAMII6>V1
MY[][&PABMC([E&;+'+@?=4]\<4 =_D49%>>Z/XNUC7/LEJC65C=!+AIY)TW*
MQBE\O:H#<9ZGDXK(TCQ=K4>D6MII\"SS1VCW;L(_-69C*X"@EAM7C[W/44 >
MM45!9RO/90321F*22-6:,G.TD9(S[5/0 4444 1S_P"HD_W35?3_ /CW_P"!
M&K$_^HD_W34&G_\ 'N/]XT 6JBCACB+;$5=QR<#&34IJM;WMM=/(L$R.T;%7
M /*GWHUMH2[75QFIZ;::O8R65[%YD$F,C.""#D$$<@@\@BLN'PE8)S--?73[
MXV#W-TSE=C;E [8R*E\3ZC>Z;IMN]@85N)[N&W#3*650[8)P",UDW'BNZ\-3
M7,/B)8I5CM_M,=Q9H1O7>J,"A)PP+ \'D4#1I#PAI8><8N?LTPD#6OGMY(WY
MW$+VSDU&G@W2TF$LC7<\H\H!YK@L0(VWH![ BHKKQO;6'V9KW3KVVCGVY:38
M"@9L E=V[TZ#C-8:^-M;34KAFTB:6U.K?V?%&BH" !R=V_EB>V *!G1:]X:.
MIV6HP6DD<$FIA4NI)4+_ "*"/E (PWH:U(M)LXM#32/)5[-8!;F-NC)C&#^%
M5]7\01:-'9>;:74TU[+Y,,,*AFW[2V#S@< \YJA)XTMET^2Y%A=F6&8P3VS%
M$>)P <'<P!R"",$YS0 U? ^D;R\IO)W^SFV#37+.5B)!VC/;*BM"7P[I\OG!
MHG_?727C_.>9$V[3]/E'%8D'CR&;56 M)?[)&FK?&\.!L!+ [AG/&W''>I3\
M0=.C@E::RO8YD\IE@"JSR+(VQ2 &/\1P0>10!IKX:L8]1>]B:YB\R0RO"DQ6
M)G(P6*^M,?PKISZ?8VD8GA%BI2WEAE*R(I&"-W<'OFLR[\;R++:Q6VCWC3M?
MBSN;=PH>(E-X(^;!R,$<XZUMZSK:Z+9I<O:RS!FQM1T4CC/)9@* (QX9TX+<
MJ4E;[3:"RE9I"2T8W=SW^9N:BD\):8[3\7 2XACAEC$I",$P%;']X!0,U37Q
M[97#HECI^H7K-:+>$0QCY8R2.<D<@J>/RI3X[L)3(UE8W][#%!'<R2P1#:L3
MC(/)!)P#P.>* +,?A'3(KZ*Y7[3B*X:YC@,[>4DC9W$+[[C4<?@O3(K:"&&2
M\B-N7\B1+A@\2-U13_<]JHP>+Q)J]RCW$:V*W:1PN(\[HS;>:23GCN<_A6C:
M>*UNK&6\32=16V$/GPRR*BK,A/!!+<9R#AL<4 :%UHUI>:0-+G61[9=G5SN.
MU@PYZ]0*CF\/Z?<0:A#+"S)?N))QN/+   CT(VC\JP&\>K<O8C3],N9WEO3:
M7,.4W1$)O&"&VG(P>O3-7$\6HDCVR6]S?WK3SJD%O$%8)&P#$Y;& 2!G/)/2
M@"U;^$].A<2N;FXG$L<OGW$Q=R4SL!/H,GBK+:!8.DJM&^);M;QL.?\ 6@@@
M_3@<5E2>/;'8C6MAJ%WFV-U((8AF)%8JP;)&&!!&WD\5;LO%MIJ.KFPL[>><
M*J,\Z[0JAUW*<$[L8(Y Q0!=OM%MM0OK2]E,T<]KN"-%(5RK8RI]0<"J[^&-
M*DL[.TDMR\%I&\<2,Q(VNNU@?7@U'K/B_3M"%\;U9A]DACF(5<F17;:-OJ<C
MFJ][XL@^U+%9^9)LF\HXC#"5C"90JG(QQCGWH T]*T6#22YAFNYBP"_Z1.9-
MJCH!GI61IW@BSM)6DN9[B?-Y)>"$2,(=Y<LI*9QD<?B,UFV7CC4;E-!F;1KD
MG4+665K>)59F*A2"IW8"\GKS6MK'BA8O!+>(-/#%2$=5>/+8+A2-OKU'UH O
M)X;TY+6QMA"QBL96F@4N3AF# Y]1\[533P3I"QO$XNIH3"\$<<L[,L".,,$!
M^[QQ]*BN?'=C80W#7]C?VLL)B_</$"[K(VU64 G(SP1U%.E\;VT/FL^F:@(;
M;9]LE\M2MJ6 .'YY(!!.W. : -J\TJUOM)?3+B,M;/&(RN<' Z<^O%9D'A'3
M8+W[6S74]R9(I#+/.78F/=MZ^FX\4VX\96-IKB:9<PS1>8Q2.X+(49MI;H&+
M $ X)':J<7C&2^UG1K>VL+J"UOVD*S7$0"RQJA(*X.1V/(Z4 ;L&C6UOK-QJ
MD33)-<*%E02'RW(& VWIG'&:TJ!THH *@3_C\D_W%_K4]0)_Q^2?[B_UH GK
M"\6Z7>ZQX>N+&P%BTTA'R7\1DB< Y*D#U]>U;M% 'C%I\+_$MIHT_P!GN-.M
MKI=3@O[2PC>1K:+RP00"W(SG/X5:T[X8ZU)K%A>ZVVG7 36)]1N43=L8.@
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MS H&<[MV#G(&,"@"Y9>!+G3M3/V'6+BTM5T]+19$"%W.]V;((P/OC!'2I8/
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M[+\I0Z;58 9SNW<9/;FJ(\5ZE9MIJV4V;*![2TGBE6,!BZIG;SO/W@<XQP:
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M;^,"M[2O"]KI5\UZ+BZN;C88U>X<'8I.2!@#J0,D\FM5K*V=90T$165@T@*
M[R.A/J>!^5 'GMKXM\2:E?.+-(U$L]Q;+!)$H$!0,$;=NW,<J,C'1O:F1?$+
M4[V9?L\420WX2VT]BI)^U*5\Y6]@&./]PUZ NDV":@VH)9VXO&&#.(QO/X]:
M>NFV:>7LM8%\IS)'B,?*QSEAZ$Y//O0!@>)=6OK/6M%TVUO[6R6^,P>>=-V-
MJ@@*"0,GGJ:YR[\::LUAY-O=QF_M_M#/)#;HT4\<3 ;\NXP">" 2>M=SJ&@V
M&J75O/>PK/Y"NJQR*&0AL9R#]!3I-"TJ:&&&73K1XH!B%&A4B/Z#M0!Y^GB?
M58O[7UX7:NG]E6MW'IVS(#.IR0<YP#DGUJQ#XF\2O(MD)809KJWBCO)84!Q(
M&+#8KGIMR#GG-=X-)T\31S?8K?S8X_*1_*&53^Z/;VIMMHNFV2;+6PMH%#^8
M!'$JC=_>X[T <*VI:W<>(])M;C6(H&MM0N;66580%G B#KE2< X.,>O(K8\.
MZ]J-WKMS8ZG=1^:1))##%$I0HK8#+(&.>, A@#FNDGTJQNAMN+.WE'F";#Q@
M_..C?7WHMM)L+.XEN+:SMX9IO]9)'&%9_J10!QAU?5I/$1TO39[:T-SJ5S')
M*T/F$*D2," 3UR:L7VK:CJ7PIU#4/M M[]+>=6FA'&Z-F4LHSQG;GVS78"QM
MEF$P@B$H8L'"#.2,$Y]2,4JVD"6[0+%&(6SF,*-ISUX]\G\Z //'EUR+5KRY
MLM9MI'M]&BG>5X RS$,Y P#A00.2.>E(_C?7+G5'-G;@0PR6Z?9610)5D569
MM[,"/O';@'[OO7?V^E6%I%Y5O9P11E/+*I& "O/'';D\>]-DT;39;F&X>QMF
MG@ 6*1H@60#H >U &+K^K7T.OZ?I-K>V^GK/#+.UW<1[PVPJ!&H) S\V3ST%
M</I'BG6(=(M;6RE3>R75VUPL0D25A.X"C>PPG?/)P17JUYIUGJ,:QWMM#<(K
M;E66,, ?49J";0M+N((X)M/M'AB8NB-"I52>20.U 'G,KWTVJZKK=X\)ECBL
M%%LZ;A%YFTD*P/3)/(Z\5JQ>)M=CFCOYI[>:RDU>?3A:)#M8*I<*V_/+93&,
M=Z[DZ?:D/FWA/F;=_P @^;;]W/T[4HL+4*H%O%A9#,!L'#]=WUY/- 'FEKX[
M\0?V>=1>&.6*:T:;:\:H+9]R@=&+.HW'.0",5M:'<7C^/I8+K5[742NE*X>W
M0)C,G< D?0^E=7#HVFV\TTT%C;12S@B5TB4%\]<\<TMEI&GZ<2;*RM[<D8/E
M1!>,YQQ[T 7:*** *47W#_O-_,T41?</^\W\S10!9@_U"?[HJ2HX/]0G^Z*D
MH AN+NWM$#W$R1*2%#,<#)J0,&7*G(/((J"\L;:_C$=U$DL88,%89&14R*%4
M*H  & !3TMYDJ]]=CAI_%6H/XEU'3DUC2+%;:Y2".&X@=Y) 55LY# =6Q6@/
M&$<%PUH\-W>W333K'':P8($1 8'+=MPY[UM6.CP65YJ%RK%VO9Q.P8#Y2%5<
M#_OD54LO#%O9:N=16XD:0F<[3C'[UE8_EMXI%%*]\=Z78V-G?2)<-9W,8E$P
M"@(I..02#D'K@'%2_P#"9V/]HM;&WO!"EV+-[HQ_NA*<8&<]#D<XQS67<_#6
MSGMY(%OI%CFMQ;R%X4=MH9B"A(^3[QSCK6RWA6V:SFMC/)MEODO2<#[RE3CZ
M?+0!4N/&,4FEWEY;6U[';10221WSV^Z%MG4CG)'IG&:GG\7V=KJ]OIEPDRRS
ME8XYL+L9V&0,;MPS],5#_P (<_\ 9MSI1UBY_LN2&2&*V\M?W:MVW8R0,\5"
M? 5L=2%T+Q@@O%O-OD(7+CL9,;MOM0 C^)=03X;+KRK";XPJP#*=FXN%Z YQ
MSZU8BUC6=*UB"PUM;6X2[21K>XLU9/F1=Q1E8GJ.A!JS+X5A?P=_PCB74J1"
M,(LP W##;@<=.HJO-X-&H>=)J^J75[.]N]O$^U8UA5_O%5 QDX')SQQ0!GWO
MQ#A6PEDL+"XFNH;BWBDMVVDA97V[@58CU'7KBM2\\86>G:A;6=Y;W,+3E%#O
MLPK/T!&[/7C(&*H+\/X?*NMVH,LTZ0JCPV\<:QF)]Z,% P3GKFG7/@*.[OI;
MF746+33Q7$I-NA=G3;T8C*J=HX'O0!V I:,44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!!_R^C_KG_6IZ@_Y?1_US_K4] !1D4AZ53AU*UFO
MIK-)5-Q#C?'W&:+-[$N26Y<(&,$<4W9&5"[5VCH,<"LSQ+<7]GX=N[O3=IN;
M=/.",N0ZJ<LOU*@BN9;QNZ>(9)F\L^'A:E4E'WC<",2D9]-AQ]104=T0K$$@
M$CIQTI2JD$%1@]1BO/[7Q5K]C*S7U@][Y>F17MPD)6,0[F8L!G[Q"X&/]FM"
M3XAZ>NIB".'?;":.!Y_.4,'<+C$?WF4;ER>V?:@#K]B<?*O'3CI0%4$X4 DY
M.!UKBE^(L<EM',-*EC%Q</;6IN)TC65D+;SD_=4;>IZYX%7;GQ6USX#O?$&F
M6^9H8I"(I&&%="01D<$#!Y'44 =517*'Q7J"J(8]"DGO(;=;B[CCG3;$IS@!
MC]YB 2!6C>>(H(/#L>LP+')#*B/&)9EA!#=,ENGTH VJ*XZR\>+JD%O'INER
M7-_*TJM;B9 L8C(#,7Z$98 >I-7$\47=Q>O;6FA74QMQ&+S,J*8&< [1DX8@
M$$X/>@#I:*XJ'XCV,UT56U=[=Q,+=XI5=Y#&"2#&.5S@X)Z^U*?'X&E6U[_9
MR?Z3-Y49%Y'Y8^7=\S]%/;![T =I1D"LC4M=&G:9;W)M))9[ETBAMD8%GD;H
MN[ICJ2>F!6;+XKO(;ZQTZ7P_="_NR^(EF0JJH1ER^<;<-GUXQB@#J,CUH!!Z
M&N$L/%FI7.K6]M':F:RDL)KB2=V574I*4SCH<8Z=\U=T[Q9<WD%JMAI=SJ#"
MUAFNI-Z1E/,4$  \,V.2!Q0!U^:,UQ=[XZCBU6XTL0(DI298)4N$D/F(A;YD
M'*]/TJ\WB233?!^DZI<6\MY<7:V\?EPX#/)(!Z\=30!TU%<?<>/(K+S;6]T]
MK;5$F2$6TDZ!&W@LK>9]W;A6]^,8I;7QU_:211:7I<MW?D2&6!9E58PC;2=_
M0@DC;CK[4 =?1G-<BGCA[V6.'2]%NKR1K3[4Z^8L>P;BI0Y_CRI&*I+X]ACD
MNKS/F6DRVHLH7*QG?(&)#,>!C;SGIB@#NZ*Q_#OB"'Q#8RSQ1^4\$S02IO#@
M.O\ =8<,""""/6MB@ HHHH **** (Y_]1)_NFH-/_P"/<?[QJ>?_ %$G^Z:@
MT_\ X]Q_O&@"W13)(_,0KN9<]U.#4'V(?\_%Q_W\- #-2TNUU6*".[C\Q(9E
MG5>VY>F?4>U26^GV=M%''!:01(C;D5(P I]1CO2?8A_S\7'_ '\-'V(?\_%Q
M_P!_#0 O]G67VT7OV2#[4!CS_+&_'INZTU]*T^19U>QMF6X.Z8&)3YA]6XY-
M+]B'_/Q<?]_#1]B'_/Q<?]_#0 DNE:?/!%!+8VTD41S&C1*50^PQQ3I-.LII
M&DDLX'=H_*9FC!)3^Z?;VI/L0_Y^+C_OX:/L0_Y^+C_OX: &C2=-6 P+86HA
M/)C$*[>F.F/2I8;*UMXXTAMH8TB!"*B !<]<>E,^Q#_GXN/^_AH^Q#_GXN/^
M_AH 6VT^SLBYM;6" R'<YBC"[CZG'6JUGH.FV,[SQ6<7GM*\OFLH+AG.6PW4
M"K'V(?\ /Q<?]_#1]B'_ #\7'_?PT $>F6$4[3QV5NDS$EG6)0Q)ZY.*C;1M
M+:!(&TZT,*,75#"NU6/4@8ZU)]B'_/Q<?]_#1]B'_/Q<?]_#0!(;6W*R*8(\
M28WC8/FQTSZ]!0EI;17$EQ';Q)-* ))%0!FQTR>]1_8A_P _%Q_W\-'V(?\
M/Q<?]_#0 '3+ W,ER;*W\^1=KR^4-S#I@GJ:1M+T]IQ.UC;&50 ',2[@!TYQ
MVI?L0_Y^+C_OX:/L0_Y^+C_OX: )%M;=/NP1K\I7A0."<D?3-->QM)$V26L+
M+L\O:T8(V_W?I[4W[$/^?BX_[^&C[$/^?BX_[^&@"2WM;>SA6&V@CAB7[J1J
M% _ 5-57[$/^?BX_[^&C[$/^?BX_[^&@"U157[$/^?BX_P"_AH^Q#_GXN/\
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M1110 4444 %%%% %*+[A_P!YOYFBB+[A_P!YOYFB@"S!_J$_W14E1P?ZA/\
M=%++YFP^5MW]MW2@!^**J?Z=Z6_YM2_Z=Z6_YM0!:HJK_IWI;_FU'^G>EO\
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M1!X>BT3RI?L<5R+I1O\ FW[MW7T[8].*VM8U6#1-)N-1N5D:&!066-=S')
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M;*,&!4C&/0^E 'J<3K)&KKG# $9&#3ZAM(#;6D,!E:4QHJ&1_O-@8R?<U-0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $'
M_+Z/^N?]:GJ#_E]'_7/^M3T (PR*SK?3YX=3N;IKR5XI?NP'[J?2M*BFFU>W
M4F4%)IOH8?B_3[K4_"E]9V<8DN)%78A8#<0P.,GZ5B:MH^N>*F#RVZ:2MO;S
M);YE$DC2R)MR2O"J!GUSGVKJ-9O_ .S-+EN\PC85&9F*KRP') /K5*#Q7HLV
MI'3X[Y6N?.:#;L8#S%ZINQC=[9I%''6?@K4#:W,_E3VVH00Q&T,DD(0S1-N!
M C4<=5R><,:+WP;J[BQOI%>>XDBG-]!"8CB:4@DCS%(( &S/7 'TKKX_%^A2
M^>4U!-D",[R%6"%0<$JQ&&YXXS0?&.A+;>>][M!E$&QHW#^81N"[<9R1R..:
M .5/@[4[:.$K#]LAM3:,;:>8,;E8T965C@ D%@1D8)%5;G0[^#6=/NFT.%XY
M]2EN4TT."L*B#;U^Z&)&['3)KK#XVTEM0TRVA=YDU!9"DJ1L0C(0"K#&0<G'
M/3'-6K'Q)8W%K))-=6ZR0P&XF",2JQ L-V2!D?*?Q% &?I.BWD'AO6+=[>.V
M>^>>2&S5LK &7 7(XY/)QQS6*/!5V;#66>T@-_.+/[+*2-RF)$!PW48(-=7'
MXKT62[CM5OE\R0@*2K!=Q&X*6Q@,1SC.:L:9KVG:SO\ L$YE"<[MC*&![@D8
M(XZB@#D;SP9J5U?ZC:QS)#IB)-/IY#<I<3##9'8+\V/]_P!JSK;P1?S1 7%I
M*OSVB2Q2R0^7(D<H9B%C49P <$\GI7J.*,4 <%?^%;B.^EN;;2[>>WCU>*\B
MMAM4%/)V/@'@'<<X[XJ-/#FI6>H-?3:7%J4/VV[D^R-(O E*E9!NXR "#GUK
MT'%+B@#SO3O!-P)W?4+.VD0Z7-;Q1DAE@=Y6<(N>P! S[5-XGTV]_P"$(\.V
M,EJMW=0WEDLT+$E7*D;LGTXZUWV*0C- 'GG_  B%SJ6HBYN=+AM;"34(9VL-
MZE0J1LI=@/ERQ(X'8<T3^%]1:6>RCTV 22:D+N+6 ZAHHPX; 'WMP4; .F*]
M# I: /.V\,:E)HMYHZZ3;Q7;+,%U?S%W.7)(/3=DC@YZ553P=>/974D]A?&5
MV@VQ+<6Z$-'DAU54"'&<?-U!]J].Q1B@#S>/P]KJ7NDWG]G0"_1(XYY 8S 8
MU<DAH\95@#U0CDU?\<>&[[7[NWQ;275I'"WE1QSB,PW.?ED;/WEQD8Y[\'-=
MSBB@##\*6^K6NA1PZV5:_5V\QHV!1AG@H!]U<8 ':MRC%% !1110 4444 %%
M%% $<_\ J)/]TU7T_P#X]_\ @1JQ/_J)/]TU7T__ (]_^!&@"WFC(H-9VGIJ
M*S7)O9(6B,A\D(.0ON:=KJY+E9I6W)[[4+/385GO+F.WB9UC#R' W,< 9]S4
M5[J]AIHD-[=QP>7$9WWGH@(!;Z9(%9'C33!JVD6MF]L;B%[^#S8P,_)O^8GV
M [UQ^LZ5KL#ZI8SVT]Y;VVE-'9W: LTR&5"$8?WU (]Q@TBCT/2O$&D:RTBZ
M=?0W#Q@%T0X91ZD'G%6+74K*]N+J"UN8I9K23RIT1LF-L9P??%<9J6H3ZAJ]
MEJ^E:1>_\2V&9GFE@,33EDVK"H/+#<0Q/0;:A\/Z/KOAW6M/GNK2U:*\1K>^
MDM79V>4DN)7R!CYBPSZ,* .Z_M"R_M/^SC<1_;?*\[R,_/LSC=CTS1;:A9WL
MUS%;7$<SVLGE3JASY;X!VGWP17'ZYX=O-5\;37ME*]E>6^GQ?9+[9N57\Q]R
MD=P5/(^AK%ET6;13?Z;;VEP+&>_C:2\V2NQ_<C+D1D,Q9\Y.<9H ]4X]*3 ]
M*\MT?2=6U5(H]5?552'2YA&3))$3*)CY9(SDMM (SFJVI2>(9WLKCR+^+4;=
M+/9Y<4S&<';YC$AMBCE@01GB@#UP8ZT;A7D\\\\>J6D;&_;5WUD))<I=@P21
M[R0H4-T"X!7&1@YJ*SM/$ICNS//>IJ0M;H72+%*1*Y!V$,3L!!P5VCVH ]=R
M*,BO,KSPS=H^HI#-JYC31UG@_P!*D/\ I@W<CGEN%XZ>U0M#XAG\0I)=37,%
MRTUN]M(L,K@1;5W*=IV 9WAMW//TH ]2=@JEF.% R2>U,@N(KF".>"19(I%#
M(ZG(8'H0:\\L]$ODM=-G8ZB]Q=S7,-Z))G(\IA)M!&<* 0N"/6M_X?VT=GX.
ML+9;>Y@EBC6.>.X#!A(  V-W;Z<4 =31110 4444 %%%% !1110 4444 %%%
M% !1110 5 G_ !^2?[B_UJ>H$_X_)/\ <7^M $](2!2U0U6*\FL72PF6*X)&
MUV&0!GGCZ4TKNQ,G972N7L@U3BU2RFU2?38[E&O8$626#/S*K9P?H<5/"LBP
MH)7#.!\Q QDUQ6H^%+G5?%6J7T%Q-IUQL@CAO(USOC*D2I^6,>A -(:=SKM/
MU6RU6*2:PN4N(HY6A9T.0'4X(_"KF:\QCT%M+5+>;2[Q]!BU"Y+VML"68$+Y
M3E5.67AOQ.34NG>&KW4)84U:WOA9I93_ &>*2=MT>9<QJY!Y<+TSG% SO9=3
MM(9VAED,;!D3+*0"S_= /0GZ5<R*\IN=%U.]T_S=7L+R[6'^SI70;F=M@82[
M0#RW(SBK5WI]V;ZZ$>G:F=5>YC;3;I2PBA@^7 )SA0!N#*1D^] 'IF13)I4A
MA>61@D:*69CT ')-<WX/T1[&&\O;OSS>W%S-_KG)VQ>8VQ5!. ,<_C7%C2=8
MO=;9VT^ZB-VEY%?1+&RQ89#Y8+ER'R0,$ 8SVH ]134+626"-+A&>>/S8@#]
M]!CYA[<C\ZM<$5YC8:%;Q3^&KJ+1;R(PVLEL2\;Y@N/DPS#/W<AN>E5X]-U,
MVL:66G:K;ZJMI<+JD\SMLG8QL %).&)<@J5Z =J /5J,BN @\&1->:9;W,5[
M+:C3G:X9[A_GN#LY8Y^]P<>E8$VD^(Y_LYO_ +>)39P):2QP-*\,BD[LX=0K
M="2PP1W[4 >O9'2C/%>>Z3%<S>,&T5;AIM,TZ4Z@95DS\[@@0M@_POO;'IBH
M?&>EZM=^(9I/]+:T>U1+)[6%I3#-D[C\KJ%;[N"V1Q0!U]YXHTJQFO(IYI ;
M-5:<K$S*I8@*N0.6.1\HYYK0L[Z*^C9XEE4*0"LL3(0< ]"/>O.=1\'&YAUN
M273Y9KB?4;1PX)!D4>5YC  X[-5J[TNZ@N95NK*^GT1-2<O;P%F9H_)01G .
M60,#D#OS0!WXN4:Z:V&[S%0.<J<8)QUZ?A4V:\SU33=8FM)AI%IJ%M9FVMAY
M,Y+2&,3,9$ W9W%<<9!QQFC2O#MS=W%C#=+?/I1O)I# \;P+&IB  P6+;"V2
M 3US0!Z9D4!@:\PCTRZMS!'KFGZK?:;$D\-K' S.R,)6V%@"#RFT*Q.!BK9B
MN'\7)H-M+*;"[:/4;A3-N>V,8&Z)B"2-[;#_ -]>M 'HF:,UP/C^TO\ 4+F&
MWBLYW@%K(\4\$+2-Y^>$PK#;TSN-9K^']4NM,U/4;B&^.K16UF]H1*P(E6-=
M^T XSG(/K0!Z/?7]MIUM]HN9-D>]4W8SRQ"C]2*M"O*]3TJ\N)I4GTK4YM8.
MJ1R_:D8^3]G$JD<YV[0HQMQG->ICI0 M%%% !1110 4444 4HON'_>;^9HHB
M^X?]YOYFB@"S!_J$_P!T5)4<'^H3_=%24 (:3-4M4M;N[@1+.[-M() Q?&>!
MU&*N(K*@#'<0.3ZT[:7)N[VL8T_BK38-4>P(NI)(W6*62*V=XXW;D*S 8!Y'
MTSS6C::E:7OG?9YUD\B5H9,'[KKU%<;J]GJL6O7$^C:;J%K>S3QGSXIT-I.H
MP&:52>#MR.!DX%4)/"+3&]L%T9H4EUR.ZEN(]JK-;EMV,@YXY!'O2*/21-&6
MVAU)QG&1TJM8ZG9ZA9K=VMPDD#$@/G R#@_J*\\F\.:C_P )9;7$6E&!;?44
M"O!%&L7V0#;R^=Y)7@KC%5%\)WUOI6GVT>CO%;V5U<?;((X8W%QNSY<BJ2 X
M XYP1GVH ]7,J #+J,],GK2^8F"=PP.ISTKR2]LDT.&T35;>._']G-'##J%P
ML<ELV]CD8R#P0/E^8;0*+2RO(H=#T6%B'U33H8M5AR=]NL8#>81VW+E.>^*
M/7-PQG/%-$L;+N5U(Z9!XKF-8%WXA\#AK"UFADF$;_9)&\MWC#@M'GMN4$?C
M7'ZMI4RQF:UT&>STRXOK)4TPL(VD=68NV%)"Y! Z\XYH ]7$L97<'4KZYXH,
ML83?O79_>SQ^=>4ZAI,R7EI(F@SQ:9/JJ/%I1=58A87WMM!VKDX.W.#CWJZN
M@WB+'<2Z'-)HHOY)1HV5+)&8U56V9VGY@S;,\;J /26D08)=0/7-5['4K74K
M9;BTG66)B0&'J"0?U!KA-&\(SSZK82ZM8%;"%+EX;223>MN&D4QHPS@D $@<
M@4S2M&N]$MM.DM_#\JO87TIN4@" SHX<*Z<_-C(ZX- 'HS2QJ,LZ@>YJC=:Q
M:64S)=.\2AHT#LAVLSG"@'OSU]*XC3/"MQJ5^)M<TD>4T%X1#*P<(\DP9.AQ
MG;SGM52?POJD^G[K_3&O?*ATX^2Y5VD,3/Y@&3R<$=>M 'I45Y'(\ZD.@A8*
M7<85LC.0>XYJ;S4&W+J-W3)ZUYKJ_AW5+BY>>*RD73OMRS-9A$=FC\A47Y"=
MIVL/NY]^<5!)X:U&VM](>#3;R\NX 1$EXD31(K2[MC -F/ Z,N<#B@#U/<!U
MIHFC9=P=2O3((Q6#?7EYJ?AG47T^R/VG][#%#< 8DVG;GW! )&>O%<18>$+Z
M2Z>%]-N$TN2\M)FBF2.+=M#^8=B' '*_6@#U0RQ[-_F*%_O9&*JZ=JEOJ<<T
MEN6*PSO;MN&/G0X/X9KA)O#-S9WZ[](:\T*"_G==.C((VNB;'5"0" P?CMNR
M*T?#^EZMI?@35+:'3TAOI)KJ2VM9I=XP[$H">_% ':B:-AE74CID&@2QE@H=
M<L,@9ZBO)K/P?J4TMW;_ &&ZATVX>R9D94@RR.WFD+&>/EVC/4BKEQX1OX_$
MLOEP7"Q?:XI;*XM8X]L$*A?DWL<H!@Y4 YS[T >FB5&)"NI(Z@'I1YL90N'4
MJ.X.17E4/AW5Y-7:YFTNZB:>&ZCOA;"*%7W#Y0C Y;U!;I75>#-.N+;2+RTN
M=/%O;%]L(DA6)Y5V@$NBDJ#GC(Z]<4 =%9:E:7]E'>VUPCV\@RKYP#^=6P0>
ME>7Z?X=DL=,TF*Y\,R36ED98[NRC5#YLAQLF"YPX !'.",^U=IX1L;O3_#\=
MO>(8G\QVC@+[S!&6)6/=WP,"@#=HHHH @_Y?1_US_K4]0?\ +Z/^N?\ 6IZ
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MP*"NQ<'&W:>0<<U>OI]1BFNE,^K1ZTAA&D6\ ?R'3:GW@!L/.[=NZ"O4L"C
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M/\: +5%5?)N_^?I?^_0_QH\F[_Y^E_[]#_&@"U157R;O_GZ7_OT/\:/)N_\
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M>(#>.6 ZBL>WN'ECT^VTS4=-A-SJ*QW,NBV_E_N_+8X.[/.1UI%'HK(LB,C
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MW54YQL8MU..XXKCO&/CK4+3XDSW$&I7T6CZ?<16[M'GRE=06DC* ?.S= >*
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M*@63'N/PXR.*[^@!GEJ&)P,GOB@1*&+!1N/4XY-/HH :% QP.*=110 4444
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M@L8M02QA+P,3(=N2=P.,G/ QTYK0L_'6C785MUQ!"\4DT4T\)1)%C^_M/?%
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MMQ_W]:C[$G_/6X_[^M0!9HJM]B3_ )ZW'_?UJ/L2?\];C_OZU %FBJWV)/\
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MQ(LL]KY0+,PQN ?J Q4$C'K4T?A.**RMK;[6Y$&HR7X.P<ERYV_3Y_TKIZ*
M..'@6/8D'V^0VS::NGW$?EC,BJ6*L#_"06/K2W/@V?4HY?[5U=KJ8PBWB98%
M0(@=6)(!Y)V@'^5=A10 @%+110 4444 0?\ +Z/^N?\ 6IZ@_P"7T?\ 7/\
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MI.,=^*[6XT^WNO(,\*2&!]\6?X&P1D?@2/QJ.'2+&W%H(K6-!9QF*WP/]6I
M! _ "@#D+SQ_,\J?V;!%);7$R6]O<,CR OY9DDRJ<G VC [Y]*6V\6>(=2>&
MVMM.M+>Y^SS2RFZ#A28W"C:.#A@<\]*Z4^&M'_LM=-73XEM%D,BQIE=KDY+
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MA3_Y^+\?\@]O4_Y]O[T=;S1S7)?V'XA_Z&-_^_8H_L/Q#_T,<G_?L4>PI_\
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MX'^%']F^)_\ H8!_WX'^%'U>/\Z_'_(/;U/^?;_#_,Z[)HR:Y'^S?$__ $,
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M ,!Q1_9'BK_H94_\!Q1[*/\ .OQ_R#VT_P#GV_P_S.OS1FN0_LCQ5_T,J?\
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M/^1_A_F=IFC-<7_8_BG_ *&0_P#?D4?V/XH_Z&1O^_(H]C'^=?C_ )![:?\
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M% #=@]*-@]*=10 W8/2C8/2G44 -V"C8*=10 W;13J* "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !H > # 2(  A$! Q$!_\0
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M1_0?P:U;Q%KGPS\#ZWXG,,NO:GX1T:^U&:,$(U_?:9:3W!52JD!YG<KP.!C
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M,\I<3<%Y5FM-*6(52,<5.-G'ZQ&*C4NTU9\JBFFMTGJ]I[@QO HD ="<NO\
ML#!/&0,9!..G'3-8&L:EIVEZ;>ZGJUY'IVFV5M)J6H7L[K'#8V%E ]P\]R[G
M8L*1+YKD]%4D]!6C?F8VRB%"SLI5 0?O\==N3@CT'8]:_G(_X+P?\%!3\'?A
MY%^RW\*_$:P?$_XFZ=+:>.+NQEC:]\&>$-6M!9+)=(-YM)=2CGV0OL\U$^=<
M[B:\WA7A3$\9Y_1X>P\)KZQ5IQJUU&3AA<.YJ57$U91ORTX1A9MW]ZI%<KNV
MO3XLXHH\*<-_VU4J4HU*=*56E2G))U:D8)1A&+5W)RFK*RVWNT?EC_P4:_X*
M_P#QW^(G[16O:;^S#\1=;\!_"7X?7EWX;AN]+O+9'\2>([&2*-M7L8%DD5K5
MC'(EO*K'S=\BCF,U[]_P1%_;$_:F^-/[9=QX*^,OQC\7_$?PR/AYX@U>?2-<
MF$EA9:S '^Q7+HAV"1)'V29^;<4XQ@5_-Q:V$.F6TE_8Z;+_ &+8!--T:ZU"
M.3RYM2CD9;^<W4B!K^ZCN9$GE>1F'E3H58Y*K^WW_!ON[0?M\3Q2+/'>7GPL
M\1/?W$9!M+F4RA@_D-DH&V##KC(V85<5_=G''A[PEPQX58R&!P2>.PG#]=5J
M_+"3J5XT5>K"?+*:BIIN34XZO5-ZG\2\'<6Y]Q)XKX/$8J-2AAYYK"HH5$X7
M<JD?9.S=FI)OET:MV/[DVV6^YRG)^9RHX.3EL#/U X/?H16G%_J8?HO_ *,2
MLYSYPD0@#<[QK@=P22 .F/?!.<^V-2-&6.-3C*@ X.>C@^@[#\^*_P Z\)4A
M5C*<&K.RY.L5&51+FZ:]#^_)>W>(G[5\R32C;I[L;W?FDK"IU/T_J*EJ-5(/
M([>WM4E=CW_KNS9[_P!=V%%%%(04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 53*Y48.<9/UR>>IXQWJY6"6E,<ZH0
M61@B <>W)^N.>!GGJ<UAB7)4*DH6YX14HMZ*R:YM>[NK+KW(MSUJ-%KW:KDG
M?:Z2<;OHM]?4^%?^"GWQ#7X;?L)_M$>)!.UK++X$UK0;:1)!'(TNKV-U8KY3
M;&^8[V?8!\X3R]Z[RR_YR/AC2[C7;WP-X>@@>ZN_$_B71]$EW*!.YN]2MT9V
MMBS/\Z*78"1L[MI9<!F_ME_X.'OB;+X2_8KA\(+(UJ/B!X@MM+FD1R)HA:J9
M&:.(,#(S&;.0K?+GUY_BZT?4-4\.7NBZQH3747BS1;J/5]'O;"W^TWL/V4QF
M.ZCMPDDIE#(&CVIE74EB"0*_OSZ+V5SP_AMQ-F<XSH_VEC8N&(C9?N\/AY4)
MJ;DX<KC4KJRO)./,[JUC^*O'_%K'<?</8"$56AE5;!U*M.=N1.C.I.IR.\^9
MVY;*T>9Z'^G'\"_"5EX%^"OPH\)VL:6T/AWP#X3TTP\(%:VT2P$R8+#:1-O'
M4]6QGK7;>)O%_AOP]I5SJFN>(M(T#3;.*6>?5=0O+:*UMH(CB6243S0$F(\E
M49P<9# L /\ .^D_X*F?\%%-)@L);[]HOXL:7X?\I;&TB\0Z/+;196,0Q1PD
M0(6@52B1/)M  8[NHKYY^*G[3?[1'Q?N9?\ A</QR\<>(+&6"6YU&P;7[^'2
M(]/5S)*D<=C<>0\E[DE8P&)&!MXS7Y5@_HQ9YF>)KYGG'$6#PM">*Q%>C#!5
M'CJ\J=?$XFK'V<8^RO>-6/ON[4N9.,FKO[O$?2!RS*9X/+,KR*&*E&A2IU?;
MR>'C"=*E"$E6O"4(2O!^[>6CB[N[/TQ_X+2_MR^#OVQOC7X9\%_"*^35_AQ\
M&KBZC;Q-;Y-IK^LS+MU.*W8QHMQ:%'*BZCED*CYC#UQN?\$$_@!XE^*?[9-U
M\;QI[0^ /@OIB65S>/!*BKXFFE,L$$5XZQV\J6D<[0,8?.:7R]["#.P;7[#?
M_!#7QO\ M/\ A?PI\4_'GQ9\(>&O@UJ4PU&Q\.>"[M;[Q+%923)]HL]0O5+6
M,4]Q!YD;AG+$D$ "O[ _V<OV:_@_^R_\,=!^%'PB\-6'A_PKIWF+*(H(8[S5
M[MANN-1U*YB1?ML]S*7D>29BP+#8 *][CGQ(X%X)\,:7AKP>L7CLSG1J87-J
MU2G44,)0Q'LH5)PJ3JIU*D5)>Y[*/QW=E9/@X-X%XLXKX]GQ_GJA1RREA5_9
M_)"$?K&*IR<HJ45&\*5E-N:G)JUDKNZ]^698XV#*&"K'OD7Y=TI9QC!# X01
MMD''S$9K^0S_ (.3?B4]Y\0/@!\+ED(M]-T[4]<U*!7\Q6GO4@>S:2$(@C$1
M<$$O(66/(";CC^NY(2?D5L+C;&K?,I\IE?+>K%1@-@?+M Z$U_!'_P %P_B2
M/B'_ ,%"_'&DVA>?3_ _AG2_#4BM+NAAN[1I()Y8U)94ED\N,-MQSU7KC\W^
MC;ET<7XL4:LY4Z5'**.(Q="K4@ITX5\10A"*FN5J$)5*K<Y:\J3T>S_1/&[,
MJ&!\/\1"K%3IXMT<'[&I4=+VG,JT91ON[N"M'7FO>W?TC_@@W;>!M,_:Q\:?
M$;Q[XGTOPXGA#X<7FC:>VLWMM864UQ+.9O/AEN9$4- LA0J%D+@;A(A&ROZ^
M/%G[9'[+'@329]9\2?'3X>Z586T4LDTLVM6K21^4CNR[(II<MM5L8/+ #'/'
M\$7[./\ P3U_:X_;!\%7GC_X!:!%=^%]$U+^PKF[D\20Z.-2NF1)+B-Q]IMG
MGBMUD7>C'(  R<&O;?&7_!%3_@I#HUA+J%[\'(_$>EV"R&ZT_2_&=A=W<^U6
MR]M%?WTD+/P542KL+$ DDX/[/XH>'OAMQQQ1.MQ7XGPP.-H8?!8+%Y9@HT94
M57PV(Q,W2HU7B:$N2<:M).2IP=VUR/2_XUP%Q7QIPQDV&PW#7AS#%X)X6$HX
M^&(K0E04HS]]P6'Y*O.I-I.3MRO57/K'_@L%_P %7?!G[6.A_P#"@/@;_:US
M\*[?5H)O&_C"XBC@@\3BQFC*V>EIN 9)'3$,S7.&56;R_E57^=/^"0'[$?C/
M]I[]I3P;\2CX8OM*^!OPCU.PU_4_&-U;S6[ZKXFTSSUL]&MWFV*/.CMG\Z=!
M=)'Y:CRY ^Y/SLUWPA\0OV:O'?A6R^-GPIU30-0TC58;A/!?BO2)8_"FN);7
M,<OV/6;I(2+FWG"[6>S;RR"Y60$ '^J;_@G_ /\ !</]G37)/#7P%^)WPZT?
M]FW7I9[;2_#]QH>D1V?PZU"2&,Q>8+^.&)DGD9K0^;?1@N9UV,X23;ZO%^&Q
MO"'APL@\*,GEFF45,/5IYCF.#K+%8B2G3BJ]:MRJ53FG&,&Z:E:F[6;32./A
MJO\ VKQW#B?CO-99-F6 KQCEN7UL/&UZTY17LW*4/XCG*-TFWR;=3^E:W*;'
MC6-HX?*58@Z[2RA%5'!SD@H  "%S@D@5\!_\%./@!JO[2'[%_P 7/AIH4$=U
MKYT9O$&AV\B&83WVBXOH!'$NTM*&5HO*WGLP))V5]V:9J-MJEK;:A8W:W^FW
M\,5S:W\;QRPWEO<*KQW%M-&[1RVTJ%6BD! VYXXR=([5=XAP'8X4A6&2@0_*
MX92K 9<8P6ZX!P?X:RK&XK)\UPN)I-_7\MK_ %QPJZ2I1<ZEXR6K52,G44X/
M6-[<R:<3^Q<VPM#,<JEEU>5\'FV&I4(5812=2I)<RE4C'2G&2DG\4_FW<_RP
M?"6N^+?!7BKPYXPT^1M-\=_"W7;.]B\Q);9KC5-,N(?M%GY+*LEK*K0"1'99
M5E/[LB/B2O[]/^"=7_!3'X-_MN?#[PSIT>KP>%OC%8Z';1^*? .JWD$.J)>P
MD6PU"!)8[%;A=158Y8H8$D<!Q\[Y!K\[O^"I7_!%>W^+VH:Y^T%^R9I.FZ7\
M5)TDE\0_#:98]*T#Q3:RK)=7E_IJ1F 6VL3RHL<)NQ'%\S GIC^3;4(?B9\"
M/B(FZ;Q?\"_BUX"NX49+E+[2=3MM5L)U:WFTNXM<_P!J:<2H>.4RRQ1JT8(9
M37]P9EA^"_I$95A,;3QL,AXDP>$J4Z?M*D>;"XNTITI5</*<O;4&U*,M(J:D
MG3ES*Z_C3"YKQ3X(YGCLO> GG7#V-Q=.=1NBZ=/$X64E&I".)4/W,VG&2:NX
MJ.N^O^I%;;C\CX4( QE=P"K'=\K(,] I(828/;.,U;$\)(1&#$$+G=U(ZG(#
M8R>H'/3DBOY//^"=G_!>&>2?0_@Q^VJ!I%U=&UT_P]\6GFEN(=10+*AN/$+H
MKM'+*9+,K.R+O+3EP/+!;^I#P]X@T#Q/I&EZ[X<U6TU;0==@M+O0]:TVXCO+
M6]@O(EFMYT>$G,4T9!3)!5N#@BOXZXOX&XDX*S.=#-\'5K4*CK+"YM4ISI83
M$4Z3L_9.5.*3J17-"#]^R>LDG)_UIPAQIPUQ5@H2R[%87#XFG2A+$992K4ZL
MJ$ZD8M*5134I2BW9VA&[T>NAV5R(U>,E2[  ,N[:"?4G!Q@YSP1R#D=^(\9>
M,-%\ ^#_ !#XTUQS#IGA70]2U^^>20(1!IT,\Y0JP.UI!"P4YX8CY6YKK(S&
MTDSL9=D!9&0@EF*D D'H03N(Z]?7)K\(O^"^?[4(^"G[*MG\*O#FJM;_ !#^
M-6J1Z);BWN&@O8?#UI!=/JLTJ0NLB13DQ('9@I!92I!KEX3R!\5\09-D&&I5
M>?,L;25>>'@Y5/JU&<9XAQ44FTH/572=UW'Q=G5;AK(<YSZ,H\V6X.K*G2E*
MRJ*K&2=T[+FBXQY=[Z]'K_(%^UU\<]5_::_:3^-WQMNS<7UWX\\7'1/ <4I\
M]K;1;8IH^D1VV1'N\F=MIV0Q!BV3MK]Z/VKO^"?P^%O_  1O^%.NOH>GP^/O
MA[>:7\2O&VH06O\ Q,;BTUJUC5[23$S.J%0CFX9I1"491;OYI,?Y%?\ !+K]
MFF?]IK]LSX.>"O[/BU'PIX$NK?QIXUN9(WN+.*STN\%Y)9W!*F-GN2D6T,#F
M57;^/C^^O]H;X5:7\6_V?/B;\(9+:%=(U[P)=Z/;1>6GE*D-C-]DB1#&P_=2
MVZ!2$.T/&0" :_J[Q@XR7!F8>'G!638RK@:&45\L>+J4FX3GAJTX4:=+$J,T
M^=.%=U:4[J"2;YKIQ_E[PLX2EQ9@^/>,LWHK&O-L!CIY=2JKF5"I3IU9WIQE
M%J$DYJW*Y7O:^Y_$#_P14^.A^#7[??P^L[R\DL=$^,VEW?A;5X9)/*AENDTV
M>XTMW&V19F2210J,(23GYUQM/]_ZW(\F1\;%)W <*",\=B!P <<Y'?G _P M
M_2]3UCX&?&32M=3[1I^O_!/XRV]I+!('CNM^D:VUI='DQN(&TV,NR@HK AB<
M<5_I?_"CX@Z7X^^"O@+XB37\$.G^)/!FCZ]<WC7,8MH%NM-M9Y99KMW\N-;<
MR#S2[?>!+$ 9'RGTG\EC7XDR+/,/!*EF&3X2BL335U7KJA";E>,4I7YI6DI-
MMII+2Y]-]&O-E2R#-LEQN)J0AE>)KX_%\R]W#X>5:O!4Y2E.-JZ44I47&/*G
M&]1IZ>6?MI?M5^&OV0_V>/&'QB\5LLTNDV,EIHNFI,D=S?Z_=VERVGVT0:.0
MR&&:/S+E8HY&6)')ZX'^>U<I\</VY/VG4M!/_P )9\6OC;XKLP]X#<RHWAB_
MN(T>;3F:21K>Q\.6+)% [I"DDT+.H@WD)]V_\%??V_'_ &R_CM+X8\#:W</\
M!O@YJ5]IVD6AGN#8>*/%MC<M;W&I0643I]N^WP,T44C1MMW[1G.*_;'_ ((3
M_L R?"'X=Q?M7?%;PS!;?%/XG6,\W@G3[^UBDO\ PAX#>2YCL,^:CFSEOX6\
M^&&/RGAB*;PQ"D^KPAA,N\'?#+&\4YQ02XNSC$5*648>LE/$*A[&JHPQ"FX2
MP\U-N4DHU%:',Y-J)P<4XK'^*GB-'AW"U6N%\%6H>VK8:;E2=+FO4FG!.$N9
MJFDN9*UE>_,?EW_P65_9B\)?LG?#']B7X3^$-/A6+2]!\1VWC;Q T*Q7WB'5
MH;.RS=WA1I UP9XKB0N;B=E4QH6;"O7.?\&_3SC]OO45\PO!:_#;6K:)V!WL
MMO#DOR3@3-$2%RP0R8WN5RWW#_P<T((W_945'8H]QX\)7<"2P@TQ"6( SD 8
MSD;M[#[Q%?$W_!OF!)^WY?HW*M\.?$ (P.T-P>N,Y)ZGKV&*^^RO&8S.?HXY
MGGV9UYXG%8S+N(*^)G5FZDJ:52K]7ITG+XH+GE%I<JA&,$KI(^6Q>64,O\:<
MJRC!PCAXY;C\LPUZ7NJNYQA*$YVMJU%N;=[2?5L_N;10Y5E)&ZX<J#G@,,CO
MR>?3DD=C@[-9;@*>,CGS/HS8S^ [5I(25R>N3^A(_I7\#4:=.G3A*GHJD>?6
MRT<IN*]5=W\^Y_;<:LJKJ)Q25.I*FI+>4HJ'.VO5JSN[KHK#J***IS2=K-^E
MNOS*"BBBJ3NDUU ****8!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%,,B D%AD<&IYHK2_Y_Y /HIGF)_>%'F)_>%'-%Z7_/_(!]%,\Q/[PH
M\Q/[PJ@'UDRJ@9<X17RTFT=2IW;CU)S^8'TK6!R,CH>162%"AAR RXSG)R0P
M!'';.<<'.#@8K&O%3I3I\UIS2C&-FW*\HIK3HKJ_D3)J$55;LZ<TU\U/KTV7
MZM(_D6_X.3_B1%J?B[X#?"4F5H=-EO?%]V@=_+E2X7R[8O&3L;RMH*D@[0%Q
MT(/PI_P0T^$VB?&+]N>[OO%.AVNMZ1X4\#7UV^G:G MY80-/+*EO<"UD22'S
M9C:R$L1N_=C:<DT[_@N=\2+?Q_\ \%"?$.A6S%[7P!X-\/>'94!1B]_Y-M/<
MS?*3M+>9@*V,!1DG%?H#_P &T?P],^N?M/?%:<@N'\'^%],W*P2.*&WU/[45
M8@*P\RS$;8R5:V((Z&O[SJT\1P7]&RAC*2K82MF."@XSI8J5!QGB?8OVG)"+
ME.4I5&W:4&[+WERZ?Q3AJ6&XJ\<Z^'QDW7HX;&5W*AR<ZE"#G9.3DDMFFN5V
M2ZW/Z+?&G[*/[,_CC3-1T+Q;\%? VM6=S ;2623P]I\=Q%!-%AGM9?L9\B1/
M,^5P,AL$'@5_'-_P5R_X)CV_[$?BB'XI?"2WO=0_9S\6RQ-=:3>XO)/!OBB6
MZGDMX[QV1!/HS1&%%C9 K*N#C(%?W7KDX:6(M/MCWJ@/WEBB4GN<YSCG(( ]
M*\A^/7P,\#?M%_"OQ;\)_'^FP:CX=\8Z9-IE[:WL G%M+)A8KZ"-B 6@)W=1
MT(X!.?Y>\-O%+/\ @SBK YQC<;CLQRU14JN!QV85:N'K1E=<U-5%65%P]V2C
MRU%:,K+FDF?OOB'X:9'Q9PI7RS)\JP>6YA!\E+'X3#PCBHJ-U:4HJC*HWJG)
MS6\6]$V?Q)_\$=OV\]7_ &3_ -HS3/A?XSULW/P6^,LPTC5+34[\RZ/X*\2L
MUHFEQ:;NE:%(IGDE,L<,8W<GJ#7]WT%Y%>0VMS:!7MYD@N-.:V;]W=07$$<\
M3JP.#'LDY!SDD$9&,?YF?[3O[.OC']EWXW>/OV=?&RW#'P?K#ZKX>UXF4SW.
MC6VH+/X;U>&658]US<,!+=R1YV ;@>X_L;_X(B?MQVO[4/[/EE\*O&>HR77Q
MB^"D/]D:X\KEVU71XI)/[(NTW/YC>59F)-P!5@HVL",-^O\ TB.!:>=Y/@O%
M;A_#83ZGF6,AA,5#*Z$*%!44X25>7LYSBH1A9RBX03BXVFG%'YWX(<78O*<U
MQ?ASQ%C\1BL9E,75HNK*5)\]IOE5%^T=1RUBH^VU:/V^GN4M+>ZNYG1K>SMI
M[J9\?/$\:;IU))[1_=S@ %O7C_-%_;/^( ^(O[7/[4/CGSFEMV^*?C/3(8W8
MM*^E:??W,$=QELG-M*T/D_W-@*XP*_T6/V@/&/\ PKSX&_%OQ:[ #0O OB2]
M0Y "SMILL<1+-@ AI8\8R6WX&<G'^8=J6H2>)=6UN_MX&FU'Q[XUUAY%(R9)
M=;UB:(J@ +$M*PC"X&6X^Z.>OZ+&#IQS'CG,XN@JU#+'"C4Q$$Z34:7-546[
M)5(-04>6][->[9WX/I(8V6,RSA7 *EBJ*Q.:4:E6C"FY^S]G7FJ<I-.',JBG
M?514==6S^]/_ ((9_#.W^'O_  3Y^&PDMX[:[\3ZQXB\0W<B1JDIAOGLQ#+(
MZ@,THBCV[VR54]P#G]@&B(=,SRR ,I\HL65R">"I.#ZG(XSUR<#YU_8Z^'T?
MPQ_9=^"/@M(C&VE^ O#AN4"D8N;BPLI;@A3@J "0 >0%.,=OH^,EPRJA!658
M\E2,Q,2"Y!'8 'KP*_EGC/%8/-^+LXKXK%5GB8YOC_8SH.O3A%K$.+3Y6X3B
M_9+D3^%+1^\[?T1PI@Z^7\.9-0I4(/#+*L&J[Y:5*;<J,6G)/G?VG=7W=F?-
M_P"TE^RA\&?VH_ >N^ _BSX4TK6;+6]+N=,AU>.QMAK^AM<QR117.D:H('NK
M*YADDW(4<*2"2!C-?YZG[97[*^K_ +)W[1'C7]GOQ'>OJ6EZ5>+?^ ]2O+F.
M9DTR296TFX#+^^:[LU$?VZ5RC$R0;<?,1_I(^+O&WA'P%X>U/Q-XJUS3O#6@
M:);7&I:IJ.J75O:PI:VD$TD[AKB2,9VH=C#+,?D4$M@?YYO_  4W_:2\._M7
M?MA?%;XI^$DD;P;IL5EX9\+M<21AM83PZ(GOM1@928VM;A400.A(?Y\D%03_
M %+]%O&\78SB3,<@C.K/A3%Y7B8XVMBJLHX;!NG1G+VM-58NG4GB(I*5.,Z?
M(U&5V[W_ )V^D1DO"_\ 8>&S'!1E_K%0S'#58>QK?O\ E56,H.<:>KBI*2AH
MDUS*]M#^G'_@@A^UEXK^.7[,^K?#3XCZDVJ>,?A!J1T'3;Z9YG?4/#5K;06]
MG,'G>1R8FB*+SMQA5 7@_O7/)%$1.T3$D$@X(QDD#'.<'@\=<XY'%?S,?\&W
MWPA\2:;\)OB9\;]7LWTW0/B)K%M#X5L91*T\5K$T;.Y=U >%FE5EVD@!]XX.
M:_9OQ#^W-^S'X:^/4_[,WBCXBZ9HGQ873H]:32KZ>WAMHH;MYE@$5[/<1B&Z
MD$,C"+"Y4#IFOQ#Q(R2G+CWBK"<-X:IBZM.MBHS]C>HTXS_>->RA)RCS>_=)
M_$TD^O[#X>YW47!V08WBNHJ$6J+I5*\^5V]DE%OFY6FE':]]#[),/VF-Y-XB
M#*!$A4M&&7[I9!AF"D9QGGZ&OSU_;<_X)J?L_P#[;'AFY3QOH,.C_$:TTR>/
MPQ\1-#CB@UC3KPP3+:272M$S7UK#(0QMG(/ VL64"OT.L-0L[RW2:PN[2[@<
M*R36EQ%<QNKGY2CQ.R%6QP22,=,XJ>ZWR1*(>)'\L*PY/WUW$$ E"%#'>H.T
M+GG%?G^59OFO#]>AC<MQ6(R[&>U4L1+$5*V%JRA%<TJ?L+23<VHITW=;Z)I2
M7V>;93E/$F'KX3&86AC<&J35&"ITI2BW97C4YFW*,;M;;;O9_P":A^V+^QA\
M3/V*/BI<_";XPVC:K97_ )^I?#WQS'YLNF^*M%B*2)!+>#*6UVD?EK<6LF%0
MSJJ8R^?VI_X(&_MY^,-+^*(_8K^)WB)M5T&]T>]USX;WNKW1DGTB:TA^V1:%
M;S&61)+?[*BP01!49=L8(&T"OI3_ (.//'/PYMO@Q\*_ YN]*U/XMR>+)7T3
M2XI8)]9TW0Y(;9]4U2257:X@BE LVB:1%#&WFY! !_"/_@E5X5UGQ)_P43_9
MXLM BEU!_#>J3ZMK>JQ!VE.CII$IN4N=JG:7.TF:7:'SR <5_>$,;B/%+P)>
M*XEPL:6*R7 XG%T<;*C%1G3P,*_[R.(J1HRYVYPE"G:HJMI:M*Y_%RRW"\!>
M,WU3AW$3>$QN/PM/%X%5Y>TINM.GS7HQ=1<D$FI/W>6ZND?Z(0NO)\[SI@%0
M![AF14=$<@;P!]TG/7&!@=>M?Y^7_!7W]J/_ (:3_;,\7S:5J"S^'O@U'-X0
MT2&!Y;BTF@AYO]1";F$5Q.HP\T05F# <C&?[(_\ @I%^TII'[+'[)'Q3^)<E
MZEKKT^DWNB^&%?RUEGUK5K4:=;NJR$-.EK!MD=T#.%48R:_SW/A!\-?$WQO^
M*G@;X96_VB?Q9\5O'5D=<U)#),R:=JDUOJ&J Q1@L1#'.7D/0+GG/7\V^C'D
M6'P7]O>(F+@EA,EP]19;6JTU&FIN&->)Y)3;O>5*C&,DM+/1[GZ7](7B2O5Q
M.3<'8"M*C5SU_5JD:3]K*=_J2YIT8\KC[)59>[)KFYW[RMK_ %Q_\&[_ .R[
M!X$^!'B?]HC7])DL?$OQ>U>ZMM(AN(W:XLO#>F7$L,!CFD7?'%>LAE*!\8).
M <FOZ)PDBJ-X1X#]HAD7'S"$HBD,.F?NCIS@<<UYQ\%?A?H_P9^$7PZ^%N@H
ML>E^!/">B^'+=4'#G3[**-Y3SP9>9@"<X<# XQZK-*%10C NR%<KSM V,1_L
M_=P!W/Y5_.O'>?UN+N*<WSW$XB<E7S.57#.4G)4J6'K5/9Q@VH^ZXNZLH\O/
MM?;]TX'X?P_"W"^59)"$%4I9>J>*O34'7J8BC'GJSAS/D;;=Z=Y6<;<UGI_G
MH?\ !8'X&0_"3]NOXU:8=--CH/Q)FG\<Z+)$B10I-J<D=HPB2,!1YSS_ #LH
M#.')/+8KW>?_ (*J>(O"/_!,3PU^RCX+UNXMOCK=WFI>'/$&I-'/<-H/PX>6
MWL8$CE$PFCO]0BB>.U(8!8Q@*,@5^C?_  <E? ]+OP[\&/VA]/B$0T34+SPI
MX@D93E8;LBXT\2.,I$'O B1Y8;I'Q@YK^7[X7?"WQK\=?B5X6^$WP_L[:X\9
M_$/5++1;;5VBDN'6&\0GSKN.%7D6QTMB5NI& "$')(K^[."*60>(/A7PAQ!Q
M)1HXO!\&9AAX9C.MB(QGB5AZ;IO"SG**<(I-R=1JLGS)NG[B/XYXPPV:\!>(
M7$7#N1RJQH\8X2MBE2I4W"*C7GSJ2E%S2MRV4?<M9ZKF9^D'_!(;]@A_VR?V
MAH-5\7Z5,OP-^#?V35=4U00R20>+?$$TEK>6^EW$UP&C9IVC>=I)%9PRLY)(
M(/\ ?3I6F:;H=E9Z)I=K':V&F:=!8V<$2@106EK L$4*@<*H5 -HX.T9&0:^
M6?V*?V3_  7^QS\"/"/P>\(6UOYVB:?$/$&KQ1E9]=UUB!>ZC>7&0999R =C
M=<;LCM]9E!!&S*<LY.<#/+*X/?O@@#CKZ&OXY\5_$-\?\58CV=2<<JPD9/+Z
M$96HPFE/FJ\D8PA>H^9I6]VG&,79R=OZB\)N!:/!G#%/Z\X2S6ORQKXNM!0G
M;GA;FFYU)12M[WO:MZ[(_E#_ .#FH 7/[*H P/,\=' Z<I8$\>YKXE_X-\9$
M7]OZ]5\+GX<^(]I[L?L\_!YZ#MT[\CK7VU_P<V[#)^RH5969IO'8?!R-PBL0
M<C'?/)S@X/(P2/BO_@WSFDC_ &[_ !*$\L0GX3^(5E=RH\J99&EMIE!Z[9(^
M3CCLQ.,?U'PW>'T5<8K*4993G,.922EK6J)/DL[WWWM8_ L[FX?2$E=T9)9M
MD]2/)6YI22IQ3O'ET7O:N[M\[K^Y6278Z+-\HE=@A']WJHSP0,^OH>.F+)GN
M!- D<*&)C/YC-*49 K@ K'@ASCL3WZ@Y-?F!_P $U/B=\3/B5HW[51^(?B)O
M$&H>$OVF/$WAGP[=3EB+#P[;:5HJ6EO$<9V11%@NWTQC(%2_M=_$[QSX2_:]
M_88\'>&/$9TGPU\0-:\;VOBC3X'R-5AL+&TDTX!?X@J2.23P%''&37\$2<O9
MX>$5\&'IMO\ FYV^G2VW4_LR%*:=107/SU9U>W+SJ#Y>M[)-7[;GZ<+J _>O
M(H2*'B0\Y!_4\' QC^+Z4>=,QC+C#DM*T".RRM" ?+*)GYSU$J9R&V9QD9\A
M^.VN7?AOX.?%GQ)IMX+"_P##_@/Q9J,-S%'YDL=QI^F7=Q9S[>,-',BS*5.1
MM'J37X9_L^_ _P")/CO]C'PW^TOJ_P"W9XL\*>/KCPYXL\=-KFJ7>GRZ)IMY
M97^JRV>GWME/J$+RV,0M(X)+8CS)0ZJL;,%#*+FEK&_6][:>G_!*M):25GVW
MT>W1=#^BRVNQ-!'<>7<JKJ3ME7:RX9N&7 R0%QG'(YQFIEDF9_E1?)8$LYD^
M=/48Y"D<\<8[GBOSZ_X)K_M$_$']I_\ 93\"_$KXGV$#^,X);[0[GQ-:VS:=
MIWCLZ>K64?BZPLV1?LD.M*5E6W&Y%"AE<[AC[\LCB0E1GS,M)M8.%?Y0<M@9
MP<\\=\\\5U0^&/33;[P-2BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!C9SP">/?W]"*B)&3D@')R,XYSS^M3X'O^9'\C5$R/EAB, ENLF"
M,D]1C@\UBZ=&4I.3E=O6T^O73ET^]D-5&WRM6]$]/.[)Z7:QQ@=#GGCL1U_&
MH?,.49#O1F )& 0,\D#!SC\/Y9;]J1G" 39/HI.1CGTQV]/PSFLXJC%J2<KI
MW7O-KYIK7<:C57Q--=?=MI]Y.,DD 9(ZX((&>G)(S_0@YHPV<;?U^OIGTJ@D
MRE9))'V8.%5&Y8H.=W P/F7;UP,CMRAN$ !+2D-G 1]Q'3EL+PO^UD]#QQD[
MQJ1D[)N]KV] D[*Z\BYF8' ("@X SS@' [^E95_.EII]Y=EODM+2XN7$C%!B
M"-Y2>^!A>3V^A JX+U5RH);9D,5(?&"?1LL/<JOK@"JMRL%S;20NL<T%Q')#
M-!*P43)*K(\9*[AAU)4CIZDU7M:5&4)U8SDE)/EITI59.*E%RMRIN+26_6_D
MSEKQG7IRH)TH*I&7OU*JI*,DFH/5^\KR?,MM%=G^9Y^VQ\2H_B7^V+^TCXXN
M6OK5[[QWJ>E)*ME>SJMIIL2VT#12"%ERKP\!21C&&-?UQ?\ !O7\.&\'?L--
MXAE,DE]XX\8:M=O=SV[6]Q-;61DV&19%CE/_ !_$(7& -Q! .:_5"^_8X_9@
MU*2XN+WX'?#J6ZNI)+FYOKCP_9SS75W*Q::>XD,8::61G)9F<,>1NQP/:/"/
M@CPA\-M)M/#WA#1M$\)^&+".5H-+TV*#3[!)9@OF210HZJA;8N< !> 6;=D?
MM_&_C'/BWP]RS@G#8+&T88*-&C;ZLXJ<*"C[/X9MN3:]]N"<TDK*R9^+<)>%
M-7AGCW,.+JN/P598IU*TE/%0FHNMS\W+"2BE9-<JYVD]FU<[*)&:!9,#.-N3
MC<<*<D\$Y*C!R<D\GFH[E3M$B]N#@D'JIR,#!SQUQD\\D\<S?_$+P1HJ!-8\
M7>&]-7!;_2M9LHL8['S)5].IQT( YS7G^M?M&_ 71X'&I_%[X>:>0N\&Z\4:
M7&".0.D[L,D'HC'(Y&1BOQ".49IC,/"D\JS6HX4XQYZ.$KQC)K;EY:,K+:^^
MMS]BGFF5X3%^T_M++Z<*K<W"6-H+>3?P^TMWZ>6Y^*G_  7:_8.'[0'PD@^/
M_P -=$6X^+'PFD6_UT:;%(-0\2^"K:UN;B^L9T0,+F2*..,1JZ, 6&,!"1_*
MC^QA^U;XF_9"_:*\'?'[P=-XFTC0+76-+T[XC>$XK26"W\0^%1+':7F@SP!%
M62XM0AEDE9D*E3^\X K^^CQ5^W=^Q/86EQIGB3X\?#.XT^YMS97-H=8L[A;B
M!HBCQW$GG[94>-BC*\>"#C)R:^#]9_:I_P""+-A+>?VC;?!N:6"262=H?"4=
MVC.T861LPXAN#*0\A8,N68'!;<3_ $KP%XAY[EW F<<$9AP-Q!Q5EV(JU<-A
M84Z=6C5P\JT'3_<QK4Y0E46OLXVA=<R;3C$_G_B_@?)I<=0XSPO&F3\/5:56
MCB<1*56G6594G)RC5K4I7IP:<7.5IVLTE:6G6?\ !3W]J#PGJ/\ P3)\>_%C
MP/JT4VD?$7PWH3>&Y8&_>.^JQP22Z>RP-)(9K1O,BGC",H=XP>'!'\'GAZ\N
M-$N]!UBQTR[M]7TG4[/Q>7N+.9HY;K3ITOHXA&XQY<\LP9TQ@[,MDG-?VZ^(
M?^"J/_!('_A"HOAMJ5YX?U[P!ITK26GA6;P;+-HMJ05/^B6LDK1C#(K$JK
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M&9YXF8OB2,:E.<E"AC,53<J,N>--RKX>,ERMOFA[/3G24G=V_I?^&?@'P?\
M!CP5X9^'O@+0]/\ "?A/PWI]GH&D:%I\=G'#Y-M:06\5S--#)F6]D%L6DED&
MYVD.X[B2?X<O^"N7[,O[5%G^V;\7OC'XC^#?CBZ\ ^((;:?P5XY\)6BZE<:?
M:I/>I"YETD27T3,)%;R)5+A""VTMM/Z,C_@YZ\,2N2_[-=[;J^UFDN?$+%)9
M%^[Y(4*(V'5<-(3FL'Q#_P '-UA?O%''^S1%<:)Y+)=V>H:R+Z2>0DD2H75
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MS-?SOZ3_ ,')O[&MY;QR:AX/\<:8PVK(CJMU&I/&5EAM2) HR02!D5Z#8_\
M!Q%^P#?Q(UYJ_BO2Y&PK(VE.WEEA_$RQG=@K@%@F,D_-T'\^5?!?Q8A@5AZG
M!N;5,12<J<ZE-8!1G)/6:2QC3;;NW=WNM6?NE+Q2\/,7B_K-/C')HPFH6IU:
MF-IRIV23@X/"14>73W7;=^A]E_\ !5+X)Q_'K]A[XX>"WTF75M0T[PU-XNT:
MV@A\VY;5/#A74H4M&0/(LTB6[JBH )'VQN0&+#\N_P#@@W_P3YU'X7?#^?\
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M$_O&$<I $'_"7:I'I2%')$*W9B:0Q,F<S1@,H)V[N#G\2=>_X.)_VP+T&W\
M_LV:!I2M(51+/PQKD\B;\&+SD6UN0IPDFTD1[LOC?M^3S35?^"VG_!5#Q2X3
MP]X"DT5GDD!C@\ ZO*S;P-B1K+I6X[2PP,D>A&37V&!\'LT454GEG!N BK+V
M>:\1U:N(5].65E%+;71W:/CL3XGX&5XPS7C3'R6KJY7P_&EAVENU%W[KKL_D
M_P!R+SXZ?\%J?&",OAS]F'X*^ K60M(CZAXWF:?83E58FV8*X! ;:V 0><9-
M<+K'PX_X+W>*TPGQ7_9T^'T<BDDJ5GFC4Y4J@.E8\X9!C+9 (YP.*_#+5O\
M@H3_ ,%J?&4,BVT'Q1T^-B65=$^'PPJ$_*%\W2O.V\@#S27P.3P*X>?XA_\
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M2%8Y&:^$S+PN\1<J?/F'#&-I1JI1@H-63[Q46W=VVLGT1]=A?$C@[%VE#/\
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M&6)CN2:*:"179)'\JY3HXB,G4J^R:5ER-J:OMR*V]]EYOM8R4)J2NI6OKO\
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M(1&2,NW 1B2NS@'."I&17\4?_!'7XE:9JO[;GA_QM^Q3^T'\</'_ .P3X=^
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ML.>V<D?B,\_2DVG_ &/^^#_\7110 H7UVGTP"OY_,<U7N&9% C7ER0QYX4
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MQHV+Z?J?\:**ZXQ459;7N(4 #H,=Z6BBJ 3 ]_S/^-&![_F?\:**Q]A3[/\
M#_( *@]<GZD_XTFQ?3]3_C1151IQB[J]]5TZ_( V+Z?J?\:<1D$'H>#116@#
M=B^GZG_&D**>PQSD$$YR,>N!^1_"BBLY4XR=W>^G;I\@&B%%;*J ,?= QDYS
2DG^G3@>E2T45:2BDELE9 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>mdbh-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6JebP9z5Z86ekhvWBybUkK/yUnor+4+CN+kpj2wVMA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:MDBH="http://mdb.com/20251231" elementFormDefault="qualified" targetNamespace="http://mdb.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://mdb.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement -  Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement -  Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/StatementsOfChangesInEquity" id="StatementsOfChangesInEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" id="StatementsOfCashFlowsSupplementalDisclosures">
          <link:definition>00000008 - Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
          <link:definition>999016 - Disclosure - Organization and Description of Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999017 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999018 - Disclosure - Segment Reporting</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EquityAndNon-controllingInterests" id="EquityAndNon-controllingInterests">
          <link:definition>999019 - Disclosure - Equity and Non-Controlling Interests</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/Deconsolidation" id="Deconsolidation">
          <link:definition>999020 - Disclosure - Deconsolidation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EquityMethodInvestment" id="EquityMethodInvestment">
          <link:definition>999021 - Disclosure - Equity Method Investment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999022 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EarningsPerShare" id="EarningsPerShare">
          <link:definition>999023 - Disclosure - Earnings Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999024 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999025 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
          <link:definition>999026 - Disclosure - Employee Benefit Plans</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" id="ExclusiveLicenseAgreementMdbMinnesotaOne">
          <link:definition>999027 - Disclosure - Exclusive License Agreement (MDB Minnesota One)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/Leases" id="Leases">
          <link:definition>999028 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999029 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999030 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999031 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999032 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999033 - Disclosure - Segment Reporting (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsTables" id="EquityAndNon-controllingInterestsTables">
          <link:definition>999034 - Disclosure - Equity and Non-Controlling Interests (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/DeconsolidationTables" id="DeconsolidationTables">
          <link:definition>999035 - Disclosure - Deconsolidation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EquityMethodInvestmentTables" id="EquityMethodInvestmentTables">
          <link:definition>999036 - Disclosure - Equity Method Investment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999037 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
          <link:definition>999038 - Disclosure - Earnings Per Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999039 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999040 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" id="OrganizationAndDescriptionOfBusinessDetailsNarrative">
          <link:definition>999041 - Disclosure - Organization and Description of Business (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" id="ScheduleOfInvestmentSecuritiesBrokerDealerDetails">
          <link:definition>999043 - Disclosure - Schedule of Investment Securities Broker Dealer (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" id="ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails">
          <link:definition>999044 - Disclosure - Schedule of Investment Securities Non-Broker Dealer (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>999045 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" id="ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails">
          <link:definition>999046 - Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" id="ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails">
          <link:definition>999047 - Disclosure - Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
          <link:definition>999048 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999049 - Disclosure - Schedule of Property And Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" id="ScheduleOfChangesInDeferredRevenueDetails">
          <link:definition>999050 - Disclosure - Schedule of Changes in Deferred Revenue (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" id="SummaryOfGrantsReceivableActivityDetails">
          <link:definition>999051 - Disclosure - Summary of Grants Receivable Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" id="ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails">
          <link:definition>999052 - Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" id="ScheduleOfStatementOfOperationBySegmentDetails">
          <link:definition>999053 - Disclosure - Schedule of Statement of Operation by Segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
          <link:definition>999054 - Disclosure - Segment Reporting (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" id="ScheduleOfEquityAndNon-controllingInterestsDetails">
          <link:definition>999055 - Disclosure - Schedule of Equity and Non-Controlling Interests (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" id="EquityAndNon-controllingInterestsDetailsNarrative">
          <link:definition>999056 - Disclosure - Equity and Non-Controlling Interests (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/DeconsolidationDetailsNarrative" id="DeconsolidationDetailsNarrative">
          <link:definition>999057 - Disclosure - Deconsolidation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" id="ScheduleOfConsolidatedBalanceSheetDetails">
          <link:definition>999058 - Disclosure - Schedule of Consolidated Balance Sheet (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" id="ScheduleOfGainOnDeconsolidationDetails">
          <link:definition>999059 - Disclosure - Schedule of Gain on Deconsolidation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" id="ScheduleOfEquityMethodInvestmentDetails">
          <link:definition>999060 - Disclosure - Schedule of Equity Method Investment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" id="EquityMethodInvestmentDetailsNarrative">
          <link:definition>999061 - Disclosure - Equity Method Investment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" id="ScheduleOfRestrictedStockUnitActivityDetails">
          <link:definition>999062 - Disclosure - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" id="ScheduleOfTime-basedStockOptionActivityDetails">
          <link:definition>999063 - Disclosure - Schedule of Time-Based Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" id="ScheduleOfMarket-basedStockOptionActivityDetails">
          <link:definition>999064 - Disclosure - Schedule of Market-Based Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999065 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" id="ScheduleOfBasicAndFullyDilutedDetails">
          <link:definition>999066 - Disclosure - Schedule of Basic and Fully Diluted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EarningsPerShareDetailsNarrative" id="EarningsPerShareDetailsNarrative">
          <link:definition>999067 - Disclosure - Earnings Per Share (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999068 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999069 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" id="EmployeeBenefitPlansDetailsNarrative">
          <link:definition>999070 - Disclosure - Employee Benefit Plans (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" id="ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative">
          <link:definition>999071 - Disclosure - Exclusive License Agreement (MDB Minnesota One) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" id="ScheduleOfOperatingLeaseCostDetails">
          <link:definition>999072 - Disclosure - Schedule of Operating Lease Cost (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" id="ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails">
          <link:definition>999073 - Disclosure - Schedule of Future payments Due Under Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999074 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" id="ScheduleOfIncomeTaxesExpensesBenefitDetails">
          <link:definition>999075 - Disclosure - Schedule of Income Taxes Expenses (benefit) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999076 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999077 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mdb.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999078 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mdbh-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mdbh-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mdbh-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mdbh-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <element id="MDBH_MDBMinnesotaOneIncMember" name="MDBMinnesotaOneIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_MayoFoundationMember" name="MayoFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SAFEMember" name="SAFEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_BrokerDealerMember" name="BrokerDealerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_WarrantsOfPubliclyTradedCompaniesMember" name="WarrantsOfPubliclyTradedCompaniesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" name="WarrantsOfNonPubliclyTradedCompaniesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_NonBrokerDealerMember" name="NonBrokerDealerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SimpleAgreementOnFutureEquitiesMember" name="SimpleAgreementOnFutureEquitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ImpairmentMember" name="ImpairmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DevelopedSoftwareMember" name="DevelopedSoftwareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_BrokerDealerAndIntellectualPropertyServiceMember" name="BrokerDealerAndIntellectualPropertyServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_TechnologyDevelopmentMember" name="TechnologyDevelopmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_OtherSegmentsMember" name="OtherSegmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EliminationsMember" name="EliminationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_BrokerDealerIntellectualPropertyServiceMember" name="BrokerDealerIntellectualPropertyServiceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_MinnesotaOneMember" name="MinnesotaOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ExozymeTechnologiesIncMember" name="ExozymeTechnologiesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ExozymesIncMember" name="ExozymesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ExozymesMember" name="ExozymesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvizyneTechnologiesIncMember" name="InvizyneTechnologiesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_MarketBasedMember" name="MarketBasedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_TimeBasedMember" name="TimeBasedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ENDRAMember" name="ENDRAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PublicVenturesMember" name="PublicVenturesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DTCMembershipRequirementsMember" name="DTCMembershipRequirementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PhaseIIclinicalMember" name="PhaseIIclinicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PhaseIIIclinicalMember" name="PhaseIIIclinicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_NewDrugApplicationFirstMember" name="NewDrugApplicationFirstMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_NewDrugApplicationMember" name="NewDrugApplicationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_USFederalTaxMember" name="USFederalTaxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_FloridaIncomeTaxMember" name="FloridaIncomeTaxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" name="InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" name="InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PayablesToCustomersCurrentAndNonCurrent" name="PayablesToCustomersCurrentAndNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" name="UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" name="UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ImpairmentOfInvestmentSecurities" name="ImpairmentOfInvestmentSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_CompensationCosts" name="CompensationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_OperatingExpenseRelatedParty" name="OperatingExpenseRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ClearingAndOtherCharges" name="ClearingAndOtherCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_NetOperatingIncomeLoss" name="NetOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_MiscellaneousIncome" name="MiscellaneousIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GainRelatedToDilutionEvents" name="GainRelatedToDilutionEvents" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeLossFromEquityMethodInvestment" name="IncomeLossFromEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ResearchAndDevelopmentGrants" name="ResearchAndDevelopmentGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_Netincomeloss1" name="Netincomeloss1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EffectOfDeconsolidationOfSubsidiary" name="EffectOfDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" name="AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DilutionOfDeferredGrantReimbursement" name="DilutionOfDeferredGrantReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PortionOfLossFromEquityInvestment" name="PortionOfLossFromEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" name="ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeRecognizedFromWarrantsReceived" name="IncomeRecognizedFromWarrantsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ImpairmentOfInvestmentsSecurities" name="ImpairmentOfInvestmentsSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncreaseDecreaseInPayablesToNoncustomers" name="IncreaseDecreaseInPayablesToNoncustomers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PaymentsToAcquireInvestmentsSecurities" name="PaymentsToAcquireInvestmentsSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ProceedsFromInvestmentsSecurities" name="ProceedsFromInvestmentsSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PaymentForDeferredGrantReimbursement" name="PaymentForDeferredGrantReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal" name="WarrantsReceivedAsPartOfInvestmentBankingDeal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" name="RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" name="InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" name="IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DisclosureDeconsolidationAbstract" name="DisclosureDeconsolidationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeconsolidationDisclosureTextBlock" name="DeconsolidationDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" name="DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ExclusiveLicenseAgreementTextBlock" name="ExclusiveLicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeconsolidationPolicyTextBlock" name="DeconsolidationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EmergingGrowthCompanyPolicyTextBlock" name="EmergingGrowthCompanyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SegregatedCashAndDepositsPolicyTextBlock" name="SegregatedCashAndDepositsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock" name="PrepaidAndOtherCurrentAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_AccountingForResearchGrantsPolicyTextBlock" name="AccountingForResearchGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" name="PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" name="ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" name="ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GrantsReceivableActivityTableTextBlock" name="GrantsReceivableActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock" name="ScheduleOfEquityAndNonControllingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock" name="ScheduleOfGainOnDeconsolidationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_AccountingPoliciesTable" name="AccountingPoliciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="MDBH_AccountingPolicies" name="AccountingPolicies" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_CashSIPCInsuredAmount" name="CashSIPCInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_PrepaidProfessionalFees" name="PrepaidProfessionalFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GrantDrawdowns" name="GrantDrawdowns" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ResearchAndDevelopmentExpenseGross" name="ResearchAndDevelopmentExpenseGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvestmentSecuritiesAtFairValue" name="InvestmentSecuritiesAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" name="InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" name="FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized" name="ContractWithCustomerLiabilityAmountsBilledNotRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GrantCostsExpensed" name="GrantCostsExpensed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GrantsForEquipmentPurchased" name="GrantsForEquipmentPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GrantFees" name="GrantFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_GrantFundsReceived" name="GrantFundsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_RemovalOfBalanceDueToDeconsolidation" name="RemovalOfBalanceDueToDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" name="InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_RealizedInvestmentGainsLossesOne" name="RealizedInvestmentGainsLossesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EquityTable" name="EquityTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="MDBH_Equity" name="Equity" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_WeightedAverageNonControllingPercentage" name="WeightedAverageNonControllingPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DueToDeconsolidation" name="DueToDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationToNonControllingInterest" name="ShareBasedCompensationToNonControllingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_OwnershipChangeOfNoncontrollingInterest" name="OwnershipChangeOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeconsolidationAbstract" name="DeconsolidationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeconsolidationTable" name="DeconsolidationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="MDBH_ScheduleOfConsolidatedBalanceSheetAbstract" name="ScheduleOfConsolidatedBalanceSheetAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleOfConsolidatedBalanceSheetTable" name="ScheduleOfConsolidatedBalanceSheetTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="MDBH_DeferredGrantReimbursement" name="DeferredGrantReimbursement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleOfGainOnDeconsolidationAbstract" name="ScheduleOfGainOnDeconsolidationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ScheduleOfGainOnDeconsolidationTable" name="ScheduleOfGainOnDeconsolidationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="MDBH_CarryingValueOfAssets" name="CarryingValueOfAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_LessCarryingValueOfFormerInvestment" name="LessCarryingValueOfFormerInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_CarryingValueOfWarrants" name="CarryingValueOfWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" name="EquityMethodInvestmentsGainRelatedToDilutionEvents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_AveragePricePerShare" name="AveragePricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_AccruedExpenses" name="AccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="MDBH_PaymentForLicensedProducts" name="PaymentForLicensedProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_BaseRent" name="BaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_AnnualOperatingCostIncreasePercentage" name="AnnualOperatingCostIncreasePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" name="EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" name="IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" name="EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" name="IncomeTaxReconciliationEquityInEquityAwardVestingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" name="IncomeTaxReconciliationModificationOfEquityAwardsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" name="IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" name="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxAssetsInStartupExpenditures" name="DeferredTaxAssetsInStartupExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxAssetsInOrganizationalExpenditures" name="DeferredTaxAssetsInOrganizationalExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxAssetsStockCompensation" name="DeferredTaxAssetsStockCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxAssetsBonusExpense" name="DeferredTaxAssetsBonusExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxAssetsImpairmentExpense" name="DeferredTaxAssetsImpairmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MDBH_DeferredTaxLiabilitiesInvestmentSecurities" name="DeferredTaxLiabilitiesInvestmentSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>mdbh-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Cover" roleURI="http://mdb.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://mdb.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfOperations" roleURI="http://mdb.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfOperationsParenthetical" roleURI="http://mdb.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfChangesInEquity" roleURI="http://mdb.com/role/StatementsOfChangesInEquity" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfCashFlows" roleURI="http://mdb.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfCashFlowsSupplementalDisclosures" roleURI="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReporting" roleURI="http://mdb.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterests" roleURI="http://mdb.com/role/EquityAndNon-controllingInterests" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Deconsolidation" roleURI="http://mdb.com/role/Deconsolidation" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestment" roleURI="http://mdb.com/role/EquityMethodInvestment" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensation" roleURI="http://mdb.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShare" roleURI="http://mdb.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#RelatedPartyTransactions" roleURI="http://mdb.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#CommitmentsAndContingencies" roleURI="http://mdb.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EmployeeBenefitPlans" roleURI="http://mdb.com/role/EmployeeBenefitPlans" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ExclusiveLicenseAgreementMdbMinnesotaOne" roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Leases" roleURI="http://mdb.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxes" roleURI="http://mdb.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SubsequentEvents" roleURI="http://mdb.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReportingTables" roleURI="http://mdb.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterestsTables" roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#DeconsolidationTables" roleURI="http://mdb.com/role/DeconsolidationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestmentTables" roleURI="http://mdb.com/role/EquityMethodInvestmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensationTables" roleURI="http://mdb.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShareTables" roleURI="http://mdb.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#LeasesTables" roleURI="http://mdb.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxesTables" roleURI="http://mdb.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfInvestmentSecuritiesBrokerDealerDetails" roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" roleURI="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" roleURI="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfChangesInDeferredRevenueDetails" roleURI="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfGrantsReceivableActivityDetails" roleURI="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" roleURI="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfStatementOfOperationBySegmentDetails" roleURI="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://mdb.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEquityAndNon-controllingInterestsDetails" roleURI="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterestsDetailsNarrative" roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#DeconsolidationDetailsNarrative" roleURI="http://mdb.com/role/DeconsolidationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfConsolidatedBalanceSheetDetails" roleURI="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfGainOnDeconsolidationDetails" roleURI="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEquityMethodInvestmentDetails" roleURI="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestmentDetailsNarrative" roleURI="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfTime-basedStockOptionActivityDetails" roleURI="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfMarket-basedStockOptionActivityDetails" roleURI="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfBasicAndFullyDilutedDetails" roleURI="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShareDetailsNarrative" roleURI="http://mdb.com/role/EarningsPerShareDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EmployeeBenefitPlansDetailsNarrative" roleURI="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfOperatingLeaseCostDetails" roleURI="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" roleURI="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#LeasesDetailsNarrative" roleURI="http://mdb.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfIncomeTaxesExpensesBenefitDetails" roleURI="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://mdb.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://mdb.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PayablesToCustomersCurrentAndNonCurrent" xlink:label="loc_MDBHPayablesToCustomersCurrentAndNonCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_MDBHPayablesToCustomersCurrentAndNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:label="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:label="loc_MDBHUnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_MDBHUnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeeIncome" xlink:label="loc_us-gaapFeeIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapFeeIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherOperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CompensationCosts" xlink:label="loc_MDBHCompensationCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_MDBHCompensationCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OperatingExpenseRelatedParty" xlink:label="loc_MDBHOperatingExpenseRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_MDBHOperatingExpenseRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommunicationsAndInformationTechnology" xlink:label="loc_us-gaapCommunicationsAndInformationTechnology" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapCommunicationsAndInformationTechnology" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ClearingAndOtherCharges" xlink:label="loc_MDBHClearingAndOtherCharges" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_MDBHClearingAndOtherCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NetOperatingIncomeLoss" xlink:label="loc_MDBHNetOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MDBHNetOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MDBHNetOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_MDBHNetOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MiscellaneousIncome" xlink:label="loc_MDBHMiscellaneousIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_MDBHMiscellaneousIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_MDBHGainRelatedToDilutionEvents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromEquityMethodInvestment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_MDBHIncomeLossFromEquityMethodInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfChangesInEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:label="loc_MDBHAccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHAccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaapEquityMethodInvestmentDividendsOrDistributions" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DilutionOfDeferredGrantReimbursement" xlink:label="loc_MDBHDilutionOfDeferredGrantReimbursement" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHDilutionOfDeferredGrantReimbursement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PortionOfLossFromEquityInvestment" xlink:label="loc_MDBHPortionOfLossFromEquityInvestment" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHPortionOfLossFromEquityInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHGainRelatedToDilutionEvents" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:label="loc_MDBHProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeRecognizedFromWarrantsReceived" xlink:label="loc_MDBHIncomeRecognizedFromWarrantsReceived" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHIncomeRecognizedFromWarrantsReceived" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentsSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentsSecurities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHImpairmentOfInvestmentsSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPayablesToCustomers" xlink:label="loc_us-gaapIncreaseDecreaseInPayablesToCustomers" />
      <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPayablesToCustomers" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncreaseDecreaseInPayablesToNoncustomers" xlink:label="loc_MDBHIncreaseDecreaseInPayablesToNoncustomers" />
      <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MDBHIncreaseDecreaseInPayablesToNoncustomers" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentsToAcquireInvestmentsSecurities" xlink:label="loc_MDBHPaymentsToAcquireInvestmentsSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_MDBHPaymentsToAcquireInvestmentsSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ProceedsFromInvestmentsSecurities" xlink:label="loc_MDBHProceedsFromInvestmentsSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_MDBHProceedsFromInvestmentsSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentForDeferredGrantReimbursement" xlink:label="loc_MDBHPaymentForDeferredGrantReimbursement" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_MDBHPaymentForDeferredGrantReimbursement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaapPaymentsForProceedsFromProductiveAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaapProceedsFromPaymentsToMinorityShareholders" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="999016 - Disclosure - Organization and Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999017 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReporting" xlink:title="999018 - Disclosure - Segment Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterests" xlink:title="999019 - Disclosure - Equity and Non-Controlling Interests" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/Deconsolidation" xlink:title="999020 - Disclosure - Deconsolidation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestment" xlink:title="999021 - Disclosure - Equity Method Investment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensation" xlink:title="999022 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShare" xlink:title="999023 - Disclosure - Earnings Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/RelatedPartyTransactions" xlink:title="999024 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EmployeeBenefitPlans" xlink:title="999026 - Disclosure - Employee Benefit Plans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" xlink:title="999027 - Disclosure - Exclusive License Agreement (MDB Minnesota One)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/Leases" xlink:title="999028 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxes" xlink:title="999029 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReportingTables" xlink:title="999033 - Disclosure - Segment Reporting (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterestsTables" xlink:title="999034 - Disclosure - Equity and Non-Controlling Interests (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/DeconsolidationTables" xlink:title="999035 - Disclosure - Deconsolidation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestmentTables" xlink:title="999036 - Disclosure - Equity Method Investment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensationTables" xlink:title="999037 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShareTables" xlink:title="999038 - Disclosure - Earnings Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/LeasesTables" xlink:title="999039 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="999041 - Disclosure - Organization and Description of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" xlink:title="999043 - Disclosure - Schedule of Investment Securities Broker Dealer (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" xlink:title="999044 - Disclosure - Schedule of Investment Securities Non-Broker Dealer (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999045 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" xlink:title="999046 - Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" xlink:title="999047 - Disclosure - Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999048 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999049 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" xlink:title="999050 - Disclosure - Schedule of Changes in Deferred Revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" xlink:title="999051 - Disclosure - Summary of Grants Receivable Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" xlink:title="999052 - Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" xlink:title="999053 - Disclosure - Schedule of Statement of Operation by Segment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReportingDetailsNarrative" xlink:title="999054 - Disclosure - Segment Reporting (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" xlink:title="999055 - Disclosure - Schedule of Equity and Non-Controlling Interests (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" xlink:title="999056 - Disclosure - Equity and Non-Controlling Interests (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/DeconsolidationDetailsNarrative" xlink:title="999057 - Disclosure - Deconsolidation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" xlink:title="999058 - Disclosure - Schedule of Consolidated Balance Sheet (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" xlink:title="999059 - Disclosure - Schedule of Gain on Deconsolidation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" xlink:title="999060 - Disclosure - Schedule of Equity Method Investment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" xlink:title="999061 - Disclosure - Equity Method Investment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" xlink:title="999062 - Disclosure - Schedule of Restricted Stock Unit Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" xlink:title="999063 - Disclosure - Schedule of Time-Based Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" xlink:title="999064 - Disclosure - Schedule of Market-Based Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999065 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" xlink:title="999066 - Disclosure - Schedule of Basic and Fully Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShareDetailsNarrative" xlink:title="999067 - Disclosure - Earnings Per Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999068 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999069 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="999070 - Disclosure - Employee Benefit Plans (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" xlink:title="999071 - Disclosure - Exclusive License Agreement (MDB Minnesota One) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" xlink:title="999072 - Disclosure - Schedule of Operating Lease Cost (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" xlink:title="999073 - Disclosure - Schedule of Future payments Due Under Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_MDBHLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_MDBHLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/LeasesDetailsNarrative" xlink:title="999074 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" xlink:title="999075 - Disclosure - Schedule of Income Taxes Expenses (benefit) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999076 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:label="loc_MDBHIncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_MDBHIncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:label="loc_MDBHIncomeTaxReconciliationEquityInEquityAwardVestingAmount" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_MDBHIncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:label="loc_MDBHIncomeTaxReconciliationModificationOfEquityAwardsAmount" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_MDBHIncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:label="loc_MDBHIncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_MDBHIncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:label="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:label="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxLiabilitiesInvestmentSecurities" xlink:label="loc_MDBHDeferredTaxLiabilitiesInvestmentSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_MDBHDeferredTaxLiabilitiesInvestmentSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxesDetailsNarrative" xlink:title="999077 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mdb.com/role/SubsequentEventsDetailsNarrative" xlink:title="999078 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>mdbh-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Cover" roleURI="http://mdb.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://mdb.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfOperations" roleURI="http://mdb.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfOperationsParenthetical" roleURI="http://mdb.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfChangesInEquity" roleURI="http://mdb.com/role/StatementsOfChangesInEquity" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfCashFlows" roleURI="http://mdb.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfCashFlowsSupplementalDisclosures" roleURI="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReporting" roleURI="http://mdb.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterests" roleURI="http://mdb.com/role/EquityAndNon-controllingInterests" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Deconsolidation" roleURI="http://mdb.com/role/Deconsolidation" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestment" roleURI="http://mdb.com/role/EquityMethodInvestment" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensation" roleURI="http://mdb.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShare" roleURI="http://mdb.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#RelatedPartyTransactions" roleURI="http://mdb.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#CommitmentsAndContingencies" roleURI="http://mdb.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EmployeeBenefitPlans" roleURI="http://mdb.com/role/EmployeeBenefitPlans" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ExclusiveLicenseAgreementMdbMinnesotaOne" roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Leases" roleURI="http://mdb.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxes" roleURI="http://mdb.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SubsequentEvents" roleURI="http://mdb.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReportingTables" roleURI="http://mdb.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterestsTables" roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#DeconsolidationTables" roleURI="http://mdb.com/role/DeconsolidationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestmentTables" roleURI="http://mdb.com/role/EquityMethodInvestmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensationTables" roleURI="http://mdb.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShareTables" roleURI="http://mdb.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#LeasesTables" roleURI="http://mdb.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxesTables" roleURI="http://mdb.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfInvestmentSecuritiesBrokerDealerDetails" roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" roleURI="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" roleURI="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfChangesInDeferredRevenueDetails" roleURI="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfGrantsReceivableActivityDetails" roleURI="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" roleURI="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfStatementOfOperationBySegmentDetails" roleURI="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://mdb.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEquityAndNon-controllingInterestsDetails" roleURI="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterestsDetailsNarrative" roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#DeconsolidationDetailsNarrative" roleURI="http://mdb.com/role/DeconsolidationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfConsolidatedBalanceSheetDetails" roleURI="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfGainOnDeconsolidationDetails" roleURI="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEquityMethodInvestmentDetails" roleURI="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestmentDetailsNarrative" roleURI="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfTime-basedStockOptionActivityDetails" roleURI="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfMarket-basedStockOptionActivityDetails" roleURI="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfBasicAndFullyDilutedDetails" roleURI="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShareDetailsNarrative" roleURI="http://mdb.com/role/EarningsPerShareDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EmployeeBenefitPlansDetailsNarrative" roleURI="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfOperatingLeaseCostDetails" roleURI="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" roleURI="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#LeasesDetailsNarrative" roleURI="http://mdb.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfIncomeTaxesExpensesBenefitDetails" roleURI="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://mdb.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://mdb.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_50" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_50" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_50" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_50" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_50" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_50" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_50" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_50" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_50" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_50" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_50" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_50" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_50" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_50" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_50" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_50" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_50" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_50" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_50" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_50" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_50" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_50" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_50" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_50" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_50" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_50" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_50" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_50" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_50" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_50" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_50" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_50" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_50" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_50" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_50" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNet_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherReceivables_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapDepositsAssets_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapEquityMethodInvestments_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapDeferredCosts_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAbstract_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOtherLiabilities_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PayablesToCustomersCurrentAndNonCurrent" xlink:label="loc_MDBHPayablesToCustomersCurrentAndNonCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_MDBHPayablesToCustomersCurrentAndNonCurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiability_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapMinorityInterest_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaapOperatingIncomeLossAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:label="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:to="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:label="loc_MDBHUnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:to="loc_MDBHUnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeeIncome" xlink:label="loc_us-gaapFeeIncome_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:to="loc_us-gaapFeeIncome_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_70" xlink:to="loc_us-gaapOtherOperatingIncome_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CompensationCosts" xlink:label="loc_MDBHCompensationCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_MDBHCompensationCosts_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OperatingExpenseRelatedParty" xlink:label="loc_MDBHOperatingExpenseRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_MDBHOperatingExpenseRelatedParty_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_us-gaapProfessionalFees_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommunicationsAndInformationTechnology" xlink:label="loc_us-gaapCommunicationsAndInformationTechnology_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_us-gaapCommunicationsAndInformationTechnology_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ClearingAndOtherCharges" xlink:label="loc_MDBHClearingAndOtherCharges_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_MDBHClearingAndOtherCharges_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_70" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NetOperatingIncomeLoss" xlink:label="loc_MDBHNetOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHNetOperatingIncomeLoss_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeAbstract" xlink:label="loc_us-gaapInterestAndOtherIncomeAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestAndOtherIncomeAbstract_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MiscellaneousIncome" xlink:label="loc_MDBHMiscellaneousIncome_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract_70" xlink:to="loc_MDBHMiscellaneousIncome_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract_70" xlink:to="loc_us-gaapOtherNonoperatingIncome_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract_70" xlink:to="loc_us-gaapInterestExpenseNonoperating_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract_70" xlink:to="loc_MDBHGainRelatedToDilutionEvents_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract_70" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromEquityMethodInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHIncomeLossFromEquityMethodInvestment_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfChangesInEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_Netincomeloss1" xlink:label="loc_MDBHNetincomeloss1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHNetincomeloss1_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectOfDeconsolidationOfSubsidiary" xlink:label="loc_MDBHEffectOfDeconsolidationOfSubsidiary_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHEffectOfDeconsolidationOfSubsidiary_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="999016 - Disclosure - Organization and Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999017 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReporting" xlink:title="999018 - Disclosure - Segment Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterests" xlink:title="999019 - Disclosure - Equity and Non-Controlling Interests" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/Deconsolidation" xlink:title="999020 - Disclosure - Deconsolidation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestment" xlink:title="999021 - Disclosure - Equity Method Investment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensation" xlink:title="999022 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShare" xlink:title="999023 - Disclosure - Earnings Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/RelatedPartyTransactions" xlink:title="999024 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EmployeeBenefitPlans" xlink:title="999026 - Disclosure - Employee Benefit Plans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" xlink:title="999027 - Disclosure - Exclusive License Agreement (MDB Minnesota One)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/Leases" xlink:title="999028 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxes" xlink:title="999029 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReportingTables" xlink:title="999033 - Disclosure - Segment Reporting (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterestsTables" xlink:title="999034 - Disclosure - Equity and Non-Controlling Interests (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/DeconsolidationTables" xlink:title="999035 - Disclosure - Deconsolidation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestmentTables" xlink:title="999036 - Disclosure - Equity Method Investment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensationTables" xlink:title="999037 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShareTables" xlink:title="999038 - Disclosure - Earnings Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/LeasesTables" xlink:title="999039 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="999041 - Disclosure - Organization and Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MDBMinnesotaOneIncMember" xlink:label="loc_MDBHMDBMinnesotaOneIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHMDBMinnesotaOneIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MayoFoundationMember" xlink:label="loc_MDBHMayoFoundationMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHMayoFoundationMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSaleOfStockPricePerShare_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherExpenses_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSharesIssuedPricePerShare_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesToAffiliate" xlink:label="loc_us-gaapAdvancesToAffiliate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapAdvancesToAffiliate_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapInvestments_100" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SAFEMember" xlink:label="loc_MDBHSAFEMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MDBHSAFEMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashFDICInsuredAmount_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CashSIPCInsuredAmount" xlink:label="loc_MDBHCashSIPCInsuredAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHCashSIPCInsuredAmount_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCash_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashUninsuredAmount_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDeposits_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDepositsAssets_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PrepaidProfessionalFees" xlink:label="loc_MDBHPrepaidProfessionalFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHPrepaidProfessionalFees_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSecurityDeposit_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapPrepaidInsurance_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherAssets_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCredit_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantDrawdowns" xlink:label="loc_MDBHGrantDrawdowns_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHGrantDrawdowns_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ResearchAndDevelopmentExpenseGross" xlink:label="loc_MDBHResearchAndDevelopmentExpenseGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHResearchAndDevelopmentExpenseGross_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_110" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" xlink:title="999043 - Disclosure - Schedule of Investment Securities Broker Dealer (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:label="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" xlink:label="loc_MDBHWarrantsOfNonPubliclyTradedCompaniesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHWarrantsOfNonPubliclyTradedCompaniesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerMember" xlink:label="loc_MDBHBrokerDealerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHBrokerDealerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValue_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" xlink:title="999044 - Disclosure - Schedule of Investment Securities Non-Broker Dealer (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:label="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SimpleAgreementOnFutureEquitiesMember" xlink:label="loc_MDBHSimpleAgreementOnFutureEquitiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHSimpleAgreementOnFutureEquitiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentMember" xlink:label="loc_MDBHImpairmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHImpairmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NonBrokerDealerMember" xlink:label="loc_MDBHNonBrokerDealerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNonBrokerDealerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValue_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHInvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999045 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValue_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" xlink:title="999046 - Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" xlink:title="999047 - Disclosure - Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999048 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LaboratoryEquipmentMember" xlink:label="loc_MDBHLaboratoryEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MDBHLaboratoryEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DevelopedSoftwareMember" xlink:label="loc_MDBHDevelopedSoftwareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MDBHDevelopedSoftwareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999049 - Disclosure - Schedule of Property And Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" xlink:title="999050 - Disclosure - Schedule of Changes in Deferred Revenue (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" xlink:title="999051 - Disclosure - Summary of Grants Receivable Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" xlink:title="999052 - Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerAndIntellectualPropertyServiceMember" xlink:label="loc_MDBHBrokerDealerAndIntellectualPropertyServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHBrokerDealerAndIntellectualPropertyServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TechnologyDevelopmentMember" xlink:label="loc_MDBHTechnologyDevelopmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHTechnologyDevelopmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OtherSegmentsMember" xlink:label="loc_MDBHOtherSegmentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHOtherSegmentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EliminationsMember" xlink:label="loc_MDBHEliminationsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHEliminationsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:label="loc_MDBHBrokerDealerIntellectualPropertyServiceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHBrokerDealerIntellectualPropertyServiceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" xlink:title="999053 - Disclosure - Schedule of Statement of Operation by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:label="loc_MDBHBrokerDealerIntellectualPropertyServiceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHBrokerDealerIntellectualPropertyServiceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TechnologyDevelopmentMember" xlink:label="loc_MDBHTechnologyDevelopmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHTechnologyDevelopmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OtherSegmentsMember" xlink:label="loc_MDBHOtherSegmentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHOtherSegmentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EliminationsMember" xlink:label="loc_MDBHEliminationsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHEliminationsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaapOperatingIncomeLossAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:label="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_MDBHInvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RealizedInvestmentGainsLossesOne" xlink:label="loc_MDBHRealizedInvestmentGainsLossesOne_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_MDBHRealizedInvestmentGainsLossesOne_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeeIncome" xlink:label="loc_us-gaapFeeIncome_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_us-gaapFeeIncome_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_us-gaapOtherOperatingIncome_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingIncomeLossAbstract_110" xlink:to="loc_us-gaapOperatingIncomeLoss_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapLaborAndRelatedExpense_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapOtherNonoperatingExpense_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapProfessionalFees_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommunicationsAndInformationTechnology" xlink:label="loc_us-gaapCommunicationsAndInformationTechnology_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapCommunicationsAndInformationTechnology_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ClearingAndOtherCharges" xlink:label="loc_MDBHClearingAndOtherCharges_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_MDBHClearingAndOtherCharges_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract_110" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_110" xlink:to="loc_us-gaapOperatingExpenses_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NetOperatingIncomeLoss" xlink:label="loc_MDBHNetOperatingIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHNetOperatingIncomeLoss_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MiscellaneousIncome" xlink:label="loc_MDBHMiscellaneousIncome_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHMiscellaneousIncome_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncome_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHGainRelatedToDilutionEvents_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_110" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_110" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromEquityMethodInvestment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHIncomeLossFromEquityMethodInvestment_110" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss_110" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_110" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_110" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_110" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReportingDetailsNarrative" xlink:title="999054 - Disclosure - Segment Reporting (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" xlink:title="999055 - Disclosure - Schedule of Equity and Non-Controlling Interests (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_Equity" xlink:label="loc_MDBHEquity" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EquityTable" xlink:label="loc_MDBHEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHEquityTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="loc_MDBHExozymeTechnologiesIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_MDBHExozymeTechnologiesIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WeightedAverageNonControllingPercentage" xlink:label="loc_MDBHWeightedAverageNonControllingPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHWeightedAverageNonControllingPercentage_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapMinorityInterest_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DueToDeconsolidation" xlink:label="loc_MDBHDueToDeconsolidation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHDueToDeconsolidation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationToNonControllingInterest" xlink:label="loc_MDBHShareBasedCompensationToNonControllingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHShareBasedCompensationToNonControllingInterest_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OwnershipChangeOfNoncontrollingInterest" xlink:label="loc_MDBHOwnershipChangeOfNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHOwnershipChangeOfNoncontrollingInterest_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" xlink:title="999056 - Disclosure - Equity and Non-Controlling Interests (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MinnesotaOneMember" xlink:label="loc_MDBHMinnesotaOneMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_MDBHMinnesotaOneMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="loc_MDBHExozymeTechnologiesIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_MDBHExozymeTechnologiesIncMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MinnesotaOneMember" xlink:label="loc_MDBHMinnesotaOneMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHMinnesotaOneMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="loc_MDBHExozymeTechnologiesIncMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHExozymeTechnologiesIncMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaapProceedsFromContributionsFromParent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromContributionsFromParent_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/DeconsolidationDetailsNarrative" xlink:title="999057 - Disclosure - Deconsolidation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationTable" xlink:label="loc_MDBHDeconsolidationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHDeconsolidationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHDeconsolidationTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesIncMember" xlink:label="loc_MDBHExozymesIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MDBHExozymesIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:label="loc_us-gaapGainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_40" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" xlink:title="999058 - Disclosure - Schedule of Consolidated Balance Sheet (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfConsolidatedBalanceSheetTable" xlink:label="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="loc_MDBHExozymesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_MDBHExozymesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrantsReceivable_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredGrantReimbursement" xlink:label="loc_MDBHDeferredGrantReimbursement_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHDeferredGrantReimbursement_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_20" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue_20" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_20" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_20" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_20" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" xlink:title="999059 - Disclosure - Schedule of Gain on Deconsolidation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfGainOnDeconsolidationTable" xlink:label="loc_MDBHScheduleOfGainOnDeconsolidationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHScheduleOfGainOnDeconsolidationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHScheduleOfGainOnDeconsolidationTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesIncMember" xlink:label="loc_MDBHExozymesIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MDBHExozymesIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaapEquityMethodInvestmentsFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentsFairValueDisclosure_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CarryingValueOfAssets" xlink:label="loc_MDBHCarryingValueOfAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHCarryingValueOfAssets_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LessCarryingValueOfFormerInvestment" xlink:label="loc_MDBHLessCarryingValueOfFormerInvestment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHLessCarryingValueOfFormerInvestment_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CarryingValueOfWarrants" xlink:label="loc_MDBHCarryingValueOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHCarryingValueOfWarrants_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount_40" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" xlink:title="999060 - Disclosure - Schedule of Equity Method Investment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" xlink:title="999061 - Disclosure - Equity Method Investment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="loc_MDBHExozymesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHExozymesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvizyneTechnologiesIncMember" xlink:label="loc_MDBHInvizyneTechnologiesIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHInvizyneTechnologiesIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" xlink:title="999062 - Disclosure - Schedule of Restricted Stock Unit Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" xlink:title="999063 - Disclosure - Schedule of Time-Based Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:label="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" xlink:title="999064 - Disclosure - Schedule of Market-Based Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:label="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999065 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AveragePricePerShare" xlink:label="loc_MDBHAveragePricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHAveragePricePerShare_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_130" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" xlink:title="999066 - Disclosure - Schedule of Basic and Fully Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShareDetailsNarrative" xlink:title="999067 - Disclosure - Earnings Per Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999068 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ENDRAMember" xlink:label="loc_MDBHENDRAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MDBHENDRAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="loc_MDBHExozymesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MDBHExozymesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOperatingExpenses_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenues_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivable_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccruedExpenses" xlink:label="loc_MDBHAccruedExpenses_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_MDBHAccruedExpenses_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999069 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CommitmentsAndContingenciesTable" xlink:label="loc_MDBHCommitmentsAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_MDBHCommitmentsAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PublicVenturesMember" xlink:label="loc_MDBHPublicVenturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MDBHPublicVenturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DTCMembershipRequirementsMember" xlink:label="loc_MDBHDTCMembershipRequirementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHDTCMembershipRequirementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NetCapital" xlink:label="loc_srtNetCapital_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_srtNetCapital_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_us-gaapLoansPayable_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RatioOfIndebtednessToNetCapital1" xlink:label="loc_us-gaapRatioOfIndebtednessToNetCapital1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_us-gaapRatioOfIndebtednessToNetCapital1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumNetCapitalRequiredForEntity1" xlink:label="loc_srtMinimumNetCapitalRequiredForEntity1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_srtMinimumNetCapitalRequiredForEntity1_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="999070 - Disclosure - Employee Benefit Plans (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" xlink:title="999071 - Disclosure - Exclusive License Agreement (MDB Minnesota One) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LicenseAgreementMember" xlink:label="loc_MDBHLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MDBHLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIclinicalMember" xlink:label="loc_MDBHPhaseIIclinicalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHPhaseIIclinicalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIIclinicalMember" xlink:label="loc_MDBHPhaseIIIclinicalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHPhaseIIIclinicalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationFirstMember" xlink:label="loc_MDBHNewDrugApplicationFirstMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNewDrugApplicationFirstMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationMember" xlink:label="loc_MDBHNewDrugApplicationMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNewDrugApplicationMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentForLicensedProducts" xlink:label="loc_MDBHPaymentForLicensedProducts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MDBHPaymentForLicensedProducts_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" xlink:title="999072 - Disclosure - Schedule of Operating Lease Cost (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" xlink:title="999073 - Disclosure - Schedule of Future payments Due Under Operating Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/LeasesDetailsNarrative" xlink:title="999074 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" xlink:title="999075 - Disclosure - Schedule of Income Taxes Expenses (benefit) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999076 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxesDetailsNarrative" xlink:title="999077 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_USFederalTaxMember" xlink:label="loc_MDBHUSFederalTaxMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_MDBHUSFederalTaxMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_FloridaIncomeTaxMember" xlink:label="loc_MDBHFloridaIncomeTaxMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_MDBHFloridaIncomeTaxMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mdb.com/role/SubsequentEventsDetailsNarrative" xlink:title="999078 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerMember" xlink:label="loc_MDBHBrokerDealerMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHBrokerDealerMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NonBrokerDealerMember" xlink:label="loc_MDBHNonBrokerDealerMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNonBrokerDealerMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DTCMembershipRequirementsMember" xlink:label="loc_MDBHDTCMembershipRequirementsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHDTCMembershipRequirementsMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIclinicalMember" xlink:label="loc_MDBHPhaseIIclinicalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHPhaseIIclinicalMember" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIIclinicalMember" xlink:label="loc_MDBHPhaseIIIclinicalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHPhaseIIIclinicalMember" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationFirstMember" xlink:label="loc_MDBHNewDrugApplicationFirstMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNewDrugApplicationFirstMember" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationMember" xlink:label="loc_MDBHNewDrugApplicationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNewDrugApplicationMember" xlink:type="arc" order="80" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>mdbh-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MDBMinnesotaOneIncMember" xlink:label="MDBH_MDBMinnesotaOneIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MDBMinnesotaOneIncMember" xlink:to="MDBH_MDBMinnesotaOneIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_MDBMinnesotaOneIncMember_lbl" xml:lang="en-US">MDB Minnesota One Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MayoFoundationMember" xlink:label="MDBH_MayoFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MayoFoundationMember" xlink:to="MDBH_MayoFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_MayoFoundationMember_lbl" xml:lang="en-US">Mayo Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SAFEMember" xlink:label="MDBH_SAFEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SAFEMember" xlink:to="MDBH_SAFEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SAFEMember_lbl" xml:lang="en-US">SAFE [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerMember" xlink:label="MDBH_BrokerDealerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BrokerDealerMember" xlink:to="MDBH_BrokerDealerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_BrokerDealerMember_lbl" xml:lang="en-US">Broker Dealer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:label="MDBH_WarrantsOfPubliclyTradedCompaniesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:to="MDBH_WarrantsOfPubliclyTradedCompaniesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_WarrantsOfPubliclyTradedCompaniesMember_lbl" xml:lang="en-US">Warrants of Publicly Traded Companies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" xlink:label="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" xlink:to="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember_lbl" xml:lang="en-US">Warrants of Non Publicly Traded Companies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NonBrokerDealerMember" xlink:label="MDBH_NonBrokerDealerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NonBrokerDealerMember" xlink:to="MDBH_NonBrokerDealerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_NonBrokerDealerMember_lbl" xml:lang="en-US">Non Broker Dealer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SimpleAgreementOnFutureEquitiesMember" xlink:label="MDBH_SimpleAgreementOnFutureEquitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SimpleAgreementOnFutureEquitiesMember" xlink:to="MDBH_SimpleAgreementOnFutureEquitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SimpleAgreementOnFutureEquitiesMember_lbl" xml:lang="en-US">Simple Agreement on Future Equities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentMember" xlink:label="MDBH_ImpairmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentMember" xlink:to="MDBH_ImpairmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ImpairmentMember_lbl" xml:lang="en-US">Impairment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LaboratoryEquipmentMember" xlink:label="MDBH_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LaboratoryEquipmentMember" xlink:to="MDBH_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DevelopedSoftwareMember" xlink:label="MDBH_DevelopedSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DevelopedSoftwareMember" xlink:to="MDBH_DevelopedSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DevelopedSoftwareMember_lbl" xml:lang="en-US">Developed Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerAndIntellectualPropertyServiceMember" xlink:label="MDBH_BrokerDealerAndIntellectualPropertyServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BrokerDealerAndIntellectualPropertyServiceMember" xlink:to="MDBH_BrokerDealerAndIntellectualPropertyServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_BrokerDealerAndIntellectualPropertyServiceMember_lbl" xml:lang="en-US">Broker Dealer And Intellectual Property Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TechnologyDevelopmentMember" xlink:label="MDBH_TechnologyDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_TechnologyDevelopmentMember" xlink:to="MDBH_TechnologyDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_TechnologyDevelopmentMember_lbl" xml:lang="en-US">Technology Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OtherSegmentsMember" xlink:label="MDBH_OtherSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OtherSegmentsMember" xlink:to="MDBH_OtherSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_OtherSegmentsMember_lbl" xml:lang="en-US">Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EliminationsMember" xlink:label="MDBH_EliminationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EliminationsMember" xlink:to="MDBH_EliminationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EliminationsMember_lbl" xml:lang="en-US">Eliminations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:label="MDBH_BrokerDealerIntellectualPropertyServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:to="MDBH_BrokerDealerIntellectualPropertyServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_BrokerDealerIntellectualPropertyServiceMember_lbl" xml:lang="en-US">Broker Dealer &amp; Intellectual Property Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MinnesotaOneMember" xlink:label="MDBH_MinnesotaOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MinnesotaOneMember" xlink:to="MDBH_MinnesotaOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_MinnesotaOneMember_lbl" xml:lang="en-US">Minnesota One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="MDBH_ExozymeTechnologiesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExozymeTechnologiesIncMember" xlink:to="MDBH_ExozymeTechnologiesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ExozymeTechnologiesIncMember_lbl" xml:lang="en-US">Exozyme Technologies Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesIncMember" xlink:label="MDBH_ExozymesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExozymesIncMember" xlink:to="MDBH_ExozymesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ExozymesIncMember_lbl" xml:lang="en-US">Exozymes Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="MDBH_ExozymesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExozymesMember" xlink:to="MDBH_ExozymesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ExozymesMember_lbl" xml:lang="en-US">Exozymes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvizyneTechnologiesIncMember" xlink:label="MDBH_InvizyneTechnologiesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvizyneTechnologiesIncMember" xlink:to="MDBH_InvizyneTechnologiesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvizyneTechnologiesIncMember_lbl" xml:lang="en-US">Invizyne Technologies Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="MDBH_MarketBasedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MarketBasedMember" xlink:to="MDBH_MarketBasedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_MarketBasedMember_lbl" xml:lang="en-US">Market Based [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="MDBH_TimeBasedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_TimeBasedMember" xlink:to="MDBH_TimeBasedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_TimeBasedMember_lbl" xml:lang="en-US">Time Based [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ENDRAMember" xlink:label="MDBH_ENDRAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ENDRAMember" xlink:to="MDBH_ENDRAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ENDRAMember_lbl" xml:lang="en-US">ENDRA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PublicVenturesMember" xlink:label="MDBH_PublicVenturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PublicVenturesMember" xlink:to="MDBH_PublicVenturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PublicVenturesMember_lbl" xml:lang="en-US">Public Ventures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DTCMembershipRequirementsMember" xlink:label="MDBH_DTCMembershipRequirementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DTCMembershipRequirementsMember" xlink:to="MDBH_DTCMembershipRequirementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DTCMembershipRequirementsMember_lbl" xml:lang="en-US">DTC Membership Requirements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LicenseAgreementMember" xlink:label="MDBH_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LicenseAgreementMember" xlink:to="MDBH_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIclinicalMember" xlink:label="MDBH_PhaseIIclinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PhaseIIclinicalMember" xlink:to="MDBH_PhaseIIclinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PhaseIIclinicalMember_lbl" xml:lang="en-US">Phase II clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIIclinicalMember" xlink:label="MDBH_PhaseIIIclinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PhaseIIIclinicalMember" xlink:to="MDBH_PhaseIIIclinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PhaseIIIclinicalMember_lbl" xml:lang="en-US">Phase III clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationFirstMember" xlink:label="MDBH_NewDrugApplicationFirstMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NewDrugApplicationFirstMember" xlink:to="MDBH_NewDrugApplicationFirstMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_NewDrugApplicationFirstMember_lbl" xml:lang="en-US">New Drug Application First [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationMember" xlink:label="MDBH_NewDrugApplicationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NewDrugApplicationMember" xlink:to="MDBH_NewDrugApplicationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_NewDrugApplicationMember_lbl" xml:lang="en-US">New Drug Application [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_USFederalTaxMember" xlink:label="MDBH_USFederalTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_USFederalTaxMember" xlink:to="MDBH_USFederalTaxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_USFederalTaxMember_lbl" xml:lang="en-US">U.S Federal Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_FloridaIncomeTaxMember" xlink:label="MDBH_FloridaIncomeTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_FloridaIncomeTaxMember" xlink:to="MDBH_FloridaIncomeTaxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_FloridaIncomeTaxMember_lbl" xml:lang="en-US">Florida Income Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:label="us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:to="us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_lbl" xml:lang="en-US">Cash segregated in compliance with regulations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Related party receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Clearing deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_lbl" xml:lang="en-US">Investment securities, at fair value, held by the licensed broker dealer (Notes 1 and 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_lbl" xml:lang="en-US">Investment securities, at fair value, held by the non-licensed broker dealer (Notes 1 and 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred costs related to deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Related party payables</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PayablesToCustomersCurrentAndNonCurrent" xlink:label="MDBH_PayablesToCustomersCurrentAndNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PayablesToCustomersCurrentAndNonCurrent" xlink:to="MDBH_PayablesToCustomersCurrentAndNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PayablesToCustomersCurrentAndNonCurrent_lbl" xml:lang="en-US">Payables to customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred shares, 10,000,000 authorized shares at no par value; 0 issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in-capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated income (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total MDB Capital Holdings, LLC equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred stock, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US">Operating income:</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:label="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:to="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_lbl" xml:lang="en-US">Unrealized (loss) on investment securities, net from the licensed broker dealer (Notes 1 and 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:label="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:to="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_lbl" xml:lang="en-US">Unrealized gain on investment securities, net from non-licensed broker dealer (Notes 1 and 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xml:lang="en-US">Realized gain on investment securities, net from the licensed broker dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeeIncome" xlink:label="us-gaap_FeeIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeeIncome" xlink:to="us-gaap_FeeIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeeIncome_lbl" xml:lang="en-US">Fee income (from our licensed broker dealer)</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="MDBH_ImpairmentOfInvestmentSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentOfInvestmentSecurities" xlink:to="MDBH_ImpairmentOfInvestmentSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_ImpairmentOfInvestmentSecurities_lbl" xml:lang="en-US">Impairment of investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncome_lbl" xml:lang="en-US">Other operating income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Total operating income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and administrative costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CompensationCosts" xlink:label="MDBH_CompensationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CompensationCosts" xlink:to="MDBH_CompensationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_CompensationCosts_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OperatingExpenseRelatedParty" xlink:label="MDBH_OperatingExpenseRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OperatingExpenseRelatedParty" xlink:to="MDBH_OperatingExpenseRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_OperatingExpenseRelatedParty_lbl" xml:lang="en-US">Operating expense, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommunicationsAndInformationTechnology" xlink:label="us-gaap_CommunicationsAndInformationTechnology" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommunicationsAndInformationTechnology" xlink:to="us-gaap_CommunicationsAndInformationTechnology_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommunicationsAndInformationTechnology_lbl" xml:lang="en-US">Information technology</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ClearingAndOtherCharges" xlink:label="MDBH_ClearingAndOtherCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ClearingAndOtherCharges" xlink:to="MDBH_ClearingAndOtherCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ClearingAndOtherCharges_lbl" xml:lang="en-US">Clearing and other charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative-other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs, net of grants $0 and $2,003 in 2024 and 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Total operating costs</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NetOperatingIncomeLoss" xlink:label="MDBH_NetOperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NetOperatingIncomeLoss" xlink:to="MDBH_NetOperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="MDBH_NetOperatingIncomeLoss_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeAbstract" xlink:label="us-gaap_InterestAndOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncomeAbstract" xlink:to="us-gaap_InterestAndOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncomeAbstract_lbl" xml:lang="en-US">Other income and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MiscellaneousIncome" xlink:label="MDBH_MiscellaneousIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MiscellaneousIncome" xlink:to="MDBH_MiscellaneousIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_MiscellaneousIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="MDBH_GainRelatedToDilutionEvents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GainRelatedToDilutionEvents" xlink:to="MDBH_GainRelatedToDilutionEvents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GainRelatedToDilutionEvents_lbl" xml:lang="en-US">Gain related to dilution events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xml:lang="en-US">Gain on deconsolidation of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net income (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:label="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:to="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_lbl" xml:lang="en-US">Net income (loss) before equity method investee</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromEquityMethodInvestment" xlink:label="MDBH_IncomeLossFromEquityMethodInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeLossFromEquityMethodInvestment" xlink:to="MDBH_IncomeLossFromEquityMethodInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeLossFromEquityMethodInvestment_lbl" xml:lang="en-US">Equity in loss of equity method investee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less net loss attributable to non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) attributable to MDB Capital Holdings, LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Income (loss) per share attributable to MDB Capital Holdings, LLC:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Income (loss) per Common Share &#8211; basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average of number Common Shares outstanding &#8211; basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Income (loss) per Common Share &#8211;diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted number of Common Shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ResearchAndDevelopmentGrants" xlink:label="MDBH_ResearchAndDevelopmentGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ResearchAndDevelopmentGrants" xlink:to="MDBH_ResearchAndDevelopmentGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ResearchAndDevelopmentGrants_lbl" xml:lang="en-US">Research and development, Grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Class A Common Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Class A Common Shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_Netincomeloss1" xlink:label="MDBH_Netincomeloss1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_Netincomeloss1" xlink:to="MDBH_Netincomeloss1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_Netincomeloss1_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_lbl" xml:lang="en-US">Ownership change of non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectOfDeconsolidationOfSubsidiary" xlink:label="MDBH_EffectOfDeconsolidationOfSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectOfDeconsolidationOfSubsidiary" xlink:to="MDBH_EffectOfDeconsolidationOfSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EffectOfDeconsolidationOfSubsidiary_lbl" xml:lang="en-US">Effect of deconsolidation of subsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized loss on investment securities, net</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:label="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:to="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_lbl" xml:lang="en-US">Accretion of investments at amortized cost (U.S Treasury Bills)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_2_lbl" xml:lang="en-US">Realized loss (gain) on investment securities, net from the licensed broker dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions_lbl" xml:lang="en-US">Effect of deconsolidation of subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred costs related to revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DilutionOfDeferredGrantReimbursement" xlink:label="MDBH_DilutionOfDeferredGrantReimbursement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DilutionOfDeferredGrantReimbursement" xlink:to="MDBH_DilutionOfDeferredGrantReimbursement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DilutionOfDeferredGrantReimbursement_lbl" xml:lang="en-US">Dilution of deferred grant reimbursement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xml:lang="en-US">Gain on deconsolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PortionOfLossFromEquityInvestment" xlink:label="MDBH_PortionOfLossFromEquityInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PortionOfLossFromEquityInvestment" xlink:to="MDBH_PortionOfLossFromEquityInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PortionOfLossFromEquityInvestment_lbl" xml:lang="en-US">Portion of loss from equity investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GainRelatedToDilutionEvents" xlink:to="MDBH_GainRelatedToDilutionEvents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_GainRelatedToDilutionEvents_2_lbl" xml:lang="en-US">Gain related to dilution events</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:label="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:to="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal_lbl" xml:lang="en-US">Warrants issued as part of an investment banking deal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xml:lang="en-US">Share of loss from equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeRecognizedFromWarrantsReceived" xlink:label="MDBH_IncomeRecognizedFromWarrantsReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeRecognizedFromWarrantsReceived" xlink:to="MDBH_IncomeRecognizedFromWarrantsReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_IncomeRecognizedFromWarrantsReceived_lbl" xml:lang="en-US">Income recognized from warrants received</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentsSecurities" xlink:label="MDBH_ImpairmentOfInvestmentsSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentOfInvestmentsSecurities" xlink:to="MDBH_ImpairmentOfInvestmentsSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ImpairmentOfInvestmentsSecurities_lbl" xml:lang="en-US">Impairment of investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Change in ROU Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Change in lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Related party receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Clearing deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (decrease) in -</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Related party payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPayablesToCustomers" xlink:label="us-gaap_IncreaseDecreaseInPayablesToCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPayablesToCustomers" xlink:to="us-gaap_IncreaseDecreaseInPayablesToCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPayablesToCustomers_lbl" xml:lang="en-US">Payables to customers</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncreaseDecreaseInPayablesToNoncustomers" xlink:label="MDBH_IncreaseDecreaseInPayablesToNoncustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncreaseDecreaseInPayablesToNoncustomers" xlink:to="MDBH_IncreaseDecreaseInPayablesToNoncustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncreaseDecreaseInPayablesToNoncustomers_lbl" xml:lang="en-US">Payables to non-customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentsToAcquireInvestmentsSecurities" xlink:label="MDBH_PaymentsToAcquireInvestmentsSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentsToAcquireInvestmentsSecurities" xlink:to="MDBH_PaymentsToAcquireInvestmentsSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_PaymentsToAcquireInvestmentsSecurities_lbl" xml:lang="en-US">Purchases of investment securities, at amortized cost (U.S. Treasury Bills)</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ProceedsFromInvestmentsSecurities" xlink:label="MDBH_ProceedsFromInvestmentsSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ProceedsFromInvestmentsSecurities" xlink:to="MDBH_ProceedsFromInvestmentsSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ProceedsFromInvestmentsSecurities_lbl" xml:lang="en-US">Proceeds from payments and maturities of investment securities, at amortized cost (U.S. Treasury Bills)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xml:lang="en-US">Accretion of equity investments</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentForDeferredGrantReimbursement" xlink:label="MDBH_PaymentForDeferredGrantReimbursement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentForDeferredGrantReimbursement" xlink:to="MDBH_PaymentForDeferredGrantReimbursement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_PaymentForDeferredGrantReimbursement_lbl" xml:lang="en-US">Deferred grant reimbursement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS - END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal" xlink:label="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal" xlink:to="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal_lbl" xml:lang="en-US">Warrants received as part of an investment banking deal</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" xlink:label="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" xlink:to="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear_lbl" xml:lang="en-US">Relinquishment of deferred costs of initial public offering from prior year</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" xlink:label="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" xlink:to="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment_lbl" xml:lang="en-US">Investment securities, at cost less impairment, received in lieu of cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" xlink:label="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" xlink:to="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering_lbl" xml:lang="en-US">Issuance of warrants to purchase Class A stock related to the initial public offering closed on September 20, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:label="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:to="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations_lbl" xml:lang="en-US">Cash segregated in compliance with regulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NoInsiderTradingFlag" xlink:label="MDBH_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NoInsiderTradingFlag" xlink:to="MDBH_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Organization and Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity and Non-Controlling Interests</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureDeconsolidationAbstract" xlink:label="MDBH_DisclosureDeconsolidationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DisclosureDeconsolidationAbstract" xlink:to="MDBH_DisclosureDeconsolidationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DisclosureDeconsolidationAbstract_lbl" xml:lang="en-US">Deconsolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationDisclosureTextBlock" xlink:label="MDBH_DeconsolidationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationDisclosureTextBlock" xlink:to="MDBH_DeconsolidationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_DeconsolidationDisclosureTextBlock_lbl" xml:lang="en-US">Deconsolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" xlink:label="MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" xlink:to="MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract_lbl" xml:lang="en-US">Exclusive License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExclusiveLicenseAgreementTextBlock" xlink:label="MDBH_ExclusiveLicenseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExclusiveLicenseAgreementTextBlock" xlink:to="MDBH_ExclusiveLicenseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ExclusiveLicenseAgreementTextBlock_lbl" xml:lang="en-US">Exclusive License Agreement (MDB Minnesota One)</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureLeasesAbstract" xlink:label="MDBH_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DisclosureLeasesAbstract" xlink:to="MDBH_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationPolicyTextBlock" xlink:label="MDBH_DeconsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationPolicyTextBlock" xlink:to="MDBH_DeconsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_DeconsolidationPolicyTextBlock_lbl" xml:lang="en-US">Deconsolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Equity method investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EmergingGrowthCompanyPolicyTextBlock" xlink:label="MDBH_EmergingGrowthCompanyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EmergingGrowthCompanyPolicyTextBlock" xlink:to="MDBH_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SegregatedCashAndDepositsPolicyTextBlock" xlink:label="MDBH_SegregatedCashAndDepositsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SegregatedCashAndDepositsPolicyTextBlock" xlink:to="MDBH_SegregatedCashAndDepositsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SegregatedCashAndDepositsPolicyTextBlock_lbl" xml:lang="en-US">Segregated Cash and Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositContractsPolicy" xlink:label="us-gaap_DepositContractsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsPolicy" xlink:to="us-gaap_DepositContractsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsPolicy_lbl" xml:lang="en-US">Clearing Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock" xlink:label="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock" xlink:to="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Secured Debt&#8211;- Revolving Credit Facility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingForResearchGrantsPolicyTextBlock" xlink:label="MDBH_AccountingForResearchGrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccountingForResearchGrantsPolicyTextBlock" xlink:to="MDBH_AccountingForResearchGrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AccountingForResearchGrantsPolicyTextBlock_lbl" xml:lang="en-US">Research Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" xlink:label="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" xlink:to="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent and Licensing Legal and Filing Fees and Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" xlink:label="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" xlink:to="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_lbl" xml:lang="en-US">Schedule of Investment Securities Broker Dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" xlink:label="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" xlink:to="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_lbl" xml:lang="en-US">Schedule of Investment Securities Non-Broker Dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantsReceivableActivityTableTextBlock" xlink:label="MDBH_GrantsReceivableActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantsReceivableActivityTableTextBlock" xlink:to="MDBH_GrantsReceivableActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GrantsReceivableActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Grants Receivable Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Long-lived Assets and Total Assets by Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Statement of Operation by Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock" xlink:label="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock" xlink:to="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock_lbl" xml:lang="en-US">Schedule of Equity and Non-Controlling Interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Balance Sheet</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock" xlink:label="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock" xlink:to="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock_lbl" xml:lang="en-US">Schedule of Gain on Deconsolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of Equity Method Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Market-Based Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Fully Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future payments Due Under Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Taxes Expenses (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="MDBH_AccountingPoliciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccountingPoliciesTable" xlink:to="MDBH_AccountingPoliciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AccountingPoliciesTable_lbl" xml:lang="en-US">AccountingPoliciesTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="MDBH_AccountingPolicies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccountingPolicies" xlink:to="MDBH_AccountingPolicies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AccountingPolicies_lbl" xml:lang="en-US">AccountingPolicies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to puchase common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Contract life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Common stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Warrants fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Estimated life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected annual volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Annual rate of dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesToAffiliate" xlink:label="us-gaap_AdvancesToAffiliate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesToAffiliate" xlink:to="us-gaap_AdvancesToAffiliate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesToAffiliate_lbl" xml:lang="en-US">Up-front fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured limits</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CashSIPCInsuredAmount" xlink:label="MDBH_CashSIPCInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CashSIPCInsuredAmount" xlink:to="MDBH_CashSIPCInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_CashSIPCInsuredAmount_lbl" xml:lang="en-US">Cash, SIPC insured limits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Unsegregated cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash uninsured limits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Revolving credit, maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid and other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Intangible assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PrepaidProfessionalFees" xlink:label="MDBH_PrepaidProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PrepaidProfessionalFees" xlink:to="MDBH_PrepaidProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PrepaidProfessionalFees_lbl" xml:lang="en-US">Prepaid professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Various prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xml:lang="en-US">Net unrealized gain (loss) on investment securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentOfInvestmentSecurities" xlink:to="MDBH_ImpairmentOfInvestmentSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ImpairmentOfInvestmentSecurities_2_lbl" xml:lang="en-US">Impairment of securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Variable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xml:lang="en-US">Credit non-usage fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Outstanding indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantDrawdowns" xlink:label="MDBH_GrantDrawdowns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantDrawdowns" xlink:to="MDBH_GrantDrawdowns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GrantDrawdowns_lbl" xml:lang="en-US">Grant drawdowns</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ResearchAndDevelopmentExpenseGross" xlink:label="MDBH_ResearchAndDevelopmentExpenseGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ResearchAndDevelopmentExpenseGross" xlink:to="MDBH_ResearchAndDevelopmentExpenseGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ResearchAndDevelopmentExpenseGross_lbl" xml:lang="en-US">Net of grant received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Patent and licensing legal and filing fees and costs</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="MDBH_InvestmentSecuritiesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValue" xlink:to="MDBH_InvestmentSecuritiesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvestmentSecuritiesAtFairValue_lbl" xml:lang="en-US">Investment securities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" xlink:label="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_lbl" xml:lang="en-US">Investment securities, at cost less impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_2_lbl" xml:lang="en-US">Investment securities, at fair value, held by the non-licensed broker dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xml:lang="en-US">Receipt from investment banking fees</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:label="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_lbl" xml:lang="en-US">Unrealized (loss) gains</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants, Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Weighted measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Developed software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized" xlink:label="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized" xlink:to="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized_lbl" xml:lang="en-US">Amounts billed but not recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_2_lbl" xml:lang="en-US">Deferred revenue, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Balance at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantCostsExpensed" xlink:label="MDBH_GrantCostsExpensed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantCostsExpensed" xlink:to="MDBH_GrantCostsExpensed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GrantCostsExpensed_lbl" xml:lang="en-US">Grant costs expensed</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantsForEquipmentPurchased" xlink:label="MDBH_GrantsForEquipmentPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantsForEquipmentPurchased" xlink:to="MDBH_GrantsForEquipmentPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GrantsForEquipmentPurchased_lbl" xml:lang="en-US">Grants for equipment purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantFees" xlink:label="MDBH_GrantFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantFees" xlink:to="MDBH_GrantFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GrantFees_lbl" xml:lang="en-US">Grant fees</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantFundsReceived" xlink:label="MDBH_GrantFundsReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantFundsReceived" xlink:to="MDBH_GrantFundsReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_GrantFundsReceived_lbl" xml:lang="en-US">Grant funds received</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RemovalOfBalanceDueToDeconsolidation" xlink:label="MDBH_RemovalOfBalanceDueToDeconsolidation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RemovalOfBalanceDueToDeconsolidation" xlink:to="MDBH_RemovalOfBalanceDueToDeconsolidation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_RemovalOfBalanceDueToDeconsolidation_lbl" xml:lang="en-US">Removal of balance due to deconsolidation of eXoZymes at November 14, 2024</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_GrantsReceivable_2_lbl" xml:lang="en-US">Balance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Long-lived assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:to="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_2_lbl" xml:lang="en-US">Unrealized (loss) on investment securities, net from the licensed broker dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:to="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_lbl" xml:lang="en-US">Investment securities, at fair value, held by the non-licensed broker dealer (1)</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RealizedInvestmentGainsLossesOne" xlink:label="MDBH_RealizedInvestmentGainsLossesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RealizedInvestmentGainsLossesOne" xlink:to="MDBH_RealizedInvestmentGainsLossesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_RealizedInvestmentGainsLossesOne_lbl" xml:lang="en-US">Realized gain on investment securities, net from the licensed broker dealer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeeIncome" xlink:to="us-gaap_FeeIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FeeIncome_2_lbl" xml:lang="en-US">Fee income from the licensed broker dealer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentOfInvestmentSecurities" xlink:to="MDBH_ImpairmentOfInvestmentSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="MDBH_ImpairmentOfInvestmentSecurities_3_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Operating expense, related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income and expense:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_2_lbl" xml:lang="en-US">Gain on deconsolidation of subsidiary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:to="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_2_lbl" xml:lang="en-US">Income (loss) before equity method investee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Less net loss attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_3_lbl" xml:lang="en-US">Unrealized (loss) on investment securities, net from the licensed broker dealer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EquityTable" xlink:label="MDBH_EquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EquityTable" xlink:to="MDBH_EquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EquityTable_lbl" xml:lang="en-US">EquityTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_Equity" xlink:label="MDBH_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_Equity" xlink:to="MDBH_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_Equity_lbl" xml:lang="en-US">Equity [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Non-controlling net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WeightedAverageNonControllingPercentage" xlink:label="MDBH_WeightedAverageNonControllingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WeightedAverageNonControllingPercentage" xlink:to="MDBH_WeightedAverageNonControllingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_WeightedAverageNonControllingPercentage_lbl" xml:lang="en-US">Weighted average non-controlling percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Net loss non-controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_MinorityInterest_2_lbl" xml:lang="en-US">Prior period balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DueToDeconsolidation" xlink:label="MDBH_DueToDeconsolidation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DueToDeconsolidation" xlink:to="MDBH_DueToDeconsolidation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DueToDeconsolidation_lbl" xml:lang="en-US">Removal of prior period balance of Exozyme due to deconsolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationToNonControllingInterest" xlink:label="MDBH_ShareBasedCompensationToNonControllingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationToNonControllingInterest" xlink:to="MDBH_ShareBasedCompensationToNonControllingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_ShareBasedCompensationToNonControllingInterest_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OwnershipChangeOfNoncontrollingInterest" xlink:label="MDBH_OwnershipChangeOfNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OwnershipChangeOfNoncontrollingInterest" xlink:to="MDBH_OwnershipChangeOfNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_OwnershipChangeOfNoncontrollingInterest_lbl" xml:lang="en-US">Ownership change of non-controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_MinorityInterest_3_lbl" xml:lang="en-US">Ending period balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Placement agent and selling agent warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Ownership interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Non-controlling interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="us-gaap_ProceedsFromContributionsFromParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromParent" xlink:to="us-gaap_ProceedsFromContributionsFromParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromParent_lbl" xml:lang="en-US">Capital infusions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Equity interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationTable" xlink:label="MDBH_DeconsolidationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationTable" xlink:to="MDBH_DeconsolidationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeconsolidationTable_lbl" xml:lang="en-US">DeconsolidationTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:label="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:to="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_lbl" xml:lang="en-US">Equity method, net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfConsolidatedBalanceSheetTable" xlink:label="MDBH_ScheduleOfConsolidatedBalanceSheetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleOfConsolidatedBalanceSheetTable" xlink:to="MDBH_ScheduleOfConsolidatedBalanceSheetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ScheduleOfConsolidatedBalanceSheetTable_lbl" xml:lang="en-US">ScheduleOfConsolidatedBalanceSheetTable [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_3_lbl" xml:lang="en-US">Grants receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred IPO Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Due to affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredGrantReimbursement" xlink:label="MDBH_DeferredGrantReimbursement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredGrantReimbursement" xlink:to="MDBH_DeferredGrantReimbursement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredGrantReimbursement_lbl" xml:lang="en-US">Deferred grant reimbursement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Paid-in-capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfGainOnDeconsolidationTable" xlink:label="MDBH_ScheduleOfGainOnDeconsolidationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleOfGainOnDeconsolidationTable" xlink:to="MDBH_ScheduleOfGainOnDeconsolidationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ScheduleOfGainOnDeconsolidationTable_lbl" xml:lang="en-US">ScheduleOfGainOnDeconsolidationTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Subtotal of quoted closing price of Class A common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Quoted closing price of Class A common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Fair value of equity method investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Carrying Value of the NCI</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CarryingValueOfAssets" xlink:label="MDBH_CarryingValueOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CarryingValueOfAssets" xlink:to="MDBH_CarryingValueOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_CarryingValueOfAssets_lbl" xml:lang="en-US">Carrying value of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LessCarryingValueOfFormerInvestment" xlink:label="MDBH_LessCarryingValueOfFormerInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LessCarryingValueOfFormerInvestment" xlink:to="MDBH_LessCarryingValueOfFormerInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_LessCarryingValueOfFormerInvestment_lbl" xml:lang="en-US">Less carrying value of former investment</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CarryingValueOfWarrants" xlink:label="MDBH_CarryingValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CarryingValueOfWarrants" xlink:to="MDBH_CarryingValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_CarryingValueOfWarrants_lbl" xml:lang="en-US">Carrying value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_3_lbl" xml:lang="en-US">Gain on deconsolidation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_EquityMethodInvestments_2_lbl" xml:lang="en-US">Equity method investments, balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:to="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_2_lbl" xml:lang="en-US">Portion of loss from Invizyne</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" xlink:label="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" xlink:to="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents_lbl" xml:lang="en-US">Gain related to dilution events</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_EquityMethodInvestments_3_lbl" xml:lang="en-US">Equity method investments, balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US">Equity Method Investment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xml:lang="en-US">Equity method investment, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentOwnedBalanceShares_2_lbl" xml:lang="en-US">Owned shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Restricted Stock Units, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Restricted Stock Units, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Restricted Stock Units, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Number of Restricted Stock Units, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_lbl" xml:lang="en-US">Number of Restricted Stock Units, Exchanged/Modified</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exchanged/Modified</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_lbl" xml:lang="en-US">Number of Restricted Stock Units, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of Restricted Stock Units, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Exercisable and vested restricted stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercisable and vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, time-based stock options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, time-based stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_lbl" xml:lang="en-US">Number of Options, exchanged/modified</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:label="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:to="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exchanged/modified</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), time-based stock options exchanged/modified</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, expired/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, time-based stock options outstanding, at the end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, time-based stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), time-based stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), exchanged/modified</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, expired/cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years), market-based stock options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Stock options to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_lbl" xml:lang="en-US">Restricted stock units, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_2_lbl" xml:lang="en-US">Number of restricted stock units, canceled or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">RSU vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">Remaining weighted average years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Cancelled shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Number of restricted stock units, cancelled and converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock unit, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unvested portion market value</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_lbl" xml:lang="en-US">Sharebased payment award amortized amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Stock-based compensation term life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price per share, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_lbl" xml:lang="en-US">Remaining stock options vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Common stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected annual volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AveragePricePerShare" xlink:label="MDBH_AveragePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AveragePricePerShare" xlink:to="MDBH_AveragePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AveragePricePerShare_lbl" xml:lang="en-US">Average price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_lbl" xml:lang="en-US">Exercisable period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss) attributable to MDB Capital Holdings, LLC</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares outstanding &#8211; basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net income (loss) per share &#8211; basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) attributable to MDB Capital Holdings, LLC</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Diluted shares outstanding &#8211;diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net income (loss) per share &#8211;diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Related party expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccruedExpenses" xlink:label="MDBH_AccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccruedExpenses" xlink:to="MDBH_AccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_AccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Value issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Tax paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CommitmentsAndContingenciesTable" xlink:label="MDBH_CommitmentsAndContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CommitmentsAndContingenciesTable" xlink:to="MDBH_CommitmentsAndContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">CommitmentsAndContingenciesTable [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_2_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NetCapital" xlink:label="srt_NetCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NetCapital" xlink:to="srt_NetCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NetCapital_lbl" xml:lang="en-US">Net capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RatioOfIndebtednessToNetCapital1" xlink:label="us-gaap_RatioOfIndebtednessToNetCapital1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RatioOfIndebtednessToNetCapital1" xlink:to="us-gaap_RatioOfIndebtednessToNetCapital1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RatioOfIndebtednessToNetCapital1_lbl" xml:lang="en-US">Percentage of aggregate indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumNetCapitalRequiredForEntity1" xlink:label="srt_MinimumNetCapitalRequiredForEntity1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumNetCapitalRequiredForEntity1" xlink:to="srt_MinimumNetCapitalRequiredForEntity1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumNetCapitalRequiredForEntity1_lbl" xml:lang="en-US">Aggregate indebtedness calculated amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Employer contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">License fee</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentForLicensedProducts" xlink:label="MDBH_PaymentForLicensedProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentForLicensedProducts" xlink:to="MDBH_PaymentForLicensedProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PaymentForLicensedProducts_lbl" xml:lang="en-US">Payments for licensed products</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DisclosureLeasesAbstract" xlink:to="MDBH_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term in years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-Term Lease, Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Total operating lease costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DisclosureLeasesAbstract" xlink:to="MDBH_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="MDBH_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Payments Due Under Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xml:lang="en-US">2029 and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less effects of discounting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRent" xlink:label="us-gaap_AdvanceRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRent" xlink:to="us-gaap_AdvanceRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvanceRent_lbl" xml:lang="en-US">Initial rent, per month</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BaseRent" xlink:label="MDBH_BaseRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BaseRent" xlink:to="MDBH_BaseRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_BaseRent_lbl" xml:lang="en-US">Base rent, per month</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AnnualOperatingCostIncreasePercentage" xlink:label="MDBH_AnnualOperatingCostIncreasePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AnnualOperatingCostIncreasePercentage" xlink:to="MDBH_AnnualOperatingCostIncreasePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AnnualOperatingCostIncreasePercentage_lbl" xml:lang="en-US">Annual operating cost increase percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Extension term of lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Option to extend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S Federal statutory income rate, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S Federal statutory income rate, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State, net of federal tax benefit, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State, net of federal tax benefit, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:label="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:to="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_lbl" xml:lang="en-US">Income/loss excluded from nontaxable entities, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_lbl" xml:lang="en-US">Income/loss excluded from nontaxable entities, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:label="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:to="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_lbl" xml:lang="en-US">Permanent differences, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Meals and entertainment, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Meals and entertainment, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock options, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock options, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:label="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:to="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount_lbl" xml:lang="en-US">Equity award vesting, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_lbl" xml:lang="en-US">Equity award vesting, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:label="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:to="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount_lbl" xml:lang="en-US">Modification of equity awards, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Equity award vesting, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Return-to-provision adjustments, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xml:lang="en-US">Return-to-provision adjustments, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:label="MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:to="MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl" xml:lang="en-US">Valuation allowance, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_lbl" xml:lang="en-US">Valuation allowance, Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_4_lbl" xml:lang="en-US">Effective rate, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective rate, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:label="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:to="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S Federal statutory income rate, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S Federal statutory income rate, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsInStartupExpenditures" xlink:label="MDBH_DeferredTaxAssetsInStartupExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsInStartupExpenditures" xlink:to="MDBH_DeferredTaxAssetsInStartupExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxAssetsInStartupExpenditures_lbl" xml:lang="en-US">Start-up expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsInOrganizationalExpenditures" xlink:label="MDBH_DeferredTaxAssetsInOrganizationalExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsInOrganizationalExpenditures" xlink:to="MDBH_DeferredTaxAssetsInOrganizationalExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxAssetsInOrganizationalExpenditures_lbl" xml:lang="en-US">Organizational expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Sec 174 &#8211; Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsStockCompensation" xlink:label="MDBH_DeferredTaxAssetsStockCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsStockCompensation" xlink:to="MDBH_DeferredTaxAssetsStockCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxAssetsStockCompensation_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsLeaseLiability" xlink:label="MDBH_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsLeaseLiability" xlink:to="MDBH_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment principally due to differences in depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsBonusExpense" xlink:label="MDBH_DeferredTaxAssetsBonusExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsBonusExpense" xlink:to="MDBH_DeferredTaxAssetsBonusExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxAssetsBonusExpense_lbl" xml:lang="en-US">Bonus expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable contribution carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsImpairmentExpense" xlink:label="MDBH_DeferredTaxAssetsImpairmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsImpairmentExpense" xlink:to="MDBH_DeferredTaxAssetsImpairmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxAssetsImpairmentExpense_lbl" xml:lang="en-US">Impairment expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxLiabilitiesInvestmentSecurities" xlink:label="MDBH_DeferredTaxLiabilitiesInvestmentSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxLiabilitiesInvestmentSecurities" xlink:to="MDBH_DeferredTaxLiabilitiesInvestmentSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MDBH_DeferredTaxLiabilitiesInvestmentSecurities_lbl" xml:lang="en-US">Investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Other noncurrent assets/(liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxesPaid_2_lbl" xml:lang="en-US">Cash taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Decrease in deferred tax assets valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3_lbl" xml:lang="en-US">Restricted stock units, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValue" xlink:to="MDBH_InvestmentSecuritiesAtFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvestmentSecuritiesAtFairValue_doc" xml:lang="en-US">Investment securities at fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PayablesToCustomersCurrentAndNonCurrent" xlink:to="MDBH_PayablesToCustomersCurrentAndNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PayablesToCustomersCurrentAndNonCurrent_doc" xml:lang="en-US">Payables to customers current and non current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentOfInvestmentSecurities" xlink:to="MDBH_ImpairmentOfInvestmentSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ImpairmentOfInvestmentSecurities_doc" xml:lang="en-US">Impairment of investment securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CompensationCosts" xlink:to="MDBH_CompensationCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_CompensationCosts_doc" xml:lang="en-US">Compensation costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OperatingExpenseRelatedParty" xlink:to="MDBH_OperatingExpenseRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_OperatingExpenseRelatedParty_doc" xml:lang="en-US">Operating expense related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ClearingAndOtherCharges" xlink:to="MDBH_ClearingAndOtherCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ClearingAndOtherCharges_doc" xml:lang="en-US">Clearing and other charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NetOperatingIncomeLoss" xlink:to="MDBH_NetOperatingIncomeLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_NetOperatingIncomeLoss_doc" xml:lang="en-US">Net operating loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MiscellaneousIncome" xlink:to="MDBH_MiscellaneousIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_MiscellaneousIncome_doc" xml:lang="en-US">Miscellaneous income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GainRelatedToDilutionEvents" xlink:to="MDBH_GainRelatedToDilutionEvents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GainRelatedToDilutionEvents_doc" xml:lang="en-US">Gain related to dilution events.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:to="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_doc" xml:lang="en-US">Net income (loss) before equity method investee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeLossFromEquityMethodInvestment" xlink:to="MDBH_IncomeLossFromEquityMethodInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeLossFromEquityMethodInvestment_doc" xml:lang="en-US">Equity in loss of equity method investee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectOfDeconsolidationOfSubsidiary" xlink:to="MDBH_EffectOfDeconsolidationOfSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EffectOfDeconsolidationOfSubsidiary_doc" xml:lang="en-US">Effect of deconsolidation of subsidiary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:to="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_doc" xml:lang="en-US">Accretion of investments at amortized cost (U.S Treasury Bills).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DilutionOfDeferredGrantReimbursement" xlink:to="MDBH_DilutionOfDeferredGrantReimbursement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DilutionOfDeferredGrantReimbursement_doc" xml:lang="en-US">Dilution of deferred grant reimbursement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PortionOfLossFromEquityInvestment" xlink:to="MDBH_PortionOfLossFromEquityInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PortionOfLossFromEquityInvestment_doc" xml:lang="en-US">Portion of loss from equity investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:to="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal_doc" xml:lang="en-US">Proceeds from warrants issued as part of investment banking deal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeRecognizedFromWarrantsReceived" xlink:to="MDBH_IncomeRecognizedFromWarrantsReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeRecognizedFromWarrantsReceived_doc" xml:lang="en-US">Income recognized from warrants received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentOfInvestmentsSecurities" xlink:to="MDBH_ImpairmentOfInvestmentsSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ImpairmentOfInvestmentsSecurities_doc" xml:lang="en-US">Impairment of investments securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncreaseDecreaseInPayablesToNoncustomers" xlink:to="MDBH_IncreaseDecreaseInPayablesToNoncustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncreaseDecreaseInPayablesToNoncustomers_doc" xml:lang="en-US">Increase decrease in payables to noncustomers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ProceedsFromInvestmentsSecurities" xlink:to="MDBH_ProceedsFromInvestmentsSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ProceedsFromInvestmentsSecurities_doc" xml:lang="en-US">Proceeds from investments securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentsToAcquireInvestmentsSecurities" xlink:to="MDBH_PaymentsToAcquireInvestmentsSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PaymentsToAcquireInvestmentsSecurities_doc" xml:lang="en-US">Payments to acquire investments securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentForDeferredGrantReimbursement" xlink:to="MDBH_PaymentForDeferredGrantReimbursement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PaymentForDeferredGrantReimbursement_doc" xml:lang="en-US">Payment for deferred grant reimbursement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal" xlink:to="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal_doc" xml:lang="en-US">Warrants received as part of investment banking deal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" xlink:to="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear_doc" xml:lang="en-US">Relienquishment of deferred costs of initial public offering from prior year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" xlink:to="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment_doc" xml:lang="en-US">Investment securities at cost less impairment received in lieu of cash payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" xlink:to="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering_doc" xml:lang="en-US">Issuance of warrants to purchase Class A stock related to the initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MDBMinnesotaOneIncMember" xlink:to="MDBH_MDBMinnesotaOneIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_MDBMinnesotaOneIncMember_doc" xml:lang="en-US">MDB Minnesota One Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MayoFoundationMember" xlink:to="MDBH_MayoFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_MayoFoundationMember_doc" xml:lang="en-US">Mayo Foundation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationPolicyTextBlock" xlink:to="MDBH_DeconsolidationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeconsolidationPolicyTextBlock_doc" xml:lang="en-US">Deconsolidation [Policy Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EmergingGrowthCompanyPolicyTextBlock" xlink:to="MDBH_EmergingGrowthCompanyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EmergingGrowthCompanyPolicyTextBlock_doc" xml:lang="en-US">Emerging Growth Company Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SegregatedCashAndDepositsPolicyTextBlock" xlink:to="MDBH_SegregatedCashAndDepositsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SegregatedCashAndDepositsPolicyTextBlock_doc" xml:lang="en-US">Segregated Cash And Deposits Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock" xlink:to="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock_doc" xml:lang="en-US">Prepaid And Other Current Assets [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PrepaidProfessionalFees" xlink:to="MDBH_PrepaidProfessionalFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PrepaidProfessionalFees_doc" xml:lang="en-US">Prepaid professional fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" xlink:to="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_doc" xml:lang="en-US">Schedule of Investment Securities Broker Dealer [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" xlink:to="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_doc" xml:lang="en-US">Schedule of Investment Securities Non Broker Dealer [TableText Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_doc" xml:lang="en-US">Investment securities at cost less impairment non broker dealer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SAFEMember" xlink:to="MDBH_SAFEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SAFEMember_doc" xml:lang="en-US">SAFE [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_doc" xml:lang="en-US">Fair value measurement with unobservable input reconciliation recurring basis asset gain loss included in other comprehensive income loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_doc" xml:lang="en-US">Property Plant And Equipment Estimated Useful Lives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LaboratoryEquipmentMember" xlink:to="MDBH_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DevelopedSoftwareMember" xlink:to="MDBH_DevelopedSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DevelopedSoftwareMember_doc" xml:lang="en-US">Developed Software [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_TechnologyDevelopmentMember" xlink:to="MDBH_TechnologyDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_TechnologyDevelopmentMember_doc" xml:lang="en-US">Technology Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized" xlink:to="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized_doc" xml:lang="en-US">Contract with customer liability amounts billed not recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccountingForResearchGrantsPolicyTextBlock" xlink:to="MDBH_AccountingForResearchGrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_AccountingForResearchGrantsPolicyTextBlock_doc" xml:lang="en-US">Accounting For Research Grants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantsReceivableActivityTableTextBlock" xlink:to="MDBH_GrantsReceivableActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GrantsReceivableActivityTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of grants receivable activity table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantCostsExpensed" xlink:to="MDBH_GrantCostsExpensed_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GrantCostsExpensed_doc" xml:lang="en-US">Amount of grant costs expensed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantsForEquipmentPurchased" xlink:to="MDBH_GrantsForEquipmentPurchased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GrantsForEquipmentPurchased_doc" xml:lang="en-US">Amount of grants for equipment purchased.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantFees" xlink:to="MDBH_GrantFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GrantFees_doc" xml:lang="en-US">Amount of grant fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantFundsReceived" xlink:to="MDBH_GrantFundsReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GrantFundsReceived_doc" xml:lang="en-US">Amount of grant funds received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RemovalOfBalanceDueToDeconsolidation" xlink:to="MDBH_RemovalOfBalanceDueToDeconsolidation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_RemovalOfBalanceDueToDeconsolidation_doc" xml:lang="en-US">Removal of balance due to deconsolidation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_GrantDrawdowns" xlink:to="MDBH_GrantDrawdowns_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_GrantDrawdowns_doc" xml:lang="en-US">Grant drawdowns.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ResearchAndDevelopmentExpenseGross" xlink:to="MDBH_ResearchAndDevelopmentExpenseGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ResearchAndDevelopmentExpenseGross_doc" xml:lang="en-US">Research and development expense gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" xlink:to="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_doc" xml:lang="en-US">Patent And Licensing Legal And Filing Fees And Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:to="MDBH_BrokerDealerIntellectualPropertyServiceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_BrokerDealerIntellectualPropertyServiceMember_doc" xml:lang="en-US">Broker Dealer &amp; Intellectual Property Service [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OtherSegmentsMember" xlink:to="MDBH_OtherSegmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_OtherSegmentsMember_doc" xml:lang="en-US">Other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EliminationsMember" xlink:to="MDBH_EliminationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EliminationsMember_doc" xml:lang="en-US">Eliminations [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RealizedInvestmentGainsLossesOne" xlink:to="MDBH_RealizedInvestmentGainsLossesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_RealizedInvestmentGainsLossesOne_doc" xml:lang="en-US">Realized investment gains losses one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExclusiveLicenseAgreementTextBlock" xlink:to="MDBH_ExclusiveLicenseAgreementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ExclusiveLicenseAgreementTextBlock_doc" xml:lang="en-US">Exclusive License Agreement [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LicenseAgreementMember" xlink:to="MDBH_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentForLicensedProducts" xlink:to="MDBH_PaymentForLicensedProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PaymentForLicensedProducts_doc" xml:lang="en-US">Payment for licensed products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PhaseIIclinicalMember" xlink:to="MDBH_PhaseIIclinicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PhaseIIclinicalMember_doc" xml:lang="en-US">Phase II clinical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PhaseIIIclinicalMember" xlink:to="MDBH_PhaseIIIclinicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PhaseIIIclinicalMember_doc" xml:lang="en-US">Phase III clinical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NewDrugApplicationFirstMember" xlink:to="MDBH_NewDrugApplicationFirstMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_NewDrugApplicationFirstMember_doc" xml:lang="en-US">New Drug Application First [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NewDrugApplicationMember" xlink:to="MDBH_NewDrugApplicationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_NewDrugApplicationMember_doc" xml:lang="en-US">New Drug Application [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BaseRent" xlink:to="MDBH_BaseRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_BaseRent_doc" xml:lang="en-US">Base rent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AnnualOperatingCostIncreasePercentage" xlink:to="MDBH_AnnualOperatingCostIncreasePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_AnnualOperatingCostIncreasePercentage_doc" xml:lang="en-US">Annual operating cost increase percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_doc" xml:lang="en-US">Lessee operating lease liability payments due after year three.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MinnesotaOneMember" xlink:to="MDBH_MinnesotaOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_MinnesotaOneMember_doc" xml:lang="en-US">Minnesota One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvizyneTechnologiesIncMember" xlink:to="MDBH_InvizyneTechnologiesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvizyneTechnologiesIncMember_doc" xml:lang="en-US">Invizyne Technologies Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExozymeTechnologiesIncMember" xlink:to="MDBH_ExozymeTechnologiesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ExozymeTechnologiesIncMember_doc" xml:lang="en-US">Exozyme Technologies Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsInStartupExpenditures" xlink:to="MDBH_DeferredTaxAssetsInStartupExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxAssetsInStartupExpenditures_doc" xml:lang="en-US">Deferred tax assets in startup expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsStockCompensation" xlink:to="MDBH_DeferredTaxAssetsStockCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxAssetsStockCompensation_doc" xml:lang="en-US">Deferred tax assets stock compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsLeaseLiability" xlink:to="MDBH_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsBonusExpense" xlink:to="MDBH_DeferredTaxAssetsBonusExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxAssetsBonusExpense_doc" xml:lang="en-US">Deferred tax assets bonus expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsImpairmentExpense" xlink:to="MDBH_DeferredTaxAssetsImpairmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxAssetsImpairmentExpense_doc" xml:lang="en-US">Deferred tax assets impairment expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxLiabilitiesInvestmentSecurities" xlink:to="MDBH_DeferredTaxLiabilitiesInvestmentSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxLiabilitiesInvestmentSecurities_doc" xml:lang="en-US">Deferred tax liabilities investment securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxAssetsInOrganizationalExpenditures" xlink:to="MDBH_DeferredTaxAssetsInOrganizationalExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredTaxAssetsInOrganizationalExpenditures_doc" xml:lang="en-US">Deferred tax assets in organizational expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock" xlink:to="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock_doc" xml:lang="en-US">Schedule Of Equity And Non Controlling Interests [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WeightedAverageNonControllingPercentage" xlink:to="MDBH_WeightedAverageNonControllingPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_WeightedAverageNonControllingPercentage_doc" xml:lang="en-US">Weighted average non-controlling percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DueToDeconsolidation" xlink:to="MDBH_DueToDeconsolidation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DueToDeconsolidation_doc" xml:lang="en-US">Due to deconsolidation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationToNonControllingInterest" xlink:to="MDBH_ShareBasedCompensationToNonControllingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationToNonControllingInterest_doc" xml:lang="en-US">Share based compensation to non controlling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OwnershipChangeOfNoncontrollingInterest" xlink:to="MDBH_OwnershipChangeOfNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_OwnershipChangeOfNoncontrollingInterest_doc" xml:lang="en-US">Ownership change of non-controlling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationDisclosureTextBlock" xlink:to="MDBH_DeconsolidationDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeconsolidationDisclosureTextBlock_doc" xml:lang="en-US">Deconsolidation Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExozymesIncMember" xlink:to="MDBH_ExozymesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ExozymesIncMember_doc" xml:lang="en-US">Exozymes Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredGrantReimbursement" xlink:to="MDBH_DeferredGrantReimbursement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DeferredGrantReimbursement_doc" xml:lang="en-US">Deferred Grant Reimbursement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock" xlink:to="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock_doc" xml:lang="en-US">Schedule Of Gain On Deconsolidation [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CarryingValueOfAssets" xlink:to="MDBH_CarryingValueOfAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_CarryingValueOfAssets_doc" xml:lang="en-US">Carrying value of assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_LessCarryingValueOfFormerInvestment" xlink:to="MDBH_LessCarryingValueOfFormerInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_LessCarryingValueOfFormerInvestment_doc" xml:lang="en-US">Less carrying value of former investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CarryingValueOfWarrants" xlink:to="MDBH_CarryingValueOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_CarryingValueOfWarrants_doc" xml:lang="en-US">Carrying value of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" xlink:to="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents_doc" xml:lang="en-US">Gain related to dilution events.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_doc" xml:lang="en-US">Income loss excluded from nontaxable entities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_doc" xml:lang="en-US">Provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_MarketBasedMember" xlink:to="MDBH_MarketBasedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_MarketBasedMember_doc" xml:lang="en-US">Market Based [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:to="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_doc" xml:lang="en-US">Income tax reconciliation income tax expenses provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award amortized amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_TimeBasedMember" xlink:to="MDBH_TimeBasedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_TimeBasedMember_doc" xml:lang="en-US">Time Based [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exchanged and modified in period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options nonvested vested and expected to vest exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exchanged and modified weighted average grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options grants in vested and expected to vest exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options remaining stock options vesting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options exchanged and modified in period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:to="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_doc" xml:lang="en-US">Equity award vesting.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:to="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award options exchanged and modified in period weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share based compensation arrangement by sharebased payment award options exchanged weighted average remaining contractual term 2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:to="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount_doc" xml:lang="en-US">Income tax reconciliation modification of equity awards amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AveragePricePerShare" xlink:to="MDBH_AveragePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_AveragePricePerShare_doc" xml:lang="en-US">Average price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term 1 vesting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" xlink:to="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding exchanged and modified weighted average remaining contractual term 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ENDRAMember" xlink:to="MDBH_ENDRAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ENDRAMember_doc" xml:lang="en-US">ENDRA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ExozymesMember" xlink:to="MDBH_ExozymesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ExozymesMember_doc" xml:lang="en-US">Exozymes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PublicVenturesMember" xlink:to="MDBH_PublicVenturesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_PublicVenturesMember_doc" xml:lang="en-US">Public Ventures [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DTCMembershipRequirementsMember" xlink:to="MDBH_DTCMembershipRequirementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_DTCMembershipRequirementsMember_doc" xml:lang="en-US">DTC Membership Requirements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccruedExpenses" xlink:to="MDBH_AccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_AccruedExpenses_doc" xml:lang="en-US">Accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:to="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount_doc" xml:lang="en-US">Income tax reconciliation equity in equity award vesting amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:to="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_doc" xml:lang="en-US">Income tax reconciliation income loss excluded from nontaxable entities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ImpairmentMember" xlink:to="MDBH_ImpairmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ImpairmentMember_doc" xml:lang="en-US">Impairment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_SimpleAgreementOnFutureEquitiesMember" xlink:to="MDBH_SimpleAgreementOnFutureEquitiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_SimpleAgreementOnFutureEquitiesMember_doc" xml:lang="en-US">Simple Agreement on Future Equities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NoInsiderTradingFlag" xlink:to="MDBH_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ResearchAndDevelopmentGrants" xlink:to="MDBH_ResearchAndDevelopmentGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_ResearchAndDevelopmentGrants_doc" xml:lang="en-US">Research and development grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BrokerDealerAndIntellectualPropertyServiceMember" xlink:to="MDBH_BrokerDealerAndIntellectualPropertyServiceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_BrokerDealerAndIntellectualPropertyServiceMember_doc" xml:lang="en-US">Broker Dealer And Intellectual Property Service [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_CashSIPCInsuredAmount" xlink:to="MDBH_CashSIPCInsuredAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_CashSIPCInsuredAmount_doc" xml:lang="en-US">Cash insured amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_Netincomeloss1" xlink:to="MDBH_Netincomeloss1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_Netincomeloss1_doc" xml:lang="en-US">The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_doc" xml:lang="en-US">Investment securities, at fair value, held by the non-licensed broker dealer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:to="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer_doc" xml:lang="en-US">Unrealized gain on investment securities, net from non-licensed broker dealer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:to="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_doc" xml:lang="en-US">Unrealized loss on investment securities, net from non-licensed broker dealer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:to="MDBH_WarrantsOfPubliclyTradedCompaniesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_WarrantsOfPubliclyTradedCompaniesMember_doc" xml:lang="en-US">Warrants of Publicly Traded Companies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" xlink:to="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_WarrantsOfNonPubliclyTradedCompaniesMember_doc" xml:lang="en-US">Warrants of Non Publicly Traded Companies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NonBrokerDealerMember" xlink:to="MDBH_NonBrokerDealerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_NonBrokerDealerMember_doc" xml:lang="en-US">Non Broker Dealer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:to="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer_doc" xml:lang="en-US">Investment securities, at fair value, held by the licensed broker dealer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_BrokerDealerMember" xlink:to="MDBH_BrokerDealerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_BrokerDealerMember_doc" xml:lang="en-US">Broker Dealer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:to="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_doc" xml:lang="en-US">Investments securities, at fair value, held by the non-licensed broker dealer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_USFederalTaxMember" xlink:to="MDBH_USFederalTaxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_USFederalTaxMember_doc" xml:lang="en-US">U.S Federal Tax [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_FloridaIncomeTaxMember" xlink:to="MDBH_FloridaIncomeTaxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MDBH_FloridaIncomeTaxMember_doc" xml:lang="en-US">Florida Income Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeTermOfLeaseMember" xlink:to="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember_lbl" xml:lang="en-US">Useful Life, Lease Term [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:to="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_4_lbl" xml:lang="en-US">UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_2_lbl" xml:lang="en-US">Operating Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_NetOperatingIncomeLoss" xlink:to="MDBH_NetOperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_NetOperatingIncomeLoss_3_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:to="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills_3_lbl" xml:lang="en-US">AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions_2_lbl" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2_lbl" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeRecognizedFromWarrantsReceived" xlink:to="MDBH_IncomeRecognizedFromWarrantsReceived_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeRecognizedFromWarrantsReceived_3_lbl" xml:lang="en-US">IncomeRecognizedFromWarrantsReceived</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Due from Related Parties, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPayablesToCustomers" xlink:to="us-gaap_IncreaseDecreaseInPayablesToCustomers_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPayablesToCustomers_2_lbl" xml:lang="en-US">Increase (Decrease) in Payables to Customers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentsToAcquireInvestmentsSecurities" xlink:to="MDBH_PaymentsToAcquireInvestmentsSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PaymentsToAcquireInvestmentsSecurities_3_lbl" xml:lang="en-US">PaymentsToAcquireInvestmentsSecurities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_PaymentForDeferredGrantReimbursement" xlink:to="MDBH_PaymentForDeferredGrantReimbursement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_PaymentForDeferredGrantReimbursement_3_lbl" xml:lang="en-US">PaymentForDeferredGrantReimbursement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_2_lbl" xml:lang="en-US">Income Taxes Paid, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:to="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations_2_lbl" xml:lang="en-US">Cash and Securities Segregated under Federal and Other Regulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationDisclosureTextBlock" xlink:to="MDBH_DeconsolidationDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeconsolidationDisclosureTextBlock_3_lbl" xml:lang="en-US">Deconsolidation Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeconsolidationPolicyTextBlock" xlink:to="MDBH_DeconsolidationPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeconsolidationPolicyTextBlock_3_lbl" xml:lang="en-US">DeconsolidationPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_2_lbl" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_3_lbl" xml:lang="en-US">Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_RealizedInvestmentGainsLossesOne" xlink:to="MDBH_RealizedInvestmentGainsLossesOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_RealizedInvestmentGainsLossesOne_3_lbl" xml:lang="en-US">RealizedInvestmentGainsLossesOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_2_lbl" xml:lang="en-US">Labor and Related Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationToNonControllingInterest" xlink:to="MDBH_ShareBasedCompensationToNonControllingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationToNonControllingInterest_3_lbl" xml:lang="en-US">ShareBasedCompensationToNonControllingInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_OwnershipChangeOfNoncontrollingInterest" xlink:to="MDBH_OwnershipChangeOfNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_OwnershipChangeOfNoncontrollingInterest_3_lbl" xml:lang="en-US">OwnershipChangeOfNoncontrollingInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" xlink:to="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents_3_lbl" xml:lang="en-US">EquityMethodInvestmentsGainRelatedToDilutionEvents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_AccruedExpenses" xlink:to="MDBH_AccruedExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_AccruedExpenses_3_lbl" xml:lang="en-US">AccruedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:to="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MDBH_DeferredTaxLiabilitiesInvestmentSecurities" xlink:to="MDBH_DeferredTaxLiabilitiesInvestmentSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MDBH_DeferredTaxLiabilitiesInvestmentSecurities_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesInvestmentSecurities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>mdbh-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Cover" roleURI="http://mdb.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://mdb.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfOperations" roleURI="http://mdb.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfOperationsParenthetical" roleURI="http://mdb.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfChangesInEquity" roleURI="http://mdb.com/role/StatementsOfChangesInEquity" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfCashFlows" roleURI="http://mdb.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#StatementsOfCashFlowsSupplementalDisclosures" roleURI="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReporting" roleURI="http://mdb.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterests" roleURI="http://mdb.com/role/EquityAndNon-controllingInterests" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Deconsolidation" roleURI="http://mdb.com/role/Deconsolidation" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestment" roleURI="http://mdb.com/role/EquityMethodInvestment" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensation" roleURI="http://mdb.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShare" roleURI="http://mdb.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#RelatedPartyTransactions" roleURI="http://mdb.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#CommitmentsAndContingencies" roleURI="http://mdb.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EmployeeBenefitPlans" roleURI="http://mdb.com/role/EmployeeBenefitPlans" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ExclusiveLicenseAgreementMdbMinnesotaOne" roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Leases" roleURI="http://mdb.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxes" roleURI="http://mdb.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SubsequentEvents" roleURI="http://mdb.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReportingTables" roleURI="http://mdb.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterestsTables" roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#DeconsolidationTables" roleURI="http://mdb.com/role/DeconsolidationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestmentTables" roleURI="http://mdb.com/role/EquityMethodInvestmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensationTables" roleURI="http://mdb.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShareTables" roleURI="http://mdb.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#LeasesTables" roleURI="http://mdb.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxesTables" roleURI="http://mdb.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" roleURI="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfInvestmentSecuritiesBrokerDealerDetails" roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" roleURI="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" roleURI="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" roleURI="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfChangesInDeferredRevenueDetails" roleURI="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SummaryOfGrantsReceivableActivityDetails" roleURI="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" roleURI="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfStatementOfOperationBySegmentDetails" roleURI="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://mdb.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEquityAndNon-controllingInterestsDetails" roleURI="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityAndNon-controllingInterestsDetailsNarrative" roleURI="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#DeconsolidationDetailsNarrative" roleURI="http://mdb.com/role/DeconsolidationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfConsolidatedBalanceSheetDetails" roleURI="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfGainOnDeconsolidationDetails" roleURI="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfEquityMethodInvestmentDetails" roleURI="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EquityMethodInvestmentDetailsNarrative" roleURI="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfTime-basedStockOptionActivityDetails" roleURI="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfMarket-basedStockOptionActivityDetails" roleURI="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfBasicAndFullyDilutedDetails" roleURI="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EarningsPerShareDetailsNarrative" roleURI="http://mdb.com/role/EarningsPerShareDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#EmployeeBenefitPlansDetailsNarrative" roleURI="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" roleURI="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfOperatingLeaseCostDetails" roleURI="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" roleURI="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#LeasesDetailsNarrative" roleURI="http://mdb.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfIncomeTaxesExpensesBenefitDetails" roleURI="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://mdb.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="mdbh-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://mdb.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PayablesToCustomersCurrentAndNonCurrent" xlink:label="loc_MDBHPayablesToCustomersCurrentAndNonCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_MDBHPayablesToCustomersCurrentAndNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaapOperatingIncomeLossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:label="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:label="loc_MDBHUnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHUnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeeIncome" xlink:label="loc_us-gaapFeeIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_us-gaapFeeIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_us-gaapOtherOperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CompensationCosts" xlink:label="loc_MDBHCompensationCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_MDBHCompensationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OperatingExpenseRelatedParty" xlink:label="loc_MDBHOperatingExpenseRelatedParty" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_MDBHOperatingExpenseRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommunicationsAndInformationTechnology" xlink:label="loc_us-gaapCommunicationsAndInformationTechnology" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapCommunicationsAndInformationTechnology" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ClearingAndOtherCharges" xlink:label="loc_MDBHClearingAndOtherCharges" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_MDBHClearingAndOtherCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NetOperatingIncomeLoss" xlink:label="loc_MDBHNetOperatingIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHNetOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeAbstract" xlink:label="loc_us-gaapInterestAndOtherIncomeAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestAndOtherIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MiscellaneousIncome" xlink:label="loc_MDBHMiscellaneousIncome" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract" xlink:to="loc_MDBHMiscellaneousIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract" xlink:to="loc_MDBHGainRelatedToDilutionEvents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterestAndOtherIncomeAbstract" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromEquityMethodInvestment" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHIncomeLossFromEquityMethodInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ResearchAndDevelopmentGrants" xlink:label="loc_MDBHResearchAndDevelopmentGrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_MDBHResearchAndDevelopmentGrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfChangesInEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_Netincomeloss1" xlink:label="loc_MDBHNetincomeloss1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHNetincomeloss1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:label="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectOfDeconsolidationOfSubsidiary" xlink:label="loc_MDBHEffectOfDeconsolidationOfSubsidiary" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHEffectOfDeconsolidationOfSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:label="loc_MDBHAccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHAccretionOfInvestmentsAtAmortizedCostUSTreasuryBills" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="loc_us-gaapEquityMethodInvestmentDividendsOrDistributions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DilutionOfDeferredGrantReimbursement" xlink:label="loc_MDBHDilutionOfDeferredGrantReimbursement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHDilutionOfDeferredGrantReimbursement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PortionOfLossFromEquityInvestment" xlink:label="loc_MDBHPortionOfLossFromEquityInvestment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHPortionOfLossFromEquityInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHGainRelatedToDilutionEvents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:label="loc_MDBHProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeRecognizedFromWarrantsReceived" xlink:label="loc_MDBHIncomeRecognizedFromWarrantsReceived" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHIncomeRecognizedFromWarrantsReceived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentsSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentsSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MDBHImpairmentOfInvestmentsSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPayablesToCustomers" xlink:label="loc_us-gaapIncreaseDecreaseInPayablesToCustomers" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPayablesToCustomers" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncreaseDecreaseInPayablesToNoncustomers" xlink:label="loc_MDBHIncreaseDecreaseInPayablesToNoncustomers" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_MDBHIncreaseDecreaseInPayablesToNoncustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentsToAcquireInvestmentsSecurities" xlink:label="loc_MDBHPaymentsToAcquireInvestmentsSecurities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_MDBHPaymentsToAcquireInvestmentsSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ProceedsFromInvestmentsSecurities" xlink:label="loc_MDBHProceedsFromInvestmentsSecurities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_MDBHProceedsFromInvestmentsSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentForDeferredGrantReimbursement" xlink:label="loc_MDBHPaymentForDeferredGrantReimbursement" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_MDBHPaymentForDeferredGrantReimbursement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaapPaymentsForProceedsFromProductiveAssets" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaapProceedsFromPaymentsToMinorityShareholders" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal" xlink:label="loc_MDBHWarrantsReceivedAsPartOfInvestmentBankingDeal" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_MDBHWarrantsReceivedAsPartOfInvestmentBankingDeal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" xlink:label="loc_MDBHRelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_MDBHRelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" xlink:label="loc_MDBHInvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_MDBHInvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" xlink:label="loc_MDBHIssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_MDBHIssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderFederalAndOtherRegulations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NoInsiderTradingFlag" xlink:label="loc_MDBHNoInsiderTradingFlag" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_MDBHNoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="999016 - Disclosure - Organization and Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999017 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReporting" xlink:title="999018 - Disclosure - Segment Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterests" xlink:title="999019 - Disclosure - Equity and Non-Controlling Interests">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/Deconsolidation" xlink:title="999020 - Disclosure - Deconsolidation">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureDeconsolidationAbstract" xlink:label="loc_MDBHDisclosureDeconsolidationAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationDisclosureTextBlock" xlink:label="loc_MDBHDeconsolidationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureDeconsolidationAbstract" xlink:to="loc_MDBHDeconsolidationDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestment" xlink:title="999021 - Disclosure - Equity Method Investment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaapEquityMethodInvestmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensation" xlink:title="999022 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShare" xlink:title="999023 - Disclosure - Earnings Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/RelatedPartyTransactions" xlink:title="999024 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EmployeeBenefitPlans" xlink:title="999026 - Disclosure - Employee Benefit Plans">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne" xlink:title="999027 - Disclosure - Exclusive License Agreement (MDB Minnesota One)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" xlink:label="loc_MDBHDisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExclusiveLicenseAgreementTextBlock" xlink:label="loc_MDBHExclusiveLicenseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" xlink:to="loc_MDBHExclusiveLicenseAgreementTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/Leases" xlink:title="999028 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureLeasesAbstract" xlink:label="loc_MDBHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxes" xlink:title="999029 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SubsequentEvents" xlink:title="999030 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999031 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationPolicyTextBlock" xlink:label="loc_MDBHDeconsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHDeconsolidationPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_MDBHEmergingGrowthCompanyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHEmergingGrowthCompanyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SegregatedCashAndDepositsPolicyTextBlock" xlink:label="loc_MDBHSegregatedCashAndDepositsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHSegregatedCashAndDepositsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositContractsPolicy" xlink:label="loc_us-gaapDepositContractsPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDepositContractsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock" xlink:label="loc_MDBHPrepaidAndOtherCurrentAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHPrepaidAndOtherCurrentAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingForResearchGrantsPolicyTextBlock" xlink:label="loc_MDBHAccountingForResearchGrantsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHAccountingForResearchGrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" xlink:label="loc_MDBHPatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHPatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" xlink:label="loc_MDBHScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" xlink:label="loc_MDBHScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_MDBHPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantsReceivableActivityTableTextBlock" xlink:label="loc_MDBHGrantsReceivableActivityTableTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHGrantsReceivableActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReportingTables" xlink:title="999033 - Disclosure - Segment Reporting (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaapLongLivedAssetsByGeographicAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapLongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterestsTables" xlink:title="999034 - Disclosure - Equity and Non-Controlling Interests (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock" xlink:label="loc_MDBHScheduleOfEquityAndNonControllingInterestsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_MDBHScheduleOfEquityAndNonControllingInterestsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/DeconsolidationTables" xlink:title="999035 - Disclosure - Deconsolidation (Tables)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureDeconsolidationAbstract" xlink:label="loc_MDBHDisclosureDeconsolidationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureDeconsolidationAbstract" xlink:to="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock" xlink:label="loc_MDBHScheduleOfGainOnDeconsolidationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureDeconsolidationAbstract" xlink:to="loc_MDBHScheduleOfGainOnDeconsolidationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestmentTables" xlink:title="999036 - Disclosure - Equity Method Investment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaapEquityMethodInvestmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensationTables" xlink:title="999037 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShareTables" xlink:title="999038 - Disclosure - Earnings Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/LeasesTables" xlink:title="999039 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureLeasesAbstract" xlink:label="loc_MDBHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxesTables" xlink:title="999040 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="999041 - Disclosure - Organization and Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_MDBHAccountingPolicies" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MDBMinnesotaOneIncMember" xlink:label="loc_MDBHMDBMinnesotaOneIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHMDBMinnesotaOneIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MayoFoundationMember" xlink:label="loc_MDBHMayoFoundationMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHMayoFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesToAffiliate" xlink:label="loc_us-gaapAdvancesToAffiliate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapAdvancesToAffiliate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_MDBHAccountingPolicies" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SAFEMember" xlink:label="loc_MDBHSAFEMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MDBHSAFEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CashSIPCInsuredAmount" xlink:label="loc_MDBHCashSIPCInsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHCashSIPCInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:label="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapCashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PrepaidProfessionalFees" xlink:label="loc_MDBHPrepaidProfessionalFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHPrepaidProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantDrawdowns" xlink:label="loc_MDBHGrantDrawdowns" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHGrantDrawdowns" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ResearchAndDevelopmentExpenseGross" xlink:label="loc_MDBHResearchAndDevelopmentExpenseGross" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHResearchAndDevelopmentExpenseGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails" xlink:title="999043 - Disclosure - Schedule of Investment Securities Broker Dealer (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_MDBHAccountingPolicies" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:label="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfNonPubliclyTradedCompaniesMember" xlink:label="loc_MDBHWarrantsOfNonPubliclyTradedCompaniesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHWarrantsOfNonPubliclyTradedCompaniesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerMember" xlink:label="loc_MDBHBrokerDealerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHBrokerDealerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails" xlink:title="999044 - Disclosure - Schedule of Investment Securities Non-Broker Dealer (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPoliciesTable" xlink:label="loc_MDBHAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccountingPolicies" xlink:label="loc_MDBHAccountingPolicies" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_MDBHAccountingPolicies" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WarrantsOfPubliclyTradedCompaniesMember" xlink:label="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHWarrantsOfPubliclyTradedCompaniesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SimpleAgreementOnFutureEquitiesMember" xlink:label="loc_MDBHSimpleAgreementOnFutureEquitiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHSimpleAgreementOnFutureEquitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentMember" xlink:label="loc_MDBHImpairmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MDBHImpairmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NonBrokerDealerMember" xlink:label="loc_MDBHNonBrokerDealerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNonBrokerDealerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHAccountingPolicies" xlink:to="loc_MDBHInvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999045 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValue" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_MDBHInvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails" xlink:title="999046 - Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:label="loc_MDBHFairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHFairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails" xlink:title="999047 - Disclosure - Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="999048 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LaboratoryEquipmentMember" xlink:label="loc_MDBHLaboratoryEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MDBHLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DevelopedSoftwareMember" xlink:label="loc_MDBHDevelopedSoftwareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MDBHDevelopedSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999049 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails" xlink:title="999050 - Disclosure - Schedule of Changes in Deferred Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized" xlink:label="loc_MDBHContractWithCustomerLiabilityAmountsBilledNotRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHContractWithCustomerLiabilityAmountsBilledNotRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails" xlink:title="999051 - Disclosure - Summary of Grants Receivable Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGrantsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantCostsExpensed" xlink:label="loc_MDBHGrantCostsExpensed" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHGrantCostsExpensed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantsForEquipmentPurchased" xlink:label="loc_MDBHGrantsForEquipmentPurchased" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHGrantsForEquipmentPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantFees" xlink:label="loc_MDBHGrantFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHGrantFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GrantFundsReceived" xlink:label="loc_MDBHGrantFundsReceived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHGrantFundsReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RemovalOfBalanceDueToDeconsolidation" xlink:label="loc_MDBHRemovalOfBalanceDueToDeconsolidation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MDBHRemovalOfBalanceDueToDeconsolidation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGrantsReceivable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails" xlink:title="999052 - Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerAndIntellectualPropertyServiceMember" xlink:label="loc_MDBHBrokerDealerAndIntellectualPropertyServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHBrokerDealerAndIntellectualPropertyServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TechnologyDevelopmentMember" xlink:label="loc_MDBHTechnologyDevelopmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHTechnologyDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OtherSegmentsMember" xlink:label="loc_MDBHOtherSegmentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHOtherSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EliminationsMember" xlink:label="loc_MDBHEliminationsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHEliminationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:label="loc_MDBHBrokerDealerIntellectualPropertyServiceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHBrokerDealerIntellectualPropertyServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails" xlink:title="999053 - Disclosure - Schedule of Statement of Operation by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BrokerDealerIntellectualPropertyServiceMember" xlink:label="loc_MDBHBrokerDealerIntellectualPropertyServiceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHBrokerDealerIntellectualPropertyServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TechnologyDevelopmentMember" xlink:label="loc_MDBHTechnologyDevelopmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHTechnologyDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OtherSegmentsMember" xlink:label="loc_MDBHOtherSegmentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHOtherSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EliminationsMember" xlink:label="loc_MDBHEliminationsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_MDBHEliminationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="loc_us-gaapOperatingIncomeLossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:label="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHUnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:label="loc_MDBHInvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHInvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_RealizedInvestmentGainsLossesOne" xlink:label="loc_MDBHRealizedInvestmentGainsLossesOne" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHRealizedInvestmentGainsLossesOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeeIncome" xlink:label="loc_us-gaapFeeIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_us-gaapFeeIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ImpairmentOfInvestmentSecurities" xlink:label="loc_MDBHImpairmentOfInvestmentSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_MDBHImpairmentOfInvestmentSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaapOtherOperatingIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_us-gaapOtherOperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingIncomeLossAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommunicationsAndInformationTechnology" xlink:label="loc_us-gaapCommunicationsAndInformationTechnology" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapCommunicationsAndInformationTechnology" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ClearingAndOtherCharges" xlink:label="loc_MDBHClearingAndOtherCharges" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_MDBHClearingAndOtherCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NetOperatingIncomeLoss" xlink:label="loc_MDBHNetOperatingIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHNetOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MiscellaneousIncome" xlink:label="loc_MDBHMiscellaneousIncome" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHMiscellaneousIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_GainRelatedToDilutionEvents" xlink:label="loc_MDBHGainRelatedToDilutionEvents" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHGainRelatedToDilutionEvents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeLossFromEquityMethodInvestment" xlink:label="loc_MDBHIncomeLossFromEquityMethodInvestment" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_MDBHIncomeLossFromEquityMethodInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SegmentReportingDetailsNarrative" xlink:title="999054 - Disclosure - Segment Reporting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails" xlink:title="999055 - Disclosure - Schedule of Equity and Non-Controlling Interests (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EquityTable" xlink:label="loc_MDBHEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_MDBHEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_Equity" xlink:label="loc_MDBHEquity" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquityTable" xlink:to="loc_MDBHEquity" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquityTable" xlink:to="loc_srtOwnershipAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="loc_MDBHExozymeTechnologiesIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_MDBHExozymeTechnologiesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_WeightedAverageNonControllingPercentage" xlink:label="loc_MDBHWeightedAverageNonControllingPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHWeightedAverageNonControllingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DueToDeconsolidation" xlink:label="loc_MDBHDueToDeconsolidation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHDueToDeconsolidation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationToNonControllingInterest" xlink:label="loc_MDBHShareBasedCompensationToNonControllingInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHShareBasedCompensationToNonControllingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_OwnershipChangeOfNoncontrollingInterest" xlink:label="loc_MDBHOwnershipChangeOfNoncontrollingInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_MDBHOwnershipChangeOfNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHEquity" xlink:to="loc_us-gaapMinorityInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative" xlink:title="999056 - Disclosure - Equity and Non-Controlling Interests (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtOwnershipAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MinnesotaOneMember" xlink:label="loc_MDBHMinnesotaOneMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_MDBHMinnesotaOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="loc_MDBHExozymeTechnologiesIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_MDBHExozymeTechnologiesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MinnesotaOneMember" xlink:label="loc_MDBHMinnesotaOneMember_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHMinnesotaOneMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymeTechnologiesIncMember" xlink:label="loc_MDBHExozymeTechnologiesIncMember_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHExozymeTechnologiesIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaapProceedsFromContributionsFromParent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromContributionsFromParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/DeconsolidationDetailsNarrative" xlink:title="999057 - Disclosure - Deconsolidation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationAbstract" xlink:label="loc_MDBHDeconsolidationAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeconsolidationTable" xlink:label="loc_MDBHDeconsolidationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDeconsolidationAbstract" xlink:to="loc_MDBHDeconsolidationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDeconsolidationTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDeconsolidationTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesIncMember" xlink:label="loc_MDBHExozymesIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MDBHExozymesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:label="loc_us-gaapGainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails" xlink:title="999058 - Disclosure - Schedule of Consolidated Balance Sheet (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfConsolidatedBalanceSheetAbstract" xlink:label="loc_MDBHScheduleOfConsolidatedBalanceSheetAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfConsolidatedBalanceSheetTable" xlink:label="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHScheduleOfConsolidatedBalanceSheetAbstract" xlink:to="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHScheduleOfConsolidatedBalanceSheetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="loc_MDBHExozymesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_MDBHExozymesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrantsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredGrantReimbursement" xlink:label="loc_MDBHDeferredGrantReimbursement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHDeferredGrantReimbursement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails" xlink:title="999059 - Disclosure - Schedule of Gain on Deconsolidation (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfGainOnDeconsolidationAbstract" xlink:label="loc_MDBHScheduleOfGainOnDeconsolidationAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ScheduleOfGainOnDeconsolidationTable" xlink:label="loc_MDBHScheduleOfGainOnDeconsolidationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHScheduleOfGainOnDeconsolidationAbstract" xlink:to="loc_MDBHScheduleOfGainOnDeconsolidationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHScheduleOfGainOnDeconsolidationTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHScheduleOfGainOnDeconsolidationTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesIncMember" xlink:label="loc_MDBHExozymesIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MDBHExozymesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaapEquityMethodInvestmentsFairValueDisclosure" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CarryingValueOfAssets" xlink:label="loc_MDBHCarryingValueOfAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHCarryingValueOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LessCarryingValueOfFormerInvestment" xlink:label="loc_MDBHLessCarryingValueOfFormerInvestment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHLessCarryingValueOfFormerInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CarryingValueOfWarrants" xlink:label="loc_MDBHCarryingValueOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MDBHCarryingValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails" xlink:title="999060 - Disclosure - Schedule of Equity Method Investment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_us-gaapEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:label="loc_us-gaapGainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_us-gaapGainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents" xlink:label="loc_MDBHEquityMethodInvestmentsGainRelatedToDilutionEvents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_MDBHEquityMethodInvestmentsGainRelatedToDilutionEvents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaapEquityMethodInvestments_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_us-gaapEquityMethodInvestments_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EquityMethodInvestmentDetailsNarrative" xlink:title="999061 - Disclosure - Equity Method Investment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" xlink:to="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="loc_MDBHExozymesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHExozymesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_InvizyneTechnologiesIncMember" xlink:label="loc_MDBHInvizyneTechnologiesIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MDBHInvizyneTechnologiesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEquityMethodInvestmentsLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails" xlink:title="999062 - Disclosure - Schedule of Restricted Stock Unit Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails" xlink:title="999063 - Disclosure - Schedule of Time-Based Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:label="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails" xlink:title="999064 - Disclosure - Schedule of Market-Based Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:label="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999065 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_MarketBasedMember" xlink:label="loc_MDBHMarketBasedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHMarketBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_TimeBasedMember" xlink:label="loc_MDBHTimeBasedMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHTimeBasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:label="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="loc_us-gaapStockOptionExercisePriceIncrease" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AveragePricePerShare" xlink:label="loc_MDBHAveragePricePerShare" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHAveragePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" xlink:label="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_MDBHSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails" xlink:title="999066 - Disclosure - Schedule of Basic and Fully Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaapCommonClassBMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EarningsPerShareDetailsNarrative" xlink:title="999067 - Disclosure - Earnings Per Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999068 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ENDRAMember" xlink:label="loc_MDBHENDRAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MDBHENDRAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_ExozymesMember" xlink:label="loc_MDBHExozymesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MDBHExozymesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AccruedExpenses" xlink:label="loc_MDBHAccruedExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_MDBHAccruedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999069 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_CommitmentsAndContingenciesTable" xlink:label="loc_MDBHCommitmentsAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_MDBHCommitmentsAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapCommitmentsAndContingencies" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PublicVenturesMember" xlink:label="loc_MDBHPublicVenturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MDBHPublicVenturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DTCMembershipRequirementsMember" xlink:label="loc_MDBHDTCMembershipRequirementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHDTCMembershipRequirementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NetCapital" xlink:label="loc_srtNetCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_srtNetCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RatioOfIndebtednessToNetCapital1" xlink:label="loc_us-gaapRatioOfIndebtednessToNetCapital1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_us-gaapRatioOfIndebtednessToNetCapital1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumNetCapitalRequiredForEntity1" xlink:label="loc_srtMinimumNetCapitalRequiredForEntity1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingencies" xlink:to="loc_srtMinimumNetCapitalRequiredForEntity1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative" xlink:title="999070 - Disclosure - Employee Benefit Plans (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative" xlink:title="999071 - Disclosure - Exclusive License Agreement (MDB Minnesota One) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" xlink:label="loc_MDBHDisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LicenseAgreementMember" xlink:label="loc_MDBHLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MDBHLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIclinicalMember" xlink:label="loc_MDBHPhaseIIclinicalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHPhaseIIclinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PhaseIIIclinicalMember" xlink:label="loc_MDBHPhaseIIIclinicalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHPhaseIIIclinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationFirstMember" xlink:label="loc_MDBHNewDrugApplicationFirstMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNewDrugApplicationFirstMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_NewDrugApplicationMember" xlink:label="loc_MDBHNewDrugApplicationMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MDBHNewDrugApplicationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaapProceedsFromLicenseFeesReceived" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromLicenseFeesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_PaymentForLicensedProducts" xlink:label="loc_MDBHPaymentForLicensedProducts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MDBHPaymentForLicensedProducts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails" xlink:title="999072 - Disclosure - Schedule of Operating Lease Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureLeasesAbstract" xlink:label="loc_MDBHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeLeasePayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails" xlink:title="999073 - Disclosure - Schedule of Future payments Due Under Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureLeasesAbstract" xlink:label="loc_MDBHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_MDBHLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_MDBHLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/LeasesDetailsNarrative" xlink:title="999074 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DisclosureLeasesAbstract" xlink:label="loc_MDBHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvanceRent" xlink:label="loc_us-gaapAdvanceRent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapAdvanceRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_BaseRent" xlink:label="loc_MDBHBaseRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_MDBHBaseRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_AnnualOperatingCostIncreasePercentage" xlink:label="loc_MDBHAnnualOperatingCostIncreasePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_MDBHAnnualOperatingCostIncreasePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MDBHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails" xlink:title="999075 - Disclosure - Schedule of Income Taxes Expenses (benefit) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999076 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:label="loc_MDBHIncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHIncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:label="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:label="loc_MDBHIncomeTaxReconciliationEquityInEquityAwardVestingAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHIncomeTaxReconciliationEquityInEquityAwardVestingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:label="loc_MDBHIncomeTaxReconciliationModificationOfEquityAwardsAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHIncomeTaxReconciliationModificationOfEquityAwardsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:label="loc_MDBHIncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHIncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:label="loc_MDBHEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:label="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_MDBHIncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsInStartupExpenditures" xlink:label="loc_MDBHDeferredTaxAssetsInStartupExpenditures" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_MDBHDeferredTaxAssetsInStartupExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsInOrganizationalExpenditures" xlink:label="loc_MDBHDeferredTaxAssetsInOrganizationalExpenditures" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_MDBHDeferredTaxAssetsInOrganizationalExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsStockCompensation" xlink:label="loc_MDBHDeferredTaxAssetsStockCompensation" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_MDBHDeferredTaxAssetsStockCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsLeaseLiability" xlink:label="loc_MDBHDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_MDBHDeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsBonusExpense" xlink:label="loc_MDBHDeferredTaxAssetsBonusExpense" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_MDBHDeferredTaxAssetsBonusExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCharitableContributionCarryforwards" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxAssetsImpairmentExpense" xlink:label="loc_MDBHDeferredTaxAssetsImpairmentExpense" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_MDBHDeferredTaxAssetsImpairmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_DeferredTaxLiabilitiesInvestmentSecurities" xlink:label="loc_MDBHDeferredTaxLiabilitiesInvestmentSecurities" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_MDBHDeferredTaxLiabilitiesInvestmentSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/IncomeTaxesDetailsNarrative" xlink:title="999077 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_USFederalTaxMember" xlink:label="loc_MDBHUSFederalTaxMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_MDBHUSFederalTaxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mdbh-20251231.xsd#MDBH_FloridaIncomeTaxMember" xlink:label="loc_MDBHFloridaIncomeTaxMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_MDBHFloridaIncomeTaxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mdb.com/role/SubsequentEventsDetailsNarrative" xlink:title="999078 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MDB
CAPITAL HOLDINGS, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001934642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-4366624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">14135
                                            Midway Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite G-150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Addison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">262-9012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class
    A Common Shares, representing Limited Liability Interests<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDBH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,178,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RBSM LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of MDB Capital Holdings, LLC and Subsidiaries (collectively, the &#8220;Company&#8221;)
as of December 31, 2025 and 2024, and the related consolidated statements of operations, equity and cash flows for each of the two years
in the period ended December 31, 2025, and the related notes (collectively referred to as the consolidated financial statements). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December
31, 2025, in conformity with accounting principles generally accepted in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong> Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,217<span></span>
</td>
<td class="nump">$ 20,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation', window );">Cash segregated in compliance with regulations</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">124<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Related party receivables</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Clearing deposits</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer', window );">Investment securities, at fair value, held by the licensed broker dealer (Notes 1 and 2)</a></td>
<td class="nump">7,166<span></span>
</td>
<td class="nump">5,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer (Notes 1 and 2)</a></td>
<td class="nump">235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">37,543<span></span>
</td>
<td class="nump">41,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred costs related to deferred revenue</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,740<span></span>
</td>
<td class="nump">71,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Related party payables</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PayablesToCustomersCurrentAndNonCurrent', window );">Payables to customers</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,161<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, 10,000,000 authorized shares at no par value; 0 issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">80,493<span></span>
</td>
<td class="nump">68,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated income (deficit)</a></td>
<td class="num">(19,803)<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total MDB Capital Holdings, LLC equity</a></td>
<td class="nump">60,690<span></span>
</td>
<td class="nump">70,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">60,579<span></span>
</td>
<td class="nump">70,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">63,740<span></span>
</td>
<td class="nump">71,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities, at fair value, held by the licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities, at fair value, held by the non-licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PayablesToCustomersCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables to customers current and non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PayablesToCustomersCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and securities deposited in a special reserve account for the exclusive benefit of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong> Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,138,632<span></span>
</td>
<td class="nump">4,950,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,138,632<span></span>
</td>
<td class="nump">4,950,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer (Notes 1 and 2)</a></td>
<td class="num">$ (331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (275)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer', window );">Unrealized gain on investment securities, net from non-licensed broker dealer (Notes 1 and 2)</a></td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain on investment securities, net from the licensed broker dealer</a></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Fee income (from our licensed broker dealer)</a></td>
<td class="nump">4,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment of investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income, net</a></td>
<td class="nump">4,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CompensationCosts', window );">Compensation</a></td>
<td class="nump">14,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_OperatingExpenseRelatedParty', window );">Operating expense, related party</a></td>
<td class="nump">1,833<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Information technology</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ClearingAndOtherCharges', window );">Clearing and other charges</a></td>
<td class="nump">556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative-other</a></td>
<td class="nump">2,239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="nump">22,637<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,322<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs, net of grants $0 and $2,003 in 2024 and 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs</a></td>
<td class="nump">22,637<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,790<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NetOperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(17,726)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28,633)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeAbstract', window );"><strong>Other income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="nump">617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="nump">61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="num">(16,973)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment', window );">Net income (loss) before equity method investee</a></td>
<td class="num">(16,984)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromEquityMethodInvestment', window );">Equity in loss of equity method investee</a></td>
<td class="num">(4,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(420)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(21,266)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,601<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less net loss attributable to non-controlling interest</a></td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(90)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="num">$ (21,245)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11,691<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share attributable to MDB Capital Holdings, LLC:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income (loss) per Common Share &#8211; basic</a></td>
<td class="num">$ (2.14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average of number Common Shares outstanding &#8211; basic</a></td>
<td class="nump">5,022,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,424,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income (loss) per Common Share &#8211;diluted</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted number of Common Shares outstanding</a></td>
<td class="nump">6,145,212<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,462,904<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share attributable to MDB Capital Holdings, LLC:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income (loss) per Common Share &#8211; basic</a></td>
<td class="num">$ (2.10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average of number Common Shares outstanding &#8211; basic</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income (loss) per Common Share &#8211;diluted</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted number of Common Shares outstanding</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Includes impairment loss of assets
from the reduced fair value of the asset.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ClearingAndOtherCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clearing and other charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ClearingAndOtherCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_CompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_CompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GainRelatedToDilutionEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain related to dilution events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GainRelatedToDilutionEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ImpairmentOfInvestmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of investment securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ImpairmentOfInvestmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) before equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeLossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity in loss of equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeLossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_MiscellaneousIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_MiscellaneousIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_NetOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_NetOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_OperatingExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating expense related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_OperatingExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain on investment securities, net from non-licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized loss on investment securities, net from non-licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommunicationsAndInformationTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in the period for communications and data processing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommunicationsAndInformationTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ResearchAndDevelopmentGrants', window );">Research and development, Grants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Common Class A [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Common Class B [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 49,406<span></span>
</td>
<td class="num">$ (12,092)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 37,321<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A Common Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Common Shares, shares</a></td>
<td class="nump">655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_Netincomeloss1', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,534<span></span>
</td>
<td class="num">(1,933)<span></span>
</td>
<td class="nump">11,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Ownership change of non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EffectOfDeconsolidationOfSubsidiary', window );">Effect of deconsolidation of subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,880<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">6,716<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,721<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="nump">70,073<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Class A Common Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class A Common Shares, shares</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,772<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_Netincomeloss1', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,245)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(21,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80,493<span></span>
</td>
<td class="num">$ (19,803)<span></span>
</td>
<td class="num">$ (111)<span></span>
</td>
<td class="nump">$ 60,579<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="nump">5,139<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EffectOfDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of deconsolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EffectOfDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_Netincomeloss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_Netincomeloss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (21,266)<span></span>
</td>
<td class="nump">$ 11,601<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment securities, net</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills', window );">Accretion of investments at amortized cost (U.S Treasury Bills)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(534)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized loss (gain) on investment securities, net from the licensed broker dealer</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,772<span></span>
</td>
<td class="nump">14,435<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Effect of deconsolidation of subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property and equipment</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred costs related to revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DilutionOfDeferredGrantReimbursement', window );">Dilution of deferred grant reimbursement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(39,307)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PortionOfLossFromEquityInvestment', window );">Portion of loss from equity investment</a></td>
<td class="nump">4,282<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal', window );">Warrants issued as part of an investment banking deal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeRecognizedFromWarrantsReceived', window );">Income recognized from warrants received</a></td>
<td class="num">(1,889)<span></span>
</td>
<td class="num">(659)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentsSecurities', window );">Impairment of investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in ROU Asset</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(1,705)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Grants receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Related party receivables</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Clearing deposits</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(1,478)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">58<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(1,033)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payables</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPayablesToCustomers', window );">Payables to customers</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncreaseDecreaseInPayablesToNoncustomers', window );">Payables to non-customers</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,684)<span></span>
</td>
<td class="num">(9,038)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PaymentsToAcquireInvestmentsSecurities', window );">Purchases of investment securities, at amortized cost (U.S. Treasury Bills)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(17,766)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ProceedsFromInvestmentsSecurities', window );">Proceeds from payments and maturities of investment securities, at amortized cost (U.S. Treasury Bills)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Accretion of equity investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PaymentForDeferredGrantReimbursement', window );">Deferred grant reimbursement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">22,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(5,733)<span></span>
</td>
<td class="nump">13,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR</a></td>
<td class="nump">21,281<span></span>
</td>
<td class="nump">7,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS - END OF YEAR</a></td>
<td class="nump">15,548<span></span>
</td>
<td class="nump">21,281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal', window );">Warrants received as part of an investment banking deal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear', window );">Relinquishment of deferred costs of initial public offering from prior year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment', window );">Investment securities, at cost less impairment, received in lieu of cash payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering', window );">Issuance of warrants to purchase Class A stock related to the initial public offering closed on September 20, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes unrealized gains and
losses on securities held by the broker-dealer.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of investments at amortized cost (U.S Treasury Bills).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DilutionOfDeferredGrantReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilution of deferred grant reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DilutionOfDeferredGrantReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GainRelatedToDilutionEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain related to dilution events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GainRelatedToDilutionEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ImpairmentOfInvestmentsSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of investments securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ImpairmentOfInvestmentsSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeRecognizedFromWarrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income recognized from warrants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeRecognizedFromWarrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncreaseDecreaseInPayablesToNoncustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payables to noncustomers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncreaseDecreaseInPayablesToNoncustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities at cost less impairment received in lieu of cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants to purchase Class A stock related to the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PaymentForDeferredGrantReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for deferred grant reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PaymentForDeferredGrantReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PaymentsToAcquireInvestmentsSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire investments securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PaymentsToAcquireInvestmentsSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PortionOfLossFromEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of loss from equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PortionOfLossFromEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ProceedsFromInvestmentsSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from investments securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ProceedsFromInvestmentsSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrants issued as part of investment banking deal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Relienquishment of deferred costs of initial public offering from prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants received as part of investment banking deal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPayablesToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change during the period, either increase or decrease, in amounts payable to customers. The term customers generally excludes other broker-dealers; persons who are principal officers, directors, and stockholders; and persons whose securities or funds are part of the regulatory net capital of the broker-dealer. Another broker-dealer's account can be classified as a customer if the account is carried as an omnibus account in compliance with certain regulations. The accounts of principal officers, directors and stockholders may be combined in the customer captions if they are not material and the combination is disclosed in the oath that is required to accompany the annual audited FOCUS Report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPayablesToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows, Supplemental Disclosures - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,217<span></span>
</td>
<td class="nump">$ 20,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations', window );">Cash segregated in compliance with regulations</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 15,548<span></span>
</td>
<td class="nump">$ 21,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash subject to withdrawal restrictions, restricted deposits held as compensating balances, and cash and securities segregated in compliance with regulations (such as cash deposited in a special reserve account for the exclusive benefit of customers).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (21,245)<span></span>
</td>
<td class="nump">$ 11,691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">We incorporate by reference
the disclosure about cybersecurity regulation that is generally applicable to MDB from section Part I, Item 1, Business &#8211; Regulation
&#8211; Data Protection ad Cybersecurity Regulation.&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not had any reportable
cybersecurity breaches, including what we may perceive or recognize as cybersecurity incidents or credible threats during the fiscal year
ended December 31, 2025. To date, as a result, there has not been any material adverse effect on our business operations or financial
condition. If there is a cybersecurity attack and an infiltration of our files, data, customer data and the like, there would be a material
adverse effect on our business, our reputation, our operations and financial condition. For example, our reputation would be damaged in
the event of a cybersecurity infiltration. If there were a cybersecurity infiltration, we could lose access to our data which would disrupt
our operations, and we even may not be able to operate. Such a loss of access might be temporary or permanent, and it might be localized
or general. The level of disruption will depend on our backup systems. Our clients financial and other data could be taken and used against
us to damage our reputation or cause harm to our clients in different ways. In the latter instance, we may be liable for monetary damages
to our clients. We may be held for cyber ransom, which would be loss to our financial resources. Our inability to operate, payment of
damages, payment of ransom, and the costs of reparation of our systems, consultants and tangential expenses will all result in damage
to our business and our financial resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MDB Holdings and its subsidiaries
including Public Ventures, our regulated broker-dealer, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_dbF_c20250101__20251231_zyoxShBxRKKj">we have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zTViQMCcuC3a">implemented</span> a comprehensive cybersecurity program aimed at identifying,
monitoring, and mitigating cybersecurity risks to the best of our ability. Our security program encompasses information security responsibilities,
incident response, and is diligently managed by our information technology department. Cybersecurity is integrated into our overall risk
management framework, with consultation from subject matter experts to assess and address potential cyber risks and their impacts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">46</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">&#160;</td></tr></table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskRoleOfManagementTextBlock_dbF_c20250101__20251231_zXSW81eyiwn4">Management is committed to
providing the Audit Committee with regular cybersecurity updates, at least annually or more often as needed, based on emerging threats
or specific incidents. These updates cover risk assessments, the current threat landscape, and any recent cybersecurity incidents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information technology
department has put in place robust governance measures for information security. This includes control requirements for change management,
patching processes, the implementation of multifactor authentication, comprehensive data backup strategies, and continuous security monitoring.
Additionally, management continues to enhance our security controls, with any significant issues promptly reported to the Audit Committee.</p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">we have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zTViQMCcuC3a">implemented</span> a comprehensive cybersecurity program aimed at identifying,
monitoring, and mitigating cybersecurity risks to the best of our ability. Our security program encompasses information security responsibilities,
incident response, and is diligently managed by our information technology department. Cybersecurity is integrated into our overall risk
management framework, with consultation from subject matter experts to assess and address potential cyber risks and their impacts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Management is committed to
providing the Audit Committee with regular cybersecurity updates, at least annually or more often as needed, based on emerging threats
or specific incidents. These updates cover risk assessments, the current threat landscape, and any recent cybersecurity incidents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zkzaZ4LO8kPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. <span id="xdx_820_znzVrhQ6zlii">Organization and Description of Business</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Capital Holdings, LLC (&#8220;the
Company&#8221; or &#8220;MDB&#8221;), a Delaware limited liability company, is a holding company that has three wholly-owned subsidiaries:
MDB CG Management Company (&#8220;MDB Management&#8221;); Public Ventures, LLC, d/b/a MDB Capital (&#8220;Public Ventures&#8221;); and
PatentVest, Inc. (&#8220;PatentVest&#8221;), and MDB Minnesota One (&#8220;M1&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Management is principally an &#8220;administrative&#8221;
entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for our US-based operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures is a U.S. registered
broker-dealer under the Securities Exchange Act of 1934, and is a member of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;)
and the Texas State Securities Board. Public Ventures operates on a fully disclosed basis with a nonrelated FINRA member firm, Interactive
Brokers, LLC (&#8220;Interactive Brokers&#8221;), and is not required to maintain a clearing deposit. Interactive Brokers is the clearing
firm and custodian of investments maintained by Public Ventures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">PatentVest is a wholly-owned subsidiary
that performs intellectual property validation services for Public Ventures&#8217;, due diligence functions on the intellectual property
of partner and prospective partner companies, and creates an intellectual property roadmap for such partner companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">M1 is a majority owned subsidiary
and was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;). The objective of
the License Agreement is for Minnesota One to develop a small molecule senescence platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On September 20, 2023, MDB completed
an initial public offering, consisting of the sale of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn4n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z0bspOUwJAEc" title="Sale of stock, number of shares issued in transaction">1.67</span> million shares of Class A Common Shares at $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbd1Aqld8785" title="Sale of stock, price per share">12.00</span> per share, for gross
proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zRtvOJlTSsK7" title="Gross proceeds">20.0</span> million. Accordingly, the Company received total gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjsfc4fiXtte" title="Gross proceeds">20.0</span> million from the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn4n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zABDTLkJSHD" title="Sale of stock, number of shares issued in transaction">1.67</span> million shares
of Class A Common Shares, or $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zW3POXn2rZgd" title="Net proceeds">17.4</span> million net of $<span id="xdx_90A_eus-gaap--OtherExpenses_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zM0S2lXoM4Za" title="Offering expenses">2.6</span> million of offering expenses. In conjunction with the IPO, the Company issued warrants
to the placement agent to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn2n3_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z27rOZeewFVg" title="Warrants to puchase common shares">16.7</span> thousand shares of Class A Common Shares, exercisable upon issuance for a period of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKTktnDm914" title="Warrants term">5</span> years at
$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBN0muUEESWh" title="Exercise price of warrants">15.00</span> per share, for a cash consideration of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFo4Y6aYbFTe" title="Cash consideration per share">0.001</span>/share. The placement agent&#8217;s warrants had a fair value of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn2n3_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5bVsPCpf8zh" title="Warrants fair value">65.4</span> thousand, as
calculated pursuant to the Black-Scholes option-pricing model and accounted for as issuance costs that were accounted for as equity instruments
and recorded against paid in capital. The inputs used to determine the fair value was Common Stock price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z285dQ5xu3Xe" title="Common stock price">12.00</span>, option exercise price
of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYQjRKCtfARa" title="Exercise price">15.00</span>, expected life in years of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9gLUmTvWgGl" title="Estimated life">2.45</span> years, with a contract life of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGG31Y8m87fi" title="Contract life">5</span> years, risk-free rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPozmDGfIN39" title="Risk-free rate">4.79</span>%, expected annual volatility
of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSttQ5itcJcj" title="Expected annual volatility">59.99</span>%, and annual rate of dividends of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuRUDrw3cnL5" title="Annual rate of dividends">0</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2024, the founding ownership
of M1 had MDB owning <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MDBMinnesotaOneIncMember_zAuSzCMlDHv3" title="Ownership percentage">67</span>% and Mayo owning <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MayoFoundationMember_zZ3hjBOHmsP5" title="Ownership percentage">33</span>% of the issued and outstanding
common stock. M1 was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo. After
the initial formation of M1 and finalization and entry into a license agreement between Mayo and M1, MDB entered into a Term Equity Purchase
Agreement (&#8220;Purchase Agreement&#8221;) to provide capital for operations of M1 in exchange for the issuance of shares of common
stock of M1 to MDB. The objective of the License Agreement is for M1 to develop a small molecule senescence platform. Under the terms
of the License Agreement M1 has paid an up-front license fee to Mayo of One Hundred Fifty Thousand Dollars ($<span id="xdx_909_eus-gaap--AdvancesToAffiliate_iI_pn3n3_c20240701_zwPm1CLki7b3" title="Up-front fees">150</span> thousand). To maintain
its rights under the License Agreement, M1 is subject to achieving certain developmental and funding milestones within designated time
periods and to paying Mayo royalties on net sales of licensed products. Under the terms of the Purchase Agreement, MDB may invest up to
$<span id="xdx_906_eus-gaap--Investments_iI_pn5n6_c20240701_zVtWwfD9CV2d" title="Investments">5.0</span> million over a five-year period into M1 in amounts and increments tied to its business operating requirements. In an ancillary agreement
to the license agreement, Mayo has the right of participation in future financings of M1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8aA90zjScb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. <span id="xdx_827_zWU5FLj60lpk">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbvuMgc7HMkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Basis of Presentation and Principles
of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accompanying consolidated financial
statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and include the financial statements of wholly-owned and majority owned subsidiaries. All material intercompany accounts
and transactions have been eliminated in consolidation. Non-controlling interests at December 31, 2025 and 2024 relate to the interests
of third parties in the partially owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The managing members of the Company
have a controlling interest in PatentVest, S.A., a company organized and based in Nicaragua (which was renamed MDB Capital, S.A in 2022).
As the Company itself does not have a controlling financial interest in this entity, management has determined PatentVest, S.A. is not
a variable interest entity and should not be consolidated as it has no ownership interests, so has excluded this entity from the Company&#8217;s
consolidated financial statements. It is the Company&#8217;s policy to reevaluate this conclusion on an annual basis or if there are significant
changes in ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84E_ecustom--DeconsolidationPolicyTextBlock_z9F9sgQUCM07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Deconsolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon the occurrence of certain events
and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated
variable interest entities. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company
records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair
value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the
carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary&#8217;s
assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company evaluated whether the
deconsolidation should be presented as a discontinued operation in its consolidated financial statements as of the deconsolidation date.
This assessment considers whether the deconsolidation constitutes a strategic shift that has, or will have, a major impact on the Company&#8217;s
operations or financial results. Based on this evaluation, the Company concluded that the deconsolidation does not meet the criteria
for presentation as a discontinued operation. Accordingly, the Consolidated Statement of Operations includes the results of operations
for the deconsolidated entity through November 14, 2024, the effective date of deconsolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zeX1leJLKmW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Equity method investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company applies the equity method
to account for investments in entities where it has the ability to exercise significant influence over the operating and financial policies
of the investee. Under the equity method, the investment in eXoZymes Inc, (&#8220;eXoZymes &#8220;), formerly Invizyne Technologies
Inc. (&#8220;Invizyne&#8221;)&#8221;, is initially recorded at cost and subsequently
adjusted to reflect the Company&#8217;s proportional share of the investee&#8217;s results of operations in its consolidated financial
statements. Equity method investments are periodically reviewed for any other-than-temporary declines in value. The Company&#8217;s investment
in eXoZymes is presented as &#8220;Equity method investment&#8221; on the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Any excess of the acquisition cost
over the Company&#8217;s share of the net fair value of eXoZymes&#8217; identifiable assets and liabilities at the acquisition date is
recognized as goodwill, which is included in the carrying amount of the investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company increases its interest
in an affiliate accounted for under the equity method while retaining significant influence, it applies the acquisition method only to
the additional interest acquired, leaving the previous interest unchanged. Conversely, when there is a decrease in the interest in an
affiliate accounted for under the equity method while retaining significant influence, the Company derecognizes a proportionate part of
its investment and recognizes any resulting gain or loss in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWOfx76LB65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We account for income taxes using the
asset and liability method, under which we would recognize the amount of taxes payable or refundable for the current year and deferred
tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns.
We measure current and deferred tax assets and liabilities based on provisions of enacted tax law. We evaluate the realization of our
deferred tax assets based on all available evidence and establish a valuation allowance to reduce deferred tax assets when it is more
likely than not that they will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zqrc9oBsVfg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period, as well as the
disclosure of contingent assets and liabilities. Some of those judgments can be subjective and complex, and therefore, actual results
could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience
and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available
information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate,
those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related
to assumptions used in the valuation of investment securities, accruals for potential liabilities, valuing equity instruments issued for
services, assumptions used in the valuation of the equity method investment and gains on the deconsolidation of the subsidiary, the estimate
of the fair value of the lease liability and related right of use assets, net realizable value of receivables, useful life of property
and equipment, determining impairment of long-lived assets, and the realization of any deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWbadvRIbCGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is an &#8220;emerging growth
company,&#8221; or &#8220;EGC&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified
by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to opt out of the
extended transition periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znoJLvxnNDo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company considers highly liquid
investments with original maturities or remaining maturities upon purchase of three months or less to be cash equivalents. There were
$<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zrDGrtDWZr0f" title="Cash Equivalents">4.5</span> million and $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zGBlfJQ1PcEf" title="Cash Equivalents">11.8</span> million cash equivalents held by the Company at December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s policy is to
maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit
Insurance Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;).
The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_pn4n6_c20251231_z9yskUhQkfTb" title="Cash, FDIC insured limits">0.25</span>
million and $<span id="xdx_906_ecustom--CashSIPCInsuredAmount_iI_pn5n6_c20251231_zFYU47D2MVbb" title="Cash, SIPC insured limits">0.5</span>
million. At December 31, 2025, the Company held $<span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20251231_zix1xGBhe045" title="Unsegregated cash">8.7</span>
million of unsegregated cash and $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zMs7qsmkP4nf" title="Cash equivalents">4.5</span>
million of cash equivalents. For the years ended December 31, 2025 and 2024, respectively, the Company had approximately $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zviXm48akQ9h" title="Cash uninsured limits">7.2</span>
million and $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zPtWfFI5fLa2" title="Cash uninsured limits">4.3</span>
million of cash and segregated cash in financial institutions in excess of FDIC insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company periodically reviews the
financial condition of the financial institutions and assesses the credit risk of such investments. The Company did not experience any
credit risk losses during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s membership agreement
with the Depository Trust Clearing Corporation (&#8220;DTCC&#8221;) requires that we maintain a line of credit with our settlement bank in the amount $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20251231_zoKJtkzFEFIf" title="Line of credit">2.0</span> million, to be drawn down upon as
needed for self-clearing operations. The Company has established a line of credit with its settlement bank, Lakeside Bank, which is collateralized
by a $<span id="xdx_901_eus-gaap--Deposits_iI_pn5n6_c20251231_zRlQibc6QRh7" title="Deposit">2.0</span> million deposit of cash at Lakeside. The collateral amount may be withdrawn, but the availability of the line of credit is dependent
upon the maintenance of such compensating balance and is included in cash and cash equivalents on the Statement of Financial Condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--SegregatedCashAndDepositsPolicyTextBlock_zEdxvQaMMd95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Segregated Cash and Deposits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">From time to time the Company provides
deposits or enters into agreements that would require funds to be held in a segregated cash account. At December 31, 2025 and 2024, respectively,
the Company had $<span id="xdx_90F_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20251231_zW4DOkMjezg" title="Cash segregated in compliance with regulations">2.3</span> million and $<span id="xdx_902_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20241231_zH4eJBfqO7pj" title="Cash segregated in compliance with regulations">0.8</span> million of segregated cash consisting of funds held in reserve for customers and non-customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--DepositContractsPolicy_zXe17lXZT4Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Clearing Deposits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is obligated to maintain
security deposits with the DTCC and National Securities Clearing Corporation (&#8220;NSCC&#8221;). At December 31, 2025 and 2024, these deposits totaled $<span id="xdx_900_eus-gaap--DepositsAssets_iI_pn5n6_c20251231_zDAy8NALC5y6" title="Clearing deposits">2.0</span> million and $<span id="xdx_90D_eus-gaap--DepositsAssets_iI_pn5n6_c20241231_zclBROS6osn9" title="Clearing deposits">1.7</span> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_84E_ecustom--PrepaidAndOtherCurrentAssetsPolicyTextBlock_zNKUuAkbGSea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Prepaid and other current assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has prepaid and other current
assets totaling $<span id="xdx_906_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20251231_zj7INjmPlGV9" title="Prepaid and other current assets">433</span> thousand at December 31, 2025 consisting of acquired intangible assets totaling $<span id="xdx_90A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20250101__20251231_z0yEmAC6bRb4" title="Intangible assets acquired">44</span> thousand, prepaid professional
fees totaling $<span id="xdx_905_ecustom--PrepaidProfessionalFees_pn3n3_c20250101__20251231_zllM01zlh6Ul" title="Prepaid professional fees">50</span> thousand, security deposits totaling $<span id="xdx_90B_eus-gaap--SecurityDeposit_iI_pn3n3_c20251231_zrMtKd7vB4x5" title="Security deposit">19</span> thousand, prepaid insurance $<span id="xdx_902_eus-gaap--PrepaidInsurance_iI_pn3n3_c20251231_zK9n860ZZMZ6" title="Prepaid insurance">169</span> thousand, various prepaid expense of $<span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20251231_zRKRbjQictU3" title="Various prepaid expense">130</span>
thousand, and other assets of $<span id="xdx_901_eus-gaap--OtherAssets_iI_pn3n3_c20251231_zxLCMJrZIVxk" title="Other assets">21</span> thousand. Prepaid and other expenses totaling $<span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20241231_z1eqPWY77Zpd" title="Prepaid and other expenses">513</span> thousand at December 31, 2024 consisting of acquired
intangible assets totaling $<span id="xdx_90B_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_z69yTaaoZwKd" title="Intangible assets acquired">44</span> thousand, prepaid professional fees totaling $<span id="xdx_900_ecustom--PrepaidProfessionalFees_pn3n3_c20240101__20241231_zO8uio7h2SUg" title="Prepaid professional fees">50</span> thousand, security deposits totaling $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn3n3_c20241231_zk8QBjBoucW4" title="Security deposit">19</span> thousand, prepaid
insurance $<span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20241231_zEeAzlURSyjc" title="Prepaid insurance">160</span> thousand, various prepaid expense of $<span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20241231_z42b4Zoa3uJ4" title="Various prepaid expense">150</span> thousand, and other assets of $<span id="xdx_90A_eus-gaap--OtherAssets_iI_pn3n3_c20241231_zRlD3U4ITts" title="Other assets">90</span> thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zepmYoy0mMLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leases of the Company consist primarily
of contracts for the right to use and direct use of an individual property. Leases were analyzed for evidence of significant additional
components and to determine if these components were separately identifiable within the context of the contract. As an accounting policy,
to account for these components, the Company has elected the practical expedient for property leases that have both lease and non-lease
components for them to be combined into a single component and account for as a lease. This policy is effective for all current and future
property operating leases and applied uniformly and will be disclosed as such within the financial statements. Operating lease assets
are included within right-of-use assets and the corresponding operating lease liabilities are included within liabilities on the Company&#8217;s
consolidated balance sheet as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has elected not to present
short-term leases on the consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not
contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other right-of-use assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. Because the
Company&#8217;s leases do not provide an implicit rate of return, the Company used the Company&#8217;s incremental borrowing rate based
on the information available at lease commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zaeBpyEiNdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Stock Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Stock-based compensation primarily
consists of restricted stock units with service or market/performance conditions. Equity awards are measured at the fair market value
of the underlying stock at the grant date. The Company recognized stock based compensation expense using the straight-line attribution
method over the requisite service period. The Company&#8217;s subsidiary issued stock-options and the fair value is determined utilizing
Black-Scholes options-pricing model. The Company accounts for forfeitures as they occur, rather than applying an estimated forfeiture
rate. For performance-based restricted stock units, the compensation cost is recognized based on the number of units expected to vest
upon the achievement of the performance conditions. Shares are issued on the vesting dates net of the applicable statutory tax withholding
to be paid by us on behalf of our employees. As a result, fewer shares are issued to the employee than the number of awards outstanding.
The Company records a liability for the tax withholding to be paid by it as a reduction to Additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--InvestmentPolicyTextBlock_zjbe21QMRo1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Investment Securities </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company strategically invests funds
in U.S. Treasury Bills, early-stage technology companies, and equity securities and options of publicly traded and privately held companies.
The Company classifies investment securities as investment securities, at amortized cost, investment securities, at fair value, or investment
securities, at cost less impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at amortized
cost</i> &#8211; From time to time the Company will hold funds in investment securities, at amortized cost. This is comprised of debt
securities held by MDB and are classified as investment securities held-to-maturity and carried at amortized cost if management has the
positive intent and ability to hold the securities to maturity. Initially, the cost of these securities was recorded, and later on, they
were assessed at amortized cost, which was modified for unamortized purchase premiums and discounts, and also for credit losses provision.
Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective-interest
method. Such amortization and accretion are included in the other operating income in the statements of operations. Interest income is
recognized when earned. The Company recognizes estimated expected credit losses over the life of the investment security through the allowance
for credit losses account. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost
basis of the investment security to present the net amount expected to be collected. In determining expected credit losses, the Company
considers relevant qualitative factors including, but not limited to, term and structure of the instrument, credit rating by rating agencies
and historic credit losses adjusted for current conditions and reasonable and supportable forecasts. The Company holds investments in
U.S. Treasury Bills or money market funds backed by U.S. Treasury Bills, so there are no expected credit losses. Declines in fair value
of these securities is due to changes in market interest rates, and because it expects to hold these securities until maturity, it does
not expect to realize any losses. There were no investment securities, at amortized cost as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at fair value
</i>- This is comprised of equity investments held by the broker dealer subsidiary and are reported at fair value with changes in fair
value recognized in the statement of operations. Purchases and sales of equity securities, consisting of common stock and warrants to
purchase common stock, are recorded based on the respective market price quotations on the trade date. Realized gains and losses on investments
represent the net gains and losses on investments sold during the period based on the average cost method. Differences between the fair
value of investments at the beginning of the year and the end of the year are recorded on the income statement as unrealized gains and
losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at cost less
impairment</i> - This is comprised of equity securities without a readily determinable fair value held by the broker dealer subsidiary,
the Company has elected to apply the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable
price changes. The Company will reassess whether such an investment qualifies for the measurement alternative at each reporting period.
In evaluating an investment for impairment or observable price changes, we will use inputs including recent financing events, as well
as other available information regarding the investee&#8217;s historical and forecasted performance. The Company has assessed this investment
and determined that the current impairment of such securities held at the year ended December 31, 2025 is accurate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities are as follows
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Broker/Dealer Securities</b></p>

<p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zQRLhofnSVV3" style="display: none">Schedule of Investment Securities Broker Dealer</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at fair value:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Common stock of publicly traded companies</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Warrants of publicly traded companies</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,937</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,330</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrants of non-publicly traded companies</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">658</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,166</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,858</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z9OkuMpESene" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Non-Broker/Dealer Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><b><span id="xdx_8BF_zJ7jauHHoWlg">Schedule of Investment Securities Non-Broker Dealer</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Investment securities, at fair value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Common stock of publicly traded companies</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">235</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">235</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at cost less impairment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Simple agreement on future equities (not market listed)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">200</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Impairment</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(200</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at cost less impairment</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zuwmTRHBqnx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For investment securities at fair value
held at the end of each year, net unrealized loss of $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20250101__20251231_zsuIBnQqld4g" title="Net unrealized gain (loss) on investment securities">246</span> thousand and $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20240101__20241231_z6mVQU83Glli" title="Net unrealized gain (loss) on investment securities">275</span> thousand were recognized in the statement of operations for
years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

<p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1icpMWXqG9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree
that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the
lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company determines the fair value
of its financial instruments based on a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value
into three levels:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - Observable inputs such as
quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - Inputs, other than quoted
prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - Unobservable inputs in which
there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s financial instruments primarily consist of cash and investment
securities. These investment securities and securities sold and not yet purchased are recorded at fair value as of the balance sheet date,
with unrealized gains and losses resulting from changes in fair value recognized in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A description of the valuation techniques
applied to the Company&#8217;s major categories of assets and liabilities measured at fair value on a recurring basis is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at fair value
and securities sold, not yet purchased: These securities are valued based on quoted prices from the exchange or other trading platform.
To the extent these securities are actively traded, valuation adjustments are not applied, and they are categorized in level 1 of the
fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A description of the valuation techniques
applied to the Company&#8217;s other financial assets and liabilities is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at amortized
cost: The fair value of U.S. Treasury Bills classified as held-to-maturity investment securities is based on the market price and is classified
as level 1 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at cost
less impairment: Non-public equity securities and simple agreements for future equity are valued based on the initial investment,
less impairment. The Company determined that an impairment is warranted. Since these securities are not actively traded, we will
apply valuation adjustments when they become available, and they are categorized in level 3 of the fair value hierarchy. The Company
fully impaired a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) that was previously valued at $<span id="xdx_907_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SAFEMember_zfEVnkDkesF5" title="Impairment of securities">100</span>
thousand and stock that was previously valued at $<span id="xdx_909_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231_zjICz0hNW6R2" title="Impairment of securities">50</span>
thousand both were held at the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z82LCnEDOUFb" style="display: none">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment securities, at fair value, held by the licensed broker dealer</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer">235</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer">235</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">132</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,463</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,595</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value </td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,806</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">132</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,463</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">7,401</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zIWcQtXRunp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zLQDKsgMVcPa" style="display: none">Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,662</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right">2,662</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receipt from investment banking fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,690</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Unrealized gain</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">111</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,463</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right">4,463</td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_zwiD6wiM66M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zYKZqfnooG2" style="display: none">Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" style="text-align: right" title="Warrants, Fair value"><span style="font-size: 10pt">4,463</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs">95.92</span> -&#160;&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs">120.3</span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" style="text-align: right" title="Weighted measurement input"><span style="font-size: 10pt">115.45</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
<p id="xdx_8AE_z2C5euSaftok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zlqM1QVW6kJb"><b>The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):</b></span></p>

<div id="xdx_C04_gL3SOFVAALMOR-YZJZHH_zKHclHGg20w9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment Securities (held by our licensed broker dealer)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">668</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,662</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">3,330</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">668</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,662</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">5,858</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zWa3Fx0mjlFf">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2024, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C04_gL3FVAMORBUIR-BRK_zQrFBAw5dIYe">&#160;</span></p>

<div id="xdx_C08_gL3FVAMORBUIR-BRK_z3xAKOAdAp5d"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" style="border-collapse: collapse; width: 96%; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">3,134</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right">3,134</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gains</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(472</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; text-align: left">Unrealized (loss) gains</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">(472</td><td style="display: none; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,662</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right">2,662</td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C05_gL3FVAMORBUIR-BRK_z2jUR5Nf99T4">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C09_gL3FVAALMORAN-L_zDICDGAXkhH3"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)</b>:</span></p>

<div id="xdx_C02_gL3FVAALMORAN-L_z8NPe4RhThA9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" style="text-align: right" title="Warrants, Fair value"><span style="font-size: 10pt">2,662</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" style="text-align: right" title="Range of inputs"><span style="font-size: 10pt">111.03</span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" style="text-align: right" title="Weighted measurement input"><span style="font-size: 10pt">111.03</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C08_gL3FVAALMORAN-L_zFRFYdbkeMvc">&#160;</span></p>

<p id="xdx_846_eus-gaap--DebtPolicyTextBlock_zgWoIHtxQztb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Secured Debt&#8211;- Revolving
Credit Facility</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company entered into a revolving
credit facility with a bank, (the &#8220;Lender&#8221;) on July 26, 2024 for a commitment of up to $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0EOvrB8hnAd" title="Revolving credit, maximum borrowing capacity">2.0</span> million and which matures <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zhhYByZAPftd" title="Maturity date">July
26, 2025</span>. The loan has a variable interest rate equal to a defined index, currently the Lender&#8217;s rate on the sale of Federal Funds,
plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zBayzkWHgzIa" title="Variable rate">2.25</span>%. The loan commenced with a calculated interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zpgvzJk0sZ65" title="Interest rate">7.75</span>%. If the Lender determines, in its sole discretion, that the index
becomes unavailable or unreliable, either temporary, indefinitely, or permanently, during the term of this loan, the Lender may amend
this loan by designating a substantially similar substitute index. The agreement provides for a quarterly payment of the greater of accrued
interest or a non-usage fee of $<span id="xdx_907_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn3n3_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zmaGjZ86t8Ae" title="Credit non-usage fee">5</span> thousand. The Company has not made any draw downs on the credit facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company granted the Lender a
security interest in a cash checking account held at the bank as collateral. The Lender has a right of setoff available from this
cash account when the line of credit is accessed. As of December 31, 2025 and 2024, there was $<span id="xdx_904_eus-gaap--Deposits_iI_pn5n6_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyQmiqWvezV7" title="Deposits">2.1</span>
and $<span id="xdx_905_eus-gaap--Deposits_iI_pn5n6_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXBTreFjla7j" title="Deposits">2.1</span> million deposited in this account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is responsible for the
payment of all of the Lender&#8217;s legal and other fees incurred in connection with administering the loan. The Company has incurred
no such costs or debt issue costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025 and 2024, there are <span id="xdx_909_eus-gaap--LineOfCredit_iI_do_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZIwhsjYOybh" title="Outstanding indebtedness"><span id="xdx_90A_eus-gaap--LineOfCredit_iI_do_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkDXvC2Zhwpe" title="Outstanding indebtedness">no</span></span> outstanding indebtedness under the credit facility and interest expense totaled $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zeQjdwsqGVrk" title="Interest payable"><span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zjlzMwhVXdI7" title="Interest payable">0</span></span>. The Company is in compliance with all
covenants under the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyma5WBbqKKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment are recorded
at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from disposition
of property and equipment are included in the statement of operations when realized. Depreciation is provided using the straight-line
method over the following estimated useful lives:</p>

<p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none">Schedule
of Estimated Useful Lives of Property
and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Developed software</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives">7</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0974">Lesser of the lease duration or the life of the improvements</span></span></span></td></tr>
  </table>
<p id="xdx_8AD_zPIXDQXW8b0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z8fPKC7TjJZh" style="display: none">Schedule of Property And Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024<span></span></b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Developed software</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right">139</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right">113</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total property and equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">139</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">113</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(22</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">117</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">90</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zSieLJh9Yjw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_ziTtwP2xkno9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company generates revenue primarily
from providing brokerage services and underwriting through Public Ventures. PatentVest and eXoZymes, have
had limited activity during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Brokerage revenues consist of (i) trade-based
commission income from executed trade orders, (ii) net realized gains and losses from proprietary trades, and (iii) other income consisting
primarily of stock loan income earned on customer accounts. Public Ventures recognizes revenue from trade-based commissions and other
income when performance obligations are satisfied through the transfer of control, as specified in the contract, of promised services
to the customers of Public Ventures. Commissions are recognized on a trade date basis. Public Ventures believes that each executed trade
order represents a single performance obligation that is fulfilled on the trade date because that is when the underlying financial instrument
is identified, the pricing is agreed upon, and the risks and rewards of ownership have been transferred to/from the customer. When another
party is involved in transferring a good or service to a customer, Public Ventures assesses whether revenue is presented based on the
gross consideration received from customers (principal) or net of amounts paid to a third party (agent). Public Ventures has determined
that it is acting as the principal as the provider of the brokerage services and therefore records this revenue on a gross basis. Clearing,
custody and trade administration fees incurred from Interactive Brokers, the Company&#8217;s clearing firm, are recorded effective as
of the trade date. The costs are treated as fulfillment costs and are recorded in operating expenses in the consolidated statements of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Brokerage revenue is measured by the
transaction price, which is defined as the amount of consideration that Public Ventures expects to receive in exchange for services to
customers. The transaction price is adjusted for estimates of known or expected variable consideration based upon the individual contract
terms. Variable consideration is recorded as a reduction to revenue based on amounts that Public Ventures expects to refund back to the
customer. There were no variable considerations for the years ended December 31, 2025, and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment banking revenues
consist of private placement and underwriting fees. The Company generally does not incur costs to obtain contracts with customers
that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions, and
therefore, as of December 31, 2025 and 2024, the Company did not have any contract assets or liabilities related to these revenues
on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into underwriting agreements, to act as an underwriter and security offerings which include distribution and sale of securities
to investors. These agreements allow non-defaulting underwriters and the issuer&#8217;s representative to seek substitute purchasers within
36 hours if the Company defaults on its commitment. If replacements are not found and the default exceeds 10% of the offering, the agreement
may be terminated without liability. Under ASC 606, revenue is recognized only upon transfer of cash from the escrow account from investors
which is the final receipt of payment, as well receipt of warrants and common stock on the date of closing, with no recognition for defaulted
or terminated portions until resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Private placement fees are related
to non-underwritten transactions such as private placements of equity securities, private investments in public equity, and Rule 144A
private offerings and are recorded on the closing date of the transaction. Client reimbursements for costs associated for private placement
fees are recorded gross within investment banking and various expense captions, excluding compensation. The Company typically receives
payments on private placements transactions at the completion of the contract. The Company views the majority of placement fees as a single
performance obligation that is satisfied when the transaction is complete, and the revenue is recognized at that point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Taxes and regulatory fees assessed
by a government authority or agency that are both imposed on and concurrent with a specified revenue-producing transaction, which are
collected by Public Ventures from a customer, are excluded from revenue and recorded against general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures does not incur any
costs to obtain contracts with customers for revenues that are eligible for deferral or receive fees prior to recognizing revenue, and
therefore, as of December 31, 2025 and 2024, Public Ventures did not have any contract assets or liabilities related to these revenues
in its consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December 31,
2025 and 2024, the Company&#8217;s technology development segment did not have any revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">PatentVest recognizes revenue when performance
obligations are satisfied by transferring promised goods and services to customers in an amount the Company expects to receive in exchange
for those goods or services. PatentVest enters into contracts that can include various combinations of its offerings which are generally
capable of being distinct and accounted for as a separate performance obligation for the entire contract or a portion of the contract.
When performance obligations are combined into a single contract, PatentVest utilizes stand-alone selling price to allocate the transaction
price among the performance obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Certain contracts or portions of contracts
are duration-based, which in the event of customer cancellation, provide PatentVest with an enforceable right to a proportional payment
for the portion of the services provided. Accordingly, revenue from duration-based contracts is recognized using a time-based measure
of progress, which PatentVest believes best depicts how it satisfies its performance obligations in these arrangements as control is continuously
transferred throughout the contract period. Revenue from certain contracts is recognized over the expected period of performance using
a single measure of progress, typically based on hours incurred. Payments received in advance of services being rendered are recorded
as a component of contract liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The PatentVest&#8217;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zzOhoIIdeFQf" style="display: none">Schedule of Changes in Deferred Revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Balance as of December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" style="width: 16%; font-size: 10pt; text-align: right" title="Deferred revenue, Balance">20</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized">20</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance as of December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" style="font-size: 10pt; text-align: right" title="Deferred revenue, Balance"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zwq8sGRWvSh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_ecustom--AccountingForResearchGrantsPolicyTextBlock_zKADqWpB076k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Research Grants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes, receives grant reimbursements, which are netted against research and development expenses in the consolidated statement of operations.
Grant reimbursements for capitalized assets are recognized over the useful life of the assets, with the unrecognized portion recorded
as deferred grant reimbursements and included in liabilities in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Grants function on a reimbursement
model are accounted for using the accrual method. They are treated as reductions to expenses, corresponding to the amount of disbursements
and obligations eligible for reimbursement. These are for permissible expenses incurred as of December 31, 2024. The reimbursements are
anticipated to be received from the respective funding entities in the following year. Management considers such receivables at December
31, 2024, to be fully collectable due to the historical experience with the Federal Government of the United States of America. Accordingly,
no allowance for credit losses on the grants receivable was recorded in the accompanying consolidated financial statements. The Company was not engaged in any research grants for the year ended December 31. 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zvvVxNvqM2t4" style="display: none">Summary of Grants Receivable Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024<span id="xdx_F5E_zzT4nWlrl6oh">(1)</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Balance at beginning of year<span id="xdx_F49_zeT54RJrBuT1">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">882</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant costs expensed</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,897</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grants for equipment purchased</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">44</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">52</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grant funds received</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(2,173</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Removal of balance due to deconsolidation of eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(702</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt">In 2024, eXoZymes was deconsolidated
from the Company&#8217;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</span></td>
</tr></table>
<p id="xdx_8A0_z4a8wDrTKNud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes has received three grants
provided by the National Institute of Health, the Department of Energy and Department of Defense through December 31, 2024. The first
grant was awarded on October 1, 2023 and the latest of these grants was set to expire on May 14, 2026, however grants can be extended,
or new phases can be granted, extending the expiration of the grant. None of the grants have commitments made by the parties, provisions
for recapture, or any other contingencies, beyond complying with the normal terms of each research and development grant. Research grants
received from organizations are subject to the contract agreement as to how eXoZymes, formerly known as eXoZymes, conducts its research
activities, and eXoZymes is required to comply with the agreement terms relating to those grants. Amounts received under research grants
are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance
with the approved grant project. eXoZymes is permitted to draw down the research grants after incurring the related expenses. Amounts
received under research grants are offset against the related research and development costs in the Company&#8217;s consolidated statement
of operations. For the years ended December 31, 2025 and 2024, grants amounting $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20251231_zx1DsG46DI38" title="Research and development costs">0</span> and $<span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_zvUD2nyd6316" title="Research and development costs">2.8</span> million, were offset against
the research and development costs. Grant drawdowns, which includes grants costs expensed, grants for equipment purchased, and grant fees,
for the years ended December 31, 2025 and 2024, totaled $<span id="xdx_90B_ecustom--GrantDrawdowns_c20250101__20251231_zX0Wcdhg4k9d" title="Grant drawdowns">0</span> and $<span id="xdx_90F_ecustom--GrantDrawdowns_pn5n6_c20240101__20241231_zTw0cXZNZD38" title="Grant drawdowns">2.0</span> million, respectively, which included grant costs expensed, grants
for equipment purchased, and grants fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zFio8zeF0yx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Research and Development Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses
relating to the development of eXoZymes&#8217; technology. For the years ended December 31, 2025 and 2024, research and development costs
prior to offset of the grants amounted to $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseGross_c20250101__20251231_zHnagssCOgN4" title="Net of grant received">0</span> and $<span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseGross_pn5n6_c20240101__20241231_zw8WD44tPH7l" title="Net of grant received">3.4</span> million, respectively, which included grant costs expensed, grants fees, and research
and development costs, net of the grant received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p id="xdx_84B_ecustom--PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_zNGl6M1zDfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Patent and Licensing Legal and Filing
Fees and Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Due to the significant uncertainty
associated with the successful development of one or more commercially viable products based on the Company&#8217;s research efforts and
related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its
intellectual property are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Patent and licensing legal and filing
fees and costs were $<span id="xdx_90A_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20250101__20251231_zAAazgXGyKU5" title="Patent and licensing legal and filing fees and costs">54</span> thousand and $<span id="xdx_902_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20240101__20241231_zE6M4QA6cWb5" title="Patent and licensing legal and filing fees and costs">296</span> thousand for the years ended December 31, 2025 and 2024, respectively. Patent and licensing
legal and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zssHT9mtPbQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>ASU 2021-10, Government Assistance
(Topic 832): Disclosures by Business Entities about Government Assistance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On January 1, 2020, The Company adopted
ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;)
and retrospectively applied the guidance to prior transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The amendments in ASU 2021-10 require
the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting
model by analogy: (1) information about the nature of the transactions and the related accounting policy used to account for the transactions;
(2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each
financial statement line item; and (3) significant terms and conditions of the transactions, including commitments and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Management does not believe that any
other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#8217;s
consolidated financial statement presentation or disclosures.</p>

<p id="xdx_85E_zcQgKELri1l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zqY4SbD7RhTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. <span id="xdx_822_zedJztFAtkf1">Segment Reporting</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In its operation of the business, management,
including the Company&#8217;s chief operating decision maker, who is also the Company&#8217;s Chief Executive Officer, reviews certain
financial information, including segmented profit and loss and balance sheet statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company currently operates in <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zba93brjOd7k" title="Number of reportable segments">two</span>
reportable segments: a broker dealer &amp; intellectual property service and technology development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The broker dealer &amp; intellectual
property service segment currently has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer
firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking
due diligence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The technology development segment
currently has two subsidiaries, eXoZymes, and M1. eXoZymes is a research and development stage
company synthetic biology company, that is consolidated in the Statement of Operations up to November 14, 2024. M1 research
and development stage company that is developing a small molecule senescence platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Non-income generating subsidiaries
for management of the business, including MDB Management are reported in the Other column in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The segments are based on the discrete
financial information reviewed by the Chief Executive Officer to make resource allocation decisions and to evaluate performance. The reportable
segments are each managed separately because they will provide a distinct product or provide services with different processes. All reported
segment revenues are derived from external customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accounting policies of the Company&#8217;s
reportable segments are in consideration of ASC 280 and the same as those described in the summary of significant accounting policies
(see Note 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89D_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_gL3LLABGATTB-CUTW_zvEk2dnfJff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following sets forth the long-lived
assets and total assets by segment at December 31, 2025 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zkO4me2B3pk8" style="display: none">Schedule of Long-lived Assets and Total Assets by Segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerAndIntellectualPropertyServiceMember_zeGm3LNUjGIj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer and<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zcbZMLyosrsl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology<br/> Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zGlPhHZ2RzWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zC2bHg5bN0Ua" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_z0NyLqDFEtca" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_pn3n3_zzu8fMKvlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-size: 10pt; text-align: justify">Long-lived assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">117</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">547</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">664</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_zrwrkCQlJ5h" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">25,128</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">38,609</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">63,740</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zsjWS16NaZB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MWGIM_zm6DXnzPilq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zPloS8TgOQDa" style="display: none">Schedule of Statement of Operation by Segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zmsUppUTSRGa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zrWrHbGhlL63" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zW5BrpeC8f9h" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z1OiMiy5lO65" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zR2CtlQalrc" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_z0HvKk5gBVg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_i01N_pn3n3_di_zLQAyD0Qvvgl" style="vertical-align: bottom; background-color: White">
    <td style="width: 30%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer <span id="xdx_F4B_zewLDUAXxTw8">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(331</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(331</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_i01I_pn3n3_z3XCdhHMah51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer (1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--RealizedInvestmentGainsLossesOne_i01_pn3n3_zMkq46JflBx4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Realized gain on investment securities, net from the licensed broker dealer <span id="xdx_F47_zDOEqJXPcqz7">(2)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FeeIncome_i01_pn3n3_z75w6lRdU654" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income from the licensed broker dealer <span id="xdx_F40_zo1u9pGYbML9">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,282</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,282</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_zxitFAN2Fjp3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherOperatingIncome_i01_pn3n3_zz7DiKDnrtk5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income <span id="xdx_F4D_zdiglk5bUe8j">(4)</span></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">861</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">861</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_pn3n3_zesmzpastxF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,911</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,911</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zJGRCuuKpyec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zsXiVkEKYe91" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LaborAndRelatedExpense_i02_pn3n3_zdiHBXM7mDxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,875</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,094</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,969</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingExpense_i02_pn3n3_zYfTjFL1toq7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,471</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">362</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,833</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_pn3n3_z3ySzdMJZG93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,005</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">868</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,937</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommunicationsAndInformationTechnology_i02_pn3n3_zJfQcRLb3Llj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">968</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">135</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,103</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ClearingAndOtherCharges_i02_pn3n3_zpPAGMTrpmre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">556</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">556</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_pn3n3_znbwBwmr5zb7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">742</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,497</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,239</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02T_pn3n3_zAOk4nWkddFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,617</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,956</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,637</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i02_pn3n3_zskYsgAMkCJl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_pn3n3_zLgZCyfaTS5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,617</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">64</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,956</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,637</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NetOperatingIncomeLoss_iT_pn3n3_zrIierldZ4T1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net operating (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,706</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(64</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,956</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(17,726</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_pn3n3_zojnS0jg4fef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--MiscellaneousIncome_pn3n3_zLrqgUQKpwvl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_pn3n3_di_z7eafuHWNQ52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(990</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">990</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherNonoperatingIncome_i01_pn3n3_zKw4Aws7eeVf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">471</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,136</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(990</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">617</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--GainRelatedToDilutionEvents_i01_pn3n3_zcBNWLxpXySk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain related to dilution events</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zTkZ8Yb74lx6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain on deconsolidation of subsidiary</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_zuFjLfJo3MTe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,150</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(13,759</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(16,973</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zMBLAtT4rIz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_pn3n3_zzgkoWOiXIw" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,161</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(13,759</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(16,984</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeLossFromEquityMethodInvestment_i01_pn3n3_ziwMXHlip1ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_iT_pn3n3_zobhMCmM7mL3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,161</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(18,041</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(21,266</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zVxxXDefdtL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_pn3n3_zdPCaBKfaeGe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,161</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(43</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(18,041</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(21,245</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span id="xdx_F0D_zEor9fRn3qpi" style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span id="xdx_F15_zgbWJ4PSadxe" style="font-size: 10pt">Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F09_zGLgxMMdFQN9" style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F17_zOe2PuXCzajk" style="font-size: 10pt">Includes realized gains on securities held by the broker-dealer.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F05_z4JoAFWJTPN1" style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span id="xdx_F11_zFxNmoNpBLpi" style="font-size: 10pt">Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F03_zUWsCc363nV3" style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span id="xdx_F12_zUyKanJjUJle" style="font-size: 10pt">Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.</span></td></tr>
  </table>
<p id="xdx_8AF_zoLhQ72RvHFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C03_gL3LLABGATTB-CUTW_zZCbmgn9oyGj">The following sets forth the long-lived
assets and total assets by segment at December 31, 2024 (in thousands):</span></p>

<div id="xdx_C0E_gL3LLABGATTB-CUTW_zk7ARLLz2F94"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_z8BIYhWOFah8" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zxfqZ3K4Y2tb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zwebjIF7XvUb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology<br/> Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zwt74Hy0bln7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z4xjSKBLaOA3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zykqqBau8oYe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrent_iI_zcB5szCPRVQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-size: 10pt; text-align: justify">Long-lived assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">91</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">641</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">732</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iI_zEbvqLQ6XxQ8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">21,754</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">50,221</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">71,976</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C07_gL3LLABGATTB-CUTW_z7w7ePXwXSrk">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zuVkSPH6Si92">&#160;</span></p>

<div id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zKvMYYxqAfxd"><table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zxDkWDamkN9a" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Statement of Operation by Segment (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zNgyo9QxRcDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zVBQNxHgGlHe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zfLHp1q4wxLk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z6aN42ks42Yi" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_z30lEVjjKxWj" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_zKRi1AQrpD9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrealizedGainLossOnInvestments_i01_zyb7rlhTFXw9" style="vertical-align: bottom; background-color: White">
    <td style="width: 30%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer  <span id="xdx_F43_zWUs8Dto14ke">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(275</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(275</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FeeIncome_i01_z6d9ZzKadMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income from the licensed broker dealer <span id="xdx_F42_z5fs0BmS5l03">(2)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,221</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,221</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_ztiPAN9vDBPc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment loss <span id="xdx_F4A_z2dxI5NLo03f">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(200</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(200</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherOperatingIncome_i01_zyNFBZXjfPZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income <span id="xdx_F4D_zt1W4aTYGOT9">(4)</span></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">411</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">411</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_zHvhMmllsUH3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,157</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,157</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zMmiKetVtgrb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvbbvLQPhjTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_i02_zqK1qW87qCrj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,226</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,062</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,769</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,057</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_i02_zrPywaAV9Cwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,301</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">185</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,486</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_zGxKygTch0B" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">820</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,206</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,086</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,112</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommunicationsAndInformationTechnology_i02_zLQaYBeMtBTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">805</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">34</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">83</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">922</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ClearingAndOtherCharges_i02_zh7JLkyObDE3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,137</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,137</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_zZ34HDAX8LPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">806</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">133</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,669</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,608</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i02T_zZhBF38SfJsa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8,095</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,435</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">17,792</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29,322</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zIHEVSPhbYY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_zvCDo2CdarEk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,095</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,903</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,792</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,790</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NetOperatingIncomeLoss_iT_z02ABQ5Zs9Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net operating (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,938</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,903</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(17,792</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(28,633</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_ztBJeXpqWF0i" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--MiscellaneousIncome_zuWi4EoOwQah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1411">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_zY0krAMLtmAj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(779</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(92</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">799</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(72</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncome_i01_zfjLtL3YPDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">465</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,510</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(799</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,179</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainRelatedToDilutionEvents_i01_zZnbGs53y3dl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gain related to dilution events</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zPqWOkFi4UC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">Gain on deconsolidation of subsidiary</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,307</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1437">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,307</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zkk18ubnFh3d" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,992</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23,155</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1443">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,023</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_zN3z37vUv7y2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1449">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_zel5TqRLBvLa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,994</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23,155</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,021</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeLossFromEquityMethodInvestment_i01_zjOzGfZpvHW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1459">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(420</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(420</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ProfitLoss_iT_zxSS0fvY1v51" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,994</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,735</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11,601</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zPA4DtmKvFQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_z4NUZU0Rd7Ig" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net income and (loss) attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,140</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,904</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">22,735</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,691</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F0C_zItwKHS2g4Kh" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F19_zX8aEhgzrEuk" style="font-size: 10pt">Includes unrealized gains and
losses on securities held by the broker-dealer.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F09_zBzu6syX8buj" style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span id="xdx_F16_zorbWRAAllIf" style="font-size: 10pt">Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F02_zyhMfb3EvK0b" style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span id="xdx_F14_ztBZbU7oANQ5" style="font-size: 10pt">Includes impairment loss of assets
from the reduced fair value of the asset.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F0E_zCCvHQu57k5a" style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span id="xdx_F1A_zdtty7wgl7m" style="font-size: 10pt">Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.</span></td>
</tr></table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zYgOk9fNWKxg">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Non-Controlling Interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity and Non-Controlling Interests</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbT32cUspVz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4. <span id="xdx_821_znnEikvNcEoh">Equity and Non-Controlling Interests</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Equity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Preferred shares &#8211; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_z4BPQ5xp2mX7" title="Preferred stock, shares authorized">10,000,000</span>
shares authorized, <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_z6MdOwb2BUW1" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zmUVNqMFALi6" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding. The board of directors may designate preferred shares to be issued, and may rank
preferred shares as junior to, on parity with or senior to other preferred shares (in each case, with respect to distributions or other
payments in respect of shares). Since the board of directors may set all the terms of any class of preferred shares, these are considered
&#8220;blank check&#8221; preferred shares. Currently the board has not defined dividend and liquidation preference, participation rights,
call prices and dates, sinking-fund requirements, or terms that may change the conversation or exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Class A Common Shares &#8211; <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zNftXpF7D32a" title="Common stock, shares authorized">95,000,000</span>
shares authorized, <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHQy6flaBmHl" title="Common stock, shares, issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zrX3IxQo2ydl" title="Common stock, shares, outstanding">4,950,632</span></span> shares issued and outstanding as of December 31, 2024. These shares are common shares and have one vote per
share. Currently there is not a defined dividend or liquidation preference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Class B Common Shares &#8211; <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zQr9uU8Y3Hql" title="Common stock, shares authorized">5,000,000</span>
shares authorized, <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZ95B7Sjniee" title="Common stock, shares, issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAKt2iGo4EGc" title="Common stock, shares, outstanding">5,000,000</span></span> issued and outstanding as of December 31, 2024. These shares are common shares and have five votes per share.
Currently there is not a defined dividend or liquidation preference. These shares may be converted one to one for Class A Common Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Placement Agent and Selling Agent
Warrants &#8211; <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zL57LYQMhBFe" title="Placement agent and selling agent warrants">43,420</span> warrants of Class A common shares have been issued as part of the private placement and the initial public offering.
The Placement Agent and Selling Agent Warrants are subject to standard anti-dilution provisions and may include cashless exercise provisions
under certain circumstances. The issuance of the Placement and Selling Agent Warrants is a customary part of compensation for the placement
or selling agent&#8217;s services in connection with prior offerings.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-Controlling Interests</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2024 M1 was incorporated.
During the year ended December 31, 2024, the ownership interest in M1, ranged from <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zPlOXYx5EBNk" title="Ownership interest rate">67.0</span>% to <span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zgIRLn3G5yNi" title="Ownership interest rate">67.9</span>% (weighted average of <span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_znwaragf88ci" title="Ownership interest rate">67.47</span> %), with
the non-controlling interest ranging from <span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zG6RFwYL43r3" title="Non-controlling interest rate">33.0</span>% to <span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zYoO7sZOuep8" title="Non-controlling interest rate">32.1</span>% (weighted average of <span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_zqybr6fXCRA4" title="Ownership interest rate">32.53</span>%).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company held a weighted average of <span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20251231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_z67fcHuaYfzl" title="Ownership interest by parent">67.84</span>% ownership interest in M1, with the remaining <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20251231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_zUgUEhVNjwBc" title="Ownership interest by NCI">32.16</span>% representing NCI. During the year
ended December 31, 2024, the ownership interest in eXoZymes, ranged from <span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zij2aaGvQ0Vh" title="Ownership interest rate">60.94</span>% to <span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zFxgOv51fUh1" title="Ownership interest rate">47.0</span>%, with the non-controlling
interest ranging from <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zgBPdVgO7LR9" title="Non-controlling interest rate">39.06</span> % to <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zLjv4TDRDaCa" title="Non-controlling interest rate">53.0</span>%. On November 14, 2024 the ownership of eXoZymes by MDB moved below 50%, therefore
on that day the eXoZymes was deconsolidated from the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During each period, controlling and
non-controlling interests changes as a result of capital infusions from MDB. For the years ended December 31, 2025,
and 2024, there were capital infusions of $<span id="xdx_907_eus-gaap--ProceedsFromContributionsFromParent_pn3n3_c20250101__20251231_z3OhzTWMfmO" title="Capital infusions">93</span> thousand (M1) and $<span id="xdx_907_eus-gaap--ProceedsFromContributionsFromParent_pn3n3_c20240101__20241231_zO1fSF66FOza" title="Capital infusions">177</span> thousand (M1), respectively. The NCI ownership will be equal to the
NCI percentage as of the reporting period. Therefore, there will be a redistribution of equity between MDB and the non-controlling interest
owner. As of December 31, 2025, the Company&#8217;s equity interest in M1 was <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zkv73oRc6s9" title="Equity interest rate">67.9</span>% to <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zjtMVKmqrHJa" title="Equity interest rate">67.8</span>%, and the remaining equity interest was owned
by the non-controlling interests as presented below. As of December 31, 2024, the Company&#8217;s equity interest in M1 was <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zTKvLFrPhfYe" title="Equity interest rate">67.9</span>% to <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zUOUseYen9Y4" title="Equity interest rate">67.0</span>%,
and the remaining equity interest was owned by the non-controlling interests as presented below (in thousands):</p>

<p id="xdx_890_ecustom--ScheduleOfEquityAndNonControllingInterestsTableTextBlock_z9Is05pwWqf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zicnOOB87EGb" style="display: none">Schedule of Equity and Non-Controlling Interests</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Non-controlling interest net loss</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--NetIncomeLoss_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zWr6RDg9fa57" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss">(64</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_ztA2iFFOG2Z1" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss">(276</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Weighted average non-controlling percentage</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z1bJQyiL07ij" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage">32.16</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zEj8rkCBjvm4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage">32.53</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net loss non-controlling interest</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zdZMLh4owWm6" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest">(21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zgRUoT5KtNzi" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest">(90</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Prior period balance</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--MinorityInterest_iS_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zMurvPsBzLN5" title="Prior period balance">(90</span></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--MinorityInterest_iS_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zKE3C98v5r68" title="Prior period balance">7</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Removal of prior period balance of eXoZymes due to deconsolidation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zxxbfXPqBvLk" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation"><span style="-sec-ix-hidden: xdx2ixbrl1562">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zcqxZHWj9WQ7" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation">(7</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zCr9gC2yi8nd" style="font-size: 10pt; text-align: right" title="Stock-based compensation"><span style="-sec-ix-hidden: xdx2ixbrl1566">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z7EZ9iT65vmj" style="font-size: 10pt; text-align: right" title="Stock-based compensation"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Ownership change of non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z6hMl72ml2h4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zRcWaomFVX13" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Ending period balance</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--MinorityInterest_iE_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zPCK1BhahCs8" title="Ending period balance">(111</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--MinorityInterest_iE_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zIZVBDMi0Gtf" title="Ending period balance">(90</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A5_z1Lzyg2PEibk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">If there is a change in the parent
ownership in a subsidiary from an additional investment or from the issuance of stock based compensation, a change of the non-controlling
ownership is recognized based on the amount invested as required, and per ASC 810-45-21A, the carrying amount of the non-controlling interest
is adjusted to reflect the change in the non-controlling ownership in the subsidiary&#8217;s net assets. Since there was a change in the
equity, a reclassification of the non-controlling interest in the subsidiary&#8217;s net assets is required and demonstrated in the ending
period balance above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deconsolidation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureDeconsolidationAbstract', window );"><strong>Deconsolidation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeconsolidationDisclosureTextBlock', window );">Deconsolidation</a></td>
<td class="text"><p id="xdx_808_ecustom--DeconsolidationDisclosureTextBlock_zgA2s0FZ7ZJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 &#8211; <span id="xdx_827_zZ5CivyykUNc">Deconsolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On November 14, 2024 (the &#8220;Deconsolidation
Date&#8221;), the Company deconsolidated eXoZymes from its financial statements due to its ownership interest falling below 50%, resulting
in the loss of a controlling financial interest. This change occurred in connection with eXoZymes&#8217; completion of its initial public
offering, which reduced the Company&#8217;s ownership stake.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The consolidated financial statements
as of December 31, 2024 reflect the inclusion of eXoZymes&#8217; financial results through the Deconsolidation Date. For the period from
November 15, 2024 through December 31, 2024, the Company accounted for its investment in eXoZymes under the equity method, recognizing
its proportionate share of eXoZymes&#8217; net loss in the amount of $<span id="xdx_903_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_pn3n3_c20241115__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zYwaPYnN6aU6" title="Equity method, net loss">420</span> thousand, based on eXoZymes&#8217; total net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_pn3n3_c20241115__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zqRhCrcg4bp4" title="Net loss">893</span> thousand
for that period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, the Company
continues to hold a 47% interest in eXoZymes Class A common stock. While the Company and eXoZymes share certain officers, board members,
and accounting personnel, the two entities operate independently. eXoZymes also utilizes professional services provided by PatentVest,
a wholly owned subsidiary of the Company&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The assessment of the potential
impairment of the Company&#8217;s equity method investments when indicators such as a history of operating losses, a negative
earnings and cash flow outlook, and the financial condition and prospects for the investee&#8217;s business segment might indicate a
loss in value. The Company has not recognized any impairment loss on investment in unconsolidated affiliate to
date.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znmQzXpgD9Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 40pt; text-align: justify">The following table represents the
consolidated balance sheet of xXoZymes immediately prior to the Deconsolidation Date (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zaLyXtrRNZ45" style="display: none">Schedule
of Consolidated Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td colspan="2" id="xdx_49E_20241231__srt--ConsolidatedEntitiesAxis__custom--ExozymesMember_zTaT0KOHYLYe" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><b>December
                                            31, 2024</b></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_zZ7Bta7BJts1" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; font-size: 10pt; text-align: left">Cash and cash equivalents</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">68</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GrantsReceivable_i01I_pn3n3_zBeZI8Qfk3d9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-left: 0.25in">Grants receivable</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">701</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pn3n3_zSb3j8rkuW35" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">441</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredOfferingCosts_i01I_pn3n3_zM7K82YpJtRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred IPO Costs</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">550</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_zPkogiIDJgB7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">710</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_zyo8gcPejVH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset, net</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,366</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_pn3n3_zMMW3LhApfK7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,836</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Deficit</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_i01I_pn3n3_zZlZGfilAbul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">851</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_i01I_pn3n3_zu2hkw194UL8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">241</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherReceivables_i01I_pn3n3_zqAZYoN9Lrph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Due to affiliates</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,479</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredGrantReimbursement_i01I_pn3n3_zvCJLMY52BEf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred grant reimbursement</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zOPU1t4Ro0xc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,417</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_i01TI_pn3n3_zvJfKbAAatkd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total liabilities</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,118</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Deficit:</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_zXc173vBPXRk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Common shares</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_z2W5ji9NjBbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Paid-in-capital</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,120</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_zlTZ9Z1if509" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,402</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_zJobKiQ0UCja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_zXIMBmWesci4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,836</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_ziXdUjgiIncb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At December 31, 2024
eXoZymes had current assets of approximately $<span id="xdx_904_eus-gaap--AssetsCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zBGLgRPknX2a" title="Current assets">10.8</span> million, total assets of approximately $<span id="xdx_90D_eus-gaap--Assets_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_z83nOlXaNTI3" title="Total assets">13.0</span> million, current liabilities of approximately
$<span id="xdx_903_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zizTKcSwYHd" title="Current liabilities">1.3</span> million and total liabilities of approximately $<span id="xdx_90E_eus-gaap--Liabilities_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zaYX6y0DKaj6" title="Total liabilities">2.6</span> million. For the year ended December 31, 2024, eXoZymes had revenues of $<span id="xdx_907_eus-gaap--Revenues_c20240101__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zkRAaCwJTjQk" title="Revenues">0</span> and
a net loss of approximately $<span id="xdx_902_eus-gaap--NetIncomeLoss_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zEU4OVlT1Rb8" title="Net loss">5.9</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfGainOnDeconsolidationTableTextBlock_zjocbmbLWKXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following represents the calculation
of the gain on deconsolidation of eXoZymes from the consolidated financial statements of the Company (in thousands, except for share
price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zhsrE4JjEvP" style="display: none">Schedule
of Gain on Deconsolidation</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt; text-align: left">eXoZymes Class A common shares retained on November 14, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_z8OxGjezDJwl" title="Class A common shares retained">3,931</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Quoted closing price of eXoZymes Class A common shares at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaqtv82MfCF9" title="Quoted closing price of Class A common shares">10.36</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Subtotal of quoted closing price of eXoZymes Class A common shares at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zKN8E9VImEtd" title="Subtotal of quoted closing price of Class A common shares">40,727</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fair value of warrants held for eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zFYz9Y9eXRe2" title="Fair value of warrants">1,327</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair value of equity method investment retained by eXoZymes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zebt75n0aUSh" title="Fair value of equity method investment">42,054</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Carrying Value of the NCI</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iNI_pn3n3_di_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zzAECntclUEh" title="Carrying Value of the NCI">(921</span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Carrying value of eXoZymes assets at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--CarryingValueOfAssets_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zjHrObnUdcc8" title="Carrying value of assets">4,282</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Less carrying value of former investment into eXoZymes&#160;&#160;at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--LessCarryingValueOfFormerInvestment_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_zLptOMZvyKp6" title="Less carrying value of former investment">(5,787</span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Carrying value of warrants held for eXoZymes at November 14,2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--CarryingValueOfWarrants_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaMrQyJUqbZa" title="Carrying value of warrants">(321</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Gain on deconsolidation</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_z40mjl1Vfus7" title="Gain on deconsolidation">39,307</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zk0nTGECPGL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeconsolidationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeconsolidationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureDeconsolidationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureDeconsolidationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text"><p id="xdx_802_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zbezwg98FQp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 &#8211; <span id="xdx_829_zp5M2beOTH1f">Equity Method Investment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On November 14, 2024, eXoZymes underwent
an initial public offering in which MDB&#8217;s ownership interest in eXoZymes decreased from <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241113__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zl6ffa1Zv9Tf" title="Ownership interest">60%</span> to <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241114__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zUCiomo9wflj" title="Ownership interest">47%</span>. MDB and eXoZymes deconsolidated
the financial statements as the investment in eXoZymes fell below <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241114__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember__srt--RangeAxis__srt--MaximumMember_zdcSFPm1e83k" title="Ownership interest">50%</span> majority ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The fair value of the equity method investment
was determined based on the number of eXoZymes shares held by MDB and the market price of eXoZymes stock on the deconsolidation date.
This valuation also included the estimated fair value of warrants held in eXoZymes, along with an assessment of the investment for any
potential impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s portion of the net loss
for the year ended December 31, 2025, was $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn4n6_c20250101__20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zNIIsWO4GPRj" title="Net loss">4.28</span> million. As of December 31, 2025, MDB owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zWmZIg4BFAd5" title="Owned shares">3.93</span> million shares of eXoZymes shares, representing
a <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvizyneTechnologiesIncMember_z81oc0FCbj0f" title="Equity method investment, percentage">46.76%</span> ownership of eXoZymes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--EquityMethodInvestmentsTextBlock_zhVkgjWMqWm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following summarizes the Company&#8217;
consolidated balance sheet equity method investment as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zFC2ZkijDefc" style="display: none">Schedule
of Equity Method Investment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrying
    Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024,
    carrying amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--EquityMethodInvestments_iS_c20250101__20251231_zzwPfe5YKIl8" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Equity method investments, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portion of loss
    from eXoZymes</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_c20250101__20251231_zgqyyMSX7w7k" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Portion of loss from Invizyne"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,282</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain related to dilution events</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--EquityMethodInvestmentsGainRelatedToDilutionEvents_c20250101__20251231_ziSrlYOB3bLl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain related to dilution events"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2025, carrying amount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--EquityMethodInvestments_iE_c20250101__20251231_zqB3C2Vu0QZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Equity method investments, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,543</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPDd0uIJVI04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. <span id="xdx_824_z3jktA0KWVCa">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 28, 2025, Mo Hayat, Chris
Marlett, George Brandon, and Anthony DiGiandomenico voluntarily relinquished their outstanding restricted stock units (RSUs) in exchange
for stock options for an equivalent number of Class A shares and similar vesting schedules. This exchange was executed as part of a broader
equity compensation strategy aimed at aligning long-term incentives with shareholder value creation. The terms of the stock options, including
exercise price and vesting schedules, were approved by the Company&#8217;s Board of Directors in accordance with the existing equity incentive
plan and Section 16 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Between April 19, 2022 and September
21, 2022, the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20220419__20220921__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLIEmyYPcSVf" title="Restricted stock units, granted">3.7</span> million restricted stock units (&#8220;RSUs&#8221;). <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_c20220419__20220921__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zThsIeTXp9z6" title="Restricted stock units, description">These units vested 20% of one-half of the total
number of RSUs, by each individual person, on the thirteenth (13) month anniversary, October 20, 2024, of the listing of the Class A Shares
on a United States national exchange, then vesting would be at a rate of 10% of one-half the number of RSUs each six months after the
date of the initial vesting, until the last vesting on the fifth year anniversary of the date of grant, at which any previously unvested
would fully vest. These RSUs were granted to officers, directors, employees, and contractors. These RSU began to vest upon the completion
of the initial public offering by the Company on September 20, 2023, compensation expense related to these RSUs has been recorded. The
Company expensed the RSUs based on the average expense over the vesting period.</span> In 2024 an additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zan42jS1kTcf" title="Stock options to purchase">295</span> thousands RSUs were
granted, <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z846gwOaERc" title="Number of restricted stock units, canceled or forfeited">320</span> thousand RSUs were either canceled or forfeited, and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvmROqV0feg8" title="RSU vested">655</span> thousand RSUs vested. The total unrecognized compensation expense
based on the share price sold in the 2022 private placement as of December 31, 2025 was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNjcxOdYQF1l" title="Unrecognized stock-based compensation">6.0</span> million. The weighted average of the remaining
restricted stock units at December 31, 2025 was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeQeQ5rW0vSj" title="Remaining weighted average years">1.6</span> years and at December 31, 2024 was <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQwnF7tFo9T2" title="Remaining weighted average years">2.4</span> years. During the year ended December 31, 2025,
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaSQjJmGISik" title="Cancelled shares">128</span> thousand RSUs were canceled due to holder leaving the Company and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQDfxkxLnOn7" title="Number of restricted stock units, cancelled and converted">1.6</span> million RSUs were exchanged and converted to stock options.
As a result of the modification, the fair value of the awards immediately after the modification was determined to be $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzjNvplrJRVi" title="Fair value">6.0</span> million compared
to the fair value of the original restricted stock unit awards of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvs415EmwFD1" title="Restricted stock unit, value">6.8</span> million immediately prior to the modification. The modification
resulted to a decrease in the aggregate fair value of the awards and in accordance with ASC 718-Compensation&#8212;Stock Compensation, no incremental compensation costs need
to be recognized over the remaining requisite service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 19, 2022 the Company granted
<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20220419__20220419__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzQYquawYwc">2</span>
million restricted stock units (&#8220;RSUs&#8221;). <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_c20220419__20220419__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxNuFCThasGb">These
units will vest 20% of one-half of the total number of RSUs, by each individual person, starting on the thirteenth (13) month anniversary
of the listing of the Class A Shares on a United States national exchange, October 20, 2024, when a Class A Share has traded in the market
on which the Class A Shares are listed for any 90 consecutive calendar days at an average price of $20.00 or more during the period commencing
the date of grant and prior to the five year anniversary of the date of grant, with an average monthly trading volume of 2 million Class
A Shares or more during the 90 consecutive calendar day period, or a Class A Shares has traded in the market on which the Class A Shares
are listed for any 90 consecutive calendar days at an average price of $25.00 or more during the period commencing the date of grant
and prior to the five year anniversary of the date of grant; provided further, that if there is a distribution of cash, stock or other
property by the Company on the Class A Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced, from time to time,
by the value of any one or more per share distributions after the date of grant until vested.</span> As these RSUs did not begin to vest
until the completion of an initial public offering, which was completed on September 20, 2023, by the Company, which was outside of the
control of the Company, compensation expense related to these RSUs has been recorded. On April 28, 2025 all of the market based RSUs
were modified and exchanged for stock options in their place. The unvested portion of the market based RSUs was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCFNbbv9hmT1" title="Unvested portion market value">8.7</span>
million and the incremental value of $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z9SwRIdmiA7">5.5</span>
million in the exchange for a total amortized amount of $<span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zJO0Bb5DxCU8" title="Sharebased payment award amortized amount">14.2</span>
million that will be amortized over the <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zUxZzeUTTuD2" title="Stock-based compensation term life">10</span></span>ten-year life
of the award. There is not an estimated unrecognized compensation expense, as all the RSUs were modified and exchanged for stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0NIG6VYd1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of restricted stock unit
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zNRnXuYqfBMe" style="display: none">Schedule
of Restricted Stock Unit Activity</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Time-Based</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Performance-Based</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of<br/> Restricted<br/> Stock Units</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of<br/> Restricted<br/> Stock Units</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Restricted stock units outstanding at December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcYZnmL3I8b5" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">2,995</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zqNSYST50oIh" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.90</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zkaJgIL5huh2" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">2,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4QJWNJ6qGGb" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">7.91</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Granted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1Xwaw4SCDn7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1725">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z2u4HiT6DUGg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1727">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zyqFuyZr33f7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1729">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zeizSkZc1sfe" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1731">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Vested</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrMbe9Lnsmbj" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">(188</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zBVBRPeCZXVd" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.69</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWs0a40oFnT1" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1737">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Exchanged/Modified</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHoRwosIwOJd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified">(1,600</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1xvaAPwrEO1" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified">10.00</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zp1OHG0r3gmk" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified">(2,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z6RbXw0kdMhg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified">7.91</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z4k47XUbV0Nf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">(128</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcihfXXzFDc4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.97</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z3zQdk8OwVLk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4GuxS4E82l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1753">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restricted stock units outstanding at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zpcXx5SInOsh" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">1,079</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zr3VC3Pa3Tzk" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.78</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zFXarj62x0Gd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z1aVgoJo0Od5" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1761">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restricted stock units at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEhKd4WFY34k" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding">655</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zptrfDqfPAS" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested">10.00</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zvHvN4N3O1ck" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztr1g4c4adQj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted stock units at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zN5XjccM0T43" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding">843</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z6Vfvyb6UDXj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested">9.93</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zw6vq84NHZei" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1775">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zAsqLiuFA3Jb" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"><span style="-sec-ix-hidden: xdx2ixbrl1777">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zetV5s6CvD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 28, 2025, in exchange for
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_ziGALF7LAPcc" title="Unvested, shares">1.6</span> million unvested time-based RSUs, stock options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zmFzdoNXFtx4" title="Stock options to purchase">1.6</span> million shares of Common Shares were granted at an exercise price of
$<span id="xdx_90B_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zq0hN5z9Hj3h" title="Exercise price per share, granted">4.25</span> per share, which was equal to the closing price of the Common Shares immediately prior to the date of grant, and are exercisable
for a period of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHbNHE9xww12" title="Exercisable period">10</span> years. One-half of the stock options vested immediately on grant, with the remaining stock options vesting ratably
over a period of <span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zt8zo2l3M0D8" title="Remaining stock options vesting period">2</span> years, subject to continued service. The inputs used to determine the fair value of this stock option grant were as
follows: (1) Common Stock price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zlgWwmoHFNgd" title="Common stock price per share">4.25</span> per share; (2) exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEqC5QGGkwi1" title="Exercise price">4.25</span> per share; (3) expected life of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zK02b7ouC7a8" title="Estimated life">10</span> years; (4) risk-free
interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNVFUN1ChH3" title="Risk-free rate">4.23</span>%; (5) expected annual volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zflp6LWiWpUi" title="Expected annual volatility">85.65</span>%; and (6) an annual dividend rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsL5AcSWJpJf" title="Expected annual volatility">0</span>%. The total unrecognized compensation
expense based on the pre-modification valuation of the shares price sold in the 2022 private placement as of December 31, 2025 was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTbTjzXUOath" title="Unrecognized stock-based compensation">6.9</span>
million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--TimeBasedMember_zLD0G36Gj603" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of time-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except
for share price and contractual life):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zaIxCcuCKHl7">Schedule
of Time-Based Stock Option Activity</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Time-based stock options outstanding at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zUFfjZngfKX1" style="font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1805">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zF8A3iUEoFi5" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1807">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-size: 10pt">Exchanged/Modified</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z8EfKrinwPr" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified">1,600</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zXQLEHweryof" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified">3.75</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zvCgtdBmjcJf" title="Weighted average remaining contractual life (in years), time-based stock options exchanged/modified">10.00</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhdt6Ax7uwm4" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNifTcXSWT6" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zL5UIVZTf7v5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zFTQtDvgYof3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Time-based stock options outstanding at December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zxeyitO6Lmaj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, at the end">1,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcbs40YBwQRd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding">3.75</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zPnmRpdpdFrk" title="Weighted average remaining contractual life (in years), time-based stock options outstanding">9.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zYKJL7GYeGgl" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrbZX0M8Po8i" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1830">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhELFJfAVxA5" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable">1,067</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zu8BnDbm2s9j" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable">3.75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zasVp7qzfOOg" title="Weighted average remaining contractual life (in years), stock options exercisable">9.32</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z1IfYhxmTf4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, on April 28, 2025, in
exchange for <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn6n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z753q2DcMUq1" title="Unvested, shares">2</span> million unvested market-based RSUs, stock options to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn6n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5Ps6Pw8u4Wg" title="Stock options to purchase">2</span> million shares of Common Shares were granted at an exercise
price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zaApLbRlFDHe" title="Exercise price per share, granted">4.25</span> per share, which was equal to the closing price of the Common Shares immediately prior to the date of grant, and are exercisable
for a period of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zlwp7UUsi3bl" title="Exercisable period">10</span> years. The stock options vest if either (a) the Common Shares has traded in the market on which the shares are listed
for at least 30 trading days at an average price per share of $<span id="xdx_905_ecustom--AveragePricePerShare_iI_pip0_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5rm3LLTF075" title="Average price per share">20.00</span> or more, whether consecutive or non-consecutive, or (b) there are
distributions of cash, stock or other property by the Company to the holders of the Common Shares, at a value per share of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pp0p0_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5IRk0iVwDtg">20.00</span> or more
in the aggregate, subject to continued service. Once vested, the stock options will be exercisable for the remainder of the <span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4ThRkF7dNca" title="Exercisable period">10</span>-year grant
date period. The total unrecognized compensation expense based on the post-modification valuation of the unamortized amount and the incremental
value as of December 31, 2025 was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMdhZ7ejTCyj" title="Unrecognized stock-based compensation">13.2</span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_896_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--MarketBasedMember_zSj7a8TViAnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of market-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price and contractual life):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z7SJ0ngWr4Ha">Schedule
of Market-Based Stock Option Activity</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Market-based stock options outstanding at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_znVElCvTtbO" style="font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1855">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z8bzdP5EKSwa" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1857">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-size: 10pt">Exchanged/Modified</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zwhp0TTKRO27" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified">2,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zPVa6oNLHFD1" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified">3.02</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztiHtKLirGWa" title="Weighted average remaining contractual life (in years), exchanged/modified">10.00</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zOqaMejvrJG5" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1865">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zqOF4ETqdDP4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1867">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zZNzSIxvM2N6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1869">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zpF6y5AKNak" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Market-based stock options outstanding at December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zb28UOMM6DM7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, at the end">2,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCjLE2mChIg5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding">3.02</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zDhONlxIRaGa" title="Weighted average remaining contractual life (in years), market-based stock options outstanding">9.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zHZbRNuMefMk" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1879">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zM9LuLdr3QY4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWSW0D39vlN6" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1883">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zcmQYB5a4R01" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1885">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zQNfMg9lWQ98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share attributable to MDB Capital Holdings, LLC:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z4AFW1sconlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. <span id="xdx_825_zs0b4gwQ1qIj">Earnings Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s computation of
earnings (loss) per share (&#8220;EPS&#8221;) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable
to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but
presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if
they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive
effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Loss per common share is computed by
dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted
loss per common share was the same for all periods presented because stock warrants outstanding were anti-dilutive, for a total of <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z87kbfmkXFh2" title="Anti-dilutive shares">43</span>
thousand warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Earning Earnings per share is presented
below for the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zVPR881P9PVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic earnings per share is calculated
at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zkaqjXOfKsOg" style="display: none">Schedule
of Basic and Fully Diluted</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsKeAY7lHbP4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqhdj2uVj8o" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z36dGnq7Fvc8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zx6NEZoPZlae" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Years Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Basic</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
    31, 2025</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    A Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Class
    B Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    A Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    B Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zXbCmKGZ1m5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Net income (loss) attributable to MDB Capital
    Holdings, LLC</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(10,768</span></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(10,477</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,817</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,875</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_zdsrVE2OJzT5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Weighted average shares outstanding &#8211; basic</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,023</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">4,424</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_z2P4Xqk9dke1" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Net income (loss) per share &#8211; basic</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(2.14</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(2.10</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">1.31</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">1.18</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fully diluted earnings per share is
calculated at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49C_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkBtQU8M7Ca2" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_492_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpgRvnXgjrMj" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49B_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJViQEtjkvYh" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49C_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zADIBaE7C4Dk" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zvw8leYB2UVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left">Net income (loss) attributable to MDB Capital Holdings, LLC</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(11,714</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(9,531</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">7,650</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">4,042</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_zMBcPh8ZtcTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted shares outstanding &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,145</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">9,463</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zbLkXkAoW93g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net income (loss) per share &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(1.91</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(1.91</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.81</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.81</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zPauISGOoIgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Class A Common Shares and Class B common
stock are equal for ownership purposes, but Class B shares have five times the voting rights of Class A shares and Class B shares can
be exchanged on a one-to-one basis for purposes of sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zy5DaESs1tE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. <span id="xdx_82A_zRReezvqviBl">Related Party Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The principal members of the Company
have a controlling interest in PatentVest, S.A. (renamed MDB Capital, S.A. in 2022), a company organized and based in Nicaragua that provides
outsourced services to the Company and other non-related entities. During the years ended December 31, 2025 and 2024, the Company paid
$<span id="xdx_909_eus-gaap--CostsAndExpensesRelatedParty_pn5n6_c20250101__20251231_zFmmqfEy9S5d" title="Related party expenses">1.8 </span>million and $<span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_pn5n6_c20240101__20241231_zIAJB4tlmxZc" title="Related party expenses">1.5</span> million, respectively, which is inclusive of expenses and fees, for contracted labor, recorded against general and
administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December 31,
2025 and 2024, PatentVest, engaged in transactions with ENDRA Life Sciences Inc &#8211; NDRA on Nasdaq, a company for which one of our
executive officer serve as a board member. Anthony DiGiandomenico, our Chief of Transactions. For the year ended December 31, 2024, there
were no revenues recognized between MDB entities and ENDRA. However, costs incurred amounting to $<span id="xdx_906_eus-gaap--OperatingExpenses_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ENDRAMember_zry4x5xp5rGl">81</span> thousand
related to transactions with ENDRA were recognized during the year. For the year ended December 31, 2025 there was no revenue or costs
recognized during the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December
31, 2025 and 2024, PatentVest engaged in transactions with eXoZymes, a company of which the Company owns 47% of recognized revenues
of $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExozymesMember_zIwL0dXdKU0d">91</span>
thousand and $<span id="xdx_90C_eus-gaap--Revenues_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExozymesMember_zkt2EhGbubua">41</span>
thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company recorded related party accrued receivables totaling $<span id="xdx_907_eus-gaap--InterestReceivable_iI_pn3n3_c20251231_zrxbUWq1s0k2" title="Interest receivable">13</span> thousand for services performed by PatentVest on behalf of eXoZymes.
Additionally, the Company recorded accrued expenses of $<span id="xdx_905_ecustom--AccruedExpenses_iI_pn3n3_c20251231_zZOjUc2ayASh" title="Accrued expenses">1</span> thousand payable to PatentVest, representing reimbursable expenses incurred
in the ordinary course of business. During the year ended December 31, 2024, the Company recorded related party accrued receivables totaling
$<span id="xdx_90F_eus-gaap--InterestReceivable_iI_pn3n3_c20241231_zgM48hmwSoa1" title="Interest receivable">64</span> thousand. This amount includes $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20240101__20241231_z9ulUjPQSuM1" title="Value issued for services">42</span> thousand for services performed by PatentVest on behalf of eXoZymes and $<span id="xdx_903_eus-gaap--IncomeTaxesPaid_pn3n3_c20240101__20241231_zrGqj35yvBkj" title="Tax paid">22</span> thousand related to
taxes paid by the Company on behalf of certain officers, which was reimbursed in full by January 31, 2025. Additionally, the Company recorded
accrued expenses of $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_c20241231_zR1FMnEN4Kz8" title="Accrued liabilities">23</span> thousand payable to officers and directors, representing reimbursable expenses incurred in the ordinary course
of business. All transactions were conducted on an arm&#8217;s-length basis and are expected to be settled in the normal course of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zE7XaO71sRXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. <span id="xdx_82D_zBhnqu6KJad7">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Legal Claims</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company may be subject to legal
claims and actions from time to time as part of its business activities. As of December 31, 2025 and 2024, the Company was not subject
to any pending or threatened legal claims or actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Net Capital Requirement (Public
Ventures)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures is subject to the uniform
net capital rule (SEC Rule 15c3-1) of the Securities and Exchange Commission (the &#8220;SEC&#8221;), which requires both the maintenance
of minimum net capital and the maintenance of maximum ratio of aggregate indebtedness to net capital. At December 31, 2025 and 2024, Public
Ventures had net capital of $<span id="xdx_90D_esrt--NetCapital_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_z11nfEJ8vmEg" title="Net capital">8.7</span> million and $<span id="xdx_907_esrt--NetCapital_iI_pn5n6_c20241231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_z4BaHx3yrAG8" title="Net capital">10.7</span> million, respectively, which was $<span id="xdx_90F_esrt--NetCapital_iI_pn4n6_c20251231_zmHNoXFBvw3c" title="Net capital">8.45</span> million and $<span id="xdx_900_esrt--NetCapital_iI_pn4n6_c20241231_zrjiJslOYAQi" title="Net capital">10.45</span> million in excess of the
minimum $<span id="xdx_90C_esrt--NetCapital_iI_pn3n3_c20241231__srt--RangeAxis__srt--MinimumMember_z7dvS3CN8DP" title="Net capital">250</span> thousand, as required by the Securities and Exchange Commission Rule 15c3-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the broker dealer had existing subordinated loans with MDB, the Parent company, totaling $<span id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_zTE1SPbeHWl5" title="Loans payable">13.2</span> million and $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_zF6aug1UB27e" title="Interest expense">1.0</span> million of accrued interest
payable, is subordinated to other liabilities of the Company, and is considered members&#8217; equity for calculating net capital, and
is not included in aggregate indebtedness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Minimum net capital is based upon
the greater of the statutory minimum net capital of $<span id="xdx_90D_esrt--NetCapital_iI_pn3n3_c20251231__srt--RangeAxis__srt--MinimumMember_zVgCntn59agb" title="Net capital">250</span>
thousand or <span id="xdx_906_eus-gaap--RatioOfIndebtednessToNetCapital1_iI_pid_dp_uPure_c20251231_zIFVH3ucJoTl" title="Percentage of aggregate indebtedness">2</span>%
of aggregate customer debits, which were $<span id="xdx_90B_esrt--MinimumNetCapitalRequiredForEntity1_iI_c20251231_z59sN8Ojxkok" title="Aggregate indebtedness calculated amount"><span id="xdx_90D_esrt--MinimumNetCapitalRequiredForEntity1_iI_c20241231_zekO2MN0yzr7" title="Aggregate indebtedness calculated amount">0</span></span>
at December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">To comply with DTCC membership requirements,
the Company has committed to maintain at least $<span id="xdx_907_esrt--NetCapital_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__custom--DTCMembershipRequirementsMember_zA4hJ1U0Of79" title="Net capital">5.0</span> million of net capital in excess of the $<span id="xdx_905_esrt--NetCapital_iI_pn3n3_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--DTCMembershipRequirementsMember_zgh8tzyFYTZ" title="Net capital">250</span> thousand minimum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">The requirement
to comply with the Uniform Net Capital Rule 15c3-1 may limit Public Ventures&#8217; ability to issue dividends to its parent company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Indemnification Provisions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures has agreed to indemnify
its clearing broker for losses that the clearing brokers may sustain from the accounts of customers. Should a customer not fulfill its
obligation on a transaction, Public Ventures may be required to buy or sell securities at prevailing market prices in the future on behalf
of its customer. The indemnification obligations of Public Ventures to its clearing brokers have no maximum amount. All unsettled trades
at December 31, 2025 and 2024, have subsequently settled with no resulting material liability to Public Ventures. For the years ended
December 31, 2025 and 2024, Public Ventures, had no material loss due to counterparty failure and had no obligations outstanding under
the indemnification arrangement as of December 31, 2025 and 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z3dzmvQHZyh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. <span id="xdx_829_zUIoaJuN5tyh">Employee Benefit Plans</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Management and eXoZymes, both sponsored individual 401(k) defined contribution plans for the benefit of each company&#8217;s eligible employees.
Public Ventures offered its employees a sponsored 401(k) defined contribution plan for the benefit of the employees; this plan was terminated
on July 30, 2021. The plans allow eligible employees to contribute a portion of their annual compensation, not to exceed annual limits
established by the Department of Treasury. eXoZymes makes matching contributions for participating employees up to a certain percentage
of the employee contributions; matching contributions were funded for the year ended December 31, 2025 and 2024. Benefits under the eXoZymes
plan were available to all employees, and employees become fully vested in the employer contribution upon receipt. For the year ended
December 31, 2025 and 2024, a total of $<span id="xdx_908_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20250101__20251231_zXwZ4CApO8Y3" title="Employer contribution">392</span> thousand and $<span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20240101__20241231_zJ8wKeNAW0Zd" title="Employer contribution">659</span> thousand, respectively, was contributed to the plans. The costs for eXoZymes
are recorded up to November 14, 2024, the date of the consolidation of eXoZymes. The majority of the expense was included in general and
administrative cost, however, for any research and development employees. their portion of the expense is recorded in research and
development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">MDB Management and eXoZymes also provide
health and related benefit plans for eligible employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exclusive License Agreement (MDB Minnesota One)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract', window );"><strong>Exclusive License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ExclusiveLicenseAgreementTextBlock', window );">Exclusive License Agreement (MDB Minnesota One)</a></td>
<td class="text"><p id="xdx_803_ecustom--ExclusiveLicenseAgreementTextBlock_zV9KIqd4mTGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. <span id="xdx_82D_zo4jPDpO1Wc5">Exclusive License Agreement (MDB Minnesota
One)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2024, M1 entered into a Patent and Know-How License Agreement (the &#8220;License Agreement&#8221;) with the Mayo for certain patent rights and associated technology pursuant to which M1 intends
to develop a small molecule senescence platform. The License Agreement grants M1 rights to develop and commercialize Mayo&#8217;s patented
technology and know-how for all fields of use on a worldwide basis. Under the terms of the License Agreement, M1 holds an exclusive license
of patent rights and a non-exclusive license for the associated technology to make, have made, use, offer for sale, sell, and import licensed
products and derivatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As part of initial consideration for
the License Agreement, M1 issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn4n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zXwIuoAClVte" title="Issuance of shares">1.98</span> million shares of common stock equity to Mayo; which at that time represented thirty-three percent
of its shares. M1 also paid an initial license fee of $<span id="xdx_903_eus-gaap--ProceedsFromLicenseFeesReceived_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zyQ6VkdsixKj" title="License fee">150</span> thousand as part of the initial consideration. M1 will pay earned royalties
on future net sales (including modest minimum annual royalties, which commence in the second year of the term of the License Agreement
and gradually increase and plateau over time, and which will be credited against earned royalties due on net sales), and a percentage
of any sublicensing income. The earned royalty commences after the first commercial sale of a licensed product. At December 31, 2025 there
were no accrued royalties recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Under the License Agreement, M1 is
required to achieve certain development milestones within designated time periods. For select development milestones, as listed below,
M1 will be required to make a payment to Mayo, also as noted below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-left: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_90C_ecustom--PaymentForLicensedProducts_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseIIclinicalMember_zmfcbZj7oNz3" title="Payments for licensed products">250</span> thousand for Phase II clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_900_ecustom--PaymentForLicensedProducts_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseIIIclinicalMember_zH9qxrElD2j6" title="Payments for licensed products">1.5</span> million for Phase III clinical trial initiation, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_908_ecustom--PaymentForLicensedProducts_pn6n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NewDrugApplicationFirstMember_zS3M5Iu2Ert6" title="Payments for licensed products">2</span> million for FDA New Drug Application (NDA) acceptance, for the first instance of a licensed product.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-left: 0.25in; text-align: justify">&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A payment of $<span id="xdx_909_ecustom--PaymentForLicensedProducts_pn6n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NewDrugApplicationMember_zUwBkglZ7Qla" title="Payments for licensed products">5</span> million for NDA approval, for each instance of a licensed product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025 the development
milestones noted above are not required to have been met and have not been met. There are other developmental milestones in the License
Agreement relating to funding of the business and to initiating various clinical trial phases over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">If M1 materially breaches the terms
of the License Agreement, and such material breach remains uncured after an opportunity to cure, Mayo may terminate the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ExclusiveLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exclusive License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ExclusiveLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zUK2O2odT5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. <span id="xdx_82C_zUOBdiWmOTd7">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For operating leases, the Company records
right-of-use assets and corresponding lease liabilities in the consolidated balance sheets for all leases with terms longer than twelve
months. The Company has one operating leases, with no variable lease costs, and no finance leases as of December 31, 2025. The Company
has three operating leases, with no variable lease costs, and no finance leases as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes was consolidated up to November 14, 2024. In October 2023, eXoZymes, made changes to an existing lease agreement that was originally entered
into in August 2021, which resulted in an extension of the lease term by an additional 14 months. The revised lease maintained the same
escalation rate for lease payments as the previous arrangement. To account for this modification, the Company reevaluated the remaining
lease term at the time of execution. As the Company was actively utilizing the premises, adjustments were made to reflect the revaluation
of both the right-to-use asset and the corresponding lease liability in line with the updated lease term. This was originally entered
into in August 2021, with a term of 60 months beginning on August 24, 2021 and ending on September 30, 2026, with an option to extend
for 60 additional months and was further modified on April 3, 2023 for an additional 21 months with the lease ending date of April 30,
2028. At the time the lease commenced, it was not probable the Company would exercise the one five-year option to extend the facility
lease; therefore, this extension option is not included in the lease analysis. The initial base rent is $<span id="xdx_906_eus-gaap--AdvanceRent_iI_pn2n3_c20230403_zOrb49EBqXHh" title="Initial rent, per month">14.3</span> thousand per month. The
lease provides for annual increases. The base rent for the lease in the final year is $<span id="xdx_906_ecustom--BaseRent_iI_pn2n3_c20230403_zHHhl4ENM1w3" title="Base rent, per month">16.7</span> thousand per month. Additionally, eXoZymes
was responsible for annual operating cost increases of <span id="xdx_906_ecustom--AnnualOperatingCostIncreasePercentage_pid_dp_uPure_c20230403__20230403_zfYeAiywufni" title="Annual operating cost increase percentage">2.5</span>%, which are included in the rent. Since eXoZymes is not consolidated for 2025,
the information above was only calculated for 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Furthermore, in October 2023, eXoZymes
made changes to a second existing lease agreement that was originally entered into in April 2023, which resulted in an extension of the
lease term by an additional <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20231031_zbZkClSu4JY4" title="Extension term of lease">12</span> months. The revised lease maintained the same escalation rate for lease payments as the previous arrangement.
To account for this modification, the Company reevaluated the remaining lease term at the time of execution. As the Company was actively
utilizing the premises, adjustments were made to reflect the revaluation of both the right-to-use asset and the corresponding lease liability
in line with the updated lease term. This was originally entered into in April 2023, with a term of <span id="xdx_901_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230430_zlnbAds7lC0c" title="Lease term">60</span> months beginning on July 1, 2023
and ending on June 30, 2028, with an <span id="xdx_900_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20231001__20231031_zwS4zRfsuX66" title="Option to extend">option to extend for 60 additional months</span>. At the time the lease commenced, it was not probable the
Company would exercise the one five-year option to extend the facility lease; therefore, this extension option is not included in the
lease analysis. The initial base rent is $<span id="xdx_90B_eus-gaap--AdvanceRent_iI_pn2n3_c20231031_zimDouZf19Fl" title="Initial rent, per month">13.3</span> thousand per month. The lease provides for annual increases. The base rent for the lease
in the final year is $<span id="xdx_909_ecustom--BaseRent_iI_pn2n3_c20231031_zOOUjB2LxYZ2" title="Base rent, per month">15.4</span> thousand per month. Additionally, eXoZymes is responsible for annual operating cost increases of <span id="xdx_900_ecustom--AnnualOperatingCostIncreasePercentage_pid_dp_uPure_c20231001__20231031_zMpkMVYzYn64" title="Annual operating cost increase percentage">3.0</span>%, which
are included in the rent. Since eXoZymes is not consolidated for 2024, the information above is only calculated for 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On July 1, 2022 the Company executed
a lease for new office space in the Dallas, Texas metropolitan area, the space was occupied on December 20, 2022. The lease with a term
of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220701_z8jj1P3YxUP4" title="Lease term">91</span> months and began once we took control of the space on December 20, 2022 and ending on July 20, 2030, without an option to extend.
The initial base rent was $<span id="xdx_90A_eus-gaap--AdvanceRent_iI_pn2n3_c20220701_zgbc6wWnRQSa" title="Initial rent, per month">12.6</span> thousand per month, after 7 months of free rent. The lease provides for annual increases. The base rent
for the lease in the final year is $<span id="xdx_90E_ecustom--BaseRent_iI_pn2n3_c20220701_zs9C7KhoVuNi" title="Base rent, per month">13.9</span> thousand per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term, and lease liabilities represent the Company&#8217;s obligation to make lease payments.
Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments
over the lease term. The Company&#8217;s uses the implicit rate in its lease calculations when it is readily determinable. Since the Company&#8217;s
leases do not provide implicit rates, to determine the present value of lease payments, management uses the Company&#8217;s estimated
incremental borrowing rate for a fully collateralized loan with a similar term of the lease that is based on the information available
at the inception of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_894_eus-gaap--LeaseCostTableTextBlock_zcyi91Cll9N7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zYDZFo55hxxa" style="display: none">Schedule
of Operating Lease Cost</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zCKawW5PDac1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zjzFaqA7Ev74" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the years ended<br/> December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands)</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating leases:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGoaBcBEOIbe" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Right-of-use assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">547</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">641</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zRFElbfZ4ZSj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">609</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">711</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Weighted average remaining lease term in years</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0EjF7nH5IDj" title="Weighted average remaining lease term in years">4.50</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z0RqdCP4mfr3" title="Weighted average remaining lease term in years">5.50</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average discount rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zmt9KFdlbMb5" style="font-size: 10pt; text-align: right" title="Weighted average discount rate">7.80</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zGXmDHvaklDb" style="font-size: 10pt; text-align: right" title="Weighted average discount rate">7.80</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20250101__20251231_zxj2KKkAE6W5" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">155</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20240101__20241231_zgaMVKNdJDza" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">152</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Right-of-use assets obtained in exchange for lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20250101__20251231_zURnBbXxJzlk" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2038">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zhuGuRj2fZg6" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2040">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating lease cost</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseCost_pn3n3_c20250101__20251231_zuuKVtWVIzRd" style="font-size: 10pt; text-align: right" title="Operating lease cost">52</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseCost_pn3n3_c20240101__20241231_zeyRz5xTtDD3" style="font-size: 10pt; text-align: right" title="Operating lease cost">147</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Short-term lease costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShortTermLeaseCost_pn3n3_c20250101__20251231_zi4tqVKiEof4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">95</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShortTermLeaseCost_pn3n3_c20240101__20241231_zbMTuMMFIOFa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total operating lease costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20250101__20251231_zv6gYrYFLE72" style="font-size: 10pt; text-align: right" title="Total operating lease costs">147</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_z09HYx2IOQjb" style="font-size: 10pt; text-align: right" title="Total operating lease costs">234</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zW7QOwEQ0Fr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv6zURXrkuzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Future payments due under operating
leases for the as of December 31, 2025 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zw3gXW3FsdC3" style="display: none">Schedule
of Future payments Due Under Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold">Year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zzbHKODGLgHg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDS7_zES5JhybPDJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt; text-align: left">2026</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right">158</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDS7_zDnAigxsp8bc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">160</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDS7_zxb1Lo3G6KT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">2028</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">163</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_maLOLLPzDS7_z9YwNxh7JEbi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2029 and thereafter</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">259</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDS7_z97i8F0RU613" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-size: 10pt">Total</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">740</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zqZ6CZSIgoaa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less effects of discounting</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(131</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgjG2x8hK6x" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">609</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zkJVMofiFoji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zJSER0ACJL27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. <span id="xdx_820_zqzQhPaHqntg">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is a limited liability
company treated as a partnership for federal and state income tax purposes, with the exception of the state of Texas, in which income
tax liabilities and/or benefits of the Company are passed through to its unitholders. Limited liability companies are subject to Texas
margin tax. Additionally, the Company&#8217;s subsidiaries, Public Ventures, MDB Management, PatentVest, and M1 are Subchapter&#160;C-corporations
subject to federal and state income taxes. As such, with the exception of the state of Texas and certain subsidiaries, the Company is
not a taxable entity; it does not directly pay federal and state income taxes and recognition has not been given to federal and state
income taxes for the operations of the Company, except as set forth in the tables below. Amounts recognized for income taxes are reported
in &#8220;income tax expense (benefit)&#8221; on the consolidated statements of operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s taxable income
or loss, which may vary substantially from the net income or net loss reported on the consolidated statements of operations, is includable
in the federal and state income tax returns of each unitholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zmkUgBiHEERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income tax expense (benefit) (including
Subchapter C-corporations) consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zfHTorENI9Hc" style="display: none">Schedule
of Income Taxes Expenses (benefit)</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_zmL8e6kRXQBh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zXFx652RV0j5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maITEBztXD_zZ7yL2tEhxv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; padding-left: 10pt">Federal</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2072">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">1</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maITEBztXD_zzv7Q7MT9qAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">State</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_znPsIyABZBZa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Federal</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_zNbpwR3ZhDbj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">State</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2082">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBztXD_zco7tXUdo9fc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zTgQHL8fh1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Total cash taxes paid net of refunds
received in 2025 was $<span id="xdx_902_eus-gaap--IncomeTaxesPaid_c20250101__20251231_zP747hdDcI9g" title="Cash taxes paid">0</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025, the Company had approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USFederalTaxMember_zmDmrqeTlnNk" title="Net operating loss carryforwards">23.3</span> million and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--FloridaIncomeTaxMember_zYrsJrIj4bEa" title="Net operating loss carryforwards">0.1</span> million of net operating loss carryforwards
for U.S. federal and Florida income tax purposes, respectively. These net operating losses may be carried forward indefinitely</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Effective for the year ended December
31, 2025, the Company adopted ASU 2023-09-Improvements to Income Tax Disclosures, prospectively. The reconciliation of income tax expense (including Subchapter C-corporations)
computed at the U.S. federal statutory income tax rate of 21% to the recognized income tax expense for the year ended December 31, 2025,
presented in accordance with the disclosure requirements of ASU 2023-09-Improvements to Income Tax Disclosures, is as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zThUWxlxqKsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfl3scupFN3l" style="display: none">Schedule
of Federal Statutory Tax Rate to The Effective Tax Rate</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year Ended December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">U.S Federal statutory income rate</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20250101__20251231_zAzgeeZpppFj" style="width: 16%; font-size: 10pt; text-align: right" title="U.S Federal statutory income rate, Amount">(4,463</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20250101__20251231_zFxJyMOFBuA4" title="U.S Federal statutory income rate, Rate">21.00</span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State, net of federal tax benefit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20250101__20251231_zbXy9kIlY7wl" style="font-size: 10pt; text-align: right" title="State, net of federal tax benefit, Amount">9</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20250101__20251231_zMr0pwJiICR1" title="State, net of federal tax benefit, Rate">(0.04</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Nontaxable or nondeductible items</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Income/loss excluded from nontaxable entities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20250101__20251231_zfzJQFRskkMi" style="font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount">944</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20250101__20251231_zhyVeG40ffe1" title="Income/loss excluded from nontaxable entities, Rate">(4.44</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_zBXuJlTncBea" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-left: 10pt">Permanent differences</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_zJdrdulDazCc" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-left: 10pt">Permanent differences</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Meals and entertainment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maMahiYA_c20250101__20251231_z0QGSTT1dyMj" style="font-size: 10pt; text-align: right" title="Meals and entertainment, Amount">7</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_maKamaLI_c20250101__20251231_zprancH9EwFl" title="Meals and entertainment, Rate">(0.04</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Stock options</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maMahiYA_c20250101__20251231_zQWDLG7PYlDh" style="font-size: 10pt; text-align: right" title="Stock options, Amount">614</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maKamaLI_c20250101__20251231_zltTUL71zoP2" title="Stock options, Rate">(3.06</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Equity award vesting</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--IncomeTaxReconciliationEquityInEquityAwardVestingAmount_pn3n3_maMahiYA_c20250101__20251231_zcq5YDq12oxd" style="font-size: 10pt; text-align: right" title="Equity award vesting, Amount">248</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_pid_dp_uPure_maKamaLI_c20250101__20251231_zqlTNBcH1AP" title="Equity award vesting, Rate">(1.24</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Modification of equity awards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--IncomeTaxReconciliationModificationOfEquityAwardsAmount_pn3n3_maMahiYA_c20250101__20251231_z3WSaoPZkhS2" style="font-size: 10pt; text-align: right" title="Modification of equity awards, Amount">2,194</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maKamaLI_c20250101__20251231_zZ9V0lzmB0q9" title="Equity award vesting, Rate">(10.95</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Return-to-provision adjustments</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20250101__20251231_zRrcBz3dkZSl" style="font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount">(44</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20250101__20251231_zW6LSLqiL1nc" title="Return-to-provision adjustments, Rate">0.22</span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_zWIBshQTkSc6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; text-align: left">Other</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_zOBsHs9AIRxh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; text-align: left">Other</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20250101__20251231_zvBKtMBpy216" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance, Amount">502</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20250101__20251231_zH8KcsFkBxYa" title="Valuation allowance, Rate">(2.52</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Effective rate</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20250101__20251231_zL9SnUxJsz4f" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Effective rate, Amount">11</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20250101__20251231_zXDBeGuz56c7" title="Effective rate, Rate">(0.05</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A reconciliation of the federal
statutory tax rate to the effective tax rate (including Subchapter&#160;C-corporations) for the year ended December 31, 2024 and
2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S Federal statutory
    income rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20240101__20241231_z5gZGmcJCLba" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S Federal statutory income rate, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,453</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20240101__20241231_zUkTSgGBrsNk" title="U.S Federal statutory income rate, Rate">21.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State, net of federal tax
    benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20240101__20241231_z055pwdywtk2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State, net of federal tax benefit, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(246</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20240101__20241231_zvUxl03iC6W3" title="State, net of federal tax benefit, Rate">(2.11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income/loss excluded from
    nontaxable entities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20240101__20241231_zCS3MINvK0Ag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20240101__20241231_zbH5oGARhAbf" title="Income/loss excluded from nontaxable entities, Rate">(68.57</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maMahiYA_c20240101__20241231_zLDKKFiB4Zxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Permanent differences, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">641</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zcJdGiB4y7ck" title="Permanent differences, Rate">5.49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return-to-provision adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20240101__20241231_zyah9TbCQK0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Return-to-provision adjustments, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zTmjsZdVVGtg" title="Return-to-provision adjustments, Rate">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maMahiYA_c20240101__20241231_zIHFoGxynuai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKamaLI_c20240101__20241231_zbTPDKiJGemb" title="Other, Rate">1.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20240101__20241231_zc4fcKcW0Pbh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20240101__20241231_zUobJyjPhofk" title="Valuation allowance, Rate">42.52</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20240101__20241231_zlpCL3taBE1k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective rate, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20240101__20241231_zLq7wG2Fh661" title="Effective rate, Rate">0.02</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zW4pGONifQD1" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt">Start-up expenditures</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">4</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">13</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Organizational expenditures</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sec 174 &#8211; Research and development costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,795</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,524</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Lease liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">128</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">149</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment principally due to differences in depreciation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Bonus expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2195">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Charitable contribution carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">53</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Intangible Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">51</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">38</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,890</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,781</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,625</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,124</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Right-of-use asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(115</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(135</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Investment securities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(212</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(264</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2228">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Deferred tax assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">327</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">399</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Other noncurrent assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2236">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zTugmM3Fiugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In assessing the realizability of deferred
tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. At December&#160;31, 2025, based on projections of future taxable
income for the periods in which the deferred tax assets are deductible, a valuation allowance of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20251231_zrhos06hqse4" title="Decrease in deferred tax assets valuation allowance">6.6</span> million was recorded
for tax carry forwards and attributes to reduce the net deferred tax assets to an amount that is more likely than not to be recognized.
The amount of deferred tax assets considered realizable could be reduced in the future if estimates of future taxable income during the
carry forward period are reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with the applicable accounting
standards, the Company recognizes only the impact of income tax positions that, based on their merits, are more likely than not to be
sustained upon audit by a taxing authority. To evaluate its current tax positions in order to identify any material uncertain tax positions,
the Company developed a policy of identifying and evaluating uncertain tax positions that considers support for each tax position, industry
standards, tax return disclosures and schedules and the significance of each position. It is the Company&#8217;s policy to recognize interest
and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company had no material uncertain tax positions
at December&#160;31, 2025 and December&#160;31, 2024. The tax years 2022 &#8211; 2025 remain open to examination for federal income tax
purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zm0IcdkhnTN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. <span id="xdx_82D_zixxhF4wmjnl">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On February 3, 2026, the Company granted<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260203__20260203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVN81gISSZgj" title="Restricted stock units, granted">
161,500</span> restricted stock units (RSUs) to employees pursuant to its equity incentive plan.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbvuMgc7HMkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Basis of Presentation and Principles
of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The accompanying consolidated financial
statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) and include the financial statements of wholly-owned and majority owned subsidiaries. All material intercompany accounts
and transactions have been eliminated in consolidation. Non-controlling interests at December 31, 2025 and 2024 relate to the interests
of third parties in the partially owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The managing members of the Company
have a controlling interest in PatentVest, S.A., a company organized and based in Nicaragua (which was renamed MDB Capital, S.A in 2022).
As the Company itself does not have a controlling financial interest in this entity, management has determined PatentVest, S.A. is not
a variable interest entity and should not be consolidated as it has no ownership interests, so has excluded this entity from the Company&#8217;s
consolidated financial statements. It is the Company&#8217;s policy to reevaluate this conclusion on an annual basis or if there are significant
changes in ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeconsolidationPolicyTextBlock', window );">Deconsolidation</a></td>
<td class="text"><p id="xdx_84E_ecustom--DeconsolidationPolicyTextBlock_z9F9sgQUCM07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Deconsolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Upon the occurrence of certain events
and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated
variable interest entities. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company
records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair
value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the
carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary&#8217;s
assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company evaluated whether the
deconsolidation should be presented as a discontinued operation in its consolidated financial statements as of the deconsolidation date.
This assessment considers whether the deconsolidation constitutes a strategic shift that has, or will have, a major impact on the Company&#8217;s
operations or financial results. Based on this evaluation, the Company concluded that the deconsolidation does not meet the criteria
for presentation as a discontinued operation. Accordingly, the Consolidated Statement of Operations includes the results of operations
for the deconsolidated entity through November 14, 2024, the effective date of deconsolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity method investment</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zeX1leJLKmW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Equity method investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company applies the equity method
to account for investments in entities where it has the ability to exercise significant influence over the operating and financial policies
of the investee. Under the equity method, the investment in eXoZymes Inc, (&#8220;eXoZymes &#8220;), formerly Invizyne Technologies
Inc. (&#8220;Invizyne&#8221;)&#8221;, is initially recorded at cost and subsequently
adjusted to reflect the Company&#8217;s proportional share of the investee&#8217;s results of operations in its consolidated financial
statements. Equity method investments are periodically reviewed for any other-than-temporary declines in value. The Company&#8217;s investment
in eXoZymes is presented as &#8220;Equity method investment&#8221; on the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Any excess of the acquisition cost
over the Company&#8217;s share of the net fair value of eXoZymes&#8217; identifiable assets and liabilities at the acquisition date is
recognized as goodwill, which is included in the carrying amount of the investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company increases its interest
in an affiliate accounted for under the equity method while retaining significant influence, it applies the acquisition method only to
the additional interest acquired, leaving the previous interest unchanged. Conversely, when there is a decrease in the interest in an
affiliate accounted for under the equity method while retaining significant influence, the Company derecognizes a proportionate part of
its investment and recognizes any resulting gain or loss in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWOfx76LB65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We account for income taxes using the
asset and liability method, under which we would recognize the amount of taxes payable or refundable for the current year and deferred
tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns.
We measure current and deferred tax assets and liabilities based on provisions of enacted tax law. We evaluate the realization of our
deferred tax assets based on all available evidence and establish a valuation allowance to reduce deferred tax assets when it is more
likely than not that they will not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zqrc9oBsVfg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period, as well as the
disclosure of contingent assets and liabilities. Some of those judgments can be subjective and complex, and therefore, actual results
could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience
and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available
information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate,
those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related
to assumptions used in the valuation of investment securities, accruals for potential liabilities, valuing equity instruments issued for
services, assumptions used in the valuation of the equity method investment and gains on the deconsolidation of the subsidiary, the estimate
of the fair value of the lease liability and related right of use assets, net realizable value of receivables, useful life of property
and equipment, determining impairment of long-lived assets, and the realization of any deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWbadvRIbCGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is an &#8220;emerging growth
company,&#8221; or &#8220;EGC&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified
by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to opt out of the
extended transition periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znoJLvxnNDo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company considers highly liquid
investments with original maturities or remaining maturities upon purchase of three months or less to be cash equivalents. There were
$<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zrDGrtDWZr0f" title="Cash Equivalents">4.5</span> million and $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zGBlfJQ1PcEf" title="Cash Equivalents">11.8</span> million cash equivalents held by the Company at December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s policy is to
maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit
Insurance Corporation (the &#8220;FDIC&#8221;) and/or by the Securities Investor Protection Corporation (the &#8220;SIPC&#8221;).
The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_pn4n6_c20251231_z9yskUhQkfTb" title="Cash, FDIC insured limits">0.25</span>
million and $<span id="xdx_906_ecustom--CashSIPCInsuredAmount_iI_pn5n6_c20251231_zFYU47D2MVbb" title="Cash, SIPC insured limits">0.5</span>
million. At December 31, 2025, the Company held $<span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20251231_zix1xGBhe045" title="Unsegregated cash">8.7</span>
million of unsegregated cash and $<span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zMs7qsmkP4nf" title="Cash equivalents">4.5</span>
million of cash equivalents. For the years ended December 31, 2025 and 2024, respectively, the Company had approximately $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zviXm48akQ9h" title="Cash uninsured limits">7.2</span>
million and $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zPtWfFI5fLa2" title="Cash uninsured limits">4.3</span>
million of cash and segregated cash in financial institutions in excess of FDIC insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company periodically reviews the
financial condition of the financial institutions and assesses the credit risk of such investments. The Company did not experience any
credit risk losses during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s membership agreement
with the Depository Trust Clearing Corporation (&#8220;DTCC&#8221;) requires that we maintain a line of credit with our settlement bank in the amount $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20251231_zoKJtkzFEFIf" title="Line of credit">2.0</span> million, to be drawn down upon as
needed for self-clearing operations. The Company has established a line of credit with its settlement bank, Lakeside Bank, which is collateralized
by a $<span id="xdx_901_eus-gaap--Deposits_iI_pn5n6_c20251231_zRlQibc6QRh7" title="Deposit">2.0</span> million deposit of cash at Lakeside. The collateral amount may be withdrawn, but the availability of the line of credit is dependent
upon the maintenance of such compensating balance and is included in cash and cash equivalents on the Statement of Financial Condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_SegregatedCashAndDepositsPolicyTextBlock', window );">Segregated Cash and Deposits</a></td>
<td class="text"><p id="xdx_842_ecustom--SegregatedCashAndDepositsPolicyTextBlock_zEdxvQaMMd95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Segregated Cash and Deposits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">From time to time the Company provides
deposits or enters into agreements that would require funds to be held in a segregated cash account. At December 31, 2025 and 2024, respectively,
the Company had $<span id="xdx_90F_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20251231_zW4DOkMjezg" title="Cash segregated in compliance with regulations">2.3</span> million and $<span id="xdx_902_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20241231_zH4eJBfqO7pj" title="Cash segregated in compliance with regulations">0.8</span> million of segregated cash consisting of funds held in reserve for customers and non-customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsPolicy', window );">Clearing Deposits</a></td>
<td class="text"><p id="xdx_843_eus-gaap--DepositContractsPolicy_zXe17lXZT4Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Clearing Deposits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is obligated to maintain
security deposits with the DTCC and National Securities Clearing Corporation (&#8220;NSCC&#8221;). At December 31, 2025 and 2024, these deposits totaled $<span id="xdx_900_eus-gaap--DepositsAssets_iI_pn5n6_c20251231_zDAy8NALC5y6" title="Clearing deposits">2.0</span> million and $<span id="xdx_90D_eus-gaap--DepositsAssets_iI_pn5n6_c20241231_zclBROS6osn9" title="Clearing deposits">1.7</span> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid and other current assets</a></td>
<td class="text"><p id="xdx_84E_ecustom--PrepaidAndOtherCurrentAssetsPolicyTextBlock_zNKUuAkbGSea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Prepaid and other current assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has prepaid and other current
assets totaling $<span id="xdx_906_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20251231_zj7INjmPlGV9" title="Prepaid and other current assets">433</span> thousand at December 31, 2025 consisting of acquired intangible assets totaling $<span id="xdx_90A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20250101__20251231_z0yEmAC6bRb4" title="Intangible assets acquired">44</span> thousand, prepaid professional
fees totaling $<span id="xdx_905_ecustom--PrepaidProfessionalFees_pn3n3_c20250101__20251231_zllM01zlh6Ul" title="Prepaid professional fees">50</span> thousand, security deposits totaling $<span id="xdx_90B_eus-gaap--SecurityDeposit_iI_pn3n3_c20251231_zrMtKd7vB4x5" title="Security deposit">19</span> thousand, prepaid insurance $<span id="xdx_902_eus-gaap--PrepaidInsurance_iI_pn3n3_c20251231_zK9n860ZZMZ6" title="Prepaid insurance">169</span> thousand, various prepaid expense of $<span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20251231_zRKRbjQictU3" title="Various prepaid expense">130</span>
thousand, and other assets of $<span id="xdx_901_eus-gaap--OtherAssets_iI_pn3n3_c20251231_zxLCMJrZIVxk" title="Other assets">21</span> thousand. Prepaid and other expenses totaling $<span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20241231_z1eqPWY77Zpd" title="Prepaid and other expenses">513</span> thousand at December 31, 2024 consisting of acquired
intangible assets totaling $<span id="xdx_90B_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_z69yTaaoZwKd" title="Intangible assets acquired">44</span> thousand, prepaid professional fees totaling $<span id="xdx_900_ecustom--PrepaidProfessionalFees_pn3n3_c20240101__20241231_zO8uio7h2SUg" title="Prepaid professional fees">50</span> thousand, security deposits totaling $<span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn3n3_c20241231_zk8QBjBoucW4" title="Security deposit">19</span> thousand, prepaid
insurance $<span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20241231_zEeAzlURSyjc" title="Prepaid insurance">160</span> thousand, various prepaid expense of $<span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20241231_z42b4Zoa3uJ4" title="Various prepaid expense">150</span> thousand, and other assets of $<span id="xdx_90A_eus-gaap--OtherAssets_iI_pn3n3_c20241231_zRlD3U4ITts" title="Other assets">90</span> thousand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zepmYoy0mMLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leases of the Company consist primarily
of contracts for the right to use and direct use of an individual property. Leases were analyzed for evidence of significant additional
components and to determine if these components were separately identifiable within the context of the contract. As an accounting policy,
to account for these components, the Company has elected the practical expedient for property leases that have both lease and non-lease
components for them to be combined into a single component and account for as a lease. This policy is effective for all current and future
property operating leases and applied uniformly and will be disclosed as such within the financial statements. Operating lease assets
are included within right-of-use assets and the corresponding operating lease liabilities are included within liabilities on the Company&#8217;s
consolidated balance sheet as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has elected not to present
short-term leases on the consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not
contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other right-of-use assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. Because the
Company&#8217;s leases do not provide an implicit rate of return, the Company used the Company&#8217;s incremental borrowing rate based
on the information available at lease commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zaeBpyEiNdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Stock Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Stock-based compensation primarily
consists of restricted stock units with service or market/performance conditions. Equity awards are measured at the fair market value
of the underlying stock at the grant date. The Company recognized stock based compensation expense using the straight-line attribution
method over the requisite service period. The Company&#8217;s subsidiary issued stock-options and the fair value is determined utilizing
Black-Scholes options-pricing model. The Company accounts for forfeitures as they occur, rather than applying an estimated forfeiture
rate. For performance-based restricted stock units, the compensation cost is recognized based on the number of units expected to vest
upon the achievement of the performance conditions. Shares are issued on the vesting dates net of the applicable statutory tax withholding
to be paid by us on behalf of our employees. As a result, fewer shares are issued to the employee than the number of awards outstanding.
The Company records a liability for the tax withholding to be paid by it as a reduction to Additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text"><p id="xdx_842_eus-gaap--InvestmentPolicyTextBlock_zjbe21QMRo1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Investment Securities </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company strategically invests funds
in U.S. Treasury Bills, early-stage technology companies, and equity securities and options of publicly traded and privately held companies.
The Company classifies investment securities as investment securities, at amortized cost, investment securities, at fair value, or investment
securities, at cost less impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at amortized
cost</i> &#8211; From time to time the Company will hold funds in investment securities, at amortized cost. This is comprised of debt
securities held by MDB and are classified as investment securities held-to-maturity and carried at amortized cost if management has the
positive intent and ability to hold the securities to maturity. Initially, the cost of these securities was recorded, and later on, they
were assessed at amortized cost, which was modified for unamortized purchase premiums and discounts, and also for credit losses provision.
Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective-interest
method. Such amortization and accretion are included in the other operating income in the statements of operations. Interest income is
recognized when earned. The Company recognizes estimated expected credit losses over the life of the investment security through the allowance
for credit losses account. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost
basis of the investment security to present the net amount expected to be collected. In determining expected credit losses, the Company
considers relevant qualitative factors including, but not limited to, term and structure of the instrument, credit rating by rating agencies
and historic credit losses adjusted for current conditions and reasonable and supportable forecasts. The Company holds investments in
U.S. Treasury Bills or money market funds backed by U.S. Treasury Bills, so there are no expected credit losses. Declines in fair value
of these securities is due to changes in market interest rates, and because it expects to hold these securities until maturity, it does
not expect to realize any losses. There were no investment securities, at amortized cost as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at fair value
</i>- This is comprised of equity investments held by the broker dealer subsidiary and are reported at fair value with changes in fair
value recognized in the statement of operations. Purchases and sales of equity securities, consisting of common stock and warrants to
purchase common stock, are recorded based on the respective market price quotations on the trade date. Realized gains and losses on investments
represent the net gains and losses on investments sold during the period based on the average cost method. Differences between the fair
value of investments at the beginning of the year and the end of the year are recorded on the income statement as unrealized gains and
losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Investment securities, at cost less
impairment</i> - This is comprised of equity securities without a readily determinable fair value held by the broker dealer subsidiary,
the Company has elected to apply the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable
price changes. The Company will reassess whether such an investment qualifies for the measurement alternative at each reporting period.
In evaluating an investment for impairment or observable price changes, we will use inputs including recent financing events, as well
as other available information regarding the investee&#8217;s historical and forecasted performance. The Company has assessed this investment
and determined that the current impairment of such securities held at the year ended December 31, 2025 is accurate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities are as follows
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Broker/Dealer Securities</b></p>

<p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zQRLhofnSVV3" style="display: none">Schedule of Investment Securities Broker Dealer</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at fair value:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Common stock of publicly traded companies</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Warrants of publicly traded companies</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,937</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,330</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrants of non-publicly traded companies</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">658</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,166</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,858</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z9OkuMpESene" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Non-Broker/Dealer Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><b><span id="xdx_8BF_zJ7jauHHoWlg">Schedule of Investment Securities Non-Broker Dealer</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Investment securities, at fair value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Common stock of publicly traded companies</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">235</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">235</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at cost less impairment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Simple agreement on future equities (not market listed)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">200</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Impairment</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(200</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at cost less impairment</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zuwmTRHBqnx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For investment securities at fair value
held at the end of each year, net unrealized loss of $<span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20250101__20251231_zsuIBnQqld4g" title="Net unrealized gain (loss) on investment securities">246</span> thousand and $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20240101__20241231_z6mVQU83Glli" title="Net unrealized gain (loss) on investment securities">275</span> thousand were recognized in the statement of operations for
years ended December 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1icpMWXqG9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree
that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the
lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company determines the fair value
of its financial instruments based on a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value
into three levels:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - Observable inputs such as
quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - Inputs, other than quoted
prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - Unobservable inputs in which
there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s financial instruments primarily consist of cash and investment
securities. These investment securities and securities sold and not yet purchased are recorded at fair value as of the balance sheet date,
with unrealized gains and losses resulting from changes in fair value recognized in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A description of the valuation techniques
applied to the Company&#8217;s major categories of assets and liabilities measured at fair value on a recurring basis is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at fair value
and securities sold, not yet purchased: These securities are valued based on quoted prices from the exchange or other trading platform.
To the extent these securities are actively traded, valuation adjustments are not applied, and they are categorized in level 1 of the
fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A description of the valuation techniques
applied to the Company&#8217;s other financial assets and liabilities is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at amortized
cost: The fair value of U.S. Treasury Bills classified as held-to-maturity investment securities is based on the market price and is classified
as level 1 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment securities, at cost
less impairment: Non-public equity securities and simple agreements for future equity are valued based on the initial investment,
less impairment. The Company determined that an impairment is warranted. Since these securities are not actively traded, we will
apply valuation adjustments when they become available, and they are categorized in level 3 of the fair value hierarchy. The Company
fully impaired a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) that was previously valued at $<span id="xdx_907_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SAFEMember_zfEVnkDkesF5" title="Impairment of securities">100</span>
thousand and stock that was previously valued at $<span id="xdx_909_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231_zjICz0hNW6R2" title="Impairment of securities">50</span>
thousand both were held at the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z82LCnEDOUFb" style="display: none">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment securities, at fair value, held by the licensed broker dealer</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer">235</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer">235</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">132</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,463</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,595</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value </td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,806</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">132</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,463</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">7,401</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zIWcQtXRunp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2025, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zLQDKsgMVcPa" style="display: none">Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,662</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right">2,662</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receipt from investment banking fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,690</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Unrealized gain</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">111</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,463</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right">4,463</td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_zwiD6wiM66M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zYKZqfnooG2" style="display: none">Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" style="text-align: right" title="Warrants, Fair value"><span style="font-size: 10pt">4,463</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs">95.92</span> -&#160;&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs">120.3</span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" style="text-align: right" title="Weighted measurement input"><span style="font-size: 10pt">115.45</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
<p id="xdx_8AE_z2C5euSaftok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zlqM1QVW6kJb"><b>The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):</b></span></p>

<div id="xdx_C04_gL3SOFVAALMOR-YZJZHH_zKHclHGg20w9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment Securities (held by our licensed broker dealer)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">668</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,662</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">3,330</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">668</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,662</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">5,858</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zWa3Fx0mjlFf">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2024, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C04_gL3FVAMORBUIR-BRK_zQrFBAw5dIYe">&#160;</span></p>

<div id="xdx_C08_gL3FVAMORBUIR-BRK_z3xAKOAdAp5d"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" style="border-collapse: collapse; width: 96%; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">3,134</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right">3,134</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gains</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(472</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; text-align: left">Unrealized (loss) gains</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">(472</td><td style="display: none; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,662</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right">2,662</td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C05_gL3FVAMORBUIR-BRK_z2jUR5Nf99T4">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span id="xdx_C09_gL3FVAALMORAN-L_zDICDGAXkhH3"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)</b>:</span></p>

<div id="xdx_C02_gL3FVAALMORAN-L_z8NPe4RhThA9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" style="text-align: right" title="Warrants, Fair value"><span style="font-size: 10pt">2,662</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" style="text-align: right" title="Range of inputs"><span style="font-size: 10pt">111.03</span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" style="text-align: right" title="Weighted measurement input"><span style="font-size: 10pt">111.03</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C08_gL3FVAALMORAN-L_zFRFYdbkeMvc">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Secured Debt&#8211;- Revolving Credit Facility</a></td>
<td class="text"><p id="xdx_846_eus-gaap--DebtPolicyTextBlock_zgWoIHtxQztb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Secured Debt&#8211;- Revolving
Credit Facility</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company entered into a revolving
credit facility with a bank, (the &#8220;Lender&#8221;) on July 26, 2024 for a commitment of up to $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0EOvrB8hnAd" title="Revolving credit, maximum borrowing capacity">2.0</span> million and which matures <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zhhYByZAPftd" title="Maturity date">July
26, 2025</span>. The loan has a variable interest rate equal to a defined index, currently the Lender&#8217;s rate on the sale of Federal Funds,
plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zBayzkWHgzIa" title="Variable rate">2.25</span>%. The loan commenced with a calculated interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zpgvzJk0sZ65" title="Interest rate">7.75</span>%. If the Lender determines, in its sole discretion, that the index
becomes unavailable or unreliable, either temporary, indefinitely, or permanently, during the term of this loan, the Lender may amend
this loan by designating a substantially similar substitute index. The agreement provides for a quarterly payment of the greater of accrued
interest or a non-usage fee of $<span id="xdx_907_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn3n3_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zmaGjZ86t8Ae" title="Credit non-usage fee">5</span> thousand. The Company has not made any draw downs on the credit facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company granted the Lender a
security interest in a cash checking account held at the bank as collateral. The Lender has a right of setoff available from this
cash account when the line of credit is accessed. As of December 31, 2025 and 2024, there was $<span id="xdx_904_eus-gaap--Deposits_iI_pn5n6_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyQmiqWvezV7" title="Deposits">2.1</span>
and $<span id="xdx_905_eus-gaap--Deposits_iI_pn5n6_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXBTreFjla7j" title="Deposits">2.1</span> million deposited in this account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company is responsible for the
payment of all of the Lender&#8217;s legal and other fees incurred in connection with administering the loan. The Company has incurred
no such costs or debt issue costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2025 and 2024, there are <span id="xdx_909_eus-gaap--LineOfCredit_iI_do_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZIwhsjYOybh" title="Outstanding indebtedness"><span id="xdx_90A_eus-gaap--LineOfCredit_iI_do_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkDXvC2Zhwpe" title="Outstanding indebtedness">no</span></span> outstanding indebtedness under the credit facility and interest expense totaled $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zeQjdwsqGVrk" title="Interest payable"><span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zjlzMwhVXdI7" title="Interest payable">0</span></span>. The Company is in compliance with all
covenants under the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyma5WBbqKKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment are recorded
at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from disposition
of property and equipment are included in the statement of operations when realized. Depreciation is provided using the straight-line
method over the following estimated useful lives:</p>

<p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none">Schedule
of Estimated Useful Lives of Property
and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Developed software</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives">7</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0974">Lesser of the lease duration or the life of the improvements</span></span></span></td></tr>
  </table>
<p id="xdx_8AD_zPIXDQXW8b0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z8fPKC7TjJZh" style="display: none">Schedule of Property And Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024<span></span></b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Developed software</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right">139</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right">113</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total property and equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">139</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">113</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(22</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">117</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">90</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zSieLJh9Yjw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_ziTtwP2xkno9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company generates revenue primarily
from providing brokerage services and underwriting through Public Ventures. PatentVest and eXoZymes, have
had limited activity during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Brokerage revenues consist of (i) trade-based
commission income from executed trade orders, (ii) net realized gains and losses from proprietary trades, and (iii) other income consisting
primarily of stock loan income earned on customer accounts. Public Ventures recognizes revenue from trade-based commissions and other
income when performance obligations are satisfied through the transfer of control, as specified in the contract, of promised services
to the customers of Public Ventures. Commissions are recognized on a trade date basis. Public Ventures believes that each executed trade
order represents a single performance obligation that is fulfilled on the trade date because that is when the underlying financial instrument
is identified, the pricing is agreed upon, and the risks and rewards of ownership have been transferred to/from the customer. When another
party is involved in transferring a good or service to a customer, Public Ventures assesses whether revenue is presented based on the
gross consideration received from customers (principal) or net of amounts paid to a third party (agent). Public Ventures has determined
that it is acting as the principal as the provider of the brokerage services and therefore records this revenue on a gross basis. Clearing,
custody and trade administration fees incurred from Interactive Brokers, the Company&#8217;s clearing firm, are recorded effective as
of the trade date. The costs are treated as fulfillment costs and are recorded in operating expenses in the consolidated statements of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Brokerage revenue is measured by the
transaction price, which is defined as the amount of consideration that Public Ventures expects to receive in exchange for services to
customers. The transaction price is adjusted for estimates of known or expected variable consideration based upon the individual contract
terms. Variable consideration is recorded as a reduction to revenue based on amounts that Public Ventures expects to refund back to the
customer. There were no variable considerations for the years ended December 31, 2025, and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Investment banking revenues
consist of private placement and underwriting fees. The Company generally does not incur costs to obtain contracts with customers
that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions, and
therefore, as of December 31, 2025 and 2024, the Company did not have any contract assets or liabilities related to these revenues
on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into underwriting agreements, to act as an underwriter and security offerings which include distribution and sale of securities
to investors. These agreements allow non-defaulting underwriters and the issuer&#8217;s representative to seek substitute purchasers within
36 hours if the Company defaults on its commitment. If replacements are not found and the default exceeds 10% of the offering, the agreement
may be terminated without liability. Under ASC 606, revenue is recognized only upon transfer of cash from the escrow account from investors
which is the final receipt of payment, as well receipt of warrants and common stock on the date of closing, with no recognition for defaulted
or terminated portions until resolution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Private placement fees are related
to non-underwritten transactions such as private placements of equity securities, private investments in public equity, and Rule 144A
private offerings and are recorded on the closing date of the transaction. Client reimbursements for costs associated for private placement
fees are recorded gross within investment banking and various expense captions, excluding compensation. The Company typically receives
payments on private placements transactions at the completion of the contract. The Company views the majority of placement fees as a single
performance obligation that is satisfied when the transaction is complete, and the revenue is recognized at that point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Taxes and regulatory fees assessed
by a government authority or agency that are both imposed on and concurrent with a specified revenue-producing transaction, which are
collected by Public Ventures from a customer, are excluded from revenue and recorded against general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Public Ventures does not incur any
costs to obtain contracts with customers for revenues that are eligible for deferral or receive fees prior to recognizing revenue, and
therefore, as of December 31, 2025 and 2024, Public Ventures did not have any contract assets or liabilities related to these revenues
in its consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the years ended December 31,
2025 and 2024, the Company&#8217;s technology development segment did not have any revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">PatentVest recognizes revenue when performance
obligations are satisfied by transferring promised goods and services to customers in an amount the Company expects to receive in exchange
for those goods or services. PatentVest enters into contracts that can include various combinations of its offerings which are generally
capable of being distinct and accounted for as a separate performance obligation for the entire contract or a portion of the contract.
When performance obligations are combined into a single contract, PatentVest utilizes stand-alone selling price to allocate the transaction
price among the performance obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Certain contracts or portions of contracts
are duration-based, which in the event of customer cancellation, provide PatentVest with an enforceable right to a proportional payment
for the portion of the services provided. Accordingly, revenue from duration-based contracts is recognized using a time-based measure
of progress, which PatentVest believes best depicts how it satisfies its performance obligations in these arrangements as control is continuously
transferred throughout the contract period. Revenue from certain contracts is recognized over the expected period of performance using
a single measure of progress, typically based on hours incurred. Payments received in advance of services being rendered are recorded
as a component of contract liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The PatentVest&#8217;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zzOhoIIdeFQf" style="display: none">Schedule of Changes in Deferred Revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Balance as of December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" style="width: 16%; font-size: 10pt; text-align: right" title="Deferred revenue, Balance">20</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized">20</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance as of December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" style="font-size: 10pt; text-align: right" title="Deferred revenue, Balance"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zwq8sGRWvSh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingForResearchGrantsPolicyTextBlock', window );">Research Grants</a></td>
<td class="text"><p id="xdx_845_ecustom--AccountingForResearchGrantsPolicyTextBlock_zKADqWpB076k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Research Grants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes, receives grant reimbursements, which are netted against research and development expenses in the consolidated statement of operations.
Grant reimbursements for capitalized assets are recognized over the useful life of the assets, with the unrecognized portion recorded
as deferred grant reimbursements and included in liabilities in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Grants function on a reimbursement
model are accounted for using the accrual method. They are treated as reductions to expenses, corresponding to the amount of disbursements
and obligations eligible for reimbursement. These are for permissible expenses incurred as of December 31, 2024. The reimbursements are
anticipated to be received from the respective funding entities in the following year. Management considers such receivables at December
31, 2024, to be fully collectable due to the historical experience with the Federal Government of the United States of America. Accordingly,
no allowance for credit losses on the grants receivable was recorded in the accompanying consolidated financial statements. The Company was not engaged in any research grants for the year ended December 31. 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zvvVxNvqM2t4" style="display: none">Summary of Grants Receivable Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024<span id="xdx_F5E_zzT4nWlrl6oh">(1)</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Balance at beginning of year<span id="xdx_F49_zeT54RJrBuT1">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">882</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant costs expensed</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,897</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grants for equipment purchased</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">44</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">52</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grant funds received</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(2,173</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Removal of balance due to deconsolidation of eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(702</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt">In 2024, eXoZymes was deconsolidated
from the Company&#8217;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</span></td>
</tr></table>
<p id="xdx_8A0_z4a8wDrTKNud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">eXoZymes has received three grants
provided by the National Institute of Health, the Department of Energy and Department of Defense through December 31, 2024. The first
grant was awarded on October 1, 2023 and the latest of these grants was set to expire on May 14, 2026, however grants can be extended,
or new phases can be granted, extending the expiration of the grant. None of the grants have commitments made by the parties, provisions
for recapture, or any other contingencies, beyond complying with the normal terms of each research and development grant. Research grants
received from organizations are subject to the contract agreement as to how eXoZymes, formerly known as eXoZymes, conducts its research
activities, and eXoZymes is required to comply with the agreement terms relating to those grants. Amounts received under research grants
are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance
with the approved grant project. eXoZymes is permitted to draw down the research grants after incurring the related expenses. Amounts
received under research grants are offset against the related research and development costs in the Company&#8217;s consolidated statement
of operations. For the years ended December 31, 2025 and 2024, grants amounting $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20251231_zx1DsG46DI38" title="Research and development costs">0</span> and $<span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_zvUD2nyd6316" title="Research and development costs">2.8</span> million, were offset against
the research and development costs. Grant drawdowns, which includes grants costs expensed, grants for equipment purchased, and grant fees,
for the years ended December 31, 2025 and 2024, totaled $<span id="xdx_90B_ecustom--GrantDrawdowns_c20250101__20251231_zX0Wcdhg4k9d" title="Grant drawdowns">0</span> and $<span id="xdx_90F_ecustom--GrantDrawdowns_pn5n6_c20240101__20241231_zTw0cXZNZD38" title="Grant drawdowns">2.0</span> million, respectively, which included grant costs expensed, grants
for equipment purchased, and grants fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zFio8zeF0yx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Research and Development Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses
relating to the development of eXoZymes&#8217; technology. For the years ended December 31, 2025 and 2024, research and development costs
prior to offset of the grants amounted to $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseGross_c20250101__20251231_zHnagssCOgN4" title="Net of grant received">0</span> and $<span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseGross_pn5n6_c20240101__20241231_zw8WD44tPH7l" title="Net of grant received">3.4</span> million, respectively, which included grant costs expensed, grants fees, and research
and development costs, net of the grant received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock', window );">Patent and Licensing Legal and Filing Fees and Costs</a></td>
<td class="text"><p id="xdx_84B_ecustom--PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_zNGl6M1zDfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Patent and Licensing Legal and Filing
Fees and Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Due to the significant uncertainty
associated with the successful development of one or more commercially viable products based on the Company&#8217;s research efforts and
related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its
intellectual property are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Patent and licensing legal and filing
fees and costs were $<span id="xdx_90A_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20250101__20251231_zAAazgXGyKU5" title="Patent and licensing legal and filing fees and costs">54</span> thousand and $<span id="xdx_902_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20240101__20241231_zE6M4QA6cWb5" title="Patent and licensing legal and filing fees and costs">296</span> thousand for the years ended December 31, 2025 and 2024, respectively. Patent and licensing
legal and filing fees and costs are included in general and administrative costs in the Company&#8217;s consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zssHT9mtPbQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>ASU 2021-10, Government Assistance
(Topic 832): Disclosures by Business Entities about Government Assistance</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On January 1, 2020, The Company adopted
ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (&#8220;ASU 2021-10&#8221;)
and retrospectively applied the guidance to prior transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The amendments in ASU 2021-10 require
the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting
model by analogy: (1) information about the nature of the transactions and the related accounting policy used to account for the transactions;
(2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each
financial statement line item; and (3) significant terms and conditions of the transactions, including commitments and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Management does not believe that any
other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#8217;s
consolidated financial statement presentation or disclosures.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccountingForResearchGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting For Research Grants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccountingForResearchGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeconsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation [Policy Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeconsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent And Licensing Legal And Filing Fees And Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid And Other Current Assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_SegregatedCashAndDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segregated Cash And Deposits Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_SegregatedCashAndDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/944-825/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock', window );">Schedule of Investment Securities Broker Dealer</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zQRLhofnSVV3" style="display: none">Schedule of Investment Securities Broker Dealer</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at fair value:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Common stock of publicly traded companies</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Warrants of publicly traded companies</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,937</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,330</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrants of non-publicly traded companies</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">658</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,166</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,858</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock', window );">Schedule of Investment Securities Non-Broker Dealer</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><b><span id="xdx_8BF_zJ7jauHHoWlg">Schedule of Investment Securities Non-Broker Dealer</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Investment securities, at fair value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Common stock of publicly traded companies</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">235</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment securities, at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">235</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment securities, at cost less impairment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Simple agreement on future equities (not market listed)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">200</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Impairment</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(200</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Investment securities, at cost less impairment</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_z82LCnEDOUFb" style="display: none">Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment securities, at fair value, held by the licensed broker dealer</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,571</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer">235</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer">235</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">132</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,463</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,595</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value </td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,806</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">132</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">4,463</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">7,401</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<b>The following table sets forth the
fair value of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Classification</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-size: 10pt; text-align: left">Investment Securities (held by our licensed broker dealer)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt; text-align: left">Equity securities - common stock</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment Securities (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Warrants</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">668</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,662</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value">3,330</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value (held by our licensed broker dealer)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,528</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">668</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">2,662</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value">5,858</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zLQDKsgMVcPa" style="display: none">Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">2,662</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right">2,662</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Receipt from investment banking fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,690</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Unrealized gain</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">111</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,463</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right">4,463</td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" style="border-collapse: collapse; width: 96%; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">3,134</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt">Beginning Balance</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">$</td><td style="display: none; font-size: 10pt; text-align: right">3,134</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Unrealized gains</td><td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(472</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; text-align: left">Unrealized (loss) gains</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">(472</td><td style="display: none; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">December 31, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,662</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">Ending Balance</td><td style="display: none; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right">2,662</td><td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
</table>

&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants</a></td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)</b>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zYKZqfnooG2" style="display: none">Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" style="text-align: right" title="Warrants, Fair value"><span style="font-size: 10pt">4,463</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs">95.92</span> -&#160;&#160;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs">120.3</span></span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" style="text-align: right" title="Weighted measurement input"><span style="font-size: 10pt">115.45</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
<b>The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)</b>:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font-size: 10pt"><b>Assets</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Valuation<br/>
Techniques</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Significant<br/>
Unobservable<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Ranges of<br/>
Inputs</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted-Average</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 33%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Warrants</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" style="text-align: right" title="Warrants, Fair value"><span style="font-size: 10pt">2,662</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Black Scholes</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Volatility</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" style="text-align: right" title="Range of inputs"><span style="font-size: 10pt">111.03</span></td>
    <td><span style="font-size: 10pt">%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" style="text-align: right" title="Weighted measurement input"><span style="font-size: 10pt">111.03</span></td>
    <td><span style="font-size: 10pt">%</span></td></tr>
  </table>
&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none">Schedule
of Estimated Useful Lives of Property
and Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%"><span style="font-size: 10pt">Laboratory equipment</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Developed software</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives">5</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives">7</span> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"><span style="-sec-ix-hidden: xdx2ixbrl0974">Lesser of the lease duration or the life of the improvements</span></span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property And Equipment</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z8fPKC7TjJZh" style="display: none">Schedule of Property And Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024<span></span></b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Developed software</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right">139</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right">113</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total property and equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">139</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">113</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(22</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">117</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">90</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The PatentVest&#8217;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zzOhoIIdeFQf" style="display: none">Schedule of Changes in Deferred Revenue</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt">Balance as of December 31, 2023</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" style="width: 16%; font-size: 10pt; text-align: right" title="Deferred revenue, Balance">20</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized">20</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Balance as of December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" style="font-size: 10pt; text-align: right" title="Deferred revenue, Balance"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Amounts billed but not recognized</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Revenue recognized</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"><span style="-sec-ix-hidden: xdx2ixbrl1006">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GrantsReceivableActivityTableTextBlock', window );">Summary of Grants Receivable Activity</a></td>
<td class="text"><p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zvvVxNvqM2t4" style="display: none">Summary of Grants Receivable Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024<span id="xdx_F5E_zzT4nWlrl6oh">(1)</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Balance at beginning of year<span id="xdx_F49_zeT54RJrBuT1">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">882</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant costs expensed</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,897</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grants for equipment purchased</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">44</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Grant fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">52</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Grant funds received</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(2,173</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Removal of balance due to deconsolidation of eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(702</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt">In 2024, eXoZymes was deconsolidated
from the Company&#8217;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</span></td>
</tr></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GrantsReceivableActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of grants receivable activity table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GrantsReceivableActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Plant And Equipment Estimated Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Investment Securities Broker Dealer [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Investment Securities Non Broker Dealer [TableText Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-lived Assets and Total Assets by Segment</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_gL3LLABGATTB-CUTW_zvEk2dnfJff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following sets forth the long-lived
assets and total assets by segment at December 31, 2025 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zkO4me2B3pk8" style="display: none">Schedule of Long-lived Assets and Total Assets by Segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerAndIntellectualPropertyServiceMember_zeGm3LNUjGIj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer and<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zcbZMLyosrsl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology<br/> Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zGlPhHZ2RzWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zC2bHg5bN0Ua" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_z0NyLqDFEtca" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_pn3n3_zzu8fMKvlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-size: 10pt; text-align: justify">Long-lived assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">117</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">547</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">664</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_zrwrkCQlJ5h" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">25,128</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">38,609</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">63,740</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

The following sets forth the long-lived
assets and total assets by segment at December 31, 2024 (in thousands):<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_z8BIYhWOFah8" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zxfqZ3K4Y2tb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zwebjIF7XvUb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology<br/> Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zwt74Hy0bln7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z4xjSKBLaOA3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_zykqqBau8oYe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrent_iI_zcB5szCPRVQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-size: 10pt; text-align: justify">Long-lived assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">91</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1285">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">641</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">732</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iI_zEbvqLQ6XxQ8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">21,754</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">50,221</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">71,976</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Statement of Operation by Segment</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MWGIM_zm6DXnzPilq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zPloS8TgOQDa" style="display: none">Schedule of Statement of Operation by Segment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zmsUppUTSRGa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zrWrHbGhlL63" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zW5BrpeC8f9h" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z1OiMiy5lO65" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zR2CtlQalrc" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_z0HvKk5gBVg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_i01N_pn3n3_di_zLQAyD0Qvvgl" style="vertical-align: bottom; background-color: White">
    <td style="width: 30%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer <span id="xdx_F4B_zewLDUAXxTw8">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(331</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(331</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_i01I_pn3n3_z3XCdhHMah51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Investment securities, at fair value, held by the non-licensed broker dealer (1)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">85</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--RealizedInvestmentGainsLossesOne_i01_pn3n3_zMkq46JflBx4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Realized gain on investment securities, net from the licensed broker dealer <span id="xdx_F47_zDOEqJXPcqz7">(2)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FeeIncome_i01_pn3n3_z75w6lRdU654" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income from the licensed broker dealer <span id="xdx_F40_zo1u9pGYbML9">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,282</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,282</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_zxitFAN2Fjp3" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherOperatingIncome_i01_pn3n3_zz7DiKDnrtk5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income <span id="xdx_F4D_zdiglk5bUe8j">(4)</span></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">861</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1119">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1120">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">861</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_pn3n3_zesmzpastxF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,911</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,911</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zJGRCuuKpyec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zsXiVkEKYe91" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LaborAndRelatedExpense_i02_pn3n3_zdiHBXM7mDxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,875</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,094</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,969</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingExpense_i02_pn3n3_zYfTjFL1toq7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,471</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">362</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,833</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_pn3n3_z3ySzdMJZG93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,005</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">868</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,937</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommunicationsAndInformationTechnology_i02_pn3n3_zJfQcRLb3Llj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">968</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">135</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,103</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ClearingAndOtherCharges_i02_pn3n3_zpPAGMTrpmre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">556</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">556</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_pn3n3_znbwBwmr5zb7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">742</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1173">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,497</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,239</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02T_pn3n3_zAOk4nWkddFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">7,617</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,956</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,637</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i02_pn3n3_zskYsgAMkCJl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_pn3n3_zLgZCyfaTS5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,617</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">64</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,956</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,637</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NetOperatingIncomeLoss_iT_pn3n3_zrIierldZ4T1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net operating (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,706</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(64</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,956</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(17,726</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_pn3n3_zojnS0jg4fef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--MiscellaneousIncome_pn3n3_zLrqgUQKpwvl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">75</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_pn3n3_di_z7eafuHWNQ52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(990</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">990</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherNonoperatingIncome_i01_pn3n3_zKw4Aws7eeVf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">471</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,136</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(990</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">617</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--GainRelatedToDilutionEvents_i01_pn3n3_zcBNWLxpXySk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain related to dilution events</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">61</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zTkZ8Yb74lx6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Gain on deconsolidation of subsidiary</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_zuFjLfJo3MTe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">(Loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,150</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(13,759</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(16,973</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zMBLAtT4rIz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_pn3n3_zzgkoWOiXIw" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,161</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(13,759</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(16,984</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncomeLossFromEquityMethodInvestment_i01_pn3n3_ziwMXHlip1ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_iT_pn3n3_zobhMCmM7mL3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(3,161</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(64</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(18,041</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(21,266</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zVxxXDefdtL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(21</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_pn3n3_zdPCaBKfaeGe" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,161</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(43</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(18,041</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(21,245</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left"><span id="xdx_F0D_zEor9fRn3qpi" style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span id="xdx_F15_zgbWJ4PSadxe" style="font-size: 10pt">Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F09_zGLgxMMdFQN9" style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span id="xdx_F17_zOe2PuXCzajk" style="font-size: 10pt">Includes realized gains on securities held by the broker-dealer.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F05_z4JoAFWJTPN1" style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span id="xdx_F11_zFxNmoNpBLpi" style="font-size: 10pt">Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left"><span id="xdx_F03_zUWsCc363nV3" style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span id="xdx_F12_zUyKanJjUJle" style="font-size: 10pt">Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.</span></td></tr>
  </table>
&#160;<table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zxDkWDamkN9a" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Statement of Operation by Segment (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zNgyo9QxRcDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Broker<br/> Dealer &amp;<br/> Intellectual<br/> Property<br/> Service</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zVBQNxHgGlHe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Technology Development</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zfLHp1q4wxLk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z6aN42ks42Yi" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_z30lEVjjKxWj" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Consolidated</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_zKRi1AQrpD9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Operating income:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--UnrealizedGainLossOnInvestments_i01_zyb7rlhTFXw9" style="vertical-align: bottom; background-color: White">
    <td style="width: 30%; font-size: 10pt; text-align: left">Unrealized (loss) on investment securities, net from the licensed broker
    dealer  <span id="xdx_F43_zWUs8Dto14ke">(1)</span></td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(275</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(275</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FeeIncome_i01_z6d9ZzKadMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fee income from the licensed broker dealer <span id="xdx_F42_z5fs0BmS5l03">(2)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,221</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1311">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,221</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_ztiPAN9vDBPc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Impairment loss <span id="xdx_F4A_z2dxI5NLo03f">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(200</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(200</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherOperatingIncome_i01_zyNFBZXjfPZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating income <span id="xdx_F4D_zt1W4aTYGOT9">(4)</span></td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">411</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1321">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">411</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_zHvhMmllsUH3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,157</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,157</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zMmiKetVtgrb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvbbvLQPhjTe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">General and administrative costs:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_i02_zqK1qW87qCrj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,226</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,062</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14,769</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">20,057</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_i02_zrPywaAV9Cwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Operating expense, related party</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,301</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">185</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,486</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_zGxKygTch0B" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">820</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,206</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,086</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,112</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommunicationsAndInformationTechnology_i02_zLQaYBeMtBTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Information technology</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">805</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">34</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">83</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">922</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ClearingAndOtherCharges_i02_zh7JLkyObDE3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Clearing and other charges</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,137</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1370">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,137</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_zZ34HDAX8LPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative-other</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">806</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">133</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,669</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,608</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i02T_zZhBF38SfJsa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">General and administrative costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8,095</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,435</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">17,792</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29,322</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zIHEVSPhbYY4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,468</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_zvCDo2CdarEk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,095</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,903</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,792</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1395">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,790</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NetOperatingIncomeLoss_iT_z02ABQ5Zs9Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net operating (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,938</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,903</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(17,792</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(28,633</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_ztBJeXpqWF0i" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other income and expense:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--MiscellaneousIncome_zuWi4EoOwQah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Miscellaneous income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1411">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">112</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_zY0krAMLtmAj" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Interest expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(779</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(92</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">799</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(72</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncome_i01_zfjLtL3YPDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">465</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,510</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(799</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,179</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--GainRelatedToDilutionEvents_i01_zZnbGs53y3dl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Gain related to dilution events</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1428">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zPqWOkFi4UC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">Gain on deconsolidation of subsidiary</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1435">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,307</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1437">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">39,307</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zkk18ubnFh3d" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,992</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23,155</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1443">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,023</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_zN3z37vUv7y2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1449">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_zel5TqRLBvLa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income (loss) before equity method investee</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,994</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">23,155</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1455">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">12,021</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncomeLossFromEquityMethodInvestment_i01_zjOzGfZpvHW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity in loss of equity method investee</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1459">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(420</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(420</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ProfitLoss_iT_zxSS0fvY1v51" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Net income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(6,140</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(4,994</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">22,735</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11,601</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zPA4DtmKvFQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less net loss attributable to non-controlling interests</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(90</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_z4NUZU0Rd7Ig" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net income and (loss) attributable to MDB Capital Holdings, LLC</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(6,140</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,904</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">22,735</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,691</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F0C_zItwKHS2g4Kh" style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F19_zX8aEhgzrEuk" style="font-size: 10pt">Includes unrealized gains and
losses on securities held by the broker-dealer.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F09_zBzu6syX8buj" style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span id="xdx_F16_zorbWRAAllIf" style="font-size: 10pt">Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F02_zyhMfb3EvK0b" style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span id="xdx_F14_ztBZbU7oANQ5" style="font-size: 10pt">Includes impairment loss of assets
from the reduced fair value of the asset.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_F0E_zCCvHQu57k5a" style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span id="xdx_F1A_zdtty7wgl7m" style="font-size: 10pt">Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.</span></td>
</tr></table>
&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Non-Controlling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock', window );">Schedule of Equity and Non-Controlling Interests</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfEquityAndNonControllingInterestsTableTextBlock_z9Is05pwWqf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zicnOOB87EGb" style="display: none">Schedule of Equity and Non-Controlling Interests</span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Non-controlling interest net loss</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--NetIncomeLoss_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zWr6RDg9fa57" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss">(64</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_ztA2iFFOG2Z1" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss">(276</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Weighted average non-controlling percentage</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z1bJQyiL07ij" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage">32.16</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zEj8rkCBjvm4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage">32.53</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net loss non-controlling interest</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zdZMLh4owWm6" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest">(21</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zgRUoT5KtNzi" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest">(90</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Prior period balance</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--MinorityInterest_iS_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zMurvPsBzLN5" title="Prior period balance">(90</span></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--MinorityInterest_iS_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zKE3C98v5r68" title="Prior period balance">7</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Removal of prior period balance of eXoZymes due to deconsolidation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zxxbfXPqBvLk" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation"><span style="-sec-ix-hidden: xdx2ixbrl1562">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zcqxZHWj9WQ7" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation">(7</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock-based compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zCr9gC2yi8nd" style="font-size: 10pt; text-align: right" title="Stock-based compensation"><span style="-sec-ix-hidden: xdx2ixbrl1566">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z7EZ9iT65vmj" style="font-size: 10pt; text-align: right" title="Stock-based compensation"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Ownership change of non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z6hMl72ml2h4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zRcWaomFVX13" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Ending period balance</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--MinorityInterest_iE_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zPCK1BhahCs8" title="Ending period balance">(111</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--MinorityInterest_iE_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zIZVBDMi0Gtf" title="Ending period balance">(90</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Equity And Non Controlling Interests [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deconsolidation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureDeconsolidationAbstract', window );"><strong>Deconsolidation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Consolidated Balance Sheet</a></td>
<td class="text"><p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znmQzXpgD9Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 40pt; text-align: justify">The following table represents the
consolidated balance sheet of xXoZymes immediately prior to the Deconsolidation Date (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zaLyXtrRNZ45" style="display: none">Schedule
of Consolidated Balance Sheet</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td>
    <td>&#160;</td><td colspan="2" id="xdx_49E_20241231__srt--ConsolidatedEntitiesAxis__custom--ExozymesMember_zTaT0KOHYLYe" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><b>December
                                            31, 2024</b></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_zZ7Bta7BJts1" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; font-size: 10pt; text-align: left">Cash and cash equivalents</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">68</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GrantsReceivable_i01I_pn3n3_zBeZI8Qfk3d9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-left: 0.25in">Grants receivable</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">701</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pn3n3_zSb3j8rkuW35" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">441</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredOfferingCosts_i01I_pn3n3_zM7K82YpJtRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Deferred IPO Costs</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">550</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_zPkogiIDJgB7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">710</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_zyo8gcPejVH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use asset, net</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,366</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_pn3n3_zMMW3LhApfK7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,836</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Deficit</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_i01I_pn3n3_zZlZGfilAbul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">851</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_i01I_pn3n3_zu2hkw194UL8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Accrued expenses</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">241</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherReceivables_i01I_pn3n3_zqAZYoN9Lrph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Due to affiliates</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,479</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredGrantReimbursement_i01I_pn3n3_zvCJLMY52BEf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred grant reimbursement</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">130</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zOPU1t4Ro0xc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,417</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_i01TI_pn3n3_zvJfKbAAatkd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Total liabilities</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,118</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Deficit:</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_zXc173vBPXRk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Common shares</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1612">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_z2W5ji9NjBbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Paid-in-capital</td>
    <td>&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,120</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_zlTZ9Z1if509" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,402</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_zJobKiQ0UCja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,282</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_zXIMBmWesci4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,836</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock', window );">Schedule of Gain on Deconsolidation</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfGainOnDeconsolidationTableTextBlock_zjocbmbLWKXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following represents the calculation
of the gain on deconsolidation of eXoZymes from the consolidated financial statements of the Company (in thousands, except for share
price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zhsrE4JjEvP" style="display: none">Schedule
of Gain on Deconsolidation</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt; text-align: left">eXoZymes Class A common shares retained on November 14, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_z8OxGjezDJwl" title="Class A common shares retained">3,931</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Quoted closing price of eXoZymes Class A common shares at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaqtv82MfCF9" title="Quoted closing price of Class A common shares">10.36</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Subtotal of quoted closing price of eXoZymes Class A common shares at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zKN8E9VImEtd" title="Subtotal of quoted closing price of Class A common shares">40,727</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Fair value of warrants held for eXoZymes at November 14, 2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zFYz9Y9eXRe2" title="Fair value of warrants">1,327</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Fair value of equity method investment retained by eXoZymes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zebt75n0aUSh" title="Fair value of equity method investment">42,054</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Carrying Value of the NCI</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iNI_pn3n3_di_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zzAECntclUEh" title="Carrying Value of the NCI">(921</span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Carrying value of eXoZymes assets at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--CarryingValueOfAssets_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zjHrObnUdcc8" title="Carrying value of assets">4,282</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Less carrying value of former investment into eXoZymes&#160;&#160;at November 14, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--LessCarryingValueOfFormerInvestment_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_zLptOMZvyKp6" title="Less carrying value of former investment">(5,787</span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Carrying value of warrants held for eXoZymes at November 14,2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--CarryingValueOfWarrants_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaMrQyJUqbZa" title="Carrying value of warrants">(321</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Gain on deconsolidation</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_z40mjl1Vfus7" title="Gain on deconsolidation">39,307</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureDeconsolidationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureDeconsolidationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Gain On Deconsolidation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investment</a></td>
<td class="text"><p id="xdx_893_eus-gaap--EquityMethodInvestmentsTextBlock_zhVkgjWMqWm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The following summarizes the Company&#8217;
consolidated balance sheet equity method investment as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zFC2ZkijDefc" style="display: none">Schedule
of Equity Method Investment</span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrying
    Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024,
    carrying amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--EquityMethodInvestments_iS_c20250101__20251231_zzwPfe5YKIl8" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Equity method investments, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portion of loss
    from eXoZymes</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_c20250101__20251231_zgqyyMSX7w7k" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Portion of loss from Invizyne"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,282</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain related to dilution events</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--EquityMethodInvestmentsGainRelatedToDilutionEvents_c20250101__20251231_ziSrlYOB3bLl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain related to dilution events"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2025, carrying amount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--EquityMethodInvestments_iE_c20250101__20251231_zqB3C2Vu0QZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Equity method investments, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,543</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0NIG6VYd1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of restricted stock unit
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zNRnXuYqfBMe" style="display: none">Schedule
of Restricted Stock Unit Activity</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Time-Based</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Performance-Based</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of<br/> Restricted<br/> Stock Units</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of<br/> Restricted<br/> Stock Units</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; text-align: left">Restricted stock units outstanding at December 31, 2024</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcYZnmL3I8b5" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">2,995</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zqNSYST50oIh" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.90</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zkaJgIL5huh2" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">2,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4QJWNJ6qGGb" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">7.91</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Granted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1Xwaw4SCDn7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1725">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z2u4HiT6DUGg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1727">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zyqFuyZr33f7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1729">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zeizSkZc1sfe" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1731">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Vested</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrMbe9Lnsmbj" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">(188</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zBVBRPeCZXVd" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.69</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWs0a40oFnT1" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1737">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Exchanged/Modified</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHoRwosIwOJd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified">(1,600</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1xvaAPwrEO1" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified">10.00</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zp1OHG0r3gmk" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified">(2,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z6RbXw0kdMhg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified">7.91</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z4k47XUbV0Nf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">(128</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcihfXXzFDc4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.97</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z3zQdk8OwVLk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4GuxS4E82l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1753">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restricted stock units outstanding at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zpcXx5SInOsh" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding">1,079</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zr3VC3Pa3Tzk" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding">9.78</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zFXarj62x0Gd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z1aVgoJo0Od5" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1761">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Restricted stock units at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEhKd4WFY34k" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding">655</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zptrfDqfPAS" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested">10.00</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zvHvN4N3O1ck" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztr1g4c4adQj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Restricted stock units at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zN5XjccM0T43" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding">843</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z6Vfvyb6UDXj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested">9.93</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zw6vq84NHZei" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1775">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zAsqLiuFA3Jb" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"><span style="-sec-ix-hidden: xdx2ixbrl1777">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember', window );">Time Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Market-Based Stock Option Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--TimeBasedMember_zLD0G36Gj603" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of time-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except
for share price and contractual life):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zaIxCcuCKHl7">Schedule
of Time-Based Stock Option Activity</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Time-based stock options outstanding at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zUFfjZngfKX1" style="font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1805">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zF8A3iUEoFi5" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1807">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-size: 10pt">Exchanged/Modified</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z8EfKrinwPr" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified">1,600</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zXQLEHweryof" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified">3.75</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zvCgtdBmjcJf" title="Weighted average remaining contractual life (in years), time-based stock options exchanged/modified">10.00</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhdt6Ax7uwm4" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNifTcXSWT6" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zL5UIVZTf7v5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zFTQtDvgYof3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Time-based stock options outstanding at December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zxeyitO6Lmaj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, at the end">1,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcbs40YBwQRd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding">3.75</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zPnmRpdpdFrk" title="Weighted average remaining contractual life (in years), time-based stock options outstanding">9.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zYKJL7GYeGgl" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrbZX0M8Po8i" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1830">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhELFJfAVxA5" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable">1,067</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zu8BnDbm2s9j" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable">3.75</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zasVp7qzfOOg" title="Weighted average remaining contractual life (in years), stock options exercisable">9.32</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember', window );">Market Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Market-Based Stock Option Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--MarketBasedMember_zSj7a8TViAnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A summary of market-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price and contractual life):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z7SJ0ngWr4Ha">Schedule
of Market-Based Stock Option Activity</span>&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Market-based stock options outstanding at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_znVElCvTtbO" style="font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1855">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z8bzdP5EKSwa" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1857">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 49%; font-size: 10pt">Exchanged/Modified</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zwhp0TTKRO27" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified">2,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zPVa6oNLHFD1" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified">3.02</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 13%; font-size: 10pt; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztiHtKLirGWa" title="Weighted average remaining contractual life (in years), exchanged/modified">10.00</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zOqaMejvrJG5" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1865">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zqOF4ETqdDP4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1867">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Expired/Cancelled</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zZNzSIxvM2N6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1869">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zpF6y5AKNak" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1871">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Market-based stock options outstanding at December 31, 2025</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zb28UOMM6DM7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, at the end">2,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCjLE2mChIg5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding">3.02</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zDhONlxIRaGa" title="Weighted average remaining contractual life (in years), market-based stock options outstanding">9.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zHZbRNuMefMk" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1879">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zM9LuLdr3QY4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1881">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stock options exercisable at December 31, 2025</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWSW0D39vlN6" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1883">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zcmQYB5a4R01" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1885">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_TimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per share attributable to MDB Capital Holdings, LLC:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Fully Diluted</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zVPR881P9PVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic earnings per share is calculated
at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zkaqjXOfKsOg" style="display: none">Schedule
of Basic and Fully Diluted</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsKeAY7lHbP4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqhdj2uVj8o" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z36dGnq7Fvc8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zx6NEZoPZlae" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
    the Years Ended</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">Basic</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
    31, 2025</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
    31, 2024</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    A Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Class
    B Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    A Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Class
    B Common Shares</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zXbCmKGZ1m5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Net income (loss) attributable to MDB Capital
    Holdings, LLC</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(10,768</span></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">(10,477</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,817</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,875</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_zdsrVE2OJzT5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Weighted average shares outstanding &#8211; basic</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,023</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">4,424</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">5,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_z2P4Xqk9dke1" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Net income (loss) per share &#8211; basic</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(2.14</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">(2.10</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">1.31</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">1.18</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Fully diluted earnings per share is
calculated at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49C_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkBtQU8M7Ca2" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_492_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpgRvnXgjrMj" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49B_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJViQEtjkvYh" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_49C_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zADIBaE7C4Dk" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class A Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Class B Common Shares</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zvw8leYB2UVa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; text-align: left">Net income (loss) attributable to MDB Capital Holdings, LLC</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(11,714</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">(9,531</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">7,650</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 11%; font-size: 10pt; text-align: right">4,042</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_zMBcPh8ZtcTl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted shares outstanding &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,145</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,000</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">9,463</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,000</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zbLkXkAoW93g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net income (loss) per share &#8211;diluted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(1.91</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(1.91</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.81</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.81</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Cost</a></td>
<td class="text"><p id="xdx_894_eus-gaap--LeaseCostTableTextBlock_zcyi91Cll9N7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zYDZFo55hxxa" style="display: none">Schedule
of Operating Lease Cost</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20251231_zCKawW5PDac1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zjzFaqA7Ev74" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the years ended<br/> December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in thousands)</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating leases:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGoaBcBEOIbe" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left">Right-of-use assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">547</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">641</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zRFElbfZ4ZSj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">609</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">711</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Weighted average remaining lease term in years</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0EjF7nH5IDj" title="Weighted average remaining lease term in years">4.50</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z0RqdCP4mfr3" title="Weighted average remaining lease term in years">5.50</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Weighted average discount rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zmt9KFdlbMb5" style="font-size: 10pt; text-align: right" title="Weighted average discount rate">7.80</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zGXmDHvaklDb" style="font-size: 10pt; text-align: right" title="Weighted average discount rate">7.80</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20250101__20251231_zxj2KKkAE6W5" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">155</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20240101__20241231_zgaMVKNdJDza" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">152</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Right-of-use assets obtained in exchange for lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20250101__20251231_zURnBbXxJzlk" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2038">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zhuGuRj2fZg6" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"><span style="-sec-ix-hidden: xdx2ixbrl2040">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating lease cost</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseCost_pn3n3_c20250101__20251231_zuuKVtWVIzRd" style="font-size: 10pt; text-align: right" title="Operating lease cost">52</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseCost_pn3n3_c20240101__20241231_zeyRz5xTtDD3" style="font-size: 10pt; text-align: right" title="Operating lease cost">147</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Short-term lease costs</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShortTermLeaseCost_pn3n3_c20250101__20251231_zi4tqVKiEof4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">95</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShortTermLeaseCost_pn3n3_c20240101__20241231_zbMTuMMFIOFa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total operating lease costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20250101__20251231_zv6gYrYFLE72" style="font-size: 10pt; text-align: right" title="Total operating lease costs">147</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_z09HYx2IOQjb" style="font-size: 10pt; text-align: right" title="Total operating lease costs">234</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future payments Due Under Operating Lease</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv6zURXrkuzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Future payments due under operating
leases for the as of December 31, 2025 are as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zw3gXW3FsdC3" style="display: none">Schedule
of Future payments Due Under Operating Lease</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold">Year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zzbHKODGLgHg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDS7_zES5JhybPDJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; font-size: 10pt; text-align: left">2026</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right">158</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDS7_zDnAigxsp8bc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">2027</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">160</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDS7_zxb1Lo3G6KT" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">2028</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">163</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_maLOLLPzDS7_z9YwNxh7JEbi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2029 and thereafter</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">259</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDS7_z97i8F0RU613" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-size: 10pt">Total</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">740</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zqZ6CZSIgoaa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less effects of discounting</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(131</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgjG2x8hK6x" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">609</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Taxes Expenses (benefit)</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zmkUgBiHEERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Income tax expense (benefit) (including
Subchapter C-corporations) consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zfHTorENI9Hc" style="display: none">Schedule
of Income Taxes Expenses (benefit)</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231_zmL8e6kRXQBh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zXFx652RV0j5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maITEBztXD_zZ7yL2tEhxv1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; padding-left: 10pt">Federal</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2072">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">1</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maITEBztXD_zzv7Q7MT9qAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">State</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_znPsIyABZBZa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Federal</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2079">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_zNbpwR3ZhDbj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">State</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2082">-</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBztXD_zco7tXUdo9fc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zThUWxlxqKsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zfl3scupFN3l" style="display: none">Schedule
of Federal Statutory Tax Rate to The Effective Tax Rate</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year Ended December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">U.S Federal statutory income rate</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20250101__20251231_zAzgeeZpppFj" style="width: 16%; font-size: 10pt; text-align: right" title="U.S Federal statutory income rate, Amount">(4,463</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20250101__20251231_zFxJyMOFBuA4" title="U.S Federal statutory income rate, Rate">21.00</span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State, net of federal tax benefit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20250101__20251231_zbXy9kIlY7wl" style="font-size: 10pt; text-align: right" title="State, net of federal tax benefit, Amount">9</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20250101__20251231_zMr0pwJiICR1" title="State, net of federal tax benefit, Rate">(0.04</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Nontaxable or nondeductible items</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Income/loss excluded from nontaxable entities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20250101__20251231_zfzJQFRskkMi" style="font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount">944</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20250101__20251231_zhyVeG40ffe1" title="Income/loss excluded from nontaxable entities, Rate">(4.44</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr id="xdx_409_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_zBXuJlTncBea" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-left: 10pt">Permanent differences</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_zJdrdulDazCc" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; padding-left: 10pt">Permanent differences</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Meals and entertainment</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maMahiYA_c20250101__20251231_z0QGSTT1dyMj" style="font-size: 10pt; text-align: right" title="Meals and entertainment, Amount">7</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_maKamaLI_c20250101__20251231_zprancH9EwFl" title="Meals and entertainment, Rate">(0.04</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Stock options</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maMahiYA_c20250101__20251231_zQWDLG7PYlDh" style="font-size: 10pt; text-align: right" title="Stock options, Amount">614</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maKamaLI_c20250101__20251231_zltTUL71zoP2" title="Stock options, Rate">(3.06</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-left: 10pt">Equity award vesting</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--IncomeTaxReconciliationEquityInEquityAwardVestingAmount_pn3n3_maMahiYA_c20250101__20251231_zcq5YDq12oxd" style="font-size: 10pt; text-align: right" title="Equity award vesting, Amount">248</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_pid_dp_uPure_maKamaLI_c20250101__20251231_zqlTNBcH1AP" title="Equity award vesting, Rate">(1.24</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 10pt">Modification of equity awards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--IncomeTaxReconciliationModificationOfEquityAwardsAmount_pn3n3_maMahiYA_c20250101__20251231_z3WSaoPZkhS2" style="font-size: 10pt; text-align: right" title="Modification of equity awards, Amount">2,194</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maKamaLI_c20250101__20251231_zZ9V0lzmB0q9" title="Equity award vesting, Rate">(10.95</span></td><td style="font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Return-to-provision adjustments</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20250101__20251231_zRrcBz3dkZSl" style="font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount">(44</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20250101__20251231_zW6LSLqiL1nc" title="Return-to-provision adjustments, Rate">0.22</span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_zWIBshQTkSc6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; text-align: left">Other</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_zOBsHs9AIRxh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-size: 10pt; text-align: left">Other</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt">&#160;</td>
    <td style="display: none; font-size: 10pt; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; text-align: right">&#160;</td><td style="display: none; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20250101__20251231_zvBKtMBpy216" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance, Amount">502</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20250101__20251231_zH8KcsFkBxYa" title="Valuation allowance, Rate">(2.52</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Effective rate</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20250101__20251231_zL9SnUxJsz4f" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Effective rate, Amount">11</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20250101__20251231_zXDBeGuz56c7" title="Effective rate, Rate">(0.05</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">A reconciliation of the federal
statutory tax rate to the effective tax rate (including Subchapter&#160;C-corporations) for the year ended December 31, 2024 and
2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S Federal statutory
    income rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20240101__20241231_z5gZGmcJCLba" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S Federal statutory income rate, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,453</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20240101__20241231_zUkTSgGBrsNk" title="U.S Federal statutory income rate, Rate">21.00</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State, net of federal tax
    benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20240101__20241231_z055pwdywtk2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State, net of federal tax benefit, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(246</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20240101__20241231_zvUxl03iC6W3" title="State, net of federal tax benefit, Rate">(2.11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income/loss excluded from
    nontaxable entities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20240101__20241231_zCS3MINvK0Ag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20240101__20241231_zbH5oGARhAbf" title="Income/loss excluded from nontaxable entities, Rate">(68.57</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maMahiYA_c20240101__20241231_zLDKKFiB4Zxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Permanent differences, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">641</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zcJdGiB4y7ck" title="Permanent differences, Rate">5.49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return-to-provision adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20240101__20241231_zyah9TbCQK0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Return-to-provision adjustments, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zTmjsZdVVGtg" title="Return-to-provision adjustments, Rate">0.04</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maMahiYA_c20240101__20241231_zIHFoGxynuai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">192</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKamaLI_c20240101__20241231_zbTPDKiJGemb" title="Other, Rate">1.65</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20240101__20241231_zc4fcKcW0Pbh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,966</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20240101__20241231_zUobJyjPhofk" title="Valuation allowance, Rate">42.52</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20240101__20241231_zlpCL3taBE1k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective rate, Amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20240101__20241231_zLq7wG2Fh661" title="Effective rate, Rate">0.02</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zW4pGONifQD1" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt">Start-up expenditures</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">4</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">13</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Organizational expenditures</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sec 174 &#8211; Research and development costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,795</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,524</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Lease liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">128</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">149</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment principally due to differences in depreciation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Bonus expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2195">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Charitable contribution carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">53</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Intangible Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">51</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">38</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,890</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,781</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,625</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,124</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Right-of-use asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(115</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(135</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Investment securities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(212</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(264</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2228">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Deferred tax assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">327</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">399</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Other noncurrent assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2236">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zW4pGONifQD1" style="display: none">Schedule
of Deferred Tax Assets and Liabilities</span></span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt">Start-up expenditures</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">4</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">13</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Organizational expenditures</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Sec 174 &#8211; Research and development costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2182">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock compensation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,795</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,524</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Lease liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">128</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">149</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Property and equipment principally due to differences in depreciation</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Bonus expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">14</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2195">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Charitable contribution carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">53</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Intangible Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">51</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">38</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">4,890</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,781</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,625</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,124</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Right-of-use asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(115</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(135</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Investment securities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(212</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(264</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2227">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2228">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Deferred tax assets</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">327</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">399</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred tax liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(327</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(399</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Other noncurrent assets/(liabilities)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2236">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesToAffiliate', window );">Up-front fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MDBMinnesotaOneIncMember', window );">MDB Minnesota One Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MayoFoundationMember', window );">Mayo Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contract life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Estimated life</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annual volatility</a></td>
<td class="nump">59.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Annual rate of dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to puchase common shares</a></td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Contract life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrants fair value</a></td>
<td class="nump">$ 65,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">1,670,000<span></span>
</td>
<td class="nump">43,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccountingPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccountingPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MDBMinnesotaOneIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MDBMinnesotaOneIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MayoFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MayoFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CashSIPCInsuredAmount', window );">Cash, SIPC insured limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Unsegregated cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash uninsured limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation', window );">Cash segregated in compliance with regulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,331,000<span></span>
</td>
<td class="nump">844,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Clearing deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
<td class="nump">513,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PrepaidProfessionalFees', window );">Prepaid professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Various prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized gain (loss) on investment securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246,000)<span></span>
</td>
<td class="num">(275,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment of securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GrantDrawdowns', window );">Grant drawdowns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ResearchAndDevelopmentExpenseGross', window );">Net of grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Patent and licensing legal and filing fees and costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit, maximum borrowing capacity</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity date</a></td>
<td class="text">Jul. 26,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Credit non-usage fee</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=MDBH_SAFEMember', window );">SAFE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment of securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes unrealized gains and
losses on securities held by the broker-dealer.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes impairment loss of assets
from the reduced fair value of the asset.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccountingPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccountingPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_CashSIPCInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash insured amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_CashSIPCInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GrantDrawdowns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant drawdowns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GrantDrawdowns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ImpairmentOfInvestmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of investment securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ImpairmentOfInvestmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PrepaidProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PrepaidProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ResearchAndDevelopmentExpenseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ResearchAndDevelopmentExpenseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and securities deposited in a special reserve account for the exclusive benefit of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=MDBH_SAFEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=MDBH_SAFEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Investment Securities Broker Dealer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 5,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_BrokerDealerMember', window );">Broker Dealer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">7,166<span></span>
</td>
<td class="nump">5,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Broker Dealer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfPubliclyTradedCompaniesMember', window );">Warrants of Publicly Traded Companies [Member] | Broker Dealer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">3,937<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfNonPubliclyTradedCompaniesMember', window );">Warrants of Non Publicly Traded Companies [Member] | Broker Dealer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">$ 658<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccountingPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccountingPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_BrokerDealerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_BrokerDealerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfPubliclyTradedCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfPubliclyTradedCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfNonPubliclyTradedCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfNonPubliclyTradedCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Investment Securities Non-Broker Dealer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 5,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer', window );">Investment securities, at cost less impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_NonBrokerDealerMember', window );">Non Broker Dealer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfPubliclyTradedCompaniesMember', window );">Warrants of Publicly Traded Companies [Member] | Non Broker Dealer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MDBH_SimpleAgreementOnFutureEquitiesMember', window );">Simple Agreement on Future Equities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer', window );">Investment securities, at cost less impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=MDBH_ImpairmentMember', window );">Impairment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccountingPolicies', window );"><strong>AccountingPolicies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer', window );">Investment securities, at cost less impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccountingPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccountingPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities at cost less impairment non broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_NonBrokerDealerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_NonBrokerDealerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfPubliclyTradedCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MDBH_WarrantsOfPubliclyTradedCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MDBH_SimpleAgreementOnFutureEquitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MDBH_SimpleAgreementOnFutureEquitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MDBH_ImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MDBH_ImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 5,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer</a></td>
<td class="nump">235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">2,806<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">4,463<span></span>
</td>
<td class="nump">2,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentSecuritiesAtFairValue', window );">Investment securities, at fair value</a></td>
<td class="nump">$ 4,463<span></span>
</td>
<td class="nump">$ 2,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment securities, at fair value, held by the non-licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section FF<br> -Paragraph Question 2<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning Balance</a></td>
<td class="nump">$ 2,662<span></span>
</td>
<td class="nump">$ 3,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Receipt from investment banking fees</a></td>
<td class="nump">1,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Unrealized (loss) gains</a></td>
<td class="nump">111<span></span>
</td>
<td class="num">(472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending Balance</a></td>
<td class="nump">$ 4,463<span></span>
</td>
<td class="nump">$ 2,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable input reconciliation recurring basis asset gain loss included in other comprehensive income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details) - Fair Value, Inputs, Level 3 [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, Fair value</a></td>
<td class="nump">$ 4,463<span></span>
</td>
<td class="nump">$ 2,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted measurement input</a></td>
<td class="nump">95.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted measurement input</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Weighted measurement input</a></td>
<td class="nump">115.45<span></span>
</td>
<td class="nump">111.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MDBH_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MDBH_DevelopedSoftwareMember', window );">Developed Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Useful Life, Lease Term [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MDBH_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=MDBH_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MDBH_DevelopedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=MDBH_DevelopedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property And Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Developed software</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized', window );">Amounts billed but not recognized</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability amounts billed not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Grants Receivable Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Balance at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GrantCostsExpensed', window );">Grant costs expensed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,897<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GrantsForEquipmentPurchased', window );">Grants for equipment purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GrantFees', window );">Grant fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GrantFundsReceived', window );">Grant funds received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,173)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RemovalOfBalanceDueToDeconsolidation', window );">Removal of balance due to deconsolidation of eXoZymes at November 14, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(702)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Balance at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2024, eXoZymes was deconsolidated
from the Company&#8217;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GrantCostsExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant costs expensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GrantCostsExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GrantFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GrantFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GrantFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant funds received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GrantFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GrantsForEquipmentPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grants for equipment purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GrantsForEquipmentPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_RemovalOfBalanceDueToDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Removal of balance due to deconsolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_RemovalOfBalanceDueToDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long-lived Assets and Total Assets by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Long-lived assets</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,740<span></span>
</td>
<td class="nump">71,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerAndIntellectualPropertyServiceMember', window );">Broker Dealer And Intellectual Property Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Long-lived assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_TechnologyDevelopmentMember', window );">Technology Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Long-lived assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_OtherSegmentsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Long-lived assets</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">38,609<span></span>
</td>
<td class="nump">50,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_EliminationsMember', window );">Eliminations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Long-lived assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerIntellectualPropertyServiceMember', window );">Broker Dealer &amp; Intellectual Property Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerAndIntellectualPropertyServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerAndIntellectualPropertyServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_TechnologyDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_TechnologyDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_OtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_OtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_EliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_EliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerIntellectualPropertyServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerIntellectualPropertyServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Statement of Operation by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (275)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RealizedInvestmentGainsLossesOne', window );">Realized gain on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Fee income from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">$ (50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Operating expense, related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,833<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Information technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ClearingAndOtherCharges', window );">Clearing and other charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative-other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,637<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,322<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,637<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,790<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NetOperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,726)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28,633)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,973)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment', window );">Income (loss) before equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,984)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromEquityMethodInvestment', window );">Equity in loss of equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(420)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,266)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,601<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(90)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,245)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,691<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(246)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(275)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerIntellectualPropertyServiceMember', window );">Broker Dealer &amp; Intellectual Property Service [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(331)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RealizedInvestmentGainsLossesOne', window );">Realized gain on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Fee income from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Operating expense, related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,005<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">820<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Information technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">968<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ClearingAndOtherCharges', window );">Clearing and other charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative-other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NetOperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,706)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,938)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(990)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(779)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,150)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,140)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment', window );">Income (loss) before equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,161)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,140)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromEquityMethodInvestment', window );">Equity in loss of equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,161)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,140)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,161)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,140)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(275)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_TechnologyDevelopmentMember', window );">Technology Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RealizedInvestmentGainsLossesOne', window );">Realized gain on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Fee income from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Operating expense, related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Information technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ClearingAndOtherCharges', window );">Clearing and other charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative-other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,435<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NetOperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,903)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(92)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,992)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment', window );">Income (loss) before equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,994)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromEquityMethodInvestment', window );">Equity in loss of equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,994)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(90)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,904)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_OtherSegmentsMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RealizedInvestmentGainsLossesOne', window );">Realized gain on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Fee income from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,094<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,769<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Operating expense, related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">185<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,086<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Information technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">135<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ClearingAndOtherCharges', window );">Clearing and other charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative-other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NetOperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,956)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,792)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,759)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment', window );">Income (loss) before equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,759)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">23,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromEquityMethodInvestment', window );">Equity in loss of equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(420)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,041)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,041)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_EliminationsMember', window );">Eliminations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer', window );">Investment securities, at fair value, held by the non-licensed broker dealer (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_RealizedInvestmentGainsLossesOne', window );">Realized gain on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeeIncome', window );">Fee income from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ImpairmentOfInvestmentSecurities', window );">Impairment loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative costs:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Operating expense, related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommunicationsAndInformationTechnology', window );">Information technology</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ClearingAndOtherCharges', window );">Clearing and other charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative-other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_NetOperatingIncomeLoss', window );">Net operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income and expense:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_MiscellaneousIncome', window );">Miscellaneous income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">799<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(990)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(799)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_GainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment', window );">Income (loss) before equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeLossFromEquityMethodInvestment', window );">Equity in loss of equity method investee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) on investment securities, net from the licensed broker dealer</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes realized gains on securities held by the broker-dealer.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Includes impairment loss of assets
from the reduced fair value of the asset.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Includes unrealized gains and
losses on securities held by the broker-dealer.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ClearingAndOtherCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clearing and other charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ClearingAndOtherCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_GainRelatedToDilutionEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain related to dilution events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_GainRelatedToDilutionEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ImpairmentOfInvestmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of investment securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ImpairmentOfInvestmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) before equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeLossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity in loss of equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeLossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments securities, at fair value, held by the non-licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_MiscellaneousIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_MiscellaneousIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_NetOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_NetOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_RealizedInvestmentGainsLossesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized investment gains losses one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_RealizedInvestmentGainsLossesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized loss on investment securities, net from non-licensed broker dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommunicationsAndInformationTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in the period for communications and data processing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommunicationsAndInformationTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerIntellectualPropertyServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_BrokerDealerIntellectualPropertyServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_TechnologyDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_TechnologyDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_OtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_OtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=MDBH_EliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=MDBH_EliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Equity and Non-Controlling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_Equity', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Non-controlling net loss</a></td>
<td class="num">$ (21,245)<span></span>
</td>
<td class="nump">$ 11,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss non-controlling interest</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Prior period balance</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending period balance</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember', window );">Exozyme Technologies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_Equity', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Non-controlling net loss</a></td>
<td class="num">$ (64)<span></span>
</td>
<td class="num">$ (276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_WeightedAverageNonControllingPercentage', window );">Weighted average non-controlling percentage</a></td>
<td class="nump">32.16%<span></span>
</td>
<td class="nump">32.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss non-controlling interest</a></td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Prior period balance</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DueToDeconsolidation', window );">Removal of prior period balance of Exozyme due to deconsolidation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationToNonControllingInterest', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_OwnershipChangeOfNoncontrollingInterest', window );">Ownership change of non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending period balance</a></td>
<td class="num">$ (111)<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DueToDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to deconsolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DueToDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_OwnershipChangeOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership change of non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_OwnershipChangeOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationToNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation to non controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationToNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_WeightedAverageNonControllingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average non-controlling percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_WeightedAverageNonControllingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Non-Controlling Interests (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Capital infusions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Minnesota One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Exozyme Technologies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Minnesota One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Exozyme Technologies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=MDBH_MinnesotaOneMember', window );">Minnesota One [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=MDBH_MinnesotaOneMember', window );">Minnesota One [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=MDBH_MinnesotaOneMember', window );">Minnesota One [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.84%<span></span>
</td>
<td class="nump">67.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.16%<span></span>
</td>
<td class="nump">32.53%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember', window );">Exozyme Technologies Inc [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember', window );">Exozyme Technologies Inc [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,138,632<span></span>
</td>
<td class="nump">4,950,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,138,632<span></span>
</td>
<td class="nump">4,950,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Placement agent and selling agent warrants</a></td>
<td class="nump">1,670,000<span></span>
</td>
<td class="nump">43,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MinnesotaOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_MinnesotaOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_ExozymeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_ExozymeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=MDBH_MinnesotaOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=MDBH_MinnesotaOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=MDBH_ExozymeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deconsolidation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee', window );">Equity method, net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,282,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,245,000)<span></span>
</td>
<td class="nump">$ 11,691,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 71,976,000<span></span>
</td>
<td class="nump">63,740,000<span></span>
</td>
<td class="nump">71,976,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,903,000<span></span>
</td>
<td class="nump">$ 3,161,000<span></span>
</td>
<td class="nump">1,903,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MDBH_ExozymesIncMember', window );">Exozymes Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee', window );">Equity method, net loss</a></td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit or loss on sales of previously unissued stock by equity investees made to investors outside the consolidated group that is not reported as operating income. Represents the difference in the parent company's carrying amount of the equity interest in the subsidiary or equity investee immediately before and after the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MDBH_ExozymesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MDBH_ExozymesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,217<span></span>
</td>
<td class="nump">$ 20,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">641<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,740<span></span>
</td>
<td class="nump">71,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due to affiliates</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,161<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Paid-in-capital</a></td>
<td class="nump">80,493<span></span>
</td>
<td class="nump">68,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(19,803)<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">60,579<span></span>
</td>
<td class="nump">70,073<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 37,321<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 63,740<span></span>
</td>
<td class="nump">71,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=MDBH_ExozymesMember', window );">Exozymes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due to affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredGrantReimbursement', window );">Deferred grant reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,118<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Paid-in-capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,402)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,836<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2024, eXoZymes was deconsolidated
from the Company&#8217;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredGrantReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredGrantReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=MDBH_ExozymesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=MDBH_ExozymesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Gain on Deconsolidation (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value of the NCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,500)<span></span>
</td>
<td class="num">$ (11,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 39,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MDBH_ExozymesIncMember', window );">Exozymes Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Subtotal of quoted closing price of Class A common shares</a></td>
<td class="nump">40,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Quoted closing price of Class A common shares</a></td>
<td class="nump">$ 10.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of equity method investment</a></td>
<td class="nump">42,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Carrying Value of the NCI</a></td>
<td class="num">(921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CarryingValueOfAssets', window );">Carrying value of assets</a></td>
<td class="nump">4,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_LessCarryingValueOfFormerInvestment', window );">Less carrying value of former investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CarryingValueOfWarrants', window );">Carrying value of warrants</a></td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation</a></td>
<td class="nump">$ 39,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_CarryingValueOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_CarryingValueOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_CarryingValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_CarryingValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_LessCarryingValueOfFormerInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Less carrying value of former investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_LessCarryingValueOfFormerInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MDBH_ExozymesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MDBH_ExozymesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Equity Method Investment (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments, balance</a></td>
<td class="nump">$ 41,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee', window );">Portion of loss from Invizyne</a></td>
<td class="num">(4,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents', window );">Gain related to dilution events</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments, balance</a></td>
<td class="nump">$ 37,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain related to dilution events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit or loss on sales of previously unissued stock by equity investees made to investors outside the consolidated group that is not reported as operating income. Represents the difference in the parent company's carrying amount of the equity interest in the subsidiary or equity investee immediately before and after the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,245)<span></span>
</td>
<td class="nump">$ 11,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_ExozymesMember', window );">Exozymes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Owned shares</a></td>
<td class="nump">3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_ExozymesMember', window );">Exozymes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_InvizyneTechnologiesIncMember', window );">Invizyne Technologies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, percentage</a></td>
<td class="nump">46.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_ExozymesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_ExozymesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_InvizyneTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MDBH_InvizyneTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Unit Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember', window );">Time Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod', window );">Number of Restricted Stock Units, Exchanged/Modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exchanged/Modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.78<span></span>
</td>
<td class="nump">$ 9.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber', window );">Exercisable and vested restricted stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Grant Date Fair Value, Exercisable and vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember', window );">Market Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod', window );">Number of Restricted Stock Units, Exchanged/Modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Exchanged/Modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Restricted Stock Units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber', window );">Exercisable and vested restricted stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Grant Date Fair Value, Exercisable and vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exchanged and modified in period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exchanged and modified weighted average grant date fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options grants in vested and expected to vest exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options nonvested vested and expected to vest exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_TimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Time-Based Stock Option Activity (Details) - Time Based [Member] - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, time-based stock options outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, time-based stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod', window );">Number of Options, exchanged/modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exchanged/modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), time-based stock options exchanged/modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, time-based stock options outstanding, at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, time-based stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), time-based stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), stock options exercisable</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exchanged and modified in period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options exchanged and modified in period weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by sharebased payment award options exchanged weighted average remaining contractual term 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_TimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Market-Based Stock Option Activity (Details) - Market Based [Member] - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, time-based stock options outstanding, beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, time-based stock options outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod', window );">Number of Options, exchanged/modified</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exchanged/modified</a></td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), exchanged/modified</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, expired/cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired/cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, time-based stock options outstanding, at the end</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, time-based stock options outstanding</a></td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), market-based stock options outstanding</a></td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, stock options exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, stock options exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exchanged and modified in period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options exchanged and modified in period weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding exchanged and modified weighted average remaining contractual term 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2025</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Sep. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock options to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription', window );">Restricted stock units, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These
units will vest 20% of one-half of the total number of RSUs, by each individual person, starting on the thirteenth (13) month anniversary
of the listing of the Class A Shares on a United States national exchange, October 20, 2024, when a Class A Share has traded in the market
on which the Class A Shares are listed for any 90 consecutive calendar days at an average price of $20.00 or more during the period commencing
the date of grant and prior to the five year anniversary of the date of grant, with an average monthly trading volume of 2 million Class
A Shares or more during the 90 consecutive calendar day period, or a Class A Shares has traded in the market on which the Class A Shares
are listed for any 90 consecutive calendar days at an average price of $25.00 or more during the period commencing the date of grant
and prior to the five year anniversary of the date of grant; provided further, that if there is a distribution of cash, stock or other
property by the Company on the Class A Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced, from time to time,
by the value of any one or more per share distributions after the date of grant until vested.<span></span>
</td>
<td class="text">These units vested 20% of one-half of the total
number of RSUs, by each individual person, on the thirteenth (13) month anniversary, October 20, 2024, of the listing of the Class A Shares
on a United States national exchange, then vesting would be at a rate of 10% of one-half the number of RSUs each six months after the
date of the initial vesting, until the last vesting on the fifth year anniversary of the date of grant, at which any previously unvested
would fully vest. These RSUs were granted to officers, directors, employees, and contractors. These RSU began to vest upon the completion
of the initial public offering by the Company on September 20, 2023, compensation expense related to these RSUs has been recorded. The
Company expensed the RSUs based on the average expense over the vesting period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of restricted stock units, cancelled and converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock unit, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock options to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod', window );">Number of restricted stock units, canceled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSU vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted average years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember', window );">Market Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock options to purchase</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod', window );">Number of restricted stock units, canceled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted average years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unvested portion market value</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount', window );">Sharebased payment award amortized amount</a></td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock-based compensation term life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share, granted</a></td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AveragePricePerShare', window );">Average price per share</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting', window );">Exercisable period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember', window );">Time Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock options to purchase</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod', window );">Number of restricted stock units, canceled or forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSU vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted average years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per share, granted</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting', window );">Remaining stock options vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Estimated life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected annual volatility</a></td>
<td class="nump">85.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected annual volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember', window );">Time Based [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average price per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award amortized amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term 1 vesting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options remaining stock options vesting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reason for increase (decrease), classified as other, in number of awards under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_MarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_MarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_TimeBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_TimeBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Basic and Fully Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="num">$ (10,768)<span></span>
</td>
<td class="nump">$ 5,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic</a></td>
<td class="nump">5,022,742<span></span>
</td>
<td class="nump">4,424,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share &#8211; basic</a></td>
<td class="num">$ (2.14)<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="num">$ (11,714)<span></span>
</td>
<td class="nump">$ 7,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares outstanding &#8211;diluted</a></td>
<td class="nump">6,145,212<span></span>
</td>
<td class="nump">9,462,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share &#8211;diluted</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="num">$ (10,477)<span></span>
</td>
<td class="nump">$ 5,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share &#8211; basic</a></td>
<td class="num">$ (2.10)<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to MDB Capital Holdings, LLC</a></td>
<td class="num">$ (9,531)<span></span>
</td>
<td class="nump">$ 4,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares outstanding &#8211;diluted</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share &#8211;diluted</a></td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details Narrative)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party expenses</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">22,637,000<span></span>
</td>
<td class="nump">30,790,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Value issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Tax paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MDBH_ENDRAMember', window );">ENDRA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MDBH_ExozymesMember', window );">Exozymes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MDBH_ENDRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MDBH_ENDRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MDBH_ExozymesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MDBH_ExozymesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CommitmentsAndContingenciesTable', window );"><strong>CommitmentsAndContingenciesTable [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_NetCapital', window );">Net capital</a></td>
<td class="nump">$ 8,450,000<span></span>
</td>
<td class="nump">10,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RatioOfIndebtednessToNetCapital1', window );">Percentage of aggregate indebtedness</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MinimumNetCapitalRequiredForEntity1', window );">Aggregate indebtedness calculated amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_DTCMembershipRequirementsMember', window );">DTC Membership Requirements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CommitmentsAndContingenciesTable', window );"><strong>CommitmentsAndContingenciesTable [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_NetCapital', window );">Net capital</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CommitmentsAndContingenciesTable', window );"><strong>CommitmentsAndContingenciesTable [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_NetCapital', window );">Net capital</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | DTC Membership Requirements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CommitmentsAndContingenciesTable', window );"><strong>CommitmentsAndContingenciesTable [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_NetCapital', window );">Net capital</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=MDBH_PublicVenturesMember', window );">Public Ventures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_CommitmentsAndContingenciesTable', window );"><strong>CommitmentsAndContingenciesTable [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_NetCapital', window );">Net capital</a></td>
<td class="nump">8,700,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest expense</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_CommitmentsAndContingenciesTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_CommitmentsAndContingenciesTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MinimumNetCapitalRequiredForEntity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of net capital required to be maintained by broker-dealer parent, calculated under Aggregate Indebtedness Standard.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MinimumNetCapitalRequiredForEntity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_NetCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net capital of broker-dealer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_NetCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RatioOfIndebtednessToNetCapital1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indebtedness divided by net capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RatioOfIndebtednessToNetCapital1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_DTCMembershipRequirementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_DTCMembershipRequirementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MDBH_PublicVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MDBH_PublicVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exclusive License Agreement (MDB Minnesota One) (Details Narrative)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_PhaseIIclinicalMember', window );">Phase II clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PaymentForLicensedProducts', window );">Payments for licensed products</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_PhaseIIIclinicalMember', window );">Phase III clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PaymentForLicensedProducts', window );">Payments for licensed products</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_NewDrugApplicationFirstMember', window );">New Drug Application First [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PaymentForLicensedProducts', window );">Payments for licensed products</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=MDBH_NewDrugApplicationMember', window );">New Drug Application [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_PaymentForLicensedProducts', window );">Payments for licensed products</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MDBH_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee</a></td>
<td class="nump">$ 150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_PaymentForLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for licensed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_PaymentForLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_PhaseIIclinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_PhaseIIclinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_PhaseIIIclinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_PhaseIIIclinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_NewDrugApplicationFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_NewDrugApplicationFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MDBH_NewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MDBH_NewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MDBH_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MDBH_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Operating Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-Term Lease, Cost</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Total operating lease costs</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future payments Due Under Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">2029 and thereafter</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less effects of discounting</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRent', window );">Initial rent, per month</a></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_BaseRent', window );">Base rent, per month</a></td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_AnnualOperatingCostIncreasePercentage', window );">Annual operating cost increase percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">91 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to extend for 60 additional months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_AnnualOperatingCostIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual operating cost increase percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_AnnualOperatingCostIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_BaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_BaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount at the balance sheet date that has been received by the entity that represents rents paid in advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Taxes Expenses (benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S Federal statutory income rate, Amount</a></td>
<td class="num">$ (4,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate', window );">U.S Federal statutory income rate, Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal tax benefit, Amount</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal tax benefit, Rate</a></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="num">(2.11%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities', window );">Income/loss excluded from nontaxable entities, Amount</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="num">$ (8,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities', window );">Income/loss excluded from nontaxable entities, Rate</a></td>
<td class="num">(4.44%)<span></span>
</td>
<td class="num">(68.57%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences', window );">Permanent differences, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment, Amount</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment, Rate</a></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options, Amount</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options, Rate</a></td>
<td class="num">(3.06%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount', window );">Equity award vesting, Amount</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting', window );">Equity award vesting, Rate</a></td>
<td class="num">(1.24%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount', window );">Modification of equity awards, Amount</a></td>
<td class="nump">$ 2,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Equity award vesting, Rate</a></td>
<td class="num">(10.95%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Return-to-provision adjustments, Amount</a></td>
<td class="num">$ (44)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments', window );">Return-to-provision adjustments, Rate</a></td>
<td class="nump">0.22%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance', window );">Valuation allowance, Amount</a></td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 4,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance', window );">Valuation allowance, Rate</a></td>
<td class="num">(2.52%)<span></span>
</td>
<td class="nump">42.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective rate, Amount</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate, Rate</a></td>
<td class="num">(0.05%)<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate', window );">U.S Federal statutory income rate, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S Federal statutory income rate, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxAssetsInStartupExpenditures', window );">Start-up expenditures</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxAssetsInOrganizationalExpenditures', window );">Organizational expenditures</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Sec 174 &#8211; Research and development costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxAssetsStockCompensation', window );">Stock compensation</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment principally due to differences in depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxAssetsBonusExpense', window );">Bonus expense</a></td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxAssetsImpairmentExpense', window );">Impairment expense</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible Assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">4,890<span></span>
</td>
<td class="nump">3,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(6,625)<span></span>
</td>
<td class="num">(6,124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Right-of-use asset</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MDBH_DeferredTaxLiabilitiesInvestmentSecurities', window );">Investment securities</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(327)<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Other noncurrent assets/(liabilities)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxAssetsBonusExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets bonus expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxAssetsBonusExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxAssetsImpairmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets impairment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxAssetsImpairmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxAssetsInOrganizationalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets in organizational expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxAssetsInOrganizationalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxAssetsInStartupExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets in startup expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxAssetsInStartupExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxAssetsStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxAssetsStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_DeferredTaxLiabilitiesInvestmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities investment securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_DeferredTaxLiabilitiesInvestmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income loss excluded from nontaxable entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity award vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation equity in equity award vesting amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income loss excluded from nontaxable entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expenses provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation modification of equity awards amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MDBH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash taxes paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Decrease in deferred tax assets valuation allowance</a></td>
<td class="nump">6,625,000<span></span>
</td>
<td class="nump">$ 6,124,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=MDBH_USFederalTaxMember', window );">U.S Federal Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">23,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=MDBH_FloridaIncomeTaxMember', window );">Florida Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=MDBH_USFederalTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=MDBH_USFederalTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=MDBH_FloridaIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=MDBH_FloridaIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - Restricted Stock Units (RSUs) [Member] - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2026</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Sep. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted</a></td>
<td class="nump">161,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>189</ContextCount>
  <ElementCount>438</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement -  Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName> Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement -  Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName> Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/StatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures</Role>
      <ShortName>Consolidated Statements of Cash Flows, Supplemental Disclosures</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Equity and Non-Controlling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EquityAndNon-controllingInterests</Role>
      <ShortName>Equity and Non-Controlling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Deconsolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/Deconsolidation</Role>
      <ShortName>Deconsolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Exclusive License Agreement (MDB Minnesota One)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne</Role>
      <ShortName>Exclusive License Agreement (MDB Minnesota One)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://mdb.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/SegmentReporting</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Equity and Non-Controlling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EquityAndNon-controllingInterestsTables</Role>
      <ShortName>Equity and Non-Controlling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/EquityAndNon-controllingInterests</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Deconsolidation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/DeconsolidationTables</Role>
      <ShortName>Deconsolidation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/Deconsolidation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Equity Method Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EquityMethodInvestmentTables</Role>
      <ShortName>Equity Method Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/EquityMethodInvestment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/Stock-basedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/EarningsPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mdb.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Organization and Description of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>Organization and Description of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Investment Securities Broker Dealer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails</Role>
      <ShortName>Schedule of Investment Securities Broker Dealer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Investment Securities Non-Broker Dealer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails</Role>
      <ShortName>Schedule of Investment Securities Non-Broker Dealer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails</Role>
      <ShortName>Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails</Role>
      <ShortName>Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Property And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails</Role>
      <ShortName>Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Summary of Grants Receivable Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails</Role>
      <ShortName>Summary of Grants Receivable Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails</Role>
      <ShortName>Schedule of Long-lived Assets and Total Assets by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Statement of Operation by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails</Role>
      <ShortName>Schedule of Statement of Operation by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Segment Reporting (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>Segment Reporting (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/SegmentReportingTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Equity and Non-Controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails</Role>
      <ShortName>Schedule of Equity and Non-Controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Equity and Non-Controlling Interests (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative</Role>
      <ShortName>Equity and Non-Controlling Interests (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/EquityAndNon-controllingInterestsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Deconsolidation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/DeconsolidationDetailsNarrative</Role>
      <ShortName>Deconsolidation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/DeconsolidationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails</Role>
      <ShortName>Schedule of Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Schedule of Gain on Deconsolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails</Role>
      <ShortName>Schedule of Gain on Deconsolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Schedule of Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails</Role>
      <ShortName>Schedule of Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Equity Method Investment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EquityMethodInvestmentDetailsNarrative</Role>
      <ShortName>Equity Method Investment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Schedule of Time-Based Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails</Role>
      <ShortName>Schedule of Time-Based Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Market-Based Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails</Role>
      <ShortName>Schedule of Market-Based Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Schedule of Basic and Fully Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails</Role>
      <ShortName>Schedule of Basic and Fully Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Earnings Per Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EarningsPerShareDetailsNarrative</Role>
      <ShortName>Earnings Per Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/EarningsPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/RelatedPartyTransactions</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Employee Benefit Plans (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative</Role>
      <ShortName>Employee Benefit Plans (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Exclusive License Agreement (MDB Minnesota One) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative</Role>
      <ShortName>Exclusive License Agreement (MDB Minnesota One) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails</Role>
      <ShortName>Schedule of Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Future payments Due Under Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails</Role>
      <ShortName>Schedule of Future payments Due Under Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/LeasesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Schedule of Income Taxes Expenses (benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails</Role>
      <ShortName>Schedule of Income Taxes Expenses (benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mdb.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mdb.com/role/SubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>mdbh-20251231.xsd</File>
    <File>mdbh-20251231_cal.xml</File>
    <File>mdbh-20251231_def.xml</File>
    <File>mdbh-20251231_lab.xml</File>
    <File>mdbh-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="11">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="932">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "MDBH",
   "nsuri": "http://mdb.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "mdbh-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mdbh-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mdbh-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mdbh-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdbh-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 330,
   "keyCustom": 108,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 20,
   "memberCustom": 33,
   "hidden": {
    "total": 300,
    "http://fasb.org/us-gaap/2025": 191,
    "http://mdb.com/20251231": 104,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 189,
   "entityCount": 1,
   "segmentCount": 58,
   "elementCount": 735,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 932,
    "http://xbrl.sec.gov/dei/2025": 43,
    "http://fasb.org/srt/2025": 11,
    "http://xbrl.sec.gov/cyd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://mdb.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://mdb.com/role/ConsolidatedBalanceSheets",
     "longName": "00000002 - Statement -  Consolidated Balance Sheets",
     "shortName": " Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement -  Consolidated Balance Sheets (Parenthetical)",
     "shortName": " Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockNoParValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://mdb.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://mdb.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ResearchAndDevelopmentGrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ResearchAndDevelopmentGrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://mdb.com/role/StatementsOfChangesInEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://mdb.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "MDBH:AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures",
     "longName": "00000008 - Statement - Consolidated Statements of Cash Flows, Supplemental Disclosures",
     "shortName": "Consolidated Statements of Cash Flows, Supplemental Disclosures",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://mdb.com/role/OrganizationAndDescriptionOfBusiness",
     "longName": "999016 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://mdb.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999017 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://mdb.com/role/SegmentReporting",
     "longName": "999018 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://mdb.com/role/EquityAndNon-controllingInterests",
     "longName": "999019 - Disclosure - Equity and Non-Controlling Interests",
     "shortName": "Equity and Non-Controlling Interests",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://mdb.com/role/Deconsolidation",
     "longName": "999020 - Disclosure - Deconsolidation",
     "shortName": "Deconsolidation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:DeconsolidationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:DeconsolidationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://mdb.com/role/EquityMethodInvestment",
     "longName": "999021 - Disclosure - Equity Method Investment",
     "shortName": "Equity Method Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://mdb.com/role/Stock-basedCompensation",
     "longName": "999022 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://mdb.com/role/EarningsPerShare",
     "longName": "999023 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://mdb.com/role/RelatedPartyTransactions",
     "longName": "999024 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://mdb.com/role/CommitmentsAndContingencies",
     "longName": "999025 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://mdb.com/role/EmployeeBenefitPlans",
     "longName": "999026 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne",
     "longName": "999027 - Disclosure - Exclusive License Agreement (MDB Minnesota One)",
     "shortName": "Exclusive License Agreement (MDB Minnesota One)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ExclusiveLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ExclusiveLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://mdb.com/role/Leases",
     "longName": "999028 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://mdb.com/role/IncomeTaxes",
     "longName": "999029 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://mdb.com/role/SubsequentEvents",
     "longName": "999030 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999031 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999032 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://mdb.com/role/SegmentReportingTables",
     "longName": "999033 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://mdb.com/role/EquityAndNon-controllingInterestsTables",
     "longName": "999034 - Disclosure - Equity and Non-Controlling Interests (Tables)",
     "shortName": "Equity and Non-Controlling Interests (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ScheduleOfEquityAndNonControllingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:ScheduleOfEquityAndNonControllingInterestsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://mdb.com/role/DeconsolidationTables",
     "longName": "999035 - Disclosure - Deconsolidation (Tables)",
     "shortName": "Deconsolidation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "MDBH:DeconsolidationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "MDBH:DeconsolidationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://mdb.com/role/EquityMethodInvestmentTables",
     "longName": "999036 - Disclosure - Equity Method Investment (Tables)",
     "shortName": "Equity Method Investment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://mdb.com/role/Stock-basedCompensationTables",
     "longName": "999037 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://mdb.com/role/EarningsPerShareTables",
     "longName": "999038 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://mdb.com/role/LeasesTables",
     "longName": "999039 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://mdb.com/role/IncomeTaxesTables",
     "longName": "999040 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
     "longName": "999041 - Disclosure - Organization and Description of Business (Details Narrative)",
     "shortName": "Organization and Description of Business (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-07-01",
      "name": "us-gaap:AdvancesToAffiliate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-07-01",
      "name": "us-gaap:AdvancesToAffiliate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
     "longName": "999043 - Disclosure - Schedule of Investment Securities Broker Dealer (Details)",
     "shortName": "Schedule of Investment Securities Broker Dealer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "MDBH:InvestmentSecuritiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_BrokerDealerMember",
      "name": "MDBH:InvestmentSecuritiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "MDBH:ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
     "longName": "999044 - Disclosure - Schedule of Investment Securities Non-Broker Dealer (Details)",
     "shortName": "Schedule of Investment Securities Non-Broker Dealer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "MDBH:InvestmentSecuritiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_NonBrokerDealerMember",
      "name": "MDBH:InvestmentSecuritiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "MDBH:ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "999045 - Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "MDBH:InvestmentSecuritiesAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_CommonStockMember",
      "name": "MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails",
     "longName": "999046 - Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)",
     "shortName": "Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails",
     "longName": "999047 - Disclosure - Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)",
     "shortName": "Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "999048 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_custom_LaboratoryEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MDBH:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_LaboratoryEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MDBH:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999049 - Disclosure - Schedule of Property And Equipment (Details)",
     "shortName": "Schedule of Property And Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails",
     "longName": "999050 - Disclosure - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails",
     "longName": "999051 - Disclosure - Summary of Grants Receivable Activity (Details)",
     "shortName": "Summary of Grants Receivable Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:GrantsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "MDBH:GrantsReceivableActivityTableTextBlock",
       "MDBH:AccountingForResearchGrantsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "MDBH:GrantCostsExpensed",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "MDBH:GrantsReceivableActivityTableTextBlock",
       "MDBH:AccountingForResearchGrantsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
     "longName": "999052 - Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)",
     "shortName": "Schedule of Long-lived Assets and Total Assets by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
     "longName": "999053 - Disclosure - Schedule of Statement of Operation by Segment (Details)",
     "shortName": "Schedule of Statement of Operation by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://mdb.com/role/SegmentReportingDetailsNarrative",
     "longName": "999054 - Disclosure - Segment Reporting (Details Narrative)",
     "shortName": "Segment Reporting (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails",
     "longName": "999055 - Disclosure - Schedule of Equity and Non-Controlling Interests (Details)",
     "shortName": "Schedule of Equity and Non-Controlling Interests (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "MDBH:ScheduleOfEquityAndNonControllingInterestsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
     "longName": "999056 - Disclosure - Equity and Non-Controlling Interests (Details Narrative)",
     "shortName": "Equity and Non-Controlling Interests (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProceedsFromContributionsFromParent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://mdb.com/role/DeconsolidationDetailsNarrative",
     "longName": "999057 - Disclosure - Deconsolidation (Details Narrative)",
     "shortName": "Deconsolidation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-11-152024-12-31_custom_ExozymesIncMember",
      "name": "us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "MDBH:DeconsolidationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
     "longName": "999058 - Disclosure - Schedule of Consolidated Balance Sheet (Details)",
     "shortName": "Schedule of Consolidated Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_ExozymesMember",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "MDBH:DeconsolidationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails",
     "longName": "999059 - Disclosure - Schedule of Gain on Deconsolidation (Details)",
     "shortName": "Schedule of Gain on Deconsolidation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-14_custom_ExozymesIncMember",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "MDBH:ScheduleOfGainOnDeconsolidationTableTextBlock",
       "MDBH:DeconsolidationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails",
     "longName": "999060 - Disclosure - Schedule of Equity Method Investment (Details)",
     "shortName": "Schedule of Equity Method Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "MDBH:EquityMethodInvestmentsGainRelatedToDilutionEvents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
     "longName": "999061 - Disclosure - Equity Method Investment (Details Narrative)",
     "shortName": "Equity Method Investment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-14_custom_ExozymesMember",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
     "longName": "999062 - Disclosure - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TimeBasedMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_TimeBasedMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
     "longName": "999063 - Disclosure - Schedule of Time-Based Stock Option Activity (Details)",
     "shortName": "Schedule of Time-Based Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_TimeBasedMember",
      "name": "MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_TimeBasedMember",
      "name": "MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
     "longName": "999064 - Disclosure - Schedule of Market-Based Stock Option Activity (Details)",
     "shortName": "Schedule of Market-Based Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_MarketBasedMember",
      "name": "MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_MarketBasedMember",
      "name": "MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999065 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_PrivatePlacementMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_PrivatePlacementMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
     "longName": "999066 - Disclosure - Schedule of Basic and Fully Diluted (Details)",
     "shortName": "Schedule of Basic and Fully Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_CommonClassAMember",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_CommonClassAMember",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://mdb.com/role/EarningsPerShareDetailsNarrative",
     "longName": "999067 - Disclosure - Earnings Per Share (Details Narrative)",
     "shortName": "Earnings Per Share (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999068 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999069 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "srt:NetCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "srt:NetCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative",
     "longName": "999070 - Disclosure - Employee Benefit Plans (Details Narrative)",
     "shortName": "Employee Benefit Plans (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative",
     "longName": "999071 - Disclosure - Exclusive License Agreement (MDB Minnesota One) (Details Narrative)",
     "shortName": "Exclusive License Agreement (MDB Minnesota One) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_PhaseIIclinicalMember",
      "name": "MDBH:PaymentForLicensedProducts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MDBH:ExclusiveLicenseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_PhaseIIclinicalMember",
      "name": "MDBH:PaymentForLicensedProducts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "MDBH:ExclusiveLicenseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails",
     "longName": "999072 - Disclosure - Schedule of Operating Lease Cost (Details)",
     "shortName": "Schedule of Operating Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails",
     "longName": "999073 - Disclosure - Schedule of Future payments Due Under Operating Lease (Details)",
     "shortName": "Schedule of Future payments Due Under Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://mdb.com/role/LeasesDetailsNarrative",
     "longName": "999074 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2023-04-03",
      "name": "us-gaap:AdvanceRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-04-03",
      "name": "us-gaap:AdvanceRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails",
     "longName": "999075 - Disclosure - Schedule of Income Taxes Expenses (benefit) (Details)",
     "shortName": "Schedule of Income Taxes Expenses (benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999076 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://mdb.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999077 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_USFederalTaxMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://mdb.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999078 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-02-032026-02-03_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "MDBH_AccountingForResearchGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AccountingForResearchGrantsPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Grants",
        "documentation": "Accounting For Research Grants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_AccountingPolicies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AccountingPolicies",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountingPolicies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountingPoliciesTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r1028"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Other",
        "documentation": "Amount of obligations incurred and payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r682",
      "r753",
      "r1032",
      "r1033"
     ]
    },
    "MDBH_AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of investments at amortized cost (U.S Treasury Bills)",
        "documentation": "Accretion of investments at amortized cost (U.S Treasury Bills).",
        "label": "AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_AccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "documentation": "Accrued expenses.",
        "label": "AccruedExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r124",
      "r532"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in-capital",
        "verboseLabel": "Paid-in-capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r743",
      "r1066"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1000",
      "r1071"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvanceRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvanceRent",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial rent, per month",
        "documentation": "Amount at the balance sheet date that has been received by the entity that represents rents paid in advance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvancesToAffiliate",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Up-front fees",
        "documentation": "Long-Term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. This does not include advances to clients."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r801",
      "r815",
      "r842"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r804",
      "r818",
      "r845"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r837",
      "r846",
      "r850",
      "r858"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "MDBH_AnnualOperatingCostIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AnnualOperatingCostIncreasePercentage",
     "presentation": [
      "http://mdb.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual operating cost increase percentage",
        "documentation": "Annual operating cost increase percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r91",
      "r126",
      "r151",
      "r153",
      "r154",
      "r195",
      "r208",
      "r226",
      "r230",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r429",
      "r434",
      "r464",
      "r511",
      "r512",
      "r520",
      "r623",
      "r705",
      "r706",
      "r718",
      "r743",
      "r746",
      "r747",
      "r760",
      "r943",
      "r944",
      "r1018"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r131",
      "r151",
      "r153",
      "r154",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r429",
      "r434",
      "r464",
      "r743",
      "r943",
      "r944",
      "r1018"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-lived assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r429",
      "r434",
      "r464",
      "r943",
      "r944",
      "r1018"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r797"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r797"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r797"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "MDBH_AveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "AveragePricePerShare",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average price per share",
        "documentation": "Average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationTables",
      "http://mdb.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "MDBH_BaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "BaseRent",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base rent, per month",
        "documentation": "Base rent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Principles of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "MDBH_BrokerDealerAndIntellectualPropertyServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "BrokerDealerAndIntellectualPropertyServiceMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Broker Dealer And Intellectual Property Service [Member]",
        "documentation": "Broker Dealer And Intellectual Property Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_BrokerDealerIntellectualPropertyServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "BrokerDealerIntellectualPropertyServiceMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Broker Dealer &amp; Intellectual Property Service [Member]",
        "documentation": "Broker Dealer &amp; Intellectual Property Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_BrokerDealerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "BrokerDealerMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Broker Dealer [Member]",
        "documentation": "Broker Dealer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r906"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed software",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r687"
     ]
    },
    "MDBH_CarryingValueOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "CarryingValueOfAssets",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value of assets",
        "documentation": "Carrying value of assets."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_CarryingValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "CarryingValueOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value of warrants",
        "documentation": "Carrying value of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsegregated cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r524",
      "r594",
      "r616",
      "r743",
      "r746",
      "r747",
      "r760",
      "r891"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r122",
      "r690"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash segregated in compliance with regulations",
        "label": "Cash and Securities Segregated under Federal and Other Regulations",
        "documentation": "Amount of cash subject to withdrawal restrictions, restricted deposits held as compensating balances, and cash and securities segregated in compliance with regulations (such as cash deposited in a special reserve account for the exclusive benefit of customers)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash segregated in compliance with regulations",
        "documentation": "Cash and securities deposited in a special reserve account for the exclusive benefit of customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows",
      "http://mdb.com/role/StatementsOfCashFlowsSupplementalDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF YEAR",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r58",
      "r148"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r58"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "negatedLabel": "Carrying Value of the NCI",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r1031"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured limits",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_CashSIPCInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "CashSIPCInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, SIPC insured limits",
        "documentation": "Cash insured amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash uninsured limits",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/Cover",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r127",
      "r128",
      "r129",
      "r151",
      "r154",
      "r180",
      "r181",
      "r188",
      "r190",
      "r198",
      "r199",
      "r244",
      "r273",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r309",
      "r312",
      "r313",
      "r316",
      "r319",
      "r326",
      "r464",
      "r571",
      "r572",
      "r573",
      "r574",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r608",
      "r631",
      "r653",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r879",
      "r909",
      "r911",
      "r920"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r198",
      "r303",
      "r312",
      "r313",
      "r314",
      "r316",
      "r319",
      "r324",
      "r326",
      "r436",
      "r571",
      "r572",
      "r573",
      "r574",
      "r719",
      "r879",
      "r907",
      "r909"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r156",
      "r327"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to puchase common shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "MDBH_ClearingAndOtherCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ClearingAndOtherCharges",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clearing and other charges",
        "documentation": "Clearing and other charges."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 10)",
        "verboseLabel": "Commitments and Contingencies [Line Items]",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r83",
      "r523",
      "r607"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r266",
      "r267",
      "r683",
      "r935",
      "r940"
     ]
    },
    "MDBH_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommitmentsAndContingenciesTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/Cover",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/Cover",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r754",
      "r755",
      "r756",
      "r757",
      "r916",
      "r917",
      "r919",
      "r1000",
      "r1064",
      "r1071"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, no par value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r608"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r608",
      "r629",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, value",
        "verboseLabel": "Common shares",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r301",
      "r308",
      "r526",
      "r743"
     ]
    },
    "us-gaap_CommunicationsAndInformationTechnology": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommunicationsAndInformationTechnology",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Information technology",
        "documentation": "The amount of expense in the period for communications and data processing expense."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://mdb.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_CompensationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "CompensationCosts",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Compensation costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r107",
      "r152",
      "r159",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r498",
      "r514",
      "r684",
      "r886",
      "r887",
      "r888",
      "r942",
      "r945",
      "r946"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r107",
      "r152",
      "r159",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r498",
      "r514",
      "r684",
      "r886",
      "r887",
      "r888",
      "r942",
      "r945",
      "r946"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Deferred Revenue",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Deferred revenue, Balance",
        "periodEndLabel": "Deferred revenue, Balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "MDBH_ContractWithCustomerLiabilityAmountsBilledNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ContractWithCustomerLiabilityAmountsBilledNotRecognized",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts billed but not recognized",
        "documentation": "Contract with customer liability amounts billed not recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r941"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r941"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r907",
      "r913",
      "r995"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r907",
      "r913",
      "r995"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r869"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r869"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r871"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r871"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r873"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r871"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r864"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r865"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r865"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r863"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r866"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r868"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r868"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r869"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r872"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r870"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r867"
     ]
    },
    "MDBH_DTCMembershipRequirementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DTCMembershipRequirementsMember",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DTC Membership Requirements [Member]",
        "documentation": "DTC Membership Requirements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r34",
      "r79",
      "r82",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r741",
      "r907",
      "r908",
      "r910",
      "r915",
      "r936",
      "r937",
      "r938",
      "r1011",
      "r1012",
      "r1027"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r283"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r741",
      "r907",
      "r908",
      "r910",
      "r915",
      "r936",
      "r937",
      "r938",
      "r1011",
      "r1012",
      "r1027"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt\u2013- Revolving Credit Facility",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "MDBH_DeconsolidationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeconsolidationAbstract",
     "auth_ref": []
    },
    "MDBH_DeconsolidationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeconsolidationDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/Deconsolidation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deconsolidation",
        "documentation": "Deconsolidation Disclosure [Text Block]",
        "label": "Deconsolidation Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on deconsolidation",
        "verboseLabel": "Gain on deconsolidation of subsidiary",
        "label": "Gain on deconsolidation",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r143"
     ]
    },
    "MDBH_DeconsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeconsolidationPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deconsolidation",
        "documentation": "Deconsolidation [Policy Text Block].",
        "label": "DeconsolidationPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DeconsolidationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeconsolidationTable",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeconsolidationTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred costs related to deferred revenue",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r894"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r913",
      "r994",
      "r995"
     ]
    },
    "MDBH_DeferredGrantReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredGrantReimbursement",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant reimbursement",
        "documentation": "Deferred Grant Reimbursement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred IPO Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r913",
      "r994",
      "r995"
     ]
    },
    "MDBH_DeferredTaxAssetsBonusExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxAssetsBonusExpense",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus expense",
        "documentation": "Deferred tax assets bonus expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Charitable contribution carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "MDBH_DeferredTaxAssetsImpairmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxAssetsImpairmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment expense",
        "documentation": "Deferred tax assets impairment expense."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DeferredTaxAssetsInOrganizationalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxAssetsInOrganizationalExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organizational expenditures",
        "documentation": "Deferred tax assets in organizational expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sec 174 \u2013 Research and development costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "MDBH_DeferredTaxAssetsInStartupExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxAssetsInStartupExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Start-up expenditures",
        "documentation": "Deferred tax assets in startup expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other noncurrent assets/(liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment principally due to differences in depreciation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "MDBH_DeferredTaxAssetsStockCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxAssetsStockCompensation",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "Deferred tax assets stock compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative",
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Decrease in deferred tax assets valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "MDBH_DeferredTaxLiabilitiesInvestmentSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DeferredTaxLiabilitiesInvestmentSecurities",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment securities",
        "documentation": "Deferred tax liabilities investment securities.",
        "label": "DeferredTaxLiabilitiesInvestmentSecurities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/EmployeeBenefitPlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employer contribution",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositContractsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositContractsPolicy",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clearing Deposits",
        "documentation": "Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clearing deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation of property and equipment",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r144",
      "r195",
      "r213",
      "r230",
      "r692",
      "r705",
      "r706"
     ]
    },
    "MDBH_DevelopedSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DevelopedSoftwareMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed Software [Member]",
        "documentation": "Developed Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DilutionOfDeferredGrantReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DilutionOfDeferredGrantReimbursement",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilution of deferred grant reimbursement",
        "documentation": "Dilution of deferred grant reimbursement."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DisclosureDeconsolidationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DisclosureDeconsolidationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deconsolidation"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DisclosureExclusiveLicenseAgreementMdbMinnesotaOneAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Operating Lease Cost",
        "terseLabel": "Schedule Of Future Payments Due Under Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r351",
      "r379",
      "r380",
      "r382",
      "r726"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Market-Based Stock Option Activity",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on deconsolidation of subsidiary",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r261",
      "r904",
      "r934"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r797"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r797",
      "r838"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "MDBH_DueToDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "DueToDeconsolidation",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Removal of prior period balance of Exozyme due to deconsolidation",
        "documentation": "Due to deconsolidation."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ENDRAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ENDRAMember",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ENDRA [Member]",
        "documentation": "ENDRA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) per share attributable to MDB Capital Holdings, LLC:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) per Common Share \u2013 basic",
        "verboseLabel": "Net income (loss) per share \u2013 basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r139",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r177",
      "r180",
      "r188",
      "r189",
      "r190",
      "r194",
      "r299",
      "r383",
      "r421",
      "r426",
      "r449",
      "r450",
      "r510",
      "r540",
      "r697"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r188",
      "r190"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) per Common Share \u2013diluted",
        "verboseLabel": "Net income (loss) per share \u2013diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r139",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r180",
      "r188",
      "r189",
      "r190",
      "r194",
      "r299",
      "r383",
      "r421",
      "r426",
      "r449",
      "r450",
      "r510",
      "r540",
      "r697"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://mdb.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r191",
      "r192",
      "r193"
     ]
    },
    "MDBH_EffectOfDeconsolidationOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EffectOfDeconsolidationOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of deconsolidation of subsidiary",
        "documentation": "Effect of deconsolidation of subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective rate, Rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r727"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S Federal statutory income rate, Rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r155",
      "r391",
      "r411",
      "r727"
     ]
    },
    "MDBH_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance, Rate"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income/loss excluded from nontaxable entities, Rate",
        "documentation": "Income loss excluded from nontaxable entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity award vesting, Rate",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r907",
      "r914",
      "r985"
     ]
    },
    "MDBH_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity award vesting, Rate",
        "documentation": "Equity award vesting."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Meals and entertainment, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r914",
      "r985",
      "r987"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options, Rate",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r907",
      "r914",
      "r985",
      "r987"
     ]
    },
    "MDBH_EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S Federal statutory income rate, Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r907",
      "r914",
      "r985",
      "r986"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, Rate",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "MDBH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return-to-provision adjustments, Rate",
        "documentation": "Provision adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State, net of federal tax benefit, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r727",
      "r907",
      "r914",
      "r985"
     ]
    },
    "MDBH_EliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EliminationsMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eliminations [Member]",
        "documentation": "Eliminations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Emerging Growth Company Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation term life",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested portion market value",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "MDBH_Equity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "Equity",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r114",
      "r116",
      "r117",
      "r135",
      "r136",
      "r137",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r175",
      "r197",
      "r246",
      "r247",
      "r260",
      "r298",
      "r328",
      "r383",
      "r409",
      "r410",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r426",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r475",
      "r490",
      "r539",
      "r558",
      "r559",
      "r560",
      "r582",
      "r653"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r243",
      "r417",
      "r464",
      "r880",
      "r881",
      "r882",
      "r996",
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of deconsolidation of subsidiary",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r4",
      "r51",
      "r534"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "verboseLabel": "Equity interest rate",
        "terseLabel": "Equity method investment, percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r464"
     ]
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of loss from equity method investment",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r904"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method investment",
        "periodStartLabel": "Equity method investments, balance",
        "periodEndLabel": "Equity method investments, balance",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r218",
      "r230",
      "r238",
      "r892",
      "r929"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r242",
      "r245",
      "r882"
     ]
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of equity method investment",
        "documentation": "Fair value portion of investments accounted under the equity method."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r689",
      "r740",
      "r893",
      "r1001",
      "r1002",
      "r1007"
     ]
    },
    "MDBH_EquityMethodInvestmentsGainRelatedToDilutionEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EquityMethodInvestmentsGainRelatedToDilutionEvents",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain related to dilution events",
        "documentation": "Gain related to dilution events.",
        "label": "EquityMethodInvestmentsGainRelatedToDilutionEvents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity method investment",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r241",
      "r464"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investment",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "MDBH_EquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "EquityTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r801",
      "r815",
      "r842"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r798",
      "r812",
      "r839"
     ]
    },
    "MDBH_ExclusiveLicenseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ExclusiveLicenseAgreementTextBlock",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOne"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exclusive License Agreement (MDB Minnesota One)",
        "documentation": "Exclusive License Agreement [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "MDBH_ExozymeTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ExozymeTechnologiesIncMember",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exozyme Technologies Inc [Member]",
        "documentation": "Exozyme Technologies Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ExozymesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ExozymesIncMember",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exozymes Inc [Member]",
        "documentation": "Exozymes Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ExozymesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ExozymesMember",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exozymes [Member]",
        "documentation": "Exozymes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants fair value",
        "verboseLabel": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r736"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r460",
      "r735"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r461",
      "r462",
      "r502",
      "r503",
      "r504",
      "r689",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r734",
      "r736",
      "r740"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r335",
      "r340",
      "r342",
      "r452",
      "r459",
      "r462",
      "r502",
      "r689",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r734",
      "r740"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r335",
      "r340",
      "r342",
      "r344",
      "r452",
      "r453",
      "r459",
      "r462",
      "r503",
      "r689",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r734",
      "r740"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r452",
      "r453",
      "r454",
      "r455",
      "r459",
      "r462",
      "r504",
      "r689",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r734",
      "r736",
      "r740"
     ]
    },
    "MDBH_FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized (loss) gains",
        "documentation": "Fair value measurement with unobservable input reconciliation recurring basis asset gain loss included in other comprehensive income loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipt from investment banking fees",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1008"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfReconciliationOfFairValueMeasurementsWithinLevel3OfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r460",
      "r735"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r461",
      "r462",
      "r502",
      "r503",
      "r504",
      "r689",
      "r714",
      "r715",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r734",
      "r736",
      "r740"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_FeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FeeIncome",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee income (from our licensed broker dealer)",
        "verboseLabel": "Fee income from the licensed broker dealer",
        "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r565"
     ]
    },
    "MDBH_FloridaIncomeTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "FloridaIncomeTaxMember",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Florida Income Tax [Member]",
        "documentation": "Florida Income Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r846"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r846"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfEquityMethodInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method, net loss",
        "verboseLabel": "Portion of loss from Invizyne",
        "documentation": "The profit or loss on sales of previously unissued stock by equity investees made to investors outside the consolidated group that is not reported as operating income. Represents the difference in the parent company's carrying amount of the equity interest in the subsidiary or equity investee immediately before and after the transaction."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_GainRelatedToDilutionEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GainRelatedToDilutionEvents",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfCashFlows",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain related to dilution events",
        "negatedLabel": "Gain related to dilution events",
        "documentation": "Gain related to dilution events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total general and administrative costs",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r633"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative costs:"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_GrantCostsExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GrantCostsExpensed",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant costs expensed",
        "documentation": "Amount of grant costs expensed."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_GrantDrawdowns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GrantDrawdowns",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant drawdowns",
        "documentation": "Grant drawdowns."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_GrantFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GrantFees",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant fees",
        "documentation": "Amount of grant fees."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_GrantFundsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GrantFundsReceived",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant funds received",
        "documentation": "Amount of grant funds received."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_GrantsForEquipmentPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GrantsForEquipmentPurchased",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants for equipment purchased",
        "documentation": "Amount of grants for equipment purchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "label": "Grants receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "MDBH_GrantsReceivableActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "GrantsReceivableActivityTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Grants Receivable Activity",
        "documentation": "Tabular disclosure of grants receivable activity table text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r797"
     ]
    },
    "MDBH_ImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ImpairmentMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment [Member]",
        "documentation": "Impairment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ImpairmentOfInvestmentSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ImpairmentOfInvestmentSecurities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of investment securities",
        "label": "Impairment of securities",
        "negatedTerseLabel": "Impairment loss",
        "documentation": "Impairment of investment securities."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ImpairmentOfInvestmentsSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ImpairmentOfInvestmentsSecurities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of investment securities",
        "documentation": "Impairment of investments securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r86",
      "r90",
      "r511",
      "r513",
      "r535",
      "r693",
      "r695",
      "r696",
      "r700",
      "r705",
      "r922",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) before equity method investee",
        "label": "Income (loss) before equity method investee",
        "documentation": "Net income (loss) before equity method investee."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IncomeLossFromEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeLossFromEquityMethodInvestment",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity in loss of equity method investee",
        "documentation": "Equity in loss of equity method investee."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IncomeRecognizedFromWarrantsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeRecognizedFromWarrantsReceived",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income recognized from warrants received",
        "documentation": "Income recognized from warrants received.",
        "label": "IncomeRecognizedFromWarrantsReceived"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r991"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r991"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r155",
      "r387",
      "r391",
      "r396",
      "r397",
      "r398",
      "r400",
      "r404",
      "r412",
      "r414",
      "r415",
      "r416",
      "r516",
      "r564",
      "r576",
      "r727"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "MDBH_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment",
       "weight": -1.0,
       "order": 2.0
      },
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://mdb.com/role/ScheduleOfIncomeTaxesExpensesBenefitDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "verboseLabel": "Income tax expense",
        "totalLabel": "Total",
        "terseLabel": "Effective rate, Amount",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r98",
      "r151",
      "r174",
      "r175",
      "r195",
      "r216",
      "r230",
      "r390",
      "r391",
      "r413",
      "r544",
      "r693",
      "r695",
      "r696",
      "r727"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r388",
      "r389",
      "r400",
      "r401",
      "r403",
      "r408",
      "r570"
     ]
    },
    "MDBH_IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IncomeTaxReconciliationEquityInEquityAwardVestingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeTaxReconciliationEquityInEquityAwardVestingAmount",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity award vesting, Amount",
        "documentation": "Income tax reconciliation equity in equity award vesting amount."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income/loss excluded from nontaxable entities, Amount",
        "documentation": "Income tax reconciliation income loss excluded from nontaxable entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S Federal statutory income rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r727"
     ]
    },
    "MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S Federal statutory income rate, Amount",
        "label": "IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences, Amount",
        "documentation": "Income tax reconciliation income tax expenses provision adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IncomeTaxReconciliationModificationOfEquityAwardsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncomeTaxReconciliationModificationOfEquityAwardsAmount",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of equity awards, Amount",
        "documentation": "Income tax reconciliation modification of equity awards amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Meals and entertainment, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r987"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return-to-provision adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r985",
      "r987"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r985",
      "r987"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r986"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State, net of federal tax benefit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r727",
      "r985"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative",
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax paid",
        "verboseLabel": "Cash taxes paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r61",
      "r905",
      "r989",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r147",
      "r405",
      "r406"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred costs related to revenue",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Clearing deposits",
        "label": "Increase (Decrease) in Deposit Assets",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Related party receivables",
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related party payables",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) decrease in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r903"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in -"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Grants receivable",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPayablesToCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPayablesToCustomers",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payables to customers",
        "label": "Increase (Decrease) in Payables to Customers",
        "documentation": "The change during the period, either increase or decrease, in amounts payable to customers. The term customers generally excludes other broker-dealers; persons who are principal officers, directors, and stockholders; and persons whose securities or funds are part of the regulatory net capital of the broker-dealer. Another broker-dealer's account can be classified as a customer if the account is carried as an omnibus account in compliance with certain regulations. The accounts of principal officers, directors and stockholders may be combined in the customer captions if they are not material and the combination is disclosed in the oath that is required to accompany the annual audited FOCUS Report."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "MDBH_IncreaseDecreaseInPayablesToNoncustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IncreaseDecreaseInPayablesToNoncustomers",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables to non-customers",
        "documentation": "Increase decrease in payables to noncustomers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r805",
      "r819",
      "r837",
      "r846",
      "r850",
      "r858"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r862"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r862"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r862"
     ]
    },
    "us-gaap_InterestAndOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncomeAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r693",
      "r696",
      "r902"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payable",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r1028"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r1073"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subtotal of quoted closing price of Class A common shares",
        "verboseLabel": "Owned shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r662",
      "r668",
      "r670",
      "r752"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Securities",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r566",
      "r567",
      "r568",
      "r569",
      "r663",
      "r664"
     ]
    },
    "MDBH_InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities, at cost less impairment",
        "documentation": "Investment securities at cost less impairment non broker dealer."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities, at cost less impairment, received in lieu of cash payment",
        "documentation": "Investment securities at cost less impairment received in lieu of cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_InvestmentSecuritiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvestmentSecuritiesAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities, at fair value",
        "documentation": "Investment securities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities, at fair value, held by the licensed broker dealer (Notes 1 and 2)",
        "documentation": "Investment securities, at fair value, held by the licensed broker dealer."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities, at fair value, held by the non-licensed broker dealer (Notes 1 and 2)",
        "verboseLabel": "Investment securities, at fair value, held by the non-licensed broker dealer",
        "documentation": "Investment securities, at fair value, held by the non-licensed broker dealer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518",
      "r746",
      "r747",
      "r748",
      "r749"
     ]
    },
    "MDBH_InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities, at fair value, held by the non-licensed broker dealer (1)",
        "documentation": "Investments securities, at fair value, held by the non-licensed broker dealer."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_InvizyneTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "InvizyneTechnologiesIncMember",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invizyne Technologies Inc [Member]",
        "documentation": "Invizyne Technologies Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants to purchase Class A stock related to the initial public offering closed on September 20, 2023",
        "documentation": "Issuance of warrants to purchase Class A stock related to the initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Compensation",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r695",
      "r899"
     ]
    },
    "MDBH_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://mdb.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r488"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_LessCarryingValueOfFormerInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "LessCarryingValueOfFormerInvestment",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less carrying value of former investment",
        "documentation": "Less carrying value of former investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://mdb.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future payments Due Under Operating Lease",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r908",
      "r915",
      "r1027"
     ]
    },
    "MDBH_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029 and thereafter",
        "documentation": "Lessee operating lease liability payments due after year three."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r908",
      "r915",
      "r1027"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r908",
      "r915",
      "r1027"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r908",
      "r915",
      "r1027"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less effects of discounting",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://mdb.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://mdb.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension term of lease",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://mdb.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://mdb.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r34",
      "r35",
      "r38",
      "r39",
      "r40",
      "r41",
      "r151",
      "r153",
      "r154",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r430",
      "r434",
      "r435",
      "r464",
      "r606",
      "r699",
      "r718",
      "r760",
      "r943",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r85",
      "r529",
      "r743",
      "r746",
      "r747",
      "r907",
      "r912",
      "r930",
      "r1010"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r121",
      "r151",
      "r153",
      "r154",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r430",
      "r434",
      "r435",
      "r464",
      "r743",
      "r943",
      "r1018",
      "r1019"
     ]
    },
    "MDBH_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding indebtedness",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r1029"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit non-usage fee",
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r37",
      "r272"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r37"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving credit, maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r37"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r1029"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-lived Assets and Total Assets by Segment",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "MDBH_MDBMinnesotaOneIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "MDBMinnesotaOneIncMember",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MDB Minnesota One Inc [Member]",
        "documentation": "MDB Minnesota One Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_MarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "MarketBasedMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Based [Member]",
        "documentation": "Market Based [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r810"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r811"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r811"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r811"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r811"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r203",
      "r268",
      "r269",
      "r270",
      "r271",
      "r346",
      "r375",
      "r376",
      "r377",
      "r384",
      "r455",
      "r507",
      "r556",
      "r557",
      "r563",
      "r598",
      "r599",
      "r661",
      "r665",
      "r666",
      "r667",
      "r669",
      "r678",
      "r679",
      "r680",
      "r681",
      "r685",
      "r686",
      "r710",
      "r719",
      "r725",
      "r728",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738",
      "r739",
      "r744",
      "r947",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "MDBH_MayoFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "MayoFoundationMember",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mayo Foundation [Member]",
        "documentation": "Mayo Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r203",
      "r268",
      "r269",
      "r270",
      "r271",
      "r346",
      "r375",
      "r376",
      "r377",
      "r384",
      "r455",
      "r507",
      "r556",
      "r557",
      "r563",
      "r598",
      "r599",
      "r661",
      "r665",
      "r666",
      "r667",
      "r669",
      "r678",
      "r679",
      "r680",
      "r681",
      "r685",
      "r686",
      "r710",
      "r719",
      "r725",
      "r728",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738",
      "r744",
      "r947",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "srt_MinimumNetCapitalRequiredForEntity1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumNetCapitalRequiredForEntity1",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate indebtedness calculated amount",
        "documentation": "Minimum amount of net capital required to be maintained by broker-dealer parent, calculated under Aggregate Indebtedness Standard."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "MDBH_MinnesotaOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "MinnesotaOneMember",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minnesota One [Member]",
        "documentation": "Minnesota One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest",
        "periodStartLabel": "Prior period balance",
        "periodEndLabel": "Ending period balance",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r84",
      "r151",
      "r153",
      "r154",
      "r244",
      "r273",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r528",
      "r610",
      "r1010"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest rate",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership interest rate",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_MiscellaneousIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "MiscellaneousIncome",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous income",
        "documentation": "Miscellaneous income."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "srt_NetCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NetCapital",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net capital",
        "documentation": "Amount of net capital of broker-dealer."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to MDB Capital Holdings, LLC",
        "label": "Net Income (Loss)",
        "verboseLabel": "Non-controlling net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r62",
      "r87",
      "r117",
      "r119",
      "r132",
      "r133",
      "r137",
      "r151",
      "r153",
      "r154",
      "r158",
      "r163",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r186",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r299",
      "r302",
      "r305",
      "r310",
      "r383",
      "r421",
      "r426",
      "r450",
      "r464",
      "r538",
      "r630",
      "r651",
      "r652",
      "r693",
      "r695",
      "r696",
      "r758",
      "r943"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less net loss attributable to non-controlling interest",
        "verboseLabel": "Less net loss attributable to non-controlling interests",
        "terseLabel": "Net loss non-controlling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r75",
      "r132",
      "r133",
      "r171",
      "r174",
      "r175",
      "r537",
      "r898"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) attributable to MDB Capital Holdings, LLC",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r141",
      "r167",
      "r168",
      "r169",
      "r170",
      "r177",
      "r178",
      "r187",
      "r190",
      "r302",
      "r305",
      "r310",
      "r426"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) attributable to MDB Capital Holdings, LLC",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r179",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r190"
     ]
    },
    "MDBH_NetOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "NetOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net operating loss",
        "documentation": "Net operating loss.",
        "label": "Net operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_Netincomeloss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "Netincomeloss1",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_NewDrugApplicationFirstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "NewDrugApplicationFirstMember",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Drug Application First [Member]",
        "documentation": "New Drug Application First [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_NewDrugApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "NewDrugApplicationMember",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Drug Application [Member]",
        "documentation": "New Drug Application [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No Insider Trading Flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_NonBrokerDealerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "NonBrokerDealerMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Broker Dealer [Member]",
        "documentation": "Non Broker Dealer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership change of non-controlling interest",
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r25",
      "r74"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r328",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1071"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://mdb.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r709",
      "r923"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "MDBH_NetOperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_OperatingExpenseRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "OperatingExpenseRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense, related party",
        "documentation": "Operating expense related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "MDBH_NetOperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating income, net",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r693",
      "r696",
      "r700",
      "r922",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLossAbstract",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r742"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r489"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/ScheduleOfFuturePaymentsDueUnderOperatingLeaseDetails",
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "totalLabel": "Total operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total operating lease costs",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r483"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset, net",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in ROU Asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r742"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term in years",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r742"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r125",
      "r519",
      "r706",
      "r746",
      "r747",
      "r760"
     ]
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and licensing legal and filing fees and costs",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r543",
      "r705"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r746",
      "r747"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative-other",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r1070"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party payables",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r521",
      "r602",
      "r603",
      "r718",
      "r746",
      "r747",
      "r760",
      "r1030",
      "r1065"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expense, related party",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income and expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other operating income",
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Various prepaid expense",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r931"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party receivables",
        "verboseLabel": "Due to affiliates",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r617",
      "r706",
      "r746",
      "r747",
      "r1032"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "MDBH_OtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "OtherSegmentsMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other [Member]",
        "documentation": "Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r803",
      "r817",
      "r844"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r806",
      "r820",
      "r847"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r806",
      "r820",
      "r847"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_OwnershipChangeOfNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "OwnershipChangeOfNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ownership change of non-controlling interest",
        "documentation": "Ownership change of non-controlling interest.",
        "label": "OwnershipChangeOfNoncontrollingInterest"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Licensing Legal and Filing Fees and Costs",
        "documentation": "Patent And Licensing Legal And Filing Fees And Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r824"
     ]
    },
    "MDBH_PayablesToCustomersCurrentAndNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PayablesToCustomersCurrentAndNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables to customers",
        "documentation": "Payables to customers current and non current."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_PaymentForDeferredGrantReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PaymentForDeferredGrantReimbursement",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred grant reimbursement",
        "documentation": "Payment for deferred grant reimbursement.",
        "label": "PaymentForDeferredGrantReimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_PaymentForLicensedProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PaymentForLicensedProducts",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for licensed products",
        "documentation": "Payment for licensed products."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments for (Proceeds from) Productive Assets",
        "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of equity investments",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "MDBH_PaymentsToAcquireInvestmentsSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PaymentsToAcquireInvestmentsSecurities",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investment securities, at amortized cost (U.S. Treasury Bills)",
        "documentation": "Payments to acquire investments securities.",
        "label": "PaymentsToAcquireInvestmentsSecurities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "MDBH_PhaseIIIclinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PhaseIIIclinicalMember",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase III clinical [Member]",
        "documentation": "Phase III clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_PhaseIIclinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PhaseIIclinicalMember",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase II clinical [Member]",
        "documentation": "Phase II clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r263"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]",
        "documentation": "Disclosure of information about crypto-asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r263"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "MDBH_PortionOfLossFromEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PortionOfLossFromEquityInvestment",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion of loss from equity investment",
        "documentation": "Portion of loss from equity investment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_PreferredStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockNoParValue",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, no par value",
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r948"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r608"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r312"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r608",
      "r629",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred shares, 10,000,000 authorized shares at no par value; 0 issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r301",
      "r307",
      "r525",
      "r743"
     ]
    },
    "MDBH_PrepaidAndOtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PrepaidAndOtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and other current assets",
        "documentation": "Prepaid And Other Current Assets [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid and other expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r711",
      "r931"
     ]
    },
    "MDBH_PrepaidProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PrepaidProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid professional fees",
        "documentation": "Prepaid professional fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributionsFromParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromContributionsFromParent",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital infusions",
        "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "MDBH_ProceedsFromInvestmentsSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ProceedsFromInvestmentsSecurities",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from payments and maturities of investment securities, at amortized cost (U.S. Treasury Bills)",
        "documentation": "Proceeds from investments securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fee",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of non-controlling interest",
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued as part of an investment banking deal",
        "documentation": "Proceeds from warrants issued as part of investment banking deal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r705",
      "r758",
      "r1068",
      "r1070"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfCashFlows",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r119",
      "r132",
      "r133",
      "r145",
      "r151",
      "r153",
      "r154",
      "r158",
      "r163",
      "r171",
      "r174",
      "r175",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r299",
      "r383",
      "r421",
      "r426",
      "r428",
      "r431",
      "r432",
      "r450",
      "r464",
      "r511",
      "r513",
      "r536",
      "r581",
      "r630",
      "r651",
      "r652",
      "r731",
      "r732",
      "r759",
      "r898",
      "r943"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r488"
     ]
    },
    "MDBH_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives of Property and Equipment",
        "documentation": "Property Plant And Equipment Estimated Useful Lives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r123",
      "r533"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      },
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r488",
      "r515",
      "r533",
      "r743"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r96",
      "r97",
      "r531"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r488"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "MDBH_PublicVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "PublicVenturesMember",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Ventures [Member]",
        "documentation": "Public Ventures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r203",
      "r268",
      "r269",
      "r270",
      "r271",
      "r334",
      "r346",
      "r375",
      "r376",
      "r377",
      "r382",
      "r384",
      "r455",
      "r505",
      "r506",
      "r507",
      "r556",
      "r557",
      "r563",
      "r598",
      "r599",
      "r661",
      "r665",
      "r666",
      "r667",
      "r669",
      "r678",
      "r679",
      "r680",
      "r681",
      "r685",
      "r686",
      "r710",
      "r719",
      "r725",
      "r728",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738",
      "r739",
      "r744",
      "r752",
      "r939",
      "r947",
      "r1004",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r203",
      "r268",
      "r269",
      "r270",
      "r271",
      "r334",
      "r346",
      "r375",
      "r376",
      "r377",
      "r382",
      "r384",
      "r455",
      "r505",
      "r506",
      "r507",
      "r556",
      "r557",
      "r563",
      "r598",
      "r599",
      "r661",
      "r665",
      "r666",
      "r667",
      "r669",
      "r678",
      "r679",
      "r680",
      "r681",
      "r685",
      "r686",
      "r710",
      "r719",
      "r725",
      "r728",
      "r729",
      "r730",
      "r736",
      "r737",
      "r738",
      "r739",
      "r744",
      "r752",
      "r939",
      "r947",
      "r1004",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_RatioOfIndebtednessToNetCapital1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RatioOfIndebtednessToNetCapital1",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of aggregate indebtedness",
        "documentation": "Indebtedness divided by net capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized gain on investment securities, net from the licensed broker dealer",
        "negatedLabel": "Realized loss (gain) on investment securities, net from the licensed broker dealer",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "MDBH_RealizedInvestmentGainsLossesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "RealizedInvestmentGainsLossesOne",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Realized gain on investment securities, net from the licensed broker dealer",
        "documentation": "Realized investment gains losses one.",
        "label": "RealizedInvestmentGainsLossesOne"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r787",
      "r798",
      "r812",
      "r839"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r157",
      "r158",
      "r237",
      "r341",
      "r345",
      "r494",
      "r495",
      "r522",
      "r530",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r628",
      "r660",
      "r1067"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r157",
      "r158",
      "r237",
      "r494",
      "r495",
      "r496",
      "r634",
      "r635",
      "r638"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r157",
      "r158",
      "r237",
      "r341",
      "r345",
      "r494",
      "r495",
      "r522",
      "r530",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r628",
      "r660",
      "r1017",
      "r1067"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r495",
      "r497",
      "r577",
      "r578",
      "r579",
      "r636",
      "r637",
      "r638",
      "r657",
      "r659"
     ]
    },
    "MDBH_RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relinquishment of deferred costs of initial public offering from prior year",
        "documentation": "Relienquishment of deferred costs of initial public offering from prior year."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_RemovalOfBalanceDueToDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "RemovalOfBalanceDueToDeconsolidation",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/SummaryOfGrantsReceivableActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Removal of balance due to deconsolidation of eXoZymes at November 14, 2024",
        "documentation": "Removal of balance due to deconsolidation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs, net of grants $0 and $2,003 in 2024 and 2024",
        "verboseLabel": "Research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r687",
      "r693",
      "r694",
      "r705",
      "r1026"
     ]
    },
    "MDBH_ResearchAndDevelopmentExpenseGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseGross",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of grant received",
        "documentation": "Research and development expense gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "MDBH_ResearchAndDevelopmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ResearchAndDevelopmentGrants",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development, Grants",
        "documentation": "Research and development grants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r799",
      "r813",
      "r840"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r800",
      "r814",
      "r841"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r807",
      "r821",
      "r848"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated income (deficit)",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r70",
      "r527",
      "r561",
      "r562",
      "r575",
      "r609",
      "r743"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r117",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r175",
      "r246",
      "r247",
      "r260",
      "r298",
      "r383",
      "r409",
      "r410",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r426",
      "r437",
      "r439",
      "r440",
      "r442",
      "r448",
      "r472",
      "r475",
      "r558",
      "r560",
      "r582",
      "r1071"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r138",
      "r151",
      "r153",
      "r154",
      "r195",
      "r209",
      "r210",
      "r224",
      "r230",
      "r233",
      "r235",
      "r236",
      "r244",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r464",
      "r511",
      "r513",
      "r705",
      "r733",
      "r746",
      "r747",
      "r943"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r742"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "MDBH_SAFEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SAFEMember",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SAFE [Member]",
        "documentation": "SAFE [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, number of shares issued in transaction",
        "verboseLabel": "Placement agent and selling agent warrants",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Taxes Expenses (benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://mdb.com/role/DeconsolidationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Consolidated Balance Sheet",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r908",
      "r915",
      "r1027"
     ]
    },
    "MDBH_ScheduleOfConsolidatedBalanceSheetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleOfConsolidatedBalanceSheetAbstract",
     "auth_ref": []
    },
    "MDBH_ScheduleOfConsolidatedBalanceSheetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleOfConsolidatedBalanceSheetTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfConsolidatedBalanceSheetTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Fully Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r188",
      "r190"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r727",
      "r985"
     ]
    },
    "MDBH_ScheduleOfEquityAndNonControllingInterestsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleOfEquityAndNonControllingInterestsTableTextBlock",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity and Non-Controlling Interests",
        "documentation": "Schedule Of Equity And Non Controlling Interests [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r243",
      "r417",
      "r464",
      "r880",
      "r881",
      "r882",
      "r996",
      "r997",
      "r998",
      "r999"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r154",
      "r240",
      "r241",
      "r243",
      "r244",
      "r464"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://mdb.com/role/EquityMethodInvestmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r151",
      "r154",
      "r240",
      "r241",
      "r243",
      "r244",
      "r464"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002"
     ]
    },
    "MDBH_ScheduleOfGainOnDeconsolidationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleOfGainOnDeconsolidationAbstract",
     "auth_ref": []
    },
    "MDBH_ScheduleOfGainOnDeconsolidationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleOfGainOnDeconsolidationTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfGainOnDeconsolidationTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ScheduleOfGainOnDeconsolidationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleOfGainOnDeconsolidationTableTextBlock",
     "presentation": [
      "http://mdb.com/role/DeconsolidationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Gain on Deconsolidation",
        "documentation": "Schedule Of Gain On Deconsolidation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r488"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r157",
      "r158",
      "r494",
      "r495",
      "r496",
      "r634",
      "r635",
      "r638"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://mdb.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Statement of Operation by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Unit Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r68",
      "r69",
      "r70",
      "r127",
      "r128",
      "r129",
      "r198",
      "r312",
      "r313",
      "r314",
      "r316",
      "r319",
      "r324",
      "r326",
      "r436",
      "r571",
      "r572",
      "r573",
      "r574",
      "r719",
      "r879",
      "r907",
      "r909"
     ]
    },
    "MDBH_ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investment Securities Broker Dealer",
        "documentation": "Schedule of Investment Securities Broker Dealer [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investment Securities Non-Broker Dealer",
        "documentation": "Schedule of Investment Securities Non Broker Dealer [TableText Block]."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r195",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r264",
      "r265",
      "r423",
      "r424",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r702",
      "r705",
      "r706",
      "r712",
      "r745",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r195",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r220",
      "r222",
      "r223",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r701",
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_SegregatedCashAndDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SegregatedCashAndDepositsPolicyTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segregated Cash and Deposits",
        "documentation": "Segregated Cash And Deposits Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Restricted Stock Units, Exchanged/Modified",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exchanged and modified in period"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Exchanged/Modified",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exchanged and modified weighted average grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Restricted Stock Units, outstanding",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Restricted Stock Units, outstanding",
        "label": "Number of restricted stock units, canceled or forfeited",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled in period."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Grant Date Fair Value, outstanding",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expired and cancelled weighted average grant date fair value.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled shares",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Restricted Stock Units, outstanding",
        "verboseLabel": "Stock options to purchase",
        "terseLabel": "Restricted stock units, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, outstanding",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Exercisable and vested",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in vested and expected to vest exercisable weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Restricted Stock Units, outstanding",
        "periodEndLabel": "Number of Restricted Stock Units, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364"
     ]
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable and vested restricted stock, outstanding",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested vested and expected to vest exercisable number.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, outstanding",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Restricted Stock Units, outstanding",
        "label": "RSU vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Grant Date Fair Value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual rate of dividends",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected annual volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected annual volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units, description",
        "documentation": "Description of reason for increase (decrease), classified as other, in number of awards under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "MDBH_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, exchanged/modified",
        "documentation": "Share based compensation arrangement by share based payment award options exchanged and modified in period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, stock options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, stock options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, expired/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, time-based stock options outstanding, beginning",
        "periodEndLabel": "Number of Options, time-based stock options outstanding, at the end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, time-based stock options outstanding",
        "periodEndLabel": "Weighted average exercise price, time-based stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationTables",
      "http://mdb.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "MDBH_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exchanged/modified",
        "documentation": "Share based compensation arrangements by share based payment award options exchanged and modified in period weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, expired/cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price per share, granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "MDBH_ShareBasedCompensationToNonControllingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "ShareBasedCompensationToNonControllingInterest",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "documentation": "Share based compensation to non controlling interest.",
        "label": "ShareBasedCompensationToNonControllingInterest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quoted closing price of Class A common shares",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased payment award amortized amount",
        "documentation": "Sharebased compensation arrangement by sharebased payment award amortized amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), time-based stock options exchanged/modified",
        "documentation": "Share based compensation arrangement by sharebased payment award options exchanged weighted average remaining contractual term 2."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), stock options exercisable",
        "verboseLabel": "Exercisable period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting": {
     "xbrltype": "durationItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable period",
        "documentation": "Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term 1 vesting"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), exchanged/modified",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding exchanged and modified weighted average remaining contractual term 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years), time-based stock options outstanding",
        "verboseLabel": "Weighted average remaining contractual life (in years), market-based stock options outstanding",
        "terseLabel": "Remaining weighted average years",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "MDBH_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting": {
     "xbrltype": "durationItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock options vesting period",
        "documentation": "Share based compensation arrangement by share based payment award options remaining stock options vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock price",
        "verboseLabel": "Common stock price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r742"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150"
     ]
    },
    "MDBH_SimpleAgreementOnFutureEquitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "SimpleAgreementOnFutureEquitiesMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple Agreement on Future Equities [Member]",
        "documentation": "Simple Agreement on Future Equities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r118",
      "r195",
      "r205",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r236",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r262",
      "r264",
      "r265",
      "r423",
      "r424",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r702",
      "r705",
      "r706",
      "r712",
      "r745",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/Cover",
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r127",
      "r128",
      "r129",
      "r151",
      "r154",
      "r180",
      "r181",
      "r188",
      "r190",
      "r198",
      "r199",
      "r244",
      "r273",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r300",
      "r301",
      "r303",
      "r304",
      "r306",
      "r309",
      "r312",
      "r313",
      "r316",
      "r319",
      "r326",
      "r464",
      "r571",
      "r572",
      "r573",
      "r574",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r608",
      "r631",
      "r653",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r879",
      "r909",
      "r911",
      "r920"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r46",
      "r47",
      "r114",
      "r116",
      "r117",
      "r135",
      "r136",
      "r137",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r175",
      "r197",
      "r246",
      "r247",
      "r260",
      "r298",
      "r328",
      "r383",
      "r409",
      "r410",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r426",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r475",
      "r490",
      "r539",
      "r558",
      "r559",
      "r560",
      "r582",
      "r653"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/Cover",
      "http://mdb.com/role/DeconsolidationDetailsNarrative",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/ScheduleOfGainOnDeconsolidationDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r197",
      "r300",
      "r301",
      "r303",
      "r306",
      "r475",
      "r508",
      "r566",
      "r583",
      "r595",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r632",
      "r633",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r695",
      "r696",
      "r753",
      "r1067"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://mdb.com/role/Cover",
      "http://mdb.com/role/StatementsOfChangesInEquity",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r197",
      "r237",
      "r300",
      "r301",
      "r303",
      "r306",
      "r475",
      "r508",
      "r566",
      "r583",
      "r595",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r608",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r632",
      "r633",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r695",
      "r696",
      "r753",
      "r1067"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r802",
      "r816",
      "r843"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock units, cancelled and converted",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r21",
      "r43",
      "r46",
      "r70",
      "r292"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative",
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Class A Common Shares, shares",
        "verboseLabel": "Issuance of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r43",
      "r70",
      "r571",
      "r653",
      "r672"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://mdb.com/role/ScheduleOfMarket-basedStockOptionActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r43",
      "r70",
      "r360"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value issued for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Class A Common Shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r43",
      "r70",
      "r582",
      "r653",
      "r672",
      "r759"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock unit, value",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r43",
      "r70"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share, granted",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total MDB Capital Holdings, LLC equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r64",
      "r610",
      "r629",
      "r654",
      "r655",
      "r743",
      "r760",
      "r907",
      "r911",
      "r912",
      "r930",
      "r1010",
      "r1071"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ConsolidatedBalanceSheets",
      "http://mdb.com/role/ScheduleOfConsolidatedBalanceSheetDetails",
      "http://mdb.com/role/StatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r30",
      "r114",
      "r115",
      "r116",
      "r117",
      "r136",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r173",
      "r246",
      "r247",
      "r260",
      "r298",
      "r328",
      "r383",
      "r409",
      "r410",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r426",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r448",
      "r465",
      "r466",
      "r470",
      "r473",
      "r490",
      "r559",
      "r560",
      "r580",
      "r610",
      "r629",
      "r654",
      "r655",
      "r676",
      "r746",
      "r747",
      "r759",
      "r907",
      "r911",
      "r912",
      "r930",
      "r1010",
      "r1071"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterests"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and Non-Controlling Interests",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r311",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r436",
      "r447",
      "r656",
      "r658",
      "r677"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://mdb.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r500"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://mdb.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r501"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "MDBH_TechnologyDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "TechnologyDevelopmentMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfLong-livedAssetsAndTotalAssetsBySegmentDetails",
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Development [Member]",
        "documentation": "Technology Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_TimeBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "TimeBasedMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://mdb.com/role/ScheduleOfTime-basedStockOptionActivityDetails",
      "http://mdb.com/role/Stock-basedCompensationDetailsNarrative",
      "http://mdb.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Based [Member]",
        "documentation": "Time Based [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1016"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://mdb.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://mdb.com/role/ExclusiveLicenseAgreementMdbMinnesotaOneDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "MDBH_USFederalTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "USFederalTaxMember",
     "presentation": [
      "http://mdb.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S Federal Tax [Member]",
        "documentation": "U.S Federal Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfCashFlows",
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized loss on investment securities, net",
        "label": "Net unrealized gain (loss) on investment securities",
        "verboseLabel": "Unrealized (loss) on investment securities, net from the licensed broker dealer",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "MDBH_UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer",
     "crdr": "credit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on investment securities, net from non-licensed broker dealer (Notes 1 and 2)",
        "documentation": "Unrealized gain on investment securities, net from non-licensed broker dealer."
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2",
     "crdr": "debit",
     "calculation": {
      "http://mdb.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mdb.com/role/ScheduleOfStatementOfOperationBySegmentDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized (loss) on investment securities, net from the licensed broker dealer (Notes 1 and 2)",
        "negatedTerseLabel": "Unrealized (loss) on investment securities, net from the licensed broker dealer",
        "documentation": "Unrealized loss on investment securities, net from non-licensed broker dealer.",
        "label": "UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://mdb.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r200",
      "r201",
      "r202",
      "r203",
      "r511",
      "r513",
      "r698"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://mdb.com/role/EarningsPerShareDetailsNarrative",
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mdb.com/role/ScheduleOfFairValueOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, Fair value",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://mdb.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract life",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "MDBH_WarrantsOfNonPubliclyTradedCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "WarrantsOfNonPubliclyTradedCompaniesMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants of Non Publicly Traded Companies [Member]",
        "documentation": "Warrants of Non Publicly Traded Companies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_WarrantsOfPubliclyTradedCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "WarrantsOfPubliclyTradedCompaniesMember",
     "presentation": [
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesBrokerDealerDetails",
      "http://mdb.com/role/ScheduleOfInvestmentSecuritiesNon-brokerDealerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants of Publicly Traded Companies [Member]",
        "documentation": "Warrants of Publicly Traded Companies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MDBH_WarrantsReceivedAsPartOfInvestmentBankingDeal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "WarrantsReceivedAsPartOfInvestmentBankingDeal",
     "crdr": "credit",
     "presentation": [
      "http://mdb.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants received as part of an investment banking deal",
        "documentation": "Warrants received as part of investment banking deal."
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://mdb.com/role/EquityAndNon-controllingInterestsDetailsNarrative",
      "http://mdb.com/role/ScheduleOfSignificantUnobservableInputsRelatedToMaterialComponentsOfLevel3WarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r455",
      "r506",
      "r685",
      "r686",
      "r736",
      "r1020",
      "r1022",
      "r1025"
     ]
    },
    "MDBH_WeightedAverageNonControllingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mdb.com/20251231",
     "localname": "WeightedAverageNonControllingPercentage",
     "presentation": [
      "http://mdb.com/role/ScheduleOfEquityAndNon-controllingInterestsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average non-controlling percentage",
        "documentation": "Weighted average non-controlling percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted number of Common Shares outstanding",
        "verboseLabel": "Diluted shares outstanding \u2013diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r190"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://mdb.com/role/ScheduleOfBasicAndFullyDilutedDetails",
      "http://mdb.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average of number Common Shares outstanding \u2013 basic",
        "verboseLabel": "Weighted average shares outstanding \u2013 basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r190"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://mdb.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "FF",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Rule 15c3-1",
   "Number": "240",
   "Section": "15c3-1",
   "Publisher": "SEC"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/944-825/tableOfContent"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001493152-26-013924-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-013924-xbrl.zip
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MS[@[4:_KV[#E]=CR%NT[4$L#!!0    ( #I;?US-+XP-EP,  &$5   *
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M.'P86!R^ @M1K<0R1=PIAXLX!Z[!*$NLM[@O4U0=,BZA2*9ADE.Y(9=+00T
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M]!I#)$H+>)2 N6A1Q $Z-PTX"+!8P,:,%ZL^A"6VJZTQ$%D:"1($1T&!\(Z
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M@9Y^'=36;YORUT_Y6ZH_ %!+ P04    "  [6W]<0W:;DO,$   >$@  "@
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M 'DAM)2$:Z*6;56W*;!Y&"CE5X'::C@*V@*S]1[(%RE((03OKVUA8"]-"5P
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ME?-@AQE/+"C075_;X#%,30+7"I&VJ&21J/L#>C/"!"L,,M?$6&ED@[3JF3*
M466;9Q1;7IF2=& RLT@_<6&0\>CGP[>'+MZ!EG2#CP;;H4 *_%"UN>Y'5(3Q
MO'UQQNELO=<I(:NN+5W!([P;3@A C@GSBHF$028BA%_A[3HSLM>5./?M'B68
MS>1)%GA;<08?Q2E\-("7/G/2FQEL/#@+ CB&1>H$!06SQR..B+6UZ#EAG*M
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M=3BQ'XKVKNX &$F##M SL8PENLX;=F:C_U7;3;'.AZ[^A+R>@;ZG*<4PSY/
M#\]O)Z!%ZNR:N=%\LT2GP]0&'-X#'.&%=X'S-M+ 8%S%;+XW\;9-LUUA^Q_,
M81>D2-?SLFJ(FR1P:*0J8R@/8,[PPTQ>.)8@(,-Z/85<8.5MWKA<(R"N*=7
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M8C SVI#I]I@=M>3DPC.@Y"4[V"4JFZBP29)DW&ZDMQ1:LI6VM8Z4JD5(.E#
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ML,0)JW [2?KNO"]FZ$22E&K.6;?CF^ ^%"HTZ]/"AG?F!)+5<;+N5[8(U]2
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M>/[Z_!_/\(\?KWYZ"7_\/U!+ P04    "  [6W]<>(A(/>J& P#[CR  #
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M-\G"+ZX/<DW\P^U?F'"OW#S9".(:U8FY)*+2.UI2[YC-P\A/5.R)WZB-)%O
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MB9FP%8ZOOZ1<@],AF"=0M%%L]BG!0OX]U<;N^9=87*@X@2PX\_R8?VJWUPM
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M$=[5V?,3,3*;W)NYR0EX-@[O_IRQR:G]U?/V=^T%(7/^5PQG>ZL^A^W;O3.
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MU*((Q-@U@:D@J!Z5:2./=Y>B;1Y%@7!Y,,/G\EO]-][J_+G]UV_/KQ^=:[I
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M3*\%Q#% 11_Z'"MPE&8=.?!?%L&F857$9E]A&#R)/X/W#6#SH*R#3FYV?6\
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M[%B9PP1@V(0_("50'^N(RT-D2<*!(A)0ZOO<&6;SZ?'09&,8N@^E0RN)$%^
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MJ+ C*S?P^Y3(H,=GD,!44"TF :8S<:7*PC#%#HQD&\U2#$;E&\TD0["W"K-
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MQI*6G"ZN44Y#;!#"?:G T97>\TR]$65F,^'&#^C>?X^E>G>%/PCB 6X4#0M
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M-'K"K4=91;8B;LA59!T".WS"&J$(+%ZPP4LOIB)OM^60C& R0K<K.D6-]E5
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M5ZBAT5_*.G#4I.KN>WE54!S O9Q&,"%?.V/IW,5]V?H@G+\+&@M&687B"+(
ME11CR0E!8-$E;I+%-[DDZR*;@)'RO^\"NW_=PA=M4E)^^G9<,+TGS7H9R4!8
M@403H72F?5DV/()U1FIH@&W6S@^O*>99W\4_#Q6.F?XI=VHBVOAWYXD&P#4J
M9#HXU?0D4#LJVRA/!W,B6:AHL!H;-_6BM\1=S+G4>T]04]\(4![)D&HGWXW
M.& >+WLW$,45N:]QB+G\V4I*/J,"OHF56SK=EJQV,E,/Z,:ZBQZC)=5ZN 20
MAO5_T8QU-VAB1>,17U-&MV.\]I*EH\P;6(9N[6H'P*74#E>'O"GOW4 )^X^X
M/V/%6[)(KN@X\)<1R:$N\?#=<(5?HBWL41J67W5"GP&[!S)YPOSR+RC BRWY
M3<^=7V_1E:#\=JJ740JV17XQN%>OK21M;*SBEMV6Z$!991IUK[LD\^O6I/]M
MD=\:J8^0U&O4NZZ'?K^S7 -1E1*G>CX<M:NL, >C$\P #6<T1F0NI![[O9%#
M%ID*[$A)!G@:O FYG8V6S#FP,ST>1/-+9QI_C>;'G[L ZS^]1B?02[6?XC_\
M5YG]JS;_M[+= XA%,HG)497-]5QQ]1^U6?U21O&_AC'\I;EJO#>QT-3\HZL)
MSE]XCJF)S&HK-I9)W;_UM1\D'JM>\.V2_T0^N3'XN:]K$P2_47]2<-X"=I0.
M]X"&'.""E>N[>B 8P:/BC1$QX!1XED6<;A'+M3MCMH2[VV4/QP,5MS>:N8*^
MJ2O#)&E<YR*<B%I2?>>.S6J$Z5!/<5VZ0;A3.!3#\+M!P?33LJ!_?J&+D!GT
MO4 *00)PD-NQE7O75#^!XCM _9FLSDIM*!15U&U50@ &YVAX@?+UD_.D87-O
M8UUM\ /A\8'C+%S5(JD:WK;S2.-J(EU/5H6=6WV'1#(OI9T!$3"6KO/?W05O
M5=?.7W+*ZJR/<]64-3QYJ5\'UF;0)T".K-*.AAS"K\#']E1;['+IB&6GA:!D
MAD&I'M9$P*PBI(=5"]Y4!^5L)Q*EMQHYJ,C7H5$A/)<B;G'%E-Q#&0'KQ+-'
M<&!2M4>_Q#T+%GC]N+BW1H"Q;O;$IR"<JF[<290DY>7!&#5>:!] (1EN36BC
M**1"&]YV9F_;K<I[$Q'<=NBVWB)T =29L8EO1RGC76/[]X_R]H!2;3L % O_
M!U5. PR%+UW>JGXJ]*;R*#)9$UZH#\40SAW#66*+_[PE_T9(#_FZ@<8:Y(4Q
M7A>JQ@XX"9+--E5 ;CFK!%Z0X8_+.SC+"?WA=Y_\X=/LE6TTMXM"2Y><+$39
M/?\TO\+['=3"&O%1".X)11: S'U5*V+=*U:4^8VS@*W< /F'8>7.HK)NC:1#
MH&VP2IG1_WA;OD USGI"LH2^"**6T6N/#WE;2.D9&#D!T6DF:TT/;6?)N[ZM
M#L)/WY>;,3W.!6T.8+:DN[IVDYQ&H7-$SU/<#=$^7":3D5GM45.7[)AW 9:5
M=]83DI7WC7GDP<,)*#!;=)]7SEM0T"K7GD$;C/L\=R')>G"A /PHA1^*S(UZ
M=;M.>5B4H,O(T ^"O<\&@".+N"'6&G7$*TGVPI8XW>LJ+%)S[10X9R/P=Z6H
M;[\ ZL][0O]:1WF#3+H$EV;.,Y_0-W? @=V[BQ\RZ;4O;[HB"G1\HX%1EQLQ
M_-]-*WL^TKXOA^,-K@HL1"PG*830G*,IPHC%ZEV9@:';C&RI"/Q3'?GYH@M+
M3*^AHTBW1#0 ^",G'T\\NZ706M6:'I2$XL!2"PAO;WWLX8R-LQ+H3C!.1+1@
M"G17P]*YKO4X  91/B+7;(9C7I!OX?%U<#UF+W@O-8)U=0PXCO(6F"<>%^H!
MQO08/3GG&TO3UVUYQW*'^T.C>0C&V>Z[?(QA1-9IF39S:<LMN".9I(B&D/)C
MA71(3(&<!9]*)TJ'>J@:]6HT1$L2"7@=XFG-K5&R15I"('[*=II.] ;V8RU:
M'GPMT?A?2?2N/'YE_EGWDX\8%;@M'N*$BM\GU-B+/)V)5&7<XS.$Y+'D<C15
MX7B5:V!UQJ1B$TK.*<_;([)GC\Y OS\8\<4"1OR08,07"QAQ 2,NJ+[S&_PC
M,O8_5AGY-H\:DR-?(\)LX."OXP(=*P.H.GDZCUFW1Z0+:V/(MAI@7PI=<2#O
M9/>(5U=*:*!$7C;<F43)515U*K]E!-U^A/QM("7V@"O ]$CU90A A 2+O_)P
M)I1F ;XQ\N!'E@?X9TS%SLTS76RG'47^;78F]?8F'_H5;M9OGS^[>/-_GSU[
M<?FWW<UO\K(9_]=O?C-Q)G[WR;/=3[_YEX?ZXOX+KXYSV*21'6)B0P/JI!!/
M&JT!07^AN>IZ-&)"Q6Y$WT:7HB%C\'4>@BZ@!E?,Y*OU8)05!&MDAC,&(-DH
MU"U1@K9 4EQ;<4;P')('KZL38!:D5VSPTM_NICL@G4\XA_2)9@E8V_=C(E=V
MJ$+/8M11'Y0&7611%7Z:TT?1[QO.4I$+[*C$Y*0 YOP%12-E?D+AUX473!8A
M=;:G&XFD0%LA@KEUOR=1NUY4FO(-8A1>7;Z[13)02_*43Z]^<HNF+;5S-/.J
MF9) 5 2-H+45Q3ZP!018*N7T* .82+P=I?I \M$]^XTI/L1+J+34$1^-A^T4
MF30E&,A?L1J=RF5_]S_+[>[3S_6I,-'#-*=;66^J:B<D>NS2!4"RKT:/\'%;
MJ:^'=:T0'/<VM?NALWH?NV]GUT]QI)82/U)F5G4N(G=BTW%C2?&^<K.;GB"O
MV^K$:LTB'Y9.+K#$QM\2)]^N]^N;2E\1[^L+0F"R(/&[8:7C?H^.OB/_=#G)
M+:K3FGE*!MQW()Y;&HOC52'O^L03\UKGP[Z_JYQC7*HPYLEYVS:"'VNSE98(
M5?2-ICZ_'4]>=/&#SWA"<_12,V!!K_I;DAFSQ#( YPRX*MG)K[4,9G'?=FP(
MQ"QIA)+S9W[S7^:?':@.DXA0Q.B\]UR$A=4%2C%FSIBH.3N"86;^E_%VAPDI
M./1;8=5)C$NA)#)Q1<!ZEDHFQH5)2D3 P957)E=/'HAGB<K,@!SC>'B.X8M*
MRA,)YRC/BS57Q(<2*3X%JV?'IV70>$8*QFC-B@B>JURU'C*<U"3!LN*%(CE1
M4+>"S[3?"X=DN5[G>I2G9Z/,%",)3#M!/?D1;;!'9S%>127'%'TJM9U EUVD
MM+38^0!V3ZIPD^3,B3UL[DI,J"L$5;+) F6WZ N2-,F9L;S1;CH/4.)V!T*2
M?$E5 !C;B1KCVZ=H:EQ_/!*@\0QP QY*8$HR2J>DE=*:FMSE"W&9K/((,++M
M7]GY;=7DPL*'J;15S2%6[0T)NHS\ P@K 5VAYF<FNR4^*N+Q4P!VW7L_@F..
MJ[_"9^59VB/WXS+_2O79 X;;$(;^(576?#9DZO*( * H+>JHI;&6NO#N)07E
MK[ZZ*=F.I>ZEY/P$/<9( 0O(/IH@U9,O"_67EW;/CM. QW7FF@X8&7^!.\=Y
M@E+PAB$36^@(\2F$-7.?PI3TM7!LX6Q35</NOAU4T3#KR+I9"3\K&?HLA OH
M2UM^'M 0% L# %..PA!ZP(Z&[XFE-?0<5R*6TT[NNAC7,Y[0^Y=1/UK*J!^R
MC/K14D9=RJCGD*5=RJB/N8P:G)!JZ@BSGNEVMA$DWS"L1HNF<P$V]2B.ZPP"
MTE=>"7Z><[0UO[QQ(UWM^YZ^M''9"9P_2CF&AKF8F737.]^CK]'TYT?H>PK4
M'4OO%Y0;I/U1LZ/*K,'$4XQ+C*DPYI,2])[7+IA',"#NL!<'ZN@2J;1D,:55
ME6Z[>6@GN.ZJ@Z>SCK#BH:?1,HQOK5['CO$)H-X4X@AG$\P@F4^WH+0L;VOM
MM0.<FPMV5,PWX.CH 4YQ=T*Y,@G+Z_> WQ5NZ*/4^"EI>CA^6(=0F#<DYX6*
M'H58"4]1>>^WY4_:E'N\4J)%\8BV]^-S3E42*2S8KUP0USRRFOFC>VWNF-D/
MB0$UX/FL!;067[5TUL#+;6KP85\!2&'S;C2P/RE 7$F2LBZTI[[##"*]U+6^
M7L%[8'Q]=:N5PYNFNX:Q36'VD0 1A0^L>3$H]3W_^/>9*9G'Q11?B7S^_'<Y
MV:=ZVNK)H$1[+P#Y0TZ("GA=HX>ER$E'_4@2]0M[FSLRM^Y4R.Y*5)B"UA%F
M8>4LH_]'Z,Z_6_M<PA:EK?4\(JD[7)5;:>G#F3H.$Z;QR6101-M"G8@H\=O]
M%A5?@UA5[&12#O)AO(AS%GI; ?C[47LTE3^$4\VL62]"NZMB[+Q S(U/:T[9
M&Y]6<%'Z[B=+@'ST3 _[^/ ;>7)A)8UNAT@#@E=E=-&.2CL&,>WE]#GC"4U:
M7@+71! ZD)6G2B'6$ZC%S-BW5.9DP_.EF^N>^ZY]8[O,[835F^;@=SNW6^SR
M& 4Z3:K=SO,M=#-V,F5<2'U_W-X]<P -AI2T*NFOB=F9Z4D[YWE S0BIZFKP
M'C&N8!O2<W;OFPAT@$)=QV2]M S=></FGX<*1P&QZ?UQ2!,D]!$B,:,( C%:
M0YBRX2U/)?^7K7?&$W*.7W(QWLUM@4[LYA\EC&C<\DBV*8L;?RWO\R_K?NL?
MQ^(LGO.$OFG=1[M1U!Q>/"O<_[UX(>7>UWMG6;;@#=U;9=C]D<H=[A]7??UW
M%Y[F+M9T3IKS*E)_<P=B/S!+-FX],(S.KQIJ&-/B?&9&[K4Y/^2]O_KL]65^
MU>)_"9")2DU@_CM8R5 !52U$Y\K[@U +E",-5P:8E;-6W=9%P=1-QI"ZX["U
MW(^WG476)0<*4E&ZJAY31&E?!=>4WN."TDE#A3^:2,_7M*FHA.<"Z4P\NW*S
ML6-)>5J;@"Z2G\UPGIY(,0A_SB"[+]]4:]3H,6X4Z^0CL^ P_?S:R+EF^/=-
MU;*H3^2:NM(QX.@T/57@:,#1(\(%'0YA/,;)+.XKWU681/XAYL]0GA4%._P^
M'(X 3%C=E_"*4,3*2YQ9>8K9(XQAZT8Q'M%72;*)#]HT(2;CO#XDR"_W?)IZ
M6^OS5Z;6N7 I83:S&J>;470QU4ZZC3)S4H,6[6Q+J*GCT#29!X ,IDUT5[OA
M^EJGKV9?J--KM4Y@;9:3](PG]%FU*ETPSC=,#F"I3 ^CJ%+!,%3]MA[%0#JK
M1TG;H,KA%LU+MP+[<MT5BBBD762(:PM6#9F2 XEZRF:#,A%7IEKJ(E[O3#8C
M_8BPTB)6$L4RLC3C3CO<^H(ZAZV)7(&(ZOJ,KJRFVP?<1M@1B,VRV.CX.35P
M@A%M>L-F1T@1<<9)O.FLA$!+:5CH NMIH^[WT2E5#YPM\1IT4_CL2I47-( U
MX@S-(?O.H3=J.*B]!C];_>BT56AZPV+NL8C<('(%;C95[^;(>$&$.NT<Y6&T
M$W(!7#-!TC+"IZ*9.Z9_*S<Q-G$R'K9$F@2'WD7/.T0%[AB*K1W5KPT00U #
M[&NEI^QB4<ZE]G7])Q#!?U6WS@?J7(3U35LMS*?GL[B^>EYD-,=I)09]!.:H
M!/]#74K!:(K$Z+9SKM:>1))C?3$ ZK-*>529!JT)A=^@G:#?EJMJ+P#.=;^_
M<8:VS[0-H.\@&,A-C_9+M^VI*'U7:W6*?N5M?>T,G3*]Y4)<"M_IIKHP_W/M
M[E<.B9W/U,Q]]3S_UDN7JDQSY>QD\D@#)3] "EW_1QCYT86*-L%1H UVH,'W
M6A^&S5X8.U'QPL>11X\SLFPEESJ,W4ZR0 *]+<+W!*,(-+T7O!7OZ2:J4EF/
M@C]Z\QDNDY5S<IU[Z1[@_<4-&AQ0JFS*[=;W>8 :1+\4?Y1[J*2+CM\HYRVE
MMRJ15IM[T(5&-,Q= ^6UHV3MM?.ZJ1'=2D975;DX4^^KXO%KABCTA>PZ\K1V
M-VTWQ*F61[/Q'IDE^30_N6=>CVY=5$.F<J XW4<7[1VZ_*5;86YY2';[UKF,
M@H[WJ$ L8]WF9F=DQVJV$4!&+*.6/D"Z-0TQ,+AGP&"GY3;IRQV-3W;O'D1W
M#S5Z<.B*'(=;KJSKK]S_#F$=A^4K]D1+.:EIFMH_N=?!*X02C_LW7T9PBWYU
MF[7"9_S?/_YM?JTUGFOPNW_T;'%@SGA"W[39OP%0^YRYIH\+'"K$D)DN8ZFN
M*E?&_VZ="?Y+=Y__5?SC_.JFKZ0%X0G6NZ)NCSY5".[3<!)STWQ)&#%APHC2
MOZK6/$J_<'NK]$F0[TPCYHE>'3_U%V292S>6ACA1[%X.0[<2(:"85WG?#WMN
MHDX//3=IR090Q3L"F,1GK.R8XYF[(PDABONFWCFZQ)2E728>T,4<<3HZ0'&
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MMZIQ-E]L18 XD'@BV*C =,-\#2:0?W+AQATLIB(ABT WK  S'/]$X (JPY$
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M*AAX0$<I&K8*@0AGE7HAT97=3PHHVE5W:-2M*8ZTX\?JH8FO*G\!>UBUVL>
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M86BM?N:F;B2]ZBSDE>17OZM L 4'UQT'6_?+B_]=D*-1BPBJ0/_\XWRSQU\
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M8G1$D5:S[]Y4_064CF+MY?MRB+NND.,"_4-3L1S2KMV4W>GO8P62?J!>JKS
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M7U)<'/0[BZJ'S$KE/BL5W5WR5N[;FWI45^!1'_$/Y^3! =_2-DTE=XMI-;:
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MQT\U^^<?TC/-D'I(9__<0SH_<4@_A@ZAAQ[+@SL*>3;9TH45P]EGMP?I&Q9
MB4[JX;;L#0;$%KUM38@F5K+@@;C9?:U&##%7Y0#CRRK"NAS+J30@( S.;K8C
M@PY?:^=^=J?D_\_>MS:Y;239?L>O0#AV;]AQT;TMR1K;X]V)D.3':'=DZTJR
MO;-?'&@2;&)$ AP\FJ)__:T\F5F5!8#LEM<:=W.XL3.C[B:!0J$J*Q\GSRGF
M6,Q,FV/MZ2K?MI%*GU#\N/_.&S'17F"4(6M4-[^B<:"$[^Z]*@T6-9Q3B<0B
M(HTL/'^SHJ0MK[]D>N:.G@+ '7HVYO5#=R@8S,OK?"8T.O3D\GG4-?*M;TKT
M#T!&?<[TM-@JR:$K;""S.],@%::516Z[0CM89ZL2$*13*N;NF Q1"B3D=.LA
MSP,T!DKG?BOBL(BZ8B%JB5WKMRQO5;=CB+YI5=/>Y0V\S!D7_V_</DT;M_,[
M-KG5CL4!*WRA)*;<>M90D!^@/L@KS?8R0[W7RPY+F3*?-51J7%-+*8E-1URN
MC"*:TD#DNK#L!F=X>B*VJIO5?$NTWT1+EV_*.6D2J;,O='6K\BT5KH%M)+Q.
MT(WSV FJ:[0%F*X%X(AQ-.RKB '*V"!%<D*3>]C]VYD?N"@\W(SGT$L3Z?N]
ME=E-PH:/3+!YF3=;X?AMGI/BDCN=<\)",<_6MVZ:UV=_(:3^V=-5N2IVZ1-G
MUCZ6,.G;OSQ]HM%1\G&^JA6*3UA$#ZEBL6@_$9]X@N+6$Z[N>V1_R/2"K)(U
M+/BTJ0?+$J'H;D4IFS&F@3F9OB?K)5A*6;749-)&GV9Z:!DF<&$M&W@JTG.$
M.3FV1+]#A$[:C"Z4 ULZ9%9N.0C=;\?L<N8ASM-8I1/<;"U'EQ' NJ(P;$7M
MZSR[3.1&H%#[H%FTFW7!9>Q$AQ^Q'*FH1VA3/5CD9YI+<EE9OHAG6%"LT:K)
M<=__S*N>HI<'(#^^X,7TC#ANZZ8J\\2%UFWOPL#TI;P)NZJ>/7OI5Y4'U!I6
M*?VNO V\(2,1+L>A6(3*W)81#71Y-\ZU6ZQ)+<XQ,P2@A8@X <)7Z,)H]6%R
MA:K>IDOW'P$D3.VKLN4&.%W34'N8L[6EWG_J!P$7 EC^P+R?,$9J52CATH'+
MY\**O.D4V.%)B\4('/Q^F (:J'&V%DR6ECBS6LV9%4]#2KV!YX*V5LW3Y?-#
MNVU1%EMY9OJA#3R'9E:?=&YC5\Z:?,LAB1F6[D(P'K-&J!M(OH(K!MF(L@[*
MN(8@P],_,'J3,"LSC]S19S!+6OVCT)C2&;S+U#DHW2[[[@,QW@C,3D=,N:QK
M=WHN1,9WBITHWGDK%I?!_7Z"@H+;>XD0S''Z($KU8=8&@C.9]1OJ/4H[%).7
MR@!GVG/*J WKWV2=NOV>] R K>?.&[++0F"RK#4X*^84W.U5-[,[N?U-$[*_
MNP=W="YI= HE@TVLMOL5V^'(A+]\%4SX-B>47-N*7H)A;[T00E:?;_(H,?KD
MFN0\/+><6/B6-$<:9N&J!N?,(S$C[N9>&\(LMP#F WEB0)Z"U#38*7N<@O^=
M!F=PMN[0YBV0=/XX"?DG=Q%6'8#I9.=7.5CVG%B!=E[=L0.FFQX.=(WHYR-Q
M>S0IBA-*C8L[B?MD3J]9X@<WS?MN63<"4 R8=^;)9R4W;U+4':4[6GF$-C(\
M\JF$QT4M0";_-N01YUYQ[H:,; G9+MC X AZ:\*1SL!5L^$[]Q 1;7E_25%^
MQ]CVM@MMI-2QHKR?BP7UH@H 7R#W4;]+:$/03!5'"3[XD*G2J?LWT-EZHWU$
MV_]^)[%NC33\XH0T_)!(PR].2,,3TO!((7OW=-A'YZC^5"2B40.B#DF53&9(
MM"]7BDXC7T<#%R\=* E,.%#D:FEN0;PYZS^P!*O)S?OD7N1\+@);R=)]:A5%
MV5-1/W734"E!T_8A7";1 ^K,V"#1($P>"5(_%*U3"FL!SN5M5#'AHBCW4.AX
MS209_O\J_;&DM^P<?OKBLWI5-_F\SEB>"I."="=-9_[6:VB55<(>^7,@" *]
MI.C'$FX ]\"7X:LZ^QQ'A^2?OD-F"M5(,#LK\:%-064#+?K*"&HER+,A[LZ\
M[VGN8H5)%H%Q123B5#' 3>95DZ^IT,RQMZH:%"$M'TL@+Y B).X7YV+V;;'H
M5PD7N7S!*<3$NGSF]I[>@R7_TC3$^I:X:9?XY'_>X0>*XVED;)KZK7,YYD6^
M(N*<EYPI_I&[PMI!DN[UU\_25S[YEKX^>ZG&RN>\L;D,3M6W(D<A4TC3)&XO
M-!)C27%)ZXB46X2]&24@B8*HF2O[BXC)M?Z[5(D O0OSH\9[GZ+6EHG ?D$Y
M5BJ:P5)R4]I5(_M(QB#W%',;CT?OUE<2X/X"G ?2K)0L;5+ENXFOA5N9 #O,
M;>+FEL-L/[,6_!L$>$MB8A*CFE<5]%;$GG+Y@?O8Y QQLS1KRDOF3#49>4G=
M1N^(/T!@,_VVS^SRR7/:Z7?X@9XRR5+BX5XDOFA6+('29OYP1WWG9E0 I4VT
M2ID)-L^CX!3Q2+4E^K2@IXSR8^+OS*FX7(%^VLM*$/*J)2KDJ@L=N9[H!8,R
M_&3A -*"J=O;,%M2O/;2NK Y;F>!9&N6;WR&&?0,;9W9S+!Z9OQD_CSE H-8
M0P8-+6A#9GC<OA173(CC5GFYUGJXT"5XZ5Y69)[GK**TVB7:^FH;SHW$*%M,
M\ZPF:Z5/%:>[!>RIU!1>?'0@"P]VEE#/2"(X2?A](' 1:$MOB*M])>:2_(R,
MFW,I!5@VS '&6MSDJV& #/$*A8)13FYR-J+'M^I9AHTCY$#!%*7<<68BRZ!!
MVWJH++DW4;$_2\.9)%(UP75NIM8!^WC\SFD> C"2DGCJ:BM0H"O2H'+5JO8G
M^,HIE^RK3?;/26"](W6@?(VJ-%*+<QF.IA[9<<M"9SFOR.!:RC.;>_,GW"&P
M;H<4\^>IR!A17,,N0UVMT+5!/.2-&XZS43,#*^!3A,W(MKALRXZ0E&^+>.JY
MQ!<P"4RO)[B$J6IQ,$OZFR0L"LEHT\4X'1N^'\J@3# 7P$<IBGDMDRS*8\N
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M!$462NZ$'94</E\RJTQBB(AM=\WTF0G@,8U?R).U^<009OL3XSQYS9VU>PS
M8,PW''BFKC4^7M*]QXOX<TETS(C,N!2]!H*1D^,]3U^X"](',P;_7-:-0;;F
MLWQ>K,L9>._<V>D+?N0&KPIXI&I)T=K-_J=?'<&I1!T<W) 8S)IMK^Q3TP@^
M#E5* 0G/EG7-4$^_TJ:>2&G1I+",=.ZXJ<%:2;84:H_3*7M,7GX6LY5E]%X'
M,=6L/G-;!\ (&2/;B8!@50V#&?6@4=!$MK-K#2>)?$!FDH^E[;)F)($>4;P4
MQ$!R8M<\7#3\Y GQP$)W(*PIE=&,M+[=FE_5;OVQ)9/UXRE$PC/(; Z+L*?
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M +4A@^H<H$2Z% \]&,!Z]AJAAL 1L6D34K32326*O_?DGZ!)GI+:2;Z2+FH
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M<>]\FU-D2*<$0&P/+QY^FJ4W+ 3N*JLKP@#F1G]7]'BIH >J*W33+8#XD\X
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M>BM3GU"_4\'$OU/3:O/S:^HSV+C-OB@OF]J]WQ#UV>?W4&B:;![UQ@C-U5S
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MB?V>0&(FYPIO9A3FMQ$+78XS4!3N,*U-O2@YYE;!3?<BV1/S/ -)Q-@"JS/
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M^8N+\\__E7:0NM+YU17Y/ATF! 9:]/1V2AH^XUNV<LOUNIB7[O,KPM:6Y*K
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M]94*4P\"["RFR=%9P5<Y8"=Z/E.E?FYKWW2/@BE*ZIE;OK9[FSMYNMLEVHG
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M(HE%*JJ4C-3T7IXI5@5XO8'K*RZ?!T*M;"CWN#/;(WQ08A %@>@Q2EN],QT
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MDJ6FOX;;J)*O13/VE="BO*;.HF6](G_K!2J_[ ,]9[G+EWTS6^;"6\_?->U
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M0ZP18@E_0#3*%!.!K!XGYA:IU\'VX#L#NF<Q'@$8Q*(XXR%(V9A=E8;#4"'
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M%5.VJK?@;D5BV*@J K,*?<3,.?@71Z]OYCH:E)L)IVM>F;5&+( 5/5H-A[-
MM;C'$3:'.TQ"@-(+5"FPB&Z<2X[N8N3@OY0@5>T=^DWQ,%5*1XIEP#'T<J2K
MH;:C$NV2M\&W4HR\T=<\IRG(12%/%>BB^!97?H!['B\7Z:+-,Y7">":-*+RA
MB3((L._++J^M"#M[^R3Z<1]A3&=&QRI&,K&1U&O8WY^] :>Z 7R^Q1&*"R2.
M,H,94OGG?O7L\2U893G[6F*0.,32%<='(6V*W23:(E^Q^89%.)5C6L%B#]:
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M#*AA9IP[T%SZ<95583]OIH7!E95RY>\ 1+_!^#*7%+9Y1=&1<ZL:;K,-95^
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MK3/@68YJ;C?6GL^Z:X[,,!X4W+.EP%X)[PM+D_Q">D* M@K\B)Q]*4F"S_-
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M]_O 2%H;8+ $$(S,%\(">@&\,29W,B:KR'V[UU'%'X;MRL7!PGQNR%._!15
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MVVHB5-9R?PT,I;'FXBKU(X<2SDQ'U1(D2)6J$L:>">7K^5=FQCS" L##IGH
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M+S-KR6])Y.U,D+F4!IG7&60NI4'F-,@<R]^DZ3*U\]^1?"]((AQFDA^K6VC
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MX^G3#[%)9^!'P!GT>/R+2WK!U XHZ)WF6<\J2T0#A#C1@,Q4-, /QZ:B 9F
M: "WUFB @UW/OC+!L0 NN5@ 775!).!2-S,5[![TX52<8=['&]!4V1<3X-*8
M0 )YQJ*0YAG7F&<L"FF>\3#SC-L)YC')Z0_EV8Y[9LNA/,X)Y662#>6M$E_+
M!,?7N*GXFCCSFJ  6QIA2R-L:80MC;"E$;:=UY:AT32J2K<72^-\L;1,K%B:
MQY&*'4GC_)&TS+8B:9PODI;96B2-FXJD95YS).T+%I*#"?=%A@72:-I,- V4
M*XMU=,B)]"$,V!#_QSJF)U0VL;HQH>\B]V6$I7?)&TVC3P1'TVBL[!R+)JPC
MY\?+,NY[HL?+I$2J9_QP;+-Z9B9>EDDR7N9@-[QV)C!>EHD5+Z.KQJJ<"8Z2
M9=(H601GFZ'=XVQC+S'C]Q+G>]O$T QVMC7*^@'>A8OKJ.XRJ"<'V+VWY;RU
MU76[02UW@T_2X1:L@DZ1.]C?1T1>LU)IISUOAI1+$VE"_ FB,[@9'%7(MV[8
MM\"R!?F'=8A*BJ6IW6];2QAHM\S:+WN(M\.X%_B-.!,@HTB!I#E2L/$[DP68
MBH!@]L?/*; A\HG_+\1/&6&M9()]V$6&87_/!8!AX=A;,$[MPE'?4@<@:1UG
M"'_?1(Y!RHK+\6GI$/N9'1];EX'%2@K$ T,9Q&,]H;BDWJ]]\D',4SN4N)D]
MO=^A"MAN;LPB 8!VD\1BNHZZ5DG*#0L"MG1?UQZ.03W9Z,0TT!3\";B%6,,!
M18G)3VT.N\Z=K&_2.!(H"0V41V9$1#HIN[=H61JA$RUJ)X1RZ:MJU+*UL(T"
M&I4^I1+^84$!>#/F3\RO!M30D6)[4$0VQ5W8'0:UHX,95GKOO0* =:/R"-NB
MWA+P&)P(C_M/D07+SB*,K#IPS"TO>SA[(F@G/$5IDG$>AGNH?9E&%<P>AI'"
MW4$*P>+Q0'Z$CQC=NKHR(J)9'1!$DX><M]K<]L0\%@<-'VR_";,&\>ZQ]L5J
M'VIX9<LRL!4'S$\8!+Z(J0O.F<R9CUB;8[[R[,Y"\N 5:=C6/%&6<469WSVG
MYXR<2)\W2RU;XK'"GPMA@38>"],1<?)L;Q+SG)3_U^9QU32QCB6#3+ [#_XV
M(>V<H)WG&]WI>S)8E 1/2>%9_(G$JHLGV<4 9R ^IEJ6&U,';<#J/<'2)GOG
MN?Q)/B3$2-:CCK<7<"HTF4WM B:>E/SOR\P$"'T%L=T1:2I!*$3K84CS=[!<
M\-?Q6< <\P+RG" ? A"2\ 'B%&!\:^1W\0/3=,P3@<-DNT%.*"833@I'WO/^
M1^<%.GW[L(-D=GQB@<;-$#9U5CNA+V1"0QX"_X) ,_')Q\\;S-ZV26B+;C#G
M00S9P9OZ;9/0XEHV._)?^UER<>>$.]59?L3Q:!RU3GC6([;L+ V! W5<UCE$
M,1,IW2VFZ>YUIKO%--V=IKN3LP]F)1S$IC(L+T2M=%=,$XD*XI4:!G::R&1Z
MV9,%H3-).M1AH9HJ8"DP.3A;]2*J&"',!'$8)[Z48=F= 7$&'$,//"_X!L8#
M-O)[M@IS;'F:NZ,^OS-;@?T1/"K[BXJA@M:4J4,V@.8(MBWMNT7SH,M]ZA=X
MDQBNRW ")Q=XM0_13,]7[.0!Z&1PT[!_!3N!0)O!XN<=F.BC]D'[,0,!.Q\=
MU[6@Z0KJ-&4@=JCI%HD?$CL*@H=]\!GQ#E@N3%8-V]]P4UK!'AF+/!*CRD8P
M7JL/41CL&\FNIV;9^W,02G/_,KV8/)196"58<Q)B#X=]_ HB1!RJPW[(1F@B
MA*X' 4-.0^XT.QZ>AW7ZQ)TCH=X33Z08H^41@1% ,YT=F=8#,&LN&!P7!KD-
M:24OHSFPT/VXQJ_S <;Y$V(LX3#C2<8%"5+5*ET+RS&H%>#>$._%!!L.#HE.
M/%%LOL H&,R,V*56^S1+2DX4\]D)2MX" XVQJ(5_C9'&D:+/-Z16 WZ"-!6Q
MZ.CM)@_=VLBQ0,$Z@A>#%\G"("2(^I:6/3"';2DD!M+40 _XN_A=&<]PHD.U
MB=J?&AZ[F%FQ+,)Q1V0G,6').,?,C*-RV&&WGAO;S4P'K4B(BISKV^8=[T@:
M$'QV-8_3Q^ *GWJ2(K O/^-OT=PLS0US\L,#,!W5/C-N%19Z4Y?^6-*8+D""
MR#)92!+^I;%C4O\PH]?<F(J3W0TNZ3)U$L*PU1)])D.KJCP9K?8$,EYV)#QH
M+T5/X=(<9WNYO622V0LW=R]S/7([E)BQ8W[TRJ=+<!XH5W1(YV3L;720'+\%
M^M33I0)T!TLE40E.?.2#%#:+SQFS!KRA8L\)LCU?EH SX7Q-\QL$&+,GA;#@
MCI,)])XS.W7"TH,> LW&08A!:#K*WDVY,>;-,.:%>*>&CGMROVLSK*5#N8,;
M;;!9R5\&R.HY('.)U9&&W?DW8O8MK1T+R@I!"1:I ^EZ:XTR4]&/!76!OF)
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M)85/:CO&WQ59IV7*!VKGOR/Y7I"R1W9#Y;J%!MBD/\F<86:580HF8H,RL5]
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MD>5[A,0G24D3G$X2Q\+H,1%Z!.VD&^X^B CQGA<,@TP3Y5 &)2M4JCFJ!![
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MN1>*F6G9PM8JD?R,.GC@3$,!3!@#43A^!*?@Y,_PX8B3^]9_1T?O@@6:W<J
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MGK$:*4:.B/;HYU]*(C<E\6*I_&IEP,J$"90+4A+^6;&X&<$POS3"EHF3*4F
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M9E?]KM7;1YRE6@"59TEX"\]6YF3G14>?IH$HQ@*"#90H5V^^GG^[4;/C_G)
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M;-$<#RQ*)04H&$UV<2J[T4!5Z<!T+S3<W%[TB\97Q?J]R5X("R>.Z/X:UO0
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MJK!%7BH<>'7\2O0($P')A!7X@K Q&\DY[/A(N9*Q8EF&VAY9<KN/6OJ<',#
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M*?QY!1(NZ4>9&1.OG2I<:Y#W@(+4<-'H>. N55=YL&T=U)RLPORHAB_;_>C
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MV&(]&/#? /^0GR\>A"%G9";HRDP1C\!  ^5WG[)(F#D/T0\^'8AA"%V4]7,
MMR<VYQ('1(\J=/VBEH7F]>4)RV+\3#;<2158EYA;_4#%'D[?HBN(44#1:Q+#
M>EBU*8O%!,;NV*P@G!7=@YD+8MHAT50WVO0'^)3,)^'OF1CE&!T^MD6&PF'#
MF'J+JC>L]6NL0NVB60ODCR,;)MS')L1#_!G/@6Z:B>.'@&A]E#C26"6^)W^
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M;>!96@H\(;B1A!2^HYOEP;'[E@[T9CO_*,Y#ZVLA5\H6BM5LH5S^EH!<9@"
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MO*N?MKW@SH]@XT &NNJ1+PEX+;^7^6](OA'X6)>NW='5(51:$BMR@^4HATX
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MYVL!>W/[A/WLP]Y14JY-[?DQRZ8V04<#!J+;J7/MN^:@XS[^.AFV@CBG%&A
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M&<P]9ZG@$(UN.?83=L)48%B$H1&6J([53P/'\%BF.)7-#QWEE#(9BF77E!M
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M*E/YS8HU6%.K!QOJ7AQQK:S1GU@O.W8;*E 0$!&%!]*(0%VLLD'XT\\PY&5
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M<)"(RI-A3] [Y10[85L?EJH:Q(D(*U"UA64GHNKPBPS<C&B;P4+ZOFN;J9)
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MU;'3X<W''4:4\SJW?H,MD(I&%UP!:W$]L$[E@EST'T4ROVLP\H(OYF'">9?
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M@>CK9HU%P?*HX!IIX'S"&E;PB!=!A6DB!18? G=4\?U]'?V^^2X,9D@Z=(9
M8L,?JL)<%. >31S=<PA]A_ISBFMC&[J  F%#T? [%0T+;[>"<I2L'RJ2G0:J
M+64QHO#(VK!P%I NP,7O##%;0.UK,(K6XP>]F?$/_Y!6GZOD^^ISAR^]V-E2
M]#Q(:*KU1!-CD?&3X,-L&+EREUW!-AX80WE35!XH"6< Y;S=<L1-C+=^^:&_
M*4&QDXS/_;X!1=97%< /X-&<!/[G_[C)]#OE'YXU=AIC0\BJ4'!&>P^:9J,
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MZWBO1(K][-VV7%^!FP:N!0E.;3.$(Q"*C)E8X,6?M8?+TJ3QSJ=C.9I>/9Z
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MT\(O1D_UQ9"[O=ED?4MZP\(_HX$0;TJKB=74@BH5$MY=O*#*41[M";G$#MC
MH6EI!&R.E+$GE!$9#*H0J66.%PPZ4@5Y^Z5RS+SO&Q<&A[0J)++I,4-:B1FO
M1;M&NRWHONMN+/-5/1<%5>*?V-LTIW4&D"8XK<-D_1ONH/WZN8C\[Y!Z2']<
MIF>V;I;IUL#UP&>K*>]2+CE]=*0:HE03WWHMD:21!,W8(X$0)9!H(W:S0H(
MPDC8FOUDQ!';D#UN)=U#9@RT99G<9G&F()XK94M,XCSG:\\6PH8M8BBMC**O
MF0:N\BS?Y)Y'[%#869$:WJIM[-*&F5MC[N)Q(OWQ7L=['>]%LL8E9_O^EZ(V
M  X>)PO*3,-BTDI:J:^CNZO?T[=YFD4M7WZXCF1(Q+U%4HB:]@%M6GXXDR-2
MDWL<;6$9MDSNL#ML8T*!SAVA *#P"8M$-Q%IP6X'3:1-E+A\"HJ46YX%%,.J
MH)DUH$X? Q9\M W=R8N]94G@AK.?]^TK.)UV-SZ%>5K3E]A;D@OP=LV\30C4
M4].H-(FD3Z62(T&R4;&G#R!!#WLE1EPHA%1E'@ 4TN'IIB1.1!E/W?)E7*+I
M!D(<O.^HBTO Y(;O^*K>5G10#ZI=TV/]_<96W[22(/S9)(RWN<=JZ=D/Z:P&
MSN1/V6=E2)0\'A>C./F3^82."E%RCLI9,@R9U1-T_C,T84:8^40P%F4.,/D]
M- ?VV* GC;'@F !#PL-*8(J KV7"VB'T,TZ4C?5VMTI#E&;PI<TYE!A.XV10
M:]]?O$\?%C<O>]4$ H]O[7;3%8HW;D )Z J?*^T>6[$>^^G2A?>QGR[!^F@4
MVPT18Z1M)A+)J6*TG7\DC 08\5C?M:>,&&Q8Y4DXUBGQFZ^Q13O"0 T!@  !
M&MGX$%@=%=:_52? 7M*1Q;6\?7DJ/_9+K/1>M&PM7M2F$K?X1H$K"-^IG?4O
M('L+8)QW7X12AI0VZVLB+W)JU)::0V.&F,(GSQR%3ZKP/G:EI0MO]@CO5.%]
MG$*3+KP3]IHC!Y?:U?+0=JJ#IXOR#+S5**<'^K@F $M)P-^[Y=X%K?FNJQR
MD2@#M7RN"Q.MK<C0"E,524(1+YS[<;1+SEK/%\-?2O[R=I.%-INGH?Z&%_M*
M]=$5S%)R'5YB;\.+D84?B>$KM;16GFA74SY+%PX\Y/Q1:")NPR.3WVR^ZN8-
MCT?TIX#^R# 72[:U*I\M%:+G?W]HU,>U(]B#3FOO)P,$AY?8S5+@071>S%9*
M1-84AG4+UE>,0@ HHQ2M)LC"4-1-:^ZR=E'5;UGU?+G)\(OD\G;GEGT7L[SW
MT)R.&%RR@M34K#Z6R,:58XYC%VXJ>PP+I OO8S(]77@?D^G[J8%";"P2*?.4
MU$E0"L^LE]K @+T49445]85IJ*+MVLZG-%]GX,^7@CY6P%_FX"O0+3--N.7H
M1;GOB _G;RF7A2,+#8\H,\-R CHI-4%'I41T5F%_2\;#YI"DA\C4S+8"49\]
MGZ5CI,T_M,O^$>DC=N"NL-F<W6/@[L.00F00KT VN'$,XEE6:"&DN.!@@WA[
MQ S!QF9AL]A%2$"O3%+TK6=?!EB&CL)\\>WRX:<D3FEADW1M<@$^?')@(E+0
M@(3U81O9CH?F=,45+\>@0KKP/@85$A_\N O[AVCU A"39>8XDC5ESCR6[.\]
M9P8;8T6B$8E4&#"R#*^K*D-1]RP94/KCR_KDLC2YR*<:I8/[!&)M$=@[9\*,
M--O@3"U.5B3J%G_>.-FV*(P=RBH2;7O_I*&L;;$5:6T5R7K>Y6R./7"^BFL$
M%0]ZX!@1>@VQ0<AN=:&SX(E)!X0:#GL#J'C;0*OJNBKV9SK7EX1;):"8W[!)
M_KR_/S2$(:]?L'L5&KH0-(V2@>&"(D.<XT9P@@. ZHGC4I1HW.HXR\%?-"2\
M._:SP#M""*W-A$E90D2K\9GD:BJ.X0Q?=BV%C* ^LFL"\ XIMC_">S_%8[ I
M5R+JN"<O_2+G0;C@Y@@G\=TZ5_L]Y(2S-)LP5VF6.2V86RM]C;7+1HVJ<U,1
M;F+_J4CPMUJ6NKBHK\T=QIO6Y0_T,XI79N! L3#SWUC<L<9C-V"0U )=):(>
M>;Q ER]B$S(9CD2SM4%9*A"-T$?W/AWI8Q_H(S*85R(:-8D9S#O21GS:B&T!
MKU':$!_>&]K 'QWHI!@RQ,0E6K( HY5L]**9K?G.-'3_09;ACTSFWZF3)O#O
MJ5MQ(FA46WBCKI4))V?Q!UD*6##B\#LUX=21")X,OYISO^P92"UQN+ I9PK?
M@<U0N-,'4/< 7.!_7W)?T+^-"Z%_&^=X$WE]# ^2^VOE9E],*SW U-:5Z:HY
M;3PP=\H41#F4IEW?](,BYF7316CE&KUE4U$KPVLY_SH5OP2P%R!'^JN3L[WO
M]86@YUUTH;<<]>]_L=T;CG\7@M\%*7^H*+JLZ *F6.,?B&HK7ZCWB?1-XB#0
M!?GD[@9UD$@S'F!\)JO >@7/XI$7 3X!G ,DUDP5=5'0T+''@L13_04%]!+5
M1Q;O"8],7K1.% :%\:<4_O04T;1YGA\N^>;PNN+@,PQSH8(O%K@#>HO('\Q+
M0Y7>\NQB]'YYR;>NVI40&F*VIZ%2;]D1F.[LH;[DGE\VI*%R+HR&+ H:<:+L
M(:!@XCF22129 /9G?RG5UOVOVVZ;#B&3_/9D0O>6K??V1&E/:Q=A8BV<3.@P
M,AD*UNRHD2##BG1 ,D"?^LB5(=#(1ADRM(*I/B>_P(03U)%S1%=9^"CP7/0I
M/Q<U15T LD/N-OCCP A\J)RH@:]DD:12T"9D<R+Y4)0Y>2""+^DJ)VM8_6I'
MJHRBRGQO>7>OU0?Y8E[^DP^A2G9[JF3 NQ:_.?G7\]TO:5,%6&8BJ%*C!$Z5
M(4E LM,$:7@RD,!';HH+UH!351D*F@;(!Q 3>IY-W^!'7? ?LOX'KO$Q"30.
ME9GVFFDAMF<38(L-?@#SS010N=KJ+96+\56)N9[_; V^I&#8)60\&D\'5Q7>
M$69^_/N?DQ.J)0+U\0V < 2\@!OA=2;( X#U"ON=^L-),T@ U,F)05R\.(\;
M5\='LOY>1$1DVZQ.&]5KP[K?,% DB9MJX"#F?WVGPLW9<"[U-4']N68@P("]
MZW5??K1.G' S(?:=NEU,P0FJ*M<7!]^I-G"-,%3;"H0?77;^ZA_S9_!/-E&:
M%/GO/P#0/B '9L#+"6Y&_@:\2X@Q \S@7B:,+?)Q$(5)83:=.5_A/!@\,3Z4
M@U!2\FBV?0?^OSY^1H#TJP-).[K(7UQ4:V?5V]O:2?WN]KZW?*KW)R.YHBS.
MGK'<&^ V+SSKV?B'P%>!CUI7Y#L@ '/%_$F.P:ZL\R/ZRX];(,^&@&Z5-RCK
M-$'7H$+6QTC020IP.R5Q+O 93D-_@\).5Z!>-3[H0YV+ E44IU,-88"B552>
MSE+ B6:IOT49/$J9:>"7VM=O"&W.\]J2#X$84I-]_:;?]5]*U>N+BR73JK#K
M7#^_>GW&28V)X30-V1G@>(<),1/*^1S=H_.LF=LJU\X?Q_>=%C<N T$WFX"W
M+] 7OU$-41L #W&F @:D;@9C@9^!]RA#ZL(B$ZIJD\DM(I.J129&/)/ZNR'H
MG"AI7]<0I)7B7Y8H0<$>! [K(R@D;5\_W [" G\U8$ @P5N]N6G>WD2&W= '
M;P*^1E^1^#6RT0 RD%W^]X6Q,<A66CW(:S23IWL]*WMYHP.K T*\-@,&,+!.
MS(!R]5W4>CVSI7&M!%9O^3Y\?<K_9A\9O>_%7WS0^4!@5:U]^8&/]F]?_><'
MA0](_1\WF7['GS@/BS\QCXS_91S<BPX__1DOD;QRZJ! J]\K4J""VA94$)*1
MZBW?A/[S>:OT,+]+'N?V04R\6\?Y/)BL;H%)G]P1P*!>8G\N<GU)+B6.072
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M<5[V<4L08S,^FU;)YQ'>"-ZI=8P=.+Q#':$(:4;:'B'26E;)YG/1H^>/-)(
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M%4HO!2Z$!-FM2+#:6_*ZOBB]C:329%,*9",$K$8)G"I#$H,TIPG2\&0@@8\
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MAL[FB\G-[5K+T,36#23Q6UN37][G+\;5Z?!WFI(UL ;X%F5=US0C][PZ.)2
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M#EFQ;[*BVQ :YM+)D8A/#?Z;"-H0?T<QWT_Y-OQ68<&_G6;P!/<@[IS/92]
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M&$\0?>+0I$'&H,%7X8@_ GPQ&3EM^.,8= D B8WS=4#'*9"0(G^$0[?_],W
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MQPJ@:)W_?.8]J0(HE+DSZ:W2?.]5]PRPT0Q03I4!+ 7P4;XY?9+OGD26WS.
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M ?$6:&%$= ]U*_&I.]]X,VO5+XZ+FCCZ>.JMFKH>7V>.MI54:.L[9H4Q:'O
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MF(09LIQK-;0+$3)NJJ)A?"6#\<CMQZIV(0D#_)D.W'IN^RTDK.\"I[.B.R]
M7F^^W<P.Y')2__2B^CXZ'5CWIAM[47[W)?3"?^TU!04"S2P![?5S?D'D*%%
MP4;UJ!)6L.%;#!-(Z>*BE"X>L^<?A:E2/ZNF3.EB;$I'#OX$E<9DPTE-KXT!
M,T.+;%+I7W1Q^FQT?B/_:1Z_3PJ]Y?"KFU*ER'&;8A!/4EN](S!E-H0H9G#K
M1;A0Q=N_]5_"<EAKCBB1(QP!1$'L$X$J@H1'\JAF_63&5..T'"N55.XX$9'?
M>S N1&;QOZ_)0TU)K7#O[<+)3;5QMR1!11]]=KUSCKYI9$OR5 @D=PCI@,$Q
M/FPYK2!A!%OL,.$[Z^[%2KQV%?D5_9+CT5DHV+#SB+MPU WY1B2DAFO\9-:L
M][AN')/OWK$07S1K/@X",K+.F^X5/.F.1 !3=@DZI[GV79<__RV6+/['KS,C
MCF%!5.?:TG$-2FFX!KG"D7\ /5 -5RE9-V-_1GBX+G$W,HFDF@'JU,ZC66;U
M0>[A.%_AO0D\(XX;-7L7L.J43BH5U^+(7W>9!P5NN1'?-POG,P9_'AAW$EON
M($2.:]<=J8"YBOP#?/3HBX@*JL#QH!&-VGTCF UM-8)&RC_-V7,@IPX?'C\D
M(Y!;M)%_Q'%M^@UB9Y7G->6RA:A"^A#TL2QE@/(#'$M0S(-0-5;3-5F94N]J
M<6Y'[KJ'2#;_<7 B:5*IQ@ZZ2[H'A1C]<BH90G^C;Y>H(?8-*N"]AULOUE$6
MGW9D>X\Y3&*!>^;&S_H=4@-.[[S5?#POZ+T+&>"O#"K>\0H$\"&@[7N5#BU,
M"UE3=(>^'-5W)<W#A,Z'>0>A8<^(TGYT_B?CVB51G-@WZ J:G5R%O)F'GX\-
M?C;8Q-Z@$6R"I/\I5&U/\2DX"%^JJ3?5VY>/5_G53G_2HQ;.L9FX4,(<].&5
MJQCK,&XB_.MM_OHF.YTIE23K\)6Q""N)P0-1_>OLO'REOT#J!:L<U=WQ+) F
M_GZ#:HE:8(."5CMKH#HR=KC%*7'&&YV3$]/:0[.L8@=WU8.,,T0^9%7<;RMH
MAE^!8X=0/X$(*?(L<LEBAY;FBZ[K$U;A((_I]@[1(J^M)3K"SY:C6"\.+W(/
MV=M^I;;<6%[(2N:8.0V/L!3-(W3Y&W.A VKY9$KNP^)G-QA6M=FT^;?SM"KW
M(]%A5I;LI=C5+88/N*,:*& $,N0''?H'DG!.506<_$ 2+(PK'V7'9'!:4120
MCF+FDC7F389<@J:@OW!Q(H/OH[S$X:0&9!/'KJC$CIX"3NJ!4SE"!!5ZN,:(
MN8.F:)4TJ'^>+![8-1;Y:<2H"09-IAG@A1ZR:S@89H2YX (,2%,8* *9/6#)
MN<^HF =5]#8PC21WC3Z%;NS@Z6&5;'K&ZA'31D(O<M#X9'K+<'_NZV(?J79@
MQXR,5CL@YX,Q)1Q%: ?S3&YFU:W )E29Z= 3SZ@\>I[J"'!"#SP/F.>P=$3"
M5UXC(]]5LQJMK\-#[9+)C)%N-Y<*-<>\13"3B>SUXKW.K] 0,@_1,"J )%L9
M2.(8D[H[73+KY-#FH6D_T',[(,]2]:Z*:YPTI#_,[V,]@COZ5%W4R,[1/5Q
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M\$?PC47-\"HH1D$=VBGI!@]> 3XXC(S!LZJN3(_L3J$1^XK_5^L-P25PDL6
M&V/!-@ACDK&QEZ^/81VLU00SMH+5F3G*N1_ZP^]E.+#;UW&RN!\%8\%R0$R1
M5(E'0UYN;#!#S@N>S9H3>O#"D5]H;89DL.R]=7D,"@M=.U/F'9'5;K$P/J2X
M&0@2,Z0C<*S1$"("?3V6)*Y#VWH:A'5/'"\&'60H)@7*M!4>]Q(I4^>'ZM@5
M#@ MF/V9/!5/ZN/;ZM^"%4,YI6TT+-NPV!*3(4%5TJCY*-0B=(A1,]RE99R0
MIPGOHCJYY&_JO[-/W,:=4$@#7R65%M92+4)-SES)' XXFQJ6,VMLL5HF&II
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MV>F8(/AM]$\\'5W2$%E'8QEJG%5S3@!G+#P#^  L7CK ]C.BO7CZ6 !F?B+
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M_#STR9!5!%P9" T1BM#5<><KJRA3=,H35N'<X?;+[.ELD+M^O+MA-\GHV]O
MC&SN@^DY-[*YG!+/<D0XLQCRG$KNZ#.(\VH.B6[H4[GIK3T2V1J-64$!'X=F
M[8=WLG)6.<VULTGN$^E:>WNE.V7R/0<064_DL]DT,(%3=S8_Q8'0=$(^F\:]
MC#KU<<71AC-9YB:"**([4$O26&D $-;D3R[]T'CJ3/OYEY>3JR1AR*6Y'O::
MC4:-+6-,7PL6<"XQU$8:.;32WK]8^'3H.B2-RUPA]0"R7P3!7X>@'T[0OP7-
M_^92K"J_9?9#JO+K#R;<P,!ATG8N#1@\Q&XG;RKT8XFA/5(I2CRHUK)[!;+
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M>]5A>AG\-56O5+?.#F6[)SV0O4HQ'/I&=NBAZ=ICJ86'PW#DG/\/4$L#!!0
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M8<^N_<)D(/N8F/7H- K\IH521P"<M<OIS)O&TCF;\^+!CU=EX_K'X@5('U5
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M*GLK-H.D5<DEU9@;8X=?A*/FW"4%91VEG6O5JS <0Y_A+1BTR';=Z=WTYY.
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M'V#$ZKF:0:YD+WYF9*"K8)X+,00700+I8S)LD&)B8@*E+LJB5_TG-J9]*!G
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MAA^J 1T9.:>GR\\WF<)75;/\'=D$B'X]ZQF'G/!%]2] +O5X)L/'*C+WVK2
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MBOBB:XQ[42Q3_T1S_XW^TU\FHGEI^;84/NS.=32K[*<+(OU2WO\^I%J%)IE
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M9M[AC64:-17W]3JHDV?GB7)35K>OW"NK"'51(1GYOCZ[C08 Q4W@B4Q4$OW
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M')2P/8,&$L+FN8HLQIQ8G&29)N1ZUYM]N0#,?<YSGN:V3YXI;.0 [>1,<TV
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MNXG+\>%I>;]0.Z BH:Q:04\W16]UF.EZEDNWS;P"ZC:R?NYDH7W+4E[P/],
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M+ P7$HCJ/3[C2UHBF&!;I%N5[('$^:*4>$&E;1*_QPIDFN?>*M9I,%^7=>^
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MX];,\?:D<4PXB "#&Z9DLR7&LH\)I6PQ( 6,-"?I+:66S2FAFFW<5.P[BQA
M> !>7#K@#4M[9WU+ZV2")J>C9(*T',P2!N_MFH.R-BS_>%-UQDSH2*92]GE#
MF/@.>VC?@';6<IZ]#5ETKEM5I2'Q@*NAF5%9C19!A.CY)#^RVF]3WE1Z[DF,
M?=]1,,LB91->#-OOPJE]"X###^D)Y$N7F\<%;QYKRK<DR7;6U-NK/R79;\NM
MRD80Y2Q+C:R'7!^KZ?:U]H>55O1[@MY?--1SGM$/4]AI:T>HJZ]DHDCPN>6@
MBE%CI55A3&]"9U"VSMB)M]LC;;C7#C='U)AV YYZ82PA>05I;KNS5X-A/J^
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M?.VM\#>I'?!NZ8:+5F+[1:(61[B@AADH/:!8R.=4S= Q6]R9K<CE_0O7OK)
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M^OCOM$8HUGU[2-+/B4L.IOO;IO_P&_Z+IA>-9-HF@EC\C<N&_X;+$1*+PE>
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MXSGOU M<IB<$H*,G>@S1"+\%Q/P 0<,*O#Y=%>\#U3C4;VHE7# [?&XS*'(
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M,SEPYB]'F:*1A'8*?%FVB&0!OZKL/X!HUMG=F6P$%6]15^Z71+*58Q$*,T>
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MJFE0@]!Y\O.(CCT?3"DBR7C<MC<)ARGJS8N^+9GU?6DK9K*47*BB*WBHLFS
M40 IAGE2O\B9BNLF5.6#EKC?_AAMX*KX(SQW#3.&2>2Z'78$:UH\0ZX.4UI>
M1BH@")7'4HO0XR$RQ*#NUR*+SQOV?0SUB@E3@N"V!*@=Y%LUROT>,CV31B%T
MP&$=$(N*NT. T7&W)4^9ML?'J>."^)3X>(?4@YZZ%25/D%O%FO'^$BEWK2/A
M:L<2;;BBC(2B(O#4[\444C_UF.:#,KUCJ\B3NATT*6\8:OY]E(WJ0(;ZB:X[
M1^_T^',0I&4J'R/E.AX_Q<1;2W5N:[:I"H2=ER_A-^ \.1]V8,C^[RN<_F^5
M3MW_H'#X SAEEJ&8-(#7P>LO%&!-VCAFHVR97WS%?@W/+T3T5#\0Z+CMMB98
M90NB1^)X][6T2NT7(]I91U^F_5(@BO+B"NB'$J;8THTZ>'+V?&E0Q)F2F-.*
M[)2^?F,-INA!W.6[I8*7'"X>C89-X@9MSJ7(UKZKO%@Q&FF1(/[KF!0>?@;)
MFCV)UKAJD9F9_WHNGO\)TKW\B=OKMK,YPY6!9L>]4A'2MR=*H_$B<>"GO]YS
M-@WXW<:#8/!/S^<W;U:O"Z6>J<5>TWR_/-!OCWKSDN.]C#B;1L$5&J*5["SA
M,HO?.?4M<R:!^(9]"TOT3<F$LBF=$OIOKH+%0$.IQ#+?,F2T^CC=U^7AS-G&
MSLCSCG<7?8Y_053'WPAE=GK ?ZUQDX?)RC0 -,UYO>:TM_9BE4;IPF5*Y7J:
M2G+.51+LC5YF$! TV^_(VF$ZM%,(C!P;[/2OT?1<HM7&*G,D^U03TF\R5%31
M=4B=D29W?=SQDKA31:!N&O<QG CKM,;Q[1GA5]X<,-CQVKC85*QF._NPW@$I
M6&XA]<%B'N7GI2$!4<*QX[+;M7+J_<GA^;*B"M-&LOW'/X V>.]PP56ER%=B
M85#.\_DLE<GTS+EI$G[E0F9*5OFVC0A;+#?Y QGZ))7L"QAHP((EMB_ 4$3D
M!HP!7Q'L_^I<I4J2TN!_+D874[4D_O3%NEK+IMY4Y(OD]>(XET2TO+@@!5<^
M)MDZ86FH1"Q7E"790:JS6N&@6]D?@!//%E*#G]NZ)UJ92M$SEQ@W32>DS[ZJ
MVL!3 PAV<Z%7KN55E4PICGG9)VVAHV4^0#+%CM8UR6/C!W&-A.\AME.^_]"T
MY?5X&S#U3:K>U OP[XG<_H>D;L:&%@SU'>;*JHDA33JZ6P3QD924EYOPOR!4
M])'?GN#!;)!GWNG8+L#^8[3Q2"]KT$-B_@(9/=$<4W/V-_A\L^Y;:U-CMI>B
MWW(WE%P@29H+WV9D:+^=*J9/"V410;VYZ[#Q&U<HK"I[LX"'LH!P3L/3C-SF
M4=HEPW,MVC4O0PWWP.](RCLM&?Y>RMX3<PPRE*S"GP;99,\&'?=()(>@)L9X
MC6)H+&D'L?/_TY"R2.A_LW+\SZ0J/U<BS5=E8AQ]KX'H87%;DKZ45=&4+Z+$
M7#R"@,-DCF3(]GK)9E_1@!QS/97NQ8W$?IUL'L5U<UEHF0 .>3/GG5OK*>8:
M$3-F(\NW0'G6^BR=YH!1$6/A0Q5&S'V]D(^AISA4>HDH0UPS%N>KO!2K>S$.
MK@8"Z_SWA' N\<),&W*9499U%.6B\9+3J^VT7O=N^M:G(>KD/*&O_/+##*GZ
M.:[N:/Q8#B%YK(MA%6K.R72D[V99V_*-8&]U)GGJ.+]@+H++JWWS!5N82_QC
MQ<?"%B(XJ-!IPSF&44-%?V  _6'QR>,5@R]4?F> T9KB*>]B+1D_6RDHE/EI
M/OFY/=?NS@-K%@E/^#!I<SV=-I#VN/:*BM9,3%-ZZ;U 7<_ B#*E@QSHF#I3
M^'X^._)&OZ7Z/1_6L55_54#$^Z$/ =^9G,E22V7KJ&^//5/7&<93[6?'Q.$5
MG$G@^0.(<CLV6$A3[HP:V3]P(V_2'IH&B;(% (PPV!@_4.U;-"BC":,_;VY1
MR,3[:,\UK\3H$OP.I6=Z@ZN(OB3HVIAE0?$+F ?6"]DEDR6V(?2;8F#N,LSJ
MYZ+(*E].P/PEAEEZ@ZKF5.25AV/SOHIOK4B4TUW!_]V<DAO]G9W1%CKJA+O8
MN@[+S !*R@(*DZQM?-HW;2R&(/OJE4#1\%$74IJ61*'VIA;F%SS]$^]6W&D<
MW 5[*Y\PYZ[R>)^.%W<7-WG8*P)4>'$_%;.V"2:K_(A'.92@/GZ1+;9%1%/U
M98J*DCC F^R)?Q  W2W;^$P",C0I+4Y#FHS9:]4K"&$4R^*,$??6=21J:288
MO_8Q%&]NW/1XHF]OG6<SM8=GV -,U*TL[N[<H2N"N39=^C4O%!6 )";R<!3K
M3.F(Q7QR#R, SO:Z]_TWK/2\E[^.+RPBO>+B\HQK=<!P!7>*Y]B?7-+2 =OK
M:.VU*WZ>%JE<Z7"#*,<@Y>J<ZS^ :CN.D?U6M&GG2_<"1P#^N;OX7#G:9$W3
M4)KRN= /'"U;-Y89O(%4T6U?;1I69IXHIOH+^H*][-J"6^?CV:VWK?.7*HX4
M+<]U2G<4 _R6^]\.YV+07NY;%,7RR]!;=#-T16%'P;Z8.9<O@LD[(:UO''(F
M/%1&:7Q1RT)T8E/=L)R? 1%--SZ[6T9J7/J-K433>=0>VGL1'5_]+R=T8@$;
M0F#>Z[EA0;.:'+XH6ZYI3Z^8-A4T>K/0G?3/&\P[-8=>161-_]YOH?QKEL:_
M+A4#F/8U-G/]#;R[\K;]\P;.UYZWI-&;T03O;6F\8#E<?(\H+0,5[:<Y/T_4
M72-?.:PTNAJ6'=U>D)(8R/8I\UE,$3HSJX3FZT\0/2.?>@WHL7LG+3!W#-?"
ML30VK@#%Z,MA,-(>8S%+?YST:/\:>77'*RS\8#Y4Q+U8V9SE*? JO6-^%$>_
M9]SVQ/<G1+FQ<<'[@8!^2*)M6X"EH9J?FSE >7N=,W&W&OF+3POE4TRD//E
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M3=@[3A7),U0%\F]1J<.*%K)?$IN2-6#1QBJ,(2Z7&"*2S_^J^C93[-W';4/
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M+(I/+MY&56)+R]Z7Y"]5*1XN1T*E->J[4HZ*L,*H>M=]J*;)4/Z]#BZZYQ]
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MOSF[*S[3L!Z:K!(?OQY.*(ON@2T9SL7+@&/$)J@1Y/6P977S6GW'1V0'K5F
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MG]?(*%@QBB76(\:V6"V_Z4;:&6?'^IZJ!K:9>&ZD3:M,6?>]QA\\(K8GO$;
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MCN,8/E!Q+]DWZE8:L]1Q<+^30+R0?J[N =2?S"Z5#',Y_V6X(\RR*5#*BK*
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MO<6 "7G?Q!4-+$UC;=.>34Z.!5#CPYL;)V@XN/+?<68+'3;R&/+>?'!04\!
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MY#]5\)T-/I!6)[N5HTNN^_B8%JBA14)D>$B/<UO/F59_\S626\=P[$<ZGBP
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M8_G"3)X9LXX<8Z9I_L.\.[61@PB@?)F8!UT&8$,H"QJW/.I/X.5'0"-I,A3
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M6@$OI&N,19-T)I#.-C,3/;$^G@K&S<KN0,?J/?@4P-G?E_(72X3G?K*I3'X
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M ;^^E!^ *RC.J2_5#.AHJD'%H,0R "#S&MA)LW?M&>_#OD8/8%,N/-Y$!>V
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M&H R$Q#!\OM*:[M(ES^MA*19<AGE,QZF/_\X!_E&BGE^0C,+^IN5?D!_.3Z
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M;GI-DJLUQZ;JB3\0;L:V]^1,1-;IK[4UR6-KK$G1F8WQ6P;G%BJE2XVM[K<
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MPU6P3GC0$^^?I6#Y1H$?WV+2WAF4F2X-(S=(IDJ(-4RZN(DUT<&'6T6QG9W
M.^)K@K6*A,'>>\0',Z!M^@4V9W',$,:VCO@N;8]44-V^N/"*CL!'T<)E"QKO
MPCU9!WX%>XHW[M ^ AP G(DJ.$SUQ72!#BD^*9#M1COZ@-&:,3U/LPT%*57
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MLF7T?1TN)J6'3M/J&\C*6\!BEQ\YST;7;W,IQT]U]%OM0>_EW0*FTTP;O=.
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M+%1QKXP3GTC>=TA7/A4A#L60]3'R$_R6MT)V2WI:W@B8-\32'T"&3:<K$$J
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MJTM5ATXI.W!! W.ZHPMVI<_SOF\DPK>_0Y3OG(^TF4V7/N)*0L6KT%\P\V-
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MS"_CD93EO9:\_GI?UYP:OJ(ZL+AV.(W<]?LJ:_X$\9=/[M_1I:6F$OS[4>W
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M,67G]SQ%,)H0U6S!WO"]%?8V/;75X3M%ZY\[FU[17  4J;-X&IF+B4O)R^/
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MNTR<C*S[N7J2#*4Z;GS)@"N"_@%_FJ\TH]/&V3' /J:%Y%6GK .F=:;?,83
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M!FV[[<]+ZVRG/=W+O5:72LH<8MB[%S43$7-^O#2W3RV?S&T=%JR4I>![X!>
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M8<6C-\:$E?QE:1SUGL$DBZ0GLD6K-!X+7C>4.H/CN<WVCDG&!)PU*9/X\@)
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M5H_7[M4,D*Z+_3)#MQ_3'2(IJU%M(S+ L.3(*D57]G!UV[76) *MV[6VD!M
MV.A?JD\=VD^S1GC^@@B=T.J15@2SD=8 R49?DF0N#[GJ!F@/8_O*J!CGW+@<
MJB-N!_)MHR.I/D*Z1[)C)'O38J>5U@!'XZPX_6NR\Y&S"#AQX:VDXM#O0()J
M?V"7&@:(-KJ)TB9T=+PC&^D=@]V0G9$UUA<55!].5*AG"[9&=0S0;?0+J4;T
M?0>-KFZFQ[<;OE>(?\5!5X0-:QE@W!B-%C73H[PCRM6WC&I\@(;$!IB6?4:U
MEY/Z]VRGT2K#X-PA]2Y"W]^.B!_"RZUFB#:1&F#8&'BE>"O'D.+N1.S[P=CA
MLEG-8K>-R@"Z<K:AB@MH_<![0MJ[:NR,J0TP+'F!ZM/B]5@:8=F0":\:SBX5
M#! M>8,:4^GUH)I-JA5)]&HF5A/*=AC?E7Q!U>GW>OS,\#-,LE>#Z:ZU#7 N
M^XJZI>SK#:#CTC8*[:!+=5O[C(DZ=VX]H0&LC0ZCA+.^,>Y(WOV:UNRF4QA
M?T[15KW/1B&^HQ[F>:CJKC!UJ&J <*/32+?E;*+&'&C-4<V5L.]A;TO14#TG
MUY09 %?R!,5I&_J)M.--TR1IP_FC=+5@$2U-:N^7ME4P0*\Q3BB7 2)NP_EA
MKEOY<S_8C("-X]2A&ZNN>-:@:UC+ .)&EU 21 _MU%WU[&$VRL!2/;$V$1B
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MHPLDYDJ%4!PN$=J8-%I99X#]0,1/=A9!#A/Q=!D4FTY"Y.#T CZ0+"33XT/
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M46\)M=>/IE$O]_XHEM@ZN>K]S 7CR=XM/F3+ZU-+8K5BV>5)]H'=0H?4*X6
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MQA<HB<B72))W&?HHEEIO_8RG'"'^MI\/VQ>_VC_\L']T^.XMFNSEPI<29&&
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M;T<;YFPU:*!^72R4&?&Y"]KEB<=#V$?"IL0"U/9N%=%:I>:VUAO>O39*S9K
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M\X.A:#LG-9POK0$& (\^'R!P_5[%32MVII4]TX?;HFD21WP)9=1* Q>2?@.
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M,%4-H $^6JQ $)DK%9!6OGMD'Y ;;:5F0S#2A)Q9=#=-6:<P@@H5[C@+O;L
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MM!UE6SK)V0[4=47VS'A@5A];R-X(5K)(4B?J@_0ESW3@M  ['_IL-[2S'?O
M4E'0O>[TRX ]N/ECJQ?)TS&A>DN[KUI31*DHB*IU*6#'3.$CQ4/=T^\AIM'"
M7P'%C5B;4I/^"QE!\B00B:"\C4@6+']3)-Q0]2%0=@+9]EQGJ /Q6EE;J#X$
MO581NG@E?ZZ7>)LQZ_/G85QYJ0])E[YK!$D4F.A3W,^"TK4/\K%GV<,[)$@>
M).B6E?IWS)^/Q][D!5,TY^?C!=/JCNU(;*:RWP/ZK=G;(GG7I=IN?>\[V&(/
MC@>Q .[;ID MA\UAS,HM[8-$2"&X1[>[FITG#/C2"3BP=(F:6B1,*8F0-%NN
M9?&P0!2?(N:-G9$E/R+,;@R1_053HK-\E'J#6(9  ^(A;)IF5D U_#:F7/:P
MX'2FO?BGM?+T>EN&1AVJ(1@^]A[;TPV)28-]'\NQL5KQL&+\S\P5S0!%$:\@
M3]QOU^JJZ4!SXV72.3VGZY0Z_7+HU4[F(W9R.0NW=0TQ#*>>>9%QS5KFU2XV
MU#$'H0#JE4.,6^3@%$E4U<L6M35<M1R4,%%2WE,XL3<LK PRMH97-[''5JHA
M,.N4DSL!8Y,;IBIM3=7.EDR':BT# <G@*F9N&=L1>EH#AU.S5;:;X% D&5S"
MS#U]D3Q'ON<CNGY VRU3L>?#78:TYZL8MRC^5:#P%BW9/Q\I8LZVRP6K?#-#
MHZ\AFT") *G-B7TV0K?866U#M(ZOI3;%U=U4M85MFQA[RT!_\A )Y:#PVUT;
MCR 7I?[&I)^>TFX][#$]94Q/.?[TE!L_#'%$8C0-Y2]951L^_6QE+@I *'CZ
MU?:#/BWG^_QBI9"5)$/B_J77',)[?N(#[X:%/P]D)ZPPU-YQ;G,!@\J](7C3
MH/_=KRHO(B;-CEVOCCAMW>TT1=ZGTZ*0.MLQ_&6RE,E]KXF)C4^DK$1"'K@Z
M].J1W*!7I62+39X^6"?9"GF09#_T*ME2-J),PL*FO2=I*"4-DPE)_&.O$B]?
M5RK?=:[^%F,>4X#-C\-&'(C%TH;8VLN+:H0\1*+,-57UZ=\4:@4(HLV@'095
M^]#9:G;U"N]@0A0G?9^(ZL\,><CB1'8N>M+Z*\0M!RU.#%C(]<6N9@$$H''4
MJ(72)7B&*<5>NOFFJ<;1)&%,4WYQ'3YJD?=[.OED/G7@6EG31,T"A)BQ4S 1
MT5=1E-3%*NLS6)R*Y(.SRB:,IDD<Q2CTI&5O%1T'BU:%!]":,YLH57,-E'0:
M!%1*^D&3S!J85$L?T&&8\.@L>L;*WU:HU5KQ9+V&"9+V6F>LRFTQ227A@F _
M%/3K*BPDK>AE3:E&&022]1D" XFVW.#=GKSN[I.?KN\83[)RU#4&&02NM?F!
M8#7V)H\6!_O7$+,F!X(L&O)X((>Y@Q3 V(/)=Y2X&'O;"KAI@0%>^I;_0C6?
M-3H/ E1M/B#XC)6'%4=0!4H)@Z@]Q""@K,D-Z. 7..WI'G6I$(+.K>E/Y5O3
MI3'LN2"]O8Y6P4]R)?7ZP*O14!&-?2')"A&*FUISOQF6ZEZ9#0F_O5YICK#[
MXYR\O/6PG^D,^\=.5=@/3]=XCH*+,.8%!<2'T:Q5I9&9.H52L1*8VDYCBFH1
M9Z2 IXJLR7Z+GH]_)1(C (7=GM^V+5$K3V5K2]U$84+=@SYS)0@AU:R>Y%E>
M='#WJM(TS((7=Q2_^"2)@O77T$^C%GE*369P;8XQX5V]\9"]YS!J;ZZM<&;=
M,6"C@I.V8U2EUKHY-XDB'$=G"97[W'O-K)=[E5KKSN<R$E4"'XBDI2(V=K9V
M[:-G/V""PFK]KK:U7O0 R=:=HQ7HU)+_D 0OE;BQ\[![_(+#1";N30OK9;U'
MJ,;Q5%\OBVR32<^VWCCV3E& 0A<_+#".)2]R_")[D:,XGI,/Z*0C'O@.QU$%
MT]3RE\77M'L/+.164RI6OA=2I#SU:MDJ"]\0@5N;B<[518!H<-*/R]  %MD=
M 5G[_J]V*(4KQ\&N*QOM06%E4+ MN(S$"K4"A<8>*M'0;4',T.* X1F*%I/0
MX__'8UPO*.#OT$WB,T3IV@_GOZ$@D00'M;J;JAFH;2+K<V%=T.\+18S4>^QB
M1K:T\G.YI?6H" FV;@+=4;Q"OI<_5<ZT:!HO,-6,"6ITMAXF71ZLBQ^>YY<2
MIC/V_VR6GY%(%DX4-K<>'9AJZX*-=Y0P'R%>WS%3G[_/SI?B%>?Q%LM3V<!>
MUJ.C)-ZZ4.24T8OX&Z[7&$7XGM=3F,Z^LGG/YSN,DK2;]3"IJ;<N@*EY.&*[
MY MD:H0N>Q:QZY*$62AW:,W-DW3;RS>\[%$55WDDJ#F"_3#5800"TE@N/:.>
M)MBKG@;IPZC1?P@@ZK(!06@L&S[5N)VK(%GXRBVMAT5(, 1 TWQV,.,VLQY3
M5^P>^\OGA$9X*9X-66XEU,%>.6O0+8OVVV"';>:LZ#5XH0VS[6 O+!IT@[ 8
MBP;4/JFW7?QE6D&1VW!-7Q6L++6T7OA"@D$$C#GN$\]+!8:".^1[5^$96ODQ
M"B0&D[B#]7C(Z 9A,>:JW_-<AQ![%XB&;/V,F'V7+). 'UVP[<YW?8E)J^YK
M/5B:+("XF;N+S^?[@@2,C&B3=^P&":\><$=H*MR#7M=N9WSK\6^135!'C,4>
M"MLR\\ZJK&H9'\*>UN.JQ0"(6"'(T'NB6WK?(!1?%Q5EN7V69;GQP1P2@C='
MQQ2W)X7D]?+;9%T'F]RFEL=XO[2%##8-,8_W3<?[IN-]TY86_/&^:=_;_7ZE
MCEV:+J^1!6_\LE[6WZ=0$@^!9"Q6G-)V1WU7$AO;M;$>@!*IULV)2^33-%PW
M\?Z5Y)HR^YW7<0EE)_+2;M:#HJ8>W'WM*L$4;3G9N5XP:/IC6(]@35; /=UD
M)G/3%&9)UJ_ML&F0#T'5-#(-6%]['Y[.P PDWEC8UEY9RTF&Y-LT@@S(]QI'
M48F(2T*7F.YF*R!MC9YVRUZ7 0B)IG%:/4V7[.T"Q;%_2U<1#4G96 )7*<*R
MJ^LR6?*T-'CM5W2T%Z(:]$-H_6(P$BZV->!0^,>?9*'P;#0G&\[9C5>(A>]8
M;8\=*1.R\H\?3\K<*#DP7P=2@5U4456!CUEC#$.>LHI"Z,Q ET/K#@YJPUIV
MQFM)S,K[\N.KB\VP[/H!QEYOYX\/, IP'1]@M.CHY:@?8!S&[?_&[_]U6 $
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MLF4!2ZP,?,#5<T$'\2^TB]LO+73_BC';T5?T+X>;\T&LN9QF'#S45G"ZSN2
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M<4&H[2VZ2JC5"L2C19YOH^P>;PIBHD]?S#=K5""'9.G*@.*( IB6&D(6">%
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M7.B) .*""I>&"UP4-;)!N'"QQF1%N[>?2/&Y>J[KLVI]TTC[Y881<I\C2E%
M7#'ATW"F44%"IRFI&X8\7_8%Q4651;VG"E'/M-&"'7!&DH-$&!TXB2T9CMEZ
MRTU1H<<"?2PQJIXQXNFL"?U[IQ*\L!/JII$X9@<BQ*@\3R*BHI!)V/NM(UK
MTMTCDB0((EGAZ>\A:350H^*9-;>4PZ0[C^,@V%UZVM,.=A5?#'(%W_#()@^"
M38X@AYSB:OW)-5?D]R*&K&;4+6ZO'^+UA#R/C!4 !P/CC@0(CFAAZ8;%W;L"
MPM3.VSYE:7R9%9%^E:4GX[EBG@QO4"QO+P"( 3(J78D\+HBX9)#O?QKEG\AV
M4\6[.U+$&+,LJ[*-5K;U-T=MOYP9Y5*?34ZJ@'@V!J^&@7L3J&/CI--CA5S,
M8TGCK)I;$7]Z>([H"[S=5B7K02DP_2JX4<GS]H*# X--!H,&(.HYP-1M.'!-
MQ%5/D%!&'>U \[-R7P40)Z>[>[S$A)T[>,1?JE/ZH$^&&8:#KN_9F[,[P\F<
M51$$"<>BU4WU2M0U@)Y8CEAM OW*C"!NQ??]Y5?QDO!$DH(LJ@K3IL&3F-2G
M#4S"OFAG!]SP3"\)@EA6>$,F79U=WJ-: W540AQ(V-\+0B/SNKH@I"!G!>V^
M8P-]7)3\W\UB<T"^ID6G 8)6SC -E[=(B62(FT%[.^A79LEWL*K)KSD6T?O5
M:T)B'U(O]U#\!((9,AYE1B']S@$..M2/9B4_--GMDH3G3SR$-OC,S<^0/O4
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MW2&'1C0X5=WP2;F$7!JMN3A*6_G@)#IGZ6,$)V=%:9CK]&3\3G44\/HSG8X
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M/;_VLD"9)0&T<JJ[A@N,3J*9\+O=QP2O1B%TX.H#MP4M(0V45@J(KL%*[ F
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M>[PL82U.5H%8P[.1NCZSA4>YT\T8=E(,/H69@M9$,%ZS?BZ2>:PMJVEW8PS
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M[*[O=7UCK%N]Y0U793#1;2QB:2;#%N!8'.OLB.2)<F7C6"F+PUK8HZ^:&&G
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M\V#+#77SZ%HU-89C]O,1R=-\5=YAPGTQ#E$ULK^]@S)Q<D8J==ZU J(:B*M
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M'UT!1AIXYB5>$;SB&T\QE0/Q>3_FJ6/W($GZ_O@:J$,N#,1 44.-33F2V.;
M@L%UFK/#-Q116EU&<5T0ZTNZWJY/"T**SW1\=!9MZ"_53O,*QIGP6OEL@G.]
MDF<C],$P<@)H:7<.OQ39"SMC$W,S)V@M#*"GQ@*-=<)$< :?XTU1IMJ9]OYG
MK[5^!Z!Z17KKW\ P9@!HR(;F9].7/N*KO"-X$Z5)?2ILD2?\D)@H(G.V)02K
M.PT'M=_>0:O ,P;T\#/5NKRN3L'4X!R0NTSSM,+\[M*KO**@4W:;KR@L%-.Y
M-0TRNOPR-U6ON<@CG.FE)#OH@0D)(\#*BW&-/(KJ2D^UQI'FOS7Q[TBQQ&69
M%GF476)U11^MJ+<YL 5L.PO6R 4GB ,X76#:=,1AK-/7IR]W=0^GVZ,=2GG=
MAU=#[.V8]T6"4\2,2ZIS4DNA1(@%)T5-5[[&PW:?S%UU1\QOB0@U2,4(J)4!
M0PP-,%W<2!NYX-3@H['^&&TP AUX:E+P7@[""%RJ#:&4!D,A*\0AF7Z)2%IL
M6:T:0:IZ; R#4F)@97*UD?!.FCXTB27B9UBTZ&&2LDKXS$@,3 --:#_F!$=9
M^G><L)MLKXNRO,TMV_(6%<\36=,7<$6J*NZS;771BMWQ^VU&U;]C5_VFK054
MMA4S/'\^/O*]6M/H0<1!S;U;^RH>TCC>I@#@TXW#*4WW6D5>K<[IZP1;V:9=
M14IXBN5Y5&'=FH.39NAU;(TKMN7K@5IP\HW'.B1@<WT'2B"<)#G'3Q4=V%9D
MR[-WHS(M'^B8(TIN<S8$846-[PW4<U?WNYH]SJG^:K>;+A@FC@2L&FCR"M8@
M#C;UG>D>S'JHV):U-9=ZC(%PE'1Q3$]*DS906CI 5JS+<A48Q%3%>U8W)>7C
MCDN,C9D+SMJA>VF#2[:>6J$*AHSC\$J9$%P/Y47^9EM2PK+%8%"$=/ Z'+5L
M_ %)$MUL?%]PCL[Q$AKB<)+C,OSDH0F6=]&.=>;UVM(B3V[HQS(N^3EI^LWX
M=W:E?Q+ J@:&:>Y8M9WB1J@&)QY?G[K')::O\IE=XHI?<%9L6%BMUSE-2U\6
M1>^KATZ.2(N*1BTPI'.&*F=7"1V>J9'LM5!<E$=+$O^)%0T[)]'GI/B<*_?&
MAQ+>ML35T-H5M/[/P3^_'I-<')\*H:21.M*'-3*0U^=7.>"BY8T [BZTI+"K
MP""*,T[5>GBQ1"O.(8)CS%)Q8/1.[/YFZD_M1'O5K2E,:E6\]T@6\%)?I)$/
MSJX1(*5]=3K_IZ1BO4^6QE2#C;XSO(HR_C=VT);^@27H\/\^9J^DVFE85&UM
M ^5&A4W%6]AR!+_?"C++!Z?4")#Z [B=': 3%%4S5BD=12'6(MBEW_O=*3H5
M."7%)TS.<91AXNZ[@ZG E'-VUD)%JQW(%'4%[TY=%OAH7"Q+E+8VC],#EZ3J
M]+[TO_8]+_V/W^ZRJ%H69"T">T'.R&Y3%3S-0769J9N*#\Z. <^XZ2(?G(,C
M0$H];ZV&&KT3)#3%G;AS77HZ-\G80AZ_D7/<F^BH 2";Y(0#X5H=Z*0; AU-
MO&NW6U<##:5^QEERNJ/Q7(Q7<3*A<W,S!N=(T'RN3!FLG:!G:AL][1"=7_"=
MFN81Z(D_ R7\(<%GI.V[^( C=K"6N?77M'K^F!=/)28O+*!>Y9MM5=YCQD)>
M12@M\GOF.;M&C&_P\U9@*M R_V."7)\P\TM2WK@PTS.\MD,:%=,B>:@B4JG:
MXI%]'#;04[Q*\YQ-PD^C#$3B^XR.W_%7?97'A)K"YUC\[_%?N.ZYK[0=FE_C
MD1JF^J'!!T>^/94W=&*<;FCW23]V-U7Y*<H_-4MI1UK]<';9ZG&3KDU]SK8)
M._99+RVN-P0_LU7"%VHI+M;X6K.G$ Z+M_67T*^['>.& A*\K4/P7JX!U)Y;
MJ(\LL.,+H8Z7O,K!GM]IEQCN7>2)U\&>;CYV(?*?H(SU'N)GG&PS?+N\(P5]
M4]7NC@+C^TN_;U.^?ZE:=1RO[O48]4BG>N>K'76#Q\:)@.5SMT+I!'$UO@G8
M*AYWC7+4,6V-:[K5RC&*?H]RNSK2/]QMTP)#1V>H(XGHN&89_+)KS6LQJT"Y
MY%K%/9,\&-8Y@-1=K7F"+N'<K6GRHS,RX2.1":]"-@&%>3KG7)DXU'\5S-2
MEIB*F2*=;ZSW\BAE"L'YJHWV'TN\W&;7Z5)?4<5!$T3/++OBU#7OU<!PT1VK
MKG/FO3)NU$X0;J]AW'(3B!41"W^@P\'1<US&).57Z=PNV4V3%U\JM@) A[L7
M^7:-Q5'DZ2_2U3XPBH][+2,;@IOQU]1<1GED&?&>](>\)T@\!K'GG"!F_ 1U
MGH=^W3\+=1X6?GA\%FW22BR1L:6U;87)0[&L/D=$F:+NKN:W6K6;$_W2U68=
M,,QV!"K7AN5)[33:E[5T<*YIVZB):38E$#%9RS*S!AB..<$<,NRQH+1DM2,5
MHXW@7%O$\7:]S=APYQQO"([%$C#]=X;Y17XYJPE/JO3O_._:%Z!Y8?.9]WKQ
MV,POI7=;V4RV_;2)/XDVD8OK(4R;#3/[-6Q$+#'ZSZCS$%9MLWU*L,+>&B=N
ML*:BMU[>\P92Q8*2Z7LZ876=4N4X?*0[*_**1#'? 3O;EE5!!Y?7:?3$2S_H
MQA1F':]C-Q?XO8&;20%B;IH+8'GTML2$749"Z# N9UF?,VU"ZFZJ,F$4)4/*
MTS3+<')3\+W[5<X&I*H4@,FF_-UV=9BS^_NPIMD)/NJ; ;QT8[%00$]< SUM
M61$9?CRVUH,=)N]%*],2>ZH1,(%4ZZ!S9)4L!*?Q0; 5%^LP.4?&OI[^$&#Z
MCAM@;SWBP9&%5Y,H>:KIBR']1A;S&1UT(+M,&LI '$QI,$J)^H(;[.C,4YNS
M7RS1#D<'GXPQU7%A9UW+^K2_<G2DDO);ST4)L5_3I2<2/,Z;<:EKN_#2"$TI
M^6-=;R.X>%F0=@YY1_U]CDR?7B?NEP-FT'TRJ&4!L<((4$F/$BT+LI_'HTVC
M=$RBZ&X^ZOSHEP3*VXW:7P!]8,,-1J*U'_$8AP"PS9.ZSS$T[8&4YX^I@CCX
MJET12)]7@4OSG9GD;#67M&6[UL5+E-TNZS'$^18_%N<LD;PLLC11I1J,T/-8
MNLO=C4[Q+KL2#.:,0"I/];@J&PX^U</$A,[\J@(E?7TF@?]/\7]W:U9PJ4(W
MQ0M>/V&"WO[3":+$^:= 4\1)8WF $T$M1L-H'K,[-.<9Q\]X'N,!K]A XAYO
MV$Y0OKK*64T'3J+37?VCV]&,$9;"G-(8[:KZP(:SF>#AYG#LTL5ZM25&Y%H<
MM<90Q]H)*_/02$ YWF'P_MIRP,--U>\ECN[.]&]VM.O!8:X[6/D.2 ,]81WT
M$)>+6:N RV)>,S T('N9% ,9,#S2 )-2&HI\]89?4!SV-C?]!7GU/73A+_C2
M %)G6@5YF7RPO3]&/;PV;E_\Z 97EU3C6E'OZ*:H</EVD2?OI G';)9]?<Q^
MXM C)H8:4?,[9S_?KKN2C^>JB#H8K&[4<6I&60N!EM.+B'5?[($& Q0%/<!Q
M1?6T"=:"A[K97#AFT33T[=OOCK:L)!KJ'BZK<%&RR(!I;%!65+;K>%Q.<H/?
M64HR*X"JYN<(5EY)ZEZ*>K30>\0QTB6NBZBHADGMCW!J+^JA#;\-E:"?@XD
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M$Y[L(?#)]F(&;^$>KZ,TYY?%YQ6)XFH;98^8K-]I/X]?$'YC0(@7W&_[/A$
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M(;[B$[PC.5ZG>MF,SHYU,'(*@E<QHY[^:OV,$*7'@^F0_/L\;/#M7 >5[$$
M&KBIHL,9ZYM)21V\78I_5^E31OOSF(I6*2YU[_E HV!*>SB_ .<R'U:+<!K+
M'&Y,G<&S%L+*1L?"-H IE:_I)1\ ZVYR"PWFZ^@?75YXB,64/A(X@2"D^\,
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ME7PI,OKD+*UV\-NO[9AT_^!=B&+E8Q" :M/SO]I92P"X/_[5M?/979]ULGW
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MGUZN;].(/A<T2FF>K[+&YMA*P0Z#G?3$RW$2>R=> S!H+( CH5U)>Z"<AK2
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M_<LA(@U423Q< !<A]\D@!N;$-B<P9+P;0[,A7T+RBZM9(,$1LO$F8R,VCRY
M*%GH0K&%@62=,7R;QZ[W-6[[,0H:%T.GD-[E["]=YQ/K]N*1)C%-N>W(-]*'
MJX18Y)O I+D!"9*'\CF)PR44!.;DPDKSP.*,_1<-F,;ZPU'BDH?9YJ,GENXA
MW@LAB2P>*2P".]D)]/P7B5\NVCMX _G@K_#D*ILR->&SW-&\51FSTJ3;]"ZF
MY7(-]\^4[3-XT0?CQ"4^\TW(.>55!)&Y_YV3N-EEU98(SHKX&T"X0K@(N),O
M\2-!>5["I:+ENK*8J^R!LV##=Q)729#+%@WU ;M1U701F@$I,AF:;T::$"G4
M( YUR(0[E#N%G@C\9*%RWUN)"\6&VJR3G[R>Z\LO<9KR[U\$RQ0.SK_0[3/5
M%RC;0%P\'Z!22_.YOB3U>+*$FS)I2'Z5,*>^+R,G$'QD-UF9RC--&R\,@Y#Q
MP4ZAQ@,^E#1CO7[]SG'T _]7^+&B[\5EPO58/[3K'8Z+(TZT&FZZ[AVQ_RK!
M", 1 ?C??G(DMI2]<)/Y$\O>B@UD<@?IQQ"W7(!P\6P$Q5J:A (E$I8H8*(8
M^&N+@SX8^$1?F*Q4!1Z;Z%6VR_*XR(>8Z J(BY$CJ=;;M%7@1%2AX A(A0$+
M1Q\8A;(8=6ZYNL$DV^T,,'4$+"Z^CB=<CR<+#(*ELNB50J(*R9M,KD?V/K!L
MS;=(HN?E#34> QC'H62;A4@;BW:MX61-/06(G\(-C<J$9L;+9I<L^YTRB+%1
M)FH(]%C2B8APL?+ 66B65J&#C5TK4M!@)!(ED3A5H0;?RMG_$>ZS=#:QZ,5U
M3I+A,I'QPL&Q&@7$M[_L&D[K?)7)<<8.'ER"<=@D#HLGPEWL9RD@D<#J9PU9
MW'RVA!::1[B8IM&E*2<?X#5V4-=:^")2D,49Y"]QL?F:9L\Y9:]@!V[370DQ
M:XXJ3F17R$<0&@C_709YG NG#RX[06[F;1HF903!;>E=\BT<HQN:YO$K[;D"
MZ8L07 +C^2MTQ?.F+JA!M@U!Y(U31,H6220&FD1>7D,4_"FI(L] EBPT1EZ"
MZ@9+K$B#8PIU5;=-775ER=OM46N_U<]Y$6]A8_LUI^LRN>/$Y@,.R@&X<$GH
MX1.QMJD5*,6>LD9*:JQ$HB4"+Q(/]BYXSA@4,/NH";8L4-:1N)@[1*;6_+H>
MWV*9WU#X*TVX.$5/V;IX"QBU\,,R#A<W^HG4H]YJ-*F&>^7$BH:;-$NREP]%
M6(]V](S%Q9%A0KM<:2!("\0K9T2'W" 4?D55NZGN<K_89F5:Y' 1C4;W6=&D
MZ6M<FX@'%T</FX1>G4=BDQY2E0Q=-Y_X@-M_@)$\"Y1\8U6T+C/XNOT))$$>
M4\8>:4XYX$:6RQL*@+N#XN+Y:+H-]SL5 L(QD H%D3BP!+]_:J4V@K>T"(OX
ME0OA@*?J!H:+HZ-HUDQT\%PF 2-1G(=\K\$W.1 J>VDG=0IG,U!(B>P67@!W
MGP&OGQ(K0)](2U2UJG0#K0]!R#43?9J^":M9<T5E3*IZ6W[,II0XKOVUWULE
M:5GX8!Z+D"&]A YP)A?Y[;3>"E2991YY9#SOJY\@_/X]9WI=/?!VG"<)+=/(
M?B]5'X+Q6QOH&_SH ./WINDCW6:O0;)<7P8))'1>EW25=;*>-(:X .%BT0B*
M]7Q[ 0I<>Y; )"JIJ,&U#^]/?:Y9\!9E;ZG%.M6/<?'$2)M6]TPH2E2-\J0C
MTBD7:4OUQELY&C\QTQ'$, @N7CC3:RAS+C<L4"0S:H4EJA*F+\Q;S#THJ(@K
MW\4A' .D+W?T)4CX#S=\!\UW;'S)XW\(KW$P06LZ+ER,/GPB^G7$@JI8>XV3
M"*3B-XF6 %[QM\",95_;/MZ&^GA)0L.B#)+J'.&)LE<^)TNL<10T+C&80GJ7
M\?MY'O\:;'?_0=JX2'T:H[!Y#56*(\LG^B(N.5L8:AB#BVUV LW]0WU^\,])
MO(U36932\KWU(;@^MY4^+=F\-=#K1W_DR@CQWR8I!P[O<SB7I_DRU4L6#P'@
M8H@CM;J3(L':=Z@A=R 7"0%\8<I23Z4NW\.DA 0%N7+2Q0NC(B^BYQ+'( @N
MECG3J^E4!:C<"DIJ4.^Y_MVYV([JC<-P\:>71NV07N>$1V/7U-!0=$%">U2&
MALK@]J&XN#%(9U\QD$2!0**^@/&S[8(H[>UMR'^/PR"QJ(9Q%#)>])"HL4%<
M>KZ])=5HOXHA*7?DP3DP81P7D+#AGKY=L_)EL=MQS10SO(E9;ELL>D?C8HH+
MJ7KA^#<"0*0%1008,AXYL^<\.#.>*3[9 >T8'TT%7JH'N#YWARHM0A*('DZ>
MJJ0LTK0,DKK1#@3>JKJ+#Y1_"3ZO%WU#Z 2%BPMC2-:.Y 1LJ\&0N+425_4I
M=S6\%Q;"?1Q*F[[J0%.=4E85\KLNZ6)=4%$S:K7ACKF^#YF$!A>3#YJ#MH\1
MR-IMI02WF^2Z754D$8[Z D IZF61 I!ZZC_55'6Q5471AN!BH94^O?E4NR*-
MS_7H-GV-__A(:9U[&]/<7B*H=S0N7KB0:KCI)V!(&\A[P:#/[]D?7%G=.-0W
M&!>#'"C5(V8"!!=[JK*'J^!=%G2X39^*@!7E3IPN1W%1,D-:E1L8+I:-HEF_
M<Z%J.!;!N[S>!K?:2"X1R.-TA<%/4Y?NY$3QN'8/V6$>:B#(^6>CUX5WLO!=
MV +&P;9]QVF89_OCD3/,2*P+MSK^'PY6769I6>4S#S.J/1HYFPRDNC#I&<"J
MQ"(<+&J*)3CS20-!SBP;O4X+6%/X 0G;*N,@W"F]#$8?^P9 T;+1C>Y>=B8-
MBO89NN=6 09_:\E>@C3^0WR6(!GK8=JAT3+7F71'?S/;P^/?[:Q*#BW7LDG;
M(HWNLU1<CLR21/0/EVUMAZHF3$6$B_,'SL):T&FY)JHG+.1H0A6G%DY2(T52
M+.$7&K]L"AHM7BD+7NC^%^B);3O"X6+Y.**UEA(*F@02' HP?0I;O/4<X7:Z
M;X+_?LF(^R37>"Z//&T"1N&0*FIO<D4'+X-)T4WJ*'!<#)M$NV8^ 0E4)!*M
M-QHTJH,9:>M9K%!Y8?3R+:4LW\2[JPVGGZ\>T*/-@<..<+A8.XYH+7&Z@B:A
M (=[7UV;Z967'2MS75\U=R[3;@#!Q4%G>H?*M3>0WE-&57!^^&P"^8&$ZRD$
MGI,'E^;C9](U;GRC\6J7)^]1/GKO#]=L8"!S?YEV--9Y$^< C8MU4TCOVZX!
M%K+D)J[;H0+%#NTJ8.R#+Y6B .5R+:,4&CN-HW"QK8]$K623&JO*7'+'0<95
MO*4.=8B_R=@6KOM5\3MCGM  #"[NN!-LR@ BH<:PM8!NQ3B]\*XSI:I[UY#^
M5.-P\:B?R&$=JMJ+^;F@)8)B7VBQR5J7SG(POG7?M.LX*6'RGU^IB4GC4>#B
MWV3ZM5(.L&*U.L%%"HA0 >6'O^LUA5I<JG[Q*GA_Y.3M5T1N2AN+*VD1C:!-
M)]]4%L$[K+6?T\)\=C0G<F0R,?_,#"WBJXK-A"H$LGUI6J,@5.% *SN/M"A9
MNLH>6/8:0^>41?0_I=*@2?+2A_#\9,1A-H82SW(H"9JQB**G"UBM7L0&Z_*C
M&:(RE!=\-8ND1;U-\X*)3YB+R_JK39 N=^(*^>?W7<PW;5"' ^H-07W/V_2!
MLCC3BV-YH0*7I/G\!,XAX: AASQ_D+PU3B6;DP!H$B7OB@_N@M94J8KV!:>+
M9)(P.)@%RD39G;"B#0YP=X(Z/RGJ ?N=%N(K6_MV=D;@$B0;>7K'3AA'Q$#/
MZ>F5:34LO?QGE;%S25.ZC@LNN-L@Y1_@.H:.NY3CUA>APU'BXNEL\[$X*) ^
MT6E6$3=/5-93#E>R,2U;S\/6\KEK+1?;C!501D.6,32O1#,@QB4_,\_*N%XX
M+A>FU2*HWJ+J@7L1J56\I7UFO_,<%X/-Q&F5G?DH! ;_F*Z./.\$9^=+%L7K
MV)/3:2<#E]QX_0;^W$Y%FG \MXJXQN_\MG3B/A/Q+AK]+/X++8KX>AZ*D!?\
M]/F=LC#.(11Q7YJ[R>&A[<^B/5,_C"^52BMZB?H_T"RJ2(8X*?S,?ZBI)JD@
M^YN+>>A&KY/Z* L&!P6M6]MY7I@&Z?NSZ-PA'P?94O;639B5I=HC3CE9UST,
MOS7=T\)<N%1O/'E_'LV;_&UPA2[=].X;6_1DEY3;=-A5Z3!5/:$/+ Y/J8KS
M$/QG4<Y9OY8O=57=>/@6S]4_U519/:1D!_/YQG2XXI6?:$GGW7\6S;)-W-^:
MINCQ? 0W.5JMONLCW09Q&J<OHO2%^A%L%?]IOH"_P\L0"O)Q9SJ_Y%:RR:J7
MJYHDU>^O\OUG98U/&JS^\X2D?0:>,8>677*8[K,THE!N.X:D-GG>JRYGP_QL
MQG,^U+AD</9Y:?>+Y((LA4?9,)PN97Z NLV[WSL6);A$S_=GF&(;\WF,X]">
MZQQ]T9H;G4]?.U-5B_0R2%:4;7^<W4$=30%"?? P_8-\!#<MT,2]<7+#ABA2
M<*K(CUY6!TO>F30KLM)Z7<0%)IE;LJHFXL$EB8=-PCWS;MM""'>':,M7R'UF
M2"G-$:L%7T^$1FBL-@W"Q<<>"K7"ZDHQQ?(#JY14[_-<B&QQ6ILE_.%8(9/I
MI. 2)._?X9C[V)Y(>,\R]8/W@,P!_%B615YPUY23[Y +8.71[/HR$UW?EO+,
M^U&.ITE90Z=SMD:?@GF)(-U?/RYL!5^:9[@$3"=,"\+ " QE_ZVM9?<>(_N\
M)MJL972\-I(KGY,X_)E/!@J VMK(&0;A^N ]%&K72\504HWU6\!H=27?#N7(
M'F$OPV3,R,*(@?&X>.)&K%;/:'5%&C#2AO/*JD48LI)&*I:MWZKK/,?%"C-Q
MVH9.CJJOM&&*JE3Y OHAPKBHRA >7'P[;!+N494Z!6(OGE)M5WR&57HO=TZH
MV'$@OK,0CWGJ<MBOO2*NV-&T,K U\.H,0,90,W4:AYJF"UZO*L;;7=+T%5^F
M-R6X5,(JQ59GT@D*%UO&D*QME@5LJY\Z-,45X*2"]]L>-[M-\SBB;,4"V(??
M)($>U#0-PL6B'@JUEK@946.)&DQ@M!=[]4ASRL=N%FET35]IDNU@EC^9B\'U
M#<;%#0=*NURI0$3T)VJ 5':R%^Y<LNQWRJYID%#&IP)UI9.$BH#3 X/6HL7'
M$V6O<6CKUSD6 2XN3J1>ZY$LT!")1W2?:&,B%2JB<'FUAE=!OGFZ?;CB!J)D
MUCH8QE&X>-='HEZ1,=] ^G/)_!:9N*>%]##!P=1/"O8?X_K<1MJT"A,;2G90
MS$,>7>]8MHZY/\"D0[W.(..<JG2?"Y+2 D8UI69H?D'>-C$WD7%.@J)@\7-9
M")>[R"1DX*T3N:GMU**H[Z/])TVBRP^^ TFX@J<YC=JFQ;!'FXX,EUC,,!-#
MBUZ].=<%EX?6';H+LN&8X0@&Q )Z&U0O(,_2&$?B%5Y$Y6O*^,NAH(TLDVWZ
M1ER=U);526 .1XE+;&:;3U=X&L3D!6JUBCV]49[ ^E0[>YS2 _&-WD]S9_@N
M]UE!\Q^X#Z*G$LZ&&:LLS3.M'I$2R]CYB515KWJYED=#R0=L"^71>Y#: QF.
M<+C$81S16J\Q!0V.205/) )28_#JP#?SXY9Q*C^'0+&RU)'N/JY"8T"<G.64
MM0V3A8G&4;CXU4>B'JM*R?[^V6\Q4@=WUK2*3'/Q39APL?+0:1SNW"-:1QVT
M$[MJ.NLE1IW,9]UZ3\"&BY=S3,6NG_FY[KZ?;FA$69"L@G>+DNI#<#'62I^V
M-?G+$U%#"1_K54UODHS%45"?V%N^O7D8KN_?2V.7!VHP44D%KFS(PKUY\+^#
M(JL_UX;1M9Q&SN<AYK .\F<QD3+_]!($.SZA'__/7VE2Y-4OG^"7O[SGT;^H
M'W[[FM-UF=S%:PK9SLOU'0WRSDF.FK<3A)$=,\O2"-)!IAR&_Y8\)R>3K;T9
MN7];1:.FWP*" ,@%$<,)@/K2\VHBH@+()DNXX<EEAI:))?JHWWY$PXL>XLR7
M]2_(HG,@\2 .(]"P@-N?I(2S_@=Y -,F5_2$'FB6/"_FW_Z.F-4'3<@F'C52
MHK!J K./F%28/4G071P\QXGT&=/(3:6'8! IN#.I6E?%!E!D:LCA_WL28 Z9
M^U?S(TW(?@IPX!L\J?MRQW<)A3!H5>ZL2<,-PQ I=1]U78;58RO/_#L8_KVG
MS_\336&7Q@5@$6WC-,X+(.ZUJAQD8L4 ""*VN%*J==.4<,+,[D,2!>I;6:ZR
MO,A5T=/NI9C!P8@X-$RC77T$B%P*%9"GU*D!$]8S[+>_>>>$"W7:V0@D2-5\
M@,-G3_I0N:I* +@C6Y-ETHB>X8ATPH5*/3PJ82I5N"!M,&_<J20)O ^XXAZG
M)2='B5J6YI=TG;&FFAW-/[]S0YLQOET)V,=M0;>Y^P;QB*]#)1W'GZ7E7I)T
M5&0F2?-BTKR9/(M7MT*.$*+'M;U\$+F?-C>S>8K -/<09;+(>UPZOWV_J&W1
MKI]A# )U!R%BDYTV8QD/KAFML;XN5E-9'ZQUO+8HZNZ*X&%]?5KQ#69>LH_+
M.$G,MZ_'(D' M,-I-]WA'HO,IZIIQ3RM^J:-1+0<#A!HU+Q/LM>DJMY#6L5]
MY&(%ES+\[O-D;.\++399U C3=?P:1S2-\B6[AATIV')8=DV,&X<!$4,G$FYH
M91]2&N726U%UC256TJ"](&UL_MQDL GTFLK_OTVOZ9HR!O5Q:Q_.XO . R)B
M[3AZ#4ZH@"+?5?#?0]F$"L6>TXE*;1];-PIDC)8+W2[+@\1=<>TX$/%W,NF6
M,N0&=:V0$<!6;4BX:UNA]%<H PI!O*1 &^S+JL1>_BN-7ZG>.,$%"(N;-(I6
M\]ZQ'QB-X16M<"15L$ERM+I=*$0J.8)81WLKX$D+ 1KF<0<<+M#F#6UN[-/A
M4#.PAUQ'%E886EQ$P\3KDH*%>*1)4$"!30;GEU<E@Y061Q^H!P-JQCH1[NH5
ME51ZO@H;4>@NB$*(AN$/C.Z".*K<.+7O6J21,#2+/*>%HQEVP81: $9-P%$0
M%,YJ/RN.RZ0)E_C0R,$UY0Y<7(SFN@Z'FL<]Y#IO> 0&;/R3,U(KRT/PX;[^
MFB!1\["7X%%N5+T2*RQHN*D*4K9RSIQ]J0X<:D[VD.ON2XG*G2T4:)C(G8!5
M=I@G98%'S50'LD=X445V!CZ4M![Y*KLJ\X)OMYFKRZ0#HF9M'[VN#I%" 8RM
MD7CBY#TMH +4 \L@NAU=?GP577?K5)P%-/NS6E]W:$0\G4"TL6A6A0 N^WWW
M538'_IXTR6$*SU[^^W6<AS)M@0^OLQ:\U'Z71T]<CA>AJ+)MO#*I!0W=P+"$
M#4=2JYW@.('[RB+I$F>.?9MS3!QA$6GM:))MS 2KJU!8#^6\I'$J F\R5FV_
M1<W,1QIOGTN6B]-AFS[V B'31C=:+>SK!?:LB9RVZLP7HFC\WZ()[BNU!Q,<
M01'JH2O%5C6$DH??[9V1?T\:+'YC"Q8701J(J5Z1 1H17R<0/<(KJM'@]8H&
M/L1-G 9I.)7W!FC\O.\C>@3O:S3X>0^S@/^!7_ :)%2<<4%V3L@WW_!@D4;[
M/[1&RD;2W1VC[,+0ZL4&_=)E%W63_)R6 D0RZ&GB)CF^($*:&_R0]%&]F<@1
M<(C1^7$/0%)$#!& "U+312K""%!&)&G?IG+,+NL(KM?..X]C2:+IFH37VS@B
M/>XAB".^[%ABA)U1B,Q4#W&6*RMB+('!%X0/]ZB\<-F_CEH\T1=&7R"H_#6-
M*%.EDJJ3WD?Z4B:!-;5W.C9$K)QA$D8O"!2R04H:K*0$M'55JN8<O(7ZQ.)!
MP^@WOI-[R5*1'_=*V<=M&MT'V[V#4_LH!.QT($ZK2R6'DVH\++D1I'=#2PJ
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M#[V-@#=@GW^B4<QVU5))HIAQS990$5HL%6$H0AFW#LZFZ\@/,U&6YT[43^*
MIBFC3UDJ_"R/L7!)\I,#AXI3L=(+;ZCQP1'-SHA\6&0G/--U1Z#NEZ9PM9B
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ML8IS]NBMR+]U>2OR_YE5OS&K?N3TBF1OCPK7Y=KQGJ].7%&W7.V.WF%O]YP
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M/7'3K;32,&%_[,N0+.63.!)/5D 6($5SW&0KK0RTC.(M][=Q^E]DOX02W92
M]<3-QM**PX3]D25SQ=F-([*S++C!)K\ED+7%S<W2HJ]FT9G*=\:RNLC(8WSY
M*APXA%N$HM*^G]LGT@7-: #<Q"]3J4+ P)U:.86_TKBHO+A8_C->D_,XBU*V
MO?&^&LE,/0INUIBAG=P5) =DR0]?O_.3+5U2OZ3VT7L](Q%9TC0QDJ=^)-P4
MM %D"@4+5ZY\ 0F]J"3P>KT1M3(YP4\TI.E68ZET' HWI:V7J*02-X,1[Q
MLGI4[7'SV@82GAZ0"=E(+<Q SWB-]KC);O:DBWL6K&XF,4GX@>B>_)Y1MN=4
ML\Z:],?-?!M(@N: .7)GG=\R/]*U> )(>6_]8_W>.N\Y*[J.7$JY('J=4WRC
MOI.6-!W%H2(^G9QS6+A.?8HV5-"@N(I6M<>_2E)B7O6C*+@8^QYZFI>C>KW1
M7Y&.6%/Y=$6*D0!33$?^ 8EFE^UJS?#AABMW.P>#A@!T>II'Y$2=>0D)JH%9
M<_'LTJIX6NAL>VA3/J^5,W'@) KN^-E+6.\7\=JCD5Q^=KZ&K ;MDFV5OAW^
M1RX=7>Z<>VW7W*;(F^-&-AA9 "I^Q[[8VM$#N=Z5-L:-;##&WHF[W!TU=XP$
M*5M'P57HM;WC5R&\UA0YJL$0]58^L;2=S[[S* D8 /1Z6^3HA0[K3)-3)-C_
M&7\]T -<:V1]D ,8#,6@YGSL;+K=WD/71/AXA/7PJQ?*IX*R W+H E 0 )XQ
M)D6KL0^9&;J.R"$-O?TAV'.DE3+E-8NZ!W(P0A]Y3/<N)6?G<Q2P<+NJO/XL
MC=>5-\<-23 2GXI?C$ET^<K\.T9]U;2IM,$-%#!"NL$9!KP?Q9/6(H[ARJ-,
M]F#PCN*VQKCW]T: RWD=&?GC.;;]]"7-]>#\.5K=M3Y"S3OI^N!>Q4/E ./<
MD?N[ZRBA'+1'YN6!Q!7'6-LEWL_U2[RR^ZSL/SL:8)0;FAKY#<'4;VOD[4<Y
M5Z0L?"1LG2R6CRS@W]<8LJKVP-E@8RKH8:^>*[0\CUTK+Z="::G6F@"AMK+L
M&&'=RMJ$S-$]_8]BU='(IFP#-H><$<X1<V.'YF0A>?_#T\_O.2GS(-ZD1.'@
MDS8&8F[%OV>$N8;=\0L(&>&O:@\4@17?GI$(]$RCK/\Y'<HTX;9V0-2M./(Z
M+#9M3"(N.(]L':7 ]:;:%HBZ%4==Y^6FR2SN:J,#7]$<B+\5QUR?M09=!#N#
M%U"40-(4"+T5IUJ'!4?"*@KLEZ\;RD"HUUL"0;?B7^L >CNC*)A?9 4A*K0/
M;<#G*D> KG.' G'%;;U:S5\\&LHKO:LZ0,%WY52KY+NO)-;!TW,.]OL//[[/
M ?]T<?9/OH4>$RK9/47;]J90D)%/IW(&'/96WL4A];DZW+%X'V-8]5;^5>>M
MW TP\Z)@)D8A 6^(X+BL<M*0D<J#*>DX3G!\24A0)4)[I 5T<\:QJ13+41 ]
M$(J1]XMVNF[CM"1-XWPVZ.Z.@[2?S!38X"Z!_K9< L^W3X0EY=W2/4V^?/(B
MK[AQF4?!0\H-%++:2G.Q?LC_[_U/]:7Q:-B9&'=V&#A?'W=#6\G5$NSE.LQ_
M..@P_\>_%/SN*.)\?Q1)<I$H"#M_2E*1B]RBTGRX[J,--U\[\9KO3DE"DJN8
MS<5_$Z[KUP'_"UUNQ>8>!7EC_N,C_[:7*BN!J9'H]2VLQ;N7<(]7!XOH6-P&
M^JG5=<3A$1C)MFX@*/5QT#8&^T(TTY9V@)W6A %6D-;!T"[LW-4)AY>(QV?*
M;22/I=O+:,5_UVV!D(R"=H_HB"HHP<76@0-Q"[YE)G3U+$S,$H:RML$!*;A6
M=!@7[;(354\Z"P!;<S[Q-8U1\53@?+G,'TE;L'OB)7'D/87;&_J%A-O'N-[J
MGJRHL,BBU&B)&>)3:->ZR.O0<&*:NLJ9&SN#?0_M=GO2RN><R706>RQ8+"\H
MXW3&+-FOV::J!1D([48>56?@$#NA#.?Q>DW3E) %>\B>_-V_[DFRB:.$/H6$
MP]1/33I_ BVN %^!>HH%6[5*B#B-UZ($KJB?-8*V#?Y5M!@+5 6T)#QLG;SG
ML"^6E7.MH78I^N/%B* JBA91;)%7D(B3_-W)9,'V:IQ4-;>31QDT*%X,BR,.
M)!/LIZ,Q/3S/\)'Q0G,FHCL.+SGB%0"6TN1HB1Q$@0Q&ABK0V-[K 2\[C7'&
M5I$6^^I ^$"K3<]O0-5F;&=V;[49!'ML!8(OC_=D$[/T,<[M=RLV3LL7H,HS
MMJ=ZR "+KK@[$J&U<UD>L7@=^51LX;K K$:&_6ZT6H36;KR1H[&4O*E#KX!=
MQYCT2E)NO92#J=D3S$9 C(DR$EAE?G:!:.2E6TGB@Q]O>@FQ/@!F(),5(;8C
MY)(,B[<!^@BQ,0)FZ)$5*4HP<DF,NS]>KS><P>8EW_'?^XB[\Y<PPY"LJ$5/
MS%U2G^(LD8M"1.>+O"]1_7#!/G.[#/+"J XKTP]@QB)9499N"(]N;:^#IS_[
M\;HPLA=LY47TCP+T*+@@B<_HIGAMYRQ+.,5)LX+5+S^\_TO=OJX.E.<Y5(::
MQ<O9?C"<9QI\7[R,6,EK41C9N[KXBCXX;Q[L,*Q RV5VYB4T62SO*@JAFL;E
M8%W&PK*_ 0(YGJD]>'1A4CYDZ[7'MHOE UU%>80B7Y0:S+=-RT:J9CF4F(&5
MP6:'T?;)FZ>)V>,Q$I6< ),1VG]J$] ,%^1)1U:%4UYXQ3B9;=/K;XWI572:
M'7KAZ%^-=OT<DO= FD$U>@XH0Z8/I#/RW-&)J#YSX'C@3IO+WS-N O-M]3:.
MWOEQE/+?AN*B->(6+TE:ZI_R>?1+?1X5H^1VHQCG_##.[# 0BF*6_&DG5+T=
MTC1*N6(\QR%7Y:2@B)]$B-ED@@^!/*7:15.?2*:(X$ZG"\+G4,)WR."X0,YA
M\GSXH3YYZGT&K-MR^$[M(XH)(3H"^@U97J;V$9B^YW0".F)I.1#'8ZV',M70
M]2$JVHZ^[13/:UU'+WQ_$-MEVW1Y+]EKBKZS2F?$_:7.2,(WU/\1TRC]E?]#
MU-*!;D & ^'L4!(RC;8HDS&<V*.,Q5O;Q,Q!0SY+B4WWW5/]O<BVZ?FA<:3*
M^^;O2,Z..J.HZX&TQ;)*S3T)1;[Y><P-T_SARZ?*PY> V=IW7)S)"Z:Z^@PH
MQ '2>V#D:3Z,FM1F_4!H(Y\//1;Q8UQR1UA.:]L:T'C3?M=IQGO-BFXXFU6-
M>, N+.V!M-W6Z('LKO(NV)NI1ASU75/'.^[,**=Q7I?@D7E\<OMYN%[;#&G4
M&2L[S_+>LZ/N*'HF8T8_8_0]<6:.C"XC2]5H$.39!15A;99UP EWWA7!L#LS
M7+@:^2)!(LF5VH=&)&FE?^ZP/!X!15<5+!U(UT]%PV%PYB6(2,#4-!T'>79V
M$G%MJG:##ME^7&_">$O(&8G(DJ9WH=>^0S8"4G8=9V7/6=$52V?WUCM'_IZD
ME.4Q^H:S$SX(VMRLDM@F.]C,-!@%?UZ:BK8Y*XU!0YZ3KWZ8)?2%W%"?4T[F
M*T9RGC\%3Y]H%)$D3KU%U'K6:T2H[ >;E:/-]L/-_O3IXFRV'W'&A_P/.[<;
M4([ UQ[F PYY'R+]NNX^!-+1C?N0KA*K7I3 8<*=;S?$2]J-TT9 2MG4RB0I
MQ@9/@7ISG"WI1J2 D\6&B!='HE5!%& 3TO5S8Q:TBZ2VP< @F.Y=X'7$?R2/
MWFO['&D$FQ3M9T4'%*7<4VQB_RD[X4RN%I( 4TO="]F> XBF-KT@(&#'$S\E
MY/>,CW3Y0MJ>I/[EAQ\;426'3K.R%TY$4XUV0&BCM =23%:-'D@,EKP+=ABC
M1ASUZ"L=[]@3 Q)HKPBX_[$170(/N)_]:?=3MT/-*?:^2(HITCEJA&V+_X4D
MP@#[3RWVW@P72^^^U4+1]$)IB5_K*HGA4\B-10'AQHKU[41,5\&J<1C7KAM:
MCGG7&0>"8=*"WINZX-55W@,M5[RK>'7,3UJRGT5ILLLDI6LO)6U/)I8-Z^W0
MDKB[2K&=44O;W^6:,%%?\".+OZ;/PM'O10#+)/=-@KJBO;?0:2LT@6/0T@F=
M[K*\Y%G<DO+_B(7]Q0L/BSGD$@O6'>W-@J[SQP@62]/J@:P86>4QD 4U%V0C
MBIT!I"/ZP[NCO0[0:7J9PH(^Q4KZ\FP_SI/68)2U1ZO!WW42J1FW-&ON&-EX
M-.!ZL4B?"3O/F&!-5,:%3ARC$=#JTG>:.QW 09\^Q;U.<9T#WI>4G?!JQ'>=
M20 ,)FV7R^+^X78(= "\$O"=31$S;-#GZ\$G8'!\EG;!*[O>_0"MX1]=0E<>
M9;]Z8<:/B%=4E-X5I=TBSE0&<F@!N^/5.^\J.2-<T*5X09[@,ZRU,5YI\>X6
MI91G='G<L5A4O]^*4$;Q\*8X-VZ,ED'X"'AUO;M*SA0==''>DQ<29>2>^/$J
MHK!KG;(OH"M4@.YX1,!X6#K7'0B^BMD]1XM_X?FC>-H1>*PS&0 J'D=<(N;8
M.#"]"BIS_\T+">/-[@&1*"$Z"P34&2I#=_PE!IC8<I[PTT6^/!>APGD8Y<H+
M^2^N:"C4BY BIP9T-LL]#GU&A(K0%>]*?_30Y^4M^5IAFL41_]$G%?L7O N:
MCP2^"L<7=V<>I6)V+A[L451U;HT&:Q8S,8@&*X;]EF/!9-<]_C,)LI#$RX,'
MX:&HO<V_><;B+X1=$"\D+(=0>_W3>;C)A(#U8]/NW9V2K-LX&EB>FA&G%4LV
M 'CH^^B.A\5R[U4JKEER\\![X@:!8.83\<0:&BRB>\$@$P_\BHA&K4KL(H^'
M_<SD@M&LP(RN/#5>9-1_CN*GA+ 7P<1UM,E2<3B/?,XSM#S^X!^:7+B;):A=
M4R'M="A*&[,CID7_DCW_.:*_9P2\+HWT^<G%Y8TJ%FL1%A)7[B[>,/B<D&46
MWM 7@,(480D]1IQ6<.  X*&O+5(>^MQQ3#E:$ X(NNQVP5B_T?3Y/$O2>$WR
M9\/3RE*TA:[RG0:;3K1A'RZMKL"%:Y]O$H3F%LG<3^D+1&ZB-[3S=,(-3;AR
MPO]6>_5"[FEKE QMO,2"[%";_I,L-W&T$IMM4%AD9]N/)%XQ;_-,_3GC!AET
M+30=!SO#V>RAEFXHH>]V!_= G=_**X9GV_*/1OX6PP&Q/7"F#_/T \[QQWKD
M"VZC BWDR1[D-7C4MWLT_N[%L@K^N0Q[J+/;?#CLVLW*QWKZL>;"U*JE><LG
M4J.>;*UGOSDSD7=\VJ=VPM+*M.;_.DQI_H_*5.)*$8C0C^#,XP=+GSP\$Y)J
MYP\?PW (-XI\ 9_^,6=OE(N^Q?*C1Z-%U#9!X*L=: PT4Z+S4TV=0'+!AJA7
M.9"O=\W"O)+WEYPP%K[YAYBZ/[_DP+K950*MECX4(">?6I+/Q^83T9('EY#G
MX^GE)<EY??_BSU'A:,:\:%4$V/'39_U5H/E7CP6Y.$$G^+Z?T,W_QL2QL@Q8
M>91I0)2JV;1(6J5C0<8!7[#(=4K6BDHQ0XSMAAX-/O?J*C4 4M4(8!Q=*MCD
M'YB_4H5:U)I]&Q*N,5TYAS@Z[Z5<'CB) G&I>^NMR46\YH>7'BM!IZ^YH3FM
M6F\ZOSOQ?["AASRU/])U0<8GLGXBK$6HHEFC%79XI$V%KI[7)?!8<J%\\M@7
MDNK%T=(..]QP+(%((7+IAFUO8QY;H=S.I#XW1/,#6/YVS-%O/D>46Z/0 (;V
MG6S@KV)?S0YFKJJ->BNR0E?(ZG&HAYD#**DP](?0KXAMZ9TED2 [B.O/KDI=
M48W7:YKO_F([A2?_ '#E5K5&F0B9]D5&-0TSOHZ9[S"& V([A<T>#^Z)FPL/
M1LDG7N-)G**#Y:OGB;X?Q:D0KD)PN)NL@QN7R< 7HY1,HYLR;2]:[0../WFI
M2(@$F\R=!G/DJKGS^U] M'"7L<K#7M*U[*?&PT75Y[V0S8>W\LY7-:YDO8DC
M88TNEGM"RT(LY8NEYH9$AT$G]TK8 !"B+[L5FVBY).*T2_8,W'LIJ:5^FAN4
M'4;%/AOVT83N*#JD"A=E25U.?5OJIKD6& Z([7KNHP"=L!NXGO&(^_F"K;R(
M_E&(1I3R2GQ&-^)?B^59EM"(&RH7)/5HF-QZ3%@K+VUO2/_4>'2M.G >D5X9
M6M3>V0T^^U,Y_&P__JG>CJ*@X%'%(\F!3=K:D0NZCO4":\STCM4 8PV&&1UA
M)6 0;%T(6Q O5-* >FS[X.47 +F#7QG"H.@R'8GH><&/4CA0)"X!%\M'YD4)
MG[D<3&W, :"O&PN45@'K$@-PUC,VH/^Y]VXAO;#>F4V')M@F/%S/Z@7MZVSB
MF^4<M?RRZ#STD@2VFLF[3&\UD_-2.08@U9>HD*1;O=K:.K):Z12L7B*BA1/L
MU>D\7J_C**=LKENFVMIBKU=R36H^D")AU)V%JLBR./C$@(M5>[?I+ECM_%2B
MM#"3A/9DZ=8M27/'EBZ5RK7F #48PE[!?A/>BRC5+5ZU9M@Q@4IEJ@'?RJ&=
M50N<==R>$-;\+2'"C)0L9$=9NEU&G,X:UYO52I'"\>0M(TFZ]O%.NC[(,NLM
MB(9<=0S;"4[G__.)1A%)XM1;1.+61!T6+6V.5FD- %W3<:9CVUKT^3:^XO.\
M2$77!*"W-46KD]8-906[^.9RQ461"<K*>-'D.DDRPCFLN"Q@3C']*)CQ2G*W
MN,(;!@7&)6G>,>J3760A2'*U'JB!2%W$U,HQNDCN6.P3$B17G#^A.J)FRK5X
MS<L+[[(GSMMBN22BT+!<1@9#H-U9&PG-&!,GI9@'W*SC*%<^,^G5NJ*=GWI+
MK14#=&GE+VV7@4\*GT^M&5IE<R,IM/*&CGCI.2P/UPMV3U?/Z7[?W#\D<NZ%
M(0G.MF6[I&RHD%'O@=%JE1M)=2#\T/5@1YA(9,LI6V1IDGI1(&KN$K;6NI04
M/=%JE!M)$HH NJA:5>[RE3"?)B2WI?9_W.O9>\.)JA\.[<#<?WI"L4*7=/7<
M CT6R+N@';[-S@4ZGM&E<GB7)/AW5OC*#DHDEXRF&U ZPS_?:20=$._H$NJ<
MG5M]<B9;Y\&BR=%JH9EXEKX)/M$[,'6MPNZ&9C6* 319?(*QN"&B7H"P+A0;
MM,UO0C4+VUED'78W-&NHR7-/DR]7C)!=?6R11#+2TM7^::B>(?NW1A/"VU*W
MW8SZ-0[Y,"*'=$2%DWT<JG+(SKD1!?$VE>Z"OM" 1/MJG2.K7?/S4,5#]D>.
M*@QTU6N/<5A\C0A+GNF&'S)](:.58M4R& *J LC.2V-0T,4X#U[$[47R&,^7
MRSPA5B&PUL90T2![(Q6,H@NA4OI<#OY1(RCHR-["%L:02[EGZ[7'MHOE UU%
M=$E]\69F@QM(@NR'1HWW8FB1"UL9?'88?;8;_I0B>\3%*46V.G-.*;+?8HKL
M!7E*KR.N$5EN%2H3--K:3D<&"B;0LV&/B8+4W9;W<&/=D>N54A[VXXP?YE>7
MRGC7:@.TR 4M.,WUI<D8NGEYSDA TRO/SQT8ZL6EK>WD%I<V)O"34X^(TJ:G
MMK9V8U&1ZY-2#JYD=MV3ESA\X:IT3)XNTTO3#2U\0XEUJUA  ."O6E[R+/PI
M+UZ89Q"FY_RPM.54YZXRQ<S1])M$S#V,>2=D='5Q?<XW1WX(#N9KP9U:-"W-
MIQ%?K^354GZ0^.;#]9T67]%8TM;Q.'@%Y0[IN%JEIQ*V7N7$"5@_1Q2^<#0:
M3R-*7<$GN@QN:"3R%HZM .^5KK/U6<Q8_%78"-Z&_R7=RH5C-LHTHM"[((,N
MS@NRB1.JND,XM)A&"'F=(W2(Q6R>1\$A#^&!K!A9B;<N/T<<L<,?+E_]9W'Q
M*[*":)+D+]RLLM!3IX\.-?Y$@LD'11-=.7;:6M29U<_"7;MIQ)&W<X<.^ATC
M&X\&91X8UZ8\+:P@\CQC@GVY)$"=IQ%(;H##P-6-1TX6H!%-24A?1.9YRM<$
M^A22LK*SST_,G!=%Z"^L]T3"PTV@L'1 +;7NCL5+DB_+7GA%I+>'TM:N1TTK
MB7=D(2PWRVVY3LOG0*/A5&*)VQE$![Y4C-Q[(4*,M-M-I>5$8FIE+*)CGV]R
MQUN?=M-7]9E(J*F>;3<DH[.$CQI-),:SA3%TL#]'C'@A_8,$'ST:W<1)LHA
M087:CA.)[@0"8,D*NE[SB<B*W,W#5P^G5XDYI._F>I@GC M')DF;3X\OGI3E
M<%YX*5$<'$"=H>)"/LD; ($NM./0&_$N:/+ 8?6"1?2KQZ@( KE72PX^ E1\
MR"=]4T@<DV$U>R^O%QQ <D5,Q@!?>;HD1P@LZ))L6SEREVR^YO/CL.XB#SP
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MY'S@TBA!%),+7!HEB$(3U7LO<G<DRRG_>^7/;LRDKJOE,2]V B @4$LGPHY
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M47F>AB$);N,\JW(5"6-2XO7M/-ITS+1>;#IBO"GI+Q=(I:PABM\RSN0,L6Y
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MXT,_G+EBKQ+0&]#PT0ZO"*J_H2SG]5S$8X8AZDJMH 7].</)J;%6L-^83=+
MP\4EO@N1^ ])3G]N3.),ZK"CQ[U8!X/J.1:?\YR>KZ8%QD'N:9LU>MZ<[COI
MWX139S)C3A>\71%V83*-;GWM(2H\P7SGY7LP\?,*<.)7I=],A&9+-Q"[-D$'
M"O$?OYV8W=59"[ZQV;*[.=?#5%MQ=NYGV;,L=L4[%-GX;Q%/;%X-JR]3KL5X
M2! 2&0#OG@24><YL@10@$_='529N/F@NGS(3MQCVE(M[RL7M_0DW\J1.N;BG
M7-PI9&H.@=0I%]=E"9]R<8?_FAN:<\K%/>7B3CG.NSQU+;(T2;THH-'*VJ6'
M_%.G1$Y#J7R[:69-9 S=1L.+9A@'T+>LW"-X<GJK_-".4X3PTB&#2"=T9V8?
M,]QX.:EI Z#=AL_='CUO+W$1&5#[BOND1^M)QU:-AWLBK'.^;9S'4>ZIR[SP
MD;#U!Y7"CDO'VTM%1 +2E>.5N""YSM_]N\@8I[287#FW2>5.YI SH[ \.XSU
M=M/T.@/[MI-4]4M^ 8<L)7VH4]# =+R]%#PD(%U9%WN;U1O*\CXV"\.H/O;V
M<N9LHG5:>EN!05M\#2EY>^ES:%"^D048T^]O$*(]H4PXFVBY$$#JDLHZ[?HW
MR4"84#;;^""^':WOX3N1XV7B#JL*;VQBWGC^&HYL)V^ 0))E!CO1=,YZF=!M
MESVPWI[&X=@/@^>.3.B^:VP(7=+97C<G,GYE.\1[>[M_)V+>8!X4)IQ2O4;)
M3RH>Q.B2H?23*D.I'#:7R"E'R63<4X[2*4?IE*-TRE$ZY2B=<I1..4JG'*6W
ME:-D_XFZR><IO<$GZARXL3QE*AE+!3MMPR5]=?JZ<@)KHP/*?<I4.F4JG3*5
M3IE*ITRE4Z92ZP8!J+AO<F4S1-K-8-2=LII&$#[^ >V4ZW3*=7+"CW?*=7)3
MCU$$BK\N]C;,3[E.CA[P3[E.<&!.N4ZN*[O]7*=OZ+$8!VX=3GE2IF@-XH=U
M(F/D&[AX..5)#03BV]'Z8;PQISPI%^<"CFR_:>/EE&/EYMI^RK$:0P]/.598
M.59CYJ((]_F[QMY29H?<>DP<>%\.Q%924'YNI*#D8^6PS*J#[9--9OOQ3FDG
MI[03PT^X$1)\2CLYI9U,(2EA"*1.:2<N2_B4=G)*.QF:_YYI)[UUZ)[P?9**
M1RMS6_)S1-/D_N&S-%FE[*?IYGQ\]@"Y*S DK 8#VL\NPKM@=SV[".51*KQ+
ML[?^*%7VE-" >FS[X.4&A)C+:A-(T<6-3<VZP2L'H)+/@"3/ T5"(1?+1\YK
MPL^#PM.B,W0 ?1V1L$YKZQ(#<(9MD-PQ^L+/]7PI\7/5U%DBLO;H*3=@#:P)
M20T _DK9]9@+?D[=6L"A,06G%-IA9/AM7FG>QB4J[:A=D,1G-&]@0==-/N[\
M:6UT/3<7'5:>8N>9FH=6YND_YU[DDS"TER+;CQ;TC=Q>*A>68-^P$?$K25*E
M)EO? NL4O+W\VM$A=$1K+]>;,-X2\D#8"_5)._]\ZWC)R<]931[CU NK?Q?W
ME;=Q^E\DO2=^O(KH'ZJL1(N??'LILO8Q<T013Y&G;S?S=H*!IREA4SVC:;>B
MJY@M"44V*5J(^'93=H<7)?YZKDJW/Q<[%4LX!R+^2?R<TJ>0[VX^;YI2HKJB
MZ#FN\Y>$5NH;@ ''UYN1+/#<.KKR*/O5"S,;H= ]Z?EV$VBM"AA?O]NG:4YD
M+>XBY_HCBQ/SY5 WG/-W\P.O@C!XT97#VC'O,%+1J3YU$$[K>I+>;EHJNIQ=
MJ^0V7\?<(N$,\!^RJ"U'HE>ML,;P;S#+<UB WOJ"6&P+_/A4_DJT4SS:-#8=
M;S=K$T>BZ(I<*3!WE+]W'?F,</8U%IZRYQM.H@2BAB_>GB[.TPMS#BLAGFPQ
M@XPL%>O=\UPMN2E.[OQ70YM]H$]"%7="]R[V07-IV4V*XWZ^,7 C(/^=9G%L
M[P+5A(E>0*AP^C:C&??>P3E'9GU<'=56A0S -Z%Z.,$["NN2<F-)ZK+NMK.X
M(<)?:<O@ WP3JHP3O8BP*BDWE'&H^79/DR]7C/##5TJX$J3W7CK6 MG^::AJ
M3O 68RRYO2T-W4W"7^.0#Q/2=#NBCLH^#H[U_K:U5"V[MZFG%_2%!B0*$+3T
M^--0'9W0=<AXX'T+)RA=4?/C'#FD(O4F1$ U?GH7+ BR=-!-69*K<PJ)MNU-
MH0HRH4L5.;-N!@5T]Y_;]2?W(0BJ5A.Z)L&&5*J\8Q9 W=<EX;A1?QX%5UD8
M;B]HF E[H2A<NB>U4O[T+XWRI^5(LW@YR\>:>5$PRT>;E</M*Z$BU3^]])@0
M2+);/_253>4]L&N6UBG+(3_;<BU>Q]%YZ"4)N#8I>"@W"JWHI"BM+@KF$[^*
M:"NIC85,KZ_U?FY(L+,6UT-R--SB5_!\X-#FVTC."ZR4E;S+VY*>@E'T:IY5
MDG0EJMK:.B(IG?;5)-+&"78)JHHRS77EI]K:8M=3D6M2'7PIH^@^Q II9P8R
M.'.E_%<7&9PY)H-;DEY'W&PG-S%7D!=N18NE]3$N2,Y9>XY#CF.2K\)R 1D/
MA%QX"V8*U039$2UT*=?.D,7S+F7-R&HZN4;&AL-@KY&=1-P)JDD[NUMA,CP+
MX"_&G82M9'W20H6O5*4398B5?3\4=CTDRXM[#;))*XIDO2M9;"Q[QIN#?"#L
MXD1#;@\ZN":M(G6@M"N&M -V29]!-@F[LW]$)WV#,<#S9'^M^^=W@\SX*+-\
M&'<>)GM+COEYE-) :!Z'\U"FY/+5#S,N["NNZ>*F*2N4HNE# WOMA_F.&XZJ
MSB[]84# ]_?WY -P,S#<%]Q0&3L3KO[(U&"@X5]%].3E;-L^@.9I,IL?/2GB
M,#BBW[:T$P=Y!TW?TPTE&6'R@33&I=?.?A-&I_Y-D5HS;%\E5%?KQ]$V9M'=
MS3W54EKS9ABM-ZQY,Z[$N]MFPR[MVKHW(YY3RU> [SR6;BLO["20\^K?ZN?5
M<K!9/MJL.IP[YU89P_KSJ[XG]CE61N'9]N@OT..JT7!N;-I0Z4I/IT8\XQ]"
M)>0"#I?ZGFY(M)=V-]X:U?&,?^:#<:D^PIF,\<U(N95[]'-4E23=R:FMK1OB
M,U=:A<P&.NQ(,D0N;R_NY5%IHLE1"^S;5KE^5%,B6IBRE&!S^1K_L5V31(U@
MK1'V;200Q%;6T ]\HOY@,H\"D1 :)22I,J.*Z5/U0CZ>0:V61JB?'@ET<2TV
M1)QOHM6.2KF,6IIBNTHZ2D;*-+HX[LD+B3*5% XML,.L.H)?9Q$=\WWQ#^(3
M^J(^;;:U=6G/-9"#G&U+>_'<]UE& L5"DV?AUENYM!M#X&UEH@'L]$)_5,\'
M%+^^BEE9NKCCJPPMPV"'"76<7)W <F E%#&/C]XK2>X\JHCJ:C3$?I^J\QK8
MRC"Z(,KUXX9Z3Z+>#R7)><8$#(J;$'D7['>=.@I'"P+N582(!:9I7C5$/+X;
M1\*@))'/Z83<1OQ2OXVHC)?GM1^-Z,Z%A(KM/3OZVPG#88:T0Q2?EMTUB'[Z
M;FXXMSH)J&J\Z!G%OTA0T-A)Y]"%!P->XF=0L&7IAB!A:45,_%\'$?%__.M1
M+'2+Y744B')@F1=*+@!X6TG3"8I#SHP=M[VI#'ZCZ7.^%0M7]S/=/,:7G"6%
M'[^-(=T@R'*3RT O*QUK=AS\=]E32/U?.4]\65;[J=N;HOG@NF#8W&U4_-NQ
MPS7SYE[499*O5Y4_3W.-JC!0\1".C*]4SW<$0K7;_GK2T(<ZECM2K40[:L#\
M1".ZSM8J.&M-T!PJ=;@:8+;R@G\4%Z78'OD'-&'HQ\TFN#2T,U)Q7D^M_NJ!
MDRBX"[T($NUMYVMN' Q;-7FP"JDJ_NU83A>/Y\5:(0R->_)[1EE!HM*(TO;"
M]I;95/BJX06$#\4&NR7IN;>AJ1>V[VG5OR,'!P \$94]KLD8^@9W$WM1PM5(
M??%YW K[WM\ ]%;Z'8%^=P5;TE6ZMSE'MW'DZQS^H,[8,0+F@C+ 9-+7J?="
M!OG1F3RE)(A(DCS&A^5!\:21OB=V1(*YU*%HH.Q&Y<'D0$ZY6XH[W,*]T2:M
MPXE&W1$[OL%L S/  O=Z;O>8\AF)R)*FPAZ"W,O]]8=&58MRH%DYTBP?RJD+
MN8.5& 7W)"T-.</K./@@. OF!0<_(KF",OJ4"4J%)$KQ,$$H(^*W'MM6&^E2
M"/N.BV]_FHJ_MO8. RSR;!?)C F?A#?4%R%7\Q4C.0J?@B>^9/'])$Z]102I
M:_/7]XT58#?XK!Q]MA]^]B=^E)KMOS#CG_B/P98&V;EW3QN4:\7\ST^"/0;$
MSB$\CT/.35S 7#TDEQ:CY,_5K ]P@N%PWW+ /=A?BZ1)B</AY$*@06]>;O39
MC<-^Q0UWH[TYVHA_&!(\_)1*X<%;+"N4JF\>),V_,260H(">,-GDU&MG3E>D
MQ'@@-Q1 J<SUJR=3%NW<*S2V0=5U@JPQMH>TH]Y5+PC4.* [3R=Y,3OVLMA^
MFSMPP,?I-O=TF]M[U;U[YC1<7_N\)?6]4!T(U]X6^[)CK)M;)526DO?*;QK)
MIZN \-X-'59 XTKHEGR]8-EJOMF$_)N"L2O*$K7UHNF#?34QEKQ T(TF-D.)
MH0?VH0O+,<-4DOM9/ C J<__9)XAV^B/?O$PO&<,ED4K07+2X0!W+/8)"1)1
MC;$\>%T143-$).>K'EC0=L0^B8Z@)T#P;)E&Q5)V%;/RVP&G)\C\5%;B0-4!
MVX:U*2T=[RY<)!Y.YOLB,3>$;UBBF(_\K>J_?E"]5;T?:98/-1-C]7RH6GLU
MF'])527T^ ZHWARY&%%.SKUX7F>Q_)R0>9(0Q0V^IAO6/JE&N'4A P$PZ7WN
MF,-=;K^B,IBT ]J^UENN#:[13=9C^FH/6]T388KO_OA(V%H1G&@^$MJ.UUN.
M<)S<%K  083RW'LIX1:VKPP[-A\)S>LSM( 5.#DFX/Q_RA<,Q8^EU04I[J?I
MC^82ZK_J:C!!%V%MNU\\<?LP(L%U=/GJ/PM#FQO-QMMGKT'17$H=A#T >N@:
MT#QR0"=LT1:M"E?OR5GE%5T,#\\Q2\7^#1!#6UNT#,(.8I#SBBZ&8PTQW<*,
MMZR_N2 .-<^NN$:N,E&L8T?=148^\Q%JJZO"6?*CREE2C#W;E(//^.BS?/B&
M&^7D06E)YB1\\R.2?:XBL%LN]L>O)'PAG^(H?5;,JNXC3LCOTA<V]+42RL!_
M$8\]?HW[BWL_T)3<,!U1FI9T^3=5>=SF0TW)0=,9*4MW0U!ZYLN4,)7X\H#,
MCH--P@'3A\&)3=/^LW-:?AA37#I?<*1QZH6HUQM*5KD96WH016EXGS?5Y:9V
M'&Y*?IM>B)EKRB^%ID1D)4I2?UM780[Z?50^N/YS?\3#<<$[)+WXI_KIM^@Z
M7M;P) ^V\^#%BWQRK[R;.FHTH>-G"W.6[%$1>RG!4/S]\.=)'.N.2;8*W#R*
M,B_<+U["47H=^2SWTA57@=Y*9K<#^T[BG&7 C\-6.5<8\M4+A=_;S/@ZZCB)
M<Q64&8>E)0@4F7*1IH@-I._4STWM6#@IML5&@/H87^9&E)G8ZGVG?J)IQ\*5
M^YS*,TB[)\O*8E>*6YR?5;<XQ8BS?,C9;LS9GYZ*4?^CY]W-< ]=F=3(4G9"
MJDY2%$2\(ES[^4+NO990E]*3\Z+MB)Q< A!0O0H(# KTE;*D\X%#*?*=;OA'
M.@A.UQT[Z:.S_&"XH$OQHG1-E.JV9Q<J1FA_['00<SF:(3/I6/8=JT<ZVUD5
M8*-@IU!W5P@3E":M%L8:T%?8UO*OS85M2Z[(WMV#J;S39LYB'F<J\N(J+U0J
M[.6_J.SEW;#"8IX5 ^>/0%:&/MG, _-Q3_PX\CFZN79(-'>^LRC%\I5Q:K:'
M_GP] W ^S&<F9X];@=F2<_=RN22^N'$Y^N@QX8NEJ2*(H0<9>4+&_& \.V+G
M2[2XW991%74P'FAZEG]'K-!E#-%7<X'W&W5Z9OX0*%I:WI5;T4V<)'D%9&X(
MBOH1MS&'^564U+L4SQFT/R@LANT]ZH2L^T'X1=_">PI\V$]@EVNRL*D[H@IF
MEN<=86LO(N*]!,XB!\[O-N.! Z.%:EF8]$983F*;7Z3/A,V#?V=)JDDVZS8:
M]MN"=K9U&6KH(I=H+U^1^-J4<;;$HE1H\"?BA<*7<RF>'Q.IPVMEI%G_D=&R
M$H>V[XW11%<+B$X/H",#?P:H,+^XHS!6<$;7'H-IT%X24YU0/M#P8)^1.^HR
M*+#H:M)5^;OHC(UO017(!:^C11@P3BJ7OV<TW5Z7_\VKX_Y*$A%+)LT74MCJ
M^M&@HG;!U]B+470/1)OV-<GMX7^ ?@ J<A<<C$/SCC&E/\4!79;EJA?+"E7R
M%$"%INM'@\K7<><B%+;)[O;#[^EPV;O@6NS-[%N*%]+SFWM:!CD[E"-!=<4%
M?V1G)M&W_7N29BQZC.]8_$(3 :W2Q0C=\-3#0D7K@K-Q&(X=V0LD"IHKX_Y7
MT4KS)*C9*%!AN^].5,*$+ENP.[S.@;:N;O^1H3HP,0\A!,YQC?GSO)[H=52/
M!?W5"[,"[3",OXJ,;C.SWF1<<'B0 \(>B&7T;;RWW(?^"%0)7/#1V>#?D4UA
M](#_#RYXXFQ'_!.&?"YKUU:1>DVCC&]$989O'!F'";2/ 16^"SZY#NSUU8>^
MM;T&B1;J%@4^\#>@BN*X<Z\?Q)-V^4 VPLZ9)X,,#M6QB3D1S?-,IJ=<C12U
M6Y+J,[74O:#JX)"?$ *#I<-$X]/7(O2=I=DF7^H"*DJ<RSQ_T,Y0D5CS[X$
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M4$L! A0#%     @ .EM_7%]<K2IK P  3A,   H              ( !
M &5X,C$M,2YH=&U02P$"% ,4    "  Z6W]<S2^,#9<#  !A%0  "@
M        @ &3 P  97@R,RTQ+FAT;5!+ 0(4 Q0    ( #I;?UQ0\QZN[@<
M .$B   *              "  5('  !E>#,Q+3$N:'1M4$L! A0#%     @
M.UM_7(0.$Q?4!P  HR$   H              ( !: \  &5X,S$M,BYH=&U0
M2P$"% ,4    "  [6W]<D?Q9B/X$  "N$@  "@              @ %D%P
M97@S,BTQ+FAT;5!+ 0(4 Q0    ( #M;?UQ#=IN2\P0  !X2   *
M      "  8H<  !E>#,R+3(N:'1M4$L! A0#%     @ .UM_7(G8Q^CK)P
MH[0   D              ( !I2$  &5X-"TS+FAT;5!+ 0(4 Q0    ( #M;
M?UQXB$@]ZH8# /N/(  ,              "  ;=)  !F;W)M,3 M:RYH=&U0
M2P$"% ,4    "  [6W]<0#X=-<PN 0 ;40$ $               @ '+T ,
M9F]R;3$P+6M?,# R+FIP9U!+ 0(4 Q0    ( #M;?UQ\HQKITWL  )1]   0
M              "  <7_! !F;W)M,3 M:U\P,#,N:G!G4$L! A0#%     @
M.UM_7,;"?4T)&   @AT! !$              ( !QGL% &UD8F@M,C R-3$R
M,S$N>'-D4$L! A0#%     @ .UM_7* 29#4)'   H&T! !4
M ( !_I,% &UD8F@M,C R-3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( #M;?UP%
MB 7XETL  &E!!0 5              "  3JP!0!M9&)H+3(P,C4Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    "  [6W]</]F+U,2C  !A4@D %0
M@ $$_ 4 ;61B:"TR,#(U,3(S,5]L86(N>&UL4$L! A0#%     @ .UM_7#]1
MY^V[;P  3:4' !4              ( !^Y\& &UD8F@M,C R-3$R,S%?<')E
:+GAM;%!+!08     #P / (@#  #I#P<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:MDBH="http://mdb.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mdbh-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-20</instant>
        </period>
    </context>
    <context id="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-20</instant>
        </period>
    </context>
    <context id="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-20</instant>
        </period>
    </context>
    <context id="From2023-09-202023-09-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-20</startDate>
            <endDate>2023-09-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_MDBMinnesotaOneIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MDBMinnesotaOneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_MayoFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MayoFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="AsOf2024-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SAFEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MDBH:SAFEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-26_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfNonPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfNonPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:BrokerDealerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:WarrantsOfPubliclyTradedCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_NonBrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NonBrokerDealerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NonBrokerDealerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SimpleAgreementOnFutureEquitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:SimpleAgreementOnFutureEquitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SimpleAgreementOnFutureEquitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:SimpleAgreementOnFutureEquitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:ImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MDBH:ImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MDBH:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DevelopedSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MDBH:DevelopedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BrokerDealerAndIntellectualPropertyServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerAndIntellectualPropertyServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TechnologyDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_OtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerIntellectualPropertyServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TechnologyDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerIntellectualPropertyServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:BrokerDealerIntellectualPropertyServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:TechnologyDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OtherSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:OtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EliminationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">MDBH:EliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonClassAMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:MinnesotaOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember5368140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember5368156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExozymeTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ExozymeTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">MDBH:ExozymeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-11-152024-12-31_custom_ExozymesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-15</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExozymesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ExozymesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-15_custom_ExozymesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-15</instant>
        </period>
    </context>
    <context id="AsOf2024-11-14_custom_ExozymesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="From2024-11-142024-11-14_custom_ExozymesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MDBH:ExozymesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-13_custom_ExozymesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-14_custom_ExozymesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="AsOf2024-11-14_custom_ExozymesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ExozymesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ExozymesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_InvizyneTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MDBH:InvizyneTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-192022-09-21_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-09-21</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-28_custom_MarketBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-28</instant>
        </period>
    </context>
    <context id="From2025-04-282025-04-28_custom_MarketBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-28</startDate>
            <endDate>2025-04-28</endDate>
        </period>
    </context>
    <context id="From2025-04-282025-04-28_custom_TimeBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-28</startDate>
            <endDate>2025-04-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-28_custom_TimeBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-28</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TimeBasedMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TimeBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MarketBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TimeBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MarketBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TimeBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:TimeBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MarketBasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:MarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ENDRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MDBH:ENDRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ExozymesMember5372140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExozymesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MDBH:ExozymesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicVenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MDBH:PublicVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicVenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MDBH:PublicVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DTCMembershipRequirementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:DTCMembershipRequirementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MinimumMember_custom_DTCMembershipRequirementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:DTCMembershipRequirementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MDBH:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PhaseIIclinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:PhaseIIclinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PhaseIIIclinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:PhaseIIIclinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NewDrugApplicationFirstMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NewDrugApplicationFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NewDrugApplicationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MDBH:NewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="From2023-04-032023-04-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_USFederalTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">MDBH:USFederalTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_FloridaIncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">MDBH:FloridaIncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2026-02-032026-02-03_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001934642</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-03</startDate>
            <endDate>2026-02-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>MDBH:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0001934642</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0038">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:EffectOfDeconsolidationOfSubsidiary
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:EffectOfDeconsolidationOfSubsidiary
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:EffectOfDeconsolidationOfSubsidiary
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:DilutionOfDeferredGrantReimbursement
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentsSecurities
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncreaseDecreaseInPayablesToNoncustomers
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:PaymentsToAcquireInvestmentsSecurities
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ProceedsFromInvestmentsSecurities
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:PaymentForDeferredGrantReimbursement
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:WarrantsReceivedAsPartOfInvestmentBankingDeal
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember"
      id="xdx2ixbrl0800"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_custom_NonBrokerDealerMember"
      id="xdx2ixbrl0811"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer
      contextRef="AsOf2025-12-31_custom_SimpleAgreementOnFutureEquitiesMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer
      contextRef="AsOf2025-12-31_custom_ImpairmentMember"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0819"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember"
      id="xdx2ixbrl0849"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_CommonStockMember"
      id="xdx2ixbrl0901"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_CommonStockMember"
      id="xdx2ixbrl0903"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0974">http://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <MDBH:ContractWithCustomerLiabilityAmountsBilledNotRecognized
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ContractWithCustomerLiabilityAmountsBilledNotRecognized
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1002"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1004"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1006"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1012"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GrantCostsExpensed
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1015"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GrantsForEquipmentPurchased
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1018"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GrantFees
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1021"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GrantFundsReceived
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1024"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:RemovalOfBalanceDueToDeconsolidation
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1027"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1030"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1031"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1066"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1068"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1074"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1089"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1090"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1091"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1095"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1096"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1097"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:RealizedInvestmentGainsLossesOne
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1101"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:RealizedInvestmentGainsLossesOne
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1102"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:RealizedInvestmentGainsLossesOne
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1103"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FeeIncome
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FeeIncome
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FeeIncome
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1109"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1113"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1114"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1115"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncome
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncome
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncome
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1143"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1149"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1163"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1168"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1169"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:MiscellaneousIncome
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1209"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:MiscellaneousIncome
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1210"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:MiscellaneousIncome
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1226"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1227"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1247"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1253"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1256"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1257"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FeeIncome
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FeeIncome
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FeeIncome
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncome
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncome
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncome
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1365"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1369"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1370"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1395"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1401"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:MiscellaneousIncome
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1411"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:MiscellaneousIncome
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1412"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:MiscellaneousIncome
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1418"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1428"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1429"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1449"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1455"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1458"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      id="xdx2ixbrl1459"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      id="xdx2ixbrl1470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      id="xdx2ixbrl1472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      id="xdx2ixbrl1479"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:DueToDeconsolidation
      contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember"
      id="xdx2ixbrl1562"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationToNonControllingInterest
      contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember"
      id="xdx2ixbrl1566"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationToNonControllingInterest
      contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember"
      id="xdx2ixbrl1568"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:OwnershipChangeOfNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember"
      id="xdx2ixbrl1570"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:OwnershipChangeOfNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember"
      id="xdx2ixbrl1572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      id="xdx2ixbrl1612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1725"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1727"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1729"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1731"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1737"
      unitRef="Shares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1751"
      unitRef="Shares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1753"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1759"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1761"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1767"
      unitRef="Shares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1769"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1775"
      unitRef="Shares"
      xsi:nil="true"/>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1777"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1805"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1807"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1815"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1817"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1819"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1820"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1828"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      id="xdx2ixbrl1830"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1855"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1857"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1865"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1867"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1869"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1871"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1879"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1881"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1883"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      id="xdx2ixbrl1885"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2038"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2040"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2082"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2182"
      unitRef="USD"
      xsi:nil="true"/>
    <MDBH:DeferredTaxAssetsBonusExpense
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2195"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2237"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000014">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000015">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000016">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000017">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000018">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000020">001-41751</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000021">MDB CAPITAL HOLDINGS, LLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000023">87-4366624</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000024">14135                                             Midway Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000025">Suite G-150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000026">Addison</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000027">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000028">75001</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000029">75001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000030">(945)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000031">262-9012</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-12-31" id="Fact000032">Class     A Common Shares, representing Limited Liability Interests</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-12-31" id="Fact000033">MDBH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-12-31" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000036">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000041">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000042">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000043">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000044">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000045">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000046"
      unitRef="Shares">5300132</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">5000000</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">22178831</dei:EntityPublicFloat>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000049">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000053">We incorporate by reference
the disclosure about cybersecurity regulation that is generally applicable to MDB from section Part I, Item 1, Business &#x2013; Regulation
&#x2013; Data Protection ad Cybersecurity Regulation.&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have not had any reportable
cybersecurity breaches, including what we may perceive or recognize as cybersecurity incidents or credible threats during the fiscal year
ended December 31, 2025. To date, as a result, there has not been any material adverse effect on our business operations or financial
condition. If there is a cybersecurity attack and an infiltration of our files, data, customer data and the like, there would be a material
adverse effect on our business, our reputation, our operations and financial condition. For example, our reputation would be damaged in
the event of a cybersecurity infiltration. If there were a cybersecurity infiltration, we could lose access to our data which would disrupt
our operations, and we even may not be able to operate. Such a loss of access might be temporary or permanent, and it might be localized
or general. The level of disruption will depend on our backup systems. Our clients financial and other data could be taken and used against
us to damage our reputation or cause harm to our clients in different ways. In the latter instance, we may be liable for monetary damages
to our clients. We may be held for cyber ransom, which would be loss to our financial resources. Our inability to operate, payment of
damages, payment of ransom, and the costs of reparation of our systems, consultants and tangential expenses will all result in damage
to our business and our financial resources.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For MDB Holdings and its subsidiaries
including Public Ventures, our regulated broker-dealer, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_dbF_c20250101__20251231_zyoxShBxRKKj"&gt;we have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zTViQMCcuC3a"&gt;implemented&lt;/span&gt; a comprehensive cybersecurity program aimed at identifying,
monitoring, and mitigating cybersecurity risks to the best of our ability. Our security program encompasses information security responsibilities,
incident response, and is diligently managed by our information technology department. Cybersecurity is integrated into our overall risk
management framework, with consultation from subject matter experts to assess and address potential cyber risks and their impacts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;


    &lt;div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="text-align: center; width: 100%"&gt;46&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
    &lt;div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 100%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskRoleOfManagementTextBlock_dbF_c20250101__20251231_zXSW81eyiwn4"&gt;Management is committed to
providing the Audit Committee with regular cybersecurity updates, at least annually or more often as needed, based on emerging threats
or specific incidents. These updates cover risk assessments, the current threat landscape, and any recent cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The information technology
department has put in place robust governance measures for information security. This includes control requirements for change management,
patching processes, the implementation of multifactor authentication, comprehensive data backup strategies, and continuous security monitoring.
Additionally, management continues to enhance our security controls, with any significant issues promptly reported to the Audit Committee.&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000054">we have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zTViQMCcuC3a"&gt;implemented&lt;/span&gt; a comprehensive cybersecurity program aimed at identifying,
monitoring, and mitigating cybersecurity risks to the best of our ability. Our security program encompasses information security responsibilities,
incident response, and is diligently managed by our information technology department. Cybersecurity is integrated into our overall risk
management framework, with consultation from subject matter experts to assess and address potential cyber risks and their impacts.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000055">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000056">Management is committed to
providing the Audit Committee with regular cybersecurity updates, at least annually or more often as needed, based on emerging threats
or specific incidents. These updates cover risk assessments, the current threat landscape, and any recent cybersecurity incidents.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <MDBH:NoInsiderTradingFlag contextRef="From2025-01-01to2025-12-31" id="Fact000058">true</MDBH:NoInsiderTradingFlag>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000059">RBSM LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000060">New York</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000061">587</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000062">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of MDB Capital Holdings, LLC and Subsidiaries (collectively, the &#x201c;Company&#x201d;)
as of December 31, 2025 and 2024, and the related consolidated statements of operations, equity and cash flows for each of the two years
in the period ended December 31, 2025, and the related notes (collectively referred to as the consolidated financial statements). In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December
31, 2025, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">13217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">20437000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">2331000</us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation>
    <us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">844000</us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">124000</us-gaap:AccountsReceivableNet>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">13000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">64000</us-gaap:OtherReceivables>
    <us-gaap:DepositsAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">2000000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">1738000</us-gaap:DepositsAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">433000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">513000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">7166000</MDBH:InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">5858000</MDBH:InvestmentSecuritiesAtFairValueHeldByLicensedBrokerDealer>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">235000</MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">37543000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">41764000</us-gaap:EquityMethodInvestments>
    <us-gaap:DeferredCosts
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">14000</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">27000</us-gaap:DeferredCosts>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">90000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">547000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">641000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">63740000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">71976000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">267000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">324000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">95000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">72000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">1000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">23000</us-gaap:OtherLiabilities>
    <MDBH:PayablesToCustomersCurrentAndNonCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">2189000</MDBH:PayablesToCustomersCurrentAndNonCurrent>
    <MDBH:PayablesToCustomersCurrentAndNonCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">773000</MDBH:PayablesToCustomersCurrentAndNonCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">609000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">711000</us-gaap:OperatingLeaseLiability>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">3161000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">1903000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000151"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000153"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">5138632</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">5138632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">4950632</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">4950632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000178"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000179"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">80493000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">68721000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000195"
      unitRef="USD">-19803000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000196"
      unitRef="USD">1442000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">60690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">70163000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-111000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">-90000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">60579000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">70073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">63740000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">71976000</us-gaap:LiabilitiesAndStockholdersEquity>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">331000</MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">275000</MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2>
    <MDBH:UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">85000</MDBH:UnrealizedGainOnInvestmentSecuritiesNetFromNonlicensedBrokerDealer>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">14000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FeeIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">4282000</us-gaap:FeeIncome>
    <us-gaap:FeeIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">2221000</us-gaap:FeeIncome>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000226"
      unitRef="USD">200000</MDBH:ImpairmentOfInvestmentSecurities>
    <us-gaap:OtherOperatingIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">861000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">411000</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">4911000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">2157000</us-gaap:OperatingIncomeLoss>
    <MDBH:CompensationCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">14969000</MDBH:CompensationCosts>
    <MDBH:CompensationCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">20057000</MDBH:CompensationCosts>
    <MDBH:OperatingExpenseRelatedParty
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">1833000</MDBH:OperatingExpenseRelatedParty>
    <MDBH:OperatingExpenseRelatedParty
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">1486000</MDBH:OperatingExpenseRelatedParty>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">1937000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">3112000</us-gaap:ProfessionalFees>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">1103000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">922000</us-gaap:CommunicationsAndInformationTechnology>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">556000</MDBH:ClearingAndOtherCharges>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000253"
      unitRef="USD">1137000</MDBH:ClearingAndOtherCharges>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">2239000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">2608000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">22637000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">29322000</us-gaap:GeneralAndAdministrativeExpense>
    <MDBH:ResearchAndDevelopmentGrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">0</MDBH:ResearchAndDevelopmentGrants>
    <MDBH:ResearchAndDevelopmentGrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">2003000</MDBH:ResearchAndDevelopmentGrants>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">1468000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">22637000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">30790000</us-gaap:OperatingCostsAndExpenses>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">-17726000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">-28633000</MDBH:NetOperatingIncomeLoss>
    <MDBH:MiscellaneousIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">75000</MDBH:MiscellaneousIncome>
    <MDBH:MiscellaneousIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">112000</MDBH:MiscellaneousIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">617000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">1179000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">72000</us-gaap:InterestExpenseNonoperating>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">61000</MDBH:GainRelatedToDilutionEvents>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">130000</MDBH:GainRelatedToDilutionEvents>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">39307000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-16973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">12023000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">-16984000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">12021000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">-4282000</MDBH:IncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-420000</MDBH:IncomeLossFromEquityMethodInvestment>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">-21266000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">11601000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000307"
      unitRef="USD">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">-90000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">-21245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">11691000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000316"
      unitRef="USDPShares">-2.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000317"
      unitRef="USDPShares">1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000319"
      unitRef="Shares">5022742</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000320"
      unitRef="Shares">4424484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000322"
      unitRef="USDPShares">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000323"
      unitRef="USDPShares">1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000326"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000328"
      unitRef="USDPShares">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000329"
      unitRef="USDPShares">1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000331"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000334"
      unitRef="USDPShares">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000335"
      unitRef="USDPShares">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000337"
      unitRef="Shares">6145212</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">9462904</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000340"
      unitRef="USDPShares">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000341"
      unitRef="USDPShares">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000344"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000346"
      unitRef="USDPShares">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000347"
      unitRef="USDPShares">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000359"
      unitRef="Shares">4951000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000361"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">68721000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">1442000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000356"
      unitRef="USD">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">70073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000370"
      unitRef="Shares">188000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000374"
      unitRef="USD">11772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">11772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <MDBH:Netincomeloss1
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">-21245000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">-21000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">-21266000</MDBH:Netincomeloss1>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000393"
      unitRef="Shares">5139000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000395"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">80493000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000389"
      unitRef="USD">-19803000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000390"
      unitRef="USD">-111000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">60579000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000404"
      unitRef="Shares">4296000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000406"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">49406000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">-12092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">37321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000415"
      unitRef="Shares">4296000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000417"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000410"
      unitRef="USD">49406000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">-12092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">37321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000433"
      unitRef="Shares">655000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">14435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">14435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <MDBH:EffectOfDeconsolidationOfSubsidiary
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">4880000</MDBH:EffectOfDeconsolidationOfSubsidiary>
    <MDBH:EffectOfDeconsolidationOfSubsidiary
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">1836000</MDBH:EffectOfDeconsolidationOfSubsidiary>
    <MDBH:EffectOfDeconsolidationOfSubsidiary
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">6716000</MDBH:EffectOfDeconsolidationOfSubsidiary>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">13534000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">-1933000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">11601000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">13534000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">-1933000</MDBH:Netincomeloss1>
    <MDBH:Netincomeloss1
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">11601000</MDBH:Netincomeloss1>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000470"
      unitRef="Shares">4951000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000472"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">68721000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">1442000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">70073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact000481"
      unitRef="Shares">4951000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000483"
      unitRef="Shares">5000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">68721000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">1442000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">70073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000488"
      unitRef="USD">-21266000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">11601000</us-gaap:ProfitLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">-246000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">-275000</us-gaap:UnrealizedGainLossOnInvestments>
    <MDBH:AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">534000</MDBH:AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000500"
      unitRef="USD">14000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">11772000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">14435000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">6716000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">22000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">230000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000512"
      unitRef="USD">-13000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">-49000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <MDBH:DilutionOfDeferredGrantReimbursement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-41000</MDBH:DilutionOfDeferredGrantReimbursement>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">39307000</us-gaap:DeconsolidationGainOrLossAmount>
    <MDBH:PortionOfLossFromEquityInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000521"
      unitRef="USD">4282000</MDBH:PortionOfLossFromEquityInvestment>
    <MDBH:PortionOfLossFromEquityInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">420000</MDBH:PortionOfLossFromEquityInvestment>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000524"
      unitRef="USD">61000</MDBH:GainRelatedToDilutionEvents>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">130000</MDBH:GainRelatedToDilutionEvents>
    <MDBH:ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000528"
      unitRef="USD">297000</MDBH:ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal>
    <MDBH:IncomeRecognizedFromWarrantsReceived
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">1889000</MDBH:IncomeRecognizedFromWarrantsReceived>
    <MDBH:IncomeRecognizedFromWarrantsReceived
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">659000</MDBH:IncomeRecognizedFromWarrantsReceived>
    <MDBH:ImpairmentOfInvestmentsSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">200000</MDBH:ImpairmentOfInvestmentsSecurities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">-20000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">95000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">1679000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">-103000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">-1705000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">-882000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000560"
      unitRef="USD">-51000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">64000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">-55000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000564"
      unitRef="USD">-11000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000566"
      unitRef="USD">262000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000567"
      unitRef="USD">1478000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000572"
      unitRef="USD">58000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">-252000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000575"
      unitRef="USD">22000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000576"
      unitRef="USD">-1033000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">-22000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">23000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInPayablesToCustomers
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">1417000</us-gaap:IncreaseDecreaseInPayablesToCustomers>
    <us-gaap:IncreaseDecreaseInPayablesToCustomers
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">772000</us-gaap:IncreaseDecreaseInPayablesToCustomers>
    <MDBH:IncreaseDecreaseInPayablesToNoncustomers
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000585"
      unitRef="USD">-1405000</MDBH:IncreaseDecreaseInPayablesToNoncustomers>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">-5684000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">-9038000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <MDBH:PaymentsToAcquireInvestmentsSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">17766000</MDBH:PaymentsToAcquireInvestmentsSecurities>
    <MDBH:ProceedsFromInvestmentsSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">42959000</MDBH:ProceedsFromInvestmentsSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">2747000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <MDBH:PaymentForDeferredGrantReimbursement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">100000</MDBH:PaymentForDeferredGrantReimbursement>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">49000</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000606"
      unitRef="USD">-546000</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000608"
      unitRef="USD">-49000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">22892000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">69000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">69000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000620"
      unitRef="USD">-5733000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">13923000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">21281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">7358000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">15548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">21281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000632"
      unitRef="USD">11000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">2000</us-gaap:IncomeTaxesPaidNet>
    <MDBH:WarrantsReceivedAsPartOfInvestmentBankingDeal
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">657000</MDBH:WarrantsReceivedAsPartOfInvestmentBankingDeal>
    <MDBH:RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">323000</MDBH:RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">100000</MDBH:InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment>
    <MDBH:IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">65000</MDBH:IssuanceOfWarrantsToPurchaseClassStockRelatedToInitialPublicOffering>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">13217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">20437000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">2331000</us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations>
    <us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">844000</us-gaap:CashAndSecuritiesSegregatedUnderFederalAndOtherRegulations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000656"
      unitRef="USD">15548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">21281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000659">&lt;p id="xdx_80D_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zkzaZ4LO8kPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;1. &lt;span id="xdx_820_znzVrhQ6zlii"&gt;Organization and Description of Business&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;MDB Capital Holdings, LLC (&#x201c;the
Company&#x201d; or &#x201c;MDB&#x201d;), a Delaware limited liability company, is a holding company that has three wholly-owned subsidiaries:
MDB CG Management Company (&#x201c;MDB Management&#x201d;); Public Ventures, LLC, d/b/a MDB Capital (&#x201c;Public Ventures&#x201d;); and
PatentVest, Inc. (&#x201c;PatentVest&#x201d;), and MDB Minnesota One (&#x201c;M1&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;MDB Management is principally an &#x201c;administrative&#x201d;
entity whose purpose is to conduct, and wherever possible, to consolidate shared services/resources, for our US-based operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Public Ventures is a U.S. registered
broker-dealer under the Securities Exchange Act of 1934, and is a member of the Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;)
and the Texas State Securities Board. Public Ventures operates on a fully disclosed basis with a nonrelated FINRA member firm, Interactive
Brokers, LLC (&#x201c;Interactive Brokers&#x201d;), and is not required to maintain a clearing deposit. Interactive Brokers is the clearing
firm and custodian of investments maintained by Public Ventures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;PatentVest is a wholly-owned subsidiary
that performs intellectual property validation services for Public Ventures&#x2019;, due diligence functions on the intellectual property
of partner and prospective partner companies, and creates an intellectual property roadmap for such partner companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;M1 is a majority owned subsidiary
and was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo Foundation for Medical Education and Research (&#x201c;Mayo&#x201d;). The objective of
the License Agreement is for Minnesota One to develop a small molecule senescence platform.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On September 20, 2023, MDB completed
an initial public offering, consisting of the sale of &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn4n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z0bspOUwJAEc" title="Sale of stock, number of shares issued in transaction"&gt;1.67&lt;/span&gt; million shares of Class A Common Shares at $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zbd1Aqld8785" title="Sale of stock, price per share"&gt;12.00&lt;/span&gt; per share, for gross
proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zRtvOJlTSsK7" title="Gross proceeds"&gt;20.0&lt;/span&gt; million. Accordingly, the Company received total gross proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zjsfc4fiXtte" title="Gross proceeds"&gt;20.0&lt;/span&gt; million from the sale of &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn4n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zABDTLkJSHD" title="Sale of stock, number of shares issued in transaction"&gt;1.67&lt;/span&gt; million shares
of Class A Common Shares, or $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zW3POXn2rZgd" title="Net proceeds"&gt;17.4&lt;/span&gt; million net of $&lt;span id="xdx_90A_eus-gaap--OtherExpenses_pn5n6_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zM0S2lXoM4Za" title="Offering expenses"&gt;2.6&lt;/span&gt; million of offering expenses. In conjunction with the IPO, the Company issued warrants
to the placement agent to purchase &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn2n3_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z27rOZeewFVg" title="Warrants to puchase common shares"&gt;16.7&lt;/span&gt; thousand shares of Class A Common Shares, exercisable upon issuance for a period of &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znKTktnDm914" title="Warrants term"&gt;5&lt;/span&gt; years at
$&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBN0muUEESWh" title="Exercise price of warrants"&gt;15.00&lt;/span&gt; per share, for a cash consideration of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFo4Y6aYbFTe" title="Cash consideration per share"&gt;0.001&lt;/span&gt;/share. The placement agent&#x2019;s warrants had a fair value of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn2n3_c20230920__20230920__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5bVsPCpf8zh" title="Warrants fair value"&gt;65.4&lt;/span&gt; thousand, as
calculated pursuant to the Black-Scholes option-pricing model and accounted for as issuance costs that were accounted for as equity instruments
and recorded against paid in capital. The inputs used to determine the fair value was Common Stock price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z285dQ5xu3Xe" title="Common stock price"&gt;12.00&lt;/span&gt;, option exercise price
of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYQjRKCtfARa" title="Exercise price"&gt;15.00&lt;/span&gt;, expected life in years of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9gLUmTvWgGl" title="Estimated life"&gt;2.45&lt;/span&gt; years, with a contract life of &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGG31Y8m87fi" title="Contract life"&gt;5&lt;/span&gt; years, risk-free rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPozmDGfIN39" title="Risk-free rate"&gt;4.79&lt;/span&gt;%, expected annual volatility
of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSttQ5itcJcj" title="Expected annual volatility"&gt;59.99&lt;/span&gt;%, and annual rate of dividends of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_c20230920__20230920__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuRUDrw3cnL5" title="Annual rate of dividends"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On July 1, 2024, the founding ownership
of M1 had MDB owning &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MDBMinnesotaOneIncMember_zAuSzCMlDHv3" title="Ownership percentage"&gt;67&lt;/span&gt;% and Mayo owning &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MayoFoundationMember_zZ3hjBOHmsP5" title="Ownership percentage"&gt;33&lt;/span&gt;% of the issued and outstanding
common stock. M1 was formed with the purpose of developing pharmaceuticals, based on patents and licensed technology from Mayo. After
the initial formation of M1 and finalization and entry into a license agreement between Mayo and M1, MDB entered into a Term Equity Purchase
Agreement (&#x201c;Purchase Agreement&#x201d;) to provide capital for operations of M1 in exchange for the issuance of shares of common
stock of M1 to MDB. The objective of the License Agreement is for M1 to develop a small molecule senescence platform. Under the terms
of the License Agreement M1 has paid an up-front license fee to Mayo of One Hundred Fifty Thousand Dollars ($&lt;span id="xdx_909_eus-gaap--AdvancesToAffiliate_iI_pn3n3_c20240701_zwPm1CLki7b3" title="Up-front fees"&gt;150&lt;/span&gt; thousand). To maintain
its rights under the License Agreement, M1 is subject to achieving certain developmental and funding milestones within designated time
periods and to paying Mayo royalties on net sales of licensed products. Under the terms of the Purchase Agreement, MDB may invest up to
$&lt;span id="xdx_906_eus-gaap--Investments_iI_pn5n6_c20240701_zVtWwfD9CV2d" title="Investments"&gt;5.0&lt;/span&gt; million over a five-year period into M1 in amounts and increments tied to its business operating requirements. In an ancillary agreement
to the license agreement, Mayo has the right of participation in future financings of M1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="-4"
      id="Fact000661"
      unitRef="Shares">1670000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000663"
      unitRef="USDPShares">12.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="-5"
      id="Fact000665"
      unitRef="USD">20000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="-5"
      id="Fact000667"
      unitRef="USD">20000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="-4"
      id="Fact000669"
      unitRef="Shares">1670000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="-5"
      id="Fact000671"
      unitRef="USD">17400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:OtherExpenses
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_CommonClassAMember"
      decimals="-5"
      id="Fact000673"
      unitRef="USD">2600000</us-gaap:OtherExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="-2"
      id="Fact000675"
      unitRef="Shares">16700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember"
      id="Fact000677">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000679"
      unitRef="USDPShares">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000681"
      unitRef="USDPShares">0.001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-09-202023-09-20_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="-2"
      id="Fact000683"
      unitRef="USD">65400</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-20_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000685"
      unitRef="USDPShares">12.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-09-20_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">15.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember"
      id="Fact000689">P2Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-09-20_us-gaap_WarrantMember"
      id="Fact000691">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Pure">0.0479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000695"
      unitRef="Pure">0.5999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2023-09-202023-09-20_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-07-01_custom_MDBMinnesotaOneIncMember"
      decimals="INF"
      id="Fact000699"
      unitRef="Pure">0.67</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-07-01_custom_MayoFoundationMember"
      decimals="INF"
      id="Fact000701"
      unitRef="Pure">0.33</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AdvancesToAffiliate
      contextRef="AsOf2024-07-01"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">150000</us-gaap:AdvancesToAffiliate>
    <us-gaap:Investments
      contextRef="AsOf2024-07-01"
      decimals="-5"
      id="Fact000705"
      unitRef="USD">5000000.0</us-gaap:Investments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000707">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8aA90zjScb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2. &lt;span id="xdx_827_zWU5FLj60lpk"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbvuMgc7HMkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles
of Consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The accompanying consolidated financial
statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) and include the financial statements of wholly-owned and majority owned subsidiaries. All material intercompany accounts
and transactions have been eliminated in consolidation. Non-controlling interests at December 31, 2025 and 2024 relate to the interests
of third parties in the partially owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The managing members of the Company
have a controlling interest in PatentVest, S.A., a company organized and based in Nicaragua (which was renamed MDB Capital, S.A in 2022).
As the Company itself does not have a controlling financial interest in this entity, management has determined PatentVest, S.A. is not
a variable interest entity and should not be consolidated as it has no ownership interests, so has excluded this entity from the Company&#x2019;s
consolidated financial statements. It is the Company&#x2019;s policy to reevaluate this conclusion on an annual basis or if there are significant
changes in ownership.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--DeconsolidationPolicyTextBlock_z9F9sgQUCM07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Deconsolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Upon the occurrence of certain events
and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated
variable interest entities. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company
records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair
value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the
carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary&#x2019;s
assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company evaluated whether the
deconsolidation should be presented as a discontinued operation in its consolidated financial statements as of the deconsolidation date.
This assessment considers whether the deconsolidation constitutes a strategic shift that has, or will have, a major impact on the Company&#x2019;s
operations or financial results. Based on this evaluation, the Company concluded that the deconsolidation does not meet the criteria
for presentation as a discontinued operation. Accordingly, the Consolidated Statement of Operations includes the results of operations
for the deconsolidated entity through November 14, 2024, the effective date of deconsolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zeX1leJLKmW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Equity method investment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company applies the equity method
to account for investments in entities where it has the ability to exercise significant influence over the operating and financial policies
of the investee. Under the equity method, the investment in eXoZymes Inc, (&#x201c;eXoZymes &#x201c;), formerly Invizyne Technologies
Inc. (&#x201c;Invizyne&#x201d;)&#x201d;, is initially recorded at cost and subsequently
adjusted to reflect the Company&#x2019;s proportional share of the investee&#x2019;s results of operations in its consolidated financial
statements. Equity method investments are periodically reviewed for any other-than-temporary declines in value. The Company&#x2019;s investment
in eXoZymes is presented as &#x201c;Equity method investment&#x201d; on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Any excess of the acquisition cost
over the Company&#x2019;s share of the net fair value of eXoZymes&#x2019; identifiable assets and liabilities at the acquisition date is
recognized as goodwill, which is included in the carrying amount of the investment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;When the Company increases its interest
in an affiliate accounted for under the equity method while retaining significant influence, it applies the acquisition method only to
the additional interest acquired, leaving the previous interest unchanged. Conversely, when there is a decrease in the interest in an
affiliate accounted for under the equity method while retaining significant influence, the Company derecognizes a proportionate part of
its investment and recognizes any resulting gain or loss in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWOfx76LB65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;We account for income taxes using the
asset and liability method, under which we would recognize the amount of taxes payable or refundable for the current year and deferred
tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns.
We measure current and deferred tax assets and liabilities based on provisions of enacted tax law. We evaluate the realization of our
deferred tax assets based on all available evidence and establish a valuation allowance to reduce deferred tax assets when it is more
likely than not that they will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zqrc9oBsVfg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period, as well as the
disclosure of contingent assets and liabilities. Some of those judgments can be subjective and complex, and therefore, actual results
could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience
and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available
information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate,
those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related
to assumptions used in the valuation of investment securities, accruals for potential liabilities, valuing equity instruments issued for
services, assumptions used in the valuation of the equity method investment and gains on the deconsolidation of the subsidiary, the estimate
of the fair value of the lease liability and related right of use assets, net realizable value of receivables, useful life of property
and equipment, determining impairment of long-lived assets, and the realization of any deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWbadvRIbCGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Emerging Growth Company&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is an &#x201c;emerging growth
company,&#x201d; or &#x201c;EGC&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified
by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to opt out of the
extended transition periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znoJLvxnNDo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company considers highly liquid
investments with original maturities or remaining maturities upon purchase of three months or less to be cash equivalents. There were
$&lt;span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zrDGrtDWZr0f" title="Cash Equivalents"&gt;4.5&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zGBlfJQ1PcEf" title="Cash Equivalents"&gt;11.8&lt;/span&gt; million cash equivalents held by the Company at December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s policy is to
maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit
Insurance Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;).
The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_pn4n6_c20251231_z9yskUhQkfTb" title="Cash, FDIC insured limits"&gt;0.25&lt;/span&gt;
million and $&lt;span id="xdx_906_ecustom--CashSIPCInsuredAmount_iI_pn5n6_c20251231_zFYU47D2MVbb" title="Cash, SIPC insured limits"&gt;0.5&lt;/span&gt;
million. At December 31, 2025, the Company held $&lt;span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20251231_zix1xGBhe045" title="Unsegregated cash"&gt;8.7&lt;/span&gt;
million of unsegregated cash and $&lt;span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zMs7qsmkP4nf" title="Cash equivalents"&gt;4.5&lt;/span&gt;
million of cash equivalents. For the years ended December 31, 2025 and 2024, respectively, the Company had approximately $&lt;span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zviXm48akQ9h" title="Cash uninsured limits"&gt;7.2&lt;/span&gt;
million and $&lt;span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zPtWfFI5fLa2" title="Cash uninsured limits"&gt;4.3&lt;/span&gt;
million of cash and segregated cash in financial institutions in excess of FDIC insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company periodically reviews the
financial condition of the financial institutions and assesses the credit risk of such investments. The Company did not experience any
credit risk losses during the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s membership agreement
with the Depository Trust Clearing Corporation (&#x201c;DTCC&#x201d;) requires that we maintain a line of credit with our settlement bank in the amount $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20251231_zoKJtkzFEFIf" title="Line of credit"&gt;2.0&lt;/span&gt; million, to be drawn down upon as
needed for self-clearing operations. The Company has established a line of credit with its settlement bank, Lakeside Bank, which is collateralized
by a $&lt;span id="xdx_901_eus-gaap--Deposits_iI_pn5n6_c20251231_zRlQibc6QRh7" title="Deposit"&gt;2.0&lt;/span&gt; million deposit of cash at Lakeside. The collateral amount may be withdrawn, but the availability of the line of credit is dependent
upon the maintenance of such compensating balance and is included in cash and cash equivalents on the Statement of Financial Condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--SegregatedCashAndDepositsPolicyTextBlock_zEdxvQaMMd95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Segregated Cash and Deposits&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;From time to time the Company provides
deposits or enters into agreements that would require funds to be held in a segregated cash account. At December 31, 2025 and 2024, respectively,
the Company had $&lt;span id="xdx_90F_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20251231_zW4DOkMjezg" title="Cash segregated in compliance with regulations"&gt;2.3&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20241231_zH4eJBfqO7pj" title="Cash segregated in compliance with regulations"&gt;0.8&lt;/span&gt; million of segregated cash consisting of funds held in reserve for customers and non-customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--DepositContractsPolicy_zXe17lXZT4Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Clearing Deposits&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is obligated to maintain
security deposits with the DTCC and National Securities Clearing Corporation (&#x201c;NSCC&#x201d;). At December 31, 2025 and 2024, these deposits totaled $&lt;span id="xdx_900_eus-gaap--DepositsAssets_iI_pn5n6_c20251231_zDAy8NALC5y6" title="Clearing deposits"&gt;2.0&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--DepositsAssets_iI_pn5n6_c20241231_zclBROS6osn9" title="Clearing deposits"&gt;1.7&lt;/span&gt; million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--PrepaidAndOtherCurrentAssetsPolicyTextBlock_zNKUuAkbGSea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Prepaid and other current assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company has prepaid and other current
assets totaling $&lt;span id="xdx_906_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20251231_zj7INjmPlGV9" title="Prepaid and other current assets"&gt;433&lt;/span&gt; thousand at December 31, 2025 consisting of acquired intangible assets totaling $&lt;span id="xdx_90A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20250101__20251231_z0yEmAC6bRb4" title="Intangible assets acquired"&gt;44&lt;/span&gt; thousand, prepaid professional
fees totaling $&lt;span id="xdx_905_ecustom--PrepaidProfessionalFees_pn3n3_c20250101__20251231_zllM01zlh6Ul" title="Prepaid professional fees"&gt;50&lt;/span&gt; thousand, security deposits totaling $&lt;span id="xdx_90B_eus-gaap--SecurityDeposit_iI_pn3n3_c20251231_zrMtKd7vB4x5" title="Security deposit"&gt;19&lt;/span&gt; thousand, prepaid insurance $&lt;span id="xdx_902_eus-gaap--PrepaidInsurance_iI_pn3n3_c20251231_zK9n860ZZMZ6" title="Prepaid insurance"&gt;169&lt;/span&gt; thousand, various prepaid expense of $&lt;span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20251231_zRKRbjQictU3" title="Various prepaid expense"&gt;130&lt;/span&gt;
thousand, and other assets of $&lt;span id="xdx_901_eus-gaap--OtherAssets_iI_pn3n3_c20251231_zxLCMJrZIVxk" title="Other assets"&gt;21&lt;/span&gt; thousand. Prepaid and other expenses totaling $&lt;span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20241231_z1eqPWY77Zpd" title="Prepaid and other expenses"&gt;513&lt;/span&gt; thousand at December 31, 2024 consisting of acquired
intangible assets totaling $&lt;span id="xdx_90B_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_z69yTaaoZwKd" title="Intangible assets acquired"&gt;44&lt;/span&gt; thousand, prepaid professional fees totaling $&lt;span id="xdx_900_ecustom--PrepaidProfessionalFees_pn3n3_c20240101__20241231_zO8uio7h2SUg" title="Prepaid professional fees"&gt;50&lt;/span&gt; thousand, security deposits totaling $&lt;span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn3n3_c20241231_zk8QBjBoucW4" title="Security deposit"&gt;19&lt;/span&gt; thousand, prepaid
insurance $&lt;span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20241231_zEeAzlURSyjc" title="Prepaid insurance"&gt;160&lt;/span&gt; thousand, various prepaid expense of $&lt;span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20241231_z42b4Zoa3uJ4" title="Various prepaid expense"&gt;150&lt;/span&gt; thousand, and other assets of $&lt;span id="xdx_90A_eus-gaap--OtherAssets_iI_pn3n3_c20241231_zRlD3U4ITts" title="Other assets"&gt;90&lt;/span&gt; thousand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zepmYoy0mMLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Leases of the Company consist primarily
of contracts for the right to use and direct use of an individual property. Leases were analyzed for evidence of significant additional
components and to determine if these components were separately identifiable within the context of the contract. As an accounting policy,
to account for these components, the Company has elected the practical expedient for property leases that have both lease and non-lease
components for them to be combined into a single component and account for as a lease. This policy is effective for all current and future
property operating leases and applied uniformly and will be disclosed as such within the financial statements. Operating lease assets
are included within right-of-use assets and the corresponding operating lease liabilities are included within liabilities on the Company&#x2019;s
consolidated balance sheet as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company has elected not to present
short-term leases on the consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not
contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other right-of-use assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. Because the
Company&#x2019;s leases do not provide an implicit rate of return, the Company used the Company&#x2019;s incremental borrowing rate based
on the information available at lease commencement date in determining the present value of lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zaeBpyEiNdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;Stock Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Stock-based compensation primarily
consists of restricted stock units with service or market/performance conditions. Equity awards are measured at the fair market value
of the underlying stock at the grant date. The Company recognized stock based compensation expense using the straight-line attribution
method over the requisite service period. The Company&#x2019;s subsidiary issued stock-options and the fair value is determined utilizing
Black-Scholes options-pricing model. The Company accounts for forfeitures as they occur, rather than applying an estimated forfeiture
rate. For performance-based restricted stock units, the compensation cost is recognized based on the number of units expected to vest
upon the achievement of the performance conditions. Shares are issued on the vesting dates net of the applicable statutory tax withholding
to be paid by us on behalf of our employees. As a result, fewer shares are issued to the employee than the number of awards outstanding.
The Company records a liability for the tax withholding to be paid by it as a reduction to Additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--InvestmentPolicyTextBlock_zjbe21QMRo1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Investment Securities &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company strategically invests funds
in U.S. Treasury Bills, early-stage technology companies, and equity securities and options of publicly traded and privately held companies.
The Company classifies investment securities as investment securities, at amortized cost, investment securities, at fair value, or investment
securities, at cost less impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Investment securities, at amortized
cost&lt;/i&gt; &#x2013; From time to time the Company will hold funds in investment securities, at amortized cost. This is comprised of debt
securities held by MDB and are classified as investment securities held-to-maturity and carried at amortized cost if management has the
positive intent and ability to hold the securities to maturity. Initially, the cost of these securities was recorded, and later on, they
were assessed at amortized cost, which was modified for unamortized purchase premiums and discounts, and also for credit losses provision.
Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective-interest
method. Such amortization and accretion are included in the other operating income in the statements of operations. Interest income is
recognized when earned. The Company recognizes estimated expected credit losses over the life of the investment security through the allowance
for credit losses account. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost
basis of the investment security to present the net amount expected to be collected. In determining expected credit losses, the Company
considers relevant qualitative factors including, but not limited to, term and structure of the instrument, credit rating by rating agencies
and historic credit losses adjusted for current conditions and reasonable and supportable forecasts. The Company holds investments in
U.S. Treasury Bills or money market funds backed by U.S. Treasury Bills, so there are no expected credit losses. Declines in fair value
of these securities is due to changes in market interest rates, and because it expects to hold these securities until maturity, it does
not expect to realize any losses. There were no investment securities, at amortized cost as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Investment securities, at fair value
&lt;/i&gt;- This is comprised of equity investments held by the broker dealer subsidiary and are reported at fair value with changes in fair
value recognized in the statement of operations. Purchases and sales of equity securities, consisting of common stock and warrants to
purchase common stock, are recorded based on the respective market price quotations on the trade date. Realized gains and losses on investments
represent the net gains and losses on investments sold during the period based on the average cost method. Differences between the fair
value of investments at the beginning of the year and the end of the year are recorded on the income statement as unrealized gains and
losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Investment securities, at cost less
impairment&lt;/i&gt; - This is comprised of equity securities without a readily determinable fair value held by the broker dealer subsidiary,
the Company has elected to apply the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable
price changes. The Company will reassess whether such an investment qualifies for the measurement alternative at each reporting period.
In evaluating an investment for impairment or observable price changes, we will use inputs including recent financing events, as well
as other available information regarding the investee&#x2019;s historical and forecasted performance. The Company has assessed this investment
and determined that the current impairment of such securities held at the year ended December 31, 2025 is accurate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities are as follows
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Broker/Dealer Securities&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zQRLhofnSVV3" style="display: none"&gt;Schedule of Investment Securities Broker Dealer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Investment securities, at fair value:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Common stock of publicly traded companies&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Warrants of publicly traded companies&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,937&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,330&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrants of non-publicly traded companies&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;658&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at fair value&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,166&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;5,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z9OkuMpESene" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Non-Broker/Dealer Securities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_8BF_zJ7jauHHoWlg"&gt;Schedule of Investment Securities Non-Broker Dealer&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Investment securities, at fair value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Common stock of publicly traded companies&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;235&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Investment securities, at cost less impairment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Simple agreement on future equities (not market listed)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Impairment&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at cost less impairment&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zuwmTRHBqnx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;For investment securities at fair value
held at the end of each year, net unrealized loss of $&lt;span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20250101__20251231_zsuIBnQqld4g" title="Net unrealized gain (loss) on investment securities"&gt;246&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20240101__20241231_z6mVQU83Glli" title="Net unrealized gain (loss) on investment securities"&gt;275&lt;/span&gt; thousand were recognized in the statement of operations for
years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1icpMWXqG9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree
that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the
lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company determines the fair value
of its financial instruments based on a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value
into three levels:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 1 - Observable inputs such as
quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 2 - Inputs, other than quoted
prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 3 - Unobservable inputs in which
there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s financial instruments primarily consist of cash and investment
securities. These investment securities and securities sold and not yet purchased are recorded at fair value as of the balance sheet date,
with unrealized gains and losses resulting from changes in fair value recognized in the statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A description of the valuation techniques
applied to the Company&#x2019;s major categories of assets and liabilities measured at fair value on a recurring basis is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities, at fair value
and securities sold, not yet purchased: These securities are valued based on quoted prices from the exchange or other trading platform.
To the extent these securities are actively traded, valuation adjustments are not applied, and they are categorized in level 1 of the
fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A description of the valuation techniques
applied to the Company&#x2019;s other financial assets and liabilities is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities, at amortized
cost: The fair value of U.S. Treasury Bills classified as held-to-maturity investment securities is based on the market price and is classified
as level 1 of the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities, at cost
less impairment: Non-public equity securities and simple agreements for future equity are valued based on the initial investment,
less impairment. The Company determined that an impairment is warranted. Since these securities are not actively traded, we will
apply valuation adjustments when they become available, and they are categorized in level 3 of the fair value hierarchy. The Company
fully impaired a Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) that was previously valued at $&lt;span id="xdx_907_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SAFEMember_zfEVnkDkesF5" title="Impairment of securities"&gt;100&lt;/span&gt;
thousand and stock that was previously valued at $&lt;span id="xdx_909_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231_zjICz0hNW6R2" title="Impairment of securities"&gt;50&lt;/span&gt;
thousand both were held at the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following table sets forth the
fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_z82LCnEDOUFb" style="display: none"&gt;Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Classification&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the licensed broker dealer&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the non-licensed broker dealer&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;235&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;235&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,595&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,806&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;7,401&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zIWcQtXRunp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2025, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zLQDKsgMVcPa" style="display: none"&gt;Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt"&gt;Beginning Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Receipt from investment banking fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,690&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Unrealized gain&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;111&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"&gt;4,463&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zwiD6wiM66M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)&lt;/b&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zYKZqfnooG2" style="display: none"&gt;Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
Techniques&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ranges of&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" style="text-align: right" title="Warrants, Fair value"&gt;&lt;span style="font-size: 10pt"&gt;4,463&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Black Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs"&gt;95.92&lt;/span&gt; -&#160;&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs"&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" style="text-align: right" title="Weighted measurement input"&gt;&lt;span style="font-size: 10pt"&gt;115.45&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_z2C5euSaftok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zlqM1QVW6kJb"&gt;&lt;b&gt;The following table sets forth the
fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C04_gL3SOFVAALMOR-YZJZHH_zKHclHGg20w9"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Classification&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;3,330&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;5,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zWa3Fx0mjlFf"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2024, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C04_gL3FVAMORBUIR-BRK_zQrFBAw5dIYe"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C08_gL3FVAMORBUIR-BRK_z3xAKOAdAp5d"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" style="border-collapse: collapse; width: 96%; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;3,134&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt"&gt;Beginning Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;3,134&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Unrealized gains&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(472&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Unrealized (loss) gains&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;(472&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C05_gL3FVAMORBUIR-BRK_z2jUR5Nf99T4"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C09_gL3FVAALMORAN-L_zDICDGAXkhH3"&gt;&lt;b&gt;The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C02_gL3FVAALMORAN-L_z8NPe4RhThA9"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
Techniques&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ranges of&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" style="text-align: right" title="Warrants, Fair value"&gt;&lt;span style="font-size: 10pt"&gt;2,662&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Black Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" style="text-align: right" title="Range of inputs"&gt;&lt;span style="font-size: 10pt"&gt;111.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" style="text-align: right" title="Weighted measurement input"&gt;&lt;span style="font-size: 10pt"&gt;111.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_C08_gL3FVAALMORAN-L_zFRFYdbkeMvc"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--DebtPolicyTextBlock_zgWoIHtxQztb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;Secured Debt&#x2013;- Revolving
Credit Facility&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company entered into a revolving
credit facility with a bank, (the &#x201c;Lender&#x201d;) on July 26, 2024 for a commitment of up to $&lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0EOvrB8hnAd" title="Revolving credit, maximum borrowing capacity"&gt;2.0&lt;/span&gt; million and which matures &lt;span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zhhYByZAPftd" title="Maturity date"&gt;July
26, 2025&lt;/span&gt;. The loan has a variable interest rate equal to a defined index, currently the Lender&#x2019;s rate on the sale of Federal Funds,
plus &lt;span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zBayzkWHgzIa" title="Variable rate"&gt;2.25&lt;/span&gt;%. The loan commenced with a calculated interest rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zpgvzJk0sZ65" title="Interest rate"&gt;7.75&lt;/span&gt;%. If the Lender determines, in its sole discretion, that the index
becomes unavailable or unreliable, either temporary, indefinitely, or permanently, during the term of this loan, the Lender may amend
this loan by designating a substantially similar substitute index. The agreement provides for a quarterly payment of the greater of accrued
interest or a non-usage fee of $&lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn3n3_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zmaGjZ86t8Ae" title="Credit non-usage fee"&gt;5&lt;/span&gt; thousand. The Company has not made any draw downs on the credit facility.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company granted the Lender a
security interest in a cash checking account held at the bank as collateral. The Lender has a right of setoff available from this
cash account when the line of credit is accessed. As of December 31, 2025 and 2024, there was $&lt;span id="xdx_904_eus-gaap--Deposits_iI_pn5n6_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyQmiqWvezV7" title="Deposits"&gt;2.1&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--Deposits_iI_pn5n6_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXBTreFjla7j" title="Deposits"&gt;2.1&lt;/span&gt; million deposited in this account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is responsible for the
payment of all of the Lender&#x2019;s legal and other fees incurred in connection with administering the loan. The Company has incurred
no such costs or debt issue costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2025 and 2024, there are &lt;span id="xdx_909_eus-gaap--LineOfCredit_iI_do_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZIwhsjYOybh" title="Outstanding indebtedness"&gt;&lt;span id="xdx_90A_eus-gaap--LineOfCredit_iI_do_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkDXvC2Zhwpe" title="Outstanding indebtedness"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding indebtedness under the credit facility and interest expense totaled $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zeQjdwsqGVrk" title="Interest payable"&gt;&lt;span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zjlzMwhVXdI7" title="Interest payable"&gt;0&lt;/span&gt;&lt;/span&gt;. The Company is in compliance with all
covenants under the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyma5WBbqKKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment are recorded
at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from disposition
of property and equipment are included in the statement of operations when realized. Depreciation is provided using the straight-line
method over the following estimated useful lives:&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none"&gt;Schedule
of Estimated Useful Lives of Property
and Equipment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Developed software&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;Lesser of the lease duration or the life of the improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zPIXDQXW8b0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z8fPKC7TjJZh" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Developed software&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"&gt;139&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;139&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;113&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zSieLJh9Yjw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_ziTtwP2xkno9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Revenue &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company generates revenue primarily
from providing brokerage services and underwriting through Public Ventures. PatentVest and eXoZymes, have
had limited activity during the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Brokerage revenues consist of (i) trade-based
commission income from executed trade orders, (ii) net realized gains and losses from proprietary trades, and (iii) other income consisting
primarily of stock loan income earned on customer accounts. Public Ventures recognizes revenue from trade-based commissions and other
income when performance obligations are satisfied through the transfer of control, as specified in the contract, of promised services
to the customers of Public Ventures. Commissions are recognized on a trade date basis. Public Ventures believes that each executed trade
order represents a single performance obligation that is fulfilled on the trade date because that is when the underlying financial instrument
is identified, the pricing is agreed upon, and the risks and rewards of ownership have been transferred to/from the customer. When another
party is involved in transferring a good or service to a customer, Public Ventures assesses whether revenue is presented based on the
gross consideration received from customers (principal) or net of amounts paid to a third party (agent). Public Ventures has determined
that it is acting as the principal as the provider of the brokerage services and therefore records this revenue on a gross basis. Clearing,
custody and trade administration fees incurred from Interactive Brokers, the Company&#x2019;s clearing firm, are recorded effective as
of the trade date. The costs are treated as fulfillment costs and are recorded in operating expenses in the consolidated statements of
operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Brokerage revenue is measured by the
transaction price, which is defined as the amount of consideration that Public Ventures expects to receive in exchange for services to
customers. The transaction price is adjusted for estimates of known or expected variable consideration based upon the individual contract
terms. Variable consideration is recorded as a reduction to revenue based on amounts that Public Ventures expects to refund back to the
customer. There were no variable considerations for the years ended December 31, 2025, and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment banking revenues
consist of private placement and underwriting fees. The Company generally does not incur costs to obtain contracts with customers
that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions, and
therefore, as of December 31, 2025 and 2024, the Company did not have any contract assets or liabilities related to these revenues
on its consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company enters into underwriting agreements, to act as an underwriter and security offerings which include distribution and sale of securities
to investors. These agreements allow non-defaulting underwriters and the issuer&#x2019;s representative to seek substitute purchasers within
36 hours if the Company defaults on its commitment. If replacements are not found and the default exceeds 10% of the offering, the agreement
may be terminated without liability. Under ASC 606, revenue is recognized only upon transfer of cash from the escrow account from investors
which is the final receipt of payment, as well receipt of warrants and common stock on the date of closing, with no recognition for defaulted
or terminated portions until resolution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Private placement fees are related
to non-underwritten transactions such as private placements of equity securities, private investments in public equity, and Rule 144A
private offerings and are recorded on the closing date of the transaction. Client reimbursements for costs associated for private placement
fees are recorded gross within investment banking and various expense captions, excluding compensation. The Company typically receives
payments on private placements transactions at the completion of the contract. The Company views the majority of placement fees as a single
performance obligation that is satisfied when the transaction is complete, and the revenue is recognized at that point in time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Taxes and regulatory fees assessed
by a government authority or agency that are both imposed on and concurrent with a specified revenue-producing transaction, which are
collected by Public Ventures from a customer, are excluded from revenue and recorded against general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Public Ventures does not incur any
costs to obtain contracts with customers for revenues that are eligible for deferral or receive fees prior to recognizing revenue, and
therefore, as of December 31, 2025 and 2024, Public Ventures did not have any contract assets or liabilities related to these revenues
in its consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the years ended December 31,
2025 and 2024, the Company&#x2019;s technology development segment did not have any revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;PatentVest recognizes revenue when performance
obligations are satisfied by transferring promised goods and services to customers in an amount the Company expects to receive in exchange
for those goods or services. PatentVest enters into contracts that can include various combinations of its offerings which are generally
capable of being distinct and accounted for as a separate performance obligation for the entire contract or a portion of the contract.
When performance obligations are combined into a single contract, PatentVest utilizes stand-alone selling price to allocate the transaction
price among the performance obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Certain contracts or portions of contracts
are duration-based, which in the event of customer cancellation, provide PatentVest with an enforceable right to a proportional payment
for the portion of the services provided. Accordingly, revenue from duration-based contracts is recognized using a time-based measure
of progress, which PatentVest believes best depicts how it satisfies its performance obligations in these arrangements as control is continuously
transferred throughout the contract period. Revenue from certain contracts is recognized over the expected period of performance using
a single measure of progress, typically based on hours incurred. Payments received in advance of services being rendered are recorded
as a component of contract liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The PatentVest&#x2019;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zzOhoIIdeFQf" style="display: none"&gt;Schedule of Changes in Deferred Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" style="width: 16%; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;Amounts billed but not recognized&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" style="font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;Amounts billed but not recognized&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zwq8sGRWvSh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--AccountingForResearchGrantsPolicyTextBlock_zKADqWpB076k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Research Grants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;eXoZymes, receives grant reimbursements, which are netted against research and development expenses in the consolidated statement of operations.
Grant reimbursements for capitalized assets are recognized over the useful life of the assets, with the unrecognized portion recorded
as deferred grant reimbursements and included in liabilities in the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Grants function on a reimbursement
model are accounted for using the accrual method. They are treated as reductions to expenses, corresponding to the amount of disbursements
and obligations eligible for reimbursement. These are for permissible expenses incurred as of December 31, 2024. The reimbursements are
anticipated to be received from the respective funding entities in the following year. Management considers such receivables at December
31, 2024, to be fully collectable due to the historical experience with the Federal Government of the United States of America. Accordingly,
no allowance for credit losses on the grants receivable was recorded in the accompanying consolidated financial statements. The Company was not engaged in any research grants for the year ended December 31. 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zvvVxNvqM2t4" style="display: none"&gt;Summary of Grants Receivable Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;span id="xdx_F5E_zzT4nWlrl6oh"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Balance at beginning of year&lt;span id="xdx_F49_zeT54RJrBuT1"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;882&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant costs expensed&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,897&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grants for equipment purchased&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;44&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant funds received&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,173&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Removal of balance due to deconsolidation of eXoZymes at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1027"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(702&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1031"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt"&gt;In 2024, eXoZymes was deconsolidated
from the Company&#x2019;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p id="xdx_8A0_z4a8wDrTKNud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;eXoZymes has received three grants
provided by the National Institute of Health, the Department of Energy and Department of Defense through December 31, 2024. The first
grant was awarded on October 1, 2023 and the latest of these grants was set to expire on May 14, 2026, however grants can be extended,
or new phases can be granted, extending the expiration of the grant. None of the grants have commitments made by the parties, provisions
for recapture, or any other contingencies, beyond complying with the normal terms of each research and development grant. Research grants
received from organizations are subject to the contract agreement as to how eXoZymes, formerly known as eXoZymes, conducts its research
activities, and eXoZymes is required to comply with the agreement terms relating to those grants. Amounts received under research grants
are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance
with the approved grant project. eXoZymes is permitted to draw down the research grants after incurring the related expenses. Amounts
received under research grants are offset against the related research and development costs in the Company&#x2019;s consolidated statement
of operations. For the years ended December 31, 2025 and 2024, grants amounting $&lt;span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20251231_zx1DsG46DI38" title="Research and development costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_zvUD2nyd6316" title="Research and development costs"&gt;2.8&lt;/span&gt; million, were offset against
the research and development costs. Grant drawdowns, which includes grants costs expensed, grants for equipment purchased, and grant fees,
for the years ended December 31, 2025 and 2024, totaled $&lt;span id="xdx_90B_ecustom--GrantDrawdowns_c20250101__20251231_zX0Wcdhg4k9d" title="Grant drawdowns"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--GrantDrawdowns_pn5n6_c20240101__20241231_zTw0cXZNZD38" title="Grant drawdowns"&gt;2.0&lt;/span&gt; million, respectively, which included grant costs expensed, grants
for equipment purchased, and grants fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zFio8zeF0yx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses
relating to the development of eXoZymes&#x2019; technology. For the years ended December 31, 2025 and 2024, research and development costs
prior to offset of the grants amounted to $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseGross_c20250101__20251231_zHnagssCOgN4" title="Net of grant received"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseGross_pn5n6_c20240101__20241231_zw8WD44tPH7l" title="Net of grant received"&gt;3.4&lt;/span&gt; million, respectively, which included grant costs expensed, grants fees, and research
and development costs, net of the grant received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_zNGl6M1zDfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Patent and Licensing Legal and Filing
Fees and Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Due to the significant uncertainty
associated with the successful development of one or more commercially viable products based on the Company&#x2019;s research efforts and
related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its
intellectual property are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90A_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20250101__20251231_zAAazgXGyKU5" title="Patent and licensing legal and filing fees and costs"&gt;54&lt;/span&gt; thousand and $&lt;span id="xdx_902_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20240101__20241231_zE6M4QA6cWb5" title="Patent and licensing legal and filing fees and costs"&gt;296&lt;/span&gt; thousand for the years ended December 31, 2025 and 2024, respectively. Patent and licensing
legal and filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zssHT9mtPbQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;ASU 2021-10, Government Assistance
(Topic 832): Disclosures by Business Entities about Government Assistance&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On January 1, 2020, The Company adopted
ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (&#x201c;ASU 2021-10&#x201d;)
and retrospectively applied the guidance to prior transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The amendments in ASU 2021-10 require
the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting
model by analogy: (1) information about the nature of the transactions and the related accounting policy used to account for the transactions;
(2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each
financial statement line item; and (3) significant terms and conditions of the transactions, including commitments and contingencies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Management does not believe that any
other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#x2019;s
consolidated financial statement presentation or disclosures.&lt;/p&gt;

&lt;p id="xdx_85E_zcQgKELri1l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000709">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zbvuMgc7HMkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Basis of Presentation and Principles
of Consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The accompanying consolidated financial
statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) and include the financial statements of wholly-owned and majority owned subsidiaries. All material intercompany accounts
and transactions have been eliminated in consolidation. Non-controlling interests at December 31, 2025 and 2024 relate to the interests
of third parties in the partially owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The managing members of the Company
have a controlling interest in PatentVest, S.A., a company organized and based in Nicaragua (which was renamed MDB Capital, S.A in 2022).
As the Company itself does not have a controlling financial interest in this entity, management has determined PatentVest, S.A. is not
a variable interest entity and should not be consolidated as it has no ownership interests, so has excluded this entity from the Company&#x2019;s
consolidated financial statements. It is the Company&#x2019;s policy to reevaluate this conclusion on an annual basis or if there are significant
changes in ownership.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <MDBH:DeconsolidationPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000711">&lt;p id="xdx_84E_ecustom--DeconsolidationPolicyTextBlock_z9F9sgQUCM07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Deconsolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Upon the occurrence of certain events
and on a regular basis, the Company evaluates whether it no longer has a controlling interest in its subsidiaries, including consolidated
variable interest entities. If the Company determines it no longer has a controlling interest, the subsidiary is deconsolidated. The Company
records a gain or loss on deconsolidation based on the difference on the deconsolidation date between (i) the aggregate of (a) the fair
value of any consideration received, (b) the fair value of any retained noncontrolling investment in the former subsidiary and (c) the
carrying amount of any noncontrolling interest in the subsidiary being deconsolidated, less (ii) the carrying amount of the former subsidiary&#x2019;s
assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company evaluated whether the
deconsolidation should be presented as a discontinued operation in its consolidated financial statements as of the deconsolidation date.
This assessment considers whether the deconsolidation constitutes a strategic shift that has, or will have, a major impact on the Company&#x2019;s
operations or financial results. Based on this evaluation, the Company concluded that the deconsolidation does not meet the criteria
for presentation as a discontinued operation. Accordingly, the Consolidated Statement of Operations includes the results of operations
for the deconsolidated entity through November 14, 2024, the effective date of deconsolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:DeconsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000713">&lt;p id="xdx_843_eus-gaap--EquityMethodInvestmentsPolicy_zeX1leJLKmW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Equity method investment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company applies the equity method
to account for investments in entities where it has the ability to exercise significant influence over the operating and financial policies
of the investee. Under the equity method, the investment in eXoZymes Inc, (&#x201c;eXoZymes &#x201c;), formerly Invizyne Technologies
Inc. (&#x201c;Invizyne&#x201d;)&#x201d;, is initially recorded at cost and subsequently
adjusted to reflect the Company&#x2019;s proportional share of the investee&#x2019;s results of operations in its consolidated financial
statements. Equity method investments are periodically reviewed for any other-than-temporary declines in value. The Company&#x2019;s investment
in eXoZymes is presented as &#x201c;Equity method investment&#x201d; on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Any excess of the acquisition cost
over the Company&#x2019;s share of the net fair value of eXoZymes&#x2019; identifiable assets and liabilities at the acquisition date is
recognized as goodwill, which is included in the carrying amount of the investment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;When the Company increases its interest
in an affiliate accounted for under the equity method while retaining significant influence, it applies the acquisition method only to
the additional interest acquired, leaving the previous interest unchanged. Conversely, when there is a decrease in the interest in an
affiliate accounted for under the equity method while retaining significant influence, the Company derecognizes a proportionate part of
its investment and recognizes any resulting gain or loss in profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000715">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWOfx76LB65j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;We account for income taxes using the
asset and liability method, under which we would recognize the amount of taxes payable or refundable for the current year and deferred
tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns.
We measure current and deferred tax assets and liabilities based on provisions of enacted tax law. We evaluate the realization of our
deferred tax assets based on all available evidence and establish a valuation allowance to reduce deferred tax assets when it is more
likely than not that they will not be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000717">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zqrc9oBsVfg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period, as well as the
disclosure of contingent assets and liabilities. Some of those judgments can be subjective and complex, and therefore, actual results
could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience
and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available
information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate,
those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related
to assumptions used in the valuation of investment securities, accruals for potential liabilities, valuing equity instruments issued for
services, assumptions used in the valuation of the equity method investment and gains on the deconsolidation of the subsidiary, the estimate
of the fair value of the lease liability and related right of use assets, net realizable value of receivables, useful life of property
and equipment, determining impairment of long-lived assets, and the realization of any deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <MDBH:EmergingGrowthCompanyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000719">&lt;p id="xdx_841_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWbadvRIbCGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Emerging Growth Company&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is an &#x201c;emerging growth
company,&#x201d; or &#x201c;EGC&#x201d; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified
by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected to opt out of the
extended transition periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000721">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znoJLvxnNDo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company considers highly liquid
investments with original maturities or remaining maturities upon purchase of three months or less to be cash equivalents. There were
$&lt;span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zrDGrtDWZr0f" title="Cash Equivalents"&gt;4.5&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zGBlfJQ1PcEf" title="Cash Equivalents"&gt;11.8&lt;/span&gt; million cash equivalents held by the Company at December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s policy is to
maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit
Insurance Corporation (the &#x201c;FDIC&#x201d;) and/or by the Securities Investor Protection Corporation (the &#x201c;SIPC&#x201d;).
The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $&lt;span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_pn4n6_c20251231_z9yskUhQkfTb" title="Cash, FDIC insured limits"&gt;0.25&lt;/span&gt;
million and $&lt;span id="xdx_906_ecustom--CashSIPCInsuredAmount_iI_pn5n6_c20251231_zFYU47D2MVbb" title="Cash, SIPC insured limits"&gt;0.5&lt;/span&gt;
million. At December 31, 2025, the Company held $&lt;span id="xdx_90B_eus-gaap--Cash_iI_pn5n6_c20251231_zix1xGBhe045" title="Unsegregated cash"&gt;8.7&lt;/span&gt;
million of unsegregated cash and $&lt;span id="xdx_905_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20251231_zMs7qsmkP4nf" title="Cash equivalents"&gt;4.5&lt;/span&gt;
million of cash equivalents. For the years ended December 31, 2025 and 2024, respectively, the Company had approximately $&lt;span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20251231_zviXm48akQ9h" title="Cash uninsured limits"&gt;7.2&lt;/span&gt;
million and $&lt;span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zPtWfFI5fLa2" title="Cash uninsured limits"&gt;4.3&lt;/span&gt;
million of cash and segregated cash in financial institutions in excess of FDIC insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company periodically reviews the
financial condition of the financial institutions and assesses the credit risk of such investments. The Company did not experience any
credit risk losses during the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s membership agreement
with the Depository Trust Clearing Corporation (&#x201c;DTCC&#x201d;) requires that we maintain a line of credit with our settlement bank in the amount $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20251231_zoKJtkzFEFIf" title="Line of credit"&gt;2.0&lt;/span&gt; million, to be drawn down upon as
needed for self-clearing operations. The Company has established a line of credit with its settlement bank, Lakeside Bank, which is collateralized
by a $&lt;span id="xdx_901_eus-gaap--Deposits_iI_pn5n6_c20251231_zRlQibc6QRh7" title="Deposit"&gt;2.0&lt;/span&gt; million deposit of cash at Lakeside. The collateral amount may be withdrawn, but the availability of the line of credit is dependent
upon the maintenance of such compensating balance and is included in cash and cash equivalents on the Statement of Financial Condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000723"
      unitRef="USD">4500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000725"
      unitRef="USD">11800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="-4"
      id="Fact000727"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <MDBH:CashSIPCInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000729"
      unitRef="USD">500000</MDBH:CashSIPCInsuredAmount>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000731"
      unitRef="USD">8700000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000733"
      unitRef="USD">4500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000735"
      unitRef="USD">7200000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000737"
      unitRef="USD">4300000</us-gaap:CashUninsuredAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000739"
      unitRef="USD">2000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:Deposits
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000741"
      unitRef="USD">2000000.0</us-gaap:Deposits>
    <MDBH:SegregatedCashAndDepositsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000743">&lt;p id="xdx_842_ecustom--SegregatedCashAndDepositsPolicyTextBlock_zEdxvQaMMd95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Segregated Cash and Deposits&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;From time to time the Company provides
deposits or enters into agreements that would require funds to be held in a segregated cash account. At December 31, 2025 and 2024, respectively,
the Company had $&lt;span id="xdx_90F_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20251231_zW4DOkMjezg" title="Cash segregated in compliance with regulations"&gt;2.3&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation_iI_pn5n6_c20241231_zH4eJBfqO7pj" title="Cash segregated in compliance with regulations"&gt;0.8&lt;/span&gt; million of segregated cash consisting of funds held in reserve for customers and non-customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:SegregatedCashAndDepositsPolicyTextBlock>
    <us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000745"
      unitRef="USD">2300000</us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation>
    <us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000747"
      unitRef="USD">800000</us-gaap:CashAndSecuritiesSegregatedUnderSecuritiesExchangeCommissionRegulation>
    <us-gaap:DepositContractsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000749">&lt;p id="xdx_843_eus-gaap--DepositContractsPolicy_zXe17lXZT4Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Clearing Deposits&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is obligated to maintain
security deposits with the DTCC and National Securities Clearing Corporation (&#x201c;NSCC&#x201d;). At December 31, 2025 and 2024, these deposits totaled $&lt;span id="xdx_900_eus-gaap--DepositsAssets_iI_pn5n6_c20251231_zDAy8NALC5y6" title="Clearing deposits"&gt;2.0&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--DepositsAssets_iI_pn5n6_c20241231_zclBROS6osn9" title="Clearing deposits"&gt;1.7&lt;/span&gt; million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DepositContractsPolicy>
    <us-gaap:DepositsAssets
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000751"
      unitRef="USD">2000000.0</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000753"
      unitRef="USD">1700000</us-gaap:DepositsAssets>
    <MDBH:PrepaidAndOtherCurrentAssetsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000755">&lt;p id="xdx_84E_ecustom--PrepaidAndOtherCurrentAssetsPolicyTextBlock_zNKUuAkbGSea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Prepaid and other current assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company has prepaid and other current
assets totaling $&lt;span id="xdx_906_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20251231_zj7INjmPlGV9" title="Prepaid and other current assets"&gt;433&lt;/span&gt; thousand at December 31, 2025 consisting of acquired intangible assets totaling $&lt;span id="xdx_90A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20250101__20251231_z0yEmAC6bRb4" title="Intangible assets acquired"&gt;44&lt;/span&gt; thousand, prepaid professional
fees totaling $&lt;span id="xdx_905_ecustom--PrepaidProfessionalFees_pn3n3_c20250101__20251231_zllM01zlh6Ul" title="Prepaid professional fees"&gt;50&lt;/span&gt; thousand, security deposits totaling $&lt;span id="xdx_90B_eus-gaap--SecurityDeposit_iI_pn3n3_c20251231_zrMtKd7vB4x5" title="Security deposit"&gt;19&lt;/span&gt; thousand, prepaid insurance $&lt;span id="xdx_902_eus-gaap--PrepaidInsurance_iI_pn3n3_c20251231_zK9n860ZZMZ6" title="Prepaid insurance"&gt;169&lt;/span&gt; thousand, various prepaid expense of $&lt;span id="xdx_903_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20251231_zRKRbjQictU3" title="Various prepaid expense"&gt;130&lt;/span&gt;
thousand, and other assets of $&lt;span id="xdx_901_eus-gaap--OtherAssets_iI_pn3n3_c20251231_zxLCMJrZIVxk" title="Other assets"&gt;21&lt;/span&gt; thousand. Prepaid and other expenses totaling $&lt;span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_pn3n3_c20241231_z1eqPWY77Zpd" title="Prepaid and other expenses"&gt;513&lt;/span&gt; thousand at December 31, 2024 consisting of acquired
intangible assets totaling $&lt;span id="xdx_90B_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_z69yTaaoZwKd" title="Intangible assets acquired"&gt;44&lt;/span&gt; thousand, prepaid professional fees totaling $&lt;span id="xdx_900_ecustom--PrepaidProfessionalFees_pn3n3_c20240101__20241231_zO8uio7h2SUg" title="Prepaid professional fees"&gt;50&lt;/span&gt; thousand, security deposits totaling $&lt;span id="xdx_908_eus-gaap--SecurityDeposit_iI_pn3n3_c20241231_zk8QBjBoucW4" title="Security deposit"&gt;19&lt;/span&gt; thousand, prepaid
insurance $&lt;span id="xdx_905_eus-gaap--PrepaidInsurance_iI_pn3n3_c20241231_zEeAzlURSyjc" title="Prepaid insurance"&gt;160&lt;/span&gt; thousand, various prepaid expense of $&lt;span id="xdx_900_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_c20241231_z42b4Zoa3uJ4" title="Various prepaid expense"&gt;150&lt;/span&gt; thousand, and other assets of $&lt;span id="xdx_90A_eus-gaap--OtherAssets_iI_pn3n3_c20241231_zRlD3U4ITts" title="Other assets"&gt;90&lt;/span&gt; thousand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:PrepaidAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000757"
      unitRef="USD">433000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000759"
      unitRef="USD">44000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <MDBH:PrepaidProfessionalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000761"
      unitRef="USD">50000</MDBH:PrepaidProfessionalFees>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000763"
      unitRef="USD">19000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000765"
      unitRef="USD">169000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000767"
      unitRef="USD">130000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000769"
      unitRef="USD">21000</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000771"
      unitRef="USD">513000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">44000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <MDBH:PrepaidProfessionalFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000775"
      unitRef="USD">50000</MDBH:PrepaidProfessionalFees>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000777"
      unitRef="USD">19000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">160000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000781"
      unitRef="USD">150000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000783"
      unitRef="USD">90000</us-gaap:OtherAssets>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000785">&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zepmYoy0mMLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Leases of the Company consist primarily
of contracts for the right to use and direct use of an individual property. Leases were analyzed for evidence of significant additional
components and to determine if these components were separately identifiable within the context of the contract. As an accounting policy,
to account for these components, the Company has elected the practical expedient for property leases that have both lease and non-lease
components for them to be combined into a single component and account for as a lease. This policy is effective for all current and future
property operating leases and applied uniformly and will be disclosed as such within the financial statements. Operating lease assets
are included within right-of-use assets and the corresponding operating lease liabilities are included within liabilities on the Company&#x2019;s
consolidated balance sheet as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company has elected not to present
short-term leases on the consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not
contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other right-of-use assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. Because the
Company&#x2019;s leases do not provide an implicit rate of return, the Company used the Company&#x2019;s incremental borrowing rate based
on the information available at lease commencement date in determining the present value of lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000787">&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zaeBpyEiNdfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;Stock Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Stock-based compensation primarily
consists of restricted stock units with service or market/performance conditions. Equity awards are measured at the fair market value
of the underlying stock at the grant date. The Company recognized stock based compensation expense using the straight-line attribution
method over the requisite service period. The Company&#x2019;s subsidiary issued stock-options and the fair value is determined utilizing
Black-Scholes options-pricing model. The Company accounts for forfeitures as they occur, rather than applying an estimated forfeiture
rate. For performance-based restricted stock units, the compensation cost is recognized based on the number of units expected to vest
upon the achievement of the performance conditions. Shares are issued on the vesting dates net of the applicable statutory tax withholding
to be paid by us on behalf of our employees. As a result, fewer shares are issued to the employee than the number of awards outstanding.
The Company records a liability for the tax withholding to be paid by it as a reduction to Additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000789">&lt;p id="xdx_842_eus-gaap--InvestmentPolicyTextBlock_zjbe21QMRo1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Investment Securities &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company strategically invests funds
in U.S. Treasury Bills, early-stage technology companies, and equity securities and options of publicly traded and privately held companies.
The Company classifies investment securities as investment securities, at amortized cost, investment securities, at fair value, or investment
securities, at cost less impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Investment securities, at amortized
cost&lt;/i&gt; &#x2013; From time to time the Company will hold funds in investment securities, at amortized cost. This is comprised of debt
securities held by MDB and are classified as investment securities held-to-maturity and carried at amortized cost if management has the
positive intent and ability to hold the securities to maturity. Initially, the cost of these securities was recorded, and later on, they
were assessed at amortized cost, which was modified for unamortized purchase premiums and discounts, and also for credit losses provision.
Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the effective-interest
method. Such amortization and accretion are included in the other operating income in the statements of operations. Interest income is
recognized when earned. The Company recognizes estimated expected credit losses over the life of the investment security through the allowance
for credit losses account. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost
basis of the investment security to present the net amount expected to be collected. In determining expected credit losses, the Company
considers relevant qualitative factors including, but not limited to, term and structure of the instrument, credit rating by rating agencies
and historic credit losses adjusted for current conditions and reasonable and supportable forecasts. The Company holds investments in
U.S. Treasury Bills or money market funds backed by U.S. Treasury Bills, so there are no expected credit losses. Declines in fair value
of these securities is due to changes in market interest rates, and because it expects to hold these securities until maturity, it does
not expect to realize any losses. There were no investment securities, at amortized cost as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Investment securities, at fair value
&lt;/i&gt;- This is comprised of equity investments held by the broker dealer subsidiary and are reported at fair value with changes in fair
value recognized in the statement of operations. Purchases and sales of equity securities, consisting of common stock and warrants to
purchase common stock, are recorded based on the respective market price quotations on the trade date. Realized gains and losses on investments
represent the net gains and losses on investments sold during the period based on the average cost method. Differences between the fair
value of investments at the beginning of the year and the end of the year are recorded on the income statement as unrealized gains and
losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Investment securities, at cost less
impairment&lt;/i&gt; - This is comprised of equity securities without a readily determinable fair value held by the broker dealer subsidiary,
the Company has elected to apply the measurement alternative of cost minus impairment, if any, plus or minus changes resulting from observable
price changes. The Company will reassess whether such an investment qualifies for the measurement alternative at each reporting period.
In evaluating an investment for impairment or observable price changes, we will use inputs including recent financing events, as well
as other available information regarding the investee&#x2019;s historical and forecasted performance. The Company has assessed this investment
and determined that the current impairment of such securities held at the year ended December 31, 2025 is accurate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities are as follows
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Broker/Dealer Securities&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zQRLhofnSVV3" style="display: none"&gt;Schedule of Investment Securities Broker Dealer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Investment securities, at fair value:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Common stock of publicly traded companies&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Warrants of publicly traded companies&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,937&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,330&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrants of non-publicly traded companies&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;658&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at fair value&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,166&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;5,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z9OkuMpESene" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Non-Broker/Dealer Securities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_8BF_zJ7jauHHoWlg"&gt;Schedule of Investment Securities Non-Broker Dealer&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Investment securities, at fair value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Common stock of publicly traded companies&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;235&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Investment securities, at cost less impairment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Simple agreement on future equities (not market listed)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Impairment&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at cost less impairment&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zuwmTRHBqnx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;For investment securities at fair value
held at the end of each year, net unrealized loss of $&lt;span id="xdx_900_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20250101__20251231_zsuIBnQqld4g" title="Net unrealized gain (loss) on investment securities"&gt;246&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_di_c20240101__20241231_z6mVQU83Glli" title="Net unrealized gain (loss) on investment securities"&gt;275&lt;/span&gt; thousand were recognized in the statement of operations for
years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <MDBH:ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000791">&lt;p id="xdx_89B_ecustom--ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock_zMvP1R6aTtJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zQRLhofnSVV3" style="display: none"&gt;Schedule of Investment Securities Broker Dealer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zUbx359wvHi5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zDF0bXiJ0Xhb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Investment securities, at fair value:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zqnr4SRWxfUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Common stock of publicly traded companies&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zibg9LDUD2d4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Warrants of publicly traded companies&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,937&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,330&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfNonPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--BrokerDealerMember_zHLr4CcqTpTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrants of non-publicly traded companies&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;658&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--BrokerDealerMember_zZRyDZBIn7fi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at fair value&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;7,166&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;5,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MDBH:ScheduleofInvestmentSecuritiesBrokerDealerTableTextBlock>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">2571000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">2528000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">3937000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">3330000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_custom_WarrantsOfNonPubliclyTradedCompaniesMember_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000799"
      unitRef="USD">658000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000802"
      unitRef="USD">7166000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_custom_BrokerDealerMember"
      decimals="-3"
      id="Fact000803"
      unitRef="USD">5858000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000805">&lt;p id="xdx_892_ecustom--ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock_z8CA9nQBrEB3" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_8BF_zJ7jauHHoWlg"&gt;Schedule of Investment Securities Non-Broker Dealer&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zsaY1v1Re4Yh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zVFJ8DiNtW3e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Investment securities, at fair value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--WarrantsOfPubliclyTradedCompaniesMember__us-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zFsBP9BpXYQh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Common stock of publicly traded companies&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;235&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--NonBrokerDealerMember_zNQaY9DJkew4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_z3vuVWvKADX2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20241231_zK43YW8cKLSc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Investment securities, at cost less impairment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--SimpleAgreementOnFutureEquitiesMember_zr9wJUh3Lvmg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Simple agreement on future equities (not market listed)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--ImpairmentMember_zZ4fbOCRdn6k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Impairment&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer_iI_pn3n3_zlViBe3xM6hc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Investment securities, at cost less impairment&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MDBH:ScheduleofInvestmentSecuritiesNonBrokerDealerTableTextBlock>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_custom_WarrantsOfPubliclyTradedCompaniesMember_custom_NonBrokerDealerMember"
      decimals="-3"
      id="Fact000807"
      unitRef="USD">235000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_custom_NonBrokerDealerMember"
      decimals="-3"
      id="Fact000810"
      unitRef="USD">235000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer
      contextRef="AsOf2024-12-31_custom_SimpleAgreementOnFutureEquitiesMember"
      decimals="-3"
      id="Fact000814"
      unitRef="USD">200000</MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer>
    <MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer
      contextRef="AsOf2024-12-31_custom_ImpairmentMember"
      decimals="-3"
      id="Fact000817"
      unitRef="USD">-200000</MDBH:InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000822"
      unitRef="USD">-246000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">-275000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000826">&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z1icpMWXqG9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Fair value is defined as the price
that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree
that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the
lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company determines the fair value
of its financial instruments based on a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value
into three levels:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 1 - Observable inputs such as
quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 2 - Inputs, other than quoted
prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 3 - Unobservable inputs in which
there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s financial instruments primarily consist of cash and investment
securities. These investment securities and securities sold and not yet purchased are recorded at fair value as of the balance sheet date,
with unrealized gains and losses resulting from changes in fair value recognized in the statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A description of the valuation techniques
applied to the Company&#x2019;s major categories of assets and liabilities measured at fair value on a recurring basis is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities, at fair value
and securities sold, not yet purchased: These securities are valued based on quoted prices from the exchange or other trading platform.
To the extent these securities are actively traded, valuation adjustments are not applied, and they are categorized in level 1 of the
fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A description of the valuation techniques
applied to the Company&#x2019;s other financial assets and liabilities is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities, at amortized
cost: The fair value of U.S. Treasury Bills classified as held-to-maturity investment securities is based on the market price and is classified
as level 1 of the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment securities, at cost
less impairment: Non-public equity securities and simple agreements for future equity are valued based on the initial investment,
less impairment. The Company determined that an impairment is warranted. Since these securities are not actively traded, we will
apply valuation adjustments when they become available, and they are categorized in level 3 of the fair value hierarchy. The Company
fully impaired a Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) that was previously valued at $&lt;span id="xdx_907_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SAFEMember_zfEVnkDkesF5" title="Impairment of securities"&gt;100&lt;/span&gt;
thousand and stock that was previously valued at $&lt;span id="xdx_909_ecustom--ImpairmentOfInvestmentSecurities_pn3n3_c20230101__20231231_zjICz0hNW6R2" title="Impairment of securities"&gt;50&lt;/span&gt;
thousand both were held at the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following table sets forth the
fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_z82LCnEDOUFb" style="display: none"&gt;Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Classification&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the licensed broker dealer&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the non-licensed broker dealer&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;235&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;235&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,595&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,806&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;7,401&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zIWcQtXRunp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2025, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zLQDKsgMVcPa" style="display: none"&gt;Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt"&gt;Beginning Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Receipt from investment banking fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,690&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Unrealized gain&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;111&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"&gt;4,463&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zwiD6wiM66M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)&lt;/b&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zYKZqfnooG2" style="display: none"&gt;Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
Techniques&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ranges of&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" style="text-align: right" title="Warrants, Fair value"&gt;&lt;span style="font-size: 10pt"&gt;4,463&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Black Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs"&gt;95.92&lt;/span&gt; -&#160;&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs"&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" style="text-align: right" title="Weighted measurement input"&gt;&lt;span style="font-size: 10pt"&gt;115.45&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_z2C5euSaftok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zlqM1QVW6kJb"&gt;&lt;b&gt;The following table sets forth the
fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C04_gL3SOFVAALMOR-YZJZHH_zKHclHGg20w9"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Classification&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;3,330&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;5,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C0C_gL3SOFVAALMOR-YZJZHH_zWa3Fx0mjlFf"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2024, the Company did not have any transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C04_gL3FVAMORBUIR-BRK_zQrFBAw5dIYe"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C08_gL3FVAMORBUIR-BRK_z3xAKOAdAp5d"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" style="border-collapse: collapse; width: 96%; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;3,134&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt"&gt;Beginning Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;3,134&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Unrealized gains&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(472&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Unrealized (loss) gains&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;(472&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C05_gL3FVAMORBUIR-BRK_z2jUR5Nf99T4"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C09_gL3FVAALMORAN-L_zDICDGAXkhH3"&gt;&lt;b&gt;The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C02_gL3FVAALMORAN-L_z8NPe4RhThA9"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
Techniques&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ranges of&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" style="text-align: right" title="Warrants, Fair value"&gt;&lt;span style="font-size: 10pt"&gt;2,662&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Black Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" style="text-align: right" title="Range of inputs"&gt;&lt;span style="font-size: 10pt"&gt;111.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" style="text-align: right" title="Weighted measurement input"&gt;&lt;span style="font-size: 10pt"&gt;111.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_C08_gL3FVAALMORAN-L_zFRFYdbkeMvc"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2023-01-012023-12-31_custom_SAFEMember"
      decimals="-3"
      id="Fact000828"
      unitRef="USD">100000</MDBH:ImpairmentOfInvestmentSecurities>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000830"
      unitRef="USD">50000</MDBH:ImpairmentOfInvestmentSecurities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000835">&lt;p id="xdx_896_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_gL3SOFVAALMOR-YZJZHH_zKNdk4IUdr21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following table sets forth the
fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025,
except for the Level 3 investment that is recorded at cost (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_z82LCnEDOUFb" style="display: none"&gt;Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Classification&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the licensed broker dealer&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yaXsnvskfc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1zvbRlmcme" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0839"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUCyH4JyD8" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnUCVVXmhe" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,571&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the non-licensed broker dealer&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQqDkj5bP8S8" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;235&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKOhKeS9lKh" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0847"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUzqOXynTn3" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbaUZ3O4Rhq4" style="font-size: 10pt; text-align: right" title="Investment securities, at fair value, held by the non-licensed broker dealer"&gt;235&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztDiVJ504s9a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVbziE4510w8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgO4XciMPO8c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5vtXKcgGd5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,595&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value &lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWZKKqn50Fb5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,806&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHc2BQpRsvM4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3bxXQ2MsHk5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20251231_zUHehZ18Lob4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;7,401&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;b&gt;The following table sets forth the
fair value of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2024,
except for the Level 3 investment that is recorded at cost (in thousands):&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zJ4jvCAPyYU1" style="border-collapse: collapse; width: 90%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Fair Value of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"&gt;Classification&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; font-size: 10pt; text-align: left"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; text-align: left"&gt;Equity securities - common stock&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq1kaSQACS4" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zan0tGANGXd9" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1sdK04Ksegc" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zau6N9aOAAFg" style="width: 10%; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Investment Securities (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfRdboQCEt34" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziw9ZEWYpvx2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5yzqaIoyP3j" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSZ9UgPeL4tl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;3,330&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets measured at fair value (held by our licensed broker dealer)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z21BZSqbm8H" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0vciQfjC1hj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3edShlEpCg2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InvestmentSecuritiesAtFairValue_iI_pn3n3_c20241231_zVvimIVVRECi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Investment securities, at fair value"&gt;5,858&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000837"
      unitRef="USD">2571000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000843"
      unitRef="USD">2571000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">235000</MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer>
    <MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">235000</MDBH:InvestmentSecuritiesAtFairValueHeldByNonlicensedBrokerDealer>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000855"
      unitRef="USD">132000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">4463000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000859"
      unitRef="USD">4595000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000861"
      unitRef="USD">2806000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact000863"
      unitRef="USD">132000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000865"
      unitRef="USD">4463000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">7401000</MDBH:InvestmentSecuritiesAtFairValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000872">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_gL3FVAMORBUIR-BRK_zubCz0KS0w3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zLQDKsgMVcPa" style="display: none"&gt;Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20250101__20251231_zOXfDIxljjqj" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zlCvYQUqiela" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zafdvOmK9mMl" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt"&gt;Beginning Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zFjOso181nYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Receipt from investment banking fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,690&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_pn3n3_zqcXodyPYKO6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Unrealized gain&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;111&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z8goyZIAlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;4,463&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_z0ImEbOhMri2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"&gt;4,463&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Reconciliation of fair value measurements
categorized within Level 3 of the fair value hierarchy (in thousands):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_304_134_pn3n3_zbHzz9SxyZf6" style="border-collapse: collapse; width: 96%; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Reconciliation of Fair Value Measurements Within Level 3 of Fair Value Hierarchy (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240101__20241231_zQKzfZdXzGI5" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zWSd3P8HiwI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;3,134&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_zh6Q81Tbfp21" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt"&gt;Beginning Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;3,134&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zX1b9OgDqn87" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Unrealized gains&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(472&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_zrn8NID0uWxk" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Unrealized (loss) gains&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;(472&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zkT9NuMx7Bz7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_zAVNeCUE3Awk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; font-size: 10pt; text-align: right"&gt;2,662&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&#160;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">2662000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">2662000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">1690000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000880"
      unitRef="USD">111000</MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">4463000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">4463000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000889">&lt;p id="xdx_890_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-L_zAkPAt4hh3K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2025 (in thousands)&lt;/b&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zYKZqfnooG2" style="display: none"&gt;Schedule of Significant Unobservable Inputs Related to Material Components of Level 3 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
Techniques&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ranges of&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGJ46KNMhby3" style="text-align: right" title="Warrants, Fair value"&gt;&lt;span style="font-size: 10pt"&gt;4,463&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Black Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MinimumMember_zerGRqZc5bTe" title="Range of inputs"&gt;95.92&lt;/span&gt; -&#160;&#160;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--MaximumMember_zjSG43wxIkNi" title="Range of inputs"&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zK3SVvf8OeW3" style="text-align: right" title="Weighted measurement input"&gt;&lt;span style="font-size: 10pt"&gt;115.45&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;b&gt;The following table present information
about significant unobservable inputs related to material components of Level 3 warrants as of December 31, 2024 (in thousands)&lt;/b&gt;:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Valuation&lt;br/&gt;
Techniques&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Significant&lt;br/&gt;
Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Ranges of&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 33%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXejIrL7q0og" style="text-align: right" title="Warrants, Fair value"&gt;&lt;span style="font-size: 10pt"&gt;2,662&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Black Scholes&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z00HWruzcq2h" style="text-align: right" title="Range of inputs"&gt;&lt;span style="font-size: 10pt"&gt;111.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNpZ25pZmljYW50IFVub2JzZXJ2YWJsZSBJbnB1dHMgUmVsYXRlZCB0byBNYXRlcmlhbCBDb21wb25lbnRzIG9mIExldmVsIDMgV2FycmFudHMgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__srt--RangeAxis__srt--WeightedAverageMember_zoW4whkUg0W3" style="text-align: right" title="Weighted measurement input"&gt;&lt;span style="font-size: 10pt"&gt;111.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000891"
      unitRef="USD">4463000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Pure">95.92</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000895"
      unitRef="Pure">120.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact000897"
      unitRef="Pure">115.45</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000899"
      unitRef="USD">2528000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000905"
      unitRef="USD">2528000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">668000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000911"
      unitRef="USD">2662000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000913"
      unitRef="USD">3330000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000915"
      unitRef="USD">2528000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact000917"
      unitRef="USD">668000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000919"
      unitRef="USD">2662000</MDBH:InvestmentSecuritiesAtFairValue>
    <MDBH:InvestmentSecuritiesAtFairValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000921"
      unitRef="USD">5858000</MDBH:InvestmentSecuritiesAtFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000923"
      unitRef="USD">3134000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">3134000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000927"
      unitRef="USD">-472000</MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">-472000</MDBH:FairValueMeasurementWithUnobservableInputReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">2662000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">2662000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000935"
      unitRef="USD">2662000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000937"
      unitRef="Pure">111.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact000939"
      unitRef="Pure">111.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000941">&lt;p id="xdx_846_eus-gaap--DebtPolicyTextBlock_zgWoIHtxQztb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;Secured Debt&#x2013;- Revolving
Credit Facility&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company entered into a revolving
credit facility with a bank, (the &#x201c;Lender&#x201d;) on July 26, 2024 for a commitment of up to $&lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z0EOvrB8hnAd" title="Revolving credit, maximum borrowing capacity"&gt;2.0&lt;/span&gt; million and which matures &lt;span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zhhYByZAPftd" title="Maturity date"&gt;July
26, 2025&lt;/span&gt;. The loan has a variable interest rate equal to a defined index, currently the Lender&#x2019;s rate on the sale of Federal Funds,
plus &lt;span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zBayzkWHgzIa" title="Variable rate"&gt;2.25&lt;/span&gt;%. The loan commenced with a calculated interest rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zpgvzJk0sZ65" title="Interest rate"&gt;7.75&lt;/span&gt;%. If the Lender determines, in its sole discretion, that the index
becomes unavailable or unreliable, either temporary, indefinitely, or permanently, during the term of this loan, the Lender may amend
this loan by designating a substantially similar substitute index. The agreement provides for a quarterly payment of the greater of accrued
interest or a non-usage fee of $&lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn3n3_c20240726__20240726__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zmaGjZ86t8Ae" title="Credit non-usage fee"&gt;5&lt;/span&gt; thousand. The Company has not made any draw downs on the credit facility.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company granted the Lender a
security interest in a cash checking account held at the bank as collateral. The Lender has a right of setoff available from this
cash account when the line of credit is accessed. As of December 31, 2025 and 2024, there was $&lt;span id="xdx_904_eus-gaap--Deposits_iI_pn5n6_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zyQmiqWvezV7" title="Deposits"&gt;2.1&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--Deposits_iI_pn5n6_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXBTreFjla7j" title="Deposits"&gt;2.1&lt;/span&gt; million deposited in this account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is responsible for the
payment of all of the Lender&#x2019;s legal and other fees incurred in connection with administering the loan. The Company has incurred
no such costs or debt issue costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2025 and 2024, there are &lt;span id="xdx_909_eus-gaap--LineOfCredit_iI_do_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZIwhsjYOybh" title="Outstanding indebtedness"&gt;&lt;span id="xdx_90A_eus-gaap--LineOfCredit_iI_do_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zkDXvC2Zhwpe" title="Outstanding indebtedness"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding indebtedness under the credit facility and interest expense totaled $&lt;span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zeQjdwsqGVrk" title="Interest payable"&gt;&lt;span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zjlzMwhVXdI7" title="Interest payable"&gt;0&lt;/span&gt;&lt;/span&gt;. The Company is in compliance with all
covenants under the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2024-07-26_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact000943"
      unitRef="USD">2000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember"
      id="Fact000945">2025-07-26</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      id="Fact000947"
      unitRef="Pure">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-07-26_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="From2024-07-262024-07-26_us-gaap_RevolvingCreditFacilityMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">5000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:Deposits
      contextRef="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact000953"
      unitRef="USD">2100000</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact000955"
      unitRef="USD">2100000</us-gaap:Deposits>
    <us-gaap:LineOfCredit
      contextRef="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fact000959"
      unitRef="USD">0</us-gaap:LineOfCredit>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000965">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyma5WBbqKKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment are recorded
at cost. Major improvements are capitalized, while maintenance and repairs are charged to expense as incurred. Gains and losses from disposition
of property and equipment are included in the statement of operations when realized. Depreciation is provided using the straight-line
method over the following estimated useful lives:&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none"&gt;Schedule
of Estimated Useful Lives of Property
and Equipment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Developed software&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;Lesser of the lease duration or the life of the improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zPIXDQXW8b0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z8fPKC7TjJZh" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Developed software&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"&gt;139&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;139&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;113&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zSieLJh9Yjw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <MDBH:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000967">&lt;p id="xdx_89C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_z2SMZIqFk2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zJpn0xSXA7Yc" style="display: none"&gt;Schedule
of Estimated Useful Lives of Property
and Equipment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 96%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-size: 10pt"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zl6LFUMCpzsi" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Developed software&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DevelopedSoftwareMember_zXEuEITjOKob" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8cJloSaFDdg" title="Property and equipment, estimated useful lives"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zH6hFzsnmtj" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23UsefulLifeTermOfLeaseMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;Lesser of the lease duration or the life of the improvements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</MDBH:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_custom_LaboratoryEquipmentMember"
      id="Fact000969">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_custom_DevelopedSoftwareMember"
      id="Fact000971">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000973">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000976">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zIGdQDsmIjw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment consist of the
following as of December 31, 2025 and 2024, respectively, (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z8fPKC7TjJZh" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zDu3cASrOjek" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zMlOAIjI3y21" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_zGuZwmqWxWGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Developed software&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"&gt;139&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; font-size: 10pt; text-align: right"&gt;113&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENz9CG_z2pDn4OK5cqj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;139&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;113&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9CG_z6sVmD9eQLr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9CG_zRDbqFrGjXz9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000978"
      unitRef="USD">139000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000979"
      unitRef="USD">113000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000981"
      unitRef="USD">139000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000982"
      unitRef="USD">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000984"
      unitRef="USD">22000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000985"
      unitRef="USD">23000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000987"
      unitRef="USD">117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000988"
      unitRef="USD">90000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000990">&lt;p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_ziTtwP2xkno9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Revenue &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company generates revenue primarily
from providing brokerage services and underwriting through Public Ventures. PatentVest and eXoZymes, have
had limited activity during the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Brokerage revenues consist of (i) trade-based
commission income from executed trade orders, (ii) net realized gains and losses from proprietary trades, and (iii) other income consisting
primarily of stock loan income earned on customer accounts. Public Ventures recognizes revenue from trade-based commissions and other
income when performance obligations are satisfied through the transfer of control, as specified in the contract, of promised services
to the customers of Public Ventures. Commissions are recognized on a trade date basis. Public Ventures believes that each executed trade
order represents a single performance obligation that is fulfilled on the trade date because that is when the underlying financial instrument
is identified, the pricing is agreed upon, and the risks and rewards of ownership have been transferred to/from the customer. When another
party is involved in transferring a good or service to a customer, Public Ventures assesses whether revenue is presented based on the
gross consideration received from customers (principal) or net of amounts paid to a third party (agent). Public Ventures has determined
that it is acting as the principal as the provider of the brokerage services and therefore records this revenue on a gross basis. Clearing,
custody and trade administration fees incurred from Interactive Brokers, the Company&#x2019;s clearing firm, are recorded effective as
of the trade date. The costs are treated as fulfillment costs and are recorded in operating expenses in the consolidated statements of
operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Brokerage revenue is measured by the
transaction price, which is defined as the amount of consideration that Public Ventures expects to receive in exchange for services to
customers. The transaction price is adjusted for estimates of known or expected variable consideration based upon the individual contract
terms. Variable consideration is recorded as a reduction to revenue based on amounts that Public Ventures expects to refund back to the
customer. There were no variable considerations for the years ended December 31, 2025, and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Investment banking revenues
consist of private placement and underwriting fees. The Company generally does not incur costs to obtain contracts with customers
that are eligible for deferral or receive fees prior to recognizing revenue related to investment banking transactions, and
therefore, as of December 31, 2025 and 2024, the Company did not have any contract assets or liabilities related to these revenues
on its consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company enters into underwriting agreements, to act as an underwriter and security offerings which include distribution and sale of securities
to investors. These agreements allow non-defaulting underwriters and the issuer&#x2019;s representative to seek substitute purchasers within
36 hours if the Company defaults on its commitment. If replacements are not found and the default exceeds 10% of the offering, the agreement
may be terminated without liability. Under ASC 606, revenue is recognized only upon transfer of cash from the escrow account from investors
which is the final receipt of payment, as well receipt of warrants and common stock on the date of closing, with no recognition for defaulted
or terminated portions until resolution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Private placement fees are related
to non-underwritten transactions such as private placements of equity securities, private investments in public equity, and Rule 144A
private offerings and are recorded on the closing date of the transaction. Client reimbursements for costs associated for private placement
fees are recorded gross within investment banking and various expense captions, excluding compensation. The Company typically receives
payments on private placements transactions at the completion of the contract. The Company views the majority of placement fees as a single
performance obligation that is satisfied when the transaction is complete, and the revenue is recognized at that point in time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Taxes and regulatory fees assessed
by a government authority or agency that are both imposed on and concurrent with a specified revenue-producing transaction, which are
collected by Public Ventures from a customer, are excluded from revenue and recorded against general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Public Ventures does not incur any
costs to obtain contracts with customers for revenues that are eligible for deferral or receive fees prior to recognizing revenue, and
therefore, as of December 31, 2025 and 2024, Public Ventures did not have any contract assets or liabilities related to these revenues
in its consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the years ended December 31,
2025 and 2024, the Company&#x2019;s technology development segment did not have any revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;PatentVest recognizes revenue when performance
obligations are satisfied by transferring promised goods and services to customers in an amount the Company expects to receive in exchange
for those goods or services. PatentVest enters into contracts that can include various combinations of its offerings which are generally
capable of being distinct and accounted for as a separate performance obligation for the entire contract or a portion of the contract.
When performance obligations are combined into a single contract, PatentVest utilizes stand-alone selling price to allocate the transaction
price among the performance obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Certain contracts or portions of contracts
are duration-based, which in the event of customer cancellation, provide PatentVest with an enforceable right to a proportional payment
for the portion of the services provided. Accordingly, revenue from duration-based contracts is recognized using a time-based measure
of progress, which PatentVest believes best depicts how it satisfies its performance obligations in these arrangements as control is continuously
transferred throughout the contract period. Revenue from certain contracts is recognized over the expected period of performance using
a single measure of progress, typically based on hours incurred. Payments received in advance of services being rendered are recorded
as a component of contract liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The PatentVest&#x2019;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zzOhoIIdeFQf" style="display: none"&gt;Schedule of Changes in Deferred Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" style="width: 16%; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;Amounts billed but not recognized&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" style="font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;Amounts billed but not recognized&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zwq8sGRWvSh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000992">&lt;p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zfe2eWlP2gw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The PatentVest&#x2019;s contract liabilities
which is presented as deferred revenue, consist of advance payments. The table below shows changes in deferred revenue (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zzOhoIIdeFQf" style="display: none"&gt;Schedule of Changes in Deferred Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20240101__20241231_zGRN9FexRDQl" style="width: 16%; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;Amounts billed but not recognized&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20240101__20241231_zYFceMgFV667" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0996"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20240101__20241231_zeaXCsMVfoL2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_c20250101__20251231_zNrKgAU1HjRi" style="font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9pt"&gt;Amounts billed but not recognized&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ContractWithCustomerLiabilityAmountsBilledNotRecognized_pn3n3_c20250101__20251231_zR4yMUzQfgWb" style="font-size: 10pt; text-align: right" title="Amounts billed but not recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn3n3_c20250101__20251231_zN7a68aqPaYj" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenue recognized"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_c20250101__20251231_zZCA7xYsEiwl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred revenue, Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1006"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000994"
      unitRef="USD">20000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">20000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <MDBH:AccountingForResearchGrantsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001008">&lt;p id="xdx_845_ecustom--AccountingForResearchGrantsPolicyTextBlock_zKADqWpB076k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Research Grants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;eXoZymes, receives grant reimbursements, which are netted against research and development expenses in the consolidated statement of operations.
Grant reimbursements for capitalized assets are recognized over the useful life of the assets, with the unrecognized portion recorded
as deferred grant reimbursements and included in liabilities in the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Grants function on a reimbursement
model are accounted for using the accrual method. They are treated as reductions to expenses, corresponding to the amount of disbursements
and obligations eligible for reimbursement. These are for permissible expenses incurred as of December 31, 2024. The reimbursements are
anticipated to be received from the respective funding entities in the following year. Management considers such receivables at December
31, 2024, to be fully collectable due to the historical experience with the Federal Government of the United States of America. Accordingly,
no allowance for credit losses on the grants receivable was recorded in the accompanying consolidated financial statements. The Company was not engaged in any research grants for the year ended December 31. 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zvvVxNvqM2t4" style="display: none"&gt;Summary of Grants Receivable Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;span id="xdx_F5E_zzT4nWlrl6oh"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Balance at beginning of year&lt;span id="xdx_F49_zeT54RJrBuT1"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;882&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant costs expensed&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,897&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grants for equipment purchased&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;44&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant funds received&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,173&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Removal of balance due to deconsolidation of eXoZymes at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1027"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(702&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1031"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt"&gt;In 2024, eXoZymes was deconsolidated
from the Company&#x2019;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p id="xdx_8A0_z4a8wDrTKNud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;eXoZymes has received three grants
provided by the National Institute of Health, the Department of Energy and Department of Defense through December 31, 2024. The first
grant was awarded on October 1, 2023 and the latest of these grants was set to expire on May 14, 2026, however grants can be extended,
or new phases can be granted, extending the expiration of the grant. None of the grants have commitments made by the parties, provisions
for recapture, or any other contingencies, beyond complying with the normal terms of each research and development grant. Research grants
received from organizations are subject to the contract agreement as to how eXoZymes, formerly known as eXoZymes, conducts its research
activities, and eXoZymes is required to comply with the agreement terms relating to those grants. Amounts received under research grants
are nonrefundable, regardless of the success of the underlying research project, to the extent that such amounts are expended in accordance
with the approved grant project. eXoZymes is permitted to draw down the research grants after incurring the related expenses. Amounts
received under research grants are offset against the related research and development costs in the Company&#x2019;s consolidated statement
of operations. For the years ended December 31, 2025 and 2024, grants amounting $&lt;span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20250101__20251231_zx1DsG46DI38" title="Research and development costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_pn5n6_c20240101__20241231_zvUD2nyd6316" title="Research and development costs"&gt;2.8&lt;/span&gt; million, were offset against
the research and development costs. Grant drawdowns, which includes grants costs expensed, grants for equipment purchased, and grant fees,
for the years ended December 31, 2025 and 2024, totaled $&lt;span id="xdx_90B_ecustom--GrantDrawdowns_c20250101__20251231_zX0Wcdhg4k9d" title="Grant drawdowns"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--GrantDrawdowns_pn5n6_c20240101__20241231_zTw0cXZNZD38" title="Grant drawdowns"&gt;2.0&lt;/span&gt; million, respectively, which included grant costs expensed, grants
for equipment purchased, and grants fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:AccountingForResearchGrantsPolicyTextBlock>
    <MDBH:GrantsReceivableActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001010">&lt;p id="xdx_89B_ecustom--GrantsReceivableActivityTableTextBlock_zZJHPaW14c85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Summary of grants receivable activity
for the years ended December 31, 2025 and 2024, is presented below (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zvvVxNvqM2t4" style="display: none"&gt;Summary of Grants Receivable Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_znEqRha0u1uj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zaR5YVggx5rl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;span id="xdx_F5E_zzT4nWlrl6oh"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GrantsReceivable_iS_pn3n3_zxAqmnQodUm9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Balance at beginning of year&lt;span id="xdx_F49_zeT54RJrBuT1"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;882&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--GrantCostsExpensed_pn3n3_zBYszimRPJil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant costs expensed&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,897&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--GrantsForEquipmentPurchased_pn3n3_ztotq5uThaig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grants for equipment purchased&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;44&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GrantFees_pn3n3_zkrGotPdFEM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--GrantFundsReceived_pn3n3_zd1r2OD2E8Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Grant funds received&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(2,173&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--RemovalOfBalanceDueToDeconsolidation_pn3n3_ziLD0WrPGhxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Removal of balance due to deconsolidation of eXoZymes at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1027"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(702&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GrantsReceivable_iE_pn3n3_zv37DVY1UBg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1030"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1031"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F03_zJR2RXktLp34" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F17_zX8rGMhjMgSe" style="font-size: 10pt"&gt;In 2024, eXoZymes was deconsolidated
from the Company&#x2019;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
</MDBH:GrantsReceivableActivityTableTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001013"
      unitRef="USD">882000</us-gaap:GrantsReceivable>
    <MDBH:GrantCostsExpensed
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001016"
      unitRef="USD">1897000</MDBH:GrantCostsExpensed>
    <MDBH:GrantsForEquipmentPurchased
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001019"
      unitRef="USD">44000</MDBH:GrantsForEquipmentPurchased>
    <MDBH:GrantFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001022"
      unitRef="USD">52000</MDBH:GrantFees>
    <MDBH:GrantFundsReceived
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001025"
      unitRef="USD">-2173000</MDBH:GrantFundsReceived>
    <MDBH:RemovalOfBalanceDueToDeconsolidation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001028"
      unitRef="USD">-702000</MDBH:RemovalOfBalanceDueToDeconsolidation>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001034"
      unitRef="USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001036"
      unitRef="USD">2800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <MDBH:GrantDrawdowns
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001038"
      unitRef="USD">0</MDBH:GrantDrawdowns>
    <MDBH:GrantDrawdowns
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001040"
      unitRef="USD">2000000.0</MDBH:GrantDrawdowns>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact001042">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zFio8zeF0yx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses
relating to the development of eXoZymes&#x2019; technology. For the years ended December 31, 2025 and 2024, research and development costs
prior to offset of the grants amounted to $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseGross_c20250101__20251231_zHnagssCOgN4" title="Net of grant received"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseGross_pn5n6_c20240101__20241231_zw8WD44tPH7l" title="Net of grant received"&gt;3.4&lt;/span&gt; million, respectively, which included grant costs expensed, grants fees, and research
and development costs, net of the grant received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <MDBH:ResearchAndDevelopmentExpenseGross
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001044"
      unitRef="USD">0</MDBH:ResearchAndDevelopmentExpenseGross>
    <MDBH:ResearchAndDevelopmentExpenseGross
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001046"
      unitRef="USD">3400000</MDBH:ResearchAndDevelopmentExpenseGross>
    <MDBH:PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001048">&lt;p id="xdx_84B_ecustom--PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock_zNGl6M1zDfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Patent and Licensing Legal and Filing
Fees and Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Due to the significant uncertainty
associated with the successful development of one or more commercially viable products based on the Company&#x2019;s research efforts and
related patent applications, all patent and licensing legal and filing fees and costs related to the development and protection of its
intellectual property are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Patent and licensing legal and filing
fees and costs were $&lt;span id="xdx_90A_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20250101__20251231_zAAazgXGyKU5" title="Patent and licensing legal and filing fees and costs"&gt;54&lt;/span&gt; thousand and $&lt;span id="xdx_902_eus-gaap--OtherCostAndExpenseOperating_pn3n3_c20240101__20241231_zE6M4QA6cWb5" title="Patent and licensing legal and filing fees and costs"&gt;296&lt;/span&gt; thousand for the years ended December 31, 2025 and 2024, respectively. Patent and licensing
legal and filing fees and costs are included in general and administrative costs in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:PatentAndLicensingLegalAndFilingFeesAndCostsPolicyTextBlock>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001050"
      unitRef="USD">54000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001052"
      unitRef="USD">296000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001054">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zssHT9mtPbQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;ASU 2021-10, Government Assistance
(Topic 832): Disclosures by Business Entities about Government Assistance&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On January 1, 2020, The Company adopted
ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (&#x201c;ASU 2021-10&#x201d;)
and retrospectively applied the guidance to prior transactions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The amendments in ASU 2021-10 require
the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting
model by analogy: (1) information about the nature of the transactions and the related accounting policy used to account for the transactions;
(2) the line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each
financial statement line item; and (3) significant terms and conditions of the transactions, including commitments and contingencies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Management does not believe that any
other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company&#x2019;s
consolidated financial statement presentation or disclosures.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001056">&lt;p id="xdx_804_eus-gaap--SegmentReportingDisclosureTextBlock_zqY4SbD7RhTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;3. &lt;span id="xdx_822_zedJztFAtkf1"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In its operation of the business, management,
including the Company&#x2019;s chief operating decision maker, who is also the Company&#x2019;s Chief Executive Officer, reviews certain
financial information, including segmented profit and loss and balance sheet statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company currently operates in &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20251231_zba93brjOd7k" title="Number of reportable segments"&gt;two&lt;/span&gt;
reportable segments: a broker dealer &amp;amp; intellectual property service and technology development.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The broker dealer &amp;amp; intellectual
property service segment currently has two subsidiaries, Public Ventures and PatentVest. Public Ventures is a full-service broker dealer
firm focusing on conducting private and public securities offerings. PatentVest offers in-depth patent research used for investment banking
due diligence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The technology development segment
currently has two subsidiaries, eXoZymes, and M1. eXoZymes is a research and development stage
company synthetic biology company, that is consolidated in the Statement of Operations up to November 14, 2024. M1 research
and development stage company that is developing a small molecule senescence platform.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Non-income generating subsidiaries
for management of the business, including MDB Management are reported in the Other column in the table below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The segments are based on the discrete
financial information reviewed by the Chief Executive Officer to make resource allocation decisions and to evaluate performance. The reportable
segments are each managed separately because they will provide a distinct product or provide services with different processes. All reported
segment revenues are derived from external customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The accounting policies of the Company&#x2019;s
reportable segments are in consideration of ASC 280 and the same as those described in the summary of significant accounting policies
(see Note 2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_gL3LLABGATTB-CUTW_zvEk2dnfJff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following sets forth the long-lived
assets and total assets by segment at December 31, 2025 (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zkO4me2B3pk8" style="display: none"&gt;Schedule of Long-lived Assets and Total Assets by Segment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;ASSETS&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerAndIntellectualPropertyServiceMember_zeGm3LNUjGIj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer and&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zcbZMLyosrsl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology&lt;br/&gt; Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zGlPhHZ2RzWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zC2bHg5bN0Ua" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_z0NyLqDFEtca" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_pn3n3_zzu8fMKvlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;Long-lived assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;117&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;547&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;664&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_zrwrkCQlJ5h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;25,128&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;38,609&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;63,740&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zsjWS16NaZB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MWGIM_zm6DXnzPilq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zPloS8TgOQDa" style="display: none"&gt;Schedule of Statement of Operation by Segment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zmsUppUTSRGa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer &amp;amp;&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zrWrHbGhlL63" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zW5BrpeC8f9h" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z1OiMiy5lO65" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20251231_zR2CtlQalrc" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_z0HvKk5gBVg5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;Operating income:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_i01N_pn3n3_di_zLQAyD0Qvvgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: left"&gt;Unrealized (loss) on investment securities, net from the licensed broker
    dealer &lt;span id="xdx_F4B_zewLDUAXxTw8"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(331&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(331&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_i01I_pn3n3_z3XCdhHMah51" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the non-licensed broker dealer (1)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;85&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1096"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;85&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--RealizedInvestmentGainsLossesOne_i01_pn3n3_zMkq46JflBx4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Realized gain on investment securities, net from the licensed broker dealer &lt;span id="xdx_F47_zDOEqJXPcqz7"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FeeIncome_i01_pn3n3_z75w6lRdU654" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fee income from the licensed broker dealer &lt;span id="xdx_F40_zo1u9pGYbML9"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_zxitFAN2Fjp3" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Impairment loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherOperatingIncome_i01_pn3n3_zz7DiKDnrtk5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other operating income &lt;span id="xdx_F4D_zdiglk5bUe8j"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1119"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1121"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_pn3n3_zesmzpastxF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating income, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,911&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1127"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,911&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zJGRCuuKpyec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zsXiVkEKYe91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LaborAndRelatedExpense_i02_pn3n3_zdiHBXM7mDxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,875&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1143"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;12,094&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,969&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherNonoperatingExpense_i02_pn3n3_zYfTjFL1toq7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Operating expense, related party&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,471&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1149"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;362&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1151"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,833&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_pn3n3_z3ySzdMJZG93" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Professional fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,005&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;868&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,937&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CommunicationsAndInformationTechnology_i02_pn3n3_zJfQcRLb3Llj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Information technology&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;968&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1161"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,103&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ClearingAndOtherCharges_i02_pn3n3_zpPAGMTrpmre" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Clearing and other charges&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;556&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1169"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;556&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_pn3n3_znbwBwmr5zb7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;General and administrative-other&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1173"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,497&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,239&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02T_pn3n3_zAOk4nWkddFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7,617&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,956&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;22,637&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i02_pn3n3_zskYsgAMkCJl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_pn3n3_zLgZCyfaTS5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,617&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,956&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;22,637&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NetOperatingIncomeLoss_iT_pn3n3_zrIierldZ4T1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net operating (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,706&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(14,956&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(17,726&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_pn3n3_zojnS0jg4fef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Other income and expense:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--MiscellaneousIncome_pn3n3_zLrqgUQKpwvl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Miscellaneous income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1210"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_pn3n3_di_z7eafuHWNQ52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(990&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;990&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1218"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherNonoperatingIncome_i01_pn3n3_zKw4Aws7eeVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;471&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,136&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(990&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;617&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--GainRelatedToDilutionEvents_i01_pn3n3_zcBNWLxpXySk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Gain related to dilution events&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1227"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zTkZ8Yb74lx6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Gain on deconsolidation of subsidiary&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_zuFjLfJo3MTe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;(Loss) before income taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,150&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(13,759&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(16,973&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zMBLAtT4rIz1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1246"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_pn3n3_zzgkoWOiXIw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income (loss) before equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,161&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(13,759&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(16,984&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeLossFromEquityMethodInvestment_i01_pn3n3_ziwMXHlip1ee" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Equity in loss of equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1256"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1259"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfitLoss_iT_pn3n3_zobhMCmM7mL3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net (loss)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,161&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(18,041&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(21,266&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zVxxXDefdtL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less net loss attributable to non-controlling interests&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1270"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_pn3n3_zdPCaBKfaeGe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to MDB Capital Holdings, LLC&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(43&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(18,041&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(21,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0D_zEor9fRn3qpi" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zgbWJ4PSadxe" style="font-size: 10pt"&gt;Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F09_zGLgxMMdFQN9" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F17_zOe2PuXCzajk" style="font-size: 10pt"&gt;Includes realized gains on securities held by the broker-dealer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F05_z4JoAFWJTPN1" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zFxNmoNpBLpi" style="font-size: 10pt"&gt;Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F03_zUWsCc363nV3" style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zUyKanJjUJle" style="font-size: 10pt"&gt;Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zoLhQ72RvHFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span id="xdx_C03_gL3LLABGATTB-CUTW_zZCbmgn9oyGj"&gt;The following sets forth the long-lived
assets and total assets by segment at December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0E_gL3LLABGATTB-CUTW_zk7ARLLz2F94"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_z8BIYhWOFah8" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;ASSETS&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zxfqZ3K4Y2tb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer &amp;amp;&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zwebjIF7XvUb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology&lt;br/&gt; Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zwt74Hy0bln7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z4xjSKBLaOA3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zykqqBau8oYe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsNoncurrent_iI_zcB5szCPRVQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;Long-lived assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;91&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;641&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;732&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Assets_iI_zEbvqLQ6XxQ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;21,754&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;50,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;71,976&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_C07_gL3LLABGATTB-CUTW_z7w7ePXwXSrk"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zuVkSPH6Si92"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zKvMYYxqAfxd"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zxDkWDamkN9a" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Statement of Operation by Segment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zNgyo9QxRcDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer &amp;amp;&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zVBQNxHgGlHe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zfLHp1q4wxLk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z6aN42ks42Yi" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_z30lEVjjKxWj" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_zKRi1AQrpD9i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;Operating income:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--UnrealizedGainLossOnInvestments_i01_zyb7rlhTFXw9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: left"&gt;Unrealized (loss) on investment securities, net from the licensed broker
    dealer  &lt;span id="xdx_F43_zWUs8Dto14ke"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(275&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(275&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FeeIncome_i01_z6d9ZzKadMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fee income from the licensed broker dealer &lt;span id="xdx_F42_z5fs0BmS5l03"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_ztiPAN9vDBPc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Impairment loss &lt;span id="xdx_F4A_z2dxI5NLo03f"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherOperatingIncome_i01_zyNFBZXjfPZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other operating income &lt;span id="xdx_F4D_zt1W4aTYGOT9"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_zHvhMmllsUH3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating income, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,157&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1328"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,157&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zMmiKetVtgrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvbbvLQPhjTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_i02_zqK1qW87qCrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,226&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,062&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,769&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,057&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_i02_zrPywaAV9Cwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Operating expense, related party&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,301&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;185&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_zGxKygTch0B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Professional fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;820&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,206&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,086&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1359"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,112&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CommunicationsAndInformationTechnology_i02_zLQaYBeMtBTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Information technology&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;805&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;34&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;83&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;922&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ClearingAndOtherCharges_i02_zh7JLkyObDE3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Clearing and other charges&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,137&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1369"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1370"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,137&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_zZ34HDAX8LPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;General and administrative-other&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;806&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,669&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1377"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,608&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i02T_zZhBF38SfJsa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8,095&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,435&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;17,792&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;29,322&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zIHEVSPhbYY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1388"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_zvCDo2CdarEk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;8,095&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,903&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1395"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--NetOperatingIncomeLoss_iT_z02ABQ5Zs9Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net operating (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(5,938&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,903&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(17,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1401"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(28,633&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_ztBJeXpqWF0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Other income and expense:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--MiscellaneousIncome_zuWi4EoOwQah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Miscellaneous income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;112&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1411"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1412"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1413"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;112&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_zY0krAMLtmAj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(779&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(92&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;799&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherNonoperatingIncome_i01_zfjLtL3YPDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;465&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(799&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,179&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GainRelatedToDilutionEvents_i01_zZnbGs53y3dl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Gain related to dilution events&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1429"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zPqWOkFi4UC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;Gain on deconsolidation of subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1435"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,307&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1437"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,307&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zkk18ubnFh3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income (loss) before income taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,992&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;23,155&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1443"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;12,023&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_zN3z37vUv7y2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1449"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_zel5TqRLBvLa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income (loss) before equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,994&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;23,155&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1455"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;12,021&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeLossFromEquityMethodInvestment_i01_zjOzGfZpvHW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Equity in loss of equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(420&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(420&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ProfitLoss_iT_zxSS0fvY1v51" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,994&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;22,735&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,601&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zPA4DtmKvFQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less net loss attributable to non-controlling interests&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1470"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1472"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1473"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_z4NUZU0Rd7Ig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net income and (loss) attributable to MDB Capital Holdings, LLC&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(4,904&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;22,735&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1479"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;11,691&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0C_zItwKHS2g4Kh" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zX8aEhgzrEuk" style="font-size: 10pt"&gt;Includes unrealized gains and
losses on securities held by the broker-dealer.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F09_zBzu6syX8buj" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F16_zorbWRAAllIf" style="font-size: 10pt"&gt;Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F02_zyhMfb3EvK0b" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F14_ztBZbU7oANQ5" style="font-size: 10pt"&gt;Includes impairment loss of assets
from the reduced fair value of the asset.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0E_zCCvHQu57k5a" style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_zdtty7wgl7m" style="font-size: 10pt"&gt;Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_C0F_gL3SOSRIBSTB-MWGIM_zYgOk9fNWKxg"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001058"
      unitRef="Segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001063">&lt;p id="xdx_89D_eus-gaap--LongLivedAssetsByGeographicAreasTableTextBlock_gL3LLABGATTB-CUTW_zvEk2dnfJff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following sets forth the long-lived
assets and total assets by segment at December 31, 2025 (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zkO4me2B3pk8" style="display: none"&gt;Schedule of Long-lived Assets and Total Assets by Segment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;ASSETS&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerAndIntellectualPropertyServiceMember_zeGm3LNUjGIj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer and&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zcbZMLyosrsl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology&lt;br/&gt; Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zGlPhHZ2RzWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zC2bHg5bN0Ua" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_z0NyLqDFEtca" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_pn3n3_zzu8fMKvlUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;Long-lived assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;117&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;547&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;664&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Assets_iI_pn3n3_zrwrkCQlJ5h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;25,128&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;38,609&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;63,740&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

The following sets forth the long-lived
assets and total assets by segment at December 31, 2024 (in thousands):&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_z8BIYhWOFah8" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Long-lived Assets and Total Assets by Segment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;ASSETS&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zxfqZ3K4Y2tb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer &amp;amp;&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zwebjIF7XvUb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology&lt;br/&gt; Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zwt74Hy0bln7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z4xjSKBLaOA3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zykqqBau8oYe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsNoncurrent_iI_zcB5szCPRVQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: justify"&gt;Long-lived assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;91&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;641&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;732&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Assets_iI_zEbvqLQ6XxQ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;21,754&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;50,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;71,976&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31_custom_BrokerDealerAndIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001065"
      unitRef="USD">117000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001067"
      unitRef="USD">547000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">664000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_BrokerDealerAndIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001071"
      unitRef="USD">25128000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001072"
      unitRef="USD">3000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001073"
      unitRef="USD">38609000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">63740000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001080">&lt;p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_gL3SOSRIBSTB-MWGIM_zm6DXnzPilq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zPloS8TgOQDa" style="display: none"&gt;Schedule of Statement of Operation by Segment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zmsUppUTSRGa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer &amp;amp;&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zrWrHbGhlL63" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zW5BrpeC8f9h" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z1OiMiy5lO65" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20251231_zR2CtlQalrc" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_z0HvKk5gBVg5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;Operating income:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2_i01N_pn3n3_di_zLQAyD0Qvvgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: left"&gt;Unrealized (loss) on investment securities, net from the licensed broker
    dealer &lt;span id="xdx_F4B_zewLDUAXxTw8"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(331&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1089"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(331&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer_i01I_pn3n3_z3XCdhHMah51" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Investment securities, at fair value, held by the non-licensed broker dealer (1)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;85&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1096"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;85&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--RealizedInvestmentGainsLossesOne_i01_pn3n3_zMkq46JflBx4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Realized gain on investment securities, net from the licensed broker dealer &lt;span id="xdx_F47_zDOEqJXPcqz7"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FeeIncome_i01_pn3n3_z75w6lRdU654" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fee income from the licensed broker dealer &lt;span id="xdx_F40_zo1u9pGYbML9"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,282&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_zxitFAN2Fjp3" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Impairment loss&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherOperatingIncome_i01_pn3n3_zz7DiKDnrtk5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other operating income &lt;span id="xdx_F4D_zdiglk5bUe8j"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1119"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1121"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingIncomeLoss_i01T_pn3n3_zesmzpastxF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating income, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,911&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1127"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,911&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zJGRCuuKpyec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zsXiVkEKYe91" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LaborAndRelatedExpense_i02_pn3n3_zdiHBXM7mDxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,875&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1143"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;12,094&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1145"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,969&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherNonoperatingExpense_i02_pn3n3_zYfTjFL1toq7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Operating expense, related party&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,471&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1149"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;362&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1151"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,833&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_pn3n3_z3ySzdMJZG93" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Professional fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,005&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;868&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,937&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CommunicationsAndInformationTechnology_i02_pn3n3_zJfQcRLb3Llj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Information technology&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;968&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1161"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,103&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ClearingAndOtherCharges_i02_pn3n3_zpPAGMTrpmre" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Clearing and other charges&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;556&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1169"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;556&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_pn3n3_znbwBwmr5zb7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;General and administrative-other&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;742&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1173"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,497&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,239&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i02T_pn3n3_zAOk4nWkddFf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;7,617&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,956&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;22,637&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i02_pn3n3_zskYsgAMkCJl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_pn3n3_zLgZCyfaTS5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7,617&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;14,956&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;22,637&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NetOperatingIncomeLoss_iT_pn3n3_zrIierldZ4T1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net operating (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(2,706&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(14,956&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(17,726&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_pn3n3_zojnS0jg4fef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Other income and expense:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--MiscellaneousIncome_pn3n3_zLrqgUQKpwvl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Miscellaneous income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1210"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;75&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestExpenseNonoperating_i01N_pn3n3_di_z7eafuHWNQ52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(990&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;990&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1218"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherNonoperatingIncome_i01_pn3n3_zKw4Aws7eeVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;471&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,136&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(990&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;617&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--GainRelatedToDilutionEvents_i01_pn3n3_zcBNWLxpXySk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Gain related to dilution events&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1227"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zTkZ8Yb74lx6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Gain on deconsolidation of subsidiary&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_zuFjLfJo3MTe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;(Loss) before income taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,150&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(13,759&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(16,973&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_zMBLAtT4rIz1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1246"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_pn3n3_zzgkoWOiXIw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income (loss) before equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,161&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(13,759&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(16,984&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeLossFromEquityMethodInvestment_i01_pn3n3_ziwMXHlip1ee" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Equity in loss of equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1256"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1259"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ProfitLoss_iT_pn3n3_zobhMCmM7mL3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net (loss)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(3,161&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(18,041&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(21,266&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zVxxXDefdtL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less net loss attributable to non-controlling interests&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1270"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_pn3n3_zdPCaBKfaeGe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to MDB Capital Holdings, LLC&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(43&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(18,041&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(21,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0D_zEor9fRn3qpi" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zgbWJ4PSadxe" style="font-size: 10pt"&gt;Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F09_zGLgxMMdFQN9" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F17_zOe2PuXCzajk" style="font-size: 10pt"&gt;Includes realized gains on securities held by the broker-dealer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F05_z4JoAFWJTPN1" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zFxNmoNpBLpi" style="font-size: 10pt"&gt;Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_F03_zUWsCc363nV3" style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zUyKanJjUJle" style="font-size: 10pt"&gt;Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zxDkWDamkN9a" style="border-collapse: collapse; width: 96%; margin-right: 0pt; margin-left: 0.25in" summary="xdx: Disclosure - Schedule of Statement of Operation by Segment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BrokerDealerIntellectualPropertyServiceMember_zNgyo9QxRcDb" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Broker&lt;br/&gt; Dealer &amp;amp;&lt;br/&gt; Intellectual&lt;br/&gt; Property&lt;br/&gt; Service&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TechnologyDevelopmentMember_zVBQNxHgGlHe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Technology Development&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OtherSegmentsMember_zfLHp1q4wxLk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_z6aN42ks42Yi" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Eliminations&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_z30lEVjjKxWj" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"&gt;Consolidated&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLossAbstract_iB_zKRi1AQrpD9i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;Operating income:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--UnrealizedGainLossOnInvestments_i01_zyb7rlhTFXw9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 30%; font-size: 10pt; text-align: left"&gt;Unrealized (loss) on investment securities, net from the licensed broker
    dealer  &lt;span id="xdx_F43_zWUs8Dto14ke"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(275&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(275&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FeeIncome_i01_z6d9ZzKadMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fee income from the licensed broker dealer &lt;span id="xdx_F42_z5fs0BmS5l03"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,221&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ImpairmentOfInvestmentSecurities_i01N_di_ztiPAN9vDBPc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Impairment loss &lt;span id="xdx_F4A_z2dxI5NLo03f"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(200&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherOperatingIncome_i01_zyNFBZXjfPZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other operating income &lt;span id="xdx_F4D_zt1W4aTYGOT9"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_zHvhMmllsUH3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating income, net&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,157&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1328"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,157&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zMmiKetVtgrb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpenseAbstract_i01B_zvbbvLQPhjTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_i02_zqK1qW87qCrj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,226&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,062&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14,769&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;20,057&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_i02_zrPywaAV9Cwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Operating expense, related party&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,301&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;185&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfessionalFees_i02_zGxKygTch0B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Professional fees&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;820&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,206&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,086&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1359"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,112&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CommunicationsAndInformationTechnology_i02_zLQaYBeMtBTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Information technology&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;805&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;34&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;83&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1365"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;922&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ClearingAndOtherCharges_i02_zh7JLkyObDE3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Clearing and other charges&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,137&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1369"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1370"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,137&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_i02_zZ34HDAX8LPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;General and administrative-other&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;806&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,669&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1377"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,608&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i02T_zZhBF38SfJsa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;General and administrative costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8,095&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,435&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;17,792&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;29,322&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i02_zIHEVSPhbYY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1388"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingExpenses_i01T_zvCDo2CdarEk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total operating costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;8,095&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,903&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;17,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1395"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,790&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--NetOperatingIncomeLoss_iT_z02ABQ5Zs9Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net operating (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(5,938&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,903&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(17,792&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1401"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(28,633&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_ztBJeXpqWF0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Other income and expense:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--MiscellaneousIncome_zuWi4EoOwQah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Miscellaneous income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;112&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1411"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1412"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1413"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;112&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_zY0krAMLtmAj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(779&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(92&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;799&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(72&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherNonoperatingIncome_i01_zfjLtL3YPDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;465&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(799&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,179&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--GainRelatedToDilutionEvents_i01_zZnbGs53y3dl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Gain related to dilution events&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1428"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1429"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1431"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeconsolidationGainOrLossAmount_i01_zPqWOkFi4UC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;Gain on deconsolidation of subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1435"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,307&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1437"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;39,307&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zkk18ubnFh3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income (loss) before income taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,992&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;23,155&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1443"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;12,023&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_zN3z37vUv7y2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1449"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment_zel5TqRLBvLa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income (loss) before equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,994&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;23,155&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1455"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;12,021&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeLossFromEquityMethodInvestment_i01_zjOzGfZpvHW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Equity in loss of equity method investee&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1459"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(420&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(420&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ProfitLoss_iT_zxSS0fvY1v51" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(4,994&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;22,735&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11,601&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_zPA4DtmKvFQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less net loss attributable to non-controlling interests&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1470"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1472"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1473"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(90&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_z4NUZU0Rd7Ig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net income and (loss) attributable to MDB Capital Holdings, LLC&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(6,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(4,904&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;22,735&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1479"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;11,691&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0C_zItwKHS2g4Kh" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zX8aEhgzrEuk" style="font-size: 10pt"&gt;Includes unrealized gains and
losses on securities held by the broker-dealer.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F09_zBzu6syX8buj" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F16_zorbWRAAllIf" style="font-size: 10pt"&gt;Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F02_zyhMfb3EvK0b" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F14_ztBZbU7oANQ5" style="font-size: 10pt"&gt;Includes impairment loss of assets
from the reduced fair value of the asset.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span id="xdx_F0E_zCCvHQu57k5a" style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_zdtty7wgl7m" style="font-size: 10pt"&gt;Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&#160;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001088"
      unitRef="USD">331000</MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2>
    <MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001092"
      unitRef="USD">331000</MDBH:UnrealizedLossOnInvestmentSecuritiesNetFromLicensedBrokerDealerNotes1And2>
    <MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001094"
      unitRef="USD">85000</MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer>
    <MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001098"
      unitRef="USD">85000</MDBH:InvestmentsSecuritiesAtFairValueHeldByNonlicensedBrokerDealer>
    <MDBH:RealizedInvestmentGainsLossesOne
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">14000</MDBH:RealizedInvestmentGainsLossesOne>
    <MDBH:RealizedInvestmentGainsLossesOne
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">14000</MDBH:RealizedInvestmentGainsLossesOne>
    <us-gaap:FeeIncome
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001106"
      unitRef="USD">4282000</us-gaap:FeeIncome>
    <us-gaap:FeeIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001110"
      unitRef="USD">4282000</us-gaap:FeeIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001118"
      unitRef="USD">861000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001122"
      unitRef="USD">861000</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001124"
      unitRef="USD">4911000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001128"
      unitRef="USD">4911000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001142"
      unitRef="USD">2875000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">12094000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001146"
      unitRef="USD">14969000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001148"
      unitRef="USD">1471000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001150"
      unitRef="USD">362000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001152"
      unitRef="USD">1833000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001154"
      unitRef="USD">1005000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001155"
      unitRef="USD">64000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001156"
      unitRef="USD">868000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001158"
      unitRef="USD">1937000</us-gaap:ProfessionalFees>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001160"
      unitRef="USD">968000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001162"
      unitRef="USD">135000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001164"
      unitRef="USD">1103000</us-gaap:CommunicationsAndInformationTechnology>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001166"
      unitRef="USD">556000</MDBH:ClearingAndOtherCharges>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001170"
      unitRef="USD">556000</MDBH:ClearingAndOtherCharges>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001172"
      unitRef="USD">742000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001174"
      unitRef="USD">1497000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001176"
      unitRef="USD">2239000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001178"
      unitRef="USD">7617000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001179"
      unitRef="USD">64000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001180"
      unitRef="USD">14956000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001182"
      unitRef="USD">22637000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001190"
      unitRef="USD">7617000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001191"
      unitRef="USD">64000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001192"
      unitRef="USD">14956000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">22637000</us-gaap:OperatingExpenses>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001196"
      unitRef="USD">-2706000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001197"
      unitRef="USD">-64000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001198"
      unitRef="USD">-14956000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001200"
      unitRef="USD">-17726000</MDBH:NetOperatingIncomeLoss>
    <MDBH:MiscellaneousIncome
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001208"
      unitRef="USD">75000</MDBH:MiscellaneousIncome>
    <MDBH:MiscellaneousIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001212"
      unitRef="USD">75000</MDBH:MiscellaneousIncome>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001214"
      unitRef="USD">990000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      decimals="-3"
      id="Fact001217"
      unitRef="USD">-990000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001220"
      unitRef="USD">471000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001222"
      unitRef="USD">1136000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-012025-12-31_custom_EliminationsMember"
      decimals="-3"
      id="Fact001223"
      unitRef="USD">-990000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001224"
      unitRef="USD">617000</us-gaap:OtherNonoperatingIncome>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001228"
      unitRef="USD">61000</MDBH:GainRelatedToDilutionEvents>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001230"
      unitRef="USD">61000</MDBH:GainRelatedToDilutionEvents>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001238"
      unitRef="USD">-3150000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001239"
      unitRef="USD">-64000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001240"
      unitRef="USD">-13759000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">-16973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001244"
      unitRef="USD">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001248"
      unitRef="USD">11000</us-gaap:IncomeTaxExpenseBenefit>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001250"
      unitRef="USD">-3161000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001251"
      unitRef="USD">-64000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001252"
      unitRef="USD">-13759000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001254"
      unitRef="USD">-16984000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001258"
      unitRef="USD">-4282000</MDBH:IncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001260"
      unitRef="USD">-4282000</MDBH:IncomeLossFromEquityMethodInvestment>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001262"
      unitRef="USD">-3161000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001263"
      unitRef="USD">-64000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001264"
      unitRef="USD">-18041000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001266"
      unitRef="USD">-21266000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001269"
      unitRef="USD">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001272"
      unitRef="USD">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001274"
      unitRef="USD">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001275"
      unitRef="USD">-43000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001276"
      unitRef="USD">-18041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001278"
      unitRef="USD">-21245000</us-gaap:NetIncomeLoss>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001284"
      unitRef="USD">91000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001286"
      unitRef="USD">641000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001288"
      unitRef="USD">732000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001290"
      unitRef="USD">21754000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001291"
      unitRef="USD">1000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001292"
      unitRef="USD">50221000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001294"
      unitRef="USD">71976000</us-gaap:Assets>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001302"
      unitRef="USD">-275000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001306"
      unitRef="USD">-275000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:FeeIncome
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001308"
      unitRef="USD">2221000</us-gaap:FeeIncome>
    <us-gaap:FeeIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001312"
      unitRef="USD">2221000</us-gaap:FeeIncome>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001314"
      unitRef="USD">200000</MDBH:ImpairmentOfInvestmentSecurities>
    <MDBH:ImpairmentOfInvestmentSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001318"
      unitRef="USD">200000</MDBH:ImpairmentOfInvestmentSecurities>
    <us-gaap:OtherOperatingIncome
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">411000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001324"
      unitRef="USD">411000</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">2157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001330"
      unitRef="USD">2157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001344"
      unitRef="USD">3226000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001345"
      unitRef="USD">2062000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001346"
      unitRef="USD">14769000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001348"
      unitRef="USD">20057000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001350"
      unitRef="USD">1301000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001352"
      unitRef="USD">185000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001354"
      unitRef="USD">1486000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001356"
      unitRef="USD">820000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001357"
      unitRef="USD">1206000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001358"
      unitRef="USD">1086000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001360"
      unitRef="USD">3112000</us-gaap:ProfessionalFees>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001362"
      unitRef="USD">805000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001363"
      unitRef="USD">34000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001364"
      unitRef="USD">83000</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001366"
      unitRef="USD">922000</us-gaap:CommunicationsAndInformationTechnology>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001368"
      unitRef="USD">1137000</MDBH:ClearingAndOtherCharges>
    <MDBH:ClearingAndOtherCharges
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001372"
      unitRef="USD">1137000</MDBH:ClearingAndOtherCharges>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001374"
      unitRef="USD">806000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001375"
      unitRef="USD">133000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001376"
      unitRef="USD">1669000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001378"
      unitRef="USD">2608000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001380"
      unitRef="USD">8095000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001381"
      unitRef="USD">3435000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001382"
      unitRef="USD">17792000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001384"
      unitRef="USD">29322000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001387"
      unitRef="USD">1468000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001390"
      unitRef="USD">1468000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001392"
      unitRef="USD">8095000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001393"
      unitRef="USD">4903000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001394"
      unitRef="USD">17792000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001396"
      unitRef="USD">30790000</us-gaap:OperatingExpenses>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001398"
      unitRef="USD">-5938000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001399"
      unitRef="USD">-4903000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001400"
      unitRef="USD">-17792000</MDBH:NetOperatingIncomeLoss>
    <MDBH:NetOperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001402"
      unitRef="USD">-28633000</MDBH:NetOperatingIncomeLoss>
    <MDBH:MiscellaneousIncome
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001410"
      unitRef="USD">112000</MDBH:MiscellaneousIncome>
    <MDBH:MiscellaneousIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001414"
      unitRef="USD">112000</MDBH:MiscellaneousIncome>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001416"
      unitRef="USD">779000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001417"
      unitRef="USD">92000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      decimals="-3"
      id="Fact001419"
      unitRef="USD">-799000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001420"
      unitRef="USD">72000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001422"
      unitRef="USD">465000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001423"
      unitRef="USD">3000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001424"
      unitRef="USD">1510000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31_custom_EliminationsMember"
      decimals="-3"
      id="Fact001425"
      unitRef="USD">-799000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001426"
      unitRef="USD">1179000</us-gaap:OtherNonoperatingIncome>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001430"
      unitRef="USD">130000</MDBH:GainRelatedToDilutionEvents>
    <MDBH:GainRelatedToDilutionEvents
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001432"
      unitRef="USD">130000</MDBH:GainRelatedToDilutionEvents>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001436"
      unitRef="USD">39307000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001438"
      unitRef="USD">39307000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001440"
      unitRef="USD">-6140000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001441"
      unitRef="USD">-4992000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001442"
      unitRef="USD">23155000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001444"
      unitRef="USD">12023000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001447"
      unitRef="USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001450"
      unitRef="USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001452"
      unitRef="USD">-6140000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001453"
      unitRef="USD">-4994000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001454"
      unitRef="USD">23155000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001456"
      unitRef="USD">12021000</MDBH:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001460"
      unitRef="USD">-420000</MDBH:IncomeLossFromEquityMethodInvestment>
    <MDBH:IncomeLossFromEquityMethodInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001462"
      unitRef="USD">-420000</MDBH:IncomeLossFromEquityMethodInvestment>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001464"
      unitRef="USD">-6140000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001465"
      unitRef="USD">-4994000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001466"
      unitRef="USD">22735000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001468"
      unitRef="USD">11601000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001471"
      unitRef="USD">-90000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001474"
      unitRef="USD">-90000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_BrokerDealerIntellectualPropertyServiceMember"
      decimals="-3"
      id="Fact001476"
      unitRef="USD">-6140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_TechnologyDevelopmentMember"
      decimals="-3"
      id="Fact001477"
      unitRef="USD">-4904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_OtherSegmentsMember"
      decimals="-3"
      id="Fact001478"
      unitRef="USD">22735000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001480"
      unitRef="USD">11691000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001486">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbT32cUspVz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;4. &lt;span id="xdx_821_znnEikvNcEoh"&gt;Equity and Non-Controlling Interests&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Equity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Preferred shares &#x2013; &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_z4BPQ5xp2mX7" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt;
shares authorized, &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20251231_z6MdOwb2BUW1" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231_zmUVNqMFALi6" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares issued and outstanding. The board of directors may designate preferred shares to be issued, and may rank
preferred shares as junior to, on parity with or senior to other preferred shares (in each case, with respect to distributions or other
payments in respect of shares). Since the board of directors may set all the terms of any class of preferred shares, these are considered
&#x201c;blank check&#x201d; preferred shares. Currently the board has not defined dividend and liquidation preference, participation rights,
call prices and dates, sinking-fund requirements, or terms that may change the conversation or exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Class A Common Shares &#x2013; &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zNftXpF7D32a" title="Common stock, shares authorized"&gt;95,000,000&lt;/span&gt;
shares authorized, &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zHQy6flaBmHl" title="Common stock, shares, issued"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zrX3IxQo2ydl" title="Common stock, shares, outstanding"&gt;4,950,632&lt;/span&gt;&lt;/span&gt; shares issued and outstanding as of December 31, 2024. These shares are common shares and have one vote per
share. Currently there is not a defined dividend or liquidation preference.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Class B Common Shares &#x2013; &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zQr9uU8Y3Hql" title="Common stock, shares authorized"&gt;5,000,000&lt;/span&gt;
shares authorized, &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zZ95B7Sjniee" title="Common stock, shares, issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zAKt2iGo4EGc" title="Common stock, shares, outstanding"&gt;5,000,000&lt;/span&gt;&lt;/span&gt; issued and outstanding as of December 31, 2024. These shares are common shares and have five votes per share.
Currently there is not a defined dividend or liquidation preference. These shares may be converted one to one for Class A Common Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Placement Agent and Selling Agent
Warrants &#x2013; &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zL57LYQMhBFe" title="Placement agent and selling agent warrants"&gt;43,420&lt;/span&gt; warrants of Class A common shares have been issued as part of the private placement and the initial public offering.
The Placement Agent and Selling Agent Warrants are subject to standard anti-dilution provisions and may include cashless exercise provisions
under certain circumstances. The issuance of the Placement and Selling Agent Warrants is a customary part of compensation for the placement
or selling agent&#x2019;s services in connection with prior offerings.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Non-Controlling Interests&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On July 1, 2024 M1 was incorporated.
During the year ended December 31, 2024, the ownership interest in M1, ranged from &lt;span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zPlOXYx5EBNk" title="Ownership interest rate"&gt;67.0&lt;/span&gt;% to &lt;span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zgIRLn3G5yNi" title="Ownership interest rate"&gt;67.9&lt;/span&gt;% (weighted average of &lt;span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_znwaragf88ci" title="Ownership interest rate"&gt;67.47&lt;/span&gt; %), with
the non-controlling interest ranging from &lt;span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zG6RFwYL43r3" title="Non-controlling interest rate"&gt;33.0&lt;/span&gt;% to &lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zYoO7sZOuep8" title="Non-controlling interest rate"&gt;32.1&lt;/span&gt;% (weighted average of &lt;span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_zqybr6fXCRA4" title="Ownership interest rate"&gt;32.53&lt;/span&gt;%).&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2025, the Company held a weighted average of &lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20251231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_z67fcHuaYfzl" title="Ownership interest by parent"&gt;67.84&lt;/span&gt;% ownership interest in M1, with the remaining &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20251231__srt--OwnershipAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--WeightedAverageMember_zUgUEhVNjwBc" title="Ownership interest by NCI"&gt;32.16&lt;/span&gt;% representing NCI. During the year
ended December 31, 2024, the ownership interest in eXoZymes, ranged from &lt;span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zij2aaGvQ0Vh" title="Ownership interest rate"&gt;60.94&lt;/span&gt;% to &lt;span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zFxgOv51fUh1" title="Ownership interest rate"&gt;47.0&lt;/span&gt;%, with the non-controlling
interest ranging from &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zgBPdVgO7LR9" title="Non-controlling interest rate"&gt;39.06&lt;/span&gt; % to &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_dp_c20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zLjv4TDRDaCa" title="Non-controlling interest rate"&gt;53.0&lt;/span&gt;%. On November 14, 2024 the ownership of eXoZymes by MDB moved below 50%, therefore
on that day the eXoZymes was deconsolidated from the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During each period, controlling and
non-controlling interests changes as a result of capital infusions from MDB. For the years ended December 31, 2025,
and 2024, there were capital infusions of $&lt;span id="xdx_907_eus-gaap--ProceedsFromContributionsFromParent_pn3n3_c20250101__20251231_z3OhzTWMfmO" title="Capital infusions"&gt;93&lt;/span&gt; thousand (M1) and $&lt;span id="xdx_907_eus-gaap--ProceedsFromContributionsFromParent_pn3n3_c20240101__20241231_zO1fSF66FOza" title="Capital infusions"&gt;177&lt;/span&gt; thousand (M1), respectively. The NCI ownership will be equal to the
NCI percentage as of the reporting period. Therefore, there will be a redistribution of equity between MDB and the non-controlling interest
owner. As of December 31, 2025, the Company&#x2019;s equity interest in M1 was &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MinimumMember_zkv73oRc6s9" title="Equity interest rate"&gt;67.9&lt;/span&gt;% to &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MinnesotaOneMember__srt--RangeAxis__srt--MaximumMember_zjtMVKmqrHJa" title="Equity interest rate"&gt;67.8&lt;/span&gt;%, and the remaining equity interest was owned
by the non-controlling interests as presented below. As of December 31, 2024, the Company&#x2019;s equity interest in M1 was &lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MinimumMember_zTKvLFrPhfYe" title="Equity interest rate"&gt;67.9&lt;/span&gt;% to &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymeTechnologiesIncMember__srt--RangeAxis__srt--MaximumMember_zUOUseYen9Y4" title="Equity interest rate"&gt;67.0&lt;/span&gt;%,
and the remaining equity interest was owned by the non-controlling interests as presented below (in thousands):&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfEquityAndNonControllingInterestsTableTextBlock_z9Is05pwWqf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zicnOOB87EGb" style="display: none"&gt;Schedule of Equity and Non-Controlling Interests&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Non-controlling interest net loss&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--NetIncomeLoss_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zWr6RDg9fa57" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss"&gt;(64&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_ztA2iFFOG2Z1" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss"&gt;(276&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Weighted average non-controlling percentage&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z1bJQyiL07ij" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage"&gt;32.16&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zEj8rkCBjvm4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage"&gt;32.53&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net loss non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zdZMLh4owWm6" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest"&gt;(21&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zgRUoT5KtNzi" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest"&gt;(90&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Prior period balance&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--MinorityInterest_iS_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zMurvPsBzLN5" title="Prior period balance"&gt;(90&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--MinorityInterest_iS_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zKE3C98v5r68" title="Prior period balance"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Removal of prior period balance of eXoZymes due to deconsolidation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zxxbfXPqBvLk" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1562"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zcqxZHWj9WQ7" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation"&gt;(7&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zCr9gC2yi8nd" style="font-size: 10pt; text-align: right" title="Stock-based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1566"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z7EZ9iT65vmj" style="font-size: 10pt; text-align: right" title="Stock-based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1568"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Ownership change of non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z6hMl72ml2h4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1570"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zRcWaomFVX13" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1572"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending period balance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--MinorityInterest_iE_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zPCK1BhahCs8" title="Ending period balance"&gt;(111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--MinorityInterest_iE_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zIZVBDMi0Gtf" title="Ending period balance"&gt;(90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z1Lzyg2PEibk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;If there is a change in the parent
ownership in a subsidiary from an additional investment or from the issuance of stock based compensation, a change of the non-controlling
ownership is recognized based on the amount invested as required, and per ASC 810-45-21A, the carrying amount of the non-controlling interest
is adjusted to reflect the change in the non-controlling ownership in the subsidiary&#x2019;s net assets. Since there was a change in the
equity, a reclassification of the non-controlling interest in the subsidiary&#x2019;s net assets is required and demonstrated in the ending
period balance above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001488"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001490"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001492"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001494"
      unitRef="Shares">95000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001496"
      unitRef="Shares">4950632</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001498"
      unitRef="Shares">4950632</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001500"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001502"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001504"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">43420</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001508"
      unitRef="Pure">0.670</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001510"
      unitRef="Pure">0.679</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001512"
      unitRef="Pure">0.6747</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001514"
      unitRef="Pure">0.330</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001516"
      unitRef="Pure">0.321</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2024-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001518"
      unitRef="Pure">0.3253</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001520"
      unitRef="Pure">0.6784</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001522"
      unitRef="Pure">0.3216</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Pure">0.6094</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001526"
      unitRef="Pure">0.470</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Pure">0.3906</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001530"
      unitRef="Pure">0.530</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001532"
      unitRef="USD">93000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:ProceedsFromContributionsFromParent
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001534"
      unitRef="USD">177000</us-gaap:ProceedsFromContributionsFromParent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001536"
      unitRef="Pure">0.679</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-12-31_custom_MinnesotaOneMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001538"
      unitRef="Pure">0.678</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MinimumMember5368140"
      decimals="INF"
      id="Fact001540"
      unitRef="Pure">0.679</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember_srt_MaximumMember5368156"
      decimals="INF"
      id="Fact001542"
      unitRef="Pure">0.670</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <MDBH:ScheduleOfEquityAndNonControllingInterestsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001544">&lt;p id="xdx_890_ecustom--ScheduleOfEquityAndNonControllingInterestsTableTextBlock_z9Is05pwWqf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zicnOOB87EGb" style="display: none"&gt;Schedule of Equity and Non-Controlling Interests&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Non-controlling interest net loss&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--NetIncomeLoss_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zWr6RDg9fa57" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss"&gt;(64&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLoss_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_ztA2iFFOG2Z1" style="width: 16%; font-size: 10pt; text-align: right" title="Non-controlling net loss"&gt;(276&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Weighted average non-controlling percentage&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z1bJQyiL07ij" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage"&gt;32.16&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WeightedAverageNonControllingPercentage_pid_dp_uPure_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zEj8rkCBjvm4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average non-controlling percentage"&gt;32.53&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net loss non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zdZMLh4owWm6" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest"&gt;(21&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zgRUoT5KtNzi" style="font-size: 10pt; text-align: right" title="Net loss non-controlling interest"&gt;(90&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Prior period balance&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--MinorityInterest_iS_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zMurvPsBzLN5" title="Prior period balance"&gt;(90&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--MinorityInterest_iS_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zKE3C98v5r68" title="Prior period balance"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Removal of prior period balance of eXoZymes due to deconsolidation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zxxbfXPqBvLk" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1562"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueToDeconsolidation_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zcqxZHWj9WQ7" style="font-size: 10pt; text-align: right" title="Removal of prior period balance of Exozyme due to deconsolidation"&gt;(7&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zCr9gC2yi8nd" style="font-size: 10pt; text-align: right" title="Stock-based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1566"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationToNonControllingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z7EZ9iT65vmj" style="font-size: 10pt; text-align: right" title="Stock-based compensation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1568"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Ownership change of non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_z6hMl72ml2h4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1570"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--OwnershipChangeOfNoncontrollingInterest_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zRcWaomFVX13" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Ownership change of non-controlling interest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1572"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Ending period balance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--MinorityInterest_iE_pn3n3_c20250101__20251231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zPCK1BhahCs8" title="Ending period balance"&gt;(111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--MinorityInterest_iE_pn3n3_c20240101__20241231__srt--OwnershipAxis__custom--ExozymeTechnologiesIncMember_zIZVBDMi0Gtf" title="Ending period balance"&gt;(90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MDBH:ScheduleOfEquityAndNonControllingInterestsTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001546"
      unitRef="USD">-64000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001548"
      unitRef="USD">-276000</us-gaap:NetIncomeLoss>
    <MDBH:WeightedAverageNonControllingPercentage
      contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="INF"
      id="Fact001550"
      unitRef="Pure">0.3216</MDBH:WeightedAverageNonControllingPercentage>
    <MDBH:WeightedAverageNonControllingPercentage
      contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="INF"
      id="Fact001552"
      unitRef="Pure">0.3253</MDBH:WeightedAverageNonControllingPercentage>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001554"
      unitRef="USD">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001556"
      unitRef="USD">-90000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001558"
      unitRef="USD">-90000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001560"
      unitRef="USD">7000</us-gaap:MinorityInterest>
    <MDBH:DueToDeconsolidation
      contextRef="From2024-01-012024-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001564"
      unitRef="USD">-7000</MDBH:DueToDeconsolidation>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001574"
      unitRef="USD">-111000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31_custom_ExozymeTechnologiesIncMember"
      decimals="-3"
      id="Fact001576"
      unitRef="USD">-90000</us-gaap:MinorityInterest>
    <MDBH:DeconsolidationDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001578">&lt;p id="xdx_808_ecustom--DeconsolidationDisclosureTextBlock_zgA2s0FZ7ZJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2013; &lt;span id="xdx_827_zZ5CivyykUNc"&gt;Deconsolidation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On November 14, 2024 (the &#x201c;Deconsolidation
Date&#x201d;), the Company deconsolidated eXoZymes from its financial statements due to its ownership interest falling below 50%, resulting
in the loss of a controlling financial interest. This change occurred in connection with eXoZymes&#x2019; completion of its initial public
offering, which reduced the Company&#x2019;s ownership stake.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The consolidated financial statements
as of December 31, 2024 reflect the inclusion of eXoZymes&#x2019; financial results through the Deconsolidation Date. For the period from
November 15, 2024 through December 31, 2024, the Company accounted for its investment in eXoZymes under the equity method, recognizing
its proportionate share of eXoZymes&#x2019; net loss in the amount of $&lt;span id="xdx_903_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_pn3n3_c20241115__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zYwaPYnN6aU6" title="Equity method, net loss"&gt;420&lt;/span&gt; thousand, based on eXoZymes&#x2019; total net loss of $&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_pn3n3_c20241115__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zqRhCrcg4bp4" title="Net loss"&gt;893&lt;/span&gt; thousand
for that period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2024, the Company
continues to hold a 47% interest in eXoZymes Class A common stock. While the Company and eXoZymes share certain officers, board members,
and accounting personnel, the two entities operate independently. eXoZymes also utilizes professional services provided by PatentVest,
a wholly owned subsidiary of the Company&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The assessment of the potential
impairment of the Company&#x2019;s equity method investments when indicators such as a history of operating losses, a negative
earnings and cash flow outlook, and the financial condition and prospects for the investee&#x2019;s business segment might indicate a
loss in value. The Company has not recognized any impairment loss on investment in unconsolidated affiliate to
date.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znmQzXpgD9Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 40pt; text-align: justify"&gt;The following table represents the
consolidated balance sheet of xXoZymes immediately prior to the Deconsolidation Date (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zaLyXtrRNZ45" style="display: none"&gt;Schedule
of Consolidated Balance Sheet&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="2" id="xdx_49E_20241231__srt--ConsolidatedEntitiesAxis__custom--ExozymesMember_zTaT0KOHYLYe" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_zZ7Bta7BJts1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;68&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GrantsReceivable_i01I_pn3n3_zBeZI8Qfk3d9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.25in"&gt;Grants receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;701&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pn3n3_zSb3j8rkuW35" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;441&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredOfferingCosts_i01I_pn3n3_zM7K82YpJtRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred IPO Costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;550&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_zPkogiIDJgB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;710&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_zyo8gcPejVH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Operating lease right-of-use asset, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,366&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Assets_i01TI_pn3n3_zMMW3LhApfK7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;3,836&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Liabilities and Deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_i01I_pn3n3_zZlZGfilAbul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;851&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_i01I_pn3n3_zu2hkw194UL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;241&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherReceivables_i01I_pn3n3_zqAZYoN9Lrph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Due to affiliates&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;5,479&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredGrantReimbursement_i01I_pn3n3_zvCJLMY52BEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred grant reimbursement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zOPU1t4Ro0xc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,417&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Liabilities_i01TI_pn3n3_zvJfKbAAatkd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8,118&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Deficit:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_zXc173vBPXRk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Common shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_z2W5ji9NjBbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Paid-in-capital&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,120&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_zlTZ9Z1if509" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Accumulated deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(8,402&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_zJobKiQ0UCja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_zXIMBmWesci4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities and deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;3,836&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_ziXdUjgiIncb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;At December 31, 2024
eXoZymes had current assets of approximately $&lt;span id="xdx_904_eus-gaap--AssetsCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zBGLgRPknX2a" title="Current assets"&gt;10.8&lt;/span&gt; million, total assets of approximately $&lt;span id="xdx_90D_eus-gaap--Assets_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_z83nOlXaNTI3" title="Total assets"&gt;13.0&lt;/span&gt; million, current liabilities of approximately
$&lt;span id="xdx_903_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zizTKcSwYHd" title="Current liabilities"&gt;1.3&lt;/span&gt; million and total liabilities of approximately $&lt;span id="xdx_90E_eus-gaap--Liabilities_iI_pn5n6_c20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zaYX6y0DKaj6" title="Total liabilities"&gt;2.6&lt;/span&gt; million. For the year ended December 31, 2024, eXoZymes had revenues of $&lt;span id="xdx_907_eus-gaap--Revenues_c20240101__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zkRAaCwJTjQk" title="Revenues"&gt;0&lt;/span&gt; and
a net loss of approximately $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_pn5n6_c20240101__20241231__dei--LegalEntityAxis__custom--ExozymesIncMember_zEU4OVlT1Rb8" title="Net loss"&gt;5.9&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfGainOnDeconsolidationTableTextBlock_zjocbmbLWKXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following represents the calculation
of the gain on deconsolidation of eXoZymes from the consolidated financial statements of the Company (in thousands, except for share
price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zhsrE4JjEvP" style="display: none"&gt;Schedule
of Gain on Deconsolidation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt; text-align: left"&gt;eXoZymes Class A common shares retained on November 14, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_z8OxGjezDJwl" title="Class A common shares retained"&gt;3,931&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Quoted closing price of eXoZymes Class A common shares at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaqtv82MfCF9" title="Quoted closing price of Class A common shares"&gt;10.36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Subtotal of quoted closing price of eXoZymes Class A common shares at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zKN8E9VImEtd" title="Subtotal of quoted closing price of Class A common shares"&gt;40,727&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value of warrants held for eXoZymes at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zFYz9Y9eXRe2" title="Fair value of warrants"&gt;1,327&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fair value of equity method investment retained by eXoZymes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zebt75n0aUSh" title="Fair value of equity method investment"&gt;42,054&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Carrying Value of the NCI&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iNI_pn3n3_di_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zzAECntclUEh" title="Carrying Value of the NCI"&gt;(921&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Carrying value of eXoZymes assets at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_ecustom--CarryingValueOfAssets_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zjHrObnUdcc8" title="Carrying value of assets"&gt;4,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Less carrying value of former investment into eXoZymes&#160;&#160;at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--LessCarryingValueOfFormerInvestment_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_zLptOMZvyKp6" title="Less carrying value of former investment"&gt;(5,787&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Carrying value of warrants held for eXoZymes at November 14,2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CarryingValueOfWarrants_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaMrQyJUqbZa" title="Carrying value of warrants"&gt;(321&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Gain on deconsolidation&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_z40mjl1Vfus7" title="Gain on deconsolidation"&gt;39,307&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zk0nTGECPGL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:DeconsolidationDisclosureTextBlock>
    <us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee
      contextRef="From2024-11-152024-12-31_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001580"
      unitRef="USD">420000</us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-152024-12-31_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001582"
      unitRef="USD">893000</us-gaap:NetIncomeLoss>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001584">&lt;p id="xdx_89C_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znmQzXpgD9Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 40pt; text-align: justify"&gt;The following table represents the
consolidated balance sheet of xXoZymes immediately prior to the Deconsolidation Date (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zaLyXtrRNZ45" style="display: none"&gt;Schedule
of Consolidated Balance Sheet&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="2" id="xdx_49E_20241231__srt--ConsolidatedEntitiesAxis__custom--ExozymesMember_zTaT0KOHYLYe" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_zZ7Bta7BJts1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; font-size: 10pt; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;68&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GrantsReceivable_i01I_pn3n3_zBeZI8Qfk3d9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: justify; padding-left: 0.25in"&gt;Grants receivable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;701&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_pn3n3_zSb3j8rkuW35" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;441&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredOfferingCosts_i01I_pn3n3_zM7K82YpJtRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred IPO Costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;550&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_zPkogiIDJgB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;710&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_zyo8gcPejVH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Operating lease right-of-use asset, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,366&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Assets_i01TI_pn3n3_zMMW3LhApfK7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;3,836&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Liabilities and Deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_i01I_pn3n3_zZlZGfilAbul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;851&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_i01I_pn3n3_zu2hkw194UL8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;241&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherReceivables_i01I_pn3n3_zqAZYoN9Lrph" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Due to affiliates&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;5,479&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredGrantReimbursement_i01I_pn3n3_zvCJLMY52BEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Deferred grant reimbursement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;130&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_i01I_pn3n3_zOPU1t4Ro0xc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,417&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Liabilities_i01TI_pn3n3_zvJfKbAAatkd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8,118&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Deficit:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockValue_i02I_pn3n3_zXc173vBPXRk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Common shares&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1612"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_z2W5ji9NjBbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Paid-in-capital&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,120&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_zlTZ9Z1if509" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Accumulated deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(8,402&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_zJobKiQ0UCja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(4,282&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_zXIMBmWesci4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities and deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;3,836&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001586"
      unitRef="USD">68000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001588"
      unitRef="USD">701000</us-gaap:GrantsReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001590"
      unitRef="USD">441000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001592"
      unitRef="USD">550000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001594"
      unitRef="USD">710000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001596"
      unitRef="USD">1366000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001598"
      unitRef="USD">3836000</us-gaap:Assets>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001600"
      unitRef="USD">851000</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001602"
      unitRef="USD">241000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001604"
      unitRef="USD">5479000</us-gaap:OtherReceivables>
    <MDBH:DeferredGrantReimbursement
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001606"
      unitRef="USD">130000</MDBH:DeferredGrantReimbursement>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001608"
      unitRef="USD">1417000</us-gaap:OperatingLeaseLiability>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001610"
      unitRef="USD">8118000</us-gaap:Liabilities>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001614"
      unitRef="USD">4120000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001616"
      unitRef="USD">-8402000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001618"
      unitRef="USD">-4282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001620"
      unitRef="USD">3836000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31_custom_ExozymesIncMember"
      decimals="-5"
      id="Fact001622"
      unitRef="USD">10800000</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_ExozymesIncMember"
      decimals="-5"
      id="Fact001624"
      unitRef="USD">13000000.0</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31_custom_ExozymesIncMember"
      decimals="-5"
      id="Fact001626"
      unitRef="USD">1300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31_custom_ExozymesIncMember"
      decimals="-5"
      id="Fact001628"
      unitRef="USD">2600000</us-gaap:Liabilities>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_ExozymesIncMember"
      decimals="0"
      id="Fact001630"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_ExozymesIncMember"
      decimals="-5"
      id="Fact001632"
      unitRef="USD">5900000</us-gaap:NetIncomeLoss>
    <MDBH:ScheduleOfGainOnDeconsolidationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001634">&lt;p id="xdx_89D_ecustom--ScheduleOfGainOnDeconsolidationTableTextBlock_zjocbmbLWKXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following represents the calculation
of the gain on deconsolidation of eXoZymes from the consolidated financial statements of the Company (in thousands, except for share
price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zhsrE4JjEvP" style="display: none"&gt;Schedule
of Gain on Deconsolidation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt; text-align: left"&gt;eXoZymes Class A common shares retained on November 14, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_z8OxGjezDJwl" title="Class A common shares retained"&gt;3,931&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Quoted closing price of eXoZymes Class A common shares at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaqtv82MfCF9" title="Quoted closing price of Class A common shares"&gt;10.36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Subtotal of quoted closing price of eXoZymes Class A common shares at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zKN8E9VImEtd" title="Subtotal of quoted closing price of Class A common shares"&gt;40,727&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value of warrants held for eXoZymes at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zFYz9Y9eXRe2" title="Fair value of warrants"&gt;1,327&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Fair value of equity method investment retained by eXoZymes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zebt75n0aUSh" title="Fair value of equity method investment"&gt;42,054&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Carrying Value of the NCI&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iNI_pn3n3_di_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zzAECntclUEh" title="Carrying Value of the NCI"&gt;(921&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Carrying value of eXoZymes assets at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_ecustom--CarryingValueOfAssets_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zjHrObnUdcc8" title="Carrying value of assets"&gt;4,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Less carrying value of former investment into eXoZymes&#160;&#160;at November 14, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--LessCarryingValueOfFormerInvestment_iI_pn3n3_c20241115__dei--LegalEntityAxis__custom--ExozymesIncMember_zLptOMZvyKp6" title="Less carrying value of former investment"&gt;(5,787&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Carrying value of warrants held for eXoZymes at November 14,2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--CarryingValueOfWarrants_iI_pn3n3_c20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_zaMrQyJUqbZa" title="Carrying value of warrants"&gt;(321&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Gain on deconsolidation&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_c20241114__20241114__dei--LegalEntityAxis__custom--ExozymesIncMember_z40mjl1Vfus7" title="Gain on deconsolidation"&gt;39,307&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</MDBH:ScheduleOfGainOnDeconsolidationTableTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2024-11-15_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001636"
      unitRef="Shares">3931000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-14_custom_ExozymesIncMember"
      decimals="INF"
      id="Fact001638"
      unitRef="USDPShares">10.36</us-gaap:SharePrice>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001640"
      unitRef="Shares">40727000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-11-142024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">1327000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="AsOf2024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001644"
      unitRef="USD">42054000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001646"
      unitRef="USD">921000</us-gaap:CashEquivalentsAtCarryingValue>
    <MDBH:CarryingValueOfAssets
      contextRef="AsOf2024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001648"
      unitRef="USD">4282000</MDBH:CarryingValueOfAssets>
    <MDBH:LessCarryingValueOfFormerInvestment
      contextRef="AsOf2024-11-15_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001650"
      unitRef="USD">-5787000</MDBH:LessCarryingValueOfFormerInvestment>
    <MDBH:CarryingValueOfWarrants
      contextRef="AsOf2024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001652"
      unitRef="USD">-321000</MDBH:CarryingValueOfWarrants>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2024-11-142024-11-14_custom_ExozymesIncMember"
      decimals="-3"
      id="Fact001654"
      unitRef="USD">39307000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001656">&lt;p id="xdx_802_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zbezwg98FQp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 6 &#x2013; &lt;span id="xdx_829_zp5M2beOTH1f"&gt;Equity Method Investment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On November 14, 2024, eXoZymes underwent
an initial public offering in which MDB&#x2019;s ownership interest in eXoZymes decreased from &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241113__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zl6ffa1Zv9Tf" title="Ownership interest"&gt;60%&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241114__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zUCiomo9wflj" title="Ownership interest"&gt;47%&lt;/span&gt;. MDB and eXoZymes deconsolidated
the financial statements as the investment in eXoZymes fell below &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20241114__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember__srt--RangeAxis__srt--MaximumMember_zdcSFPm1e83k" title="Ownership interest"&gt;50%&lt;/span&gt; majority ownership.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The fair value of the equity method investment
was determined based on the number of eXoZymes shares held by MDB and the market price of eXoZymes stock on the deconsolidation date.
This valuation also included the estimated fair value of warrants held in eXoZymes, along with an assessment of the investment for any
potential impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s portion of the net loss
for the year ended December 31, 2025, was $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_pn4n6_c20250101__20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zNIIsWO4GPRj" title="Net loss"&gt;4.28&lt;/span&gt; million. As of December 31, 2025, MDB owned &lt;span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ExozymesMember_zWmZIg4BFAd5" title="Owned shares"&gt;3.93&lt;/span&gt; million shares of eXoZymes shares, representing
a &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvizyneTechnologiesIncMember_z81oc0FCbj0f" title="Equity method investment, percentage"&gt;46.76%&lt;/span&gt; ownership of eXoZymes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--EquityMethodInvestmentsTextBlock_zhVkgjWMqWm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following summarizes the Company&#x2019;
consolidated balance sheet equity method investment as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zFC2ZkijDefc" style="display: none"&gt;Schedule
of Equity Method Investment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carrying
    Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2024,
    carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EquityMethodInvestments_iS_c20250101__20251231_zzwPfe5YKIl8" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Equity method investments, balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41,764&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Portion of loss
    from eXoZymes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_c20250101__20251231_zgqyyMSX7w7k" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Portion of loss from Invizyne"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gain related to dilution events&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--EquityMethodInvestmentsGainRelatedToDilutionEvents_c20250101__20251231_ziSrlYOB3bLl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain related to dilution events"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2025, carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EquityMethodInvestments_iE_c20250101__20251231_zqB3C2Vu0QZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Equity method investments, balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37,543&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-11-13_custom_ExozymesMember"
      decimals="INF"
      id="Fact001658"
      unitRef="Pure">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-11-14_custom_ExozymesMember"
      decimals="INF"
      id="Fact001660"
      unitRef="Pure">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-11-14_custom_ExozymesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001662"
      unitRef="Pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_ExozymesMember"
      decimals="-4"
      id="Fact001664"
      unitRef="USD">4280000</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-12-31_custom_ExozymesMember"
      decimals="INF"
      id="Fact001666"
      unitRef="Shares">3.93</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-12-31_custom_InvizyneTechnologiesIncMember"
      decimals="INF"
      id="Fact001668"
      unitRef="Pure">0.4676</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001670">&lt;p id="xdx_893_eus-gaap--EquityMethodInvestmentsTextBlock_zhVkgjWMqWm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The following summarizes the Company&#x2019;
consolidated balance sheet equity method investment as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zFC2ZkijDefc" style="display: none"&gt;Schedule
of Equity Method Investment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carrying
    Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2024,
    carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EquityMethodInvestments_iS_c20250101__20251231_zzwPfe5YKIl8" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%" title="Equity method investments, balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41,764&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Portion of loss
    from eXoZymes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee_c20250101__20251231_zgqyyMSX7w7k" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Portion of loss from Invizyne"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gain related to dilution events&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--EquityMethodInvestmentsGainRelatedToDilutionEvents_c20250101__20251231_ziSrlYOB3bLl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain related to dilution events"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December 31, 2025, carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EquityMethodInvestments_iE_c20250101__20251231_zqB3C2Vu0QZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Equity method investments, balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37,543&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001672"
      unitRef="USD">41764000</us-gaap:EquityMethodInvestments>
    <us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001674"
      unitRef="USD">-4282000</us-gaap:GainOrLossOnSaleOfPreviouslyUnissuedStockByEquityInvestee>
    <MDBH:EquityMethodInvestmentsGainRelatedToDilutionEvents
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001676"
      unitRef="USD">61000</MDBH:EquityMethodInvestmentsGainRelatedToDilutionEvents>
    <us-gaap:EquityMethodInvestments
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001678"
      unitRef="USD">37543000</us-gaap:EquityMethodInvestments>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001680">&lt;p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPDd0uIJVI04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;7. &lt;span id="xdx_824_z3jktA0KWVCa"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On April 28, 2025, Mo Hayat, Chris
Marlett, George Brandon, and Anthony DiGiandomenico voluntarily relinquished their outstanding restricted stock units (RSUs) in exchange
for stock options for an equivalent number of Class A shares and similar vesting schedules. This exchange was executed as part of a broader
equity compensation strategy aimed at aligning long-term incentives with shareholder value creation. The terms of the stock options, including
exercise price and vesting schedules, were approved by the Company&#x2019;s Board of Directors in accordance with the existing equity incentive
plan and Section 16 of the Exchange Act.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Between April 19, 2022 and September
21, 2022, the Company granted &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20220419__20220921__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLIEmyYPcSVf" title="Restricted stock units, granted"&gt;3.7&lt;/span&gt; million restricted stock units (&#x201c;RSUs&#x201d;). &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_c20220419__20220921__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zThsIeTXp9z6" title="Restricted stock units, description"&gt;These units vested 20% of one-half of the total
number of RSUs, by each individual person, on the thirteenth (13) month anniversary, October 20, 2024, of the listing of the Class A Shares
on a United States national exchange, then vesting would be at a rate of 10% of one-half the number of RSUs each six months after the
date of the initial vesting, until the last vesting on the fifth year anniversary of the date of grant, at which any previously unvested
would fully vest. These RSUs were granted to officers, directors, employees, and contractors. These RSU began to vest upon the completion
of the initial public offering by the Company on September 20, 2023, compensation expense related to these RSUs has been recorded. The
Company expensed the RSUs based on the average expense over the vesting period.&lt;/span&gt; In 2024 an additional &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zan42jS1kTcf" title="Stock options to purchase"&gt;295&lt;/span&gt; thousands RSUs were
granted, &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z846gwOaERc" title="Number of restricted stock units, canceled or forfeited"&gt;320&lt;/span&gt; thousand RSUs were either canceled or forfeited, and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvmROqV0feg8" title="RSU vested"&gt;655&lt;/span&gt; thousand RSUs vested. The total unrecognized compensation expense
based on the share price sold in the 2022 private placement as of December 31, 2025 was $&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zNjcxOdYQF1l" title="Unrecognized stock-based compensation"&gt;6.0&lt;/span&gt; million. The weighted average of the remaining
restricted stock units at December 31, 2025 was &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zeQeQ5rW0vSj" title="Remaining weighted average years"&gt;1.6&lt;/span&gt; years and at December 31, 2024 was &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQwnF7tFo9T2" title="Remaining weighted average years"&gt;2.4&lt;/span&gt; years. During the year ended December 31, 2025,
&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaSQjJmGISik" title="Cancelled shares"&gt;128&lt;/span&gt; thousand RSUs were canceled due to holder leaving the Company and &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQDfxkxLnOn7" title="Number of restricted stock units, cancelled and converted"&gt;1.6&lt;/span&gt; million RSUs were exchanged and converted to stock options.
As a result of the modification, the fair value of the awards immediately after the modification was determined to be $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzjNvplrJRVi" title="Fair value"&gt;6.0&lt;/span&gt; million compared
to the fair value of the original restricted stock unit awards of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvs415EmwFD1" title="Restricted stock unit, value"&gt;6.8&lt;/span&gt; million immediately prior to the modification. The modification
resulted to a decrease in the aggregate fair value of the awards and in accordance with ASC 718-Compensation&#x2014;Stock Compensation, no incremental compensation costs need
to be recognized over the remaining requisite service period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On April 19, 2022 the Company granted
&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20220419__20220419__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZzQYquawYwc"&gt;2&lt;/span&gt;
million restricted stock units (&#x201c;RSUs&#x201d;). &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription_c20220419__20220419__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxNuFCThasGb"&gt;These
units will vest 20% of one-half of the total number of RSUs, by each individual person, starting on the thirteenth (13) month anniversary
of the listing of the Class A Shares on a United States national exchange, October 20, 2024, when a Class A Share has traded in the market
on which the Class A Shares are listed for any 90 consecutive calendar days at an average price of $20.00 or more during the period commencing
the date of grant and prior to the five year anniversary of the date of grant, with an average monthly trading volume of 2 million Class
A Shares or more during the 90 consecutive calendar day period, or a Class A Shares has traded in the market on which the Class A Shares
are listed for any 90 consecutive calendar days at an average price of $25.00 or more during the period commencing the date of grant
and prior to the five year anniversary of the date of grant; provided further, that if there is a distribution of cash, stock or other
property by the Company on the Class A Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced, from time to time,
by the value of any one or more per share distributions after the date of grant until vested.&lt;/span&gt; As these RSUs did not begin to vest
until the completion of an initial public offering, which was completed on September 20, 2023, by the Company, which was outside of the
control of the Company, compensation expense related to these RSUs has been recorded. On April 28, 2025 all of the market based RSUs
were modified and exchanged for stock options in their place. The unvested portion of the market based RSUs was $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCFNbbv9hmT1" title="Unvested portion market value"&gt;8.7&lt;/span&gt;
million and the incremental value of $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z9SwRIdmiA7"&gt;5.5&lt;/span&gt;
million in the exchange for a total amortized amount of $&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zJO0Bb5DxCU8" title="Sharebased payment award amortized amount"&gt;14.2&lt;/span&gt;
million that will be amortized over the &lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zUxZzeUTTuD2" title="Stock-based compensation term life"&gt;10&lt;/span&gt;&lt;/span&gt;ten-year life
of the award. There is not an estimated unrecognized compensation expense, as all the RSUs were modified and exchanged for stock options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0NIG6VYd1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A summary of restricted stock unit
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zNRnXuYqfBMe" style="display: none"&gt;Schedule
of Restricted Stock Unit Activity&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Time-Based&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Performance-Based&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Restricted&lt;br/&gt; Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Restricted&lt;br/&gt; Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; text-align: left"&gt;Restricted stock units outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcYZnmL3I8b5" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;2,995&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zqNSYST50oIh" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.90&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zkaJgIL5huh2" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4QJWNJ6qGGb" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;7.91&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1Xwaw4SCDn7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z2u4HiT6DUGg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1727"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zyqFuyZr33f7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zeizSkZc1sfe" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1731"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Vested&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrMbe9Lnsmbj" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;(188&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zBVBRPeCZXVd" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.69&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWs0a40oFnT1" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Exchanged/Modified&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHoRwosIwOJd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified"&gt;(1,600&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1xvaAPwrEO1" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified"&gt;10.00&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zp1OHG0r3gmk" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified"&gt;(2,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z6RbXw0kdMhg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified"&gt;7.91&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z4k47XUbV0Nf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;(128&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcihfXXzFDc4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.97&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z3zQdk8OwVLk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4GuxS4E82l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1753"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Restricted stock units outstanding at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zpcXx5SInOsh" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;1,079&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zr3VC3Pa3Tzk" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.78&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zFXarj62x0Gd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z1aVgoJo0Od5" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Restricted stock units at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEhKd4WFY34k" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;655&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zptrfDqfPAS" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;10.00&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zvHvN4N3O1ck" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztr1g4c4adQj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1769"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Restricted stock units at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zN5XjccM0T43" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;843&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z6Vfvyb6UDXj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;9.93&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zw6vq84NHZei" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1775"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zAsqLiuFA3Jb" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zetV5s6CvD72" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On April 28, 2025, in exchange for
&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_ziGALF7LAPcc" title="Unvested, shares"&gt;1.6&lt;/span&gt; million unvested time-based RSUs, stock options to purchase &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn5n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zmFzdoNXFtx4" title="Stock options to purchase"&gt;1.6&lt;/span&gt; million shares of Common Shares were granted at an exercise price of
$&lt;span id="xdx_90B_eus-gaap--StockOptionExercisePriceIncrease_pip0_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zq0hN5z9Hj3h" title="Exercise price per share, granted"&gt;4.25&lt;/span&gt; per share, which was equal to the closing price of the Common Shares immediately prior to the date of grant, and are exercisable
for a period of &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHbNHE9xww12" title="Exercisable period"&gt;10&lt;/span&gt; years. One-half of the stock options vested immediately on grant, with the remaining stock options vesting ratably
over a period of &lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zt8zo2l3M0D8" title="Remaining stock options vesting period"&gt;2&lt;/span&gt; years, subject to continued service. The inputs used to determine the fair value of this stock option grant were as
follows: (1) Common Stock price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zlgWwmoHFNgd" title="Common stock price per share"&gt;4.25&lt;/span&gt; per share; (2) exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEqC5QGGkwi1" title="Exercise price"&gt;4.25&lt;/span&gt; per share; (3) expected life of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zK02b7ouC7a8" title="Estimated life"&gt;10&lt;/span&gt; years; (4) risk-free
interest rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNVFUN1ChH3" title="Risk-free rate"&gt;4.23&lt;/span&gt;%; (5) expected annual volatility of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zflp6LWiWpUi" title="Expected annual volatility"&gt;85.65&lt;/span&gt;%; and (6) an annual dividend rate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250428__20250428__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsL5AcSWJpJf" title="Expected annual volatility"&gt;0&lt;/span&gt;%. The total unrecognized compensation
expense based on the pre-modification valuation of the shares price sold in the 2022 private placement as of December 31, 2025 was $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zTbTjzXUOath" title="Unrecognized stock-based compensation"&gt;6.9&lt;/span&gt;
million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--TimeBasedMember_zLD0G36Gj603" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A summary of time-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except
for share price and contractual life):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zaIxCcuCKHl7"&gt;Schedule
of Time-Based Stock Option Activity&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Time-based stock options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zUFfjZngfKX1" style="font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zF8A3iUEoFi5" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 49%; font-size: 10pt"&gt;Exchanged/Modified&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z8EfKrinwPr" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zXQLEHweryof" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified"&gt;3.75&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zvCgtdBmjcJf" title="Weighted average remaining contractual life (in years), time-based stock options exchanged/modified"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhdt6Ax7uwm4" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1815"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNifTcXSWT6" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zL5UIVZTf7v5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zFTQtDvgYof3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Time-based stock options outstanding at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zxeyitO6Lmaj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, at the end"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcbs40YBwQRd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding"&gt;3.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zPnmRpdpdFrk" title="Weighted average remaining contractual life (in years), time-based stock options outstanding"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zYKJL7GYeGgl" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrbZX0M8Po8i" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhELFJfAVxA5" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;1,067&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zu8BnDbm2s9j" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;3.75&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zasVp7qzfOOg" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z1IfYhxmTf4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In addition, on April 28, 2025, in
exchange for &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn6n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z753q2DcMUq1" title="Unvested, shares"&gt;2&lt;/span&gt; million unvested market-based RSUs, stock options to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn6n6_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5Ps6Pw8u4Wg" title="Stock options to purchase"&gt;2&lt;/span&gt; million shares of Common Shares were granted at an exercise
price of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zaApLbRlFDHe" title="Exercise price per share, granted"&gt;4.25&lt;/span&gt; per share, which was equal to the closing price of the Common Shares immediately prior to the date of grant, and are exercisable
for a period of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zlwp7UUsi3bl" title="Exercisable period"&gt;10&lt;/span&gt; years. The stock options vest if either (a) the Common Shares has traded in the market on which the shares are listed
for at least 30 trading days at an average price per share of $&lt;span id="xdx_905_ecustom--AveragePricePerShare_iI_pip0_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5rm3LLTF075" title="Average price per share"&gt;20.00&lt;/span&gt; or more, whether consecutive or non-consecutive, or (b) there are
distributions of cash, stock or other property by the Company to the holders of the Common Shares, at a value per share of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pp0p0_c20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z5IRk0iVwDtg"&gt;20.00&lt;/span&gt; or more
in the aggregate, subject to continued service. Once vested, the stock options will be exercisable for the remainder of the &lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting_pp0p0_dtY_c20250428__20250428__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4ThRkF7dNca" title="Exercisable period"&gt;10&lt;/span&gt;-year grant
date period. The total unrecognized compensation expense based on the post-modification valuation of the unamortized amount and the incremental
value as of December 31, 2025 was $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMdhZ7ejTCyj" title="Unrecognized stock-based compensation"&gt;13.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--MarketBasedMember_zSj7a8TViAnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A summary of market-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price and contractual life):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z7SJ0ngWr4Ha"&gt;Schedule
of Market-Based Stock Option Activity&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Market-based stock options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_znVElCvTtbO" style="font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1855"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z8bzdP5EKSwa" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 49%; font-size: 10pt"&gt;Exchanged/Modified&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zwhp0TTKRO27" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zPVa6oNLHFD1" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified"&gt;3.02&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztiHtKLirGWa" title="Weighted average remaining contractual life (in years), exchanged/modified"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zOqaMejvrJG5" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1865"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zqOF4ETqdDP4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1867"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zZNzSIxvM2N6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1869"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zpF6y5AKNak" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, expired/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Market-based stock options outstanding at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zb28UOMM6DM7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, at the end"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCjLE2mChIg5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding"&gt;3.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zDhONlxIRaGa" title="Weighted average remaining contractual life (in years), market-based stock options outstanding"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zHZbRNuMefMk" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1879"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zM9LuLdr3QY4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWSW0D39vlN6" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1883"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zcmQYB5a4R01" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1885"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zQNfMg9lWQ98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-04-192022-09-21_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001682"
      unitRef="Shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription
      contextRef="From2022-04-192022-09-21_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001684">These units vested 20% of one-half of the total
number of RSUs, by each individual person, on the thirteenth (13) month anniversary, October 20, 2024, of the listing of the Class A Shares
on a United States national exchange, then vesting would be at a rate of 10% of one-half the number of RSUs each six months after the
date of the initial vesting, until the last vesting on the fifth year anniversary of the date of grant, at which any previously unvested
would fully vest. These RSUs were granted to officers, directors, employees, and contractors. These RSU began to vest upon the completion
of the initial public offering by the Company on September 20, 2023, compensation expense related to these RSUs has been recorded. The
Company expensed the RSUs based on the average expense over the vesting period.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="Fact001686"
      unitRef="Shares">295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="Fact001688"
      unitRef="Shares">320000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="Fact001690"
      unitRef="Shares">655000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact001692"
      unitRef="USD">6000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember"
      id="Fact001694">P1Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PrivatePlacementMember"
      id="Fact001696">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001698"
      unitRef="Shares">128000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001700"
      unitRef="Shares">1600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001702"
      unitRef="USD">6000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001704"
      unitRef="USD">6800000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001705"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription
      contextRef="From2022-04-192022-04-19_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001706">These
units will vest 20% of one-half of the total number of RSUs, by each individual person, starting on the thirteenth (13) month anniversary
of the listing of the Class A Shares on a United States national exchange, October 20, 2024, when a Class A Share has traded in the market
on which the Class A Shares are listed for any 90 consecutive calendar days at an average price of $20.00 or more during the period commencing
the date of grant and prior to the five year anniversary of the date of grant, with an average monthly trading volume of 2 million Class
A Shares or more during the 90 consecutive calendar day period, or a Class A Shares has traded in the market on which the Class A Shares
are listed for any 90 consecutive calendar days at an average price of $25.00 or more during the period commencing the date of grant
and prior to the five year anniversary of the date of grant; provided further, that if there is a distribution of cash, stock or other
property by the Company on the Class A Shares, then the foregoing average amounts of $20.00 or $25.00 will be reduced, from time to time,
by the value of any one or more per share distributions after the date of grant until vested.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2025-04-28_custom_MarketBasedMember"
      decimals="-5"
      id="Fact001708"
      unitRef="USD">8700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-04-28_custom_MarketBasedMember"
      decimals="-5"
      id="Fact001709"
      unitRef="USD">5500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      decimals="-5"
      id="Fact001711"
      unitRef="USD">14200000</MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardAmortizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      id="Fact001713">P10Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001715">&lt;p id="xdx_891_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0NIG6VYd1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A summary of restricted stock unit
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zNRnXuYqfBMe" style="display: none"&gt;Schedule
of Restricted Stock Unit Activity&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Time-Based&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Performance-Based&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Restricted&lt;br/&gt; Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Restricted&lt;br/&gt; Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; text-align: left"&gt;Restricted stock units outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcYZnmL3I8b5" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;2,995&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zqNSYST50oIh" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.90&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zkaJgIL5huh2" style="width: 11%; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4QJWNJ6qGGb" style="width: 11%; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;7.91&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1Xwaw4SCDn7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z2u4HiT6DUGg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1727"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zyqFuyZr33f7" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1729"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zeizSkZc1sfe" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1731"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Vested&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrMbe9Lnsmbj" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;(188&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zBVBRPeCZXVd" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.69&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWs0a40oFnT1" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1737"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Exchanged/Modified&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zHoRwosIwOJd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified"&gt;(1,600&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z1xvaAPwrEO1" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified"&gt;10.00&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zp1OHG0r3gmk" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, Exchanged/Modified"&gt;(2,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z6RbXw0kdMhg" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exchanged/Modified"&gt;7.91&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z4k47XUbV0Nf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;(128&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcihfXXzFDc4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.97&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z3zQdk8OwVLk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z4GuxS4E82l" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1753"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Restricted stock units outstanding at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zpcXx5SInOsh" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;1,079&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zr3VC3Pa3Tzk" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;9.78&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zFXarj62x0Gd" style="font-size: 10pt; text-align: right" title="Number of Restricted Stock Units, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z1aVgoJo0Od5" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Restricted stock units at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zEhKd4WFY34k" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;655&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zptrfDqfPAS" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;10.00&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zvHvN4N3O1ck" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1767"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztr1g4c4adQj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1769"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Restricted stock units at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zN5XjccM0T43" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;843&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z6Vfvyb6UDXj" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;9.93&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zw6vq84NHZei" style="font-size: 10pt; text-align: right" title="Exercisable and vested restricted stock, outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1775"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zAsqLiuFA3Jb" style="font-size: 10pt; text-align: right" title="Weighted Average Grant Date Fair Value, Exercisable and vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001717"
      unitRef="Shares">2995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001719"
      unitRef="USDPShares">9.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      decimals="-3"
      id="Fact001721"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_MarketBasedMember"
      decimals="INF"
      id="Fact001723"
      unitRef="USDPShares">7.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001733"
      unitRef="Shares">188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001735"
      unitRef="USDPShares">9.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001739"
      unitRef="Shares">-1600000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001741"
      unitRef="USDPShares">10.00</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      decimals="-3"
      id="Fact001743"
      unitRef="Shares">-2000000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedInPeriod>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      decimals="INF"
      id="Fact001745"
      unitRef="USDPShares">7.91</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExchangedAndModifiedWeightedAverageGrantDateFairValue>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001747"
      unitRef="Shares">-128000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledInPeriod>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001749"
      unitRef="USDPShares">9.97</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredAndCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001755"
      unitRef="Shares">1079000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001757"
      unitRef="USDPShares">9.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001763"
      unitRef="Shares">655000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001765"
      unitRef="USDPShares">10.00</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001771"
      unitRef="Shares">843000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedVestedAndExpectedToVestExercisableNumber>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001773"
      unitRef="USDPShares">9.93</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      decimals="-5"
      id="Fact001779"
      unitRef="Shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      decimals="-5"
      id="Fact001781"
      unitRef="Shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001783"
      unitRef="USDPShares">4.25</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      id="Fact001785">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      id="Fact001787">P2Y</MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRemainingStockOptionsVesting>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-04-28_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001789"
      unitRef="USDPShares">4.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-04-28_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001791"
      unitRef="USDPShares">4.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      id="Fact001793">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Pure">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001797"
      unitRef="Pure">0.8565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-04-282025-04-28_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001799"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-12-31_custom_TimeBasedMember_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact001801"
      unitRef="USD">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="Fact001803">&lt;p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--TimeBasedMember_zLD0G36Gj603" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A summary of time-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except
for share price and contractual life):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zaIxCcuCKHl7"&gt;Schedule
of Time-Based Stock Option Activity&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 96%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Time-based stock options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zUFfjZngfKX1" style="font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zF8A3iUEoFi5" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 49%; font-size: 10pt"&gt;Exchanged/Modified&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_z8EfKrinwPr" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zXQLEHweryof" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified"&gt;3.75&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zvCgtdBmjcJf" title="Weighted average remaining contractual life (in years), time-based stock options exchanged/modified"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhdt6Ax7uwm4" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1815"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zsNifTcXSWT6" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zL5UIVZTf7v5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zFTQtDvgYof3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Time-based stock options outstanding at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zxeyitO6Lmaj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, time-based stock options outstanding, at the end"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zcbs40YBwQRd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, time-based stock options outstanding"&gt;3.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zPnmRpdpdFrk" title="Weighted average remaining contractual life (in years), time-based stock options outstanding"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zYKJL7GYeGgl" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zrbZX0M8Po8i" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zhELFJfAVxA5" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;1,067&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zu8BnDbm2s9j" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;3.75&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TimeBasedMember_zasVp7qzfOOg" title="Weighted average remaining contractual life (in years), stock options exercisable"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001809"
      unitRef="Shares">1600000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod>
    <MDBH:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001811"
      unitRef="USDPShares">3.75</MDBH:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice>
    <MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="Fact001813">P10Y</MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExchangedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001822"
      unitRef="Shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001824"
      unitRef="USDPShares">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="Fact001826">P9Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="-3"
      id="Fact001832"
      unitRef="Shares">1067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_TimeBasedMember"
      decimals="INF"
      id="Fact001834"
      unitRef="USDPShares">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_TimeBasedMember"
      id="Fact001836">P9Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      decimals="-6"
      id="Fact001838"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      decimals="-6"
      id="Fact001840"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      decimals="INF"
      id="Fact001842"
      unitRef="USDPShares">4.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      id="Fact001844">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <MDBH:AveragePricePerShare
      contextRef="AsOf2025-04-28_custom_MarketBasedMember"
      decimals="INF"
      id="Fact001846"
      unitRef="USDPShares">20.00</MDBH:AveragePricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-04-28_custom_MarketBasedMember"
      decimals="0"
      id="Fact001847"
      unitRef="USDPShares">20.00</us-gaap:SharesIssuedPricePerShare>
    <MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting
      contextRef="From2025-04-282025-04-28_custom_MarketBasedMember"
      id="Fact001849">P10Y</MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1Vesting>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-12-31_us-gaap_PrivatePlacementMember"
      decimals="-5"
      id="Fact001851"
      unitRef="USD">13200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="Fact001853">&lt;p id="xdx_896_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__custom--MarketBasedMember_zSj7a8TViAnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A summary of market-based stock option
activity during the year ended December 31, 2025 and the year ended December 31, 2024 is presented below (in thousands, except for share
price and contractual life):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z7SJ0ngWr4Ha"&gt;Schedule
of Market-Based Stock Option Activity&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life (in Years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Market-based stock options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_znVElCvTtbO" style="font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1855"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_z8bzdP5EKSwa" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 49%; font-size: 10pt"&gt;Exchanged/Modified&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zwhp0TTKRO27" style="width: 13%; font-size: 10pt; text-align: right" title="Number of Options, exchanged/modified"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zPVa6oNLHFD1" style="width: 13%; font-size: 10pt; text-align: right" title="Weighted average exercise price, exchanged/modified"&gt;3.02&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_ztiHtKLirGWa" title="Weighted average remaining contractual life (in years), exchanged/modified"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zOqaMejvrJG5" style="font-size: 10pt; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1865"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zqOF4ETqdDP4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1867"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;Expired/Cancelled&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zZNzSIxvM2N6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of Options, expired/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1869"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zpF6y5AKNak" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, expired/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1871"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Market-based stock options outstanding at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zb28UOMM6DM7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of Options, market-based stock options outstanding, at the end"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zCjLE2mChIg5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, market-based stock options outstanding"&gt;3.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zDhONlxIRaGa" title="Weighted average remaining contractual life (in years), market-based stock options outstanding"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zHZbRNuMefMk" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1879"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zM9LuLdr3QY4" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Stock options exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zWSW0D39vlN6" style="font-size: 10pt; text-align: right" title="Number of Options, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1883"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--MarketBasedMember_zcmQYB5a4R01" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, stock options exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1885"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      decimals="-3"
      id="Fact001859"
      unitRef="Shares">2000000</MDBH:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriod>
    <MDBH:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      decimals="INF"
      id="Fact001861"
      unitRef="USDPShares">3.02</MDBH:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangedAndModifiedInPeriodWeightedAverageExercisePrice>
    <MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="Fact001863">P10Y</MDBH:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingExchangedAndModifiedWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      decimals="-3"
      id="Fact001873"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_MarketBasedMember"
      decimals="INF"
      id="Fact001875"
      unitRef="USDPShares">3.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_MarketBasedMember"
      id="Fact001877">P9Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001887">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z4AFW1sconlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;8. &lt;span id="xdx_825_zs0b4gwQ1qIj"&gt;Earnings Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s computation of
earnings (loss) per share (&#x201c;EPS&#x201d;) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable
to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but
presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if
they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive
effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Loss per common share is computed by
dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted
loss per common share was the same for all periods presented because stock warrants outstanding were anti-dilutive, for a total of &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z87kbfmkXFh2" title="Anti-dilutive shares"&gt;43&lt;/span&gt;
thousand warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Earning Earnings per share is presented
below for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zVPR881P9PVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Basic earnings per share is calculated
at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zkaqjXOfKsOg" style="display: none"&gt;Schedule
of Basic and Fully Diluted&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsKeAY7lHbP4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqhdj2uVj8o" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z36dGnq7Fvc8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zx6NEZoPZlae" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;For
    the Years Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    A Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    B Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    A Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    B Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zXbCmKGZ1m5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Net income (loss) attributable to MDB Capital
    Holdings, LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10,768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10,477&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,817&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,875&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_zdsrVE2OJzT5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,424&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_z2P4Xqk9dke1" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Net income (loss) per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2.14&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.18&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Fully diluted earnings per share is
calculated at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_49C_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkBtQU8M7Ca2" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_492_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpgRvnXgjrMj" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_49B_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJViQEtjkvYh" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_49C_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zADIBaE7C4Dk" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class A Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class B Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class A Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class B Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zvw8leYB2UVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; font-size: 10pt; text-align: left"&gt;Net income (loss) attributable to MDB Capital Holdings, LLC&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(11,714&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(9,531&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;7,650&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;4,042&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_zMBcPh8ZtcTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Diluted shares outstanding &#x2013;diluted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;6,145&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9,463&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zbLkXkAoW93g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net income (loss) per share &#x2013;diluted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1.91&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1.91&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.81&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.81&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zPauISGOoIgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Class A Common Shares and Class B common
stock are equal for ownership purposes, but Class B shares have five times the voting rights of Class A shares and Class B shares can
be exchanged on a one-to-one basis for purposes of sale.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact001889"
      unitRef="Shares">43000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001891">&lt;p id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zVPR881P9PVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Basic earnings per share is calculated
at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zkaqjXOfKsOg" style="display: none"&gt;Schedule
of Basic and Fully Diluted&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zsKeAY7lHbP4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zqhdj2uVj8o" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z36dGnq7Fvc8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zx6NEZoPZlae" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; display: none; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;For
    the Years Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    A Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    B Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    A Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Class
    B Common Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zXbCmKGZ1m5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Net income (loss) attributable to MDB Capital
    Holdings, LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10,768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(10,477&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,817&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,875&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_zdsrVE2OJzT5" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Weighted average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,023&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,424&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-size: 10pt; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_pid_z2P4Xqk9dke1" style="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Net income (loss) per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2.14&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(2.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1.18&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Fully diluted earnings per share is
calculated at follows for the years ended December 31, 2025 and 2024 (in thousands, except for share price):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_49C_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zkBtQU8M7Ca2" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_492_20250101__20251231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zpgRvnXgjrMj" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_49B_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJViQEtjkvYh" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_49C_20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zADIBaE7C4Dk" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class A Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class B Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class A Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Class B Common Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_zvw8leYB2UVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; font-size: 10pt; text-align: left"&gt;Net income (loss) attributable to MDB Capital Holdings, LLC&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(11,714&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;(9,531&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;7,650&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; font-size: 10pt; text-align: right"&gt;4,042&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_zMBcPh8ZtcTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Diluted shares outstanding &#x2013;diluted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;6,145&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9,463&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_pid_zbLkXkAoW93g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Net income (loss) per share &#x2013;diluted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1.91&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(1.91&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.81&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;0.81&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001893"
      unitRef="USD">-10768000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001894"
      unitRef="USD">-10477000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001895"
      unitRef="USD">5817000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001896"
      unitRef="USD">5875000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001898"
      unitRef="Shares">5023000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001899"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001900"
      unitRef="Shares">4424000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001901"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001903"
      unitRef="USDPShares">-2.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001904"
      unitRef="USDPShares">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001905"
      unitRef="USDPShares">1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001906"
      unitRef="USDPShares">1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001908"
      unitRef="USD">-11714000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001909"
      unitRef="USD">-9531000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001910"
      unitRef="USD">7650000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001911"
      unitRef="USD">4042000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001913"
      unitRef="Shares">6145000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001914"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact001915"
      unitRef="Shares">9463000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact001916"
      unitRef="Shares">5000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001918"
      unitRef="USDPShares">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001919"
      unitRef="USDPShares">-1.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001920"
      unitRef="USDPShares">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact001921"
      unitRef="USDPShares">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001923">&lt;p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zy5DaESs1tE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;9. &lt;span id="xdx_82A_zRReezvqviBl"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The principal members of the Company
have a controlling interest in PatentVest, S.A. (renamed MDB Capital, S.A. in 2022), a company organized and based in Nicaragua that provides
outsourced services to the Company and other non-related entities. During the years ended December 31, 2025 and 2024, the Company paid
$&lt;span id="xdx_909_eus-gaap--CostsAndExpensesRelatedParty_pn5n6_c20250101__20251231_zFmmqfEy9S5d" title="Related party expenses"&gt;1.8 &lt;/span&gt;million and $&lt;span id="xdx_907_eus-gaap--CostsAndExpensesRelatedParty_pn5n6_c20240101__20241231_zIAJB4tlmxZc" title="Related party expenses"&gt;1.5&lt;/span&gt; million, respectively, which is inclusive of expenses and fees, for contracted labor, recorded against general and
administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the years ended December 31,
2025 and 2024, PatentVest, engaged in transactions with ENDRA Life Sciences Inc &#x2013; NDRA on Nasdaq, a company for which one of our
executive officer serve as a board member. Anthony DiGiandomenico, our Chief of Transactions. For the year ended December 31, 2024, there
were no revenues recognized between MDB entities and ENDRA. However, costs incurred amounting to $&lt;span id="xdx_906_eus-gaap--OperatingExpenses_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ENDRAMember_zry4x5xp5rGl"&gt;81&lt;/span&gt; thousand
related to transactions with ENDRA were recognized during the year. For the year ended December 31, 2025 there was no revenue or costs
recognized during the year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the years ended December
31, 2025 and 2024, PatentVest engaged in transactions with eXoZymes, a company of which the Company owns 47% of recognized revenues
of $&lt;span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExozymesMember_zIwL0dXdKU0d"&gt;91&lt;/span&gt;
thousand and $&lt;span id="xdx_90C_eus-gaap--Revenues_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExozymesMember_zkt2EhGbubua"&gt;41&lt;/span&gt;
thousand.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2025, the Company recorded related party accrued receivables totaling $&lt;span id="xdx_907_eus-gaap--InterestReceivable_iI_pn3n3_c20251231_zrxbUWq1s0k2" title="Interest receivable"&gt;13&lt;/span&gt; thousand for services performed by PatentVest on behalf of eXoZymes.
Additionally, the Company recorded accrued expenses of $&lt;span id="xdx_905_ecustom--AccruedExpenses_iI_pn3n3_c20251231_zZOjUc2ayASh" title="Accrued expenses"&gt;1&lt;/span&gt; thousand payable to PatentVest, representing reimbursable expenses incurred
in the ordinary course of business. During the year ended December 31, 2024, the Company recorded related party accrued receivables totaling
$&lt;span id="xdx_90F_eus-gaap--InterestReceivable_iI_pn3n3_c20241231_zgM48hmwSoa1" title="Interest receivable"&gt;64&lt;/span&gt; thousand. This amount includes $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn3n3_c20240101__20241231_z9ulUjPQSuM1" title="Value issued for services"&gt;42&lt;/span&gt; thousand for services performed by PatentVest on behalf of eXoZymes and $&lt;span id="xdx_903_eus-gaap--IncomeTaxesPaid_pn3n3_c20240101__20241231_zrGqj35yvBkj" title="Tax paid"&gt;22&lt;/span&gt; thousand related to
taxes paid by the Company on behalf of certain officers, which was reimbursed in full by January 31, 2025. Additionally, the Company recorded
accrued expenses of $&lt;span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_c20241231_zR1FMnEN4Kz8" title="Accrued liabilities"&gt;23&lt;/span&gt; thousand payable to officers and directors, representing reimbursable expenses incurred in the ordinary course
of business. All transactions were conducted on an arm&#x2019;s-length basis and are expected to be settled in the normal course of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001925"
      unitRef="USD">1800000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001927"
      unitRef="USD">1500000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_ENDRAMember"
      decimals="-3"
      id="Fact001928"
      unitRef="USD">81000</us-gaap:OperatingExpenses>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_ExozymesMember5372140"
      decimals="-3"
      id="Fact001929"
      unitRef="USD">91000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_ExozymesMember"
      decimals="-3"
      id="Fact001930"
      unitRef="USD">41000</us-gaap:Revenues>
    <us-gaap:InterestReceivable
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001932"
      unitRef="USD">13000</us-gaap:InterestReceivable>
    <MDBH:AccruedExpenses
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001934"
      unitRef="USD">1000</MDBH:AccruedExpenses>
    <us-gaap:InterestReceivable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001936"
      unitRef="USD">64000</us-gaap:InterestReceivable>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001938"
      unitRef="USD">42000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001940"
      unitRef="USD">22000</us-gaap:IncomeTaxesPaid>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001942"
      unitRef="USD">23000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001944">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zE7XaO71sRXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;10. &lt;span id="xdx_82D_zBhnqu6KJad7"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Legal Claims&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company may be subject to legal
claims and actions from time to time as part of its business activities. As of December 31, 2025 and 2024, the Company was not subject
to any pending or threatened legal claims or actions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Net Capital Requirement (Public
Ventures)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Public Ventures is subject to the uniform
net capital rule (SEC Rule 15c3-1) of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), which requires both the maintenance
of minimum net capital and the maintenance of maximum ratio of aggregate indebtedness to net capital. At December 31, 2025 and 2024, Public
Ventures had net capital of $&lt;span id="xdx_90D_esrt--NetCapital_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_z11nfEJ8vmEg" title="Net capital"&gt;8.7&lt;/span&gt; million and $&lt;span id="xdx_907_esrt--NetCapital_iI_pn5n6_c20241231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_z4BaHx3yrAG8" title="Net capital"&gt;10.7&lt;/span&gt; million, respectively, which was $&lt;span id="xdx_90F_esrt--NetCapital_iI_pn4n6_c20251231_zmHNoXFBvw3c" title="Net capital"&gt;8.45&lt;/span&gt; million and $&lt;span id="xdx_900_esrt--NetCapital_iI_pn4n6_c20241231_zrjiJslOYAQi" title="Net capital"&gt;10.45&lt;/span&gt; million in excess of the
minimum $&lt;span id="xdx_90C_esrt--NetCapital_iI_pn3n3_c20241231__srt--RangeAxis__srt--MinimumMember_z7dvS3CN8DP" title="Net capital"&gt;250&lt;/span&gt; thousand, as required by the Securities and Exchange Commission Rule 15c3-1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the year ended December 31,
2025, the broker dealer had existing subordinated loans with MDB, the Parent company, totaling $&lt;span id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_zTE1SPbeHWl5" title="Loans payable"&gt;13.2&lt;/span&gt; million and $&lt;span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn5n6_c20251231__srt--TitleOfIndividualAxis__custom--PublicVenturesMember_zF6aug1UB27e" title="Interest expense"&gt;1.0&lt;/span&gt; million of accrued interest
payable, is subordinated to other liabilities of the Company, and is considered members&#x2019; equity for calculating net capital, and
is not included in aggregate indebtedness.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Minimum net capital is based upon
the greater of the statutory minimum net capital of $&lt;span id="xdx_90D_esrt--NetCapital_iI_pn3n3_c20251231__srt--RangeAxis__srt--MinimumMember_zVgCntn59agb" title="Net capital"&gt;250&lt;/span&gt;
thousand or &lt;span id="xdx_906_eus-gaap--RatioOfIndebtednessToNetCapital1_iI_pid_dp_uPure_c20251231_zIFVH3ucJoTl" title="Percentage of aggregate indebtedness"&gt;2&lt;/span&gt;%
of aggregate customer debits, which were $&lt;span id="xdx_90B_esrt--MinimumNetCapitalRequiredForEntity1_iI_c20251231_z59sN8Ojxkok" title="Aggregate indebtedness calculated amount"&gt;&lt;span id="xdx_90D_esrt--MinimumNetCapitalRequiredForEntity1_iI_c20241231_zekO2MN0yzr7" title="Aggregate indebtedness calculated amount"&gt;0&lt;/span&gt;&lt;/span&gt;
at December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;To comply with DTCC membership requirements,
the Company has committed to maintain at least $&lt;span id="xdx_907_esrt--NetCapital_iI_pn5n6_c20251231__us-gaap--AwardTypeAxis__custom--DTCMembershipRequirementsMember_zA4hJ1U0Of79" title="Net capital"&gt;5.0&lt;/span&gt; million of net capital in excess of the $&lt;span id="xdx_905_esrt--NetCapital_iI_pn3n3_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--DTCMembershipRequirementsMember_zgh8tzyFYTZ" title="Net capital"&gt;250&lt;/span&gt; thousand minimum.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;The requirement
to comply with the Uniform Net Capital Rule 15c3-1 may limit Public Ventures&#x2019; ability to issue dividends to its parent company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;Indemnification Provisions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Public Ventures has agreed to indemnify
its clearing broker for losses that the clearing brokers may sustain from the accounts of customers. Should a customer not fulfill its
obligation on a transaction, Public Ventures may be required to buy or sell securities at prevailing market prices in the future on behalf
of its customer. The indemnification obligations of Public Ventures to its clearing brokers have no maximum amount. All unsettled trades
at December 31, 2025 and 2024, have subsequently settled with no resulting material liability to Public Ventures. For the years ended
December 31, 2025 and 2024, Public Ventures, had no material loss due to counterparty failure and had no obligations outstanding under
the indemnification arrangement as of December 31, 2025 and 2024.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <srt:NetCapital
      contextRef="AsOf2025-12-31_custom_PublicVenturesMember"
      decimals="-5"
      id="Fact001946"
      unitRef="USD">8700000</srt:NetCapital>
    <srt:NetCapital
      contextRef="AsOf2024-12-31_custom_PublicVenturesMember"
      decimals="-5"
      id="Fact001948"
      unitRef="USD">10700000</srt:NetCapital>
    <srt:NetCapital
      contextRef="AsOf2025-12-31"
      decimals="-4"
      id="Fact001950"
      unitRef="USD">8450000</srt:NetCapital>
    <srt:NetCapital
      contextRef="AsOf2024-12-31"
      decimals="-4"
      id="Fact001952"
      unitRef="USD">10450000</srt:NetCapital>
    <srt:NetCapital
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="-3"
      id="Fact001954"
      unitRef="USD">250000</srt:NetCapital>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-12-31_custom_PublicVenturesMember"
      decimals="-5"
      id="Fact001956"
      unitRef="USD">13200000</us-gaap:LoansPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_PublicVenturesMember"
      decimals="-5"
      id="Fact001958"
      unitRef="USD">1000000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <srt:NetCapital
      contextRef="AsOf2025-12-31_srt_MinimumMember"
      decimals="-3"
      id="Fact001960"
      unitRef="USD">250000</srt:NetCapital>
    <us-gaap:RatioOfIndebtednessToNetCapital1
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001962"
      unitRef="Pure">0.02</us-gaap:RatioOfIndebtednessToNetCapital1>
    <srt:MinimumNetCapitalRequiredForEntity1
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001964"
      unitRef="USD">0</srt:MinimumNetCapitalRequiredForEntity1>
    <srt:MinimumNetCapitalRequiredForEntity1
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001966"
      unitRef="USD">0</srt:MinimumNetCapitalRequiredForEntity1>
    <srt:NetCapital
      contextRef="AsOf2025-12-31_custom_DTCMembershipRequirementsMember"
      decimals="-5"
      id="Fact001968"
      unitRef="USD">5000000.0</srt:NetCapital>
    <srt:NetCapital
      contextRef="AsOf2025-12-31_srt_MinimumMember_custom_DTCMembershipRequirementsMember"
      decimals="-3"
      id="Fact001970"
      unitRef="USD">250000</srt:NetCapital>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001972">&lt;p id="xdx_807_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z3dzmvQHZyh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;11. &lt;span id="xdx_829_zUIoaJuN5tyh"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;MDB Management and eXoZymes, both sponsored individual 401(k) defined contribution plans for the benefit of each company&#x2019;s eligible employees.
Public Ventures offered its employees a sponsored 401(k) defined contribution plan for the benefit of the employees; this plan was terminated
on July 30, 2021. The plans allow eligible employees to contribute a portion of their annual compensation, not to exceed annual limits
established by the Department of Treasury. eXoZymes makes matching contributions for participating employees up to a certain percentage
of the employee contributions; matching contributions were funded for the year ended December 31, 2025 and 2024. Benefits under the eXoZymes
plan were available to all employees, and employees become fully vested in the employer contribution upon receipt. For the year ended
December 31, 2025 and 2024, a total of $&lt;span id="xdx_908_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20250101__20251231_zXwZ4CApO8Y3" title="Employer contribution"&gt;392&lt;/span&gt; thousand and $&lt;span id="xdx_905_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20240101__20241231_zJ8wKeNAW0Zd" title="Employer contribution"&gt;659&lt;/span&gt; thousand, respectively, was contributed to the plans. The costs for eXoZymes
are recorded up to November 14, 2024, the date of the consolidation of eXoZymes. The majority of the expense was included in general and
administrative cost, however, for any research and development employees. their portion of the expense is recorded in research and
development costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;MDB Management and eXoZymes also provide
health and related benefit plans for eligible employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001974"
      unitRef="USD">392000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001976"
      unitRef="USD">659000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <MDBH:ExclusiveLicenseAgreementTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001978">&lt;p id="xdx_803_ecustom--ExclusiveLicenseAgreementTextBlock_zV9KIqd4mTGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;12. &lt;span id="xdx_82D_zo4jPDpO1Wc5"&gt;Exclusive License Agreement (MDB Minnesota
One)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On July 1, 2024, M1 entered into a Patent and Know-How License Agreement (the &#x201c;License Agreement&#x201d;) with the Mayo for certain patent rights and associated technology pursuant to which M1 intends
to develop a small molecule senescence platform. The License Agreement grants M1 rights to develop and commercialize Mayo&#x2019;s patented
technology and know-how for all fields of use on a worldwide basis. Under the terms of the License Agreement, M1 holds an exclusive license
of patent rights and a non-exclusive license for the associated technology to make, have made, use, offer for sale, sell, and import licensed
products and derivatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As part of initial consideration for
the License Agreement, M1 issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn4n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zXwIuoAClVte" title="Issuance of shares"&gt;1.98&lt;/span&gt; million shares of common stock equity to Mayo; which at that time represented thirty-three percent
of its shares. M1 also paid an initial license fee of $&lt;span id="xdx_903_eus-gaap--ProceedsFromLicenseFeesReceived_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zyQ6VkdsixKj" title="License fee"&gt;150&lt;/span&gt; thousand as part of the initial consideration. M1 will pay earned royalties
on future net sales (including modest minimum annual royalties, which commence in the second year of the term of the License Agreement
and gradually increase and plateau over time, and which will be credited against earned royalties due on net sales), and a percentage
of any sublicensing income. The earned royalty commences after the first commercial sale of a licensed product. At December 31, 2025 there
were no accrued royalties recorded.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Under the License Agreement, M1 is
required to achieve certain development milestones within designated time periods. For select development milestones, as listed below,
M1 will be required to make a payment to Mayo, also as noted below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; padding-left: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A payment of $&lt;span id="xdx_90C_ecustom--PaymentForLicensedProducts_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseIIclinicalMember_zmfcbZj7oNz3" title="Payments for licensed products"&gt;250&lt;/span&gt; thousand for Phase II clinical trial initiation, for the first instance of a licensed product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A payment of $&lt;span id="xdx_900_ecustom--PaymentForLicensedProducts_pn5n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseIIIclinicalMember_zH9qxrElD2j6" title="Payments for licensed products"&gt;1.5&lt;/span&gt; million for Phase III clinical trial initiation, for the first instance of a licensed product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A payment of $&lt;span id="xdx_908_ecustom--PaymentForLicensedProducts_pn6n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NewDrugApplicationFirstMember_zS3M5Iu2Ert6" title="Payments for licensed products"&gt;2&lt;/span&gt; million for FDA New Drug Application (NDA) acceptance, for the first instance of a licensed product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding-left: 0.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A payment of $&lt;span id="xdx_909_ecustom--PaymentForLicensedProducts_pn6n6_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NewDrugApplicationMember_zUwBkglZ7Qla" title="Payments for licensed products"&gt;5&lt;/span&gt; million for NDA approval, for each instance of a licensed product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2025 the development
milestones noted above are not required to have been met and have not been met. There are other developmental milestones in the License
Agreement relating to funding of the business and to initiating various clinical trial phases over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;If M1 materially breaches the terms
of the License Agreement, and such material breach remains uncured after an opportunity to cure, Mayo may terminate the License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

</MDBH:ExclusiveLicenseAgreementTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_custom_LicenseAgreementMember"
      decimals="-4"
      id="Fact001980"
      unitRef="Shares">1980000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="From2025-01-012025-12-31_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact001982"
      unitRef="USD">150000</us-gaap:ProceedsFromLicenseFeesReceived>
    <MDBH:PaymentForLicensedProducts
      contextRef="From2025-01-012025-12-31_custom_PhaseIIclinicalMember"
      decimals="-3"
      id="Fact001984"
      unitRef="USD">250000</MDBH:PaymentForLicensedProducts>
    <MDBH:PaymentForLicensedProducts
      contextRef="From2025-01-012025-12-31_custom_PhaseIIIclinicalMember"
      decimals="-5"
      id="Fact001986"
      unitRef="USD">1500000</MDBH:PaymentForLicensedProducts>
    <MDBH:PaymentForLicensedProducts
      contextRef="From2025-01-012025-12-31_custom_NewDrugApplicationFirstMember"
      decimals="-6"
      id="Fact001988"
      unitRef="USD">2000000</MDBH:PaymentForLicensedProducts>
    <MDBH:PaymentForLicensedProducts
      contextRef="From2025-01-012025-12-31_custom_NewDrugApplicationMember"
      decimals="-6"
      id="Fact001990"
      unitRef="USD">5000000</MDBH:PaymentForLicensedProducts>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001992">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zUK2O2odT5s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;13. &lt;span id="xdx_82C_zUOBdiWmOTd7"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;For operating leases, the Company records
right-of-use assets and corresponding lease liabilities in the consolidated balance sheets for all leases with terms longer than twelve
months. The Company has one operating leases, with no variable lease costs, and no finance leases as of December 31, 2025. The Company
has three operating leases, with no variable lease costs, and no finance leases as of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;eXoZymes was consolidated up to November 14, 2024. In October 2023, eXoZymes, made changes to an existing lease agreement that was originally entered
into in August 2021, which resulted in an extension of the lease term by an additional 14 months. The revised lease maintained the same
escalation rate for lease payments as the previous arrangement. To account for this modification, the Company reevaluated the remaining
lease term at the time of execution. As the Company was actively utilizing the premises, adjustments were made to reflect the revaluation
of both the right-to-use asset and the corresponding lease liability in line with the updated lease term. This was originally entered
into in August 2021, with a term of 60 months beginning on August 24, 2021 and ending on September 30, 2026, with an option to extend
for 60 additional months and was further modified on April 3, 2023 for an additional 21 months with the lease ending date of April 30,
2028. At the time the lease commenced, it was not probable the Company would exercise the one five-year option to extend the facility
lease; therefore, this extension option is not included in the lease analysis. The initial base rent is $&lt;span id="xdx_906_eus-gaap--AdvanceRent_iI_pn2n3_c20230403_zOrb49EBqXHh" title="Initial rent, per month"&gt;14.3&lt;/span&gt; thousand per month. The
lease provides for annual increases. The base rent for the lease in the final year is $&lt;span id="xdx_906_ecustom--BaseRent_iI_pn2n3_c20230403_zHHhl4ENM1w3" title="Base rent, per month"&gt;16.7&lt;/span&gt; thousand per month. Additionally, eXoZymes
was responsible for annual operating cost increases of &lt;span id="xdx_906_ecustom--AnnualOperatingCostIncreasePercentage_pid_dp_uPure_c20230403__20230403_zfYeAiywufni" title="Annual operating cost increase percentage"&gt;2.5&lt;/span&gt;%, which are included in the rent. Since eXoZymes is not consolidated for 2025,
the information above was only calculated for 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Furthermore, in October 2023, eXoZymes
made changes to a second existing lease agreement that was originally entered into in April 2023, which resulted in an extension of the
lease term by an additional &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20231031_zbZkClSu4JY4" title="Extension term of lease"&gt;12&lt;/span&gt; months. The revised lease maintained the same escalation rate for lease payments as the previous arrangement.
To account for this modification, the Company reevaluated the remaining lease term at the time of execution. As the Company was actively
utilizing the premises, adjustments were made to reflect the revaluation of both the right-to-use asset and the corresponding lease liability
in line with the updated lease term. This was originally entered into in April 2023, with a term of &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20230430_zlnbAds7lC0c" title="Lease term"&gt;60&lt;/span&gt; months beginning on July 1, 2023
and ending on June 30, 2028, with an &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20231001__20231031_zwS4zRfsuX66" title="Option to extend"&gt;option to extend for 60 additional months&lt;/span&gt;. At the time the lease commenced, it was not probable the
Company would exercise the one five-year option to extend the facility lease; therefore, this extension option is not included in the
lease analysis. The initial base rent is $&lt;span id="xdx_90B_eus-gaap--AdvanceRent_iI_pn2n3_c20231031_zimDouZf19Fl" title="Initial rent, per month"&gt;13.3&lt;/span&gt; thousand per month. The lease provides for annual increases. The base rent for the lease
in the final year is $&lt;span id="xdx_909_ecustom--BaseRent_iI_pn2n3_c20231031_zOOUjB2LxYZ2" title="Base rent, per month"&gt;15.4&lt;/span&gt; thousand per month. Additionally, eXoZymes is responsible for annual operating cost increases of &lt;span id="xdx_900_ecustom--AnnualOperatingCostIncreasePercentage_pid_dp_uPure_c20231001__20231031_zMpkMVYzYn64" title="Annual operating cost increase percentage"&gt;3.0&lt;/span&gt;%, which
are included in the rent. Since eXoZymes is not consolidated for 2024, the information above is only calculated for 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On July 1, 2022 the Company executed
a lease for new office space in the Dallas, Texas metropolitan area, the space was occupied on December 20, 2022. The lease with a term
of &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20220701_z8jj1P3YxUP4" title="Lease term"&gt;91&lt;/span&gt; months and began once we took control of the space on December 20, 2022 and ending on July 20, 2030, without an option to extend.
The initial base rent was $&lt;span id="xdx_90A_eus-gaap--AdvanceRent_iI_pn2n3_c20220701_zgbc6wWnRQSa" title="Initial rent, per month"&gt;12.6&lt;/span&gt; thousand per month, after 7 months of free rent. The lease provides for annual increases. The base rent
for the lease in the final year is $&lt;span id="xdx_90E_ecustom--BaseRent_iI_pn2n3_c20220701_zs9C7KhoVuNi" title="Base rent, per month"&gt;13.9&lt;/span&gt; thousand per month.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term, and lease liabilities represent the Company&#x2019;s obligation to make lease payments.
Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments
over the lease term. The Company&#x2019;s uses the implicit rate in its lease calculations when it is readily determinable. Since the Company&#x2019;s
leases do not provide implicit rates, to determine the present value of lease payments, management uses the Company&#x2019;s estimated
incremental borrowing rate for a fully collateralized loan with a similar term of the lease that is based on the information available
at the inception of the lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--LeaseCostTableTextBlock_zcyi91Cll9N7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zYDZFo55hxxa" style="display: none"&gt;Schedule
of Operating Lease Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231_zCKawW5PDac1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zjzFaqA7Ev74" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;For the years ended&lt;br/&gt; December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating leases:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGoaBcBEOIbe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;547&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;641&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zRFElbfZ4ZSj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;609&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;711&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Weighted average remaining lease term in years&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0EjF7nH5IDj" title="Weighted average remaining lease term in years"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z0RqdCP4mfr3" title="Weighted average remaining lease term in years"&gt;5.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zmt9KFdlbMb5" style="font-size: 10pt; text-align: right" title="Weighted average discount rate"&gt;7.80&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zGXmDHvaklDb" style="font-size: 10pt; text-align: right" title="Weighted average discount rate"&gt;7.80&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20250101__20251231_zxj2KKkAE6W5" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities"&gt;155&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20240101__20241231_zgaMVKNdJDza" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities"&gt;152&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20250101__20251231_zURnBbXxJzlk" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2038"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zhuGuRj2fZg6" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2040"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseCost_pn3n3_c20250101__20251231_zuuKVtWVIzRd" style="font-size: 10pt; text-align: right" title="Operating lease cost"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseCost_pn3n3_c20240101__20241231_zeyRz5xTtDD3" style="font-size: 10pt; text-align: right" title="Operating lease cost"&gt;147&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Short-term lease costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShortTermLeaseCost_pn3n3_c20250101__20251231_zi4tqVKiEof4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShortTermLeaseCost_pn3n3_c20240101__20241231_zbMTuMMFIOFa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;87&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total operating lease costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20250101__20251231_zv6gYrYFLE72" style="font-size: 10pt; text-align: right" title="Total operating lease costs"&gt;147&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_z09HYx2IOQjb" style="font-size: 10pt; text-align: right" title="Total operating lease costs"&gt;234&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zW7QOwEQ0Fr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv6zURXrkuzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Future payments due under operating
leases for the as of December 31, 2025 are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zw3gXW3FsdC3" style="display: none"&gt;Schedule
of Future payments Due Under Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zzbHKODGLgHg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDS7_zES5JhybPDJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;158&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDS7_zDnAigxsp8bc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;160&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDS7_zxb1Lo3G6KT" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;163&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_maLOLLPzDS7_z9YwNxh7JEbi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;2029 and thereafter&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;259&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDS7_z97i8F0RU613" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-size: 10pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;740&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zqZ6CZSIgoaa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less effects of discounting&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(131&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgjG2x8hK6x" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;609&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zkJVMofiFoji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AdvanceRent
      contextRef="AsOf2023-04-03"
      decimals="-2"
      id="Fact001994"
      unitRef="USD">14300</us-gaap:AdvanceRent>
    <MDBH:BaseRent
      contextRef="AsOf2023-04-03"
      decimals="-2"
      id="Fact001996"
      unitRef="USD">16700</MDBH:BaseRent>
    <MDBH:AnnualOperatingCostIncreasePercentage
      contextRef="From2023-04-032023-04-03"
      decimals="INF"
      id="Fact001998"
      unitRef="Pure">0.025</MDBH:AnnualOperatingCostIncreasePercentage>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-10-31" id="Fact002000">P12M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2023-04-30" id="Fact002002">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2023-10-012023-10-31" id="Fact002004">option to extend for 60 additional months</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:AdvanceRent
      contextRef="AsOf2023-10-31"
      decimals="-2"
      id="Fact002006"
      unitRef="USD">13300</us-gaap:AdvanceRent>
    <MDBH:BaseRent
      contextRef="AsOf2023-10-31"
      decimals="-2"
      id="Fact002008"
      unitRef="USD">15400</MDBH:BaseRent>
    <MDBH:AnnualOperatingCostIncreasePercentage
      contextRef="From2023-10-012023-10-31"
      decimals="INF"
      id="Fact002010"
      unitRef="Pure">0.030</MDBH:AnnualOperatingCostIncreasePercentage>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2022-07-01" id="Fact002012">P91M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AdvanceRent
      contextRef="AsOf2022-07-01"
      decimals="-2"
      id="Fact002014"
      unitRef="USD">12600</us-gaap:AdvanceRent>
    <MDBH:BaseRent
      contextRef="AsOf2022-07-01"
      decimals="-2"
      id="Fact002016"
      unitRef="USD">13900</MDBH:BaseRent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002018">&lt;p id="xdx_894_eus-gaap--LeaseCostTableTextBlock_zcyi91Cll9N7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zYDZFo55hxxa" style="display: none"&gt;Schedule
of Operating Lease Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20251231_zCKawW5PDac1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zjzFaqA7Ev74" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;For the years ended&lt;br/&gt; December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating leases:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zGoaBcBEOIbe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;547&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;641&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zRFElbfZ4ZSj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;609&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;711&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Weighted average remaining lease term in years&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z0EjF7nH5IDj" title="Weighted average remaining lease term in years"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z0RqdCP4mfr3" title="Weighted average remaining lease term in years"&gt;5.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_zmt9KFdlbMb5" style="font-size: 10pt; text-align: right" title="Weighted average discount rate"&gt;7.80&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zGXmDHvaklDb" style="font-size: 10pt; text-align: right" title="Weighted average discount rate"&gt;7.80&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20250101__20251231_zxj2KKkAE6W5" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities"&gt;155&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_c20240101__20241231_zgaMVKNdJDza" style="font-size: 10pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities"&gt;152&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20250101__20251231_zURnBbXxJzlk" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2038"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zhuGuRj2fZg6" style="font-size: 10pt; text-align: right" title="Right-of-use assets obtained in exchange for lease liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2040"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseCost_pn3n3_c20250101__20251231_zuuKVtWVIzRd" style="font-size: 10pt; text-align: right" title="Operating lease cost"&gt;52&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseCost_pn3n3_c20240101__20241231_zeyRz5xTtDD3" style="font-size: 10pt; text-align: right" title="Operating lease cost"&gt;147&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Short-term lease costs&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShortTermLeaseCost_pn3n3_c20250101__20251231_zi4tqVKiEof4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShortTermLeaseCost_pn3n3_c20240101__20241231_zbMTuMMFIOFa" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;87&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total operating lease costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeasePayments_pn3n3_c20250101__20251231_zv6gYrYFLE72" style="font-size: 10pt; text-align: right" title="Total operating lease costs"&gt;147&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_z09HYx2IOQjb" style="font-size: 10pt; text-align: right" title="Total operating lease costs"&gt;234&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002020"
      unitRef="USD">547000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002021"
      unitRef="USD">641000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002023"
      unitRef="USD">609000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002024"
      unitRef="USD">711000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact002026">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact002028">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact002030"
      unitRef="Pure">0.0780</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002032"
      unitRef="Pure">0.0780</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002034"
      unitRef="USD">155000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002036"
      unitRef="USD">152000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002042"
      unitRef="USD">52000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002044"
      unitRef="USD">147000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002045"
      unitRef="USD">95000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002046"
      unitRef="USD">87000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002048"
      unitRef="USD">147000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002050"
      unitRef="USD">234000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002052">&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv6zURXrkuzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Future payments due under operating
leases for the as of December 31, 2025 are as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zw3gXW3FsdC3" style="display: none"&gt;Schedule
of Future payments Due Under Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-size: 10pt; font-weight: bold"&gt;Year&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zzbHKODGLgHg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzDS7_zES5JhybPDJ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; font-size: 10pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;158&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzDS7_zDnAigxsp8bc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;160&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzDS7_zxb1Lo3G6KT" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;163&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_maLOLLPzDS7_z9YwNxh7JEbi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;2029 and thereafter&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;259&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzDS7_z97i8F0RU613" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-size: 10pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;740&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zqZ6CZSIgoaa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less effects of discounting&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(131&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zgjG2x8hK6x" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;609&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002054"
      unitRef="USD">158000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002056"
      unitRef="USD">160000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002058"
      unitRef="USD">163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <MDBH:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002060"
      unitRef="USD">259000</MDBH:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002062"
      unitRef="USD">740000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002064"
      unitRef="USD">131000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002066"
      unitRef="USD">609000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002068">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zJSER0ACJL27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;14. &lt;span id="xdx_820_zqzQhPaHqntg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company is a limited liability
company treated as a partnership for federal and state income tax purposes, with the exception of the state of Texas, in which income
tax liabilities and/or benefits of the Company are passed through to its unitholders. Limited liability companies are subject to Texas
margin tax. Additionally, the Company&#x2019;s subsidiaries, Public Ventures, MDB Management, PatentVest, and M1 are Subchapter&#160;C-corporations
subject to federal and state income taxes. As such, with the exception of the state of Texas and certain subsidiaries, the Company is
not a taxable entity; it does not directly pay federal and state income taxes and recognition has not been given to federal and state
income taxes for the operations of the Company, except as set forth in the tables below. Amounts recognized for income taxes are reported
in &#x201c;income tax expense (benefit)&#x201d; on the consolidated statements of operations.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s taxable income
or loss, which may vary substantially from the net income or net loss reported on the consolidated statements of operations, is includable
in the federal and state income tax returns of each unitholder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zmkUgBiHEERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Income tax expense (benefit) (including
Subchapter C-corporations) consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zfHTorENI9Hc" style="display: none"&gt;Schedule
of Income Taxes Expenses (benefit)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231_zmL8e6kRXQBh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zXFx652RV0j5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Current taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maITEBztXD_zZ7yL2tEhxv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maITEBztXD_zzv7Q7MT9qAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_znPsIyABZBZa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_zNbpwR3ZhDbj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2082"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBztXD_zco7tXUdo9fc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zTgQHL8fh1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 61pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Total cash taxes paid net of refunds
received in 2025 was $&lt;span id="xdx_902_eus-gaap--IncomeTaxesPaid_c20250101__20251231_zP747hdDcI9g" title="Cash taxes paid"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2025, the Company had approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--USFederalTaxMember_zmDmrqeTlnNk" title="Net operating loss carryforwards"&gt;23.3&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityNameAxis__custom--FloridaIncomeTaxMember_zYrsJrIj4bEa" title="Net operating loss carryforwards"&gt;0.1&lt;/span&gt; million of net operating loss carryforwards
for U.S. federal and Florida income tax purposes, respectively. These net operating losses may be carried forward indefinitely&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Effective for the year ended December
31, 2025, the Company adopted ASU 2023-09-Improvements to Income Tax Disclosures, prospectively. The reconciliation of income tax expense (including Subchapter C-corporations)
computed at the U.S. federal statutory income tax rate of 21% to the recognized income tax expense for the year ended December 31, 2025,
presented in accordance with the disclosure requirements of ASU 2023-09-Improvements to Income Tax Disclosures, is as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zThUWxlxqKsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zfl3scupFN3l" style="display: none"&gt;Schedule
of Federal Statutory Tax Rate to The Effective Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;U.S Federal statutory income rate&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20250101__20251231_zAzgeeZpppFj" style="width: 16%; font-size: 10pt; text-align: right" title="U.S Federal statutory income rate, Amount"&gt;(4,463&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20250101__20251231_zFxJyMOFBuA4" title="U.S Federal statutory income rate, Rate"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;State, net of federal tax benefit&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20250101__20251231_zbXy9kIlY7wl" style="font-size: 10pt; text-align: right" title="State, net of federal tax benefit, Amount"&gt;9&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20250101__20251231_zMr0pwJiICR1" title="State, net of federal tax benefit, Rate"&gt;(0.04&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Income/loss excluded from nontaxable entities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20250101__20251231_zfzJQFRskkMi" style="font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;944&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20250101__20251231_zhyVeG40ffe1" title="Income/loss excluded from nontaxable entities, Rate"&gt;(4.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_zBXuJlTncBea" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-left: 10pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_zJdrdulDazCc" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-left: 10pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Meals and entertainment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maMahiYA_c20250101__20251231_z0QGSTT1dyMj" style="font-size: 10pt; text-align: right" title="Meals and entertainment, Amount"&gt;7&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_maKamaLI_c20250101__20251231_zprancH9EwFl" title="Meals and entertainment, Rate"&gt;(0.04&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Stock options&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maMahiYA_c20250101__20251231_zQWDLG7PYlDh" style="font-size: 10pt; text-align: right" title="Stock options, Amount"&gt;614&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maKamaLI_c20250101__20251231_zltTUL71zoP2" title="Stock options, Rate"&gt;(3.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Equity award vesting&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IncomeTaxReconciliationEquityInEquityAwardVestingAmount_pn3n3_maMahiYA_c20250101__20251231_zcq5YDq12oxd" style="font-size: 10pt; text-align: right" title="Equity award vesting, Amount"&gt;248&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_pid_dp_uPure_maKamaLI_c20250101__20251231_zqlTNBcH1AP" title="Equity award vesting, Rate"&gt;(1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Modification of equity awards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncomeTaxReconciliationModificationOfEquityAwardsAmount_pn3n3_maMahiYA_c20250101__20251231_z3WSaoPZkhS2" style="font-size: 10pt; text-align: right" title="Modification of equity awards, Amount"&gt;2,194&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maKamaLI_c20250101__20251231_zZ9V0lzmB0q9" title="Equity award vesting, Rate"&gt;(10.95&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Return-to-provision adjustments&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20250101__20251231_zRrcBz3dkZSl" style="font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount"&gt;(44&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20250101__20251231_zW6LSLqiL1nc" title="Return-to-provision adjustments, Rate"&gt;0.22&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_zWIBshQTkSc6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_zOBsHs9AIRxh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20250101__20251231_zvBKtMBpy216" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance, Amount"&gt;502&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20250101__20251231_zH8KcsFkBxYa" title="Valuation allowance, Rate"&gt;(2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Effective rate&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20250101__20251231_zL9SnUxJsz4f" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Effective rate, Amount"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20250101__20251231_zXDBeGuz56c7" title="Effective rate, Rate"&gt;(0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A reconciliation of the federal
statutory tax rate to the effective tax rate (including Subchapter&#160;C-corporations) for the year ended December 31, 2024 and
2024 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S Federal statutory
    income rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20240101__20241231_z5gZGmcJCLba" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S Federal statutory income rate, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,453&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20240101__20241231_zUkTSgGBrsNk" title="U.S Federal statutory income rate, Rate"&gt;21.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State, net of federal tax
    benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20240101__20241231_z055pwdywtk2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State, net of federal tax benefit, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(246&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20240101__20241231_zvUxl03iC6W3" title="State, net of federal tax benefit, Rate"&gt;(2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income/loss excluded from
    nontaxable entities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20240101__20241231_zCS3MINvK0Ag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20240101__20241231_zbH5oGARhAbf" title="Income/loss excluded from nontaxable entities, Rate"&gt;(68.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maMahiYA_c20240101__20241231_zLDKKFiB4Zxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Permanent differences, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zcJdGiB4y7ck" title="Permanent differences, Rate"&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Return-to-provision adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20240101__20241231_zyah9TbCQK0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Return-to-provision adjustments, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zTmjsZdVVGtg" title="Return-to-provision adjustments, Rate"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maMahiYA_c20240101__20241231_zIHFoGxynuai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;192&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKamaLI_c20240101__20241231_zbTPDKiJGemb" title="Other, Rate"&gt;1.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20240101__20241231_zc4fcKcW0Pbh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20240101__20241231_zUobJyjPhofk" title="Valuation allowance, Rate"&gt;42.52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20240101__20241231_zlpCL3taBE1k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective rate, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20240101__20241231_zLq7wG2Fh661" title="Effective rate, Rate"&gt;0.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zW4pGONifQD1" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Start-up expenditures&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Organizational expenditures&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Sec 174 &#x2013; Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2182"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,795&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,524&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Lease liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;128&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;149&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Property and equipment principally due to differences in depreciation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Bonus expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2195"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Charitable contribution carryforwards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Impairment expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;53&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Intangible Assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;51&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;38&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,890&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,781&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(6,625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(6,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(115&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Investment securities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(264&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets/(liabilities)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Other noncurrent assets/(liabilities)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2236"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zTugmM3Fiugi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In assessing the realizability of deferred
tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which
those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. At December&#160;31, 2025, based on projections of future taxable
income for the periods in which the deferred tax assets are deductible, a valuation allowance of approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pn5n6_c20251231_zrhos06hqse4" title="Decrease in deferred tax assets valuation allowance"&gt;6.6&lt;/span&gt; million was recorded
for tax carry forwards and attributes to reduce the net deferred tax assets to an amount that is more likely than not to be recognized.
The amount of deferred tax assets considered realizable could be reduced in the future if estimates of future taxable income during the
carry forward period are reduced.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In accordance with the applicable accounting
standards, the Company recognizes only the impact of income tax positions that, based on their merits, are more likely than not to be
sustained upon audit by a taxing authority. To evaluate its current tax positions in order to identify any material uncertain tax positions,
the Company developed a policy of identifying and evaluating uncertain tax positions that considers support for each tax position, industry
standards, tax return disclosures and schedules and the significance of each position. It is the Company&#x2019;s policy to recognize interest
and penalties, if any, related to unrecognized tax benefits in income tax expense. The Company had no material uncertain tax positions
at December&#160;31, 2025 and December&#160;31, 2024. The tax years 2022 &#x2013; 2025 remain open to examination for federal income tax
purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002070">&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zmkUgBiHEERg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Income tax expense (benefit) (including
Subchapter C-corporations) consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zfHTorENI9Hc" style="display: none"&gt;Schedule
of Income Taxes Expenses (benefit)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231_zmL8e6kRXQBh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zXFx652RV0j5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Current taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maITEBztXD_zZ7yL2tEhxv1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maITEBztXD_zzv7Q7MT9qAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred taxes&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_znPsIyABZBZa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maITEBztXD_zNbpwR3ZhDbj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2082"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBztXD_zco7tXUdo9fc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002073"
      unitRef="USD">1000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002075"
      unitRef="USD">11000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002076"
      unitRef="USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002084"
      unitRef="USD">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002085"
      unitRef="USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact002087"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31_custom_USFederalTaxMember"
      decimals="-5"
      id="Fact002089"
      unitRef="USD">23300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31_custom_FloridaIncomeTaxMember"
      decimals="-5"
      id="Fact002091"
      unitRef="USD">100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002093">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zThUWxlxqKsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zfl3scupFN3l" style="display: none"&gt;Schedule
of Federal Statutory Tax Rate to The Effective Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;U.S Federal statutory income rate&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20250101__20251231_zAzgeeZpppFj" style="width: 16%; font-size: 10pt; text-align: right" title="U.S Federal statutory income rate, Amount"&gt;(4,463&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20250101__20251231_zFxJyMOFBuA4" title="U.S Federal statutory income rate, Rate"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;State, net of federal tax benefit&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20250101__20251231_zbXy9kIlY7wl" style="font-size: 10pt; text-align: right" title="State, net of federal tax benefit, Amount"&gt;9&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20250101__20251231_zMr0pwJiICR1" title="State, net of federal tax benefit, Rate"&gt;(0.04&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Nontaxable or nondeductible items&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Income/loss excluded from nontaxable entities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20250101__20251231_zfzJQFRskkMi" style="font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;944&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20250101__20251231_zhyVeG40ffe1" title="Income/loss excluded from nontaxable entities, Rate"&gt;(4.44&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_zBXuJlTncBea" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-left: 10pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_zJdrdulDazCc" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; padding-left: 10pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Meals and entertainment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_pn3n3_maMahiYA_c20250101__20251231_z0QGSTT1dyMj" style="font-size: 10pt; text-align: right" title="Meals and entertainment, Amount"&gt;7&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_pid_dp_uPure_maKamaLI_c20250101__20251231_zprancH9EwFl" title="Meals and entertainment, Rate"&gt;(0.04&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Stock options&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maMahiYA_c20250101__20251231_zQWDLG7PYlDh" style="font-size: 10pt; text-align: right" title="Stock options, Amount"&gt;614&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maKamaLI_c20250101__20251231_zltTUL71zoP2" title="Stock options, Rate"&gt;(3.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Equity award vesting&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IncomeTaxReconciliationEquityInEquityAwardVestingAmount_pn3n3_maMahiYA_c20250101__20251231_zcq5YDq12oxd" style="font-size: 10pt; text-align: right" title="Equity award vesting, Amount"&gt;248&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting_pid_dp_uPure_maKamaLI_c20250101__20251231_zqlTNBcH1AP" title="Equity award vesting, Rate"&gt;(1.24&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-left: 10pt"&gt;Modification of equity awards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--IncomeTaxReconciliationModificationOfEquityAwardsAmount_pn3n3_maMahiYA_c20250101__20251231_z3WSaoPZkhS2" style="font-size: 10pt; text-align: right" title="Modification of equity awards, Amount"&gt;2,194&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maKamaLI_c20250101__20251231_zZ9V0lzmB0q9" title="Equity award vesting, Rate"&gt;(10.95&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Return-to-provision adjustments&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20250101__20251231_zRrcBz3dkZSl" style="font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount"&gt;(44&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20250101__20251231_zW6LSLqiL1nc" title="Return-to-provision adjustments, Rate"&gt;0.22&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_zWIBshQTkSc6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_zOBsHs9AIRxh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right" title="Return-to-provision adjustments, Amount"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20250101__20251231_zvBKtMBpy216" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Valuation allowance, Amount"&gt;502&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20250101__20251231_zH8KcsFkBxYa" title="Valuation allowance, Rate"&gt;(2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Effective rate&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20250101__20251231_zL9SnUxJsz4f" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Effective rate, Amount"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20250101__20251231_zXDBeGuz56c7" title="Effective rate, Rate"&gt;(0.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;A reconciliation of the federal
statutory tax rate to the effective tax rate (including Subchapter&#160;C-corporations) for the year ended December 31, 2024 and
2024 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S Federal statutory
    income rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate_pn3n3_maMahiYA_c20240101__20241231_z5gZGmcJCLba" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S Federal statutory income rate, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,453&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maKamaLI_c20240101__20241231_zUkTSgGBrsNk" title="U.S Federal statutory income rate, Rate"&gt;21.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State, net of federal tax
    benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maMahiYA_c20240101__20241231_z055pwdywtk2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State, net of federal tax benefit, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(246&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maKamaLI_c20240101__20241231_zvUxl03iC6W3" title="State, net of federal tax benefit, Rate"&gt;(2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income/loss excluded from
    nontaxable entities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities_pn3n3_maMahiYA_c20240101__20241231_zCS3MINvK0Ag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Income/loss excluded from nontaxable entities, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities_pid_dp_uPure_maKamaLI_c20240101__20241231_zbH5oGARhAbf" title="Income/loss excluded from nontaxable entities, Rate"&gt;(68.57&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences_pn3n3_maMahiYA_c20240101__20241231_zLDKKFiB4Zxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Permanent differences, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zcJdGiB4y7ck" title="Permanent differences, Rate"&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Return-to-provision adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maMahiYA_c20240101__20241231_zyah9TbCQK0h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Return-to-provision adjustments, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maKamaLI_c20240101__20241231_zTmjsZdVVGtg" title="Return-to-provision adjustments, Rate"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationOtherReconcilingItems_pn3n3_maMahiYA_c20240101__20241231_zIHFoGxynuai" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;192&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maKamaLI_c20240101__20241231_zbTPDKiJGemb" title="Other, Rate"&gt;1.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance_pn3n3_maMahiYA_c20240101__20241231_zc4fcKcW0Pbh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,966&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance_pid_dp_uPure_maKamaLI_c20240101__20241231_zUobJyjPhofk" title="Valuation allowance, Rate"&gt;42.52&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_mtMahiYA_c20240101__20241231_zlpCL3taBE1k" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective rate, Amount"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKamaLI_c20240101__20241231_zLq7wG2Fh661" title="Effective rate, Rate"&gt;0.02&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zW4pGONifQD1" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Start-up expenditures&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Organizational expenditures&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Sec 174 &#x2013; Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2182"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,795&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,524&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Lease liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;128&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;149&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Property and equipment principally due to differences in depreciation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Bonus expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2195"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Charitable contribution carryforwards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Impairment expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;53&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Intangible Assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;51&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;38&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,890&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,781&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(6,625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(6,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(115&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Investment securities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(264&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets/(liabilities)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Other noncurrent assets/(liabilities)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2236"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002095"
      unitRef="USD">-4463000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <MDBH:EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002097"
      unitRef="Pure">0.2100</MDBH:EffectiveIncomeTaxRateReconciliationOfFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002099"
      unitRef="USD">9000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002101"
      unitRef="Pure">-0.0004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <MDBH:IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002103"
      unitRef="USD">944000</MDBH:IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities>
    <MDBH:EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002105"
      unitRef="Pure">-0.0444</MDBH:EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002109"
      unitRef="USD">7000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002111"
      unitRef="Pure">-0.0004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002113"
      unitRef="USD">614000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002115"
      unitRef="Pure">-0.0306</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <MDBH:IncomeTaxReconciliationEquityInEquityAwardVestingAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002117"
      unitRef="USD">248000</MDBH:IncomeTaxReconciliationEquityInEquityAwardVestingAmount>
    <MDBH:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002119"
      unitRef="Pure">-0.0124</MDBH:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityAwardVesting>
    <MDBH:IncomeTaxReconciliationModificationOfEquityAwardsAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002121"
      unitRef="USD">2194000</MDBH:IncomeTaxReconciliationModificationOfEquityAwardsAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002123"
      unitRef="Pure">-0.1095</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002125"
      unitRef="USD">-44000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <MDBH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002127"
      unitRef="Pure">0.0022</MDBH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <MDBH:IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002131"
      unitRef="USD">502000</MDBH:IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance>
    <MDBH:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002133"
      unitRef="Pure">-0.0252</MDBH:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002135"
      unitRef="USD">11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002137"
      unitRef="Pure">-0.0005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <MDBH:IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002139"
      unitRef="USD">2453000</MDBH:IncomeTaxReconciliationIncomeTaxExpenseBenefitOfFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002141"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002143"
      unitRef="USD">-246000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002145"
      unitRef="Pure">-0.0211</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <MDBH:IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002147"
      unitRef="USD">-8009000</MDBH:IncomeTaxReconciliationIncomeLossExcludedFromNontaxableEntities>
    <MDBH:EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002149"
      unitRef="Pure">-0.6857</MDBH:EffectiveIncomeTaxRateReconciliationIncomeLossExcludedFromNontaxableEntities>
    <MDBH:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002151"
      unitRef="USD">641000</MDBH:IncomeTaxReconciliationIncomeTaxExpenseBenefitPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002153"
      unitRef="Pure">0.0549</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002155"
      unitRef="USD">5000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <MDBH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002157"
      unitRef="Pure">0.0004</MDBH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002159"
      unitRef="USD">192000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002161"
      unitRef="Pure">0.0165</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <MDBH:IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002163"
      unitRef="USD">4966000</MDBH:IncomeTaxReconciliationChangeInDeferredTaxAssetValuationAllowance>
    <MDBH:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002165"
      unitRef="Pure">0.4252</MDBH:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002167"
      unitRef="USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002169"
      unitRef="Pure">0.0002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002171">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zijKLusBly9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Significant components of the deferred
tax assets and liabilities (including Subchapter C-corporations) were as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zW4pGONifQD1" style="display: none"&gt;Schedule
of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_z7KyjAjKPr0j" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zbayncmJpCY4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zOhE6eHTdF22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsInStartupExpenditures_i01I_pn3n3_z0pStMYk9xVh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Start-up expenditures&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsInOrganizationalExpenditures_i01I_pn3n3_zuqC8lBkrb19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Organizational expenditures&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_zSzWWFgSyBHd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Sec 174 &#x2013; Research and development costs&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2182"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsStockCompensation_i01I_pn3n3_zs26HxDV2Wjf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Stock compensation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,795&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,524&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3n3_zZ3S6wqVc1Hd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Lease liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;128&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;149&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_i01I_pn3n3_znfglrQ30dW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Property and equipment principally due to differences in depreciation&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsBonusExpense_i01I_pn3n3_ztABvizfysx2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Bonus expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2195"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_i01I_pn3n3_zK0Ezg1MVPNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Charitable contribution carryforwards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsImpairmentExpense_i01I_pn3n3_zhPorG7E1S01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Impairment expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;53&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pn3n3_zDZTyf2jjCLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Intangible Assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;51&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;38&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_i01I_pn3n3_z48rWoaxn8e2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;4,890&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;3,781&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_zZVGiPfri0Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(6,625&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(6,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNz5VD_zhFLgPov3wKa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxLiabilitiesNetAbstract_iB_zh39DJul5FCf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_pn3n3_di_maDTLzxyZ_zcR3KGzxw7ql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 10pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(115&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;(135&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesInvestmentSecurities_i01NI_pn3n3_di_maDTLzxyZ_z2gJCJM9IOVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Investment securities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(212&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(264&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01NTI_pn3n3_di_msDTALNz5VD_mtDTLzxyZ_zbZktxIp2ZDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i01TI_pn3n3_mtDTALNz5VD_zS7nNHBp8uie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets/(liabilities)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2227"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Net deferred tax assets and liabilities
were classified on the consolidated balance sheets as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_zSrPpvpvhm01" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zhZaUGLkSUlh" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTAGzNdz_maDTANzXjO_maDTALNzm7g_zvMv0LZmstRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-size: 10pt; text-align: left"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-size: 10pt; text-align: right"&gt;399&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_msDTALNzm7g_zZZOUq3uSh8a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(327&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(399&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzm7g_z6haG6uQIGqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Other noncurrent assets/(liabilities)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2236"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <MDBH:DeferredTaxAssetsInStartupExpenditures
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002176"
      unitRef="USD">4000</MDBH:DeferredTaxAssetsInStartupExpenditures>
    <MDBH:DeferredTaxAssetsInStartupExpenditures
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002177"
      unitRef="USD">13000</MDBH:DeferredTaxAssetsInStartupExpenditures>
    <MDBH:DeferredTaxAssetsInOrganizationalExpenditures
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002179"
      unitRef="USD">14000</MDBH:DeferredTaxAssetsInOrganizationalExpenditures>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002183"
      unitRef="USD">3000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <MDBH:DeferredTaxAssetsStockCompensation
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002185"
      unitRef="USD">1795000</MDBH:DeferredTaxAssetsStockCompensation>
    <MDBH:DeferredTaxAssetsStockCompensation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002186"
      unitRef="USD">2524000</MDBH:DeferredTaxAssetsStockCompensation>
    <MDBH:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002188"
      unitRef="USD">128000</MDBH:DeferredTaxAssetsLeaseLiability>
    <MDBH:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002189"
      unitRef="USD">149000</MDBH:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002191"
      unitRef="USD">2000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002192"
      unitRef="USD">3000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <MDBH:DeferredTaxAssetsBonusExpense
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002194"
      unitRef="USD">14000</MDBH:DeferredTaxAssetsBonusExpense>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002197"
      unitRef="USD">1000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002198"
      unitRef="USD">1000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <MDBH:DeferredTaxAssetsImpairmentExpense
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002200"
      unitRef="USD">53000</MDBH:DeferredTaxAssetsImpairmentExpense>
    <MDBH:DeferredTaxAssetsImpairmentExpense
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002201"
      unitRef="USD">11000</MDBH:DeferredTaxAssetsImpairmentExpense>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002203"
      unitRef="USD">51000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002204"
      unitRef="USD">38000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002206"
      unitRef="USD">4890000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002207"
      unitRef="USD">3781000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002209"
      unitRef="USD">6625000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002210"
      unitRef="USD">6124000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002212"
      unitRef="USD">327000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002213"
      unitRef="USD">399000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002218"
      unitRef="USD">115000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002219"
      unitRef="USD">135000</us-gaap:DeferredTaxLiabilitiesOther>
    <MDBH:DeferredTaxLiabilitiesInvestmentSecurities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002221"
      unitRef="USD">212000</MDBH:DeferredTaxLiabilitiesInvestmentSecurities>
    <MDBH:DeferredTaxLiabilitiesInvestmentSecurities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002222"
      unitRef="USD">264000</MDBH:DeferredTaxLiabilitiesInvestmentSecurities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002224"
      unitRef="USD">327000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002225"
      unitRef="USD">399000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002230"
      unitRef="USD">327000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002231"
      unitRef="USD">399000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002233"
      unitRef="USD">327000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002234"
      unitRef="USD">399000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact002239"
      unitRef="USD">6600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002241">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zm0IcdkhnTN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;15. &lt;span id="xdx_82D_zixxhF4wmjnl"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On February 3, 2026, the Company granted&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260203__20260203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVN81gISSZgj" title="Restricted stock units, granted"&gt;
161,500&lt;/span&gt; restricted stock units (RSUs) to employees pursuant to its equity incentive plan.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2026-02-032026-02-03_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002243"
      unitRef="Shares">161500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl1012"
          xlink:label="xdx2ixbrl1012"
          xlink:type="locator"/>
        <link:footnote id="Footnote001032" xlink:label="Footnote001032" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2024, eXoZymes was deconsolidated
from the Company&#x2019;s consolidated financial statements. As all grant-related costs were associated with eXoZymes, no grant-related
figures are reported for 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1012"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001013"
          xlink:label="Fact001013"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001013"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001016"
          xlink:label="Fact001016"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001016"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001019"
          xlink:label="Fact001019"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001019"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001022"
          xlink:label="Fact001022"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001022"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001025"
          xlink:label="Fact001025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001025"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001028"
          xlink:label="Fact001028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001028"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1031"
          xlink:label="xdx2ixbrl1031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1031"
          xlink:to="Footnote001032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001088"
          xlink:label="Fact001088"
          xlink:type="locator"/>
        <link:footnote id="Footnote001279" xlink:label="Footnote001279" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes unrealized losses on securities
    held by the broker-dealer and non-broker dealer.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001088"
          xlink:to="Footnote001279"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1089"
          xlink:label="xdx2ixbrl1089"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1089"
          xlink:to="Footnote001279"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1090"
          xlink:label="xdx2ixbrl1090"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1090"
          xlink:to="Footnote001279"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1091"
          xlink:label="xdx2ixbrl1091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1091"
          xlink:to="Footnote001279"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001092"
          xlink:label="Fact001092"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001092"
          xlink:to="Footnote001279"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001100"
          xlink:label="Fact001100"
          xlink:type="locator"/>
        <link:footnote id="Footnote001280" xlink:label="Footnote001280" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes realized gains on securities held by the broker-dealer.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001100"
          xlink:to="Footnote001280"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1101"
          xlink:label="xdx2ixbrl1101"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1101"
          xlink:to="Footnote001280"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1102"
          xlink:label="xdx2ixbrl1102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1102"
          xlink:to="Footnote001280"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1103"
          xlink:label="xdx2ixbrl1103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1103"
          xlink:to="Footnote001280"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001104"
          xlink:label="Fact001104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001104"
          xlink:to="Footnote001280"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001106"
          xlink:label="Fact001106"
          xlink:type="locator"/>
        <link:footnote id="Footnote001281" xlink:label="Footnote001281" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes fee income generated for the broker-dealer from investment banking activities, including advisory services, capital raising, and other related financial transactions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001106"
          xlink:to="Footnote001281"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1107"
          xlink:label="xdx2ixbrl1107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1107"
          xlink:to="Footnote001281"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1108"
          xlink:label="xdx2ixbrl1108"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1108"
          xlink:to="Footnote001281"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1109"
          xlink:label="xdx2ixbrl1109"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1109"
          xlink:to="Footnote001281"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001110"
          xlink:label="Fact001110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001110"
          xlink:to="Footnote001281"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001118"
          xlink:label="Fact001118"
          xlink:type="locator"/>
        <link:footnote id="Footnote001282" xlink:label="Footnote001282" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes fees earned from self-clearing activities by the broker-dealer and professional fees generated by PatentVest services.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001118"
          xlink:to="Footnote001282"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1119"
          xlink:label="xdx2ixbrl1119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1119"
          xlink:to="Footnote001282"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1120"
          xlink:label="xdx2ixbrl1120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1120"
          xlink:to="Footnote001282"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1121"
          xlink:label="xdx2ixbrl1121"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1121"
          xlink:to="Footnote001282"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001122"
          xlink:label="Fact001122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001122"
          xlink:to="Footnote001282"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001302"
          xlink:label="Fact001302"
          xlink:type="locator"/>
        <link:footnote id="Footnote001481" xlink:label="Footnote001481" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes unrealized gains and
losses on securities held by the broker-dealer.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001302"
          xlink:to="Footnote001481"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1303"
          xlink:label="xdx2ixbrl1303"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1303"
          xlink:to="Footnote001481"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1304"
          xlink:label="xdx2ixbrl1304"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1304"
          xlink:to="Footnote001481"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1305"
          xlink:label="xdx2ixbrl1305"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1305"
          xlink:to="Footnote001481"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001306"
          xlink:label="Fact001306"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001306"
          xlink:to="Footnote001481"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001308"
          xlink:label="Fact001308"
          xlink:type="locator"/>
        <link:footnote id="Footnote001482" xlink:label="Footnote001482" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes fee income generated
for the broker from investment banking activities, including advisory services, capital raising, and other related financial transactions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001308"
          xlink:to="Footnote001482"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1309"
          xlink:label="xdx2ixbrl1309"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1309"
          xlink:to="Footnote001482"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1310"
          xlink:label="xdx2ixbrl1310"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1310"
          xlink:to="Footnote001482"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1311"
          xlink:label="xdx2ixbrl1311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1311"
          xlink:to="Footnote001482"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001312"
          xlink:label="Fact001312"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001312"
          xlink:to="Footnote001482"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001314"
          xlink:label="Fact001314"
          xlink:type="locator"/>
        <link:footnote id="Footnote001483" xlink:label="Footnote001483" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes impairment loss of assets
from the reduced fair value of the asset.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001314"
          xlink:to="Footnote001483"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001318"
          xlink:label="Fact001318"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001318"
          xlink:to="Footnote001483"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001320"
          xlink:label="Fact001320"
          xlink:type="locator"/>
        <link:footnote id="Footnote001484" xlink:label="Footnote001484" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes fees earned from self-clearing
activities and professional fees generated by PatentVest services.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001320"
          xlink:to="Footnote001484"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1321"
          xlink:label="xdx2ixbrl1321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1321"
          xlink:to="Footnote001484"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1322"
          xlink:label="xdx2ixbrl1322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1322"
          xlink:to="Footnote001484"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1323"
          xlink:label="xdx2ixbrl1323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1323"
          xlink:to="Footnote001484"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001324"
          xlink:label="Fact001324"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001324"
          xlink:to="Footnote001484"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
